Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific nTPM"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific nTPM"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific nTPM"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific nTPM"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific nTPM"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific nTPM"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific nTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific nTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [nTPM]"	"Tissue RNA - adrenal gland [nTPM]"	"Tissue RNA - amygdala [nTPM]"	"Tissue RNA - appendix [nTPM]"	"Tissue RNA - basal ganglia [nTPM]"	"Tissue RNA - bone marrow [nTPM]"	"Tissue RNA - breast [nTPM]"	"Tissue RNA - cerebellum [nTPM]"	"Tissue RNA - cerebral cortex [nTPM]"	"Tissue RNA - cervix [nTPM]"	"Tissue RNA - choroid plexus [nTPM]"	"Tissue RNA - colon [nTPM]"	"Tissue RNA - duodenum [nTPM]"	"Tissue RNA - endometrium 1 [nTPM]"	"Tissue RNA - epididymis [nTPM]"	"Tissue RNA - esophagus [nTPM]"	"Tissue RNA - fallopian tube [nTPM]"	"Tissue RNA - gallbladder [nTPM]"	"Tissue RNA - heart muscle [nTPM]"	"Tissue RNA - hippocampal formation [nTPM]"	"Tissue RNA - hypothalamus [nTPM]"	"Tissue RNA - kidney [nTPM]"	"Tissue RNA - liver [nTPM]"	"Tissue RNA - lung [nTPM]"	"Tissue RNA - lymph node [nTPM]"	"Tissue RNA - medulla oblongata [nTPM]"	"Tissue RNA - midbrain [nTPM]"	"Tissue RNA - olfactory bulb [nTPM]"	"Tissue RNA - ovary [nTPM]"	"Tissue RNA - pancreas [nTPM]"	"Tissue RNA - parathyroid gland [nTPM]"	"Tissue RNA - pituitary gland [nTPM]"	"Tissue RNA - placenta [nTPM]"	"Tissue RNA - pons [nTPM]"	"Tissue RNA - prostate [nTPM]"	"Tissue RNA - rectum [nTPM]"	"Tissue RNA - retina [nTPM]"	"Tissue RNA - salivary gland [nTPM]"	"Tissue RNA - seminal vesicle [nTPM]"	"Tissue RNA - skeletal muscle [nTPM]"	"Tissue RNA - skin 1 [nTPM]"	"Tissue RNA - small intestine [nTPM]"	"Tissue RNA - smooth muscle [nTPM]"	"Tissue RNA - spinal cord [nTPM]"	"Tissue RNA - spleen [nTPM]"	"Tissue RNA - stomach 1 [nTPM]"	"Tissue RNA - testis [nTPM]"	"Tissue RNA - thalamus [nTPM]"	"Tissue RNA - thymus [nTPM]"	"Tissue RNA - thyroid gland [nTPM]"	"Tissue RNA - tongue [nTPM]"	"Tissue RNA - tonsil [nTPM]"	"Tissue RNA - urinary bladder [nTPM]"	"Tissue RNA - vagina [nTPM]"	"Tissue RNA - white matter [nTPM]"	"Cell RNA - A-431 [nTPM]"	"Cell RNA - A549 [nTPM]"	"Cell RNA - AF22 [nTPM]"	"Cell RNA - AN3-CA [nTPM]"	"Cell RNA - ASC diff [nTPM]"	"Cell RNA - ASC TERT1 [nTPM]"	"Cell RNA - BEWO [nTPM]"	"Cell RNA - BJ [nTPM]"	"Cell RNA - BJ hTERT+ [nTPM]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [nTPM]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [nTPM]"	"Cell RNA - CACO-2 [nTPM]"	"Cell RNA - CAPAN-2 [nTPM]"	"Cell RNA - Daudi [nTPM]"	"Cell RNA - EFO-21 [nTPM]"	"Cell RNA - fHDF/TERT166 [nTPM]"	"Cell RNA - GAMG [nTPM]"	"Cell RNA - HaCaT [nTPM]"	"Cell RNA - HAP1 [nTPM]"	"Cell RNA - HBEC3-KT [nTPM]"	"Cell RNA - HBF TERT88 [nTPM]"	"Cell RNA - HDLM-2 [nTPM]"	"Cell RNA - HEK 293 [nTPM]"	"Cell RNA - HEL [nTPM]"	"Cell RNA - HeLa [nTPM]"	"Cell RNA - Hep G2 [nTPM]"	"Cell RNA - HHSteC [nTPM]"	"Cell RNA - HL-60 [nTPM]"	"Cell RNA - HMC-1 [nTPM]"	"Cell RNA - HSkMC [nTPM]"	"Cell RNA - hTCEpi [nTPM]"	"Cell RNA - hTEC/SVTERT24-B [nTPM]"	"Cell RNA - hTERT-HME1 [nTPM]"	"Cell RNA - hTERT-RPE1 [nTPM]"	"Cell RNA - HUVEC TERT2 [nTPM]"	"Cell RNA - JURKAT [nTPM]"	"Cell RNA - K-562 [nTPM]"	"Cell RNA - Karpas-707 [nTPM]"	"Cell RNA - LHCN-M2 [nTPM]"	"Cell RNA - MCF7 [nTPM]"	"Cell RNA - MOLT-4 [nTPM]"	"Cell RNA - NB-4 [nTPM]"	"Cell RNA - NTERA-2 [nTPM]"	"Cell RNA - OE19 [nTPM]"	"Cell RNA - PC-3 [nTPM]"	"Cell RNA - REH [nTPM]"	"Cell RNA - RH-30 [nTPM]"	"Cell RNA - RPMI-8226 [nTPM]"	"Cell RNA - RPTEC TERT1 [nTPM]"	"Cell RNA - RT4 [nTPM]"	"Cell RNA - SCLC-21H [nTPM]"	"Cell RNA - SH-SY5Y [nTPM]"	"Cell RNA - SiHa [nTPM]"	"Cell RNA - SK-BR-3 [nTPM]"	"Cell RNA - SK-MEL-30 [nTPM]"	"Cell RNA - SuSa [nTPM]"	"Cell RNA - T-47d [nTPM]"	"Cell RNA - THP-1 [nTPM]"	"Cell RNA - TIME [nTPM]"	"Cell RNA - U-138 MG [nTPM]"	"Cell RNA - U-2 OS [nTPM]"	"Cell RNA - U-2197 [nTPM]"	"Cell RNA - U-251 MG [nTPM]"	"Cell RNA - U-266/70 [nTPM]"	"Cell RNA - U-266/84 [nTPM]"	"Cell RNA - U-698 [nTPM]"	"Cell RNA - U-87 MG [nTPM]"	"Cell RNA - U-937 [nTPM]"	"Cell RNA - WM-115 [nTPM]"	"Blood RNA - basophil [nTPM]"	"Blood RNA - classical monocyte [nTPM]"	"Blood RNA - eosinophil [nTPM]"	"Blood RNA - gdT-cell [nTPM]"	"Blood RNA - intermediate monocyte [nTPM]"	"Blood RNA - MAIT T-cell [nTPM]"	"Blood RNA - memory B-cell [nTPM]"	"Blood RNA - memory CD4 T-cell [nTPM]"	"Blood RNA - memory CD8 T-cell [nTPM]"	"Blood RNA - myeloid DC [nTPM]"	"Blood RNA - naive B-cell [nTPM]"	"Blood RNA - naive CD4 T-cell [nTPM]"	"Blood RNA - naive CD8 T-cell [nTPM]"	"Blood RNA - neutrophil [nTPM]"	"Blood RNA - NK-cell [nTPM]"	"Blood RNA - non-classical monocyte [nTPM]"	"Blood RNA - plasmacytoid DC [nTPM]"	"Blood RNA - T-reg [nTPM]"	"Blood RNA - total PBMC [nTPM]"	"Brain RNA - amygdala [nTPM]"	"Brain RNA - basal ganglia [nTPM]"	"Brain RNA - cerebellum [nTPM]"	"Brain RNA - cerebral cortex [nTPM]"	"Brain RNA - hippocampal formation [nTPM]"	"Brain RNA - hypothalamus [nTPM]"	"Brain RNA - medulla oblongata [nTPM]"	"Brain RNA - midbrain [nTPM]"	"Brain RNA - olfactory bulb [nTPM]"	"Brain RNA - pons [nTPM]"	"Brain RNA - spinal cord [nTPM]"	"Brain RNA - thalamus [nTPM]"	"Brain RNA - white matter [nTPM]"	"Single Cell Type RNA - Adipocytes [nTPM]"	"Single Cell Type RNA - Alveolar cells type 1 [nTPM]"	"Single Cell Type RNA - Alveolar cells type 2 [nTPM]"	"Single Cell Type RNA - Astrocytes [nTPM]"	"Single Cell Type RNA - B-cells [nTPM]"	"Single Cell Type RNA - Basal keratinocytes [nTPM]"	"Single Cell Type RNA - Basal prostatic cells [nTPM]"	"Single Cell Type RNA - Basal respiratory cells [nTPM]"	"Single Cell Type RNA - Basal squamous epithelial cells [nTPM]"	"Single Cell Type RNA - Bipolar cells [nTPM]"	"Single Cell Type RNA - Breast glandular cells [nTPM]"	"Single Cell Type RNA - Breast myoepithelial cells [nTPM]"	"Single Cell Type RNA - Cardiomyocytes [nTPM]"	"Single Cell Type RNA - Cholangiocytes [nTPM]"	"Single Cell Type RNA - Club cells [nTPM]"	"Single Cell Type RNA - Collecting duct cells [nTPM]"	"Single Cell Type RNA - Cone photoreceptor cells [nTPM]"	"Single Cell Type RNA - Cytotrophoblasts [nTPM]"	"Single Cell Type RNA - dendritic cells [nTPM]"	"Single Cell Type RNA - Distal enterocytes [nTPM]"	"Single Cell Type RNA - Distal tubular cells [nTPM]"	"Single Cell Type RNA - Ductal cells [nTPM]"	"Single Cell Type RNA - Early spermatids [nTPM]"	"Single Cell Type RNA - Endometrial ciliated cells [nTPM]"	"Single Cell Type RNA - Endometrial stromal cells [nTPM]"	"Single Cell Type RNA - Endothelial cells [nTPM]"	"Single Cell Type RNA - Enteroendocrine cells [nTPM]"	"Single Cell Type RNA - Erythroid cells [nTPM]"	"Single Cell Type RNA - Excitatory neurons [nTPM]"	"Single Cell Type RNA - Exocrine glandular cells [nTPM]"	"Single Cell Type RNA - Extravillous trophoblasts [nTPM]"	"Single Cell Type RNA - Fibroblasts [nTPM]"	"Single Cell Type RNA - Gastric mucus-secreting cells [nTPM]"	"Single Cell Type RNA - Glandular and luminal cells [nTPM]"	"Single Cell Type RNA - granulocytes [nTPM]"	"Single Cell Type RNA - Granulosa cells [nTPM]"	"Single Cell Type RNA - Hepatic stellate cells [nTPM]"	"Single Cell Type RNA - Hepatocytes [nTPM]"	"Single Cell Type RNA - Hofbauer cells [nTPM]"	"Single Cell Type RNA - Horizontal cells [nTPM]"	"Single Cell Type RNA - Inhibitory neurons [nTPM]"	"Single Cell Type RNA - Intestinal goblet cells [nTPM]"	"Single Cell Type RNA - Ionocytes [nTPM]"	"Single Cell Type RNA - Kupffer cells [nTPM]"	"Single Cell Type RNA - Langerhans cells [nTPM]"	"Single Cell Type RNA - Late spermatids [nTPM]"	"Single Cell Type RNA - Leydig cells [nTPM]"	"Single Cell Type RNA - Macrophages [nTPM]"	"Single Cell Type RNA - Melanocytes [nTPM]"	"Single Cell Type RNA - Microglial cells [nTPM]"	"Single Cell Type RNA - monocytes [nTPM]"	"Single Cell Type RNA - Muller glia cells [nTPM]"	"Single Cell Type RNA - NK-cells [nTPM]"	"Single Cell Type RNA - Oligodendrocyte precursor cells [nTPM]"	"Single Cell Type RNA - Oligodendrocytes [nTPM]"	"Single Cell Type RNA - Pancreatic endocrine cells [nTPM]"	"Single Cell Type RNA - Paneth cells [nTPM]"	"Single Cell Type RNA - Peritubular cells [nTPM]"	"Single Cell Type RNA - Plasma cells [nTPM]"	"Single Cell Type RNA - Prostatic glandular cells [nTPM]"	"Single Cell Type RNA - Proximal enterocytes [nTPM]"	"Single Cell Type RNA - Proximal tubular cells [nTPM]"	"Single Cell Type RNA - Respiratory ciliated cells [nTPM]"	"Single Cell Type RNA - Rod photoreceptor cells [nTPM]"	"Single Cell Type RNA - Sertoli cells [nTPM]"	"Single Cell Type RNA - Skeletal myocytes [nTPM]"	"Single Cell Type RNA - Smooth muscle cells [nTPM]"	"Single Cell Type RNA - Spermatocytes [nTPM]"	"Single Cell Type RNA - Spermatogonia [nTPM]"	"Single Cell Type RNA - Squamous epithelial cells [nTPM]"	"Single Cell Type RNA - Suprabasal keratinocytes [nTPM]"	"Single Cell Type RNA - Syncytiotrophoblasts [nTPM]"	"Single Cell Type RNA - T-cells [nTPM]"	"Single Cell Type RNA - Theca cells [nTPM]"	"Single Cell Type RNA - Undifferentiated cells [nTPM]"	"Single Cell Type RNA - Urothelial cells [nTPM]"
KLK3	"APS, PSA"	ENSG00000142515	"Kallikrein related peptidase 3"	P07288	19	50854915-50860764	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	320	"prostate: 8083.1"	"Cell type enriched"	"Detected in some"	77	"Prostatic glandular cells: 3438.6"	"Cancer enriched"	"Detected in some"	3905	"prostate cancer: 4241.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	173	"BEWO: 31.7;NB-4: 27.8;RPMI-8226: 19.3;SH-SY5Y: 10.5;U-2197: 10.7"									"CAB000070, HPA000764"	Enhanced				"Secreted in male reproductive system"	NA	NA		7000000			"CAB000070: , HPA000764: AB_1079700"	"unprognostic (5.06e-3)"	"unprognostic (5.60e-2)"	"unprognostic (9.93e-2)"	"unprognostic (3.90e-2)"		"unprognostic (1.09e-2)"				"unprognostic (1.26e-2)"	"unprognostic (1.88e-2)"	"unprognostic (1.54e-1)"	"unprognostic (5.13e-3)"	"unprognostic (1.94e-1)"	"unprognostic (4.64e-1)"	"unprognostic (3.15e-1)"		4.4	7.6	0.0	5.7	0.0	0.0	9.0	0.0	0.0	0.4	0.0	2.3	4.9	1.6	14.5	0.2	4.0	0.0	0.4	0.0	0.0	1.4	1.5	1.2	1.7	0.0	0.0	0.0	0.3	0.9	0.6	0.2	0.3	0.0	8083.1	1.2	0.0	4.5	25.2	0.3	0.4	3.8	0.0	0.0	0.2	1.0	7.0	0.0	0.0	0.8	0.0	0.0	0.5	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	31.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.8	0.0	0.0	0.0	0.0	0.0	19.3	0.1	0.0	0.0	10.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	39.0	0.0	0.0	0.0	12.4	1.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.0	0.0	0.4	2.6	0.0	0.0	0.2	0.0	0.0	3.4	0.0	0.0	0.0	12.9	0.0	0.0	0.0	0.0	0.1	9.0	0.0	0.0	0.0	1.8	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	3438.6	0.1	0.1	0.0	0.0	0.0	0.0	6.9	0.1	0.0	0.0	0.0	0.0	4.2	0.2	0.4	44.6
KLK2		ENSG00000167751	"Kallikrein related peptidase 2"	P20151	19	50861568-50880567	"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	87	"prostate: 571.2"	"Cell type enriched"	"Detected in some"	40	"Prostatic glandular cells: 777.2"	"Cancer enriched"	"Detected in some"	1666	"prostate cancer: 989.9"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BEWO: 3.5;NB-4: 5.6"									HPA000764	Supported				"Secreted in male reproductive system"	NA	NA					"HPA000764: AB_1079700"	"unprognostic (3.05e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.69e-1)"	"unprognostic (8.53e-2)"		"unprognostic (1.15e-1)"		"unprognostic (8.97e-2)"	"unprognostic (3.22e-1)"	"unprognostic (6.44e-2)"	"unprognostic (8.06e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.11e-3)"	"unprognostic (7.56e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.04e-1)"	0.7	1.2	3.8	1.2	2.8	6.5	0.5	5.1	5.0	0.1	2.4	0.4	1.5	0.6	1.1	0.5	0.3	0.2	0.3	2.8	1.8	0.4	0.8	0.5	1.0	3.1	2.2	3.1	0.4	0.0	0.8	0.0	0.2	3.7	571.2	0.3	1.8	1.9	0.4	1.0	0.8	1.0	0.1	1.5	0.7	0.5	3.0	2.2	0.0	1.9	0.0	0.2	0.2	0.0	4.1	0.9	0.6	0.3	0.7	0.0	0.4	3.5	0.2	0.1	0.1	0.1	0.3	0.4	1.0	0.1	0.0	0.3	0.9	0.1	0.0	0.1	0.9	0.6	0.0	0.7	0.0	0.0	0.1	1.7	0.2	0.1	0.1	0.2	0.2	0.0	0.6	0.7	0.9	0.2	1.0	0.6	5.6	0.5	0.9	0.0	0.4	0.0	1.6	0.0	1.1	0.5	0.5	0.1	0.7	0.6	0.1	0.5	0.2	0.4	0.6	1.0	2.6	0.9	0.8	1.8	0.4	1.0	0.6	0.7	0.4	0.6	0.5	0.3	0.3	0.2	0.3	0.2	0.3	0.1	0.6	0.2	0.4	1.7	0.4	0.2	0.5	0.1	0.2	3.8	2.8	5.1	5.0	2.8	1.8	3.1	2.2	3.1	3.7	1.5	2.2	4.1	0.0	0.0	0.6	0.0	0.2	0.3	10.2	0.0	0.0	0.0	16.1	2.8	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.8	1.5	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	5.2	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	777.2	0.0	0.1	0.0	0.0	0.0	0.0	1.8	19.3	7.2	0.0	0.9	0.0	0.6	1.7	0.0	12.0
CHRNA2		ENSG00000120903	"Cholinergic receptor nicotinic alpha 2 subunit"	Q15822	8	27459756-27479883	"Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease variant, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	14	"brain: 77.3;prostate: 29.3"	"Cell type enhanced"	"Detected in some"		"Bipolar cells: 6.5;Inhibitory neurons: 14.8;Prostatic glandular cells: 2.4;Theca cells: 3.4"	"Cancer enriched"	"Detected in single"	421	"prostate cancer: 30.2"	"Region enhanced"	"Detected in many"		"thalamus: 77.3"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			HPA048348			Supported	"Nucleoplasm,Plasma membrane,Cytokinetic bridge"		Yes	NA			"Plasma membrane"	"Nucleoplasm, Cytokinetic bridge"	"HPA048348: "	"unprognostic (1.10e-2)"	"unprognostic (1.47e-1)"			"unprognostic (2.23e-2)"	"unprognostic (3.19e-1)"	"unprognostic (6.19e-2)"	"unprognostic (6.29e-3)"			"unprognostic (1.19e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.91e-1)"	"unprognostic (7.60e-2)"	"unprognostic (1.70e-1)"	"unprognostic (1.47e-1)"		0.0	0.5	13.0	0.2	8.2	0.9	1.5	37.7	3.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.5	6.5	0.0	0.0	0.2	0.1	15.1	21.7	0.0	0.0	0.2	0.0	0.3	0.0	4.3	29.3	0.0	3.7	0.0	0.0	0.1	0.2	0.3	0.0	2.7	0.1	0.0	0.0	77.3	2.9	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	13.0	8.2	37.7	3.0	1.5	6.5	15.1	21.7	0.0	4.3	2.7	77.3	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.3	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0
TGM4	TGP	ENSG00000163810	"Transglutaminase 4"	P49221	3	44874608-44914990	"Cancer-related genes, Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins"		"Acyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	376	"prostate: 438.3"	"Cell type enriched"	"Detected in some"	20	"Prostatic glandular cells: 226.6"	"Cancer enriched"	"Detected in single"	312	"prostate cancer: 75.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 4.9;hTERT-HME1: 1.3;NB-4: 2.7;RPMI-8226: 2.0;SH-SY5Y: 1.4"	"Not detected"	"Not detected"							"CAB033571, HPA073290"	Enhanced					NA	NA					"CAB033571: AB_2287329, HPA073290: "	"unprognostic (4.40e-2)"	"unprognostic (4.68e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.17e-3)"	"unprognostic (2.84e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.41e-2)"	"unprognostic (1.65e-1)"	"unprognostic (8.56e-3)"	"unprognostic (5.08e-2)"	"unprognostic (1.44e-8)"	"unprognostic (1.10e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.68e-1)"	"unprognostic (6.41e-2)"	0.0	1.1	0.0	0.2	0.0	0.5	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	438.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	1.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.1	0.0	0.0	2.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.8	0.3	0.0	0.3	0.3	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.5	4.2	0.7	0.0	0.0	0.1	0.1	0.9	0.0	0.2	0.0	0.0	0.5	0.2	0.1	0.0	0.0	5.7	0.8	0.6	0.4	0.0	0.0	0.2	0.0	0.3	1.3	0.0	1.5	0.0	0.0	0.4	0.0	0.1	0.0	0.3	0.2	0.0	0.0	0.0	11.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.2	0.0	0.4	0.0	226.6	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.1	0.3	0.0	0.4	1.0	0.2	0.1	0.2	2.4
ACP3	"ACP-3, ACPP, PAP, TM-PAP"	ENSG00000014257	"Acid phosphatase 3"	P15309	3	132317369-132368298	"Cancer-related genes, Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Hydrolase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	76	"prostate: 3676.7"	"Group enriched"	"Detected in some"	5	"Cytotrophoblasts: 13.9;Hofbauer cells: 4.7;Syncytiotrophoblasts: 8.9"	"Cancer enriched"	"Detected in many"	275	"prostate cancer: 1227.2"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in many"		"eosinophil: 139.7"	"Lineage enhanced"	"Detected in many"		"granulocytes: 139.7"	"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 17.7;OE19: 22.3;RPMI-8226: 58.0;U-698: 17.2;U-87 MG: 14.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB000071, HPA004335, HPA063916"	Enhanced				"Secreted to blood"	NA	NA	460000	480000			"CAB000071: , HPA004335: AB_1079684, HPA063916: AB_2685152"	"unprognostic (6.67e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.76e-1)"	"unprognostic (7.77e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.58e-2)"	"unprognostic (2.46e-1)"	"unprognostic (7.41e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.78e-3)"	"unprognostic (2.14e-1)"	"unprognostic (5.95e-2)"	"unprognostic (9.38e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.91e-2)"	"unprognostic (1.71e-1)"	3.1	5.4	0.9	7.4	1.3	17.7	3.4	0.8	1.4	3.4	1.4	3.7	3.2	1.4	17.4	48.1	2.2	1.5	0.5	1.1	1.8	29.1	1.4	4.5	1.9	1.5	1.0	0.8	1.1	2.7	3.9	0.5	10.9	1.4	3676.7	6.5	0.4	10.7	0.8	0.2	27.2	3.4	1.8	1.1	1.8	3.2	2.4	1.2	1.0	2.4	0.2	6.6	1.8	12.2	2.2	0.5	0.1	0.0	0.0	0.2	0.9	11.7	0.3	17.7	0.1	0.0	0.4	0.4	10.6	0.8	0.0	0.1	4.8	0.0	0.1	0.0	0.1	0.5	2.0	0.4	0.2	0.2	7.3	0.1	1.1	1.6	0.1	0.0	0.2	0.0	0.0	0.1	2.7	0.2	0.1	0.0	13.5	0.7	22.3	2.1	0.1	0.0	58.0	5.0	6.5	0.0	4.1	0.1	2.0	0.6	1.7	0.3	6.5	0.0	0.1	0.1	2.5	0.1	0.8	0.4	17.2	14.9	12.7	0.2	0.1	30.2	139.7	0.2	26.9	0.2	0.7	0.0	0.0	35.3	0.0	0.0	0.0	26.4	2.6	25.8	2.4	0.0	10.1	0.9	1.3	0.8	1.4	1.1	1.8	1.5	1.0	0.8	1.4	1.1	1.2	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	13.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.8	1.3	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0
OR51E2	PSGR	ENSG00000167332	"Olfactory receptor family 51 subfamily E member 2"	Q9H255	11	4680171-4697854	"Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"intestine: 8.5;prostate: 29.2"	"Cell type enriched"	"Detected in some"	6	"Enteroendocrine cells: 77.4"	"Cancer enriched"	"Detected in some"	274	"prostate cancer: 217.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 1.9;BJ hTERT+: 1.1;hTERT-RPE1: 1.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (1.98e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.09e-3)"	"unprognostic (1.57e-2)"	"unprognostic (8.00e-4)"	"unprognostic (3.61e-2)"	"unprognostic (6.27e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.05e-2)"	"unprognostic (3.46e-2)"	"unprognostic (2.97e-1)"	"unprognostic (3.61e-1)"	"unprognostic (5.04e-5)"	"unprognostic (3.34e-2)"	"unprognostic (4.66e-2)"	"unprognostic (5.76e-2)"	"unprognostic (3.29e-1)"	0.7	0.2	0.3	1.0	0.4	0.1	0.5	0.4	0.5	0.5	0.6	8.5	0.2	1.3	0.3	0.0	0.5	0.3	0.1	0.5	0.3	0.2	0.0	0.0	0.0	0.4	0.3	0.4	0.6	0.1	0.0	0.0	4.0	0.5	29.2	2.2	0.1	0.0	2.3	0.4	0.2	0.8	2.1	0.1	0.0	0.4	0.3	0.4	0.0	0.1	0.4	0.0	0.4	0.2	0.6	0.0	0.0	0.0	0.0	0.2	1.9	0.0	0.0	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.4	0.5	0.5	0.3	0.4	0.3	0.4	0.5	0.1	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.1	77.4	0.0	1.8	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	12.2	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1
NPY	PYY4	ENSG00000122585	"Neuropeptide Y"	P01303	7	24284188-24291862	"FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Neuropeptide	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"adrenal gland: 123.8;brain: 288.7;prostate: 335.8"	"Group enriched"	"Detected in some"	4	"Inhibitory neurons: 56.7;Prostatic glandular cells: 100.6"	"Cancer enriched"	"Detected in many"	187	"prostate cancer: 1214.9"	"Region enriched"	"Detected in all"	6	"hypothalamus: 288.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	34	"SH-SY5Y: 700.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB016733, CAB034368, HPA036636, HPA044572, HPA056798"	Supported	Supported	Enhanced	"Golgi apparatus"	"Secreted to blood"	NA	NA	30700000	21000	"Golgi apparatus"		"CAB016733: , CAB034368: AB_2298657, HPA036636: , HPA044572: AB_2678996, HPA056798: AB_2630371"			"unprognostic (2.00e-1)"	"prognostic unfavorable (5.78e-4)"	"unprognostic (4.15e-1)"					"unprognostic (3.76e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.87e-1)"	"unprognostic (6.30e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.52e-1)"		1.8	123.8	32.1	12.9	51.3	5.6	2.2	10.4	39.5	1.1	11.3	2.6	9.8	0.3	0.3	2.3	0.5	1.1	0.6	30.6	288.7	0.3	0.2	0.3	0.0	26.1	26.6	27.3	0.5	8.9	0.1	4.8	0.0	18.0	335.8	1.9	4.4	0.4	3.9	0.2	0.2	13.2	1.2	14.8	0.0	8.9	1.2	24.8	0.2	0.9	0.2	0.0	1.4	24.0	29.8	0.0	0.0	2.5	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.5	1.4	2.0	0.0	0.2	20.5	0.0	0.6	0.0	0.0	0.8	700.2	0.0	0.0	0.0	0.2	0.0	1.5	0.0	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.1	51.3	10.4	39.5	30.6	288.7	26.1	26.6	27.3	18.0	14.8	24.8	29.8	0.0	0.0	0.0	2.0	0.5	0.1	1.3	0.0	0.0	1.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.1	13.4	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.5	0.8	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	56.7	0.0	0.0	0.0	0.0	16.1	0.3	0.7	1.8	1.0	0.0	0.8	0.0	2.0	1.9	0.3	0.0	0.4	0.0	100.6	0.0	0.0	0.0	0.7	0.0	15.6	0.3	2.4	2.8	0.0	0.0	5.1	0.3	0.0	0.0	2.0
TRGC1	"C1, TCRGC1"	ENSG00000211689	"T cell receptor gamma constant 1"		7	38257879-38265678	"Predicted membrane proteins, T-cell receptor genes"				"Evidence at transcript level"	"Evidence at transcript level"			"Group enriched"	"Detected in some"	8	"bone marrow: 32.0;prostate: 77.3"	"Group enriched"	"Detected in some"	5	"dendritic cells: 95.8;NK-cells: 230.7;Prostatic glandular cells: 61.9;T-cells: 65.6"	"Cancer enriched"	"Detected in some"	141	"prostate cancer: 107.1"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in many"	4	"gdT-cell: 384.7"	"Lineage enriched"	"Detected in many"	4	"T-cells: 384.7"	"Cell line enhanced"	"Detected in some"		"HL-60: 21.0;MCF7: 89.8;SK-BR-3: 49.6;U-937: 45.5"															NA	NA						"unprognostic (2.37e-2)"	"unprognostic (2.38e-4)"	"unprognostic (3.43e-3)"	"unprognostic (6.04e-4)"	"unprognostic (1.04e-2)"	"unprognostic (3.77e-3)"	"unprognostic (1.33e-3)"	"unprognostic (3.80e-2)"	"unprognostic (3.55e-2)"	"unprognostic (3.33e-3)"	"unprognostic (2.82e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.15e-1)"	"unprognostic (2.98e-1)"	"unprognostic (8.36e-2)"	"unprognostic (2.56e-2)"	0.4	0.2	1.4	1.1	1.5	32.0	2.1	1.3	2.2	0.1	1.0	0.5	1.1	0.2	0.5	0.1	0.3	1.0	0.2	1.3	1.5	0.8	0.8	1.9	2.0	1.7	2.0	1.0	0.1	0.0	0.0	0.2	0.5	1.8	77.3	0.6	0.0	0.4	0.2	0.1	0.1	1.4	0.2	1.4	6.1	0.6	0.4	1.8	7.1	0.3	0.0	1.3	0.6	0.2	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	21.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	89.8	0.2	11.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	49.6	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	45.5	0.0	3.8	0.3	0.5	384.7	0.4	56.7	0.2	6.8	33.5	0.3	0.0	2.3	21.7	1.8	87.5	0.3	0.5	0.1	43.7	1.4	1.5	1.3	2.2	1.3	1.5	1.7	2.0	1.0	1.8	1.4	1.8	1.4	0.5	0.0	1.1	0.0	2.1	0.0	1.3	0.0	0.0	0.0	1.8	0.6	0.2	0.0	0.6	0.0	0.0	0.0	95.8	0.1	0.0	0.0	2.3	0.0	0.1	0.5	1.2	2.7	0.0	0.0	0.0	0.5	0.5	0.1	0.0	0.0	2.2	0.9	0.1	0.0	0.0	0.2	0.0	1.9	0.0	0.9	0.0	2.1	0.0	0.0	19.5	0.0	230.7	0.0	0.0	0.0	0.0	0.0	14.3	61.9	0.0	0.3	0.7	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.0	0.1	65.6	0.0	0.3	1.2
TRGV9	"TCRGV9, V2"	ENSG00000211695	"T cell receptor gamma variable 9"	Q99603	7	38317017-38318861	"Predicted intracellular proteins, T-cell receptor genes"	"Adaptive immunity, Immunity, Innate immunity"	Receptor		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"placenta: 1.9;prostate: 5.5"	"Group enriched"	"Detected in some"	4	"dendritic cells: 14.6;NK-cells: 22.6;T-cells: 37.7"	"Cancer enriched"	"Detected in single"	126	"prostate cancer: 13.6"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in many"	13	"gdT-cell: 426.5"	"Lineage enriched"	"Detected in many"	13	"T-cells: 426.5"	"Group enriched"	"Detected in some"	6	"MCF7: 7.7;NB-4: 2.4;U-937: 8.6"	"Not detected"	"Not detected"													NA	NA						"unprognostic (1.07e-1)"	"unprognostic (1.18e-1)"			"unprognostic (1.30e-1)"	"unprognostic (3.98e-3)"	"unprognostic (4.43e-2)"	"unprognostic (4.13e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.51e-3)"	"unprognostic (2.41e-1)"	"unprognostic (6.60e-4)"	"unprognostic (1.29e-1)"	"unprognostic (4.95e-1)"	0.4	0.0	0.4	0.5	0.7	1.1	0.1	0.3	0.7	0.1	0.2	0.2	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.4	0.7	0.0	0.2	0.4	0.5	0.7	0.9	0.3	0.0	0.1	0.0	0.0	1.9	0.7	5.5	0.2	0.8	0.1	0.0	0.0	0.0	0.2	0.0	0.4	1.6	0.3	0.1	0.5	1.5	0.0	0.0	0.4	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	7.7	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	8.6	0.0	0.0	0.3	0.1	426.5	0.6	29.0	0.1	1.6	19.7	0.4	0.0	0.7	8.4	1.4	33.2	0.1	0.5	0.1	38.8	0.4	0.7	0.3	0.7	0.4	0.7	0.7	0.9	0.3	0.7	0.4	0.5	0.7	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	4.6	0.0	0.0	0.1	1.1	0.1	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	22.6	0.0	0.0	0.0	0.0	0.0	5.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.7	0.0	0.0	0.0
RLN1	H1	ENSG00000107018	"Relaxin 1"	P04808	9	5334930-5339876	"Plasma proteins, Predicted secreted proteins"		Hormone		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	71	"prostate: 23.7"	"Cell type enhanced"	"Detected in some"		"Cholangiocytes: 2.8;Enteroendocrine cells: 4.8;Prostatic glandular cells: 10.6;Spermatocytes: 2.4;Spermatogonia: 3.1"	"Cancer enriched"	"Detected in some"	106	"prostate cancer: 67.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HEL: 1.2"														"Secreted to blood"	NA	NA						"unprognostic (7.12e-6)"	"unprognostic (2.32e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.04e-1)"		"unprognostic (4.32e-2)"	"unprognostic (3.44e-1)"	"unprognostic (5.14e-2)"	"unprognostic (4.08e-4)"	"unprognostic (8.15e-2)"	"unprognostic (2.89e-4)"	"unprognostic (8.82e-3)"	"unprognostic (3.23e-2)"	"unprognostic (3.23e-2)"	"unprognostic (1.53e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	23.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.4	0.0	0.9	0.2	0.0	0.5	1.0	0.8	0.2	2.8	0.1	0.0	0.0	0.7	0.3	0.0	0.0	0.6	1.6	0.7	0.2	0.1	4.8	1.7	0.0	0.5	0.4	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.4	0.0	0.0	0.4	10.6	0.0	0.4	1.0	0.8	0.0	0.2	0.1	2.4	3.1	0.0	0.1	1.1	1.6	0.1	0.2	0.3
NKX3-1	"BAPX2, NKX3.1, NKX3A"	ENSG00000167034	"NK3 homeobox 1"	Q99801	8	23678697-23682938	"Cancer-related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"prostate: 306.0"	"Group enriched"	"Detected in many"	6	"Basal prostatic cells: 51.0;Prostatic glandular cells: 124.8"	"Cancer enriched"	"Detected in many"	65	"prostate cancer: 392.7"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"eosinophil: 54.0;neutrophil: 51.6"	"Lineage enriched"	"Detected in many"	21	"granulocytes: 54.0"	"Cell line enhanced"	"Detected in many"		"GAMG: 25.7;SiHa: 26.1;U-138 MG: 25.8;U-251 MG: 23.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA025693, HPA078571"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA025693: AB_1854522, HPA078571: AB_2732384"	"unprognostic (1.47e-2)"	"unprognostic (4.03e-2)"	"unprognostic (2.67e-1)"	"unprognostic (5.87e-2)"	"unprognostic (2.56e-6)"	"unprognostic (6.90e-3)"	"unprognostic (1.13e-1)"	"unprognostic (4.11e-3)"	"unprognostic (9.42e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.00e-2)"	"unprognostic (1.87e-1)"	"unprognostic (4.37e-2)"	"unprognostic (4.60e-2)"	"unprognostic (3.88e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.69e-1)"	1.6	3.9	1.3	1.5	1.3	2.2	2.1	1.6	1.5	1.1	1.1	1.1	1.4	1.6	1.3	3.8	1.8	1.1	2.6	1.3	2.9	1.0	4.1	1.4	1.2	1.8	1.3	0.9	2.8	1.8	1.0	0.9	0.8	1.7	306.0	0.5	1.7	62.5	1.8	3.3	0.4	1.0	1.9	1.7	0.8	1.4	24.2	1.6	0.5	0.7	3.9	1.6	3.0	1.9	1.8	4.9	3.7	0.0	8.7	3.1	0.7	7.1	6.7	4.2	13.8	16.2	2.1	5.5	0.0	1.0	5.0	25.7	1.2	3.5	7.6	10.9	0.0	1.8	3.4	2.6	5.5	6.0	0.0	1.2	1.2	2.0	14.0	0.8	8.5	0.7	20.1	0.2	0.0	5.5	1.6	11.8	1.0	2.0	0.0	2.6	0.0	5.5	0.5	0.8	5.7	1.6	0.4	26.1	4.8	0.4	9.9	3.5	0.5	0.9	25.8	9.1	2.0	23.0	0.0	0.0	0.0	12.5	2.6	3.2	10.2	0.0	54.0	1.0	0.1	0.2	2.2	0.4	1.0	0.1	1.8	1.4	2.5	51.6	0.6	0.1	0.0	0.0	0.3	1.3	1.3	1.6	1.5	1.3	2.9	1.8	1.3	0.9	1.7	1.7	1.6	1.8	6.0	3.2	5.3	0.0	4.1	5.6	51.0	4.1	4.6	3.7	13.5	6.5	9.8	1.5	4.7	0.0	8.4	0.3	0.3	1.0	0.0	2.7	2.7	1.3	2.0	6.8	6.6	0.0	0.4	7.0	1.4	9.1	5.1	2.2	0.0	0.8	4.6	4.9	0.3	3.3	0.4	1.2	2.0	0.3	9.4	6.1	2.1	2.5	1.8	0.0	0.6	4.9	0.0	0.5	0.1	5.2	0.1	6.4	1.0	124.8	0.4	0.7	1.4	4.5	0.0	11.4	5.1	1.8	2.1	2.5	2.0	0.3	2.5	0.8	1.1	12.2
OR51C1P	"OR51C2P, OR51C3P, OST734"	ENSG00000197674	"Olfactory receptor family 51 subfamily C member 1 pseudogene"		11	4690423-4697831	"Predicted membrane proteins"				"No human protein/transcript evidence"	"No human protein/transcript evidence"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	18	"Enteroendocrine cells: 1.8"	"Cancer enriched"	"Detected in single"	65	"prostate cancer: 3.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA																	"unprognostic (1.82e-1)"						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KLK4	"EMSP, EMSP1, KLK-L1, PRSS17, PSTS"	ENSG00000167749	"Kallikrein related peptidase 4"	Q9Y5K2	19	50906352-50910738	"Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	Biomineralization	"Hydrolase, Protease, Serine protease"	"Amelogenesis imperfecta, Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	32	"prostate: 288.8"	"Cell type enriched"	"Detected in some"	15	"Prostatic glandular cells: 106.1"	"Cancer enriched"	"Detected in many"	55	"prostate cancer: 463.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 6.4;HaCaT: 7.9;OE19: 7.3;SK-BR-3: 5.1"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"spinal cord: 4.5"	HPA051839	Enhanced				"Secreted in male reproductive system"	NA	NA					"HPA051839: AB_2681632"	"unprognostic (3.58e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.66e-3)"	"unprognostic (3.11e-2)"	"unprognostic (4.35e-1)"	"unprognostic (3.18e-1)"	"unprognostic (6.66e-2)"	"unprognostic (9.69e-2)"	"unprognostic (8.23e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.07e-1)"	"unprognostic (4.20e-3)"	"unprognostic (3.27e-3)"	"unprognostic (2.21e-2)"	"unprognostic (1.64e-2)"	"unprognostic (1.34e-1)"	0.4	2.9	0.6	1.5	0.3	1.1	1.7	1.6	1.1	4.6	0.0	3.0	7.3	4.4	1.1	2.1	0.6	1.0	0.1	0.3	0.3	0.6	1.2	0.3	0.8	1.5	0.7	0.1	0.1	0.9	1.0	0.0	0.3	1.4	288.8	3.7	0.5	4.9	2.7	3.5	9.0	5.1	0.3	0.4	0.3	1.9	1.2	0.5	0.1	3.9	1.3	0.8	1.2	0.2	1.1	4.1	1.6	0.2	0.2	0.0	0.0	3.5	0.0	0.0	0.0	0.0	3.5	6.4	0.4	0.3	0.1	0.2	7.9	0.0	4.2	0.0	1.1	1.1	1.3	3.8	1.4	0.0	1.4	1.7	0.0	1.9	0.0	0.0	0.2	0.0	0.3	0.7	3.3	0.0	1.0	0.1	2.0	0.1	7.3	0.3	0.3	0.4	0.9	0.0	2.6	0.0	0.4	0.3	5.1	0.0	0.2	4.0	0.3	0.9	0.2	0.2	1.0	0.2	2.0	0.9	0.4	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	1.6	1.1	0.3	0.3	1.5	0.7	0.1	1.4	0.4	0.5	1.1	0.1	0.0	0.0	0.0	0.0	0.3	3.6	0.0	0.0	0.6	0.5	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.6	0.0	2.6	0.1	0.0	0.0	0.1	0.2	0.0	1.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.7	0.0	0.0	0.0	0.4	0.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	106.1	0.2	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.3	0.0	0.6	0.0	0.0	3.3	1.0	2.6
SLC45A3	"IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein"	ENSG00000158715	"Solute carrier family 45 member 3"	Q96JT2	1	205657851-205680509	"Cancer-related genes, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"prostate: 309.1"	"Cell type enhanced"	"Detected in many"		"Gastric mucus-secreting cells: 19.9;granulocytes: 119.2;Oligodendrocytes: 47.1;Prostatic glandular cells: 67.2"	"Cancer enriched"	"Detected in all"	49	"prostate cancer: 539.9"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	382	"basophil: 40.5"	"Lineage enriched"	"Detected in single"	382	"granulocytes: 40.5"	"Cell line enriched"	"Detected in many"	29	"HMC-1: 834.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA019073, HPA019075"	Enhanced		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA019073: AB_1857177, HPA019075: AB_1857179"	"unprognostic (1.80e-1)"	"unprognostic (1.08e-3)"	"unprognostic (3.13e-2)"	"prognostic unfavorable (4.04e-5)"	"unprognostic (6.93e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.03e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.96e-1)"	"prognostic favorable (7.33e-5)"	1.3	3.6	6.2	3.2	14.9	0.8	1.6	14.6	9.7	3.8	0.3	4.8	4.6	1.7	0.5	1.6	2.1	3.9	1.5	5.1	10.2	2.2	11.3	3.5	2.7	18.4	15.4	2.2	2.7	0.8	0.3	4.7	0.5	18.9	309.1	3.2	0.2	2.8	0.6	5.7	1.4	4.8	1.0	13.7	12.5	17.0	1.4	13.3	0.5	1.0	2.3	0.8	2.8	1.1	42.3	9.7	3.0	2.8	2.7	0.0	0.1	2.2	1.3	0.3	3.3	2.7	7.1	18.0	2.7	4.6	0.3	3.0	3.5	1.6	3.3	0.5	3.9	2.9	29.0	0.6	2.0	1.9	5.0	834.2	0.3	1.1	2.3	0.0	2.2	9.4	4.5	4.9	1.7	1.4	2.3	0.8	8.5	12.2	16.7	10.7	1.0	4.1	1.5	3.7	13.7	1.2	2.9	1.5	20.6	3.9	2.3	4.7	1.4	9.6	1.4	9.5	3.5	7.1	0.4	0.6	0.4	1.8	1.5	7.1	40.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.2	14.9	14.6	9.7	5.1	10.2	18.4	15.4	2.2	18.9	13.7	13.3	42.3	0.2	0.0	3.2	1.0	4.0	0.0	1.0	0.6	0.0	0.4	1.5	1.8	2.0	2.8	1.0	1.8	0.0	0.5	0.1	5.7	0.0	1.7	0.2	1.9	0.2	1.7	0.0	3.4	0.2	0.5	0.1	0.7	19.9	0.2	119.2	0.2	0.7	6.6	1.9	0.0	0.3	6.9	2.0	1.0	0.3	0.4	1.8	2.0	0.0	0.0	0.6	0.1	0.0	2.0	47.1	3.9	8.0	1.5	0.3	67.2	0.9	1.8	3.2	0.1	6.6	0.1	0.8	0.0	2.6	0.4	0.1	0.0	0.9	0.2	6.7	0.9
MYL2	CMH10	ENSG00000111245	"Myosin light chain 2"	P10916	12	110910819-110921443	"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Predicted intracellular proteins"		"Motor protein, Muscle protein, Myosin"	"Cardiomyopathy, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	70	"heart muscle: 26352.1;skeletal muscle: 29242.5;tongue: 19998.9"	"Cell type enriched"	"Detected in some"	80	"Cardiomyocytes: 27611.5"	"Group enriched"	"Detected in some"	46	"head and neck cancer: 31.5;prostate cancer: 25.5"	"Region enriched"	"Detected in single"	8	"hypothalamus: 5.3"	"Group enriched"	"Detected in some"	12	"memory B-cell: 1.1;naive B-cell: 1.2"	"Lineage enriched"	"Detected in single"	12	"B-cells: 1.2"	"Cell line enhanced"	"Detected in some"		"EFO-21: 4.2;HSkMC: 8.8;U-2 OS: 17.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA019763, HPA039262"	Supported		Uncertain	Microtubules		NA	NA		180000	Microtubules		"HPA019763: AB_1854243, HPA039262: AB_2676418"	"unprognostic (2.07e-2)"	"unprognostic (1.37e-1)"		"unprognostic (1.39e-1)"		"prognostic unfavorable (2.60e-4)"		"unprognostic (1.32e-1)"	"unprognostic (4.05e-2)"	"unprognostic (4.82e-2)"	"unprognostic (2.05e-2)"	"unprognostic (2.20e-1)"		"unprognostic (1.76e-1)"	"unprognostic (2.84e-1)"	"unprognostic (3.55e-1)"		6.2	4.5	0.0	0.1	0.0	0.7	29.7	0.0	0.0	1.5	0.0	3.7	0.6	2.2	0.0	360.1	0.5	9.5	26352.1	0.0	5.3	2.9	5.5	5.1	15.3	0.6	0.5	0.0	2.4	5.8	0.0	2.5	0.1	0.2	252.0	0.1	0.0	109.6	0.2	29242.5	12.6	3.2	0.3	0.1	2.1	3.5	2.1	0.0	1.0	13.5	19998.9	1.1	2.2	4.0	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	4.2	0.0	0.2	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	8.8	0.0	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	17.7	0.0	0.1	0.0	0.0	1.7	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.6	0.5	0.0	0.2	0.1	0.0	0.1	1.1	0.0	0.0	0.0	1.5	0.1	0.0	0.1	0.0	0.0	0.0	0.0	27611.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	235.7	0.0	0.0	0.0	0.0	0.0	53.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	4.2	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	342.2	138.8	0.1	0.1	0.0	0.0	0.0	3.3	0.0	0.1	0.0
LMAN1L	"ERGIC-53L, ERGL"	ENSG00000140506	"Lectin, mannose binding 1 like"	Q9HAT1	15	74812716-74825757	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"heart muscle: 20.8;lymphoid tissue: 25.9;prostate: 61.4;salivary gland: 20.9"	"Cell type enhanced"	"Detected in some"		"Cone photoreceptor cells: 2.1;Late spermatids: 2.6;Prostatic glandular cells: 10.9;Spermatocytes: 7.3;Spermatogonia: 2.4"	"Cancer enriched"	"Detected in single"	45	"prostate cancer: 2.2"	"Region enhanced"	"Detected in many"		"cerebellum: 11.4"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"Daudi: 1.1"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"spinal cord: 1.4"							NA	NA										"unprognostic (4.51e-1)"							"unprognostic (2.44e-1)"		"unprognostic (4.26e-2)"	"unprognostic (3.09e-1)"			0.0	1.8	0.1	0.2	0.6	0.0	0.0	11.4	0.7	0.1	0.0	0.1	0.1	0.0	0.3	0.6	0.0	0.0	20.8	0.2	0.2	0.0	0.0	0.0	0.3	2.1	0.7	0.0	0.0	0.0	0.0	0.2	0.0	8.3	61.4	0.1	4.2	20.9	0.0	0.1	0.1	0.3	0.0	2.2	25.9	4.7	1.3	0.2	0.1	0.0	0.0	0.1	0.1	0.1	3.8	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.1	0.0	0.3	0.0	0.1	0.7	0.0	0.0	0.7	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	11.4	0.7	0.2	0.2	2.1	0.7	0.0	8.3	2.2	0.2	3.8	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	1.2	0.1	0.1	0.1	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.1	0.0	1.3	0.0	0.0	0.4	7.3	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2
BEND4	"CCDC4, FLJ35632, FLJ43965"	ENSG00000188848	"BEN domain containing 4"	Q6ZU67	4	42110853-42152878	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 3.2;prostate: 3.3;testis: 9.5"	"Cell type enhanced"	"Detected in some"		"B-cells: 8.1;Inhibitory neurons: 6.2;Muller glia cells: 10.7;Spermatogonia: 38.3"	"Group enriched"	"Detected in some"	43	"prostate cancer: 6.3;testis cancer: 5.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 33.2;HEK 293: 7.9;HEL: 21.1;MOLT-4: 13.1;SuSa: 15.4;U-698: 13.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA036850	Uncertain		Approved	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"		NA	NA			"Nucleoli fibrillar center"	"Nucleoplasm, Cytosol"	"HPA036850: AB_10600787"	"unprognostic (3.62e-4)"	"unprognostic (3.82e-1)"	"unprognostic (4.82e-2)"	"unprognostic (5.96e-3)"	"unprognostic (2.97e-3)"	"unprognostic (1.10e-1)"	"unprognostic (3.81e-2)"	"unprognostic (4.00e-1)"	"unprognostic (2.97e-1)"	"unprognostic (5.58e-2)"	"unprognostic (6.71e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.54e-5)"	"unprognostic (3.48e-1)"	"unprognostic (1.49e-1)"	"unprognostic (4.58e-3)"	"unprognostic (4.24e-1)"	0.0	0.0	0.8	1.1	0.8	0.8	0.0	0.0	1.5	0.0	0.1	0.2	0.2	0.1	0.0	0.0	0.0	0.1	0.0	1.4	0.9	0.0	0.1	0.2	2.1	1.2	3.2	0.7	0.1	0.0	0.0	1.0	0.3	2.1	3.3	0.2	1.1	0.0	0.0	0.0	0.0	1.2	0.1	0.2	1.2	0.2	9.5	1.1	1.1	0.0	0.0	1.6	0.2	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.6	0.0	33.2	0.0	0.0	0.0	7.9	21.1	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.4	0.0	7.0	0.0	0.1	0.0	0.0	13.1	0.0	6.2	0.0	1.9	0.0	0.0	0.0	0.0	0.0	4.7	0.8	0.0	0.0	0.0	15.4	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.2	13.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.0	1.5	1.4	0.9	1.2	3.2	0.7	2.1	0.2	1.1	1.6	0.4	0.0	0.0	0.0	8.1	0.0	0.1	0.0	0.0	1.2	0.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.6	0.0	3.4	4.4	0.0	0.0	0.3	0.0	0.0	0.0	4.8	2.5	0.0	0.0	3.3	6.2	0.0	0.0	0.0	0.0	1.5	0.0	0.3	0.0	0.0	0.1	10.7	0.0	3.5	0.2	0.0	0.0	0.0	3.9	1.7	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.6	38.3	0.0	0.0	0.0	1.5	2.2	0.0	0.0
MSMB	"IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94"	ENSG00000263639	"Microseminoprotein beta"	P08118	10	46033307-46048180	"Cancer-related genes, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	17	"prostate: 9466.5"	"Cell type enriched"	"Detected in many"	4	"Prostatic glandular cells: 10715.4"	"Cancer enriched"	"Detected in many"	42	"prostate cancer: 3435.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 25.6;NB-4: 21.6;RPMI-8226: 11.3;SH-SY5Y: 6.1;SK-BR-3: 5.9;U-2197: 12.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB026357, HPA051257"	Enhanced				"Secreted in male reproductive system"	NA	NA		6000000			"CAB026357: , HPA051257: AB_2681410"	"unprognostic (6.47e-2)"	"unprognostic (7.21e-3)"		"unprognostic (1.37e-2)"		"unprognostic (8.18e-3)"	"unprognostic (4.28e-3)"	"unprognostic (9.24e-3)"	"unprognostic (1.66e-1)"	"unprognostic (8.66e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.55e-2)"		"unprognostic (2.01e-1)"	"unprognostic (7.04e-2)"	"unprognostic (1.39e-1)"	"prognostic favorable (7.19e-4)"	5.1	4.6	0.0	3.0	0.0	0.1	20.7	0.0	0.0	3.2	0.0	1.6	10.4	0.3	45.5	12.4	4.7	3.0	0.5	0.0	0.0	1.8	1.8	30.2	0.2	0.0	0.0	0.0	0.3	2.3	0.2	0.5	0.6	0.0	9466.5	0.1	0.0	32.1	0.6	0.4	36.5	2.3	0.0	0.0	0.7	557.1	10.2	0.0	1.1	0.8	0.0	10.1	7.2	2.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	25.6	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.9	0.0	0.0	0.3	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.4	21.6	0.2	0.0	0.0	0.0	0.0	11.3	0.0	1.6	1.0	6.1	0.0	5.9	0.0	0.2	0.4	0.0	0.0	0.0	0.0	12.2	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.3	0.0	195.9	586.4	0.0	0.0	6.4	1.3	0.0	4.3	2203.2	0.0	0.0	2.1	0.1	0.3	0.0	0.1	48.9	0.6	0.0	10.7	0.0	0.0	0.1	0.2	0.4	9.5	404.2	0.2	1.3	0.0	0.0	1.2	0.2	0.0	0.0	0.8	419.1	0.0	0.0	78.8	0.3	30.5	3.6	0.0	0.0	0.0	0.0	0.0	0.0	1.8	29.6	0.0	0.8	10715.4	0.3	0.0	570.6	0.0	0.0	0.0	271.0	0.5	1.4	0.0	0.4	1.5	14.3	0.0	0.1	192.4
POTEH	"A26C3, ACTBL1, CT104.7, POTE22"	ENSG00000198062	"POTE ankyrin domain family member H"	Q6S545	22	15690026-15721631	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	19	"prostate: 2.2;testis: 1.5"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	28	"prostate cancer: 1.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																	NA	NA						"unprognostic (4.66e-2)"											"unprognostic (1.02e-1)"						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FOLH1	"FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA"	ENSG00000086205	"Folate hydrolase 1"	Q04609	11	49145092-49208638	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Carboxypeptidase, Dipeptidase, Hydrolase, Metalloprotease, Multifunctional enzyme, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 268.8;prostate: 76.7"	"Cell type enriched"	"Detected in some"	8	"Oligodendrocytes: 367.6"	"Cancer enriched"	"Detected in many"	27	"prostate cancer: 142.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 2.3;RPMI-8226: 1.7;SK-BR-3: 1.8;TIME: 1.3;WM-115: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001451, HPA010593"	Enhanced					NA	NA					"CAB001451: AB_563979, HPA010593: AB_1079685"	"unprognostic (1.33e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (5.24e-5)"	"unprognostic (2.55e-1)"	"unprognostic (8.31e-2)"	"prognostic favorable (4.25e-4)"	"unprognostic (1.32e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.67e-3)"	"unprognostic (2.13e-2)"	"unprognostic (2.72e-1)"	"prognostic unfavorable (1.30e-6)"	"unprognostic (4.81e-2)"	"unprognostic (7.27e-2)"	"unprognostic (4.74e-3)"	"unprognostic (4.04e-1)"	1.9	1.2	18.9	0.9	34.0	0.7	4.8	25.8	24.0	1.9	7.5	0.7	268.8	1.7	0.9	1.5	3.6	10.3	0.5	17.5	24.7	13.6	35.8	1.3	0.9	32.5	28.6	13.0	1.0	0.4	0.2	0.0	0.3	31.5	76.7	0.5	4.0	53.3	0.6	0.2	1.7	83.6	1.0	26.4	2.4	1.1	0.8	27.2	0.1	1.0	0.2	0.6	1.4	0.3	60.0	0.1	0.0	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.1	0.1	2.3	0.2	0.0	0.5	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.4	0.0	0.0	0.1	0.1	1.7	0.0	0.0	0.2	0.7	0.0	1.8	0.3	0.2	0.3	0.0	1.3	0.1	0.9	0.2	0.1	0.0	0.2	0.0	0.0	0.4	2.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	18.9	34.0	25.8	24.0	17.5	24.7	32.5	28.6	13.0	31.5	26.4	27.2	60.0	0.5	0.0	0.6	0.0	0.0	0.3	0.7	0.1	0.6	0.0	8.2	7.0	0.3	0.0	1.9	0.0	0.0	0.0	0.5	0.0	7.9	0.0	5.2	2.1	0.5	5.0	0.0	0.0	0.5	0.0	0.0	2.2	0.0	2.8	0.0	0.0	2.9	25.9	0.1	0.0	1.0	1.1	0.0	0.3	0.0	1.4	1.5	0.2	3.6	1.0	0.0	17.4	0.0	0.0	367.6	0.0	1.2	0.4	0.0	43.0	0.8	32.4	0.1	0.6	0.0	0.0	0.4	1.1	1.5	1.5	0.9	0.0	0.2	0.5	0.2	0.6
TRPM8		ENSG00000144481	"Transient receptor potential cation channel subfamily M member 8"	Q7Z2W7	2	233917373-234019522	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sensory transduction, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	57	"liver: 31.7;prostate: 80.9"	"Group enriched"	"Detected in some"	5	"Hepatocytes: 45.2;Prostatic glandular cells: 16.3"	"Cancer enriched"	"Detected in some"	27	"prostate cancer: 72.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"GAMG: 3.4;Karpas-707: 5.5;RPTEC TERT1: 8.1;SK-MEL-30: 8.9;WM-115: 5.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (4.41e-3)"	"unprognostic (7.91e-2)"	"unprognostic (1.11e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.05e-1)"	"unprognostic (4.60e-3)"	"prognostic favorable (7.15e-4)"	"unprognostic (3.28e-2)"	"unprognostic (3.71e-1)"	"unprognostic (9.88e-3)"	"unprognostic (7.10e-3)"	"unprognostic (4.69e-2)"	"unprognostic (3.36e-5)"	"unprognostic (1.11e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.18e-1)"	"unprognostic (5.53e-2)"	0.0	0.2	0.6	0.2	0.3	0.1	0.0	0.3	0.3	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.4	0.2	0.1	31.7	0.0	0.1	0.2	0.9	0.2	0.0	0.0	0.1	0.5	0.0	0.3	80.9	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.9	0.2	0.4	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.5	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.4	0.6	8.1	0.0	0.5	0.3	0.0	0.1	8.9	0.0	0.3	0.5	0.0	0.0	0.0	0.2	0.0	1.2	2.0	0.0	0.7	0.0	5.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.6	0.3	0.3	0.3	0.4	0.2	0.2	0.9	0.2	0.3	0.1	0.2	0.7	0.0	0.0	0.0	0.0	0.0	0.4	5.5	0.1	0.0	0.7	0.2	0.0	1.1	2.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.4	2.3	1.2	0.6	0.5	0.0	2.7	0.3	1.7	0.0	0.3	0.0	4.4	0.0	0.1	0.7	45.2	0.3	0.0	0.9	0.0	0.0	0.6	0.8	3.9	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.1	16.3	0.0	0.0	0.0	0.2	0.0	0.4	0.2	1.3	0.6	0.0	0.1	0.0	0.5	0.0	0.0	4.1
SEMG2	SGII	ENSG00000124157	"Semenogelin 2"	Q02383	20	45221373-45224458	"Plasma proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	149	"seminal vesicle: 10504.6"	"Group enriched"	"Detected in some"	9	"Basal prostatic cells: 1.2;Collecting duct cells: 3.7;Early spermatids: 1.2;Late spermatids: 1.8;Prostatic glandular cells: 1.9"	"Cancer enriched"	"Detected in single"	25	"prostate cancer: 9.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA042767, HPA042835"	Enhanced				"Secreted in male reproductive system"	NA	NA		5000000			"HPA042767: AB_10959312, HPA042835: AB_10964060"												"unprognostic (1.39e-1)"		"unprognostic (2.17e-1)"				0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	70.4	0.0	0.0	0.0	10504.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PABPC1L2B	RBM32B	ENSG00000184388	"Poly(A) binding protein cytoplasmic 1 like 2B"	Q5JQF8	X	73002939-73006106	"Predicted intracellular proteins"		RNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 5.8;pituitary gland: 2.1;prostate: 2.7;salivary gland: 2.1;testis: 1.7"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 1.7;Excitatory neurons: 2.2;Inhibitory neurons: 2.7;Oligodendrocytes: 1.7"	"Cancer enriched"	"Detected in single"	23	"prostate cancer: 2.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"NTERA-2: 1.1"									HPA041573	Approved					NA	NA					"HPA041573: AB_2677556"					"unprognostic (1.73e-1)"							"unprognostic (2.26e-1)"			"unprognostic (3.31e-1)"			0.0	0.6	2.1	0.0	2.3	0.0	0.0	0.5	5.8	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	1.7	2.8	0.0	0.0	0.0	0.0	2.0	1.4	2.2	0.0	0.0	0.0	2.1	0.0	2.0	2.7	0.0	0.4	2.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.7	1.7	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.3	0.5	5.8	1.7	2.8	2.0	1.4	2.2	2.0	0.1	1.7	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0
OR51E1	"GPR136, GPR164, OR51E1P, OR52A3P"	ENSG00000180785	"Olfactory receptor family 51 subfamily E member 1"	Q8TCB6	11	4643420-4655488	"G-protein coupled receptors, Predicted membrane proteins"	"Olfaction, Sensory transduction"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adipose tissue: 5.8;placenta: 7.5;prostate: 6.6"	"Group enriched"	"Detected in some"	7	"Adipocytes: 44.1;Enteroendocrine cells: 21.3;Sertoli cells: 26.3;Smooth muscle cells: 31.8"	"Cancer enriched"	"Detected in many"	21	"prostate cancer: 34.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	107	"SCLC-21H: 10.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB019995, HPA051439"	Approved					NA	NA					"CAB019995: AB_10283600, HPA051439: AB_2681487"	"unprognostic (6.67e-3)"	"unprognostic (2.34e-3)"	"unprognostic (9.71e-2)"	"unprognostic (4.87e-5)"	"unprognostic (3.55e-2)"	"unprognostic (9.80e-3)"	"unprognostic (1.76e-1)"	"unprognostic (2.30e-3)"	"unprognostic (2.00e-2)"	"unprognostic (3.94e-3)"	"unprognostic (7.36e-2)"	"unprognostic (6.15e-2)"	"prognostic unfavorable (1.23e-6)"	"unprognostic (2.72e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.61e-1)"	"unprognostic (2.86e-1)"	5.8	0.0	0.2	0.7	0.2	0.0	2.4	0.2	0.4	0.4	0.3	1.6	0.4	0.9	0.3	0.1	0.6	0.5	2.6	0.2	0.2	0.7	0.0	0.0	0.1	0.2	0.2	0.1	0.5	0.1	0.1	0.5	7.5	0.2	6.6	0.8	0.0	0.2	0.6	2.1	0.2	1.3	1.0	0.2	0.1	0.7	0.2	0.2	0.0	0.5	4.0	0.2	0.6	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.4	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	44.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.1	0.3	3.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.1	0.3	4.1	21.3	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	1.7	0.0	0.0	0.1	0.0	0.0	3.2	0.0	0.0	0.5	0.0	0.3	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	3.4	0.1	0.0	0.0	0.0	26.3	0.7	31.8	0.0	0.2	0.1	0.3	0.0	0.1	0.8	0.1	0.2
TMEFF2	"CT120.2, HPP1, TENB2, TPEF, TR"	ENSG00000144339	"Transmembrane protein with EGF like and two follistatin like domains 2"	Q9UIK5	2	191949043-192194933	"Predicted membrane proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 33.7;prostate: 36.9;seminal vesicle: 13.4"	"Cell type enhanced"	"Detected in some"		"Excitatory neurons: 416.1;Inhibitory neurons: 382.0;Oligodendrocyte precursor cells: 210.6;Oligodendrocytes: 1337.5"	"Cancer enriched"	"Detected in some"	21	"prostate cancer: 57.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"AF22: 36.9;LHCN-M2: 107.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA015587	Approved				"Secreted in male reproductive system"	NA	NA					"HPA015587: AB_1858069"	"unprognostic (2.12e-3)"	"unprognostic (5.37e-1)"	"unprognostic (3.10e-1)"	"unprognostic (5.89e-7)"	"unprognostic (4.96e-2)"	"unprognostic (1.27e-1)"	"unprognostic (8.82e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.86e-1)"	"unprognostic (5.55e-2)"	"unprognostic (2.09e-2)"	"unprognostic (3.79e-2)"	"unprognostic (4.17e-3)"	"unprognostic (1.55e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.20e-1)"	0.2	2.3	30.8	0.1	25.9	0.0	0.3	15.6	28.3	0.1	6.4	0.9	0.6	0.0	8.2	1.2	0.1	1.7	1.1	28.7	24.7	0.0	0.0	0.1	0.0	24.3	22.7	26.8	0.2	0.0	0.0	0.3	0.0	26.1	36.9	1.5	3.4	0.1	13.4	0.3	0.2	0.6	0.1	17.4	0.0	0.9	0.7	26.7	0.0	0.2	0.6	0.1	0.8	0.5	33.7	0.0	0.9	36.9	0.0	5.6	5.8	0.1	0.1	0.7	1.8	2.2	0.0	0.0	0.0	0.0	10.3	4.5	0.0	2.3	0.0	7.1	0.0	0.1	0.1	0.3	0.0	0.7	0.0	0.0	15.6	0.0	2.0	10.8	9.0	0.1	0.0	0.0	0.0	107.1	0.0	0.0	0.1	2.8	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.3	0.8	0.0	0.0	0.0	0.4	0.0	0.0	0.0	2.1	0.0	0.2	2.8	0.0	0.0	0.0	7.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.8	25.9	15.6	28.3	28.7	24.7	24.3	22.7	26.8	26.1	17.4	26.7	33.7	0.1	0.0	0.0	11.8	0.0	0.1	0.1	0.0	0.0	16.6	0.0	0.0	1.7	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.3	0.0	0.0	416.1	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	102.6	382.0	0.5	0.0	0.0	0.7	2.3	26.4	0.0	0.0	11.2	0.0	0.6	0.0	210.6	1337.5	0.0	0.0	8.6	0.0	5.7	0.1	0.0	0.0	1.6	6.6	24.6	0.6	1.2	2.6	0.3	0.3	0.0	0.4	0.0	0.0	0.1
GNMT		ENSG00000124713	"Glycine N-methyltransferase"	Q14749	6	42960754-42963880	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		"Methyltransferase, Transferase"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"liver: 298.9;pancreas: 605.1"	"Cell type enriched"	"Detected in many"	10	"Hepatocytes: 842.9"	"Group enriched"	"Detected in many"	20	"liver cancer: 69.6;prostate cancer: 49.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"Hep G2: 8.5;SCLC-21H: 9.5;T-47d: 6.1"	"Region enriched"	"Detected in some"	4	"cerebellum: 15.7"	"Low region specificity"	"Detected in many"			HPA027501	Enhanced		Approved	Cytosol		NA	NA		390000	Cytosol		"HPA027501: AB_1849879"	"unprognostic (1.53e-2)"	"unprognostic (8.02e-4)"	"unprognostic (3.11e-2)"	"unprognostic (4.24e-3)"	"unprognostic (3.91e-2)"	"unprognostic (6.40e-4)"	"prognostic favorable (1.86e-4)"	"unprognostic (4.08e-6)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-2)"	"unprognostic (1.63e-3)"	"unprognostic (2.52e-1)"	"unprognostic (3.50e-3)"	"unprognostic (1.03e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.49e-2)"	"unprognostic (4.92e-2)"	0.8	0.9	2.8	1.3	2.9	3.9	7.1	3.1	2.8	0.8	2.3	0.6	0.2	0.9	2.2	0.6	1.4	0.5	3.2	2.9	2.5	0.9	298.9	2.0	1.0	2.2	1.7	2.8	1.9	605.1	0.2	8.5	0.4	2.4	20.5	0.3	2.2	9.8	1.2	1.9	0.9	1.6	0.5	1.8	2.9	51.2	0.7	2.2	1.8	1.9	0.4	1.2	0.8	0.7	2.8	0.4	0.3	1.4	3.9	0.4	0.1	0.2	0.3	1.6	0.6	0.9	0.0	0.1	1.3	0.1	0.3	0.7	0.4	0.2	0.2	0.2	1.6	1.2	1.0	0.9	8.5	0.0	0.9	1.8	0.3	0.0	0.3	0.1	0.9	0.0	3.0	1.2	1.5	0.2	1.8	1.6	3.0	0.1	0.4	0.4	1.4	1.3	0.8	0.6	0.2	9.5	1.3	0.1	1.3	0.6	0.4	6.1	2.8	0.3	0.7	0.7	0.4	0.8	1.0	1.0	1.1	0.1	1.6	0.8	0.0	0.1	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.2	0.0	0.1	0.2	0.5	0.0	0.0	0.7	0.0	0.1	2.8	2.9	3.1	2.8	2.9	2.5	2.2	1.7	2.8	2.4	1.8	2.2	2.8	0.3	0.0	2.2	5.5	2.8	0.3	5.2	0.7	0.0	1.7	10.2	14.7	5.4	24.3	0.2	1.8	0.0	0.1	1.7	0.0	3.9	0.5	0.2	1.6	0.2	2.2	0.0	77.9	18.4	0.9	0.1	0.3	0.5	0.8	0.0	2.6	24.3	842.9	0.7	1.7	18.2	0.0	6.1	28.9	0.7	0.1	0.9	1.1	0.0	11.2	0.3	0.2	0.0	7.1	4.7	0.6	0.0	2.6	0.5	17.9	0.3	3.4	4.6	0.3	0.0	0.2	0.6	0.6	0.7	0.0	0.1	0.1	3.0	0.0	0.2	1.9
LMOD2		ENSG00000170807	"Leiomodin 2"	Q6P5Q4	7	123655866-123664290	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	39	"heart muscle: 785.5;skeletal muscle: 942.6;tongue: 800.6"	"Cell type enriched"	"Detected in some"	26	"Cardiomyocytes: 1432.4"	"Group enriched"	"Detected in some"	20	"head and neck cancer: 3.5;prostate cancer: 1.4"	"Region enhanced"	"Detected in single"		"midbrain: 1.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HSkMC: 1.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA046370, HPA051039"	Enhanced		Uncertain	"Plasma membrane,Actin filaments,Cytosol"		NA	NA			"Plasma membrane"	"Actin filaments, Cytosol"	"HPA046370: , HPA051039: AB_2681321"	"unprognostic (2.55e-1)"			"unprognostic (1.14e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.38e-3)"	"unprognostic (1.18e-1)"	"unprognostic (5.50e-1)"	"unprognostic (5.69e-2)"	"unprognostic (6.98e-2)"		"unprognostic (2.13e-2)"	"unprognostic (1.43e-3)"	"unprognostic (3.37e-2)"	"unprognostic (1.51e-1)"		"unprognostic (1.82e-3)"	0.2	0.1	0.2	0.0	0.0	0.6	0.5	0.1	0.5	0.0	0.2	0.1	0.0	0.0	0.0	21.4	0.0	0.1	785.5	0.3	0.0	0.0	0.2	0.3	0.3	0.0	1.0	0.0	0.1	0.2	0.0	0.1	0.8	0.0	10.3	0.0	0.1	10.1	0.0	942.6	0.3	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.2	0.2	800.6	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.5	0.3	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1432.4	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	1.4	0.5	0.4	9.4	0.0	0.0	0.1	0.0	0.1	27.2	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	54.9	7.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
SLC30A4	ZNT4	ENSG00000104154	"Solute carrier family 30 member 4"	O14863	15	45479606-45522755	"Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport, Zinc transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"prostate: 40.2"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 76.3;Late spermatids: 78.5;Prostatic glandular cells: 39.2;Spermatocytes: 52.1"	"Cancer enriched"	"Detected in all"	20	"prostate cancer: 34.3"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.64e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.71e-1)"	"unprognostic (9.49e-2)"	"unprognostic (1.98e-1)"	"unprognostic (3.29e-2)"	"unprognostic (6.15e-2)"	"unprognostic (9.74e-2)"	"unprognostic (7.38e-3)"	"unprognostic (1.51e-1)"	"prognostic favorable (6.02e-4)"	"unprognostic (2.66e-2)"	"unprognostic (4.72e-3)"	"unprognostic (1.29e-2)"	"unprognostic (9.83e-2)"	"unprognostic (8.28e-3)"	"unprognostic (2.01e-3)"	2.8	1.8	2.9	1.9	8.3	0.8	1.9	3.5	4.5	2.4	1.8	3.3	7.0	2.9	2.8	4.2	2.0	2.0	2.0	3.0	3.0	4.2	2.6	1.8	2.8	3.2	3.2	3.7	2.5	1.9	4.2	1.5	3.4	3.6	40.2	3.1	3.8	1.4	2.2	1.7	2.5	8.6	3.4	2.3	3.1	2.0	6.4	3.9	1.0	4.8	1.9	3.4	1.8	2.6	7.7	1.8	2.1	0.6	4.7	8.3	5.8	0.4	4.5	4.1	2.7	3.8	0.3	1.5	6.9	1.5	4.7	1.1	1.2	2.0	2.1	2.5	1.7	1.8	0.1	2.0	0.1	5.3	0.1	3.5	4.9	3.4	3.6	0.9	4.2	3.2	3.2	1.0	3.8	5.1	0.8	2.4	0.3	0.1	0.4	0.4	3.6	4.0	1.1	2.2	0.4	1.5	2.3	3.0	3.4	0.8	0.6	2.9	0.2	6.1	4.0	2.3	4.9	1.5	7.0	5.5	1.7	1.7	0.2	3.1	1.3	0.1	0.1	2.2	0.1	2.1	2.0	1.5	1.3	0.2	3.5	1.5	2.1	0.5	1.3	0.1	0.2	0.2	0.7	2.9	8.3	3.5	4.5	3.0	3.0	3.2	3.2	3.7	3.6	2.3	3.9	7.7	6.7	3.2	3.9	5.5	6.6	6.8	2.2	1.1	6.8	3.2	2.8	2.2	3.1	0.0	0.1	1.8	16.7	1.0	3.9	15.2	0.0	1.3	76.3	5.0	8.4	6.9	1.2	0.4	14.0	1.1	0.9	7.5	4.6	12.7	1.3	1.9	11.0	3.3	3.1	13.5	9.4	7.1	0.0	1.6	30.8	78.5	6.2	4.4	7.2	9.4	5.3	4.3	10.3	6.0	28.8	0.7	22.0	8.2	6.0	39.2	32.4	12.5	0.7	2.2	6.6	6.2	5.2	52.1	19.9	7.4	6.5	0.3	5.4	3.6	5.1	1.7
SPZ1	"FLJ25709, NYD-TSP1, PPP1R148"	ENSG00000164299	"Spermatogenic leucine zipper 1"	Q9BXG8	5	80319625-80321842	"Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"testis: 28.2"	"Group enriched"	"Detected in some"	40	"Early spermatids: 309.3;Late spermatids: 740.0"	"Group enriched"	"Detected in some"	20	"prostate cancer: 1.0;testis cancer: 0.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA															"unprognostic (1.67e-1)"		"unprognostic (1.25e-1)"		"unprognostic (2.22e-1)"	"unprognostic (2.73e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	309.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	740.0	3.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	13.1	0.0	0.0	3.8	2.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
ANO7	"IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G"	ENSG00000146205	"Anoctamin 7"	Q6IWH7	2	241188509-241225377	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 14.8;prostate: 70.2;stomach 1: 28.3"	"Group enriched"	"Detected in many"	5	"Gastric mucus-secreting cells: 80.0;Intestinal goblet cells: 53.4"	"Cancer enriched"	"Detected in many"	19	"prostate cancer: 32.7"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"BEWO: 2.2;Hep G2: 2.3;OE19: 2.5"	"Low region specificity"	"Detected in many"							HPA078464	Enhanced					NA	NA					"HPA078464: "	"unprognostic (1.93e-2)"	"unprognostic (3.45e-3)"	"unprognostic (1.09e-3)"	"unprognostic (5.13e-2)"	"unprognostic (1.35e-2)"	"unprognostic (8.76e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.96e-2)"	"unprognostic (8.45e-2)"	"unprognostic (2.90e-2)"	"unprognostic (4.94e-2)"	"unprognostic (4.82e-3)"	"unprognostic (6.09e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.53e-2)"	0.3	0.3	0.2	1.0	0.6	3.6	0.2	0.3	1.0	0.3	0.0	10.4	10.8	0.5	0.0	0.2	0.3	0.0	0.2	0.1	0.4	0.2	0.1	0.1	0.0	1.2	0.2	0.2	0.5	0.4	0.0	0.2	0.1	0.6	70.2	10.2	0.0	4.9	0.2	0.0	0.2	14.8	0.1	0.2	0.3	28.3	0.2	0.5	0.0	0.2	0.0	0.0	0.2	0.2	1.6	0.0	0.2	0.0	0.0	0.0	0.0	2.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.2	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.1	2.5	0.1	0.0	0.0	0.4	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.1	0.1	0.0	0.4	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.6	0.3	1.0	0.1	0.4	1.2	0.2	0.2	0.6	0.2	0.5	1.6	1.2	0.0	0.0	1.6	0.7	0.3	0.8	0.8	1.2	0.2	1.9	2.7	1.6	0.0	0.2	0.0	0.0	0.6	0.1	2.6	0.0	2.7	0.1	0.8	0.7	2.1	3.0	0.0	4.8	4.2	5.6	2.0	80.0	1.9	0.0	12.4	2.9	3.9	1.5	0.0	2.7	53.4	0.0	1.3	0.0	0.0	3.4	0.7	1.8	7.5	0.0	1.4	0.0	1.0	6.9	6.4	1.9	2.2	0.5	11.9	3.6	2.8	0.0	0.6	0.0	0.8	1.0	0.1	1.7	0.1	0.0	0.7	0.3	2.6	2.4	0.8
ACTA1	"ACTA, NEM3"	ENSG00000143632	"Actin alpha 1, skeletal muscle"	P68133	1	229431245-229434098	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Muscle protein"	"Disease variant, Nemaline myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"skeletal muscle: 134678.2"	"Group enriched"	"Detected in some"	36	"Cardiomyocytes: 1901.9;Skeletal myocytes: 1541.2"	"Group enriched"	"Detected in many"	18	"head and neck cancer: 133.1;prostate cancer: 34.7"	"Low region specificity"	"Detected in many"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	22	"BEWO: 469.2"	"Low region specificity"	"Detected in all"							"CAB000045, HPA041264, HPA041271"	Enhanced					NA	NA		2800000000			"CAB000045: AB_2242301, HPA041264: AB_2677383, HPA041271: AB_2677386"	"unprognostic (5.59e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.77e-1)"	"unprognostic (3.07e-4)"	"unprognostic (5.75e-3)"	"unprognostic (3.84e-3)"	"unprognostic (1.86e-1)"	"unprognostic (7.61e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.24e-1)"	"unprognostic (2.64e-3)"	"unprognostic (2.50e-1)"	"unprognostic (1.56e-3)"	"unprognostic (9.40e-4)"	"unprognostic (2.61e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.01e-1)"	11.6	3.8	1.2	1.6	1.1	0.3	20.0	1.8	2.8	1.0	0.8	6.9	0.3	3.1	0.0	609.8	0.6	1.6	5048.3	1.2	2.6	2.5	7.4	7.7	2.2	0.8	1.1	1.1	4.7	7.4	0.0	4.7	1.2	1.0	166.3	0.0	0.1	595.8	0.7	134678.2	25.6	5.3	67.0	0.6	3.1	5.1	2.5	1.1	3.1	14.6	21052.7	0.9	3.1	5.4	1.0	0.2	0.2	0.1	0.4	0.0	0.1	469.2	0.0	0.0	0.3	0.1	0.5	0.1	0.3	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.1	1.4	0.2	0.5	21.5	0.0	0.5	0.7	20.8	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.3	0.1	0.0	0.2	0.5	0.2	0.0	0.2	0.3	0.3	0.2	0.0	0.3	0.2	0.5	0.2	4.3	0.1	0.0	0.3	0.4	0.6	0.3	0.2	0.5	0.5	0.6	1.0	0.3	0.3	0.6	0.3	18.3	16.5	34.2	11.5	25.4	8.4	6.7	9.4	11.2	23.6	6.4	7.2	11.5	18.8	8.2	24.1	7.5	15.7	45.4	1.2	1.1	1.8	2.8	1.2	2.6	0.8	1.1	1.1	1.0	0.6	1.1	1.0	0.2	0.0	0.0	0.3	0.1	0.5	0.4	0.8	0.0	0.8	0.3	2.2	1901.9	0.0	0.1	0.0	4.2	1.7	0.0	0.0	0.0	1.9	0.4	0.1	0.4	38.1	0.0	0.0	0.6	0.0	3.3	43.6	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.1	0.0	0.0	2.1	0.3	0.0	9.7	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.4	0.0	0.4	0.3	0.3	0.0	0.0	0.0	0.0	0.0	1541.2	46.6	1.1	0.2	0.7	0.4	0.3	8.2	0.1	0.1	0.2
MYL1		ENSG00000168530	"Myosin light chain 1"	P05976	2	210290150-210315174	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Motor protein, Muscle protein, Myosin"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	88	"skeletal muscle: 22012.9;tongue: 15729.5"	"Cell type enriched"	"Detected in some"	246	"Skeletal myocytes: 492.9"	"Group enriched"	"Detected in some"	18	"head and neck cancer: 36.0;prostate cancer: 12.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	4	"HSkMC: 51.4"	"Region enriched"	"Detected in single"	4	"olfactory bulb: 4.0"	"Low region specificity"	"Detected in all"			"HPA046859, HPA063034, HPA073827"	Enhanced				"Intracellular and membrane"	NA	NA		21000000			"HPA046859: AB_2679842, HPA063034: AB_2684927, HPA073827: "						"prognostic unfavorable (6.59e-4)"									"unprognostic (1.88e-1)"			1.7	0.5	0.1	0.0	0.1	0.0	3.4	0.0	0.1	0.1	0.0	0.9	0.0	0.5	0.0	214.5	0.0	0.0	1.8	0.2	0.0	0.8	1.0	0.9	0.0	0.0	0.0	0.0	0.6	1.1	0.0	0.4	0.0	0.0	165.7	0.0	0.0	171.6	0.0	22012.9	2.7	0.7	0.0	0.2	0.4	0.7	0.5	0.0	7.4	2.4	15729.5	0.9	0.1	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	51.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	2.1	0.0	0.0	0.0	11.5	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	492.9	2.0	0.1	0.2	0.0	0.0	0.0	1.6	0.0	0.0	0.1
TRGC2	"TCRGC2, TRGC2(2X), TRGC2(3X)"	ENSG00000227191	"T cell receptor gamma constant 2"		7	38239580-38249572	"Predicted membrane proteins, T-cell receptor genes"				"Evidence at transcript level"	"Evidence at transcript level"			"Tissue enhanced"	"Detected in many"		"bone marrow: 30.8;lymphoid tissue: 34.9;prostate: 23.9"	"Group enriched"	"Detected in some"	7	"dendritic cells: 149.1;NK-cells: 90.6;T-cells: 122.0"	"Cancer enriched"	"Detected in many"	18	"prostate cancer: 26.2"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"gdT-cell: 720.5"	"Lineage enriched"	"Detected in many"	5	"T-cells: 720.5"	"Cell line enhanced"	"Detected in some"		"HL-60: 11.4;JURKAT: 36.6;NB-4: 29.9;SK-BR-3: 9.8;U-937: 53.9"															NA	NA						"unprognostic (2.79e-3)"	"prognostic favorable (1.06e-5)"	"unprognostic (1.62e-4)"	"unprognostic (3.52e-5)"	"unprognostic (3.34e-1)"	"unprognostic (1.46e-3)"	"unprognostic (8.79e-4)"	"unprognostic (4.60e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.91e-3)"	"unprognostic (1.12e-1)"	"unprognostic (3.90e-1)"	"unprognostic (2.48e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.77e-1)"	"unprognostic (5.91e-3)"	2.5	1.2	8.5	5.2	10.4	30.8	1.8	8.5	14.9	1.3	7.3	3.6	4.5	1.3	3.2	1.1	2.2	3.9	0.9	8.3	9.2	1.6	3.6	9.8	17.7	11.4	10.1	7.4	0.5	0.8	0.2	1.0	0.5	10.3	23.9	4.1	0.1	1.8	0.8	0.4	0.5	8.0	1.0	9.0	30.0	3.8	2.2	9.6	34.9	2.1	0.1	7.0	3.4	2.3	9.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	11.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	36.6	0.0	0.0	0.0	3.7	1.2	29.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	0.0	0.0	0.0	8.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	53.9	0.0	1.1	1.3	1.4	720.5	1.2	287.4	0.6	64.8	341.6	1.0	0.3	13.5	212.9	4.9	149.7	1.0	1.2	1.3	167.5	8.5	10.4	8.5	14.9	8.3	9.2	11.4	10.1	7.4	10.3	9.0	9.6	9.4	1.2	0.0	2.4	0.0	2.4	0.0	0.2	0.0	0.0	0.0	1.0	1.3	0.7	1.5	0.6	0.0	0.0	0.0	149.1	0.3	0.0	0.2	15.5	0.2	0.1	0.8	0.0	6.6	0.0	0.0	0.0	0.4	2.6	0.2	0.0	0.2	3.9	1.0	0.0	0.0	0.0	0.5	0.0	3.5	0.0	6.7	0.0	2.8	0.0	0.0	10.6	0.0	90.6	0.0	0.0	0.0	0.0	0.4	14.2	2.8	0.0	0.5	0.0	0.0	0.0	0.2	1.3	0.8	0.2	0.3	0.0	0.3	122.0	0.0	0.2	0.3
HOXB13		ENSG00000159184	"Homeobox B13"	Q92826	17	48724763-48728750	"Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	13	"intestine: 41.5;prostate: 83.0"	"Cell type enhanced"	"Detected in some"		"Distal enterocytes: 144.7;Enteroendocrine cells: 195.2;Intestinal goblet cells: 77.0;Paneth cells: 71.3;Prostatic glandular cells: 61.9;Undifferentiated cells: 81.6"	"Cancer enriched"	"Detected in many"	17	"prostate cancer: 187.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	13	"PC-3: 173.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB004438, HPA062852, HPA065019"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB004438: AB_627744, HPA062852: AB_2684880, HPA065019: AB_2685406"	"unprognostic (4.81e-2)"	"unprognostic (2.57e-2)"	"unprognostic (4.40e-2)"	"unprognostic (1.33e-2)"	"unprognostic (5.85e-3)"	"unprognostic (1.88e-2)"	"unprognostic (1.19e-2)"	"unprognostic (3.19e-2)"	"unprognostic (1.17e-2)"	"unprognostic (6.65e-2)"	"unprognostic (1.74e-1)"	"unprognostic (4.27e-2)"	"unprognostic (4.73e-11)"	"unprognostic (1.39e-2)"	"unprognostic (4.50e-2)"		"unprognostic (1.12e-1)"	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	24.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	83.0	41.5	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	1.6	4.6	0.0	1.9	6.0	0.0	13.2	0.0	0.0	0.5	0.6	0.0	0.2	0.0	2.5	3.0	0.0	3.0	0.0	1.4	0.0	8.7	0.0	0.1	1.0	4.2	2.5	1.5	0.0	0.0	0.0	4.0	0.4	0.0	0.0	0.0	0.0	0.0	2.1	0.8	0.0	0.7	0.0	0.0	0.3	0.0	2.2	173.0	0.0	1.4	0.1	0.0	0.4	0.0	0.0	2.7	0.0	4.4	0.5	0.0	0.5	0.0	0.5	4.7	4.7	1.3	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.2	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.0	144.7	0.0	0.0	0.6	0.0	0.0	0.2	195.2	0.0	0.0	0.0	0.3	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	77.0	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	71.3	0.0	0.0	61.9	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.4	0.0	0.0	0.1	0.2	0.1	81.6	14.6
PAGE4	"CT16.7, GAGEC1, PAGE-4"	ENSG00000101951	"PAGE family member 4"	O60829	X	49829260-49834264	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"epididymis: 879.5;placenta: 1031.7"	"Group enriched"	"Detected in some"	10	"Cytotrophoblasts: 13314.7;Syncytiotrophoblasts: 8524.1"	"Group enriched"	"Detected in some"	17	"liver cancer: 14.8;prostate cancer: 7.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 10.2;U-266/70: 11.7;U-266/84: 45.1"					"Not detected"	"Not detected"			HPA023880	Enhanced		Approved	"Golgi apparatus,Vesicles"		NA	NA			Vesicles	"Golgi apparatus"	"HPA023880: AB_1854930"				"unprognostic (8.56e-2)"			"unprognostic (1.47e-1)"			"unprognostic (1.04e-1)"		"unprognostic (4.82e-3)"			"unprognostic (5.37e-2)"			0.1	5.8	0.1	0.3	0.2	0.0	0.0	0.1	0.5	3.9	0.1	0.2	0.4	51.7	879.5	0.0	21.6	0.0	0.4	0.1	0.1	0.9	0.3	0.2	0.0	0.1	0.1	0.0	3.7	2.5	0.0	1.3	1031.7	0.1	173.2	0.0	0.0	0.6	77.9	2.4	0.0	0.3	24.4	0.0	0.3	0.2	5.7	0.1	0.1	0.0	0.0	0.0	0.2	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	10.2	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	2.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	1.7	0.2	0.0	0.0	0.0	0.1	0.0	0.1	11.7	45.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.5	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	13314.7	0.0	0.0	0.0	0.0	4.4	1.9	72.5	25.9	0.0	0.0	0.0	0.0	905.4	72.5	0.0	1.9	0.0	0.0	0.0	0.0	1052.1	0.0	0.0	0.0	0.0	0.0	0.0	8.9	0.9	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.7	48.8	20.7	0.0	0.0	8524.1	0.3	0.0	0.0	0.1
ADAM7	"EAPI, GP-83"	ENSG00000069206	"ADAM metallopeptidase domain 7"	Q9H2U9	8	24440930-24526970	"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	237	"epididymis: 3759.0"	"Cell type enriched"	"Detected in some"	7	"Early spermatids: 128.3"	"Group enriched"	"Detected in some"	16	"prostate cancer: 1.0;renal cancer: 0.5"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	30	"BEWO: 2.4;NB-4: 6.1;RPMI-8226: 1.7;SH-SY5Y: 1.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA008879	Enhanced				"Intracellular and membrane"	NA	NA					"HPA008879: AB_10601789"												"unprognostic (1.03e-3)"	"unprognostic (3.96e-4)"					0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	3759.0	0.0	0.0	0.0	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.6	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	15.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.1	0.3	0.1	0.6	0.2	0.0	1.2	0.0	0.7	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	128.3	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	16.7	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CHRM1		ENSG00000168539	"Cholinergic receptor muscarinic 1"	P11229	11	62908679-62921807	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"brain: 27.2;prostate: 29.9;salivary gland: 29.1"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 2.9;Breast myoepithelial cells: 3.6;Excitatory neurons: 8.7;Inhibitory neurons: 7.8;Intestinal goblet cells: 3.2;Melanocytes: 3.6;Oligodendrocyte precursor cells: 3.0;Prostatic glandular cells: 4.4"	"Cancer enriched"	"Detected in some"	16	"prostate cancer: 27.9"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"MCF7: 3.7;OE19: 12.3"	"Low region specificity"	"Detected in many"							HPA014101	Enhanced	Supported				NA	NA					"HPA014101: AB_1854210"	"unprognostic (3.19e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.31e-2)"	"unprognostic (7.94e-2)"	"unprognostic (2.29e-1)"		"unprognostic (1.16e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.76e-1)"	"unprognostic (2.08e-1)"	"unprognostic (8.57e-4)"	"unprognostic (4.88e-1)"	"unprognostic (6.43e-2)"	"unprognostic (1.75e-1)"		0.0	3.3	12.2	0.3	22.9	0.0	2.7	0.0	27.2	0.0	0.0	0.8	0.4	0.1	0.0	0.3	0.2	0.1	0.1	21.8	6.3	0.2	0.0	2.5	0.0	4.0	1.2	25.0	0.0	0.6	0.3	0.2	0.2	6.9	29.9	0.8	0.1	29.1	0.0	0.0	2.6	0.7	0.0	0.0	0.0	1.4	0.1	1.3	0.0	0.2	0.0	0.0	0.0	0.1	12.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.1	0.0	12.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.9	0.4	0.1	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.2	22.9	0.0	27.2	21.8	6.3	4.0	1.2	25.0	6.9	0.0	1.3	12.7	0.1	0.0	0.0	2.9	0.0	0.1	0.2	0.0	0.0	0.0	1.8	3.6	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	8.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	7.8	3.2	0.0	0.0	0.3	0.0	0.0	0.0	3.6	1.0	0.0	0.0	0.0	3.0	1.0	0.0	0.1	0.0	0.0	4.4	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.5	0.1
PABPC1L2A	RBM32A	ENSG00000186288	"Poly(A) binding protein cytoplasmic 1 like 2A"	Q5JQF8	X	73077276-73079512	"Predicted intracellular proteins"		RNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 6.7;prostate: 2.6"	"Group enriched"	"Detected in some"	10	"Early spermatids: 14.3;Late spermatids: 48.5"	"Cancer enriched"	"Detected in single"	15	"prostate cancer: 1.8"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"NTERA-2: 1.5"									HPA041573	Approved					NA	NA					"HPA041573: AB_2677556"					"unprognostic (4.30e-2)"							"unprognostic (2.19e-1)"			"unprognostic (3.22e-1)"			0.0	1.0	3.6	0.0	4.3	0.0	0.0	2.6	6.5	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	3.5	5.5	0.0	0.0	0.0	0.0	3.0	2.1	3.8	0.0	0.0	0.1	2.0	0.0	3.7	2.6	0.0	1.1	1.8	0.2	0.0	0.0	0.1	0.0	0.8	0.2	0.0	1.7	4.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	4.3	2.6	6.5	3.5	5.5	3.0	2.1	3.8	3.7	0.8	4.0	6.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	48.5	0.3	0.0	0.0	0.0	0.0	0.5	0.0	3.0	1.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RFPL2	RNF79	ENSG00000128253	"Ret finger protein like 2"	O75678	22	32190435-32205001	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	7	"brain: 8.6;prostate: 3.8"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 17.6;Inhibitory neurons: 8.6"	"Cancer enriched"	"Detected in single"	15	"prostate cancer: 5.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											"HPA046608, HPA048320, HPA072380"	Approved		Approved	"Nuclear speckles,Plasma membrane"		NA	NA			"Nuclear speckles"	"Plasma membrane"	"HPA046608: , HPA048320: AB_2680356, HPA072380: AB_2686515"	"unprognostic (3.81e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.29e-2)"	"unprognostic (9.66e-3)"	"unprognostic (2.54e-1)"	"unprognostic (9.90e-2)"	"unprognostic (2.59e-1)"	"unprognostic (6.02e-3)"	"unprognostic (2.22e-2)"	"unprognostic (3.44e-2)"	"unprognostic (8.64e-3)"	"prognostic favorable (4.16e-4)"	"unprognostic (2.04e-4)"	"unprognostic (6.02e-2)"	"unprognostic (3.28e-2)"	"unprognostic (5.62e-7)"	"unprognostic (3.50e-2)"	0.0	0.6	2.5	0.0	3.5	0.4	0.0	0.7	8.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	3.6	0.0	0.1	0.0	0.1	3.1	2.6	3.1	0.3	0.0	0.0	0.1	0.0	4.7	3.8	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.1	0.0	0.2	3.8	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.7	0.2	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	3.5	0.7	8.6	3.5	3.6	3.1	2.6	3.1	4.7	1.0	3.8	6.7	0.1	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.7	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	2.7	17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	8.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.5	1.2	0.0	0.0	0.0	0.0	3.1	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1
B3GNT6	B3Gn-T6	ENSG00000198488	"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6"	Q6ZMB0	11	77034398-77041973	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		"Glycosyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"intestine: 22.0;salivary gland: 6.5;stomach 1: 25.1"	"Group enriched"	"Detected in some"	20	"Gastric mucus-secreting cells: 23.0;Intestinal goblet cells: 60.8"	"Group enriched"	"Detected in some"	14	"colorectal cancer: 6.3;lung cancer: 3.9;pancreatic cancer: 5.1;prostate cancer: 5.0;stomach cancer: 4.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA039805	Enhanced				"Intracellular and membrane"	NA	NA					"HPA039805: AB_2676690"		"unprognostic (1.71e-1)"	"prognostic favorable (2.31e-4)"	"unprognostic (4.79e-2)"	"unprognostic (5.42e-2)"	"unprognostic (7.64e-2)"		"unprognostic (1.95e-1)"		"unprognostic (2.72e-1)"	"unprognostic (1.23e-2)"	"unprognostic (7.77e-2)"		"unprognostic (2.19e-1)"		"unprognostic (9.30e-2)"	"unprognostic (1.71e-1)"	0.1	0.0	0.1	2.5	0.1	0.0	0.0	0.0	0.2	0.0	0.0	22.0	5.5	0.0	0.0	3.6	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	17.0	0.0	6.5	0.0	0.0	0.1	7.1	0.3	0.0	0.0	25.1	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.1	0.1	0.2	0.2	0.0	0.2	0.0	0.1	0.3	0.1	0.0	0.5	0.0	0.1	0.0	0.6	0.2	0.0	0.0	0.1	0.1	0.4	0.0	1.0	0.0	0.0	0.0	1.4	2.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.0	0.2	23.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1	60.8	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.6	1.4	0.0	0.0	0.3	1.2	0.1	0.2	0.0	0.0	0.7	0.2	0.0	0.1	0.0	0.0	0.0	0.2	0.0	1.5	0.2
BRINP3	"DBCCR1L, DBCCR1L1, FAM5C"	ENSG00000162670	"BMP/retinoic acid inducible neural specific 3"	Q76B58	1	190097658-190478404	"Predicted intracellular proteins, Predicted secreted proteins"	"Cell cycle, Growth arrest"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.0;intestine: 18.0"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 266.7;Excitatory neurons: 333.7;Inhibitory neurons: 129.7;Oligodendrocyte precursor cells: 1079.2"	"Group enriched"	"Detected in some"	14	"breast cancer: 3.4;glioma: 8.6;prostate cancer: 3.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	4	"SCLC-21H: 14.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054693	Uncertain				"Secreted in other tissues"	NA	NA					"HPA054693: AB_2682575"	"unprognostic (3.18e-2)"		"unprognostic (1.22e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.40e-1)"			"unprognostic (1.72e-1)"			"unprognostic (8.25e-2)"	"unprognostic (3.65e-1)"		"unprognostic (2.38e-2)"	"unprognostic (2.62e-1)"	"unprognostic (9.84e-2)"	"unprognostic (4.58e-3)"	0.3	1.8	16.7	0.6	16.6	0.0	1.4	18.6	17.3	0.2	0.0	6.7	4.6	0.3	3.0	1.7	0.4	1.6	5.3	27.0	22.5	2.3	0.0	1.2	0.0	12.1	15.9	13.8	0.0	0.0	0.0	0.2	0.0	13.3	6.8	6.8	0.7	1.6	5.1	0.1	0.1	18.0	0.6	9.8	0.0	0.2	3.4	20.2	0.1	2.2	0.0	0.1	0.5	0.0	14.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.5	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.7	16.6	18.6	17.3	27.0	22.5	12.1	15.9	13.8	13.3	9.8	20.2	14.9	0.0	0.0	0.0	266.7	0.0	0.0	0.1	0.0	0.0	0.7	0.3	0.4	2.3	0.0	0.0	3.7	0.0	0.0	0.0	2.0	3.9	0.0	63.3	0.0	0.0	0.1	1.2	0.0	333.7	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	129.7	2.8	0.0	0.0	0.0	10.5	0.0	0.1	0.0	8.4	0.0	0.0	0.0	1079.2	4.3	0.0	10.8	0.0	0.0	1.0	8.1	0.3	0.0	0.1	0.0	0.0	5.8	2.0	0.7	0.1	0.0	0.0	0.0	0.0	5.2	0.1
SEMG1	"CT103, SEMG"	ENSG00000124233	"Semenogelin 1"	P04279	20	45207033-45209768	"Plasma proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	147	"seminal vesicle: 30689.9"	"Group enriched"	"Detected in some"	18	"Basal prostatic cells: 7.5;Prostatic glandular cells: 3.4"	"Cancer enriched"	"Detected in some"	14	"prostate cancer: 20.7"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	239	"eosinophil: 26.8"	"Lineage enriched"	"Detected in single"	269	"granulocytes: 26.8"	"Cell line enhanced"	"Detected in some"		"NTERA-2: 1.3;THP-1: 3.1"									"HPA042476, HPA064892"	Enhanced				"Secreted in male reproductive system"	NA	NA		7000000			"HPA042476: AB_10794799, HPA064892: AB_2732724"			"unprognostic (3.71e-1)"								"unprognostic (2.92e-2)"	"unprognostic (1.44e-1)"		"unprognostic (3.32e-1)"			"unprognostic (1.11e-2)"	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.0	1.5	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	208.9	0.0	0.0	0.0	30689.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1
TRGJP2	"JP2, TCRGJP2"	ENSG00000211688	"T cell receptor gamma joining P2"		7	38256337-38256396	"Predicted intracellular proteins, T-cell receptor genes"				"Evidence at transcript level"	"Evidence at transcript level"			"Group enriched"	"Detected in many"	5	"bone marrow: 65.0;brain: 50.4;lung: 28.9;lymphoid tissue: 30.7;prostate: 32.7"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in some"	14	"prostate cancer: 17.4"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"gdT-cell: 367.0"	"Group enriched"	"Detected in many"	85	"NK-cells: 186.9;T-cells: 367.0"	"Group enriched"	"Detected in some"	8	"HL-60: 61.6;NB-4: 66.3;SK-BR-3: 18.3;THP-1: 36.2;U-937: 72.4"															NA	NA													"unprognostic (2.09e-1)"				"unprognostic (5.05e-2)"						1.3	0.0	10.9	4.9	27.1	65.0	5.5	10.3	50.4	1.4	4.3	2.8	4.3	1.5	0.0	1.3	1.6	1.3	0.0	10.6	14.7	0.0	4.5	28.9	12.5	36.7	22.1	6.2	0.0	0.0	0.0	0.0	0.5	23.2	32.7	2.6	0.7	0.0	0.0	0.0	2.0	8.2	2.7	11.6	30.7	6.2	3.5	17.7	20.8	2.2	0.0	13.6	1.9	0.0	13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	61.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	66.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	18.3	4.6	0.0	0.0	36.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	72.4	0.0	0.3	1.4	1.8	367.0	0.2	94.8	0.2	33.3	142.4	0.4	0.3	3.1	81.3	3.2	186.9	0.5	0.4	1.8	42.1	10.9	27.1	10.3	50.4	10.6	14.7	36.7	22.1	6.2	23.2	11.6	17.7	13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GCSAML	"C1orf150, FLJ44728"	ENSG00000169224	"Germinal center associated signaling and motility like"	Q5JQS6	1	247507058-247577690	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 5.2;prostate: 5.5"	"Cell type enriched"	"Detected in some"	24	"granulocytes: 223.3"	"Cancer enriched"	"Detected in single"	13	"prostate cancer: 1.9"	"Region enhanced"	"Detected in some"		"cerebellum: 5.2"	"Immune cell enriched"	"Detected in single"	661	"basophil: 227.7"	"Lineage enriched"	"Detected in single"	661	"granulocytes: 227.7"	"Group enriched"	"Detected in some"	71	"HEL: 151.8;HMC-1: 564.8"					"Low region specificity"	"Detected in all"			"HPA027507, HPA027510"	Uncertain		Approved	Cytosol		NA	NA			Cytosol		"HPA027507: AB_10600756, HPA027510: AB_2672309"	"unprognostic (5.68e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.07e-3)"	"unprognostic (3.48e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.76e-4)"	"unprognostic (3.21e-1)"	"unprognostic (6.14e-2)"	"unprognostic (5.42e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.81e-1)"	"unprognostic (9.51e-3)"	"unprognostic (3.13e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.40e-2)"	0.4	0.2	0.4	0.8	0.4	1.8	1.1	5.2	0.7	0.7	0.4	1.2	1.5	0.8	0.5	1.1	0.3	1.4	0.2	0.3	0.4	0.1	0.2	2.2	0.3	0.4	0.8	0.4	0.1	0.4	0.1	0.0	0.3	3.5	5.5	1.5	1.2	0.3	0.4	0.2	0.7	1.4	0.6	0.1	0.4	1.0	3.4	0.4	0.7	0.3	0.7	0.3	0.7	0.3	1.2	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.8	0.8	0.2	0.1	0.0	0.1	151.8	0.2	0.0	0.0	0.3	564.8	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	1.0	0.1	0.3	0.3	5.0	0.2	0.1	0.0	0.2	0.1	0.3	0.0	0.1	0.1	0.4	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.5	0.4	0.0	0.0	0.3	0.2	0.0	2.3	0.1	0.4	227.7	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.3	0.3	0.2	0.2	0.2	0.2	0.1	0.2	0.5	0.4	0.4	5.2	0.7	0.3	0.4	0.4	0.8	0.4	3.5	0.1	0.4	1.2	0.0	0.0	4.4	0.0	0.1	0.6	0.1	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	1.9	0.0	9.1	0.0	0.1	0.6	0.0	5.0	0.4	0.0	0.0	0.3	0.0	0.0	223.3	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.7	7.8	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.3	2.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	8.3	1.7	0.0	0.6	0.0	1.4	0.1	0.0	0.2
PEBP4	"CORK1, hPEBP4, MGC22776"	ENSG00000134020	"Phosphatidylethanolamine binding protein 4"	Q96S96	8	22713251-23000000	"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"epididymis: 385.9;skeletal muscle: 677.1;tongue: 586.5"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 109.0;Alveolar cells type 2: 177.3;Cardiomyocytes: 144.7;Muller glia cells: 198.7"	"Group enriched"	"Detected in many"	13	"lung cancer: 11.4;prostate cancer: 23.7;thyroid cancer: 35.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"U-266/70: 3.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA025064	Uncertain				"Secreted in other tissues"	NA	NA		190000000			"HPA025064: AB_1855174"	"unprognostic (1.34e-2)"	"unprognostic (2.97e-2)"	"unprognostic (4.11e-2)"	"unprognostic (3.66e-1)"	"unprognostic (3.35e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.66e-4)"	"unprognostic (1.18e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.90e-2)"	"unprognostic (8.76e-3)"	"unprognostic (9.70e-8)"	"unprognostic (1.13e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.48e-1)"	"unprognostic (4.59e-1)"	1.0	3.4	11.5	0.3	14.8	0.0	3.4	21.5	9.5	0.6	17.1	0.5	0.0	0.5	385.9	6.9	2.3	1.1	184.5	8.0	20.7	2.5	0.9	116.1	0.8	18.3	18.5	6.0	1.7	34.8	83.4	13.3	0.4	19.1	46.2	0.2	13.0	21.3	2.8	677.1	1.2	0.6	0.4	7.8	0.8	9.2	6.6	25.6	1.2	57.2	586.5	1.6	0.3	0.5	15.2	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.9	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.9	0.0	0.0	0.0	0.0	11.5	14.8	21.5	9.5	8.0	20.7	18.3	18.5	6.0	19.1	7.8	25.6	15.2	1.5	109.0	177.3	15.3	2.2	1.9	1.0	0.1	0.0	10.2	5.7	4.7	144.7	0.0	7.4	1.8	2.1	0.8	1.4	0.3	3.9	0.0	34.8	1.7	2.0	2.4	0.0	0.0	10.0	9.3	0.2	10.1	2.0	7.0	7.6	0.4	3.9	0.7	1.2	10.1	9.6	0.3	2.0	0.0	0.8	28.4	3.4	1.4	1.8	6.5	0.1	198.7	5.2	6.6	0.9	0.3	0.1	10.9	1.5	23.8	0.5	5.9	2.9	8.6	0.0	25.2	2.1	14.8	1.2	0.0	0.9	0.0	1.6	1.1	0.3	1.0
RDH11	"ARSDR1, MDT1, SDR7C1"	ENSG00000072042	"Retinol dehydrogenase 11"	Q8TC12	14	67676800-67695793	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		Oxidoreductase	"Cataract, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"prostate: 587.2"	"Cell type enhanced"	"Detected in all"		"Hepatocytes: 241.8;Muller glia cells: 299.7;Prostatic glandular cells: 285.7"	"Cancer enriched"	"Detected in all"	13	"prostate cancer: 286.6"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB046011	Enhanced				"Intracellular and membrane"	NA	NA		340000			"CAB046011: AB_11129613"	"unprognostic (1.38e-1)"	"unprognostic (6.86e-3)"	"unprognostic (1.77e-1)"	"prognostic favorable (2.62e-4)"	"unprognostic (6.06e-2)"	"prognostic unfavorable (2.89e-5)"	"unprognostic (9.29e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.05e-1)"	"unprognostic (3.58e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.27e-1)"	"prognostic favorable (1.30e-7)"	"unprognostic (1.65e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.18e-1)"	"unprognostic (4.74e-2)"	23.8	60.0	41.8	24.7	44.5	14.0	29.0	51.1	54.8	32.9	37.8	29.4	34.4	33.5	86.7	34.9	23.7	43.1	17.4	43.6	48.4	106.9	154.4	35.2	20.6	50.7	49.1	40.5	29.2	42.9	80.4	23.6	22.1	51.1	587.2	31.7	74.6	44.6	34.7	8.4	28.6	24.1	44.0	49.5	22.4	32.2	28.6	48.4	31.0	62.3	13.6	26.4	34.6	30.6	60.9	183.7	81.9	71.3	82.0	111.5	100.4	59.3	68.0	134.2	83.7	150.9	68.6	216.7	31.7	51.2	64.6	104.8	142.5	104.0	150.8	113.7	63.0	42.6	65.1	40.7	69.0	106.9	24.3	46.0	94.4	98.0	109.3	92.0	63.9	97.4	87.0	52.1	101.1	77.2	97.5	72.2	38.8	40.4	49.7	92.8	53.6	87.4	45.8	194.1	93.0	73.8	62.0	71.2	89.7	99.1	58.2	100.7	38.3	74.2	89.5	101.1	38.9	49.5	47.5	40.0	40.7	115.8	66.0	74.3	282.4	71.1	104.0	62.3	57.7	68.2	39.0	67.7	61.5	51.3	45.5	67.3	64.8	11.0	56.3	65.4	59.1	65.1	115.8	41.8	44.5	51.1	54.8	43.6	48.4	50.7	49.1	40.5	51.1	49.5	48.4	60.9	27.0	25.6	66.0	38.2	29.2	11.5	40.0	77.9	16.5	53.5	45.4	24.5	20.4	68.6	59.9	47.8	50.1	24.9	32.4	26.8	7.9	92.5	2.5	21.9	50.9	39.3	43.3	29.2	33.3	84.0	38.1	37.5	19.9	38.2	29.2	46.3	47.8	241.8	35.8	79.1	37.6	28.9	89.5	42.4	15.4	6.1	43.2	35.9	35.6	17.8	39.8	299.7	37.0	70.4	43.4	61.2	36.7	56.1	27.3	285.7	17.5	56.0	23.9	97.0	46.0	29.7	38.7	25.8	24.0	20.2	19.2	63.5	29.8	66.7	25.3	46.1
AZGP1	"ZA2G, ZAG"	ENSG00000160862	"Alpha-2-glycoprotein 1, zinc-binding"	P25311	7	99966720-99976042	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 2832.6;salivary gland: 3880.0"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 1315.5;Breast myoepithelial cells: 704.8;Hepatocytes: 4270.8;Ionocytes: 901.3;Prostatic glandular cells: 1691.9;Urothelial cells: 674.2"	"Group enriched"	"Detected in many"	12	"breast cancer: 412.6;liver cancer: 273.6;prostate cancer: 469.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Hep G2: 56.6;OE19: 158.9;RPMI-8226: 130.4;T-47d: 41.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA012582, HPA012876, CAB016087, CAB032276"	Enhanced		Approved	Nucleoplasm,Vesicles	"Secreted to blood"	NA	NA	55200000000	74000000000	Vesicles	Nucleoplasm	"CAB016087: AB_667849, CAB032276: AB_2062580, HPA012582: AB_1845226, HPA012876: "	"unprognostic (8.14e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.41e-1)"	"unprognostic (5.42e-3)"	"unprognostic (4.98e-2)"	"unprognostic (5.74e-3)"	"prognostic favorable (2.90e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.85e-1)"	"unprognostic (2.19e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.79e-1)"	"prognostic favorable (1.53e-4)"	"unprognostic (2.18e-1)"	"unprognostic (2.08e-2)"	"unprognostic (9.80e-2)"	"unprognostic (3.51e-3)"	129.8	3.9	17.4	2.8	28.0	0.4	1072.2	23.6	22.9	2.5	16.4	6.8	31.1	1.5	2.5	22.2	3.0	39.1	67.4	15.6	23.4	329.8	2832.6	14.9	0.4	22.9	23.6	14.9	6.1	758.5	0.1	1.3	0.5	29.9	1060.6	4.3	3.6	3880.0	40.6	1.7	188.9	28.9	0.3	14.8	1.4	317.7	26.1	23.1	0.8	1.9	2.3	1.5	5.8	7.6	26.1	0.2	0.0	0.0	0.0	11.3	0.0	5.5	0.0	0.0	0.0	0.0	0.1	4.0	14.2	0.7	0.0	0.1	0.9	0.0	0.0	0.1	0.0	0.1	0.3	0.1	56.6	4.9	1.5	0.1	0.6	0.2	0.0	0.0	0.1	0.0	0.0	0.3	29.9	0.0	0.0	0.0	5.1	0.2	158.9	0.0	0.0	1.7	130.4	0.0	0.0	0.0	2.0	1.0	25.4	13.0	0.0	41.8	0.0	0.0	0.5	0.1	1.8	0.9	1.9	0.8	0.4	0.0	0.5	14.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	28.0	23.6	22.9	15.6	23.4	22.9	23.6	14.9	29.9	14.8	23.1	26.1	9.9	22.4	276.8	0.0	14.7	4.2	422.1	25.3	0.0	0.0	1315.5	704.8	115.9	451.8	63.0	5.5	2.1	0.0	10.4	5.5	46.9	11.7	1.9	1.4	1.2	14.2	12.4	85.5	0.1	254.2	0.0	7.7	94.8	5.5	3.8	1.2	65.3	4270.8	0.0	0.0	0.1	13.1	901.3	93.1	0.7	4.2	0.9	14.8	62.2	1.0	2.0	23.7	0.0	7.5	7.3	221.5	6.4	0.0	0.3	1691.9	15.3	596.1	6.3	0.3	0.0	0.0	11.9	7.4	0.4	9.9	9.7	0.0	12.3	0.1	12.6	674.2
STEAP2	"IPCA-1, PCANAP1, STAMP1, STMP"	ENSG00000157214	"STEAP2 metalloreductase"	Q8NFT2	7	90167590-90238137	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Electron transport, Ion transport, Iron transport, Transport"	Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"prostate: 128.8"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 68.0;Inhibitory neurons: 53.0;Prostatic glandular cells: 102.9"	"Cancer enriched"	"Detected in many"	12	"prostate cancer: 88.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"A549: 22.5;CAPAN-2: 48.1;U-138 MG: 27.4"	"Low region specificity"	"Detected in all"							"HPA029115, HPA055603"	Uncertain		Supported	Vesicles		NA	NA			Vesicles		"HPA029115: AB_10603894, HPA055603: "	"unprognostic (6.26e-3)"	"unprognostic (2.48e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.20e-4)"	"unprognostic (2.34e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.67e-3)"	"unprognostic (7.91e-2)"	"unprognostic (1.70e-1)"	"unprognostic (9.92e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.71e-2)"	"unprognostic (9.73e-2)"	"unprognostic (6.11e-2)"	"unprognostic (9.86e-5)"	"unprognostic (3.69e-2)"	13.7	3.7	8.3	12.0	13.1	0.0	13.2	10.9	17.6	8.0	8.1	13.7	6.2	7.1	2.7	6.9	14.5	10.2	10.4	12.5	10.6	6.9	4.0	20.7	0.5	6.5	7.4	11.8	17.3	8.2	10.2	19.6	0.2	7.3	128.8	7.7	3.9	12.0	6.9	1.4	4.5	9.1	10.9	6.9	2.7	11.1	1.1	7.5	3.3	8.0	1.6	1.7	16.0	9.1	8.5	3.2	22.5	0.5	6.3	11.5	11.1	0.3	2.8	5.8	0.4	0.8	4.2	48.1	0.0	0.3	7.5	8.8	1.8	4.9	3.5	0.8	0.0	4.7	0.0	0.1	1.1	1.0	0.0	0.1	8.1	0.8	11.5	2.3	9.4	6.1	0.0	0.0	0.4	6.6	0.0	0.0	0.7	9.1	0.0	2.5	0.0	0.0	0.2	10.3	6.6	0.7	2.1	3.5	0.0	0.1	1.0	16.8	0.0	5.1	27.4	6.0	3.8	2.4	0.1	0.0	0.0	11.7	0.0	1.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	8.3	13.1	10.9	17.6	12.5	10.6	6.5	7.4	11.8	7.3	6.9	7.5	8.5	0.6	0.0	1.1	18.6	0.2	4.8	21.6	20.6	9.1	7.5	16.1	10.3	18.0	18.6	19.4	12.9	2.1	0.0	0.1	15.9	0.0	1.1	0.5	2.8	3.7	2.2	15.7	2.7	68.0	7.4	0.0	27.6	10.7	2.9	0.0	30.4	3.6	5.8	0.0	1.7	53.0	9.8	10.2	0.0	6.2	0.8	15.5	0.7	0.0	2.8	0.0	23.1	0.0	27.6	2.6	11.4	24.0	15.4	0.0	102.9	13.1	10.8	16.0	1.3	0.0	14.7	5.8	3.1	6.2	4.1	5.4	0.0	0.5	9.8	13.8	25.3
B3GAT1	"CD57, GlcAT-P, HNK-1, LEU7, NK-1"	ENSG00000109956	"Beta-1,3-glucuronyltransferase 1"	Q9P2W7	11	134378504-134412242	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins"		Transferase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 195.4"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 27.4;Bipolar cells: 37.0;Excitatory neurons: 37.2;Inhibitory neurons: 30.4;Muller glia cells: 116.2;Oligodendrocyte precursor cells: 33.2;Oligodendrocytes: 77.8"	"Group enriched"	"Detected in some"	11	"glioma: 10.8;prostate cancer: 3.5;thyroid cancer: 4.1"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"gdT-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"T-cells: 1.1"	"Cell line enhanced"	"Detected in some"		"AF22: 23.1;HMC-1: 25.3;NTERA-2: 22.1;SH-SY5Y: 8.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002500, CAB010893, HPA069468, HPA074314"	Enhanced		Enhanced	Vesicles	"Secreted in brain"	NA	NA			Vesicles		"CAB002500: AB_563601, CAB010893: AB_1078474, HPA069468: AB_2686138, HPA074314: "	"unprognostic (6.72e-2)"	"unprognostic (3.97e-4)"	"unprognostic (2.13e-2)"	"unprognostic (1.40e-3)"	"unprognostic (5.52e-2)"	"unprognostic (2.60e-3)"	"unprognostic (6.30e-2)"	"unprognostic (1.96e-2)"	"unprognostic (8.74e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.57e-3)"	"unprognostic (1.58e-1)"	"unprognostic (9.34e-3)"	"unprognostic (3.87e-3)"	"unprognostic (2.42e-1)"	"unprognostic (4.07e-2)"	"unprognostic (2.26e-2)"	0.2	4.2	147.5	0.4	129.4	1.0	3.9	112.4	195.4	0.3	38.4	0.7	0.5	1.4	0.2	0.2	0.4	0.3	0.2	184.7	98.8	1.8	5.9	0.6	2.1	132.8	147.9	122.8	0.2	0.4	0.0	4.5	0.1	128.7	2.8	0.1	24.0	1.2	0.4	0.1	0.4	0.6	0.1	132.3	1.4	35.2	0.9	117.4	0.4	6.3	0.2	0.4	0.7	0.3	177.1	0.0	0.0	23.1	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.7	3.9	0.0	0.9	1.2	1.6	0.0	0.0	0.0	0.7	0.1	0.2	0.0	0.1	0.1	25.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.1	0.0	0.1	22.1	1.1	0.0	0.4	0.0	1.7	0.0	0.1	3.1	8.4	0.0	0.0	0.0	1.5	0.1	0.0	0.1	0.0	2.3	0.1	0.0	0.1	0.0	0.1	0.2	0.1	5.8	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	147.5	129.4	112.4	195.4	184.7	98.8	132.8	147.9	122.8	128.7	132.3	117.4	177.1	0.1	0.0	0.0	27.4	0.1	0.0	0.0	0.0	0.0	37.0	1.2	0.8	1.1	2.8	0.0	0.0	4.2	0.0	14.4	0.1	0.0	0.0	1.8	0.1	0.1	0.4	1.8	0.4	37.2	0.0	0.0	0.1	0.0	0.2	0.0	0.1	0.4	4.7	0.1	23.5	30.4	0.0	0.0	0.3	0.0	3.9	0.0	0.2	0.0	3.7	0.0	116.2	15.5	33.2	77.8	0.0	0.0	0.4	7.5	0.9	0.0	1.9	0.0	8.6	0.0	0.1	0.2	0.2	0.8	0.0	0.0	0.1	3.8	0.0	0.0	0.3
ADRB1	ADRB1R	ENSG00000043591	"Adrenoceptor beta 1"	P08588	10	114043866-114046904	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 20.4;lung: 13.2;placenta: 29.3"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 85.7;Cytotrophoblasts: 84.5;Sertoli cells: 52.6;Syncytiotrophoblasts: 38.4"	"Cancer enriched"	"Detected in many"	10	"prostate cancer: 12.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 7.1;PC-3: 2.6;THP-1: 4.5;TIME: 5.8;U-937: 3.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA067972	Enhanced					NA	NA					"HPA067972: AB_2685936"	"unprognostic (1.45e-3)"	"unprognostic (1.18e-3)"	"unprognostic (1.44e-1)"	"unprognostic (4.92e-2)"	"unprognostic (3.22e-1)"	"unprognostic (8.88e-2)"	"unprognostic (9.28e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.77e-4)"	"unprognostic (1.33e-1)"	"unprognostic (7.80e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.44e-1)"	3.1	0.3	4.7	0.3	10.1	0.6	2.3	1.0	11.0	0.0	0.3	2.4	0.9	0.1	0.1	0.9	0.1	0.1	20.4	6.6	3.9	1.1	1.4	13.2	0.2	3.0	3.8	7.1	0.0	1.3	0.8	0.8	29.3	4.0	4.5	0.6	2.1	5.4	0.1	2.3	0.3	1.9	0.1	0.8	1.5	0.7	0.5	4.0	0.1	0.6	0.0	0.3	0.7	0.1	7.8	1.4	0.8	0.1	0.8	0.0	0.0	0.2	0.1	0.0	0.1	0.1	0.3	1.0	0.2	0.2	0.0	0.4	0.3	0.1	0.1	0.1	7.1	0.4	0.3	0.1	0.1	0.0	0.2	0.4	0.0	0.7	0.0	1.3	0.1	0.1	1.0	0.0	0.1	0.1	0.8	1.1	0.9	0.3	0.2	2.6	0.2	0.2	0.1	0.0	1.1	0.1	0.2	0.0	0.5	0.0	0.3	0.2	4.5	5.8	0.2	0.1	0.1	0.1	0.0	0.0	0.3	0.0	3.4	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	10.1	1.0	11.0	6.6	3.9	3.0	3.8	7.1	4.0	0.8	4.0	7.8	1.1	19.2	7.8	15.0	0.5	1.0	3.9	0.8	1.2	21.8	1.0	0.5	85.7	2.8	9.8	0.0	0.0	84.5	3.0	0.1	1.9	0.1	0.1	0.4	0.6	11.3	0.0	0.0	12.8	0.2	5.2	5.3	0.0	0.3	0.0	0.0	0.4	0.2	4.4	13.5	2.5	3.3	2.0	2.2	1.6	0.2	0.0	2.8	1.8	7.5	0.6	0.7	3.1	1.0	0.3	0.1	1.4	0.4	1.2	6.1	0.8	0.0	12.1	1.7	52.6	0.4	8.2	0.5	0.2	0.1	0.0	38.4	4.8	0.0	0.6	3.9
FEV	Pet-1	ENSG00000163497	"FEV transcription factor, ETS family member"	Q99581	2	218981087-218985184	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 21.6"	"Cell type enriched"	"Detected in some"	32	"Enteroendocrine cells: 744.9"	"Group enriched"	"Detected in some"	10	"pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4"	"Region enhanced"	"Detected in many"		"midbrain: 21.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HMC-1: 35.5;SH-SY5Y: 43.8"	"Region enhanced"	"Detected in single"		"midbrain: 1.9"	"Group enriched"	"Detected in some"	5	"midbrain: 4.8;pons: 2.7"	HPA067679		Supported	Supported	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA067679: AB_2685884"			"unprognostic (4.58e-1)"		"unprognostic (1.60e-1)"					"unprognostic (7.21e-2)"	"prognostic favorable (4.85e-4)"	"unprognostic (2.87e-1)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.15e-1)"			0.1	2.3	0.3	0.0	1.4	0.0	0.0	0.1	0.8	0.0	0.0	1.2	4.3	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.0	6.2	21.6	0.0	0.0	1.3	0.0	2.6	0.0	10.4	2.2	1.8	0.4	0.0	0.0	0.0	0.0	2.1	0.0	0.1	0.0	3.2	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	35.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	5.1	43.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.4	0.1	0.8	0.5	0.2	6.2	21.6	0.0	10.4	0.1	5.6	5.2	0.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	1.2	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	744.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	22.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.5	0.0	0.2	6.0	0.0	0.0	3.4	1.2	0.0	0.0	0.8	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.4	0.1
SPINK8		ENSG00000229453	"Serine peptidase inhibitor Kazal type 8 (putative)"	P0C7L1	3	48306842-48328341	"Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"		"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	6	"bone marrow: 11.6;breast: 44.6"	"Group enriched"	"Detected in some"	5	"Breast glandular cells: 22.1;Breast myoepithelial cells: 9.9"	"Group enriched"	"Detected in some"	10	"breast cancer: 8.6;glioma: 9.6;prostate cancer: 2.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	10	"eosinophil: 1.3;neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	12	"granulocytes: 1.7"	"Cell line enriched"	"Detected in some"	60	"SK-BR-3: 73.2"	"Region enriched"	"Detected in many"	9	"hippocampal formation: 73.7"	"Low region specificity"	"Detected in all"			HPA053151	Uncertain				"Secreted to blood"	NA	NA					"HPA053151: AB_2682059"	"prognostic unfavorable (8.47e-4)"			"unprognostic (1.98e-1)"	"unprognostic (1.75e-2)"					"unprognostic (1.99e-1)"		"unprognostic (1.15e-1)"					"unprognostic (1.20e-1)"	0.0	0.0	2.0	0.0	2.0	11.6	44.6	2.4	4.6	0.0	0.3	0.0	0.1	0.0	2.5	2.9	0.2	0.0	0.0	2.9	1.7	0.0	0.0	0.1	0.0	2.8	1.7	1.9	0.0	0.4	0.0	0.2	0.2	2.5	0.5	0.0	0.3	2.1	0.3	0.0	0.1	0.0	0.0	1.3	0.6	0.0	0.3	1.9	0.0	0.0	0.0	0.0	0.1	0.2	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	73.2	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	2.0	2.0	2.4	4.6	2.9	1.7	2.8	1.7	1.9	2.5	1.3	1.9	2.8	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.0	0.0	22.1	9.9	0.0	0.0	0.4	0.0	0.0	0.5	0.1	0.0	0.0	0.0	1.1	0.1	0.0	1.2	0.0	0.0	2.7	1.3	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	2.0	0.0	0.0	0.7	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.0	1.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.6
KLHL41	"KBTBD10, Krp1, SARCOSIN"	ENSG00000239474	"Kelch like family member 41"	O60662	2	169509702-169526258	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"			"Disease variant, Nemaline myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	42	"skeletal muscle: 5086.1;tongue: 3504.5"	"Group enriched"	"Detected in some"	21	"Cardiomyocytes: 108.1;Skeletal myocytes: 251.8"	"Group enriched"	"Detected in some"	9	"head and neck cancer: 10.8;prostate cancer: 3.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"HSkMC: 21.6;LHCN-M2: 35.4;RH-30: 55.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA021165, HPA021753, HPA021760"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Plasma membrane"	"HPA021165: AB_1852087, HPA021753: AB_1852089, HPA021760: AB_1852091"	"unprognostic (2.44e-2)"	"unprognostic (6.12e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.36e-3)"	"unprognostic (2.05e-1)"	"unprognostic (5.46e-3)"	"unprognostic (1.88e-1)"	"unprognostic (5.38e-2)"	"unprognostic (6.65e-4)"	"unprognostic (9.64e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.69e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.52e-1)"	1.2	0.5	1.8	0.2	1.4	0.0	2.0	3.2	1.9	1.0	1.3	1.1	0.1	0.8	1.5	75.7	1.2	6.8	101.2	1.3	1.6	0.6	0.9	2.8	0.3	1.1	2.7	1.2	1.1	1.1	0.5	5.8	0.1	1.5	50.4	0.3	16.2	52.6	0.7	5086.1	3.0	0.8	0.6	1.1	0.8	1.3	2.6	3.0	1.7	2.3	3504.5	0.3	5.9	0.9	1.7	0.0	0.1	0.0	0.6	0.4	2.7	0.0	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.1	0.0	0.0	0.0	4.3	0.1	0.0	0.0	0.2	0.2	0.0	21.6	0.5	0.3	0.0	0.2	0.1	0.2	0.1	0.0	35.4	0.1	0.1	0.2	0.0	0.0	0.2	0.0	55.9	0.0	0.2	0.1	0.7	0.1	0.1	0.0	1.5	0.1	0.0	0.1	0.0	0.4	0.2	0.4	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	1.4	3.2	1.9	1.3	1.6	1.1	2.7	1.2	1.5	1.1	3.0	1.7	0.0	0.0	0.5	1.3	0.0	0.1	0.5	0.1	0.0	2.4	0.2	0.1	108.1	0.0	2.0	0.0	8.4	0.0	0.0	0.1	0.0	0.5	5.8	1.3	0.2	1.0	1.2	0.0	4.1	0.5	0.0	6.4	0.0	0.1	0.0	0.2	0.4	0.2	0.2	0.0	4.6	0.1	0.0	0.3	0.0	2.9	0.9	0.8	0.0	3.7	0.0	0.7	0.0	1.5	2.3	0.7	0.1	1.2	0.0	0.3	0.0	0.3	4.1	5.8	0.0	251.8	1.8	4.1	0.4	0.0	0.0	0.0	0.3	0.2	0.0	0.1
MASP1	"CRARF, MASP, PRSS5"	ENSG00000127241	"Mannan binding lectin serine peptidase 1"	P48740	3	187217282-187291980	"Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	"Complement activation lectin pathway, Immunity, Innate immunity"	"Hydrolase, Protease, Serine protease"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 117.2;liver: 185.0"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 28.1;Cardiomyocytes: 38.1;Cholangiocytes: 20.0;Endometrial stromal cells: 30.6;Fibroblasts: 16.4;Hepatic stellate cells: 23.2;Hepatocytes: 65.8"	"Group enriched"	"Detected in some"	9	"glioma: 6.8;liver cancer: 7.7;prostate cancer: 3.0;renal cancer: 3.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"BJ: 133.3;BJ hTERT+: 498.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001617, HPA009641"	Supported		Enhanced	Nucleoplasm,Cytosol	"Secreted to blood"	No	NA	8670000000	1900000000	"Nucleoplasm, Cytosol"		"HPA001617: AB_1079314, HPA009641: AB_1079313"	"unprognostic (1.67e-1)"	"unprognostic (1.02e-2)"	"unprognostic (1.99e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.25e-6)"	"prognostic favorable (2.20e-4)"	"unprognostic (9.92e-2)"	"unprognostic (3.22e-1)"	"unprognostic (2.29e-1)"	"unprognostic (4.18e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.82e-3)"	"unprognostic (3.56e-3)"	"unprognostic (1.97e-1)"	"unprognostic (7.85e-2)"	"unprognostic (4.29e-1)"	6.3	3.7	9.6	1.3	8.8	0.0	2.8	14.3	8.0	98.7	4.4	39.0	1.9	89.2	3.4	11.2	17.9	5.1	117.2	9.6	23.8	4.8	185.0	6.1	1.0	19.0	15.4	4.7	2.7	0.2	0.3	1.0	9.1	15.5	46.4	5.6	0.0	2.3	52.8	37.8	5.5	7.6	44.8	21.3	0.8	1.6	0.5	13.3	0.2	3.3	19.1	4.3	10.0	62.1	32.8	0.0	0.0	0.3	0.4	15.7	17.3	0.1	133.3	498.3	1.8	0.9	0.0	0.0	0.1	0.0	40.8	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.4	2.6	0.0	0.0	2.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.1	0.2	0.0	0.0	5.4	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.6	8.8	14.3	8.0	9.6	23.8	19.0	15.4	4.7	15.5	21.3	13.3	32.8	1.1	0.0	1.8	28.1	0.2	2.9	0.1	0.2	0.0	0.0	0.0	0.0	38.1	20.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.9	0.7	30.6	2.0	0.0	0.0	0.2	0.0	0.3	16.4	0.0	0.7	0.0	0.2	23.2	65.8	0.4	0.0	0.9	0.0	0.0	1.9	3.7	7.5	2.5	0.3	1.8	1.0	0.0	0.0	0.0	10.1	0.2	0.0	0.0	0.7	0.1	0.1	0.0	2.4	0.0	0.0	0.0	5.4	4.5	0.0	0.0	0.2	1.7	0.1	0.5	5.1	0.0	0.1
MYH7	"CMD1S, CMH1, MPD1"	ENSG00000092054	"Myosin heavy chain 7"	P12883	14	23412740-23435660	"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin"	"Cardiomyopathy, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	62	"heart muscle: 4312.8;skeletal muscle: 14692.0;tongue: 5426.5"	"Cell type enriched"	"Detected in some"	127	"Cardiomyocytes: 10295.8"	"Group enriched"	"Detected in some"	9	"head and neck cancer: 12.2;prostate cancer: 15.4"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	31	"HSkMC: 11.4"	"Low region specificity"	"Detected in many"							"HPA001239, HPA001349, CAB015384"	Enhanced		Uncertain	"Focal adhesion sites"		NA	NA		43000000	"Focal adhesion sites"		"CAB015384: AB_2147279, HPA001239: AB_1079438, HPA001349: AB_1079437"	"unprognostic (6.49e-2)"	"unprognostic (8.27e-5)"	"unprognostic (1.56e-1)"	"unprognostic (3.04e-3)"	"unprognostic (4.30e-1)"	"unprognostic (7.33e-3)"		"unprognostic (8.60e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.79e-1)"	"unprognostic (5.38e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.28e-2)"	1.7	1.3	2.0	0.0	1.6	0.1	2.6	0.2	1.1	0.3	1.2	1.0	0.5	0.4	0.0	130.3	0.1	1.1	4312.8	1.2	2.1	0.9	1.4	3.2	1.5	1.1	1.4	0.8	0.7	7.8	0.0	1.5	0.0	0.7	77.5	0.0	0.0	37.3	0.0	14692.0	3.2	0.9	0.0	0.7	0.5	0.9	1.4	2.4	0.1	1.9	5426.5	0.1	0.2	1.2	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	1.6	0.2	1.1	1.2	2.1	1.1	1.4	0.8	0.7	0.7	2.4	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10295.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.2	0.0	80.9	0.0	0.0	0.2	3.1	0.0	70.5	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.7	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	3.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	52.2	51.2	0.1	2.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0
RPS4Y2	RPS4Y2P	ENSG00000280969	"Ribosomal protein S4 Y-linked 2"	Q8TD47	Y	20756108-20781032	"Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"prostate: 1.9;testis: 1.1"	"Cell type enhanced"	"Detected in some"		"B-cells: 3.5;Basal keratinocytes: 3.2;Basal prostatic cells: 3.5;Langerhans cells: 3.4;Prostatic glandular cells: 2.1;Spermatogonia: 2.6;Suprabasal keratinocytes: 5.8"	"Cancer enriched"	"Detected in single"	9	"prostate cancer: 1.8"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in some"	6	"neutrophil: 7.4"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 7.4"	"Cell line enriched"	"Detected in single"	5	"U-266/84: 2.0"									HPA000857	Uncertain					NA	NA					"HPA000857: AB_1079849"					"unprognostic (1.50e-2)"							"unprognostic (3.63e-1)"		"unprognostic (6.39e-6)"	"unprognostic (5.92e-2)"			0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	1.2	0.1	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	3.2	3.5	0.6	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.3	3.4	0.0	0.9	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	2.1	0.0	0.0	0.0	0.0	0.0	1.7	0.6	1.1	2.6	0.0	5.8	0.3	0.4	0.0	0.0	1.3
ABCC4	"EST170205, MOAT-B, MOATB, MRP4"	ENSG00000125257	"ATP binding cassette subfamily C member 4"	O15439	13	95019835-95301475	"Enzymes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Transporters"	Transport	Translocase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 41.5"	"Cell type enhanced"	"Detected in many"		"Erythroid cells: 51.3;granulocytes: 53.9;Microglial cells: 203.3"	"Cancer enriched"	"Detected in all"	8	"prostate cancer: 90.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"HEL: 245.7;HMC-1: 256.3;RPTEC TERT1: 69.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002476	Enhanced		Supported	"Nucleoli,Golgi apparatus,Plasma membrane"		NA	NA			"Plasma membrane"	"Nucleoli, Golgi apparatus"	"HPA002476: AB_1844434"	"unprognostic (8.77e-2)"	"unprognostic (1.94e-2)"	"unprognostic (1.48e-1)"	"prognostic unfavorable (9.89e-4)"	"unprognostic (2.83e-2)"	"unprognostic (1.23e-1)"	"unprognostic (7.45e-3)"	"unprognostic (2.40e-2)"	"unprognostic (9.96e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.55e-2)"	"prognostic favorable (2.25e-10)"	"unprognostic (7.44e-3)"	"unprognostic (1.67e-1)"	"unprognostic (5.55e-2)"	"unprognostic (2.35e-2)"	2.0	1.3	2.4	6.2	2.1	4.1	6.9	2.7	2.3	5.0	7.1	8.7	5.0	3.5	19.0	2.0	10.3	6.1	2.0	2.2	5.1	18.2	1.3	7.6	3.9	4.2	3.0	1.3	3.8	3.3	22.7	1.4	2.1	4.3	41.5	8.6	0.9	1.5	5.5	5.4	2.6	5.5	6.3	4.5	4.1	5.2	4.7	3.6	3.9	7.8	1.7	6.4	15.6	1.8	5.1	18.5	31.7	5.3	9.4	9.5	12.3	1.3	14.4	14.3	12.6	10.9	43.8	13.2	10.2	9.3	19.5	9.0	24.0	7.9	7.1	15.8	30.7	12.1	245.7	8.8	8.8	19.2	28.6	256.3	9.4	3.2	9.1	18.5	17.9	16.4	11.3	25.8	0.4	17.1	5.9	5.4	4.6	6.2	22.3	7.9	7.7	14.3	26.9	69.3	40.4	12.5	9.3	4.8	1.2	10.1	5.9	0.0	15.1	27.0	13.3	8.6	11.2	17.3	0.1	0.0	4.0	25.4	16.0	6.6	0.2	0.5	0.2	1.3	0.6	1.1	1.4	1.0	1.5	1.8	1.6	0.6	1.5	0.3	1.9	2.3	0.3	1.5	1.3	2.4	2.1	2.7	2.3	2.2	5.1	4.2	3.0	1.3	4.3	4.5	3.6	5.1	4.6	9.6	32.7	28.4	5.8	4.2	7.0	7.3	4.0	0.1	0.6	0.6	4.5	8.6	9.1	23.9	22.9	0.1	2.0	2.7	0.0	6.9	3.8	4.2	11.3	19.8	0.0	51.3	13.6	3.1	0.4	5.7	6.1	6.0	53.9	9.5	2.9	0.6	4.5	0.0	10.3	4.0	0.0	2.5	8.1	2.0	6.8	10.7	1.8	203.3	13.5	0.5	4.1	16.1	2.5	2.9	8.3	1.9	8.3	27.1	0.5	26.4	4.7	0.8	0.0	8.2	3.1	0.9	8.3	3.4	7.5	0.3	6.4	17.3	9.2	4.5
ACADL	"ACAD4, LCAD"	ENSG00000115361	"Acyl-CoA dehydrogenase long chain"	P28330	2	210187126-210225447	"Enzymes, Metabolic proteins, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism"	Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 28.3;pancreas: 28.6"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 70.9;Early spermatids: 85.6;Late spermatids: 69.4;Leydig cells: 46.9;Peritubular cells: 46.6;Proximal tubular cells: 31.5"	"Group enriched"	"Detected in many"	8	"liver cancer: 2.2;prostate cancer: 6.8;renal cancer: 8.8;thyroid cancer: 4.6"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 2.4;RPTEC TERT1: 2.6;SuSa: 2.3;U-2 OS: 1.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA011990	Enhanced	Supported				NA	NA					"HPA011990: AB_1844465"	"unprognostic (6.29e-3)"	"unprognostic (7.61e-2)"		"unprognostic (1.40e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.33e-2)"	"unprognostic (7.66e-3)"	"unprognostic (3.24e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.99e-1)"	"prognostic favorable (1.58e-11)"	"unprognostic (4.22e-3)"	"unprognostic (1.18e-4)"	"unprognostic (8.81e-3)"	"unprognostic (1.06e-1)"	12.0	1.1	0.7	0.1	0.6	0.0	8.1	0.6	1.1	3.4	0.8	0.5	0.0	0.7	1.1	0.5	4.0	0.6	2.1	0.6	1.1	20.0	28.3	10.1	0.0	0.7	0.6	0.6	12.8	28.6	4.5	2.9	1.0	0.6	20.8	0.1	0.0	6.8	4.9	9.6	2.6	0.4	0.1	0.6	0.0	5.6	3.1	0.6	1.5	23.9	5.1	0.0	1.0	3.8	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.9	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	2.6	0.5	0.0	0.1	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.6	1.1	0.6	1.1	0.7	0.6	0.6	0.6	0.6	0.6	0.7	0.2	28.9	70.9	1.0	0.0	0.6	1.4	1.1	1.2	0.2	1.3	0.5	1.1	8.6	7.6	22.0	2.1	8.8	0.0	0.0	15.6	4.0	85.6	7.1	0.4	0.2	0.0	0.0	0.2	11.9	0.3	4.9	3.6	5.9	2.5	0.8	0.7	23.0	0.5	0.0	13.3	0.0	0.0	0.3	0.4	69.4	46.9	0.4	0.0	4.7	0.0	0.2	0.0	7.5	0.3	3.9	0.0	46.6	0.0	8.2	0.0	31.5	2.4	0.2	0.0	7.6	13.7	0.7	0.7	0.7	1.0	6.3	0.4	0.1	0.0	0.7
ACSM1	"BUCS1, MACS1"	ENSG00000166743	"Acyl-CoA synthetase medium chain family member 1"	Q08AH1	16	20623237-20698890	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism"	Ligase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	21	"breast: 227.5"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 13.2;Late spermatids: 23.2;Theca cells: 8.4"	"Group enriched"	"Detected in many"	8	"liver cancer: 14.7;prostate cancer: 36.7"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"eosinophil: 1.3;memory B-cell: 1.7"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	4	"NTERA-2: 15.6"	"Not detected"	"Not detected"							HPA046291	Uncertain					NA	NA					"HPA046291: AB_10960704"	"unprognostic (1.08e-2)"	"unprognostic (3.07e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.86e-2)"	"unprognostic (5.49e-4)"	"unprognostic (1.66e-1)"	"unprognostic (3.50e-2)"	"unprognostic (9.46e-2)"	"unprognostic (3.10e-1)"	"unprognostic (8.44e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.64e-1)"	"unprognostic (8.24e-2)"	"unprognostic (3.79e-2)"	"unprognostic (3.01e-1)"	"unprognostic (9.58e-2)"	"unprognostic (2.33e-3)"	0.3	0.5	0.3	0.0	0.3	3.6	227.5	0.4	0.4	1.7	0.2	1.0	0.5	2.1	0.4	0.4	2.2	0.4	0.4	0.3	0.3	1.1	10.8	0.5	0.3	0.4	0.3	0.2	2.6	1.6	0.9	0.1	0.0	0.5	3.8	0.6	0.1	1.8	0.6	0.3	1.3	0.7	0.8	0.3	0.5	2.2	4.4	0.4	0.4	0.5	0.2	0.2	1.0	1.4	0.4	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.0	0.1	0.1	0.0	0.6	0.0	0.0	0.0	0.1	0.0	1.2	0.0	0.8	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.1	0.0	0.1	15.6	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.5	0.0	0.4	0.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	0.0	0.0	0.0	1.7	0.2	0.0	0.0	0.8	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.3	0.3	0.4	0.4	0.3	0.3	0.4	0.3	0.2	0.5	0.3	0.4	0.4	0.1	0.0	0.0	0.3	1.0	0.6	2.6	1.2	1.2	0.0	2.5	2.4	1.0	5.7	1.4	0.0	0.0	0.2	0.2	1.6	1.9	4.2	13.2	1.4	0.2	1.5	1.2	1.3	0.8	2.3	0.1	0.7	2.0	0.8	0.0	2.8	3.6	1.3	0.2	0.0	0.7	2.9	0.0	0.3	2.8	23.2	4.4	0.6	0.0	0.0	1.7	0.0	0.0	1.0	1.3	1.2	3.7	7.2	0.0	2.5	0.6	1.4	3.7	0.0	0.0	0.1	0.2	0.8	0.2	1.1	1.6	0.1	0.3	8.4	2.5	1.4
AGTR1	"AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R"	ENSG00000144891	"Angiotensin II receptor type 1"	P30556	3	148697784-148743008	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease variant, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 97.4;placenta: 142.8"	"Cell type enhanced"	"Detected in some"		"Fibroblasts: 53.1;Hepatocytes: 30.9;Leydig cells: 145.1;Sertoli cells: 144.7;Smooth muscle cells: 71.2"	"Group enriched"	"Detected in many"	8	"breast cancer: 9.6;liver cancer: 9.8;prostate cancer: 6.8;renal cancer: 2.8"	"Group enriched"	"Detected in some"	6	"hypothalamus: 6.1;medulla oblongata: 2.2;midbrain: 7.3;pons: 2.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 176.8;ASC TERT1: 24.4;BJ hTERT+ SV40 Large T+: 34.8;HBF TERT88: 53.9;HSkMC: 32.2"					"Low region specificity"	"Detected in all"			HPA003596	Enhanced		Uncertain	Vesicles		NA	NA			Vesicles		"HPA003596: AB_1845163"	"unprognostic (2.19e-1)"	"unprognostic (1.17e-1)"	"unprognostic (8.78e-2)"	"unprognostic (2.48e-4)"	"unprognostic (5.28e-3)"	"unprognostic (1.55e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.28e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.08e-2)"	"unprognostic (9.25e-3)"	"unprognostic (4.11e-2)"	"unprognostic (4.79e-2)"	"unprognostic (3.21e-3)"	"unprognostic (1.46e-1)"	"unprognostic (2.54e-1)"	"unprognostic (5.41e-3)"	52.7	38.5	0.3	1.8	0.7	0.0	40.2	0.3	0.4	3.4	0.4	15.3	0.9	3.5	2.8	2.8	9.9	6.3	7.7	0.4	6.1	18.6	97.4	10.5	0.7	2.2	7.3	0.2	3.9	3.5	2.9	3.9	142.8	2.6	5.4	4.4	0.9	4.8	4.2	11.7	12.9	4.3	4.6	0.2	9.1	6.5	2.2	0.5	3.0	14.3	13.9	0.2	14.7	6.2	0.3	0.0	1.0	0.8	0.0	176.8	24.4	0.0	0.2	3.9	34.8	20.0	0.0	0.0	0.0	0.0	2.6	0.2	0.0	0.0	0.0	53.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	32.2	0.0	3.4	1.8	1.0	0.0	0.0	0.0	0.0	8.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.4	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.3	0.4	0.4	6.1	2.2	7.3	0.2	2.6	0.2	0.5	0.3	20.5	0.0	0.6	0.0	0.0	3.4	0.2	0.0	0.0	0.0	1.3	0.9	6.3	2.8	0.0	0.0	0.0	0.5	0.3	0.1	0.0	0.1	0.8	0.0	0.3	3.8	23.5	0.0	0.1	7.6	0.3	53.1	0.5	0.0	0.0	0.0	17.5	30.9	0.7	0.0	0.0	0.2	0.0	0.3	3.5	1.7	145.1	0.5	1.8	2.8	0.0	5.7	0.0	0.0	0.1	0.5	0.0	7.5	0.4	1.1	0.0	0.1	0.0	0.1	144.7	7.6	71.2	0.0	1.8	0.3	1.7	0.3	0.5	0.3	0.0	0.1
ELOVL2	Ssc2	ENSG00000197977	"ELOVL fatty acid elongase 2"	Q9NXB9	6	10980759-11044305	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism"	Transferase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 52.9;placenta: 35.6;retina: 28.1"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 95.0;Cone photoreceptor cells: 29.2;Extravillous trophoblasts: 19.7;Sertoli cells: 19.7;Spermatocytes: 23.0"	"Group enriched"	"Detected in many"	8	"breast cancer: 11.9;glioma: 25.8;liver cancer: 24.0;melanoma: 14.2;prostate cancer: 9.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+ SV40 Large T+ RasG12V: 29.9;GAMG: 31.2;HBF TERT88: 29.0;Hep G2: 23.4;RH-30: 31.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"prognostic favorable (6.73e-5)"	"unprognostic (4.20e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.28e-5)"	"unprognostic (4.06e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.89e-1)"	"unprognostic (5.73e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.56e-1)"	"unprognostic (6.92e-3)"	"unprognostic (1.78e-2)"	"unprognostic (1.04e-12)"	"unprognostic (9.98e-4)"	"unprognostic (8.86e-2)"	"unprognostic (3.41e-1)"	"unprognostic (9.47e-2)"	1.2	0.9	9.0	1.5	10.2	0.0	4.9	10.1	14.0	0.1	4.6	0.4	0.2	0.5	2.3	0.4	0.2	0.6	3.2	9.1	22.4	0.2	52.9	0.2	0.5	10.2	9.2	8.6	0.2	2.6	9.8	3.0	35.6	9.5	5.3	0.1	28.1	0.7	0.4	1.0	0.2	0.3	0.7	9.8	0.0	0.1	11.7	9.6	1.1	1.8	1.0	0.9	2.1	0.1	14.5	0.0	5.3	20.1	0.0	0.0	0.0	11.5	0.4	1.0	17.7	29.9	0.0	0.0	0.0	0.0	1.1	31.2	0.0	21.3	0.0	29.0	0.0	18.2	0.1	0.4	23.4	0.9	0.4	4.8	0.2	0.0	13.7	0.0	1.0	0.0	0.9	1.2	0.0	0.4	0.1	12.1	0.2	3.8	0.0	17.4	16.6	31.8	0.0	0.0	0.3	8.0	9.1	0.0	0.0	7.5	16.1	3.7	9.3	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.0	10.2	10.1	14.0	9.1	22.4	10.2	9.2	8.6	9.5	9.8	9.6	14.5	0.5	0.0	0.0	95.0	0.1	0.1	0.0	0.0	0.0	2.2	7.8	1.3	1.2	8.6	0.0	0.0	29.2	2.3	0.0	0.0	0.0	7.2	10.1	0.0	0.5	1.9	0.0	0.0	2.5	1.0	19.7	8.0	0.0	0.0	0.0	0.3	0.0	17.5	1.2	0.0	5.9	0.0	0.0	0.0	0.0	14.9	0.9	0.1	0.0	6.5	0.0	4.9	0.0	4.5	16.8	1.0	0.0	0.4	0.0	1.9	0.0	0.1	0.0	11.8	19.7	0.1	3.9	23.0	8.9	0.2	0.0	1.6	0.1	0.0	0.0	0.1
FCN2	"EBP-37, FCNL, ficolin-2, P35"	ENSG00000160339	"Ficolin 2"	Q15485	9	134880810-134887523	"Plasma proteins, Predicted secreted proteins"	"Complement activation lectin pathway, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"liver: 100.5"	"Cell type enriched"	"Detected in some"	18	"Hepatic stellate cells: 1192.6"	"Group enriched"	"Detected in some"	8	"breast cancer: 1.0;liver cancer: 2.0;prostate cancer: 1.1;renal cancer: 0.5"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"classical monocyte: 5.5;intermediate monocyte: 4.6"	"Low lineage specificity"	"Detected in many"			"Not detected"	"Not detected"							"Region enriched"	"Detected in some"	23	"spinal cord: 38.6"						"Secreted to blood"	NA	NA	8100000000	1400000000				"unprognostic (1.91e-1)"	"unprognostic (1.07e-1)"			"unprognostic (6.96e-4)"		"unprognostic (3.73e-2)"	"unprognostic (2.09e-2)"		"unprognostic (3.81e-1)"	"unprognostic (2.82e-1)"	"unprognostic (3.13e-2)"	"unprognostic (1.06e-2)"		"unprognostic (1.05e-1)"	"unprognostic (3.07e-1)"		4.7	24.8	0.3	0.0	0.3	0.1	7.7	0.2	0.5	0.3	0.4	0.0	0.1	0.1	0.2	0.1	0.3	0.1	0.2	0.5	0.3	6.2	100.5	0.1	0.1	0.3	0.5	0.2	0.5	0.5	0.2	3.1	0.0	0.3	3.2	0.0	0.0	3.2	0.4	0.1	0.2	0.1	0.0	0.2	3.1	0.2	0.2	0.3	0.0	2.1	0.1	0.0	0.4	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	5.5	0.0	0.0	4.6	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	1.1	0.0	2.2	0.0	0.0	9.0	0.3	0.3	0.2	0.5	0.5	0.3	0.3	0.5	0.2	0.3	0.2	0.3	0.3	0.1	0.0	0.0	0.7	3.8	0.0	0.1	0.0	0.0	0.0	3.8	0.4	0.1	12.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.6	0.0	34.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1192.6	12.6	0.0	0.0	0.1	0.0	0.0	64.1	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.1
GLYATL1	"FLJ34646, MGC15397"	ENSG00000166840	"Glycine-N-acyltransferase like 1"	Q969I3	11	58905398-59043527	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		"Acyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"liver: 581.1"	"Group enriched"	"Detected in some"	4	"Hepatocytes: 234.3;Proximal tubular cells: 797.1"	"Group enriched"	"Detected in some"	8	"liver cancer: 14.1;prostate cancer: 13.3;renal cancer: 10.1"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 2.0;Daudi: 4.9;RPTEC TERT1: 1.5;U-2197: 1.2"									HPA039501	Supported		Uncertain	"Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	Cytosol	"HPA039501: AB_2676545"	"unprognostic (9.46e-3)"	"unprognostic (5.33e-2)"	"unprognostic (3.90e-5)"	"unprognostic (3.93e-3)"	"unprognostic (3.54e-3)"	"unprognostic (2.17e-1)"	"prognostic favorable (3.69e-4)"	"unprognostic (3.62e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.92e-1)"	"prognostic favorable (3.03e-5)"	"unprognostic (1.50e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.86e-2)"	"unprognostic (4.55e-2)"	0.0	0.0	0.1	0.0	0.1	0.0	1.3	0.3	0.4	0.1	0.3	0.4	1.6	0.1	0.7	0.1	1.3	0.9	0.0	0.1	0.3	142.7	581.1	0.0	0.1	0.9	0.4	0.0	0.0	1.7	2.6	0.0	0.0	1.1	11.2	0.3	0.2	1.9	0.0	0.0	0.5	0.2	0.0	0.3	0.1	2.7	0.1	0.2	2.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.2	0.1	0.5	0.4	2.0	0.0	4.9	0.0	0.3	0.4	0.0	0.0	0.0	0.8	0.0	0.2	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.5	0.0	0.1	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.6	0.0	1.2	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.4	0.1	0.3	0.9	0.4	0.0	1.1	0.3	0.2	0.5	0.0	0.0	0.0	0.0	3.5	0.0	0.1	0.0	0.0	0.0	1.8	0.0	0.3	12.8	0.0	14.7	0.0	0.0	0.0	0.1	107.6	0.1	0.0	2.5	0.1	0.5	0.0	8.0	0.7	0.6	0.0	0.1	0.0	0.1	0.0	0.1	5.0	234.3	0.0	0.0	0.8	0.1	0.0	8.1	0.0	0.0	0.0	3.1	1.8	0.0	0.0	0.0	0.0	0.5	0.2	0.3	0.0	0.0	0.0	1.3	0.0	797.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	1.9	0.1	0.9	0.2
KCNC2	Kv3.2	ENSG00000166006	"Potassium voltage-gated channel subfamily C member 2"	Q96PR1	12	75040077-75209839	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 48.5"	"Group enriched"	"Detected in some"	51	"Excitatory neurons: 389.6;Inhibitory neurons: 1425.5"	"Group enriched"	"Detected in some"	8	"breast cancer: 1.5;prostate cancer: 4.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019664, CAB022571"	Uncertain					NA	NA					"CAB022571: , HPA019664: AB_1855578"	"unprognostic (2.01e-1)"				"unprognostic (1.14e-1)"		"unprognostic (2.68e-1)"				"unprognostic (5.58e-3)"	"unprognostic (4.46e-2)"		"unprognostic (3.39e-2)"				0.0	0.0	11.4	0.0	16.2	0.0	1.8	0.0	47.3	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	6.9	8.5	0.0	0.2	0.0	0.0	22.4	16.2	20.3	0.0	0.0	0.0	7.1	0.0	27.3	2.6	0.0	9.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	48.5	0.0	0.0	0.1	0.0	0.0	0.0	38.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	16.2	0.0	47.3	6.9	8.5	22.4	16.2	20.3	27.3	0.0	48.5	38.6	0.0	0.0	0.0	17.6	0.0	0.0	2.9	0.0	0.0	15.9	16.7	7.7	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.3	0.0	0.0	389.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1425.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.2	0.0	2.6	0.0	14.1	14.8	0.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	7.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2
NCAPD3	"CAP-D3, FLJ42888, hCAP-D3, hcp-6, hHCP-6, KIAA0056"	ENSG00000151503	"Non-SMC condensin II complex subunit D3"	P42695	11	134150113-134225454	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA condensation, Mitosis"		"Disease variant, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"prostate: 59.0"	"Low cell type specificity"	"Detected in many"			"Cancer enriched"	"Detected in all"	8	"prostate cancer: 50.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA040286			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA040286: AB_2676918"	"unprognostic (4.27e-2)"	"unprognostic (6.05e-2)"	"unprognostic (7.78e-3)"	"unprognostic (8.22e-3)"	"unprognostic (2.79e-1)"	"unprognostic (4.29e-2)"	"unprognostic (2.15e-3)"	"unprognostic (2.56e-1)"	"unprognostic (4.32e-2)"	"unprognostic (4.75e-1)"	"unprognostic (2.79e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.93e-2)"	"unprognostic (3.35e-2)"	"unprognostic (3.94e-1)"	"unprognostic (3.48e-1)"	4.5	5.5	1.9	3.1	2.1	10.1	4.9	4.0	4.0	3.9	2.2	4.0	3.6	4.0	3.3	7.2	3.9	2.6	4.5	3.2	1.4	3.6	8.9	4.9	4.2	2.2	1.4	2.3	3.4	4.5	2.0	7.1	3.1	2.2	59.0	1.5	4.5	5.7	0.9	3.8	9.0	5.5	1.4	1.1	6.2	5.2	9.6	1.8	3.1	6.0	0.9	1.7	3.8	5.3	3.2	5.5	1.9	12.3	25.3	1.8	1.3	10.6	11.5	1.9	3.5	4.0	5.6	3.4	6.1	11.1	3.5	9.8	6.1	3.5	5.2	4.4	9.2	21.7	26.6	5.1	8.5	2.3	13.1	15.4	1.7	1.1	5.1	2.0	3.6	2.6	11.6	7.1	4.7	4.2	6.0	10.9	15.1	8.6	5.5	13.8	2.9	13.7	8.5	4.1	3.2	22.1	13.4	9.1	5.9	1.7	10.0	9.7	6.9	1.7	11.8	5.7	11.8	9.9	4.5	4.5	5.5	8.3	16.4	15.2	1.6	3.3	1.6	5.7	2.7	2.2	2.3	3.7	3.8	2.5	5.2	5.5	5.8	1.6	1.7	2.2	8.0	6.5	1.9	1.9	2.1	4.0	4.0	3.2	1.4	2.2	1.4	2.3	2.2	1.1	1.8	3.2	7.7	3.2	8.1	8.5	12.1	9.2	4.4	6.0	8.0	20.2	9.9	8.6	6.7	2.8	7.0	12.9	10.4	13.0	13.2	5.4	0.0	2.7	7.2	7.8	12.8	5.6	7.8	32.8	19.7	2.6	9.9	7.5	7.7	9.0	2.5	19.6	5.7	9.7	8.8	11.8	16.7	7.2	10.2	6.4	8.7	10.4	4.7	10.9	1.8	15.0	17.1	9.0	17.5	11.1	16.0	2.8	1.6	4.1	22.9	8.8	3.2	3.6	4.9	20.9	0.0	9.5	9.2	21.5	14.4	10.7	9.1	4.5	14.2	11.3	11.6	3.4
PDLIM5	"Enh, LIM"	ENSG00000163110	"PDZ and LIM domain 5"	Q96HC4	4	94451857-94668227	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	7	"heart muscle: 635.2;skeletal muscle: 1174.5;tongue: 581.1"	"Cell type enriched"	"Detected in all"	4	"Cardiomyocytes: 1844.2"	"Cancer enriched"	"Detected in all"	8	"prostate cancer: 132.0"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in all"	5	"basophil: 219.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 219.7"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013511, HPA016740, HPA020026"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA		1200000	"Plasma membrane"	"Nucleoplasm, Focal adhesion sites"	"CAB013511: AB_2533388, HPA016740: AB_1855153, HPA020026: AB_1855154"	"unprognostic (6.20e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.08e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.46e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.15e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.04e-1)"	42.1	26.3	21.2	25.8	24.1	60.2	39.9	23.9	22.6	27.5	79.3	34.4	33.6	95.6	11.4	73.0	40.9	47.9	635.2	21.6	94.7	35.2	83.4	22.2	16.4	31.7	27.7	16.1	27.4	30.4	12.3	17.7	68.3	24.6	89.3	31.0	18.3	40.5	69.5	1174.5	20.8	34.7	106.8	22.6	24.3	31.3	12.8	23.8	11.0	25.7	581.1	21.3	46.3	27.8	22.1	31.4	87.2	33.6	13.0	71.7	51.3	13.0	71.6	59.9	40.1	32.6	80.8	66.3	12.0	72.0	72.3	21.0	31.8	46.5	68.2	65.9	24.1	19.3	43.7	53.8	32.2	103.7	14.6	38.3	66.4	58.4	96.1	74.0	177.9	93.5	13.2	19.2	12.5	86.2	29.8	15.0	4.8	11.4	66.7	36.6	7.2	24.7	11.1	45.0	94.6	16.5	21.8	38.9	88.7	20.3	26.7	10.3	5.2	113.7	103.7	17.3	46.1	44.1	9.5	13.0	12.7	56.5	10.3	24.9	219.7	23.4	21.0	12.1	40.6	9.7	10.5	12.0	12.8	19.5	7.6	7.9	10.4	22.6	9.2	44.6	6.6	11.8	15.2	21.2	24.1	23.9	22.6	21.6	94.7	31.7	27.7	16.1	24.6	22.6	23.8	22.1	107.4	44.8	23.6	184.1	22.1	194.4	380.3	92.1	63.7	4.7	90.2	67.4	1844.2	62.9	82.9	49.7	31.3	13.7	18.5	180.0	13.7	95.0	19.2	68.7	11.8	117.2	109.4	27.6	4.9	95.1	96.5	97.8	84.6	108.7	52.0	29.1	137.8	207.0	38.8	1.7	20.7	107.4	36.7	60.6	75.3	9.1	41.3	59.8	62.2	104.0	41.6	86.2	12.3	181.5	43.1	139.2	166.8	66.5	23.2	300.7	117.5	73.6	70.0	35.8	78.9	96.7	134.7	23.8	34.4	107.3	157.0	23.8	31.1	6.8	74.0	217.5
PRAC2	"C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253"	ENSG00000229637	"PRAC2 small nuclear protein"	D3DTV9	17	48723185-48724758	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"			"Group enriched"	"Detected in some"	4	"intestine: 9.8;prostate: 13.4"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 36.2;Distal enterocytes: 17.5;Early spermatids: 32.9;Enteroendocrine cells: 31.9;Intestinal goblet cells: 15.5;Late spermatids: 60.5;Prostatic glandular cells: 20.2;Undifferentiated cells: 22.7;Urothelial cells: 30.1"	"Cancer enriched"	"Detected in many"	8	"prostate cancer: 26.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"PC-3: 49.3;REH: 20.0"														"Intracellular and membrane"	NA	NA						"unprognostic (1.22e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.26e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.63e-2)"			"unprognostic (9.98e-2)"	"unprognostic (3.27e-2)"		"unprognostic (9.77e-2)"	"unprognostic (8.97e-2)"		"unprognostic (1.01e-1)"	"unprognostic (1.82e-1)"		"unprognostic (1.82e-1)"	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	13.4	9.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	2.5	2.5	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	1.9	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.1	0.0	6.5	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	1.2	49.3	20.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.2	0.0	2.8	0.0	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.5	0.0	0.0	32.9	0.0	0.0	0.1	31.9	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	15.5	0.0	0.0	0.3	60.5	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.4	0.0	20.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.0	22.7	30.1
TCAP	"CMD1N, LGMD2G, T-cap, TELE, telethonin"	ENSG00000173991	Titin-cap	O15273	17	39665349-39666554	"Disease related genes, Human disease related genes, Predicted intracellular proteins"			"Cardiomyopathy, Disease variant, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	45	"heart muscle: 4049.4;skeletal muscle: 15979.8;tongue: 5883.1"	"Cell type enriched"	"Detected in many"	7	"Cardiomyocytes: 2473.2"	"Group enriched"	"Detected in many"	8	"head and neck cancer: 20.2;prostate cancer: 11.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"NB-4: 5.3;SK-BR-3: 8.4"	"Region enhanced"	"Detected in many"		"cerebral cortex: 15.8"	"Low region specificity"	"Detected in some"			"CAB004591, HPA026477"	Enhanced					NA	NA		36000			"CAB004591: AB_628340, HPA026477: AB_1857888"	"unprognostic (5.29e-2)"	"unprognostic (9.29e-2)"	"unprognostic (2.40e-3)"	"unprognostic (4.32e-3)"	"unprognostic (8.79e-2)"	"unprognostic (3.68e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.34e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.12e-4)"	"unprognostic (2.62e-1)"	"unprognostic (4.51e-2)"	"unprognostic (8.59e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.78e-1)"	"prognostic favorable (4.55e-4)"	3.5	4.2	11.9	0.8	14.2	2.9	5.8	12.8	16.2	2.9	10.2	2.6	0.7	2.2	0.0	190.5	2.6	1.9	4049.4	11.0	11.8	3.1	3.4	8.5	3.3	12.4	12.8	10.9	3.6	2.7	0.9	5.4	0.9	12.6	108.0	0.1	1.1	138.7	1.6	15979.8	4.3	2.5	0.8	11.2	3.2	2.7	3.5	12.2	1.0	5.0	5883.1	0.9	1.7	3.0	12.0	0.1	2.5	1.7	2.2	0.2	0.3	0.6	0.4	0.2	0.4	0.5	0.9	1.5	1.0	1.6	0.3	1.7	0.9	0.3	0.0	0.0	0.9	2.6	0.7	2.0	0.4	0.1	0.6	0.3	0.7	0.3	1.0	0.1	1.0	0.2	1.1	1.6	0.3	0.0	1.1	0.7	5.3	1.0	0.9	0.6	0.7	1.5	0.7	0.8	0.2	1.0	1.7	1.3	8.4	1.1	0.9	0.6	1.1	1.1	0.8	1.0	1.4	0.5	3.7	2.0	0.5	0.6	1.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	11.9	14.2	12.8	16.2	11.0	11.8	12.4	12.8	10.9	12.6	11.2	12.2	12.0	3.3	0.0	0.0	8.1	0.7	1.7	0.5	0.3	0.0	1.5	1.5	0.9	2473.2	5.7	0.3	1.8	0.0	0.1	0.3	0.4	1.9	0.3	0.4	0.9	0.5	29.0	3.0	1.3	2.2	0.0	0.0	68.5	1.5	0.6	0.0	0.8	2.2	0.0	0.4	10.1	2.7	1.1	0.0	0.6	2.0	0.1	0.3	2.9	1.8	1.0	0.1	0.8	0.0	1.0	2.6	0.5	0.6	0.4	0.9	0.7	0.5	0.3	0.6	1.7	6.6	336.9	25.4	1.0	1.2	0.0	2.0	0.4	1.9	0.5	1.2	0.7
TRGV10	"TCRGV10, V3P"	ENSG00000211694	"T cell receptor gamma variable 10 (non-functional)"		7	38299811-38300322	"Predicted intracellular proteins, T-cell receptor genes"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.2;lymphoid tissue: 14.1"	"Cell type enhanced"	"Detected in some"		"dendritic cells: 7.5;Plasma cells: 7.1;T-cells: 29.9"	"Cancer enriched"	"Detected in many"	8	"prostate cancer: 7.3"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"gdT-cell: 196.5"	"Lineage enriched"	"Detected in many"	8	"T-cells: 196.5"	"Group enriched"	"Detected in some"	24	"NB-4: 79.7;U-937: 20.5"															NA	NA						"unprognostic (1.59e-2)"	"unprognostic (4.53e-3)"	"unprognostic (5.13e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.54e-2)"	"unprognostic (1.22e-4)"	"unprognostic (2.47e-3)"	"unprognostic (2.24e-1)"	"unprognostic (2.50e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.24e-4)"	"unprognostic (2.68e-1)"	"unprognostic (9.00e-2)"	"unprognostic (5.10e-2)"	"unprognostic (2.07e-2)"	1.1	0.6	0.1	2.7	0.2	14.2	1.8	0.1	0.5	1.2	0.9	2.0	2.2	0.8	0.7	1.1	1.3	3.3	0.4	0.1	0.1	0.6	1.8	4.1	11.0	0.4	0.2	0.0	0.3	0.2	0.1	0.2	0.4	0.3	6.1	2.7	0.0	1.1	0.7	0.2	0.6	4.1	0.6	0.3	14.1	2.6	0.3	0.3	12.6	1.1	0.0	5.0	3.8	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	79.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	20.5	0.0	0.7	0.4	1.0	196.5	0.1	156.1	0.5	47.2	137.6	0.2	0.1	11.3	159.7	2.9	26.0	0.3	0.8	0.1	33.3	0.1	0.2	0.1	0.5	0.1	0.1	0.4	0.2	0.0	0.3	0.3	0.3	0.3	0.1	0.0	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.5	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0	2.1	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	29.9	0.0	0.0	0.0
ACER1	ASAH3	ENSG00000167769	"Alkaline ceramidase 1"	Q8TDN7	19	6306142-6333612	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Lipid metabolism, Sphingolipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"skin 1: 84.3"	"Cell type enhanced"	"Detected in some"		"Excitatory neurons: 2.7;Inhibitory neurons: 2.1;Melanocytes: 1.8;Spermatocytes: 1.7;Suprabasal keratinocytes: 5.8"	"Group enriched"	"Detected in some"	7	"head and neck cancer: 1.0;melanoma: 2.2;prostate cancer: 0.6"	"Not detected"	"Not detected"			"Low immune cell specificity"	"Detected in some"			"Lineage enriched"	"Detected in single"	4	"T-cells: 1.2"	"Cell line enhanced"	"Detected in single"		"T-47d: 2.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.13e-2)"	"unprognostic (2.87e-4)"		"unprognostic (5.04e-2)"	"unprognostic (6.18e-2)"	"unprognostic (8.16e-4)"	"unprognostic (7.27e-4)"	"unprognostic (2.17e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.02e-4)"	"unprognostic (1.02e-1)"	"unprognostic (1.30e-5)"	"unprognostic (2.11e-1)"	"unprognostic (4.44e-2)"	"unprognostic (4.22e-1)"	"unprognostic (2.24e-1)"	0.1	0.1	0.1	0.1	0.0	0.1	3.3	0.3	0.1	1.7	0.2	0.0	0.0	0.2	0.2	12.3	0.2	0.0	0.0	0.1	0.2	0.0	0.5	0.0	0.6	0.1	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	1.7	0.0	0.0	3.3	0.1	0.5	84.3	0.2	0.1	0.0	0.3	0.0	1.1	0.1	1.3	0.0	0.0	0.7	0.0	5.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	1.2	0.5	0.0	0.1	0.7	0.7	0.1	0.3	0.0	0.1	0.8	0.2	0.1	0.0	0.3	0.1	0.1	0.2	0.1	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.2	0.0	0.0	2.7	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	2.1	0.0	0.0	0.0	0.5	0.1	0.9	1.0	1.8	0.0	0.0	0.0	0.0	1.0	0.5	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.7	1.0	0.0	5.8	0.0	0.4	0.0	0.0	0.1
CA3	"CAIII, Car3"	ENSG00000164879	"Carbonic anhydrase 3"	P07451	8	85373436-85449040	"Enzymes, FDA approved drug targets, Metabolic proteins, Plasma proteins, Predicted intracellular proteins"		Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"skeletal muscle: 5323.9"	"Group enriched"	"Detected in many"	8	"Erythroid cells: 221.3;Skeletal myocytes: 304.0"	"Group enriched"	"Detected in many"	7	"glioma: 23.1;prostate cancer: 9.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"HEL: 47.3;RH-30: 78.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004967, HPA021775, HPA026700"	Enhanced					NA	NA		53000000			"CAB004967: AB_437014, HPA021775: AB_1845990, HPA026700: AB_1845991"	"prognostic favorable (4.24e-6)"	"unprognostic (1.40e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.22e-3)"	"unprognostic (4.71e-2)"	"unprognostic (8.43e-3)"	"unprognostic (3.56e-2)"	"unprognostic (4.04e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.68e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.54e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.96e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.19e-1)"	43.8	3.9	3.7	0.3	2.2	9.9	6.5	2.5	3.7	5.1	1.2	1.6	1.9	8.3	2.1	65.3	9.8	2.2	19.6	2.1	3.6	2.0	2.4	24.8	0.4	2.8	2.0	1.8	1.4	1.3	1.0	3.8	0.3	2.2	90.3	1.1	5.6	15.5	2.7	5323.9	5.3	4.4	19.2	2.3	0.8	4.1	2.9	2.0	1.4	3.0	1027.8	0.6	1.5	5.5	2.7	2.0	0.0	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	1.1	0.0	0.1	0.0	0.1	0.2	0.3	0.3	0.0	0.5	0.2	47.3	0.0	1.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	7.6	0.0	0.0	78.0	0.0	1.5	0.0	0.1	0.0	0.0	0.0	0.0	1.4	0.0	2.1	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	3.7	2.2	2.5	3.7	2.1	3.6	2.8	2.0	1.8	2.2	2.3	2.0	2.7	0.3	3.2	4.2	2.3	0.1	0.5	1.7	0.6	1.2	0.0	14.5	0.6	1.0	5.7	0.6	0.0	6.2	1.1	0.4	0.4	0.0	0.6	24.1	0.4	0.2	2.2	0.0	221.3	2.2	0.2	0.2	9.1	0.0	0.7	0.0	0.2	2.5	0.3	0.4	0.0	2.5	0.4	0.0	0.3	0.4	7.0	0.3	2.5	0.0	0.0	0.0	29.6	0.0	1.5	0.7	0.2	1.7	0.0	0.0	0.5	8.5	0.6	1.0	1.6	0.0	304.0	5.1	0.6	1.3	0.2	1.0	1.6	1.4	0.3	0.9	0.3
CRISP3	"Aeg2, CRISP-3, CRS3, dJ442L6.3, SGP28"	ENSG00000096006	"Cysteine rich secretory protein 3"	P54108	6	49727376-49744437	"Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"fallopian tube: 1214.1;salivary gland: 2328.9"	"Group enriched"	"Detected in some"	7	"Endometrial ciliated cells: 182.2;Glandular and luminal cells: 551.5"	"Group enriched"	"Detected in many"	7	"breast cancer: 31.9;pancreatic cancer: 59.8;prostate cancer: 85.6"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	19	"neutrophil: 2.5;non-classical monocyte: 1.2"	"Group enriched"	"Detected in many"	19	"granulocytes: 2.5;monocytes: 1.2"	"Group enriched"	"Detected in some"	20	"HEL: 12.3;RT4: 4.1;SK-BR-3: 9.3;T-47d: 4.4"					"Not detected"	"Not detected"			HPA054392	Supported				"Secreted in other tissues"	NA	NA		420000000			"HPA054392: AB_2682472"	"unprognostic (1.28e-2)"	"unprognostic (7.01e-2)"		"unprognostic (8.93e-2)"		"unprognostic (5.56e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.22e-4)"	"unprognostic (5.30e-2)"	"unprognostic (6.70e-2)"	"unprognostic (9.16e-2)"	"unprognostic (4.34e-3)"		"unprognostic (1.91e-1)"			"unprognostic (1.93e-1)"	0.2	0.7	0.0	0.0	0.0	385.4	3.9	0.0	0.0	30.1	0.0	0.1	0.4	1.7	0.1	269.2	1214.1	23.3	0.8	0.0	0.0	0.1	0.9	1.3	0.0	0.0	0.0	0.0	0.5	5.6	0.0	0.5	0.6	0.0	2.9	0.0	0.0	2328.9	112.9	0.3	3.5	0.2	0.1	0.0	2.6	0.3	0.2	0.0	0.3	0.2	0.0	4.1	4.7	141.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	9.3	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	1.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	1.0	0.0	0.0	0.0	2.1	5.6	0.0	21.5	13.1	3.7	0.0	0.0	0.0	0.0	0.0	1.5	0.0	182.2	47.2	0.8	0.0	0.4	0.0	3.7	0.0	0.2	0.0	551.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	23.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.1	1.5	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	1.7	0.1	0.0	26.8
DNAH8	hdhc9	ENSG00000124721	"Dynein axonemal heavy chain 8"	Q96JB1	6	38715311-39030792	"Plasma proteins, Predicted intracellular proteins"		"Motor protein"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"epididymis: 2.6;prostate: 2.2;testis: 7.9"	"Group enriched"	"Detected in some"	4	"Early spermatids: 35.4;Late spermatids: 13.2;Spermatocytes: 33.3"	"Cancer enriched"	"Detected in single"	7	"prostate cancer: 2.5"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	8	"basophil: 2.5"	"Lineage enriched"	"Detected in single"	8	"granulocytes: 2.5"	"Cell line enriched"	"Detected in some"	8	"HMC-1: 47.1"	"Not detected"	"Not detected"							HPA028447	Uncertain					NA	NA					"HPA028447: AB_10599600"	"unprognostic (2.83e-1)"	"unprognostic (4.46e-4)"	"unprognostic (1.27e-1)"	"unprognostic (5.24e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.22e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.47e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.17e-9)"	"unprognostic (1.46e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.48e-3)"	0.0	0.0	0.1	0.3	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.2	0.0	0.0	0.0	0.1	0.0	1.6	0.1	0.0	0.0	0.9	0.1	7.9	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	47.1	0.0	0.0	0.0	0.0	0.0	5.9	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.9	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	35.4	0.0	0.0	0.2	0.0	0.0	2.7	0.0	0.1	0.2	1.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	13.2	1.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	1.7	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.1	33.3	5.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0
GRIN3A	GluN3A	ENSG00000198785	"Glutamate ionotropic receptor NMDA type subunit 3A"	Q8TCU5	9	101569352-101738647	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 4.3"	"Cell type enriched"	"Detected in some"	5	"Inhibitory neurons: 220.7"	"Cancer enriched"	"Detected in single"	7	"prostate cancer: 3.4"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	5	"SCLC-21H: 1.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.29e-1)"	"unprognostic (7.10e-3)"	"unprognostic (3.01e-5)"	"unprognostic (3.39e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.06e-4)"	"unprognostic (1.74e-1)"	"unprognostic (2.59e-1)"	"unprognostic (7.56e-2)"	"unprognostic (7.34e-3)"	"unprognostic (1.16e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.87e-1)"	"unprognostic (9.41e-2)"	0.1	0.1	2.5	0.2	4.3	0.1	0.2	0.0	3.1	1.5	0.0	0.3	0.1	0.3	0.3	0.1	0.1	0.0	0.4	2.7	2.0	0.1	0.2	0.2	0.4	1.2	1.8	3.6	0.8	0.1	0.0	0.1	0.0	1.5	0.6	0.2	0.9	0.2	0.9	0.2	0.3	0.2	0.1	0.4	0.7	0.1	0.3	3.6	0.1	0.1	0.1	0.2	0.1	0.1	3.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.1	1.8	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.3	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	2.5	4.3	0.0	3.1	2.7	2.0	1.2	1.8	3.6	1.5	0.4	3.6	3.1	0.2	0.0	0.0	5.2	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.0	1.0	0.0	0.0	0.0	4.2	0.0	0.0	0.1	0.0	0.0	1.8	0.2	0.1	0.6	0.0	0.0	37.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	220.7	0.0	0.0	2.4	1.1	0.8	0.9	0.2	0.0	0.0	0.1	0.1	0.0	1.5	1.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	6.6	0.0	0.8	0.2	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.0
KCNN2	"hSK2, KCa2.2"	ENSG00000080709	"Potassium calcium-activated channel subfamily N member 2"	Q9H2S1	5	114055926-114496500	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 28.0;brain: 21.0;liver: 31.6"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 36.2;Excitatory neurons: 149.9;Inhibitory neurons: 97.0;Oligodendrocyte precursor cells: 63.3"	"Group enriched"	"Detected in some"	7	"glioma: 3.5;melanoma: 3.2;prostate cancer: 12.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 17.5;NTERA-2: 6.4;SK-MEL-30: 12.9;THP-1: 21.8;U-937: 7.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038221	Uncertain		Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA038221: AB_10673044"	"unprognostic (9.22e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.04e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.23e-2)"	"unprognostic (4.61e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.25e-1)"	0.3	28.0	9.0	0.2	12.0	0.0	0.5	12.5	15.1	1.8	2.5	0.9	0.3	2.9	0.3	0.2	0.4	0.4	6.8	21.0	9.9	4.0	31.6	2.3	0.4	11.1	7.5	7.3	0.8	4.5	0.4	7.7	0.0	7.6	9.7	0.7	2.5	0.5	4.3	9.6	1.3	0.3	2.0	9.7	0.5	0.7	3.1	7.0	0.2	0.3	6.7	0.2	2.4	1.0	12.4	0.1	0.0	0.0	0.0	0.0	0.0	2.1	17.5	2.7	0.3	0.0	0.0	0.2	0.0	0.5	0.0	2.3	0.0	2.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.8	0.0	0.2	0.0	0.3	0.0	1.4	6.4	0.0	0.0	0.0	0.0	0.8	0.2	0.1	2.1	0.0	0.0	0.2	12.9	0.4	0.3	21.8	0.3	0.0	0.5	1.8	0.0	0.1	0.0	0.1	2.0	7.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.0	12.0	12.5	15.1	21.0	9.9	11.1	7.5	7.3	7.6	9.7	7.0	12.4	1.4	0.0	1.1	36.2	0.0	0.3	0.3	0.0	0.0	7.9	0.6	1.3	15.1	0.0	0.0	0.0	2.1	0.0	0.0	0.3	0.0	0.6	0.6	0.5	0.0	8.2	0.0	0.0	149.9	0.9	0.0	0.8	0.0	1.3	0.0	0.8	5.0	18.3	0.0	0.0	97.0	1.0	0.0	1.0	0.3	0.5	0.0	0.1	21.4	6.5	0.0	0.4	0.0	63.3	9.2	1.0	0.1	0.0	1.2	4.7	0.0	0.7	0.0	7.8	0.0	0.1	0.3	0.3	6.5	0.3	0.3	0.0	0.0	0.2	0.5	0.6
LUZP2		ENSG00000187398	"Leucine zipper protein 2"	Q86TE4	11	24496970-25082638	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"brain: 29.2"	"Cell type enriched"	"Detected in some"	5	"Oligodendrocyte precursor cells: 1890.0"	"Group enriched"	"Detected in some"	7	"glioma: 3.5;prostate cancer: 4.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HaCaT: 10.9;HAP1: 4.4;HeLa: 1.9;hTERT-RPE1: 3.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039007, HPA046161"	Enhanced	Supported	Approved	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted in brain"	NA	NA			"Nucleoplasm, Cytosol"	"Plasma membrane"	"HPA039007: AB_2676307, HPA046161: AB_2679564"	"unprognostic (4.49e-2)"	"unprognostic (2.74e-2)"	"unprognostic (8.63e-2)"	"unprognostic (3.50e-1)"	"unprognostic (5.22e-3)"	"unprognostic (3.38e-1)"	"unprognostic (4.88e-2)"	"unprognostic (5.67e-4)"	"unprognostic (2.40e-1)"	"unprognostic (5.66e-2)"	"unprognostic (6.16e-3)"	"unprognostic (4.09e-2)"	"unprognostic (5.18e-3)"	"unprognostic (9.41e-3)"	"unprognostic (4.18e-2)"	"unprognostic (2.17e-1)"	"unprognostic (9.64e-2)"	0.3	6.5	8.2	0.1	8.7	0.1	0.5	13.2	7.2	0.1	1.0	0.8	0.1	0.2	0.0	0.1	0.0	0.1	0.1	6.2	13.7	0.2	0.9	0.2	0.0	12.1	29.2	6.1	0.0	0.0	0.0	0.6	0.0	14.1	2.4	0.6	1.1	0.1	0.1	0.0	0.1	0.2	0.3	17.4	0.1	0.1	0.5	16.0	0.0	0.0	0.6	0.0	0.3	0.1	17.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	10.9	4.4	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.1	0.2	0.0	1.1	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	8.2	8.7	13.2	7.2	6.2	13.7	12.1	29.2	6.1	14.1	17.4	16.0	17.4	0.3	0.0	0.0	11.4	0.0	0.6	0.1	0.0	1.8	6.9	0.3	1.7	0.6	0.0	0.0	3.7	0.0	0.0	0.1	1.2	0.0	0.0	33.7	0.6	0.7	0.1	0.0	0.0	149.4	0.0	0.1	2.6	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	371.4	1.7	0.0	0.0	0.0	6.4	0.9	0.1	0.0	4.7	0.0	0.3	0.0	1890.0	9.1	0.2	23.9	0.0	0.0	4.5	0.0	0.7	0.0	0.8	0.0	0.4	0.3	0.3	0.6	0.9	0.3	0.1	0.0	2.4	1.5	1.6
MB	PVALB	ENSG00000198125	Myoglobin	P02144	22	35606764-35637951	"Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Oxygen transport, Transport"	"Muscle protein"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	37	"heart muscle: 11523.2;skeletal muscle: 41097.5;tongue: 29343.1"	"Cell type enriched"	"Detected in many"	12	"Cardiomyocytes: 5182.1"	"Group enriched"	"Detected in many"	7	"breast cancer: 13.6;head and neck cancer: 31.1;prostate cancer: 30.4"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	6	"NK-cell: 1.3"	"Lineage enriched"	"Detected in single"	6	"NK-cells: 1.3"	"Cell line enriched"	"Detected in some"	4	"SK-BR-3: 175.6"	"Low region specificity"	"Detected in many"							"CAB000060, HPA003123"	Enhanced					NA	NA	13500000	140000000			"CAB000060: , HPA003123: AB_1079442"	"unprognostic (7.51e-2)"	"unprognostic (3.92e-3)"	"unprognostic (1.07e-1)"	"unprognostic (7.71e-2)"	"unprognostic (2.35e-1)"	"unprognostic (4.66e-3)"	"unprognostic (5.78e-3)"	"unprognostic (1.18e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.74e-3)"	"unprognostic (1.17e-2)"	"unprognostic (8.34e-2)"	"unprognostic (1.51e-2)"	"unprognostic (2.35e-1)"	"unprognostic (3.44e-3)"	"unprognostic (1.19e-2)"	6.6	4.6	1.0	1.5	1.0	0.3	43.9	1.0	2.3	2.9	0.7	14.7	1.9	2.3	0.3	742.4	18.8	4.1	11523.2	0.8	1.7	2.7	5.9	15.0	5.4	1.2	1.2	0.7	5.4	27.1	16.3	10.7	3.1	1.1	216.1	13.0	0.2	370.1	0.5	41097.5	16.3	11.2	1.4	0.9	2.1	3.8	4.6	1.3	0.8	8.6	29343.1	1.9	1.3	4.5	1.0	1.9	7.6	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.2	0.0	0.0	4.6	0.7	0.1	0.3	1.0	0.8	0.2	0.0	0.0	5.4	0.3	0.1	0.5	0.1	0.0	0.0	0.2	0.1	0.2	0.4	0.0	0.2	0.0	0.0	0.5	0.5	0.0	19.2	0.1	0.6	0.0	1.9	2.3	0.9	0.5	8.0	0.0	6.4	1.5	0.2	19.0	175.6	0.0	0.3	39.4	0.1	0.4	0.5	1.2	2.2	0.2	0.0	0.0	0.2	0.3	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	1.0	1.0	1.0	2.3	0.8	1.7	1.2	1.2	0.7	1.1	0.9	1.3	1.0	0.3	0.0	0.0	0.3	0.1	0.3	4.3	12.5	0.0	0.0	30.7	23.9	5182.1	0.0	30.8	0.0	0.0	0.1	0.5	3.8	0.0	4.7	20.1	20.2	0.1	40.7	11.5	0.0	0.0	0.2	0.0	145.2	0.0	0.2	0.0	0.8	0.0	0.4	0.0	0.0	0.1	114.6	14.2	0.0	0.4	70.0	0.0	2.1	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.8	0.7	0.0	21.8	2.6	0.1	19.9	0.0	0.0	420.9	42.0	0.3	0.7	0.6	0.1	0.3	2.8	0.1	2.9	15.1
NRAP		ENSG00000197893	"Nebulin related anchoring protein"	Q86VF7	10	113588714-113664070	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"skeletal muscle: 2386.3;tongue: 1155.0"	"Cell type enriched"	"Detected in some"	9	"Cardiomyocytes: 534.1"	"Group enriched"	"Detected in some"	7	"head and neck cancer: 8.2;prostate cancer: 3.1"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA037953, HPA037954, HPA075074"	Enhanced		Approved	"Vesicles,Intermediate filaments,Cytosol"		NA	NA			"Intermediate filaments"	"Vesicles, Cytosol"	"HPA037953: AB_2675755, HPA037954: AB_10672394, HPA075074: "	"unprognostic (1.13e-1)"	"unprognostic (2.95e-1)"	"unprognostic (3.61e-2)"	"unprognostic (2.05e-2)"	"unprognostic (5.75e-2)"	"unprognostic (1.97e-2)"	"unprognostic (1.25e-2)"	"unprognostic (3.03e-3)"	"unprognostic (3.72e-2)"	"unprognostic (4.20e-2)"	"unprognostic (6.40e-2)"	"unprognostic (2.88e-1)"	"unprognostic (5.39e-4)"	"unprognostic (8.21e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.16e-1)"		0.3	0.1	0.1	0.0	0.3	0.0	0.4	0.0	0.3	0.0	0.0	0.6	0.0	0.0	0.0	25.0	0.0	0.2	331.9	0.1	0.1	0.1	0.5	0.4	0.1	0.4	0.2	0.3	0.1	0.4	0.0	0.3	0.0	0.1	20.6	1.0	0.0	22.2	0.0	2386.3	0.6	0.1	0.0	0.0	0.1	0.3	0.6	0.2	0.0	0.4	1155.0	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.3	0.1	0.1	0.4	0.2	0.3	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.3	0.0	0.5	0.1	0.0	0.0	0.0	0.1	0.0	534.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	1.4	0.1	0.0	3.7	0.0	0.0	0.3	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	4.8	0.0	0.0	0.3	2.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	57.3	3.3	1.0	2.3	0.0	0.1	0.0	0.2	0.0	0.5	0.0
PI15	P25TI	ENSG00000137558	"Peptidase inhibitor 15"	O43692	8	74824534-74855029	"Predicted secreted proteins"		"Developmental protein, Protease inhibitor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 54.9;prostate: 31.3;smooth muscle: 50.3"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 36.8;Breast glandular cells: 73.2;Breast myoepithelial cells: 13.6;Prostatic glandular cells: 19.3;Smooth muscle cells: 36.2;Urothelial cells: 15.7"	"Group enriched"	"Detected in many"	7	"breast cancer: 11.1;melanoma: 8.6;prostate cancer: 18.8"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"AF22: 23.3;SH-SY5Y: 21.3;SK-MEL-30: 30.0;U-266/70: 7.9"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	9	"spinal cord: 6.3"	"HPA006593, HPA030057"	Uncertain		Approved	Vesicles,Cytosol	"Secreted in other tissues"	NA	NA			Vesicles	Cytosol	"HPA006593: AB_1078568, HPA030057: AB_10602143"	"unprognostic (2.77e-1)"	"unprognostic (1.57e-2)"	"unprognostic (3.41e-1)"	"unprognostic (1.88e-2)"	"unprognostic (3.22e-1)"	"unprognostic (3.24e-1)"	"unprognostic (2.94e-2)"	"unprognostic (2.33e-3)"	"unprognostic (1.87e-1)"	"unprognostic (2.25e-1)"	"unprognostic (3.65e-2)"	"unprognostic (1.85e-2)"	"unprognostic (8.63e-14)"	"unprognostic (2.54e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.60e-2)"	"unprognostic (2.05e-2)"	5.9	1.1	0.7	54.9	0.9	0.0	22.3	0.2	2.0	9.4	0.1	7.0	0.2	20.0	2.1	2.6	21.1	1.5	1.4	0.8	2.3	0.9	0.2	2.2	0.6	1.3	0.5	0.9	6.3	0.3	0.0	0.5	0.3	0.8	31.3	4.7	0.6	2.0	6.8	0.4	0.3	4.7	50.3	1.2	1.3	0.7	0.5	1.9	0.5	0.6	0.2	0.2	8.4	6.6	0.7	0.0	0.0	23.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.3	0.0	0.0	1.1	21.3	0.0	0.1	30.0	0.4	0.5	0.5	0.0	0.0	0.5	0.0	0.1	7.9	3.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	0.2	2.0	0.8	2.3	1.3	0.5	0.9	0.8	1.2	1.9	0.7	0.2	0.0	0.0	2.3	0.1	0.1	36.8	0.0	0.6	0.2	73.2	13.6	0.5	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	1.6	0.2	9.1	2.5	0.0	0.0	4.3	0.0	0.4	3.9	0.5	0.3	0.0	0.0	0.0	0.0	0.1	0.0	3.6	0.0	0.0	0.0	0.6	1.9	0.9	0.2	3.6	1.0	0.0	0.0	0.0	0.5	2.0	0.0	0.0	0.0	0.1	19.3	0.0	0.1	0.0	0.5	0.0	1.7	36.2	0.0	0.0	0.4	0.0	0.1	0.4	0.0	0.0	15.7
PPP3CA	"CALN, CALNA, CNA1, PPP2B"	ENSG00000138814	"Protein phosphatase 3 catalytic subunit alpha"	Q08209	4	101023409-101348278	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Calmodulin-binding, Hydrolase, Protein phosphatase"	"Craniosynostosis, Disease variant, Dwarfism, Epilepsy, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 138.9"	"Cell type enhanced"	"Detected in all"		"Excitatory neurons: 933.8;Inhibitory neurons: 403.0;Oligodendrocyte precursor cells: 348.3"	"Cancer enriched"	"Detected in all"	7	"prostate cancer: 98.1"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012778, CAB018581"	Enhanced		Enhanced	Nucleoplasm,Cytosol		NA	NA		94000	Nucleoplasm	Cytosol	"CAB018581: AB_2168324, HPA012778: AB_1855660"	"unprognostic (6.66e-2)"	"unprognostic (1.96e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.56e-1)"	"unprognostic (7.81e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.08e-1)"	"unprognostic (7.87e-2)"	"unprognostic (3.49e-3)"	"prognostic unfavorable (3.82e-4)"	"unprognostic (3.38e-2)"	"unprognostic (2.51e-2)"	"unprognostic (5.12e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.84e-2)"	"unprognostic (5.74e-2)"	24.9	17.7	48.9	15.8	138.9	17.3	20.7	84.1	120.0	17.2	10.9	19.6	11.7	11.9	13.2	14.6	13.9	13.4	9.2	115.2	63.3	11.3	17.1	20.1	14.8	37.8	31.5	74.9	18.0	9.5	9.0	9.1	13.2	47.1	66.6	16.2	27.9	22.4	38.8	51.6	23.1	13.0	15.6	31.4	14.7	22.6	10.7	37.1	12.9	13.3	29.2	18.5	20.9	16.2	79.5	48.3	33.8	9.3	18.0	50.4	37.9	15.8	51.9	47.8	19.8	21.6	18.3	59.0	22.4	20.9	47.6	25.6	23.5	33.3	69.6	34.9	56.0	15.1	35.4	45.8	25.2	36.8	59.0	17.8	39.6	35.6	45.3	51.4	39.1	38.8	14.5	14.4	61.1	33.5	58.0	12.2	44.2	15.4	55.7	20.7	22.1	83.2	26.5	20.0	38.3	71.5	26.2	43.1	35.4	24.6	12.5	32.3	33.4	42.1	48.7	54.8	44.7	34.7	28.5	31.5	40.1	26.6	31.5	13.1	82.5	31.0	73.5	35.7	33.1	41.6	74.1	33.2	34.8	28.2	62.8	15.5	31.0	123.7	65.1	45.1	51.9	25.3	21.1	48.9	138.9	84.1	120.0	115.2	63.3	37.8	31.5	74.9	47.1	31.4	37.1	79.5	143.3	76.9	58.6	284.1	96.8	168.8	36.2	29.5	34.7	89.8	93.8	51.8	25.0	38.6	21.9	31.3	39.6	39.6	81.4	60.0	33.2	21.3	3.2	39.3	56.2	100.8	127.4	32.0	933.8	31.6	84.0	75.6	59.1	42.8	35.4	22.1	53.2	39.7	38.3	18.5	403.0	44.2	14.2	61.8	135.3	8.4	65.0	58.2	92.5	281.1	64.3	21.2	56.7	348.3	139.1	53.3	115.4	60.9	63.8	127.6	23.9	51.9	25.3	82.9	13.1	66.9	67.5	12.7	26.5	27.9	172.0	27.5	69.1	76.2	55.9	39.5
SPOCK1	"SPOCK, testican-1, TIC1"	ENSG00000152377	"SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1"	Q08629	5	136975298-137598379	"Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 175.0"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 252.8;Inhibitory neurons: 349.9;Muller glia cells: 243.8;Oligodendrocyte precursor cells: 273.4;Oligodendrocytes: 913.1;Peritubular cells: 150.1"	"Cancer enriched"	"Detected in all"	7	"prostate cancer: 83.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 573.1;hTERT-RPE1: 1112.8;HUVEC TERT2: 594.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007450, HPA026770"	Uncertain		Approved	Vesicles	"Secreted to blood"	NA	NA			Vesicles		"HPA007450: AB_10603116, HPA026770: "	"unprognostic (1.05e-1)"	"unprognostic (9.25e-2)"	"prognostic unfavorable (1.93e-4)"	"unprognostic (1.58e-1)"	"unprognostic (1.96e-1)"	"prognostic unfavorable (1.93e-5)"	"unprognostic (5.83e-3)"	"prognostic unfavorable (9.08e-4)"	"unprognostic (1.00e-2)"	"prognostic unfavorable (4.72e-4)"	"unprognostic (9.09e-3)"	"unprognostic (1.60e-1)"	"prognostic unfavorable (3.77e-5)"	"prognostic unfavorable (9.40e-4)"	"unprognostic (1.26e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.90e-2)"	25.1	41.8	70.4	4.1	100.9	0.3	19.2	125.3	118.9	25.8	20.0	18.7	1.2	44.5	34.6	6.1	18.7	18.7	54.7	104.9	84.2	24.5	0.2	2.9	0.6	94.8	106.0	69.9	4.9	5.6	13.9	9.9	9.3	99.5	66.2	3.2	49.1	7.7	25.7	17.7	7.6	4.6	31.0	72.2	8.6	9.1	21.9	110.6	7.5	9.5	7.2	0.4	11.4	21.9	175.0	4.6	0.9	299.4	0.4	573.1	116.0	0.4	100.6	90.0	207.7	115.9	0.0	0.6	0.4	0.2	206.7	53.3	4.4	1.4	70.3	65.3	17.8	0.6	0.2	16.7	0.0	4.0	0.0	0.4	203.8	28.5	128.6	23.2	1112.8	594.4	0.2	0.0	0.4	60.5	0.5	0.0	0.2	19.1	0.0	28.4	0.0	0.2	0.0	140.3	9.4	3.7	14.4	49.9	0.8	0.1	35.6	0.4	1.2	98.9	294.0	10.6	102.1	28.5	0.1	0.1	0.1	159.4	4.4	136.9	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	70.4	100.9	125.3	118.9	104.9	84.2	94.8	106.0	69.9	99.5	72.2	110.6	175.0	2.0	0.0	0.0	91.7	0.0	1.8	1.6	5.8	0.0	9.7	0.4	0.4	58.8	1.5	0.4	22.0	2.1	0.4	0.0	0.2	1.9	0.6	12.0	4.2	37.9	8.4	35.0	0.0	252.8	1.4	0.3	58.8	0.0	2.9	0.0	0.1	1.1	0.0	0.9	8.4	349.9	0.1	16.2	1.2	3.0	9.5	17.4	1.6	7.2	17.8	2.3	243.8	0.0	273.4	913.1	2.0	0.1	150.1	0.1	40.9	0.0	3.1	0.9	7.3	13.1	11.6	16.4	7.4	7.1	0.7	1.4	0.1	0.4	0.0	0.3	3.2
SPON2	DIL1	ENSG00000159674	"Spondin 2"	Q9BUD6	4	1166932-1208962	"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion, Immunity, Innate immunity"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 188.7"	"Cell type enhanced"	"Detected in many"		"dendritic cells: 427.0;Endometrial stromal cells: 256.6;Extravillous trophoblasts: 355.8;Fibroblasts: 257.7;NK-cells: 1096.8"	"Cancer enriched"	"Detected in all"	7	"prostate cancer: 243.7"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in many"		"gdT-cell: 255.9"	"Lineage enriched"	"Detected in all"	5	"T-cells: 255.9"	"Group enriched"	"Detected in many"	5	"HHSteC: 303.8;HSkMC: 546.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA040170, HPA066095"	Approved		Approved	Vesicles	"Secreted to blood"	NA	NA		2600000	Vesicles		"HPA040170: AB_2676868, HPA066095: AB_2685615"	"unprognostic (1.22e-1)"	"unprognostic (3.56e-1)"	"unprognostic (3.07e-2)"	"prognostic favorable (2.03e-4)"	"unprognostic (7.64e-2)"	"unprognostic (6.28e-2)"	"unprognostic (2.70e-3)"	"unprognostic (2.28e-3)"	"unprognostic (2.76e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.01e-2)"	"prognostic unfavorable (9.22e-4)"	57.2	40.7	4.0	18.9	6.0	19.6	51.1	15.2	3.9	157.3	3.9	51.3	18.7	188.7	4.4	41.0	50.1	32.5	33.2	3.1	6.4	36.4	79.7	63.6	4.0	2.3	4.3	2.4	34.7	18.9	0.9	15.2	19.3	3.4	112.7	7.3	0.8	29.1	8.5	19.3	37.5	64.1	43.1	0.2	27.2	44.1	4.8	1.8	1.8	16.4	6.7	1.0	68.9	94.8	2.3	0.4	0.6	0.0	0.0	10.2	79.0	3.0	6.2	5.0	0.8	1.0	0.0	0.1	1.8	9.7	26.9	0.9	45.0	0.0	0.2	0.0	0.3	0.1	0.2	3.0	12.7	303.8	0.2	1.5	546.6	0.0	0.6	0.0	0.0	0.0	4.1	0.3	9.2	0.0	0.3	5.3	12.2	3.5	9.7	0.7	1.0	3.3	7.9	0.0	0.0	1.7	1.1	1.1	0.0	2.9	1.7	0.4	1.5	0.1	0.2	0.9	20.5	0.0	1.3	2.7	0.6	0.1	6.5	0.0	3.7	0.9	1.0	255.9	1.1	5.5	0.7	33.1	105.8	0.4	1.0	14.4	96.8	9.8	50.4	2.2	42.9	0.1	123.2	4.0	6.0	15.2	3.9	3.1	6.4	2.3	4.3	2.4	3.4	0.2	1.8	2.3	9.8	0.0	5.6	1.3	6.6	36.8	2.0	82.5	2.2	3.7	5.1	3.8	4.0	24.3	43.0	1.8	0.0	3.4	427.0	9.7	1.9	3.8	0.2	12.7	256.6	5.7	13.8	4.0	8.4	1.3	355.8	257.7	10.7	6.6	6.3	0.2	15.4	40.4	12.8	0.0	0.6	9.7	73.2	5.8	15.4	0.5	29.8	9.5	26.6	6.5	9.2	0.9	1096.8	0.5	0.7	1.5	6.7	9.4	64.0	15.8	16.3	28.3	32.6	0.4	6.6	22.5	89.9	0.2	0.5	21.3	21.5	38.9	100.8	8.1	7.9	13.2
TMPRSS2	PRSS10	ENSG00000184012	"Transmembrane serine protease 2"	O15393	21	41464300-41531116	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 282.9;stomach 1: 147.6"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 404.8;Gastric mucus-secreting cells: 155.4;Paneth cells: 368.3;Prostatic glandular cells: 203.4;Proximal enterocytes: 159.6;Urothelial cells: 166.6"	"Cancer enriched"	"Detected in many"	7	"prostate cancer: 250.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 22.8;MCF7: 10.5;OE19: 35.9;RT4: 57.8;SK-BR-3: 11.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"HPA034493, HPA035787"	Enhanced		Supported	"Plasma membrane"	"Secreted in other tissues"	NA	NA			"Plasma membrane"		"HPA034493: , HPA035787: AB_2674782"	"unprognostic (4.80e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.16e-1)"	"prognostic favorable (2.56e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.05e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.51e-3)"	"unprognostic (9.43e-2)"	"unprognostic (9.02e-3)"	"unprognostic (6.24e-2)"	"unprognostic (6.43e-2)"	"prognostic favorable (7.86e-6)"	"unprognostic (2.00e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.15e-2)"	0.6	0.2	0.4	14.0	0.4	0.1	20.2	0.2	0.5	5.1	2.5	103.9	79.2	1.0	2.8	36.4	10.8	24.3	0.2	0.3	0.4	47.7	33.8	40.2	0.2	0.5	0.3	0.5	0.2	112.3	4.0	1.5	0.2	0.3	282.9	78.7	0.2	76.9	7.8	0.1	6.8	90.3	3.3	0.1	0.2	147.6	1.5	0.2	0.8	19.4	0.1	10.3	36.0	7.7	0.5	0.1	0.0	0.1	0.0	0.1	0.1	2.3	0.0	0.0	0.1	0.1	22.8	3.3	0.1	0.4	0.1	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.1	3.7	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	0.3	0.0	0.1	0.1	0.0	10.5	0.3	1.0	2.3	35.9	0.2	0.1	0.0	2.6	1.3	57.8	0.2	0.7	0.3	11.7	0.3	0.4	8.8	0.0	0.0	0.1	0.6	0.6	0.1	0.0	0.2	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.2	0.5	0.3	0.4	0.5	0.3	0.5	0.3	0.1	0.2	0.5	0.1	51.3	109.8	0.0	1.7	0.3	30.9	6.8	0.0	0.0	34.0	25.8	0.6	32.9	42.1	47.8	0.0	0.7	1.1	404.8	23.5	39.2	21.3	7.4	0.5	1.3	18.0	2.7	0.2	60.4	0.1	1.0	155.4	5.8	7.0	0.0	0.4	32.0	0.1	0.0	0.1	84.1	44.7	0.3	0.3	4.8	0.0	2.0	10.6	0.0	0.6	0.0	0.0	0.0	0.0	65.1	368.3	0.0	0.0	203.4	159.6	3.8	36.6	0.0	0.0	1.6	2.0	0.4	1.4	2.1	0.1	0.3	1.1	0.0	105.7	166.6
TTC6	"C14orf25, NCRNA00291"	ENSG00000139865	"Tetratricopeptide repeat domain 6"	Q86TZ1	14	37595847-38041442	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"breast: 8.0;prostate: 17.6"	"Cell type enhanced"	"Detected in some"		"Breast glandular cells: 13.8;Club cells: 11.1;Early spermatids: 39.1;Late spermatids: 18.1;Spermatocytes: 10.7"	"Group enriched"	"Detected in some"	7	"breast cancer: 2.2;prostate cancer: 3.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Hep G2: 8.4;MCF7: 12.2;RT4: 8.4;T-47d: 22.8"	"Not detected"	"Not detected"			"Region enriched"	"Detected in some"	7	"midbrain: 9.7"	HPA069293			Approved	Centrosome		NA	NA			Centrosome		"HPA069293: AB_2686110"	"unprognostic (7.92e-2)"	"unprognostic (6.95e-2)"	"unprognostic (9.22e-2)"	"unprognostic (1.98e-1)"	"unprognostic (7.06e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.60e-4)"	"unprognostic (6.75e-2)"	"unprognostic (2.07e-2)"	"unprognostic (4.08e-4)"	"unprognostic (5.60e-2)"	"unprognostic (8.91e-8)"	"unprognostic (1.76e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.60e-1)"	"unprognostic (6.07e-3)"	0.0	0.0	2.8	0.2	0.9	0.0	8.0	0.9	0.8	0.0	1.0	1.0	0.6	0.0	0.0	0.4	0.3	0.7	0.0	0.6	2.4	0.0	3.5	1.1	0.0	2.2	6.2	0.6	0.0	0.0	0.0	0.3	0.0	1.2	17.6	0.5	0.0	2.7	0.1	0.0	0.6	0.7	0.0	5.3	0.0	3.6	5.9	3.1	0.0	0.0	0.0	0.1	1.4	0.3	0.9	0.7	0.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.6	0.0	0.4	0.0	0.0	2.4	1.3	0.2	0.0	0.0	3.4	0.0	1.2	8.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	12.2	0.0	0.0	0.0	1.7	4.5	0.0	0.0	0.0	1.0	8.4	2.4	0.0	0.0	4.5	0.0	0.0	22.8	0.0	0.0	0.0	0.3	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.9	0.9	0.8	0.6	2.4	2.2	6.2	0.6	1.2	5.3	3.1	0.9	0.2	0.0	8.4	0.3	0.1	0.0	2.8	1.5	6.2	0.0	13.8	6.9	0.8	1.5	11.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	39.1	0.0	0.0	0.4	7.7	0.0	6.4	0.0	0.0	0.4	7.1	0.1	0.0	0.0	0.0	2.5	0.0	0.0	1.0	0.7	0.0	0.0	0.0	18.1	0.9	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.0	0.8	0.4	0.0	4.9	0.0	0.0	7.5	0.0	0.0	0.2	0.4	10.7	1.9	2.3	0.0	0.0	0.3	0.0	1.1	3.1
ACOXL	FLJ11042	ENSG00000153093	"Acyl-CoA oxidase like"	Q9NUZ1	2	110732539-111120610	"Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in many"		"epididymis: 7.3;lung: 9.3"	"Cell type enriched"	"Detected in some"	5	"Alveolar cells type 2: 41.9"	"Group enriched"	"Detected in some"	6	"lung cancer: 0.6;prostate cancer: 1.1;testis cancer: 2.1;urothelial cancer: 2.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"A-431: 12.1;RPMI-8226: 22.0;RT4: 29.3;U-266/70: 18.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA035392, HPA035393"			Supported	Nucleoli,Cytosol		NA	NA			Cytosol	Nucleoli	"HPA035392: AB_2674604, HPA035393: AB_2674605"	"unprognostic (1.62e-1)"	"unprognostic (7.30e-2)"	"unprognostic (6.77e-4)"	"unprognostic (2.93e-7)"	"unprognostic (1.32e-2)"	"unprognostic (7.84e-5)"	"unprognostic (1.28e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.31e-2)"	"unprognostic (7.24e-2)"	"unprognostic (3.24e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.72e-1)"	"prognostic favorable (6.48e-4)"	1.1	0.6	0.6	0.5	0.7	1.5	0.1	0.2	0.5	0.4	0.1	0.5	0.5	0.5	7.3	0.4	0.3	0.6	1.2	0.4	0.1	0.5	0.3	9.3	0.9	0.4	0.3	0.5	0.2	1.0	2.9	0.3	0.7	0.5	3.2	0.3	0.7	0.6	0.0	1.3	0.7	0.6	0.1	0.0	0.6	0.5	3.2	0.3	0.3	0.8	0.0	1.2	4.7	0.1	0.6	12.1	0.2	0.3	0.2	0.1	0.0	0.8	0.1	0.0	0.0	0.0	0.9	0.7	0.3	0.5	0.1	0.3	1.3	0.0	0.1	0.0	0.3	3.5	0.2	0.5	0.5	0.0	0.0	0.3	0.1	1.2	0.0	0.1	0.3	0.0	0.6	1.8	1.8	0.1	4.4	0.9	0.4	4.2	0.0	0.3	0.6	0.2	22.0	0.0	29.3	2.5	1.0	0.3	0.5	0.1	0.6	0.4	1.2	0.3	0.2	1.0	0.2	0.1	18.7	4.8	0.7	0.0	0.1	0.1	0.7	0.3	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.0	0.9	0.2	0.2	0.2	0.1	0.1	0.6	0.7	0.2	0.5	0.4	0.1	0.4	0.3	0.5	0.5	0.0	0.3	0.6	0.3	0.0	41.9	0.0	1.0	0.3	0.3	0.0	0.0	0.6	0.1	0.3	0.5	0.0	0.7	0.0	0.0	0.0	0.1	1.3	0.0	0.2	5.4	0.2	0.1	0.2	1.2	0.0	2.2	0.0	0.0	0.4	0.0	0.8	0.0	5.9	0.0	0.0	0.1	0.0	2.0	0.3	0.0	0.0	0.8	8.1	0.0	0.2	0.0	0.0	0.0	0.1	1.0	1.0	1.3	0.1	2.3	0.0	7.5	0.8	0.0	0.1	0.1	0.3	0.0	0.2	0.3	1.6	2.7	0.0	0.3	0.0	1.1	0.0	0.2	0.8
CDH26	VR20	ENSG00000124215	"Cadherin 26"	Q8IXH8	20	59958423-60034011	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 8.0"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 17.9;Club cells: 18.7;Oligodendrocytes: 14.9;Respiratory ciliated cells: 39.6;Syncytiotrophoblasts: 14.9"	"Group enriched"	"Detected in some"	6	"cervical cancer: 1.5;head and neck cancer: 0.9;lung cancer: 2.3;prostate cancer: 3.6;urothelial cancer: 3.2"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"RT4: 36.4"	"Low region specificity"	"Detected in some"							"HPA015722, HPA047578"	Uncertain		Supported	"Plasma membrane,Microtubules"		NA	NA			"Plasma membrane"	Microtubules	"HPA015722: AB_2077659, HPA047578: AB_2680091"	"unprognostic (2.42e-1)"	"prognostic favorable (7.62e-4)"	"unprognostic (4.71e-4)"	"unprognostic (8.17e-2)"	"unprognostic (9.40e-2)"	"unprognostic (9.95e-3)"	"unprognostic (6.65e-2)"	"prognostic favorable (3.75e-4)"	"unprognostic (1.37e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.26e-4)"	"unprognostic (8.24e-3)"	"unprognostic (9.96e-7)"	"unprognostic (1.85e-2)"	"unprognostic (2.73e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.04e-1)"	0.8	0.4	1.2	0.3	1.6	1.0	0.8	1.3	1.9	2.1	0.5	0.6	0.4	0.6	0.5	3.4	2.0	0.4	0.7	1.1	0.9	0.4	0.3	2.1	0.4	1.6	1.6	1.0	0.3	0.5	0.3	1.7	0.4	1.9	8.0	0.3	0.4	2.0	0.5	1.0	0.5	0.8	0.4	0.8	0.8	1.2	0.7	1.5	0.9	0.6	0.3	3.0	2.7	1.3	2.9	0.0	0.7	0.2	0.0	0.6	0.2	0.4	0.2	0.0	0.1	0.0	0.8	0.8	0.1	0.5	0.0	0.0	1.9	0.0	0.0	0.0	0.2	0.1	7.9	0.1	0.1	0.0	0.3	0.3	0.1	1.1	0.1	0.0	0.0	0.0	0.4	0.0	0.3	0.3	0.3	0.3	0.4	0.4	0.0	0.1	0.0	0.0	0.7	0.1	36.4	0.8	0.1	0.4	0.2	0.1	0.4	0.2	0.4	0.2	0.0	0.0	1.0	0.0	0.3	0.2	0.0	0.0	1.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	1.6	1.3	1.9	1.1	0.9	1.6	1.6	1.0	1.9	0.8	1.5	2.9	4.3	6.4	6.1	17.9	0.1	0.1	1.2	6.6	0.0	0.5	1.6	0.5	0.7	0.0	18.7	0.0	0.0	1.7	0.0	0.2	0.0	0.0	3.2	2.1	0.4	2.1	0.0	2.5	9.3	0.0	0.0	0.3	0.0	0.4	1.3	0.0	0.7	0.1	0.6	0.0	8.4	0.0	6.1	1.3	0.4	1.7	0.0	1.4	0.0	7.5	0.6	0.2	1.0	7.1	14.9	0.0	0.0	0.0	0.4	10.9	0.2	0.1	39.6	0.0	0.0	0.5	2.4	0.9	0.2	0.2	0.0	14.9	0.2	0.1	0.2	7.4
COL26A1	"EMI6, EMID2, Emu2"	ENSG00000160963	"Collagen type XXVI alpha 1 chain"	Q96A83	7	101362875-101559024	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 13.3;liver: 5.6"	"Group enriched"	"Detected in some"	7	"Excitatory neurons: 68.4;Inhibitory neurons: 18.5"	"Group enriched"	"Detected in many"	6	"endometrial cancer: 12.6;ovarian cancer: 5.7;prostate cancer: 4.6;testis cancer: 14.7"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	45	"plasmacytoid DC: 9.2"	"Lineage enriched"	"Detected in single"	45	"dendritic cells: 9.2"	"Cell line enhanced"	"Detected in some"		"AF22: 30.0;BEWO: 23.9;HAP1: 10.7;NTERA-2: 25.4;SuSa: 19.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			HPA027059	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	NA	NA			Vesicles		"HPA027059: AB_1848142"	"unprognostic (5.94e-3)"	"unprognostic (2.16e-2)"	"unprognostic (2.19e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.35e-1)"	"prognostic favorable (2.32e-5)"	"unprognostic (1.48e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.85e-2)"	"unprognostic (1.26e-3)"	"unprognostic (1.78e-1)"	"unprognostic (4.24e-3)"	"unprognostic (3.60e-1)"	"unprognostic (1.50e-1)"	"unprognostic (7.48e-4)"	"unprognostic (2.83e-3)"	0.0	4.5	5.4	0.1	8.1	0.2	0.1	0.5	13.3	0.2	0.6	0.0	0.0	0.3	0.1	0.0	0.3	0.1	0.0	9.9	3.8	2.1	5.6	0.4	0.5	1.5	1.3	7.3	0.5	2.2	3.9	0.9	0.3	4.5	2.2	0.0	0.0	0.0	0.5	0.0	0.3	0.0	0.0	0.3	0.2	0.3	1.0	1.9	1.2	0.1	0.0	0.1	0.2	0.1	5.8	0.0	0.8	30.0	1.9	0.0	0.0	23.9	0.0	0.0	0.0	0.0	1.3	0.0	0.1	4.7	0.0	0.1	0.0	10.7	0.0	0.0	1.0	1.3	0.0	0.0	7.9	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	25.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	1.6	0.0	0.0	0.2	19.2	0.3	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.2	0.0	0.0	5.4	8.1	0.5	13.3	9.9	3.8	1.5	1.3	7.3	4.5	0.3	1.9	5.8	0.0	0.0	0.0	3.3	0.7	0.0	0.3	0.0	0.0	0.0	0.1	0.3	1.2	0.0	0.0	5.5	0.0	0.3	0.0	0.0	0.0	0.2	1.5	0.1	1.7	0.1	0.0	0.0	68.4	0.6	0.4	0.5	0.0	0.2	0.0	1.0	0.0	3.6	0.1	0.0	18.5	0.0	0.0	0.0	0.0	3.5	0.0	0.5	0.0	5.6	0.0	0.0	0.0	3.5	2.1	0.2	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	2.0	0.0	0.0	0.4	0.0	0.9	0.0	0.4
CPNE4	"COPN4, CPN4"	ENSG00000196353	"Copine 4"	Q96A23	3	131533555-132285410	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"brain: 26.1;prostate: 25.5"	"Cell type enriched"	"Detected in some"	10	"Excitatory neurons: 351.2"	"Cancer enriched"	"Detected in some"	6	"prostate cancer: 22.4"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 6.2;AF22: 5.7;Karpas-707: 1.7;RT4: 1.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA032036, HPA078300"	Enhanced		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA032036: AB_10600898, HPA078300: AB_2732377"	"unprognostic (7.38e-2)"	"unprognostic (2.12e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.22e-4)"	"unprognostic (2.53e-2)"	"unprognostic (1.41e-2)"	"unprognostic (8.81e-3)"	"unprognostic (3.40e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.57e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.29e-2)"	"unprognostic (9.10e-3)"	"unprognostic (1.18e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.51e-1)"	0.6	0.5	3.9	0.1	26.1	0.0	0.2	0.0	14.0	0.2	0.0	0.3	0.7	0.2	0.6	0.3	0.4	0.0	0.9	15.8	5.8	1.0	0.1	0.4	0.0	8.5	5.1	15.4	0.0	0.2	1.9	3.0	0.0	1.9	25.5	0.2	2.0	0.4	3.8	0.0	0.3	0.5	0.3	0.0	0.9	0.6	1.4	14.2	0.0	0.3	0.1	0.0	0.1	0.4	7.0	0.0	6.2	5.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	1.7	0.8	0.4	0.0	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.3	1.9	0.8	0.4	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.7	1.4	0.1	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	3.9	26.1	0.0	14.0	15.8	5.8	8.5	5.1	15.4	1.9	0.0	14.2	7.0	0.9	0.0	0.0	8.8	0.0	0.3	0.4	0.1	0.0	0.8	0.0	0.0	17.5	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.6	0.1	0.6	4.9	0.0	351.2	0.0	0.0	0.6	3.6	0.6	0.0	0.2	0.0	0.0	0.1	1.7	33.0	0.1	0.0	0.0	0.3	5.6	0.3	1.1	0.0	8.4	0.6	0.3	0.0	8.5	7.1	0.1	0.0	0.0	0.0	17.0	0.0	2.6	0.3	0.6	0.0	0.0	0.4	1.4	1.1	0.3	0.1	0.0	0.0	0.1	0.0	0.9
KL		ENSG00000133116	Klotho	Q9UEF7	13	33016423-33066143	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"		"Glycosidase, Hormone, Hydrolase"	"Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 129.9;parathyroid gland: 136.2"	"Cell type enriched"	"Detected in some"	7	"Proximal tubular cells: 123.3"	"Group enriched"	"Detected in many"	6	"prostate cancer: 5.9;renal cancer: 17.8"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"HMC-1: 2.4;SK-BR-3: 4.5"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basal ganglia: 13.3;cerebral cortex: 6.7;hippocampal formation: 7.4;medulla oblongata: 4.2"						"Secreted to blood"	NA	NA	510000					"unprognostic (1.32e-1)"	"unprognostic (3.10e-1)"	"unprognostic (2.35e-1)"	"unprognostic (2.73e-3)"	"unprognostic (3.37e-1)"	"unprognostic (1.15e-4)"	"unprognostic (3.06e-2)"	"unprognostic (6.50e-2)"	"unprognostic (2.22e-2)"	"unprognostic (2.60e-1)"	"prognostic favorable (4.44e-4)"	"unprognostic (9.46e-2)"	"prognostic favorable (1.29e-9)"	"unprognostic (4.76e-3)"	"unprognostic (1.91e-1)"	"unprognostic (2.86e-2)"	"unprognostic (1.07e-1)"	3.0	1.4	0.9	0.8	3.0	0.1	2.5	0.8	1.2	1.8	38.0	1.6	2.8	1.2	8.8	1.1	0.8	1.3	1.1	4.2	1.2	129.9	0.4	3.6	1.0	0.7	0.9	0.6	0.1	1.2	136.2	0.3	30.7	0.6	8.1	0.9	0.0	0.8	2.5	0.7	0.6	2.6	1.2	0.5	2.5	2.1	0.5	1.2	0.5	1.3	1.6	0.5	1.6	0.6	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	4.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	3.0	0.8	1.2	4.2	1.2	0.7	0.9	0.6	0.6	0.5	1.2	0.7	15.8	0.0	0.5	0.0	0.6	0.1	0.2	0.0	0.0	0.0	0.6	0.3	1.0	0.0	0.7	12.9	0.0	0.2	0.0	0.4	5.9	0.0	1.8	0.1	2.5	10.2	16.3	0.4	1.2	0.0	0.1	1.6	0.0	0.1	0.0	0.1	1.1	0.2	2.8	0.0	0.5	1.1	0.0	0.9	1.0	0.8	0.3	1.9	0.0	6.5	0.9	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	3.6	1.8	123.3	0.7	0.0	0.0	1.1	2.3	1.4	0.5	0.0	0.1	0.1	1.1	0.1	1.9	0.1
LY6L		ENSG00000261667	"Lymphocyte antigen 6 family member L"	H3BQJ8	8	143080457-143083001	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"brain: 1.0;kidney: 1.5"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	6	"prostate cancer: 2.8"	"Region enhanced"	"Detected in single"		"midbrain: 1.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"									NA	NA																				"unprognostic (5.25e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	1.5	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
NUDT10	"DIPP3a, hDIPP3alpha"	ENSG00000122824	"Nudix hydrolase 10"	Q8NFP7	X	51332231-51337525	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"testis: 26.5"	"Group enriched"	"Detected in many"	5	"Hepatic stellate cells: 60.3;Peritubular cells: 29.0"	"Group enriched"	"Detected in many"	6	"glioma: 5.0;prostate cancer: 5.4;testis cancer: 7.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 7.5;HAP1: 14.2;HEK 293: 10.5;NTERA-2: 25.8;SH-SY5Y: 5.6;U-2 OS: 12.7"									"HPA047027, HPA057684"	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA047027: AB_2679907, HPA057684: AB_2683501"	"unprognostic (2.61e-2)"	"unprognostic (1.12e-2)"	"unprognostic (7.40e-3)"	"unprognostic (7.84e-2)"	"unprognostic (1.82e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.06e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.49e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.51e-3)"	"unprognostic (1.80e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.12e-2)"	"unprognostic (5.04e-5)"	0.5	1.7	9.5	0.8	10.7	1.6	0.8	4.5	9.5	5.8	3.0	2.3	0.5	5.3	16.3	1.1	3.6	1.4	0.7	9.2	10.3	3.8	1.3	0.3	0.4	5.8	6.5	9.3	17.0	0.3	0.0	2.1	0.0	6.6	15.1	0.7	1.5	0.5	14.7	0.1	0.4	1.0	4.1	4.4	3.4	1.2	26.5	10.3	0.4	0.6	0.2	0.3	3.9	3.6	10.0	0.0	0.0	7.5	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	1.2	0.0	14.2	0.6	0.0	0.0	10.5	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	25.8	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	12.7	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	9.5	10.7	4.5	9.5	9.2	10.3	5.8	6.5	9.3	6.6	4.4	10.3	10.0	0.2	0.0	1.3	0.7	0.2	1.0	4.9	0.6	1.8	0.5	0.1	1.5	0.2	0.0	0.6	0.0	0.0	0.7	0.4	0.0	0.0	0.0	1.5	0.7	3.5	2.5	0.0	0.8	5.0	0.0	1.0	3.1	0.0	0.1	0.0	5.0	60.3	0.3	0.2	0.0	1.9	0.0	0.0	1.9	0.4	6.2	5.9	0.1	1.8	1.0	0.0	1.7	0.0	3.5	0.6	0.0	0.0	29.0	1.4	2.8	0.0	0.1	0.0	0.5	0.0	1.5	1.9	3.8	7.8	0.4	0.1	0.4	0.2	0.9	0.0	0.2
NWD1		ENSG00000188039	"NACHT and WD repeat domain containing 1"	Q149M9	19	16719847-16817963	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"choroid plexus: 166.2"	"Group enriched"	"Detected in some"	4	"Astrocytes: 41.4;Endometrial ciliated cells: 83.9;Respiratory ciliated cells: 92.0"	"Cancer enriched"	"Detected in many"	6	"prostate cancer: 9.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"U-937: 11.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA075476			Approved	Nucleoli,Cytosol		NA	NA			"Nucleoli, Cytosol"		"HPA075476: "	"unprognostic (5.29e-3)"	"unprognostic (3.08e-2)"	"unprognostic (3.05e-2)"	"prognostic favorable (2.55e-4)"	"unprognostic (2.49e-1)"	"unprognostic (4.20e-4)"	"unprognostic (6.54e-2)"	"unprognostic (5.15e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.60e-1)"	"unprognostic (7.94e-2)"	"unprognostic (1.76e-1)"	"unprognostic (9.20e-2)"	"unprognostic (1.31e-1)"	"unprognostic (5.09e-2)"	"unprognostic (3.53e-2)"	"unprognostic (3.25e-1)"	0.0	0.0	5.1	0.0	5.5	0.1	0.2	9.5	7.6	1.3	166.2	0.5	0.0	0.2	0.4	0.2	12.7	0.2	0.0	13.3	10.2	0.2	0.0	1.3	0.0	6.1	9.2	3.0	0.0	1.5	0.0	0.7	0.0	7.6	6.8	0.1	1.1	1.3	1.9	0.0	0.2	0.0	0.0	2.8	0.0	0.8	0.2	8.9	0.2	0.7	0.0	0.0	0.1	0.0	3.5	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.4	2.4	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.4	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	11.7	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.1	5.5	9.5	7.6	13.3	10.2	6.1	9.2	3.0	7.6	2.8	8.9	3.5	0.0	0.0	1.5	41.4	0.3	0.3	1.7	3.5	0.0	0.2	0.5	0.3	0.9	0.0	4.5	0.0	0.0	0.1	0.0	0.4	0.0	0.1	17.9	83.9	0.8	0.3	1.2	0.0	2.4	0.0	0.2	0.3	0.0	3.7	0.0	0.1	0.0	0.0	0.1	0.0	1.4	0.6	2.0	0.0	0.4	3.3	0.6	0.3	0.0	0.0	0.0	8.9	0.0	1.5	1.2	0.2	0.4	0.0	0.0	4.0	0.0	0.1	92.0	0.6	0.0	1.1	1.4	0.0	0.2	0.0	0.1	1.1	0.4	0.0	0.4	1.4
RAB3B		ENSG00000169213	"RAB3B, member RAS oncogene family"	P20337	1	51907956-51990700	"Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 25.2;pituitary gland: 10.7;prostate: 11.1"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 147.4;Alveolar cells type 2: 103.2;Enteroendocrine cells: 293.8;Pancreatic endocrine cells: 92.8"	"Group enriched"	"Detected in many"	6	"prostate cancer: 19.4;testis cancer: 6.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 125.8;BJ hTERT+: 48.4;fHDF/TERT166: 45.8;TIME: 97.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003159, CAB023293"	Enhanced		Approved	"Cell Junctions"		NA	NA			"Cell Junctions"		"CAB023293: , HPA003159: AB_1856005"	"unprognostic (1.10e-1)"	"unprognostic (2.20e-3)"	"unprognostic (5.43e-3)"	"unprognostic (1.65e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.38e-2)"	"unprognostic (1.20e-2)"	"unprognostic (8.77e-3)"	"unprognostic (2.79e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.02e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.15e-2)"	0.0	3.0	10.1	0.6	8.7	0.2	0.8	2.9	14.6	0.0	0.0	1.6	0.7	0.1	0.2	0.0	0.2	1.3	0.0	11.0	17.4	0.5	0.7	0.0	0.1	11.4	18.0	11.3	1.5	1.0	0.0	10.7	1.7	25.2	11.1	2.3	1.7	0.3	0.1	0.5	1.9	0.9	0.3	1.7	0.1	1.2	0.3	17.6	0.2	0.0	0.0	0.1	0.1	0.1	11.6	1.8	8.5	1.2	1.3	0.2	2.3	0.2	125.8	48.4	24.8	12.0	10.4	3.7	0.6	2.0	45.8	3.6	0.1	15.4	13.0	41.7	0.0	1.1	0.1	0.6	3.4	2.1	0.0	0.1	1.1	0.4	41.1	9.4	15.4	7.8	1.1	0.4	0.4	27.9	0.3	0.1	0.1	19.9	2.4	1.2	0.3	0.2	0.2	4.0	0.8	4.3	1.1	0.1	0.3	0.1	24.6	0.2	0.3	97.9	24.0	8.8	0.5	41.5	0.2	0.6	0.4	21.9	0.1	1.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	10.1	8.7	2.9	14.6	11.0	17.4	11.4	18.0	11.3	25.2	1.7	17.6	11.6	1.4	147.4	103.2	0.3	1.1	2.4	6.2	0.3	0.0	5.0	2.2	3.4	0.7	12.8	27.9	0.0	2.1	0.5	0.4	2.0	3.9	4.0	2.4	1.5	1.3	8.2	293.8	0.0	6.6	18.4	0.3	13.9	3.6	1.4	7.6	27.9	0.7	2.7	0.3	0.0	48.1	14.7	14.2	1.3	1.2	1.3	0.6	3.7	1.8	1.0	1.0	31.2	1.0	1.5	1.5	92.8	1.4	1.2	2.3	18.8	1.4	0.2	29.5	3.7	0.0	4.1	4.8	10.4	4.3	0.0	1.4	4.0	3.3	1.1	1.6	2.7
SLC2A12	"GLUT12, GLUT8"	ENSG00000146411	"Solute carrier family 2 member 12"	Q8TD20	6	133987581-134052624	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Sugar transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"choroid plexus: 72.2"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 24.8;Oligodendrocytes: 14.5;Syncytiotrophoblasts: 36.7"	"Cancer enriched"	"Detected in many"	6	"prostate cancer: 18.2"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 7.6;hTERT-RPE1: 14.8;SuSa: 21.7;U-2 OS: 7.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031593, HPA031594"	Approved		Supported	"Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane"	"Cell Junctions"	"HPA031593: AB_10600810, HPA031594: AB_2673948"	"unprognostic (2.06e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.69e-2)"	"unprognostic (5.55e-3)"	"unprognostic (2.18e-1)"	"unprognostic (6.02e-2)"	"unprognostic (2.24e-3)"	"unprognostic (2.54e-2)"	"unprognostic (2.08e-2)"	"unprognostic (3.69e-2)"	"unprognostic (2.38e-1)"	"unprognostic (1.83e-1)"	"unprognostic (2.33e-3)"	"unprognostic (3.04e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.55e-3)"	0.4	1.1	3.6	0.3	4.9	0.0	1.2	7.7	4.7	2.2	72.2	1.4	7.3	8.3	2.1	6.2	2.8	2.7	10.8	5.8	3.5	5.9	6.8	3.1	0.1	2.6	3.7	3.5	1.2	1.1	2.3	1.5	1.6	3.2	22.6	1.0	2.4	5.1	9.4	3.8	2.5	9.9	3.1	1.5	0.1	14.4	0.4	3.5	1.0	0.2	4.1	1.2	3.5	1.2	3.4	2.5	0.9	2.3	0.0	1.4	0.7	0.1	1.5	5.4	0.7	2.9	0.0	7.6	0.3	1.2	0.1	5.7	5.9	0.0	0.5	1.0	0.0	5.3	0.0	0.8	0.1	0.2	0.0	0.0	1.0	0.5	0.6	0.1	14.8	0.4	0.4	0.5	0.8	0.1	0.8	0.1	0.1	2.0	0.0	0.5	0.0	1.0	2.2	1.6	0.8	0.2	0.7	0.1	2.1	0.0	21.7	0.1	0.0	0.1	0.2	7.6	0.2	0.9	3.2	2.4	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.6	4.9	7.7	4.7	5.8	3.5	2.6	3.7	3.5	3.2	1.5	3.5	3.4	0.2	0.0	7.7	24.8	0.1	2.0	1.0	3.3	8.6	0.4	0.5	2.2	6.3	0.0	2.2	0.0	0.0	2.0	0.1	1.2	3.9	1.5	0.1	3.4	0.4	2.3	4.2	0.0	8.0	0.2	0.6	2.2	2.6	1.6	0.0	0.4	0.0	1.1	0.3	0.0	3.2	0.2	6.1	0.0	0.3	0.0	0.0	0.1	0.0	4.7	0.1	9.8	0.0	4.5	14.5	1.1	2.4	1.5	1.6	10.5	0.5	0.5	10.4	0.5	0.0	2.1	1.3	0.0	0.0	8.6	1.8	36.7	0.2	3.5	0.4	1.3
SRD5A2		ENSG00000277893	"Steroid 5 alpha-reductase 2"	P31213	2	31522480-31580938	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Transporters"	"Differentiation, Sexual differentiation"	Oxidoreductase	"Cancer-related genes, Disease variant, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	15	"epididymis: 23.8;fallopian tube: 20.6;liver: 61.3;prostate: 16.9;seminal vesicle: 18.2"	"Group enriched"	"Detected in some"	5	"Early spermatids: 71.7;Endometrial ciliated cells: 29.6;Hepatocytes: 20.0;Late spermatids: 59.9"	"Group enriched"	"Detected in some"	6	"endometrial cancer: 1.1;liver cancer: 4.2;prostate cancer: 3.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"RT4: 1.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (6.75e-3)"	"unprognostic (2.00e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-3)"	"unprognostic (5.92e-3)"	"unprognostic (3.37e-2)"	"unprognostic (2.79e-3)"	"unprognostic (6.56e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.39e-2)"	"unprognostic (3.06e-2)"	"unprognostic (9.79e-3)"	"unprognostic (6.61e-6)"	"unprognostic (4.37e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.48e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.2	23.8	0.0	20.6	0.0	0.0	0.0	0.0	0.3	61.3	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.9	0.0	0.1	0.0	18.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.0	0.2	0.0	0.0	0.0	1.6	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.1	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.6	2.8	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	71.7	29.6	0.2	0.2	0.0	0.0	0.9	0.0	0.0	1.9	0.0	0.5	0.0	0.0	0.4	20.0	0.0	0.0	1.0	0.0	0.0	0.3	0.0	59.9	0.6	0.1	0.0	3.7	0.0	0.0	0.0	0.5	0.9	0.1	0.0	1.2	0.0	0.7	0.0	0.3	7.3	0.0	0.0	0.0	0.2	1.2	0.8	0.0	0.0	0.0	0.1	0.0	0.0	8.6
STEAP1	"PRSS24, STEAP"	ENSG00000164647	"STEAP family member 1"	Q9UHE8	7	90154456-90164829	"Cancer-related genes, Predicted membrane proteins, Transporters"	"Electron transport, Ion transport, Iron transport, Transport"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 84.6"	"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 140.5;Club cells: 72.6;Prostatic glandular cells: 85.1;Theca cells: 64.4;Urothelial cells: 54.0"	"Cancer enriched"	"Detected in all"	6	"prostate cancer: 94.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 105.1;CAPAN-2: 135.2;U-138 MG: 169.2"	"Low region specificity"	"Detected in many"							HPA030985	Uncertain					NA	NA					"HPA030985: AB_2673686"	"unprognostic (2.88e-3)"	"unprognostic (2.29e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.21e-3)"	"unprognostic (9.20e-3)"	"unprognostic (2.03e-1)"	"unprognostic (1.33e-2)"	"unprognostic (6.74e-3)"	"unprognostic (6.36e-2)"	"unprognostic (6.45e-3)"	"unprognostic (8.31e-3)"	"unprognostic (3.79e-1)"	"unprognostic (2.60e-2)"	"unprognostic (4.39e-2)"	"unprognostic (2.42e-1)"	"unprognostic (6.09e-2)"	"unprognostic (1.38e-1)"	33.2	2.2	1.3	33.2	1.7	0.0	18.7	1.1	2.3	9.7	1.6	18.3	5.2	4.2	0.8	12.7	10.8	16.6	4.8	1.4	1.3	6.7	27.8	14.3	0.3	1.6	1.1	1.5	6.1	6.0	0.3	3.7	0.7	1.3	84.6	13.8	0.7	15.2	2.1	1.3	4.3	7.9	27.1	1.2	2.5	14.0	4.2	1.3	0.9	5.0	2.5	4.7	34.9	5.9	1.4	26.9	52.5	3.3	9.8	105.1	89.5	0.9	17.8	20.5	2.4	2.7	38.8	135.2	0.3	0.9	28.9	43.5	5.3	22.0	22.6	5.1	0.0	7.6	0.1	0.5	13.0	4.3	0.0	0.1	59.7	3.7	68.0	37.4	16.6	92.6	7.3	1.2	74.0	29.6	0.4	0.0	0.9	15.7	1.3	23.2	0.1	0.0	0.3	20.8	5.5	0.0	1.2	6.4	0.2	12.1	1.9	29.4	0.4	50.8	169.2	8.0	83.9	22.8	14.0	0.5	0.1	83.4	0.0	15.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	1.1	2.3	1.4	1.3	1.6	1.1	1.5	1.3	1.2	1.3	1.4	1.8	0.0	0.5	2.3	0.3	4.2	41.9	140.5	7.4	0.1	12.8	11.4	0.8	5.7	72.6	1.8	0.0	0.0	0.6	7.0	0.0	3.4	0.4	1.3	4.9	4.5	7.2	0.0	5.3	38.6	0.1	25.2	10.7	4.6	0.0	10.5	1.8	33.1	0.5	0.0	1.7	4.3	24.4	0.8	5.4	1.1	0.9	1.3	7.2	0.0	0.0	10.5	0.0	1.5	1.3	44.4	20.5	1.5	1.3	85.1	2.5	14.7	13.1	0.3	6.6	6.0	26.9	17.1	36.9	12.2	2.3	0.3	0.4	64.4	16.6	54.0
SYNPO2L	FLJ12921	ENSG00000166317	"Synaptopodin 2 like"	Q9H987	10	73644881-73663803	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	18	"heart muscle: 264.8;skeletal muscle: 281.9;tongue: 88.0"	"Cell type enriched"	"Detected in some"	52	"Cardiomyocytes: 665.1"	"Group enriched"	"Detected in some"	6	"breast cancer: 1.5;head and neck cancer: 1.4;prostate cancer: 0.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"CACO-2: 4.1;HSkMC: 3.2;RH-30: 3.0;SK-BR-3: 3.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA055192, HPA057142"	Enhanced		Supported	"Nuclear speckles,Cell Junctions,Cytosol"		NA	NA			"Nuclear speckles"	"Cell Junctions, Cytosol"	"HPA055192: AB_2682732, HPA057142: AB_2683348"	"unprognostic (2.75e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.20e-3)"	"unprognostic (3.65e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.33e-1)"	"unprognostic (4.54e-2)"	"unprognostic (3.30e-1)"	"unprognostic (2.49e-2)"	"unprognostic (4.50e-2)"	"unprognostic (2.32e-1)"	"unprognostic (7.44e-4)"	"unprognostic (1.09e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.72e-2)"	"unprognostic (1.34e-1)"	0.1	0.5	0.6	0.1	0.8	0.3	3.6	0.8	0.8	0.2	0.1	0.0	0.1	0.1	0.1	11.9	0.1	0.1	264.8	0.7	0.4	0.1	0.1	1.3	0.2	0.8	0.6	0.4	0.2	0.4	0.0	0.1	0.6	0.7	3.1	0.0	0.4	4.8	0.0	281.9	0.3	0.0	0.0	0.5	0.2	0.1	0.3	0.5	0.1	0.2	88.0	0.2	0.1	1.1	0.7	0.0	0.0	0.4	0.1	0.0	0.0	0.3	0.5	0.6	0.1	0.0	4.1	0.2	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.2	0.0	0.3	0.1	0.0	3.2	0.0	0.6	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	3.0	0.1	0.0	0.1	0.1	0.1	0.0	3.2	0.0	0.1	0.1	0.1	0.0	0.2	0.4	0.0	0.1	0.5	0.0	0.0	0.0	0.2	0.0	0.6	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.1	0.2	0.0	0.0	0.6	0.8	0.8	0.8	0.7	0.4	0.8	0.6	0.4	0.7	0.5	0.5	0.7	0.5	3.2	0.0	0.3	0.9	1.5	1.4	0.0	2.2	1.9	1.0	0.8	665.1	0.0	0.7	0.0	2.1	0.2	0.5	0.0	0.0	0.0	2.6	0.1	0.4	5.0	0.0	0.0	0.3	0.0	0.2	12.6	0.0	0.3	1.3	0.3	0.0	0.4	0.2	0.0	0.9	0.0	0.0	0.6	2.1	1.1	0.9	0.8	1.8	1.0	0.3	0.4	0.0	1.5	1.1	0.0	0.0	0.4	0.3	0.9	0.0	0.2	0.7	1.2	0.0	12.0	5.2	0.8	1.3	0.4	0.4	0.0	0.7	0.2	0.0	1.0
TBL1Y	TBL1	ENSG00000092377	"Transducin beta like 1 Y-linked"	Q9BQ87	Y	6910686-7101970	"Disease related genes, Human disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	Activator	"Deafness, Disease variant, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"prostate: 3.0;thyroid gland: 1.6"	"Cell type enhanced"	"Detected in some"		"Basal squamous epithelial cells: 3.4;Inhibitory neurons: 2.2;Oligodendrocyte precursor cells: 1.0;Squamous epithelial cells: 5.7;Urothelial cells: 1.1"	"Cancer enriched"	"Detected in single"	6	"prostate cancer: 1.7"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"U-698: 12.3"									"HPA050857, HPA060073"	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA050857: , HPA060073: AB_2684196"						"unprognostic (2.81e-3)"	"unprognostic (2.94e-1)"	"unprognostic (3.06e-1)"			"unprognostic (7.76e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.77e-2)"	"unprognostic (1.47e-1)"		"unprognostic (3.24e-2)"	0.2	0.0	0.2	0.0	1.1	0.0	0.3	0.1	0.3	0.0	0.3	0.1	0.0	0.0	0.1	0.3	0.0	0.4	0.0	0.0	0.2	0.4	0.6	0.1	0.0	0.8	0.1	0.0	0.0	0.4	0.0	0.0	0.1	0.4	3.0	0.1	0.0	0.8	0.3	0.4	0.2	0.0	0.0	0.4	0.0	0.2	0.3	0.6	0.0	1.6	0.1	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.6	0.0	0.0	0.0	0.0	1.9	0.0	2.2	1.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.1	0.3	0.0	0.2	0.8	0.1	0.0	0.4	0.4	0.6	0.3	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.2	3.4	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	2.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.1	0.0	0.0	0.0	0.5	0.0	0.4	0.1	0.0	0.0	0.0	0.1	0.0	0.2	5.7	0.0	0.3	0.0	0.0	0.0	1.1
UPK3A	UPK3	ENSG00000100373	"Uroplakin 3A"	O75631	22	45284949-45295874	"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"			"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"prostate: 21.5;skeletal muscle: 35.4;urinary bladder: 48.4"	"Cell type enhanced"	"Detected in some"		"Basal prostatic cells: 15.0;monocytes: 22.6;Prostatic glandular cells: 54.1;Proximal enterocytes: 29.8;Urothelial cells: 24.5"	"Group enriched"	"Detected in many"	6	"prostate cancer: 35.3;urothelial cancer: 78.0"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"myeloid DC: 86.6"	"Group enriched"	"Detected in many"	16	"dendritic cells: 86.6;monocytes: 32.0"	"Group enriched"	"Detected in some"	5	"Hep G2: 29.9;RT4: 48.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA018407, HPA018415"	Enhanced		Uncertain	"Nuclear membrane,Nuclear bodies"		NA	NA			"Nuclear membrane"	"Nuclear bodies"	"HPA018407: AB_1858641, HPA018415: AB_1858640"	"unprognostic (1.27e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-1)"	"unprognostic (9.42e-2)"	"unprognostic (3.98e-5)"	"unprognostic (1.69e-2)"	"unprognostic (4.82e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.18e-1)"	"unprognostic (6.49e-5)"	"unprognostic (2.01e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.05e-3)"	0.2	0.1	0.1	0.5	0.1	1.5	0.2	0.1	0.4	0.0	0.3	1.0	0.0	0.1	0.1	0.3	0.3	0.9	0.1	0.1	0.4	0.0	0.0	0.2	0.9	0.3	0.2	0.0	0.1	0.2	5.0	0.7	0.0	0.2	21.5	0.7	0.0	2.8	0.2	35.4	0.0	1.3	0.1	0.2	1.1	0.1	0.1	0.1	0.7	2.3	4.6	0.9	48.4	1.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.9	0.0	4.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.5	0.0	4.6	0.0	0.1	0.0	0.2	0.0	48.9	0.1	0.0	0.2	0.8	0.0	0.0	0.1	5.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.1	0.0	0.0	0.0	0.0	21.2	0.0	0.0	25.8	0.0	1.2	0.0	0.1	86.6	0.5	0.0	0.0	3.6	0.4	32.0	32.9	0.0	7.4	0.1	0.1	0.1	0.4	0.1	0.4	0.3	0.2	0.0	0.2	0.2	0.1	0.3	0.2	0.0	0.0	0.7	1.2	0.1	15.0	0.1	0.0	0.1	4.6	3.6	0.2	2.8	0.1	0.0	0.0	0.0	4.0	3.3	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	1.7	0.0	0.1	3.5	0.0	4.8	8.7	1.7	0.3	6.4	0.0	0.0	22.6	0.8	2.1	0.0	0.0	0.0	9.3	0.0	0.1	54.1	29.8	0.0	0.1	0.0	0.0	1.6	0.5	0.0	0.4	0.0	0.4	0.1	0.2	0.0	4.4	24.5
ADAM2	"CT15, FTNB, PH-30b, PH30"	ENSG00000104755	"ADAM metallopeptidase domain 2"	Q99965	8	39743735-39838289	"Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	133	"testis: 38.5"	"Group enriched"	"Detected in some"	4	"Early spermatids: 28.2;Spermatocytes: 96.8"	"Cancer enriched"	"Detected in single"	5	"prostate cancer: 1.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB022390, HPA024621, HPA026581"	Enhanced					NA	NA					"CAB022390: , HPA024621: AB_1844576, HPA026581: AB_1844577"				"unprognostic (4.74e-2)"								"unprognostic (1.67e-3)"					"unprognostic (3.82e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	15.1	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.8	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0
AFF3	"LAF4, MLLT2-like"	ENSG00000144218	"AF4/FMR2 family member 3"	P51826	2	99545419-100192428	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"B-cells: 154.9;Excitatory neurons: 491.3;Inhibitory neurons: 300.7;Oligodendrocyte precursor cells: 211.6"	"Group enriched"	"Detected in many"	5	"breast cancer: 11.4;prostate cancer: 7.3"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"memory B-cell: 31.0;naive B-cell: 44.2;plasmacytoid DC: 23.9"	"Group enriched"	"Detected in many"	17	"B-cells: 44.2;dendritic cells: 23.9"	"Cell line enhanced"	"Detected in many"		"Daudi: 51.1;U-698: 56.5"	"Low region specificity"	"Detected in all"							"HPA044512, HPA053379"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA044512: AB_10795984, HPA053379: AB_2682133"	"unprognostic (1.05e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.30e-1)"	"unprognostic (4.88e-3)"	"unprognostic (1.02e-1)"	"unprognostic (4.98e-5)"	"unprognostic (1.11e-3)"	"unprognostic (3.04e-2)"	"unprognostic (8.75e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.95e-3)"	"unprognostic (7.57e-2)"	"prognostic unfavorable (5.64e-4)"	"unprognostic (6.40e-3)"	"unprognostic (6.79e-2)"	"unprognostic (3.69e-2)"	"unprognostic (7.87e-3)"	3.4	1.6	2.0	6.2	4.2	11.3	11.7	18.0	13.9	3.3	0.0	4.4	1.1	7.8	0.8	3.5	4.5	2.2	4.3	10.5	5.2	1.4	1.7	6.6	14.3	2.8	0.9	2.8	6.4	0.4	0.1	4.4	6.2	6.2	16.3	2.2	4.3	1.9	2.5	0.7	0.8	6.0	6.0	0.0	7.4	4.6	5.5	0.7	7.8	1.2	0.7	12.3	6.8	2.3	10.3	0.2	0.0	18.0	6.4	0.0	0.6	0.0	2.8	0.7	5.6	1.9	0.0	0.0	51.1	0.1	3.8	12.4	0.2	0.5	0.0	4.0	14.3	6.3	0.0	0.0	0.0	0.4	0.2	12.4	0.8	0.0	12.8	0.2	13.8	0.0	2.2	0.3	0.1	0.0	0.1	4.3	0.3	1.8	0.0	3.2	7.5	0.0	0.3	0.0	0.0	17.4	6.5	0.0	0.3	11.0	1.5	17.9	16.5	6.7	19.1	3.4	0.5	2.9	0.8	0.1	56.5	15.9	1.5	2.0	0.6	0.5	0.1	0.0	0.5	0.3	31.0	0.2	0.0	5.1	44.2	1.9	0.0	0.0	1.0	0.4	23.9	0.0	0.8	2.0	4.2	18.0	13.9	10.5	5.2	2.8	0.9	2.8	6.2	0.0	0.7	10.3	1.2	6.4	40.9	41.8	154.9	1.8	0.4	0.0	1.8	21.8	78.9	37.7	11.1	0.0	3.7	0.0	12.5	0.4	32.8	0.1	0.0	0.0	33.9	0.9	19.8	6.0	22.9	3.4	491.3	0.0	0.2	13.5	1.1	1.1	0.0	31.6	0.7	1.2	1.8	47.1	300.7	0.5	0.0	9.2	18.2	38.5	10.8	16.5	14.2	66.5	5.2	6.8	0.0	211.6	46.7	0.0	0.1	21.1	0.8	14.3	0.1	1.9	0.0	1.7	0.0	1.1	8.5	10.5	9.8	0.0	1.3	0.1	6.1	5.7	0.6	0.3
ALDH1A3	"ALDH6, RALDH3"	ENSG00000184254	"Aldehyde dehydrogenase 1 family member A3"	P47895	15	100877714-100916626	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		Oxidoreductase	"Disease variant, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 135.7;urinary bladder: 126.3"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 175.4;Endometrial stromal cells: 247.9;Leydig cells: 194.5;Prostatic glandular cells: 580.3;Urothelial cells: 468.7"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 80.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"A-431: 363.3;HaCaT: 441.7;HBEC3-KT: 1096.9;hTERT-RPE1: 347.7;U-2197: 619.0;U-87 MG: 484.7;WM-115: 516.1"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"olfactory bulb: 4.5;spinal cord: 15.8"	"HPA046271, HPA064749"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA046271: AB_10965992, HPA064749: AB_2685344"	"unprognostic (6.87e-2)"	"unprognostic (2.23e-1)"	"unprognostic (6.20e-3)"	"unprognostic (1.21e-3)"	"unprognostic (1.76e-2)"	"unprognostic (1.14e-1)"	"unprognostic (6.28e-2)"	"unprognostic (5.46e-2)"	"unprognostic (9.62e-2)"	"unprognostic (4.53e-2)"	"unprognostic (3.64e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.25e-2)"	"unprognostic (2.61e-2)"	"unprognostic (2.12e-1)"	"unprognostic (7.34e-2)"	"unprognostic (6.07e-3)"	63.2	11.5	3.1	41.8	2.8	0.6	30.8	4.5	5.0	37.4	13.3	14.1	15.1	8.3	30.6	29.0	25.1	17.2	8.9	3.1	3.5	8.3	5.4	9.9	3.0	4.4	3.6	2.8	6.2	15.2	9.1	7.5	8.4	3.1	135.7	9.0	0.3	94.5	49.8	5.9	3.9	25.4	41.2	3.0	3.1	12.9	16.8	3.0	1.6	2.5	7.0	15.9	126.3	22.5	4.0	363.3	43.5	0.6	0.7	75.0	32.8	1.4	3.2	3.2	1.9	0.8	1.0	285.8	2.6	4.7	97.1	55.7	441.7	8.8	1096.9	6.7	0.1	2.0	1.7	20.1	0.3	25.5	1.4	1.9	23.5	29.8	24.4	4.5	347.7	4.0	0.0	0.7	2.4	1.8	3.8	0.2	1.2	9.0	9.6	316.3	0.7	4.2	2.3	0.2	283.6	0.3	25.4	113.9	94.9	33.3	3.6	9.3	3.2	58.3	0.3	1.0	619.0	14.2	0.7	3.4	1.5	484.7	0.2	516.1	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.1	2.8	4.5	5.0	3.1	3.5	4.4	3.6	2.8	3.1	3.0	3.0	4.0	10.0	16.0	6.3	0.3	0.5	0.6	175.4	70.5	4.6	0.0	64.6	18.9	2.0	1.5	141.6	103.0	0.0	9.6	0.9	1.0	3.9	70.5	1.2	20.6	247.9	11.6	3.5	0.0	2.9	1.4	0.5	48.9	1.1	11.7	5.7	0.0	1.8	0.1	1.2	0.0	2.3	2.1	30.5	0.0	1.3	8.5	194.5	3.3	0.0	1.0	0.6	0.0	0.0	36.7	4.6	29.4	0.0	135.4	0.0	580.3	0.1	0.7	78.7	0.0	13.1	20.4	11.5	0.5	0.9	2.9	1.6	4.9	2.0	1.5	0.8	468.7
ALOX15B	15-LOX-2	ENSG00000179593	"Arachidonate 15-lipoxygenase type B"	O15296	17	8039034-8049134	"Enzymes, Metabolic proteins, Predicted intracellular proteins"	"Lipid metabolism"	"Dioxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 112.8;prostate: 73.7"	"Cell type enhanced"	"Detected in some"		"Alveolar cells type 2: 75.8;Basal respiratory cells: 22.0;Kupffer cells: 42.2;monocytes: 87.9;Prostatic glandular cells: 25.6;Squamous epithelial cells: 44.4"	"Cancer enriched"	"Detected in all"	5	"prostate cancer: 91.2"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"classical monocyte: 3.9;myeloid DC: 4.3"	"Group enriched"	"Detected in many"	8	"dendritic cells: 4.3;monocytes: 3.9"	"Cell line enhanced"	"Detected in some"		"HHSteC: 7.7;HSkMC: 16.6;hTCEpi: 35.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010562	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA010562: AB_2668305"	"unprognostic (1.76e-2)"	"unprognostic (6.47e-2)"	"unprognostic (2.56e-1)"	"unprognostic (2.28e-3)"	"unprognostic (1.67e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.28e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.44e-2)"	"unprognostic (4.59e-1)"	"unprognostic (1.59e-2)"	"unprognostic (9.37e-2)"	"unprognostic (1.48e-1)"	"unprognostic (2.32e-2)"	"unprognostic (9.49e-2)"	2.1	1.7	0.9	1.3	1.2	0.4	112.8	0.8	3.8	6.5	0.7	1.7	0.1	1.1	1.0	39.4	1.6	0.7	0.6	0.8	1.0	0.5	0.4	24.7	3.0	1.7	0.8	0.6	0.7	1.4	0.2	0.5	1.3	2.1	73.7	0.3	0.3	3.7	0.1	0.3	27.1	3.8	0.1	1.0	3.8	4.4	0.5	1.0	0.7	1.9	0.1	7.6	1.8	33.6	2.0	0.1	0.0	0.0	0.1	0.5	0.7	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	7.7	0.0	0.0	16.6	35.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.2	0.5	0.0	0.1	0.0	0.9	0.9	1.2	0.8	3.8	0.8	1.0	1.7	0.8	0.6	2.1	1.0	1.0	2.0	1.4	0.0	75.8	0.0	0.3	3.1	0.6	22.0	7.4	0.0	19.8	12.3	0.3	1.5	8.2	0.0	0.0	0.2	0.2	0.2	0.0	0.1	1.3	0.0	0.8	0.4	0.0	0.0	0.2	0.4	0.0	0.2	0.0	0.2	1.3	0.0	0.7	0.3	4.2	0.0	0.0	0.0	2.0	42.2	1.1	0.8	0.0	15.4	5.4	0.0	87.9	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.4	25.6	0.0	0.0	2.2	0.0	0.0	0.1	1.3	0.6	0.8	44.4	1.1	0.8	0.0	0.0	0.0	2.2
C22orf42		ENSG00000205856	"Chromosome 22 open reading frame 42"	Q6IC83	22	32149006-32159322	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	11	"brain: 9.1;testis: 10.6"	"Group enriched"	"Detected in some"	8	"Early spermatids: 95.7;Late spermatids: 31.3"	"Group enriched"	"Detected in some"	5	"pancreatic cancer: 0.8;prostate cancer: 1.0"	"Group enriched"	"Detected in many"	5	"amygdala: 2.4;hypothalamus: 6.5;midbrain: 2.5;pons: 2.9;thalamus: 9.1"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA019531	Enhanced					NA	NA					"HPA019531: AB_1853016"					"unprognostic (5.67e-2)"						"unprognostic (6.13e-3)"	"unprognostic (8.21e-3)"		"unprognostic (7.06e-2)"	"unprognostic (4.54e-2)"			0.0	0.0	2.4	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.7	2.5	0.0	0.0	0.4	0.0	0.9	0.0	2.9	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	10.6	9.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.9	0.0	0.3	0.0	6.5	0.7	2.5	0.0	2.9	0.1	9.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	95.7	0.2	0.0	0.1	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	31.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CACNG4	"MGC11138, MGC24983"	ENSG00000075461	"Calcium voltage-gated channel auxiliary subunit gamma 4"	Q9UBN1	17	66964707-67033398	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 33.4;prostate: 11.8"	"Cell type enriched"	"Detected in some"	6	"Oligodendrocyte precursor cells: 145.3"	"Group enriched"	"Detected in many"	5	"breast cancer: 30.3;glioma: 35.8;ovarian cancer: 14.8;prostate cancer: 10.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	6	"SH-SY5Y: 387.4"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"basal ganglia: 118.1"	"HPA005803, HPA065370"	Enhanced		Approved	Vesicles		NA	NA			Vesicles		"HPA005803: AB_2667439, HPA065370: AB_2685480"	"unprognostic (1.27e-1)"	"unprognostic (3.16e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.05e-2)"	"unprognostic (6.42e-2)"	"unprognostic (8.64e-3)"	"unprognostic (2.91e-1)"	"unprognostic (7.08e-2)"	"unprognostic (3.37e-2)"	"unprognostic (3.85e-2)"	"unprognostic (6.03e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.38e-10)"	"unprognostic (8.57e-3)"	"unprognostic (1.23e-1)"	"unprognostic (8.71e-2)"	"unprognostic (4.28e-1)"	0.2	0.8	26.4	0.1	33.4	0.0	5.4	6.0	22.6	0.4	3.3	0.5	0.2	0.5	0.1	0.2	4.2	0.4	0.1	13.0	15.4	0.1	0.0	5.8	0.0	15.7	15.1	15.8	0.1	0.4	1.2	0.3	0.7	21.4	11.8	0.1	0.8	1.7	1.3	0.1	0.4	0.1	1.1	10.0	0.0	1.5	0.2	21.1	0.0	0.1	0.0	0.0	0.4	0.7	10.6	6.4	4.1	15.6	0.0	0.0	0.0	4.4	0.0	0.0	1.4	0.0	4.6	0.2	0.0	0.2	0.0	41.2	64.1	0.1	0.0	0.0	0.0	0.3	0.0	1.8	3.7	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	34.5	0.1	0.3	15.7	7.3	0.0	0.0	0.4	8.7	0.0	11.1	15.8	387.4	3.6	10.4	0.0	38.1	38.5	0.0	0.0	0.0	0.0	0.1	3.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.4	33.4	6.0	22.6	13.0	15.4	15.7	15.1	15.8	21.4	10.0	21.1	10.6	0.0	3.2	1.3	0.0	0.0	0.0	1.1	0.3	0.0	0.2	6.4	3.4	1.3	0.0	1.4	0.0	0.0	0.3	0.1	0.6	0.0	0.1	2.6	1.0	0.2	0.1	7.7	0.0	1.8	0.2	0.2	0.2	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	20.8	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	3.7	0.0	3.4	0.0	145.3	0.3	0.7	0.2	0.0	0.0	2.6	0.0	0.0	1.9	0.2	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.7
CAMKK2	"CAMKK, CAMKKB, KIAA0787, MGC15254"	ENSG00000110931	"Calcium/calmodulin dependent protein kinase kinase 2"	Q96RR4	12	121237675-121298308	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Calmodulin-binding, Kinase, Serine/threonine-protein kinase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 138.5"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 64.8;Horizontal cells: 62.2;Late spermatids: 89.6"	"Cancer enriched"	"Detected in all"	5	"prostate cancer: 56.3"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 32.7;eosinophil: 62.1;intermediate monocyte: 42.3;myeloid DC: 15.9;neutrophil: 39.2;non-classical monocyte: 39.5"	"Group enriched"	"Detected in all"	5	"dendritic cells: 15.9;granulocytes: 62.1;monocytes: 42.3"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017389, HPA063713"	Approved	Supported	Supported	Cytosol		NA	NA			Cytosol		"HPA017389: AB_1845956, HPA063713: "	"unprognostic (5.08e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.62e-3)"	"unprognostic (2.80e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.76e-2)"	"unprognostic (5.01e-2)"	"unprognostic (1.70e-1)"	"unprognostic (1.75e-1)"	"unprognostic (4.13e-1)"	"unprognostic (3.34e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.38e-1)"	25.1	16.8	41.2	17.2	50.4	31.1	22.9	138.5	61.0	21.7	20.0	22.7	25.9	23.1	10.9	17.7	27.8	13.0	17.6	43.2	31.0	16.7	31.1	23.8	15.4	26.6	29.7	50.5	27.6	17.0	12.5	11.9	15.5	63.0	29.8	19.6	7.1	18.7	24.1	11.6	18.4	26.8	20.8	20.9	39.9	24.2	7.0	26.1	13.5	17.3	11.3	15.7	26.2	21.3	44.1	27.9	20.5	16.3	30.9	46.7	43.0	22.8	22.0	23.8	19.0	17.3	21.4	12.1	43.0	18.1	48.1	14.1	22.7	20.0	25.8	15.1	29.3	35.9	22.0	14.4	21.3	31.1	50.0	20.0	28.2	37.2	18.0	41.4	26.0	45.0	33.5	25.2	23.6	18.4	27.2	55.8	40.6	11.7	24.9	22.7	35.3	18.4	37.7	18.8	32.1	60.2	22.4	31.5	16.5	19.1	12.9	39.7	62.0	32.2	14.8	11.8	13.1	13.0	84.8	55.6	32.7	27.7	34.4	16.0	2.0	32.7	62.1	4.7	42.3	4.6	4.8	3.5	4.2	15.9	2.8	3.2	3.8	39.2	8.6	39.5	3.6	3.3	15.8	41.2	50.4	138.5	61.0	43.2	31.0	26.6	29.7	50.5	63.0	20.9	26.1	44.1	25.4	9.6	5.6	9.8	5.7	7.9	6.0	8.1	8.0	22.2	11.6	10.5	8.2	12.8	8.3	9.2	2.1	9.2	10.6	18.2	3.9	9.6	16.0	6.5	19.6	21.9	34.3	12.0	64.8	10.4	8.2	18.0	13.3	10.9	6.3	23.3	15.0	19.7	7.9	62.2	21.4	16.2	8.2	14.8	15.6	89.6	20.5	16.6	8.8	12.2	36.3	5.4	12.3	10.1	19.3	8.5	10.9	31.6	11.9	16.5	26.6	9.6	7.2	7.0	19.7	7.7	20.6	0.8	2.9	13.3	6.0	3.4	7.6	32.7	17.6	6.3
CCK		ENSG00000187094	Cholecystokinin	P06307	3	42257825-42266185	"Plasma proteins, Predicted secreted proteins"		Hormone		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"brain: 274.4;choroid plexus: 110.8;intestine: 116.7"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 40.1;Excitatory neurons: 154.8;Fibroblasts: 42.5;Inhibitory neurons: 157.7;Melanocytes: 40.9;Oligodendrocytes: 40.9;Prostatic glandular cells: 63.8"	"Group enriched"	"Detected in many"	5	"glioma: 4.0;pancreatic cancer: 1.8;prostate cancer: 3.5;stomach cancer: 1.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"OE19: 236.5"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebral cortex: 74.4"	"HPA045039, HPA069515"	Enhanced	Supported			"Secreted to blood"	NA	NA	43700000				"HPA045039: , HPA069515: AB_2732135"	"unprognostic (3.36e-1)"	"unprognostic (1.58e-1)"	"unprognostic (1.92e-1)"	"unprognostic (1.40e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.70e-1)"		"unprognostic (2.39e-3)"		"unprognostic (1.97e-2)"	"unprognostic (3.91e-1)"	"unprognostic (8.77e-2)"		"unprognostic (1.35e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.37e-1)"	"unprognostic (5.10e-2)"	0.1	0.9	153.7	0.5	200.3	0.0	0.2	104.1	274.4	0.0	110.8	3.5	116.7	0.0	0.0	0.3	0.5	0.0	0.1	174.6	133.7	0.2	0.4	3.4	0.0	135.3	117.3	198.7	0.1	0.4	0.0	18.5	1.2	136.9	19.7	0.1	4.5	0.2	0.2	0.2	0.3	17.1	0.2	110.5	0.0	2.2	2.4	126.0	0.2	0.1	0.0	0.0	0.1	0.1	167.4	0.0	2.5	0.0	0.0	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	9.7	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	236.5	0.1	0.0	0.0	1.1	25.0	0.1	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	153.7	200.3	104.1	274.4	174.6	133.7	135.3	117.3	198.7	136.9	110.5	126.0	167.4	0.4	0.0	0.0	40.1	0.2	5.7	1.3	0.3	0.6	6.8	1.3	1.9	0.3	0.0	0.2	5.5	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.2	0.1	2.5	0.0	0.0	154.8	0.4	0.1	42.5	5.1	0.4	0.0	0.0	1.4	0.0	0.1	0.0	157.7	11.4	2.0	0.3	3.0	0.3	0.0	0.6	40.9	34.7	0.0	36.7	0.0	34.7	40.9	0.7	0.0	0.0	0.0	63.8	0.6	0.1	0.0	3.5	0.0	0.8	6.4	0.1	1.7	0.0	1.3	10.5	0.0	0.0	0.5	8.7
COX6A2		ENSG00000156885	"Cytochrome c oxidase subunit 6A2"	Q02221	16	31427731-31428360	"Disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Transporters"		Oxidoreductase	"Disease variant, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	43	"heart muscle: 2939.2;skeletal muscle: 6806.0;tongue: 2114.7"	"Cell type enriched"	"Detected in some"	18	"Cardiomyocytes: 4861.8"	"Group enriched"	"Detected in many"	5	"head and neck cancer: 9.3;liver cancer: 2.9;prostate cancer: 3.6"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	150	"NK-cell: 15.0"	"Lineage enriched"	"Detected in single"	150	"NK-cells: 15.0"	"Cell line enriched"	"Detected in some"	4	"U-266/84: 13.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.66e-1)"	"unprognostic (1.73e-3)"			"unprognostic (2.09e-2)"	"unprognostic (1.25e-2)"	"unprognostic (1.68e-2)"		"unprognostic (3.88e-1)"	"unprognostic (5.61e-2)"	"unprognostic (7.20e-2)"	"unprognostic (8.71e-2)"	"unprognostic (6.20e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.65e-1)"			1.5	0.9	1.6	0.1	1.0	0.0	2.9	2.1	2.3	0.4	0.2	1.1	1.1	1.1	0.0	75.5	0.9	0.0	2939.2	0.8	1.5	4.4	16.0	3.4	0.4	1.4	1.7	0.7	1.2	3.0	2.9	12.0	0.1	5.2	39.2	0.0	1.0	92.8	0.1	6806.0	2.4	1.2	0.0	0.7	0.5	1.3	1.3	2.4	0.5	2.0	2114.7	0.1	0.3	1.4	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.1	1.6	1.0	2.1	2.3	0.8	1.5	1.4	1.7	0.7	5.2	0.7	2.4	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.6	0.2	0.4	4861.8	2.8	0.0	3.7	0.0	0.0	0.4	0.0	5.9	0.0	0.0	0.0	0.1	48.8	0.0	0.0	0.0	0.4	0.0	96.2	0.0	0.1	0.0	0.2	0.4	75.7	2.9	3.3	0.0	0.1	0.0	1.6	0.0	0.8	0.3	1.3	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.1	1.3	24.9	0.0	4.2	19.7	258.0	53.7	0.2	1.2	0.0	0.0	0.0	2.1	0.0	0.0	0.0
CREB3L4	"AIbZIP, ATCE1, CREB3, CREB4, hJAL"	ENSG00000143578	"CAMP responsive element binding protein 3 like 4"	Q8TEY5	1	153967534-153974361	"Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation, Unfolded protein response"	"Activator, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"prostate: 107.2"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 49.9;Breast myoepithelial cells: 40.1;Intestinal goblet cells: 56.9;Prostatic glandular cells: 49.3"	"Group enriched"	"Detected in all"	5	"breast cancer: 47.8;endometrial cancer: 28.7;prostate cancer: 109.9"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 81.8;OE19: 82.7;SK-BR-3: 174.6;T-47d: 139.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA038122	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Mitochondria"		No	No			"Nucleoplasm, Nuclear membrane"	Mitochondria	"HPA038122: AB_10669516"	"unprognostic (1.35e-1)"	"unprognostic (4.71e-2)"	"unprognostic (8.13e-3)"	"prognostic favorable (7.21e-4)"	"unprognostic (2.04e-1)"	"unprognostic (1.40e-2)"	"unprognostic (5.51e-3)"	"unprognostic (5.02e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.40e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.70e-1)"	"unprognostic (7.12e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.06e-1)"	"unprognostic (8.83e-2)"	"unprognostic (9.34e-3)"	6.3	8.6	4.2	4.5	3.6	7.6	48.7	4.2	4.7	30.8	4.1	11.6	11.5	13.1	13.1	8.3	19.4	6.8	4.8	3.4	3.6	7.5	14.1	5.8	6.0	3.7	3.8	2.7	17.6	13.3	6.8	6.2	6.4	3.7	107.2	15.3	5.0	44.2	7.7	5.7	10.2	9.1	5.8	4.0	7.6	29.6	5.3	3.4	12.1	11.4	5.4	7.5	6.8	7.0	4.6	7.5	10.6	9.8	10.9	6.9	10.0	24.7	6.2	7.2	8.3	7.3	5.1	31.0	13.9	31.7	2.6	6.1	12.0	14.5	9.7	4.5	11.4	5.9	10.3	11.7	8.9	5.6	4.9	8.5	10.9	9.2	7.9	17.9	7.5	7.4	16.5	8.1	16.9	3.8	81.8	9.3	3.8	6.7	82.7	12.7	20.9	10.3	26.1	9.0	5.3	18.5	20.1	6.6	174.6	16.8	12.8	139.9	14.9	4.5	2.5	7.3	5.2	4.9	31.4	17.3	10.6	5.3	8.5	8.2	1.5	2.9	2.2	3.4	1.2	4.5	4.5	1.9	2.4	5.0	4.8	1.8	3.5	0.1	9.4	1.7	5.7	1.8	2.5	4.2	3.6	4.2	4.7	3.4	3.6	3.7	3.8	2.7	3.7	4.0	3.4	4.6	7.2	6.4	13.1	3.6	6.2	2.9	13.1	10.1	6.8	5.3	49.9	40.1	2.0	7.2	20.3	1.8	2.1	12.9	5.6	3.6	9.8	14.0	0.4	10.6	5.2	6.9	9.0	8.6	0.4	13.3	17.0	4.8	10.7	13.5	5.7	8.7	4.2	14.2	5.4	0.0	0.4	56.9	6.1	7.5	2.0	0.6	7.2	5.1	5.4	0.0	2.8	6.6	8.2	1.5	2.2	7.9	4.3	2.2	5.3	49.3	4.0	4.1	16.6	8.8	19.7	3.1	5.0	7.4	10.6	6.3	3.0	4.2	4.5	7.6	10.9	7.0
DCXR	"DCR, HCR2, KIDCR, P34H, SDR20C1"	ENSG00000169738	"Dicarbonyl and L-xylulose reductase"	Q7Z4W1	17	82035136-82037709	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Carbohydrate metabolism, Glucose metabolism, Xylose metabolism"	Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	7	"liver: 1866.7"	"Cell type enhanced"	"Detected in all"		"Distal tubular cells: 812.0;Hepatocytes: 3510.3;Proximal tubular cells: 2919.4"	"Group enriched"	"Detected in all"	5	"liver cancer: 305.9;prostate cancer: 163.4"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 365.2;MCF7: 446.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023371, HPA023863"	Enhanced		Uncertain	Nucleoli,Microtubules		NA	NA		4000000	"Nucleoli, Microtubules"		"HPA023371: AB_1847530, HPA023863: AB_1847531"	"unprognostic (3.33e-2)"	"unprognostic (1.67e-3)"	"unprognostic (3.75e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.43e-2)"	"unprognostic (4.54e-3)"	"unprognostic (1.86e-2)"	"unprognostic (3.05e-1)"	"unprognostic (2.56e-2)"	"prognostic favorable (4.70e-4)"	"unprognostic (1.72e-1)"	"prognostic favorable (2.13e-4)"	"unprognostic (1.81e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.10e-2)"	100.5	44.3	79.1	15.3	82.3	25.5	108.6	87.2	112.0	46.9	68.5	42.7	29.4	39.8	283.7	97.4	59.7	10.9	101.1	72.5	85.3	242.2	1866.7	61.5	16.8	95.8	84.6	70.1	70.6	72.2	46.5	64.4	20.3	91.2	139.2	21.1	9.8	104.3	33.9	188.8	81.9	44.8	10.5	76.3	36.0	168.3	45.1	90.6	26.3	61.2	81.3	19.8	49.3	62.6	85.2	50.3	68.2	32.8	56.4	123.2	31.8	80.4	25.0	33.9	68.5	48.4	122.0	21.3	100.3	47.4	35.9	9.4	57.4	59.6	52.6	24.1	21.4	145.9	96.9	48.8	365.2	143.2	75.6	114.5	44.6	62.2	22.7	79.8	16.0	41.1	61.1	112.4	76.3	36.5	446.2	63.7	184.1	35.0	242.9	71.3	57.9	42.0	135.3	53.3	71.9	85.5	51.0	35.5	287.5	46.0	19.7	213.4	74.5	20.5	36.6	45.0	48.9	48.2	73.7	56.2	50.2	31.4	83.0	26.7	49.5	92.6	77.9	66.5	92.0	64.1	86.8	83.0	64.7	151.3	99.2	117.7	85.4	47.2	108.9	88.1	121.6	98.9	110.1	79.1	82.3	87.2	112.0	72.5	85.3	95.8	84.6	70.1	91.2	76.3	90.6	85.2	29.0	51.3	198.2	16.6	133.6	58.5	200.3	113.5	109.8	16.0	301.8	269.2	120.7	183.0	123.4	178.4	18.8	372.1	116.6	152.9	812.0	41.4	6.0	67.0	50.9	44.6	54.7	335.7	4.7	42.6	450.6	65.0	151.4	102.3	64.7	62.7	138.5	3510.3	164.7	21.9	9.0	170.4	189.2	165.7	65.6	22.6	70.8	82.3	179.7	1.9	52.8	145.1	78.2	5.5	10.5	30.4	135.7	47.4	98.6	215.2	158.9	2919.4	55.4	26.5	19.7	40.6	79.6	10.3	48.2	219.9	73.2	342.6	135.7	118.6	154.6	178.8
DHRS7	"retDSR4, SDR34C1"	ENSG00000100612	"Dehydrogenase/reductase 7"	Q9Y394	14	60144119-60169856	"Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 620.9"	"Cell type enhanced"	"Detected in all"		"Proximal enterocytes: 840.4"	"Cancer enriched"	"Detected in all"	5	"prostate cancer: 199.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031121, HPA078401"	Enhanced		Approved	Nucleoplasm,Mitochondria		No	No			"Nucleoplasm, Mitochondria"		"HPA031121: AB_10600803, HPA078401: "	"prognostic favorable (6.42e-4)"	"unprognostic (5.20e-2)"	"unprognostic (6.70e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.69e-1)"	"prognostic unfavorable (2.51e-4)"	"unprognostic (4.65e-2)"	"unprognostic (4.31e-2)"	"unprognostic (2.62e-1)"	"prognostic unfavorable (7.99e-4)"	"unprognostic (1.73e-1)"	"unprognostic (1.59e-1)"	"prognostic favorable (1.92e-10)"	"unprognostic (8.35e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-1)"	57.7	104.3	52.0	44.2	54.1	61.5	59.1	59.6	76.0	49.3	52.2	73.7	109.9	50.3	97.4	44.6	46.3	59.7	47.1	50.7	62.1	101.5	147.6	64.7	45.9	61.0	58.2	52.0	65.4	77.4	228.7	55.1	29.9	63.8	413.6	70.2	112.1	320.2	135.8	620.9	40.0	182.5	51.4	59.8	45.7	184.0	9.9	54.2	39.6	121.4	137.2	49.8	52.2	41.4	65.9	221.3	52.9	41.8	89.3	219.6	74.4	42.8	74.3	186.4	26.5	59.0	37.3	149.8	21.5	41.7	76.8	78.0	92.7	57.2	108.3	34.5	156.1	36.0	53.7	28.7	60.9	110.1	71.8	1.7	63.3	116.7	47.6	153.0	50.8	52.5	66.2	18.2	52.6	61.4	59.2	40.9	67.2	18.6	151.2	55.4	42.7	50.8	24.4	118.3	70.5	83.4	99.8	72.6	118.0	168.2	52.7	72.7	32.5	35.8	126.6	38.7	36.9	44.2	18.3	7.9	45.0	62.6	64.8	93.5	743.5	213.1	519.6	335.7	159.1	340.6	184.4	238.9	298.5	185.0	167.0	134.6	258.5	835.4	294.7	224.0	388.8	215.5	450.2	52.0	54.1	59.6	76.0	50.7	62.1	61.0	58.2	52.0	63.8	59.8	54.2	65.9	109.6	54.5	102.5	16.0	72.2	34.0	70.3	233.2	52.3	25.7	81.2	57.4	27.6	160.2	138.4	86.5	83.4	29.6	210.4	101.3	19.6	222.5	2.1	56.2	55.5	89.7	46.5	20.4	12.2	165.9	88.7	87.9	120.8	120.0	178.5	22.9	48.5	166.4	94.4	42.1	19.0	102.2	386.6	54.5	70.6	3.5	82.3	98.7	108.5	16.9	172.5	94.4	299.7	26.2	20.1	210.6	114.5	84.2	99.0	263.4	840.4	44.1	57.0	70.7	85.5	66.4	73.7	1.6	2.9	47.0	25.4	20.8	152.1	19.7	79.2	47.1
DNASE2B	DLAD	ENSG00000137976	"Deoxyribonuclease 2 beta"	Q8WZ79	1	84398484-84415018	"Enzymes, Predicted intracellular proteins"		"Endonuclease, Hydrolase, Nuclease"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enriched"	"Detected in some"	25	"salivary gland: 171.8"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 1.9;Hofbauer cells: 5.8;Kupffer cells: 1.6;Late spermatids: 3.1;Macrophages: 4.2;Paneth cells: 1.7;Prostatic glandular cells: 2.0"	"Group enriched"	"Detected in some"	5	"melanoma: 2.8;prostate cancer: 9.3"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Intracellular and membrane"	NA	NA						"unprognostic (2.24e-1)"	"unprognostic (3.57e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.70e-2)"	"unprognostic (3.70e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.62e-2)"	"unprognostic (9.87e-2)"	"unprognostic (7.90e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.82e-5)"	"unprognostic (5.38e-2)"	"unprognostic (1.97e-1)"	"unprognostic (6.79e-2)"	"unprognostic (3.08e-3)"	0.4	0.1	0.3	0.0	0.6	0.0	0.4	0.3	1.0	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.8	0.0	0.3	2.4	0.7	0.7	0.5	0.4	0.1	0.8	0.0	0.3	0.0	0.6	6.8	0.5	0.0	171.8	0.0	1.6	0.0	0.1	0.0	0.4	0.4	0.8	0.4	0.4	0.2	0.1	0.3	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.3	1.0	0.4	0.8	0.7	0.5	0.4	0.6	0.4	0.4	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.9	0.0	0.0	0.0	1.2	0.0	0.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	5.8	0.0	0.4	0.1	0.0	1.6	0.0	3.1	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.0	1.7	0.0	0.1	2.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1
ENTPD5	"CD39L4, NTPDase-5, PCPH"	ENSG00000187097	"Ectonucleoside triphosphate diphosphohydrolase 5 (inactive)"	O75356	14	73958010-74019399	"Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Hydrolase	Proto-oncogene	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 108.2;kidney: 96.1;liver: 265.9"	"Cell type enhanced"	"Detected in all"		"Distal enterocytes: 209.3;Hepatocytes: 134.8;Intestinal goblet cells: 77.1;Proximal enterocytes: 87.0"	"Group enriched"	"Detected in all"	5	"liver cancer: 18.2;prostate cancer: 39.9"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basophil: 18.3;eosinophil: 9.4"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 18.3"	"Cell line enhanced"	"Detected in all"		"RT4: 57.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002927	Enhanced				"Secreted to blood"	NA	NA		5900000			"HPA002927: AB_1078744"	"unprognostic (4.19e-1)"	"unprognostic (9.63e-3)"	"unprognostic (3.11e-2)"	"unprognostic (2.06e-2)"	"unprognostic (1.98e-1)"	"unprognostic (3.87e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.34e-1)"	"unprognostic (6.01e-2)"	"unprognostic (6.20e-2)"	"unprognostic (2.55e-1)"	"prognostic favorable (3.95e-5)"	"unprognostic (1.25e-1)"	"unprognostic (5.06e-2)"	"unprognostic (1.76e-1)"	"unprognostic (6.92e-3)"	8.3	7.8	5.3	11.5	7.5	8.1	12.5	7.2	6.4	6.8	6.8	95.5	72.8	6.4	7.8	11.4	5.7	12.2	7.7	5.3	6.4	96.1	265.9	6.6	5.6	7.6	7.7	4.7	6.8	5.0	7.8	5.0	5.6	7.7	38.0	108.2	9.5	10.7	4.4	15.1	8.2	68.9	9.8	7.3	6.0	42.7	8.7	7.1	4.6	6.2	9.2	5.7	17.1	7.2	9.4	9.5	7.8	8.2	15.1	16.5	15.5	9.4	9.6	7.9	6.4	7.1	5.6	10.9	10.6	4.7	12.8	6.0	10.8	8.5	14.1	7.2	8.8	4.0	7.9	5.7	30.9	15.5	4.7	8.8	12.9	14.0	8.7	18.2	8.8	13.1	17.1	8.8	15.4	9.7	13.6	5.4	5.6	2.5	8.5	15.7	6.0	8.0	5.2	11.4	57.1	5.8	6.0	16.6	12.9	9.2	6.4	18.7	4.1	10.8	12.6	12.7	7.5	7.2	10.1	16.9	8.3	8.0	8.8	11.5	18.3	1.2	9.4	2.5	2.3	1.3	1.4	1.3	1.8	1.7	1.5	2.1	2.1	0.1	0.5	1.4	0.9	1.6	1.3	5.3	7.5	7.2	6.4	5.3	6.4	7.6	7.7	4.7	7.7	7.3	7.1	9.4	8.0	16.0	6.7	8.1	4.9	3.7	6.2	8.9	5.2	6.6	15.0	7.9	5.2	10.0	11.3	7.3	4.2	8.2	4.3	209.3	25.4	6.9	19.5	10.0	13.6	7.0	16.2	36.6	5.9	12.9	6.7	7.9	23.0	25.8	1.3	9.6	9.7	134.8	6.2	10.1	8.2	77.1	14.2	9.7	1.9	12.7	2.8	5.2	5.4	11.2	5.4	4.9	8.2	2.0	11.3	9.1	58.4	5.7	3.6	28.5	87.0	63.1	6.4	12.2	13.1	6.0	5.9	27.2	19.1	8.5	3.4	3.3	4.9	10.3	60.9	39.0
FOXA1	HNF3A	ENSG00000129514	"Forkhead box A1"	P55317	14	37589552-37596059	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 75.4;stomach 1: 28.3"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 113.8;Basal squamous epithelial cells: 76.8;Breast glandular cells: 87.9;Enteroendocrine cells: 84.6;Prostatic glandular cells: 89.8;Respiratory ciliated cells: 66.7;Urothelial cells: 154.5"	"Group enriched"	"Detected in many"	5	"breast cancer: 80.0;prostate cancer: 127.0"	"Region enhanced"	"Detected in single"		"midbrain: 3.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"Hep G2: 48.9;MCF7: 105.3;PC-3: 69.5;RT4: 96.7;SK-BR-3: 97.0;T-47d: 135.9"	"Region enhanced"	"Detected in some"		"midbrain: 1.1"	"Region enriched"	"Detected in single"	6	"midbrain: 5.4"	"CAB011595, HPA050505"	Enhanced		Supported	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			Nucleoplasm	"Nucleoli fibrillar center"	"CAB011595: AB_2104842, HPA050505: AB_2681148"	"unprognostic (1.61e-1)"	"unprognostic (8.80e-2)"	"unprognostic (1.12e-1)"	"unprognostic (4.65e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.54e-2)"	"unprognostic (6.30e-2)"	"unprognostic (0.00e+0)"	"unprognostic (3.67e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.69e-2)"	"prognostic favorable (1.00e-4)"	0.2	0.1	0.0	1.6	0.0	0.0	22.6	0.0	0.0	0.8	0.0	12.5	8.4	0.1	0.6	12.0	2.4	2.3	0.0	0.0	0.7	0.1	27.1	7.6	0.0	0.1	3.0	0.0	0.0	0.5	0.0	0.7	0.0	0.1	75.4	10.5	0.0	19.4	0.3	0.0	1.2	4.9	0.2	0.3	0.0	28.3	0.4	0.5	0.0	0.0	0.0	2.3	20.7	4.5	0.0	4.9	4.4	0.0	2.8	0.0	0.0	0.5	0.0	0.4	0.0	0.0	21.3	2.7	0.0	1.4	0.0	0.1	23.4	13.2	3.3	0.1	0.0	23.4	0.0	4.1	48.9	0.0	0.0	0.2	0.0	0.7	0.0	0.4	1.9	0.0	0.4	0.9	0.0	0.0	105.3	0.1	0.3	0.0	32.0	69.5	0.0	1.1	0.4	9.9	96.7	11.8	0.0	4.8	97.0	0.0	0.0	135.9	0.4	0.0	0.9	0.1	0.4	3.2	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	3.0	0.0	0.1	0.3	0.5	0.0	0.3	28.9	43.5	0.0	0.1	1.0	113.8	47.8	76.8	0.0	87.9	34.8	1.3	30.0	52.3	3.7	0.0	0.0	0.5	27.5	0.0	1.5	0.4	2.7	0.2	1.2	84.6	0.0	0.0	2.4	0.0	1.0	35.7	4.4	2.5	0.0	1.1	31.7	0.0	0.0	0.0	34.9	42.7	0.9	0.3	0.9	0.0	0.7	3.6	0.0	1.0	0.0	0.0	0.0	0.0	4.3	27.2	0.0	1.2	89.8	4.9	0.0	66.7	0.0	0.0	0.0	2.3	0.9	1.2	62.9	0.1	0.0	1.4	0.1	27.9	154.5
GATA2	NFE1B	ENSG00000179348	"GATA binding protein 2"	P23769	3	128479427-128493201	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Phagocytosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Extravillous trophoblasts: 261.6;Glandular and luminal cells: 116.5;granulocytes: 638.7;Syncytiotrophoblasts: 321.4"	"Group enriched"	"Detected in all"	5	"endometrial cancer: 12.7;prostate cancer: 36.7;urothelial cancer: 13.2"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	330	"basophil: 513.2"	"Lineage enriched"	"Detected in single"	4344	"granulocytes: 513.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 281.0;HEL: 360.7;HMC-1: 187.4;SH-SY5Y: 325.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005633, CAB024847"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB024847: , HPA005633: AB_1078954"	"unprognostic (1.71e-1)"	"unprognostic (8.90e-2)"	"unprognostic (1.12e-1)"	"unprognostic (8.61e-2)"	"unprognostic (8.67e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.96e-3)"	"unprognostic (7.30e-2)"	"unprognostic (3.98e-2)"	"unprognostic (4.12e-2)"	"unprognostic (3.58e-2)"	"unprognostic (3.04e-1)"	"prognostic favorable (2.04e-4)"	"unprognostic (2.50e-1)"	"unprognostic (8.07e-2)"	"unprognostic (2.08e-1)"	"prognostic favorable (5.22e-5)"	15.1	9.9	8.2	2.8	4.2	5.1	12.9	3.5	4.8	31.7	4.0	6.0	4.4	43.0	7.2	4.9	50.1	10.8	15.1	3.6	2.9	18.1	1.3	35.1	2.8	6.9	6.2	1.6	4.3	13.8	7.0	9.8	22.7	8.0	54.8	2.9	0.1	4.9	52.7	6.5	8.1	8.6	10.9	3.5	11.5	6.7	2.8	7.0	0.8	7.4	5.3	1.3	34.1	24.1	5.6	24.4	5.9	1.3	15.9	2.0	0.6	281.0	53.8	45.2	18.0	6.5	10.0	10.7	0.5	14.8	31.9	1.5	25.5	14.7	0.0	7.6	0.0	8.3	360.7	42.9	16.0	4.0	36.8	187.4	0.3	0.3	0.7	0.3	2.9	28.6	0.2	96.7	0.5	0.4	9.0	0.1	74.2	1.0	0.2	1.8	0.1	7.0	0.4	0.5	21.5	21.8	325.9	13.6	70.1	2.4	14.4	13.5	15.0	52.0	1.2	0.7	12.7	7.4	0.1	0.0	0.2	0.6	2.5	3.7	513.2	0.0	1.5	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	3.9	8.2	4.2	3.5	4.8	3.6	2.9	6.9	6.2	1.6	8.0	3.5	7.0	5.6	69.0	6.4	27.7	0.0	0.9	4.8	25.5	0.0	1.2	0.2	1.5	1.5	5.7	0.0	1.8	75.4	0.0	63.4	2.3	0.5	1.9	0.2	10.1	74.2	43.2	75.4	3.0	62.4	0.0	14.2	261.6	8.8	0.5	116.5	638.7	0.9	57.5	0.2	10.8	0.0	0.0	0.3	0.0	0.3	4.6	6.4	0.6	7.9	8.8	15.9	0.7	0.1	0.0	0.0	0.0	0.9	0.0	0.4	5.4	29.5	0.0	0.2	0.7	0.2	0.0	2.2	11.0	0.6	4.7	0.9	2.4	321.4	14.0	0.2	0.3	10.5
GJC3	"CX30.2, GJE1"	ENSG00000176402	"Gap junction protein gamma 3"	Q8NFK1	7	99923266-99929620	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 8.7;pancreas: 11.1;salivary gland: 11.8"	"Cell type enhanced"	"Detected in some"		"Breast glandular cells: 36.3;Breast myoepithelial cells: 26.9;Exocrine glandular cells: 24.0;Pancreatic endocrine cells: 12.8;Prostatic glandular cells: 13.0"	"Group enriched"	"Detected in many"	5	"breast cancer: 3.8;melanoma: 3.0;prostate cancer: 3.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"OE19: 1.3;SK-MEL-30: 2.3;U-2197: 1.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA015024	Uncertain					NA	NA					"HPA015024: AB_1847132"	"unprognostic (9.31e-2)"	"unprognostic (6.43e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.25e-2)"	"unprognostic (2.54e-1)"	"unprognostic (2.88e-2)"	"unprognostic (7.68e-2)"	"unprognostic (9.14e-2)"	"unprognostic (6.71e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.88e-3)"	"unprognostic (1.14e-1)"	"unprognostic (4.17e-1)"	"unprognostic (3.49e-1)"	"unprognostic (5.81e-3)"	1.3	0.5	0.9	0.1	1.0	0.1	8.7	0.2	1.5	0.3	0.0	0.4	0.4	0.2	0.0	0.2	0.3	0.3	0.4	1.2	0.4	1.0	2.8	0.2	0.2	0.4	0.5	1.0	0.4	11.1	0.0	0.4	1.0	0.6	4.7	0.0	1.0	11.8	0.1	0.2	2.2	0.3	0.2	0.0	0.3	1.4	1.8	0.7	0.1	0.3	0.2	0.0	0.3	0.3	1.5	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.0	0.0	0.0	0.4	0.2	0.2	0.0	0.0	0.0	0.1	0.3	0.1	0.9	0.0	0.1	0.1	0.1	0.0	0.0	0.2	0.0	0.4	0.7	0.5	0.6	0.1	0.5	0.2	0.4	1.1	1.3	0.0	0.0	0.4	0.3	0.0	0.4	0.1	0.2	0.1	0.3	2.3	0.5	0.7	0.0	0.3	0.1	0.4	1.8	0.1	0.1	0.5	0.0	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.9	1.0	0.2	1.5	1.2	0.4	0.4	0.5	1.0	0.6	0.0	0.7	1.5	1.1	3.2	3.7	0.0	0.4	0.3	4.9	1.4	0.0	0.0	36.3	26.9	0.0	4.3	2.1	1.8	0.0	0.0	0.6	0.0	1.9	0.4	0.4	0.0	0.0	1.5	1.2	0.0	0.7	24.0	0.0	0.2	0.0	0.0	4.5	0.2	1.1	5.0	0.1	0.0	0.4	0.1	8.2	0.0	0.3	1.1	0.3	0.1	0.0	0.0	0.6	4.0	0.0	0.0	0.6	12.8	0.0	0.0	0.0	13.0	0.0	9.7	0.3	0.0	0.0	0.0	0.3	1.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	9.4
IGSF21	"MGC15730, RP11-121A23.1"	ENSG00000117154	"Immunoglobin superfamily member 21"	Q96ID5	1	18107798-18378483	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 52.1"	"Group enriched"	"Detected in some"	4	"Bipolar cells: 177.8;Excitatory neurons: 82.2;Microglial cells: 74.9;Oligodendrocyte precursor cells: 141.3"	"Group enriched"	"Detected in many"	5	"breast cancer: 4.1;glioma: 8.6;prostate cancer: 3.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"SCLC-21H: 19.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA		23000				"unprognostic (1.87e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.50e-3)"	"unprognostic (7.06e-2)"	"unprognostic (3.29e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.66e-2)"	"unprognostic (7.87e-2)"	"unprognostic (2.77e-3)"	"unprognostic (4.34e-2)"	"unprognostic (2.33e-1)"	"unprognostic (7.85e-4)"	"unprognostic (3.76e-5)"	"unprognostic (2.10e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.63e-2)"	1.8	4.9	23.2	0.4	33.7	0.4	3.1	39.9	52.1	1.4	7.9	0.8	0.0	1.0	0.5	1.0	1.0	0.9	0.8	35.9	16.6	1.1	0.4	1.5	0.2	24.0	22.3	29.1	0.6	1.9	10.5	1.6	1.4	25.4	3.8	0.3	9.5	1.2	1.1	0.3	0.8	0.4	0.3	17.3	13.1	0.6	0.8	22.8	0.8	0.6	0.4	0.7	3.9	1.1	31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.2	33.7	39.9	52.1	35.9	16.6	24.0	22.3	29.1	25.4	17.3	22.8	31.4	0.1	0.0	0.0	3.6	0.6	0.3	0.2	0.0	0.0	177.8	9.2	2.7	0.6	1.5	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	5.9	0.0	0.0	1.8	3.0	0.0	82.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	28.9	0.1	0.0	23.6	4.0	12.8	0.6	12.8	0.0	74.9	0.0	6.3	0.0	141.3	2.4	0.1	1.3	0.0	0.0	0.9	0.0	0.0	0.0	13.0	6.6	4.5	0.2	0.4	0.6	0.0	0.1	0.0	0.0	0.0	0.2	0.2
INSL5		ENSG00000172410	"Insulin like 5"	Q9Y5Q6	1	66797741-66801256	"Predicted secreted proteins"		Hormone		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	104	"intestine: 130.1"	"Cell type enriched"	"Detected in some"	365	"Enteroendocrine cells: 8836.2"	"Group enriched"	"Detected in some"	5	"colorectal cancer: 1.2;prostate cancer: 0.7"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"							"HPA030100, CAB033849"	Enhanced				"Secreted to blood"	NA	NA	38500000				"CAB033849: AB_2264904, HPA030100: AB_10601915"	"unprognostic (2.48e-1)"		"unprognostic (4.41e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.18e-1)"					"unprognostic (2.76e-2)"		"unprognostic (1.30e-1)"	"unprognostic (2.62e-2)"			"unprognostic (7.53e-2)"		0.0	0.0	1.0	0.0	0.9	0.0	0.1	0.8	1.1	0.0	1.0	76.1	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.8	0.9	0.3	0.0	0.0	0.0	0.9	0.8	0.8	0.0	0.0	0.0	0.2	0.0	0.8	0.1	130.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.4	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.9	0.8	1.1	0.8	0.9	0.9	0.8	0.8	0.8	1.2	0.9	0.8	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.2	0.0	0.0	0.2	0.3	0.0	0.0	8836.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	22.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	14.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.1	11.4	0.0
IRX4		ENSG00000113430	"Iroquois homeobox 4"	P78413	5	1877413-1887236	"Plasma proteins, Predicted intracellular proteins, Transcription factors"		DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 16.0;prostate: 10.0;salivary gland: 9.5;skin 1: 20.2;vagina: 12.3"	"Group enriched"	"Detected in some"	4	"Basal keratinocytes: 48.6;Basal squamous epithelial cells: 50.7;Breast myoepithelial cells: 15.6;Prostatic glandular cells: 13.3;Squamous epithelial cells: 26.5;Suprabasal keratinocytes: 20.2"	"Group enriched"	"Detected in many"	5	"cervical cancer: 5.4;head and neck cancer: 7.3;lung cancer: 1.8;prostate cancer: 6.9;testis cancer: 7.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 41.8;HaCaT: 16.3;HBEC3-KT: 8.1;MCF7: 8.3"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	12	"medulla oblongata: 1.2;pons: 1.5"	HPA064094			Uncertain	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"HPA064094: "	"unprognostic (1.00e-2)"	"unprognostic (1.00e-1)"			"unprognostic (1.90e-1)"	"unprognostic (3.01e-1)"		"unprognostic (1.35e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.35e-1)"	"unprognostic (7.52e-2)"		"unprognostic (7.54e-2)"	"unprognostic (4.26e-1)"		"unprognostic (1.70e-2)"	0.1	0.0	0.4	0.0	0.0	0.1	3.2	0.7	0.2	1.7	0.0	0.0	0.0	0.0	0.0	16.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.6	0.0	0.0	0.0	0.0	0.9	0.0	0.9	10.0	0.0	0.0	9.5	0.0	0.6	20.2	0.0	0.0	0.1	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	12.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	41.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	16.3	0.0	8.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.0	8.3	1.1	0.1	0.1	4.3	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.3	2.1	0.0	0.0	0.0	3.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.2	0.0	0.0	0.7	0.6	0.0	0.9	0.1	0.2	0.3	0.0	0.0	0.0	0.0	0.0	48.6	2.8	0.1	50.7	0.0	1.4	15.6	6.7	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	6.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	3.0	0.3	0.0	0.2	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.3	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.1	1.1	26.5	20.2	3.7	0.0	0.0	0.0	1.7
ISL1	"Isl-1, ISLET1"	ENSG00000016082	"ISL LIM homeobox 1"	P61371	5	51383448-51394730	"Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 23.1;seminal vesicle: 19.4;vagina: 16.0"	"Cell type enhanced"	"Detected in many"		"Bipolar cells: 207.5;Cytotrophoblasts: 34.4;Enteroendocrine cells: 91.6;Horizontal cells: 43.7;Syncytiotrophoblasts: 34.2"	"Group enriched"	"Detected in some"	5	"cervical cancer: 1.1;pancreatic cancer: 4.1;prostate cancer: 2.1;stomach cancer: 1.6;testis cancer: 1.4"	"Group enriched"	"Detected in many"	4	"hypothalamus: 7.8;thalamus: 3.6"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	16	"SH-SY5Y: 297.1"	"Group enriched"	"Detected in many"	8	"basal ganglia: 13.8;hypothalamus: 15.0;thalamus: 6.0"	"Group enriched"	"Detected in some"	9	"basal ganglia: 5.8;hypothalamus: 5.4"	"HPA048613, HPA057416"	Approved		Approved	"Nucleoplasm,Nuclear speckles,Mitochondria"		NA	NA			Nucleoplasm	"Nuclear speckles, Mitochondria"	"HPA048613: , HPA057416: AB_2683431"	"unprognostic (4.97e-2)"	"unprognostic (2.22e-2)"	"unprognostic (1.69e-1)"	"unprognostic (2.41e-3)"		"unprognostic (5.52e-2)"		"unprognostic (6.79e-2)"	"unprognostic (9.21e-2)"	"unprognostic (9.42e-2)"	"unprognostic (5.55e-3)"	"unprognostic (1.77e-1)"		"unprognostic (1.48e-1)"	"unprognostic (2.48e-1)"	"unprognostic (9.11e-3)"	"unprognostic (4.39e-3)"	1.3	1.4	0.8	0.0	1.3	0.0	0.1	0.0	1.4	4.7	0.0	1.1	2.4	0.1	0.1	0.1	0.0	0.0	0.0	0.0	7.8	0.0	0.0	0.0	0.0	0.7	0.3	0.5	0.0	4.8	0.0	2.2	7.9	1.2	12.1	2.4	23.1	1.2	19.4	0.0	1.1	0.7	0.1	0.1	0.0	10.1	1.6	3.6	4.3	0.3	0.0	0.4	0.7	16.0	0.2	0.0	0.0	0.0	3.4	0.0	0.0	0.2	3.0	3.8	0.0	0.0	0.3	2.7	0.0	2.5	0.0	0.0	2.2	4.6	3.4	0.0	0.0	7.1	0.0	12.6	0.0	0.2	0.0	0.0	0.0	0.8	0.0	0.3	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.9	3.2	0.0	3.0	0.0	0.0	0.0	19.1	297.1	0.0	0.0	0.0	11.6	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.3	0.0	1.4	0.0	7.8	0.7	0.3	0.5	1.2	0.1	3.6	0.2	0.0	0.0	0.0	0.0	0.1	1.5	5.1	11.8	0.0	207.5	0.0	0.0	0.2	0.0	2.8	0.0	4.2	34.4	0.0	0.5	0.0	0.1	17.3	0.0	0.0	1.7	91.6	0.0	0.0	0.0	10.9	6.1	11.7	0.0	0.0	0.0	0.0	0.0	2.7	43.7	0.0	1.9	8.2	0.0	0.4	3.2	0.3	0.1	0.0	0.0	0.0	4.1	0.0	0.0	0.0	4.2	0.0	0.0	0.0	1.1	0.0	0.0	0.8	11.8	0.0	0.0	4.0	2.5	7.3	0.0	1.0	34.2	0.0	0.0	0.2	5.6
LRRC26	bA350O14.10	ENSG00000184709	"Leucine rich repeat containing 26"	Q2I0M4	9	137168758-137170051	"Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"salivary gland: 292.4"	"Cell type enriched"	"Detected in many"	5	"Intestinal goblet cells: 598.0"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 47.6"	"Region enhanced"	"Detected in single"		"cerebellum: 2.5"	"Immune cell enriched"	"Detected in single"	1177	"plasmacytoid DC: 117.6"	"Lineage enriched"	"Detected in single"	1177	"dendritic cells: 117.6"	"Cell line enriched"	"Detected in some"	6	"RPMI-8226: 130.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA056312	Approved		Supported	"Nucleoli fibrillar center,Plasma membrane"		NA	NA			"Plasma membrane"	"Nucleoli fibrillar center"	"HPA056312: AB_2683098"	"unprognostic (1.75e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.04e-2)"	"prognostic favorable (4.82e-6)"	"unprognostic (3.39e-1)"	"unprognostic (1.67e-2)"	"unprognostic (1.82e-1)"	"unprognostic (2.13e-2)"		"unprognostic (1.98e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.75e-1)"		"prognostic favorable (3.48e-4)"	"unprognostic (3.27e-1)"		"unprognostic (2.29e-1)"	0.0	0.0	0.1	0.3	0.3	0.0	7.4	2.5	0.5	0.4	0.0	10.3	1.7	1.1	0.0	2.8	1.1	0.0	0.0	0.5	0.4	0.0	0.0	0.2	0.0	0.2	0.1	0.1	0.0	0.6	0.0	0.1	0.0	0.8	53.6	0.5	0.0	292.4	0.5	0.0	4.8	7.2	0.0	0.1	0.1	5.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.0	0.0	0.0	5.4	0.7	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.1	0.9	0.1	0.3	0.7	20.8	0.1	130.9	0.0	0.0	1.0	0.2	0.5	6.0	0.0	0.0	2.7	0.5	0.1	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.6	0.0	0.5	0.1	0.3	2.5	0.5	0.5	0.4	0.2	0.1	0.1	0.8	0.1	0.1	0.1	0.6	0.0	0.0	0.3	1.2	1.0	1.7	0.5	0.0	0.0	101.2	64.4	0.4	4.3	1.0	0.0	0.0	0.1	81.8	15.2	1.9	0.1	0.5	13.0	1.6	1.0	9.0	0.0	0.1	0.4	0.0	0.4	9.2	21.3	0.0	0.0	0.0	0.0	0.1	0.0	0.3	598.0	4.1	0.0	0.9	1.1	0.0	1.4	56.9	0.0	0.6	0.0	0.0	0.0	0.1	0.2	11.8	0.0	0.6	28.4	28.8	0.1	0.4	0.0	0.0	0.0	0.4	0.2	2.8	3.5	0.3	0.0	0.6	0.0	24.3	3.7
LTF	HLF2	ENSG00000012223	Lactotransferrin	P02788	3	46435645-46485234	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Immunity, Ion transport, Iron transport, Osteogenesis, Transcription, Transcription regulation, Transport"	"Antibiotic, Antimicrobial, DNA-binding, Heparin-binding, Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"bone marrow: 4295.9;salivary gland: 1172.0"	"Cell type enriched"	"Detected in many"	5	"Breast glandular cells: 1519.6"	"Group enriched"	"Detected in all"	5	"breast cancer: 239.0;endometrial cancer: 170.3;glioma: 152.6;prostate cancer: 195.2"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	23	"neutrophil: 5.4;non-classical monocyte: 17.0"	"Group enriched"	"Detected in many"	23	"granulocytes: 5.4;monocytes: 17.0"	"Group enriched"	"Detected in some"	11	"RPMI-8226: 43.2;TIME: 14.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB008646, CAB016201, HPA057177, HPA059976"	Enhanced				"Secreted to blood"	NA	NA		350000000			"CAB008646: AB_1618695, CAB016201: AB_629860, HPA057177: AB_2683361, HPA059976: AB_2684185"	"unprognostic (7.24e-3)"	"unprognostic (2.43e-1)"	"unprognostic (5.94e-2)"	"unprognostic (3.41e-2)"	"unprognostic (7.14e-3)"	"unprognostic (3.45e-2)"	"unprognostic (6.43e-3)"	"unprognostic (2.52e-1)"	"unprognostic (1.92e-1)"	"unprognostic (4.21e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.04e-1)"	"prognostic favorable (6.30e-5)"	"unprognostic (1.66e-2)"	"unprognostic (3.53e-1)"	"unprognostic (2.05e-1)"	"unprognostic (9.09e-3)"	4.9	1.2	2.3	36.4	3.2	4295.9	336.8	6.5	4.2	663.9	2.5	2.8	1.2	4.2	158.8	23.2	4.4	7.6	4.2	3.0	6.8	102.3	3.3	29.7	8.7	4.6	20.2	0.7	0.5	18.8	6.2	7.0	3.1	10.5	155.5	2.2	0.9	1172.0	382.4	1.7	11.9	5.2	1.9	7.2	71.0	334.6	0.4	16.1	30.0	10.2	1.7	348.4	2.4	1.2	9.6	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.7	0.1	0.0	0.0	1.9	0.5	0.0	0.0	0.0	0.3	0.1	0.3	0.0	0.0	0.7	0.1	0.1	0.0	0.1	0.6	43.2	0.2	0.2	0.0	0.3	0.1	0.0	0.0	0.1	0.1	0.0	14.3	0.0	0.3	1.2	0.1	0.6	0.0	0.1	0.1	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	17.0	0.4	0.0	29.5	2.3	3.2	6.5	4.2	3.0	6.8	4.6	20.2	0.7	10.5	7.2	16.1	9.6	15.5	0.0	2.8	0.7	4.3	1.1	8.6	82.8	0.0	0.0	1519.6	198.4	1.0	2.8	298.0	71.7	0.0	0.0	6.2	0.1	0.0	1.4	1.2	0.3	0.2	8.8	0.0	3.0	0.1	0.9	0.2	2.5	56.1	2.3	1.3	0.1	5.0	0.0	0.0	0.0	0.0	0.2	14.2	0.0	0.7	1.5	5.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.1	0.0	0.1	78.6	0.0	18.6	14.9	0.0	0.0	0.3	9.9	0.2	0.1	15.4	0.1	0.1	4.0	0.1	0.1	101.7
MYH11	"SMHC, SMMHC"	ENSG00000133392	"Myosin heavy chain 11"	P35749	16	15703135-15857028	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin"	"Aortic aneurysm, Cancer-related genes, Disease variant, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 2272.9;seminal vesicle: 1681.4;urinary bladder: 2065.2"	"Group enriched"	"Detected in many"	8	"Peritubular cells: 1669.7;Sertoli cells: 624.5;Smooth muscle cells: 964.6"	"Group enriched"	"Detected in many"	5	"prostate cancer: 173.2;stomach cancer: 125.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.7;RPMI-8226: 1.4;U-698: 7.1"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"midbrain: 39.8"	"CAB002302, HPA014539, HPA015310"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		23000000	"Plasma membrane, Cytosol"		"CAB002302: AB_563902, HPA014539: AB_1234906, HPA015310: AB_1854261"	"unprognostic (7.99e-2)"	"unprognostic (3.07e-2)"	"unprognostic (4.18e-2)"	"unprognostic (9.21e-3)"	"unprognostic (6.70e-2)"	"unprognostic (2.75e-2)"	"prognostic favorable (1.10e-5)"	"unprognostic (1.41e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.19e-3)"	"unprognostic (4.06e-2)"	"unprognostic (9.53e-2)"	"unprognostic (5.00e-2)"	"unprognostic (5.45e-3)"	134.5	39.0	5.0	110.1	11.4	0.2	79.1	5.1	14.7	352.1	28.4	2272.9	96.2	1083.7	221.6	766.8	611.4	252.8	52.9	4.8	5.8	20.8	9.3	109.9	9.5	12.3	8.0	3.9	145.2	10.8	2.9	11.7	68.7	6.3	769.4	295.8	0.4	84.0	1681.4	41.5	55.4	491.6	1062.7	5.5	46.4	839.5	61.4	6.0	3.0	46.4	34.9	5.4	2065.2	316.9	6.8	0.0	0.1	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.6	0.2	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.9	0.0	0.2	0.2	7.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.1	0.0	5.0	11.4	5.1	14.7	4.8	5.8	12.3	8.0	3.9	6.3	5.5	6.0	6.8	7.6	0.0	1.8	0.0	4.4	13.3	2.1	1.7	5.7	2.7	5.3	122.3	40.5	0.0	1.9	0.0	8.4	0.3	3.4	0.4	0.0	0.2	50.2	4.7	19.5	12.8	1.2	0.8	0.8	0.4	0.3	22.2	0.0	3.4	0.0	27.3	6.4	0.1	1.1	0.0	5.2	0.5	0.0	2.2	17.3	46.2	42.9	2.8	12.4	15.9	3.7	0.3	3.1	1.5	10.7	0.4	0.2	1669.7	2.4	5.6	0.1	0.2	2.5	1.9	624.5	4.3	964.6	3.1	8.8	3.5	18.6	0.0	5.7	34.7	0.4	2.6
NKAIN1	"FAM77C, FLJ12650"	ENSG00000084628	"Sodium/potassium transporting ATPase interacting 1"	Q4KMZ8	1	31179745-31239887	"Predicted membrane proteins, Transporters"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	5	"adrenal gland: 24.4;brain: 18.6;skeletal muscle: 19.6;tongue: 12.0"	"Cell type enriched"	"Detected in some"	12	"Oligodendrocytes: 43.9"	"Group enriched"	"Detected in many"	5	"breast cancer: 17.2;glioma: 4.6;prostate cancer: 10.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 21.2;AN3-CA: 35.8;NTERA-2: 92.7;SCLC-21H: 27.3;SH-SY5Y: 43.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006873	Uncertain					NA	NA					"HPA006873: AB_1848410"	"unprognostic (1.58e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.54e-2)"	"unprognostic (6.11e-5)"	"unprognostic (6.59e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.30e-4)"	"unprognostic (1.04e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.78e-2)"	"unprognostic (2.01e-2)"	"unprognostic (8.07e-2)"	"unprognostic (6.31e-9)"	"unprognostic (1.00e-2)"	"unprognostic (8.83e-3)"	"unprognostic (1.62e-4)"	"unprognostic (5.50e-2)"	0.1	24.4	8.6	0.2	14.2	0.0	0.4	16.5	10.8	0.2	3.2	0.2	0.1	0.6	3.5	0.6	0.1	0.0	0.0	11.7	11.5	0.2	0.0	0.0	0.0	17.7	16.4	7.4	0.1	0.2	0.6	2.2	0.3	18.6	1.0	0.1	1.5	0.4	0.3	19.6	1.7	0.1	0.2	5.8	0.0	0.1	0.3	12.1	0.2	0.0	12.0	0.0	0.0	0.5	13.7	0.0	0.4	21.2	35.8	0.2	0.0	0.3	0.1	0.0	0.4	0.1	0.4	0.2	0.0	0.7	0.4	0.4	0.0	5.3	0.0	0.1	0.0	1.5	0.0	0.3	0.3	0.2	0.4	0.1	0.1	0.1	0.4	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.3	0.8	92.7	0.0	0.9	0.0	0.3	0.1	0.1	3.6	27.3	43.9	1.0	0.3	2.5	2.4	9.6	0.4	0.0	0.0	0.5	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6	14.2	16.5	10.8	11.7	11.5	17.7	16.4	7.4	18.6	5.8	12.1	13.7	0.0	0.0	0.0	0.3	0.0	0.4	0.1	0.2	0.0	0.5	0.5	0.1	0.3	0.0	0.2	0.0	0.0	0.3	0.0	0.0	1.9	0.2	0.0	0.1	1.1	0.0	0.0	0.0	3.6	0.0	0.3	0.3	0.0	0.2	0.0	0.2	0.0	0.0	0.1	0.0	3.3	0.0	2.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.5	43.9	0.1	0.0	0.0	0.0	0.3	0.0	0.8	0.1	0.5	0.0	0.3	0.3	0.8	1.2	0.3	1.4	0.4	0.0	0.1	0.0	0.2
PDE9A		ENSG00000160191	"Phosphodiesterase 9A"	O76083	21	42653621-42775509	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 69.8"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 90.8;Paneth cells: 105.3;Proximal enterocytes: 233.5"	"Cancer enriched"	"Detected in all"	5	"prostate cancer: 31.5"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"naive CD4 T-cell: 3.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"AF22: 29.7;EFO-21: 30.0;MCF7: 23.2;NB-4: 34.7;NTERA-2: 41.2;SCLC-21H: 22.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011380, HPA011978"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Plasma membrane"	"HPA011380: AB_1855132, HPA011978: "	"unprognostic (5.75e-2)"	"unprognostic (9.92e-3)"	"unprognostic (3.50e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.40e-1)"	"unprognostic (5.06e-2)"	"unprognostic (3.99e-2)"	"unprognostic (6.02e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.25e-2)"	"unprognostic (5.01e-2)"	"unprognostic (1.90e-2)"	"unprognostic (4.01e-3)"	"unprognostic (1.97e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.79e-1)"	9.5	11.2	11.5	3.9	14.0	0.5	10.9	13.4	13.0	6.5	7.8	69.8	3.0	5.1	19.6	3.7	10.7	6.9	3.8	10.1	11.6	17.6	4.3	4.9	4.8	13.0	13.3	9.1	3.5	4.1	6.6	10.0	10.4	12.9	38.8	16.5	10.8	12.8	15.9	2.5	6.5	47.7	8.9	10.4	18.5	13.5	1.9	14.3	7.9	6.6	4.8	3.2	19.1	6.2	11.4	0.0	2.8	29.7	3.7	0.0	0.8	0.5	0.0	0.0	0.0	0.0	3.2	18.2	0.0	30.0	0.0	2.2	0.0	2.7	9.8	0.0	0.0	10.4	0.0	0.0	6.4	2.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.5	0.0	0.0	23.2	1.5	34.7	41.2	14.6	0.0	0.0	0.0	1.2	20.4	7.6	22.5	13.5	5.2	0.0	0.5	7.0	0.2	19.1	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	12.4	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.9	0.2	0.1	0.2	3.1	0.6	0.4	0.9	0.0	0.4	1.0	0.3	11.5	14.0	13.4	13.0	10.1	11.6	13.0	13.3	9.1	12.9	10.4	14.3	11.4	18.6	3.2	5.0	43.4	1.6	1.0	10.9	4.2	6.2	26.4	13.4	12.6	1.6	5.7	2.4	18.4	0.0	0.0	1.0	90.8	29.4	7.3	0.6	18.1	8.5	11.9	13.1	3.2	5.6	2.4	0.1	5.9	1.5	26.8	1.3	6.1	5.7	0.9	7.5	35.3	10.8	25.8	8.2	1.3	0.8	2.2	11.8	1.6	28.4	31.9	1.1	11.0	0.0	29.1	16.6	5.3	105.3	6.0	0.2	28.1	233.5	8.9	1.3	2.8	13.1	0.5	6.4	0.4	2.3	0.5	0.6	0.4	3.8	16.9	24.4	15.0
PLA1A	ps-PLA1	ENSG00000144837	"Phospholipase A1 member A"	Q53H76	3	119597875-119629811	"Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"epididymis: 139.6;parathyroid gland: 66.3;seminal vesicle: 67.8"	"Cell type enhanced"	"Detected in many"		"Collecting duct cells: 14.7;Endothelial cells: 14.3;Hepatocytes: 26.0;Langerhans cells: 15.6;Peritubular cells: 14.3"	"Group enriched"	"Detected in many"	5	"liver cancer: 14.8;melanoma: 55.4;prostate cancer: 24.2;renal cancer: 21.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	18	"SK-MEL-30: 25.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA059740			Approved	"Nucleoplasm,Nuclear speckles,Cytoplasmic bodies"	"Secreted in other tissues"	NA	NA		420000	"Nuclear speckles, Cytoplasmic bodies"	Nucleoplasm	"HPA059740: AB_2684118"	"unprognostic (1.35e-1)"	"prognostic favorable (2.81e-7)"	"unprognostic (2.24e-2)"	"unprognostic (3.46e-2)"	"unprognostic (3.18e-2)"	"unprognostic (1.94e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.43e-1)"	"unprognostic (3.87e-1)"	"unprognostic (1.43e-2)"	"unprognostic (1.25e-1)"	"unprognostic (9.09e-2)"	"unprognostic (1.55e-3)"	"unprognostic (9.53e-3)"	"unprognostic (3.94e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.67e-1)"	4.9	0.7	12.1	3.5	10.3	0.3	3.5	10.4	16.5	4.7	23.7	2.8	1.1	4.8	139.6	1.5	5.7	2.8	4.3	11.2	10.7	7.8	39.9	21.4	15.7	12.0	11.0	9.2	1.1	3.8	66.3	1.7	9.9	11.9	9.1	2.5	1.1	3.6	67.8	16.4	0.7	3.6	8.9	12.2	1.0	4.5	3.8	14.1	1.6	6.9	3.1	8.7	4.0	1.9	15.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.2	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.8	0.3	0.5	0.1	0.0	0.2	0.0	0.0	25.0	0.0	0.0	0.0	1.3	0.0	0.1	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	12.1	10.3	10.4	16.5	11.2	10.7	12.0	11.0	9.2	11.9	12.2	14.1	15.3	6.5	0.0	1.7	0.0	0.0	0.6	0.5	0.4	0.6	0.0	0.1	0.1	2.8	2.8	1.0	14.7	0.0	0.2	0.1	0.0	1.9	4.7	6.6	0.1	0.1	14.3	1.8	0.0	0.2	2.2	0.0	1.6	0.0	0.9	1.3	0.7	7.9	26.0	1.6	0.0	0.1	0.1	0.0	1.0	15.6	3.2	0.3	5.4	1.8	4.7	4.2	0.0	0.0	0.0	0.0	1.3	0.6	14.3	0.0	0.5	0.0	5.1	7.5	0.1	0.0	0.9	5.9	0.0	0.2	0.0	0.6	1.9	0.1	0.0	0.1	0.2
PLA2G5		ENSG00000127472	"Phospholipase A2 group V"	P39877	1	20028179-20091911	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins"	"Fatty acid metabolism, Lipid degradation, Lipid metabolism, Phagocytosis, Phospholipid degradation, Phospholipid metabolism"	Hydrolase	"Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 112.5;ovary: 48.0"	"Cell type enhanced"	"Detected in some"		"Cardiomyocytes: 75.3;Cone photoreceptor cells: 70.9;Leydig cells: 81.4;Peritubular cells: 73.4;Sertoli cells: 263.0;Smooth muscle cells: 63.1"	"Group enriched"	"Detected in many"	5	"glioma: 13.0;prostate cancer: 3.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"U-2197: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA053361	Approved				"Secreted in other tissues"	NA	NA					"HPA053361: AB_2682127"	"unprognostic (2.78e-2)"	"unprognostic (1.14e-2)"	"unprognostic (5.68e-3)"	"unprognostic (6.16e-2)"	"unprognostic (2.01e-2)"	"unprognostic (5.93e-2)"	"unprognostic (2.12e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.15e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.70e-3)"	"unprognostic (6.00e-5)"	"unprognostic (2.87e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.54e-1)"	"unprognostic (4.97e-3)"	6.7	1.5	7.8	1.5	9.4	0.0	3.5	9.6	14.5	1.0	18.7	21.5	0.7	1.9	0.9	4.5	6.5	2.0	112.5	8.2	8.5	0.1	6.2	8.1	0.6	9.6	9.5	6.9	48.0	0.9	0.0	0.8	4.8	8.5	15.0	2.3	19.1	2.7	7.7	0.5	1.7	3.0	3.3	8.1	1.6	6.4	10.2	10.0	0.0	2.4	0.3	1.2	17.7	1.7	8.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	9.4	9.6	14.5	8.2	8.5	9.6	9.5	6.9	8.5	8.1	10.0	8.5	0.7	0.0	0.5	25.8	0.0	0.4	0.0	0.0	0.0	11.6	0.2	1.3	75.3	0.0	0.0	0.0	70.9	0.1	0.0	0.0	0.0	0.0	1.3	0.0	0.0	5.1	0.0	0.0	0.2	0.0	0.1	30.8	0.0	0.0	0.0	6.7	10.8	0.1	0.3	0.0	0.2	0.0	0.0	1.2	0.7	4.9	81.4	0.5	0.0	1.9	0.0	30.8	0.0	0.5	0.1	0.0	0.0	73.4	0.0	1.3	0.0	0.0	0.0	32.1	263.0	0.5	63.1	0.6	0.7	0.0	0.4	0.3	0.1	0.0	0.0	0.1
PRAC1	"C17orf92, PRAC"	ENSG00000159182	"PRAC1 small nuclear protein"	Q96KF2	17	48721719-48722518	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Group enriched"	"Detected in some"	12	"intestine: 208.4;prostate: 109.9"	"Group enriched"	"Detected in some"	5	"Distal enterocytes: 326.1;Enteroendocrine cells: 908.1;Intestinal goblet cells: 717.3;Paneth cells: 328.7;Undifferentiated cells: 624.3"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 291.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	32	"PC-3: 379.0"									HPA047871	Uncertain		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA047871: AB_2680195"			"unprognostic (7.59e-2)"									"unprognostic (2.43e-2)"			"unprognostic (2.04e-1)"			0.0	0.1	0.2	0.0	0.1	0.0	0.4	0.2	0.3	2.1	0.1	107.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.4	0.2	0.0	0.0	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	109.9	208.4	0.0	0.0	0.6	0.1	0.1	0.0	0.0	0.0	0.0	1.0	0.1	0.3	0.0	0.0	0.0	0.0	12.5	12.9	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	379.0	11.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.8	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.2	0.3	0.1	0.4	0.3	0.1	0.1	0.1	0.0	0.3	0.4	0.0	0.0	0.0	0.0	1.0	0.0	110.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	326.1	0.0	0.0	0.7	0.0	0.0	0.4	908.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	717.3	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	328.7	0.0	0.0	101.9	0.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.9	0.0	624.3	63.1
PRR16	DSC54	ENSG00000184838	"Proline rich 16"	Q569H4	5	120464300-120687332	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"tongue: 30.7"	"Group enriched"	"Detected in many"	9	"Excitatory neurons: 171.6;Inhibitory neurons: 188.9"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 13.3"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 77.3;BJ hTERT+: 83.9;fHDF/TERT166: 102.1;HSkMC: 62.5;hTERT-RPE1: 103.0;LHCN-M2: 97.9;U-138 MG: 117.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049254	Approved		Approved	Nucleoplasm,Midbody,Cytosol		Yes	No			Nucleoplasm	"Midbody, Cytosol"	"HPA049254: AB_2680693"	"unprognostic (1.71e-1)"	"unprognostic (3.87e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.20e-1)"	"unprognostic (6.61e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.42e-2)"	"unprognostic (8.33e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.76e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.54e-8)"	"unprognostic (3.05e-2)"	"unprognostic (9.13e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.38e-3)"	7.7	2.9	1.8	5.2	2.2	0.2	8.0	6.2	3.6	15.0	0.0	4.8	1.8	11.9	1.5	1.8	7.1	5.8	12.9	2.0	2.6	3.0	0.9	9.9	1.1	3.3	2.3	2.1	5.7	2.0	1.1	1.8	9.8	3.5	9.4	4.6	7.0	2.7	2.4	26.7	3.7	5.0	8.3	0.4	2.5	4.0	2.4	1.6	0.7	4.4	30.7	0.9	9.6	10.1	2.6	3.7	0.0	8.0	0.0	22.2	77.3	0.0	37.0	83.9	51.5	39.1	0.0	0.2	0.0	0.0	102.1	9.3	0.0	8.1	0.9	53.8	0.0	1.9	0.0	1.2	0.0	21.5	0.2	0.1	62.5	8.9	15.4	48.0	103.0	1.7	0.0	0.1	0.1	97.9	0.0	0.0	0.0	0.9	0.0	1.4	0.0	6.2	0.0	4.3	0.0	0.3	16.1	0.1	0.0	1.1	6.1	0.1	0.1	0.5	117.9	13.3	3.8	19.4	0.3	0.0	0.0	6.7	0.2	4.1	0.1	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.3	1.8	2.2	6.2	3.6	2.0	2.6	3.3	2.3	2.1	3.5	0.4	1.6	2.6	1.4	0.0	0.0	14.0	0.4	1.3	6.2	0.0	0.0	7.5	1.5	1.9	3.2	0.0	0.0	0.0	14.6	0.1	0.1	0.0	0.0	0.1	16.8	0.9	18.9	0.8	0.0	0.0	171.6	0.0	0.0	13.5	0.0	0.8	0.0	0.2	0.4	0.0	0.5	15.2	188.9	0.0	0.0	1.8	2.7	11.6	2.8	1.0	1.8	9.4	0.1	2.6	0.0	7.5	3.9	0.2	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.7	0.0	1.4	9.6	0.9	1.4	0.5	0.6	0.5	0.4	3.1	0.0	0.7
PTPRT	"KIAA0283, RPTPrho"	ENSG00000196090	"Protein tyrosine phosphatase receptor type T"	O14522	20	42072752-43189970	"Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 22.9;fallopian tube: 10.9"	"Group enriched"	"Detected in some"	14	"Excitatory neurons: 500.7;Inhibitory neurons: 700.2;Oligodendrocyte precursor cells: 418.7"	"Group enriched"	"Detected in many"	5	"breast cancer: 5.1;prostate cancer: 1.9"	"Region enhanced"	"Detected in many"		"cerebral cortex: 22.9"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"BEWO: 1.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017336, CAB069423"	Approved					NA	NA					"CAB069423: AB_1622602, HPA017336: AB_1855943"	"unprognostic (7.17e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.61e-3)"	"unprognostic (1.08e-2)"	"unprognostic (5.95e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.31e-2)"	"unprognostic (6.93e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.37e-6)"	"unprognostic (3.16e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.17e-1)"	0.1	0.2	5.1	0.1	9.4	0.0	2.7	0.0	22.9	0.7	0.0	0.1	0.5	0.0	0.2	0.0	10.9	0.1	0.2	5.7	4.8	0.1	0.2	1.1	0.4	0.3	0.5	7.3	0.0	0.4	0.0	3.0	2.8	3.2	0.2	0.0	3.7	1.0	2.6	0.0	0.3	0.3	0.0	0.0	0.1	0.8	1.6	0.5	6.4	0.0	0.1	0.4	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	9.4	0.0	22.9	5.7	4.8	0.3	0.5	7.3	3.2	0.0	0.5	4.9	0.4	0.0	1.1	13.1	0.0	0.9	0.0	0.0	0.0	36.2	2.6	6.9	1.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	3.2	0.1	0.2	0.0	0.0	500.7	0.0	0.0	1.2	0.0	0.2	0.0	3.3	6.4	0.2	0.2	5.0	700.2	0.0	0.0	0.3	0.3	12.6	0.0	0.1	0.0	8.4	0.0	10.3	0.0	418.7	8.3	0.0	0.0	0.0	0.0	0.1	0.0	0.2	18.5	2.1	0.0	0.5	0.2	0.0	1.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1
RAB6C	WTH3	ENSG00000222014	"RAB6C, member RAS oncogene family"	Q9H0N0	2	129979666-129982738	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 3.8;breast: 2.5;parathyroid gland: 3.6"	"Group enriched"	"Detected in some"	4	"Cardiomyocytes: 10.3;Oligodendrocytes: 3.3"	"Group enriched"	"Detected in some"	5	"breast cancer: 0.7;prostate cancer: 1.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"BEWO: 2.5;HMC-1: 2.2;REH: 5.4;T-47d: 3.2;U-266/70: 2.1"									HPA059131	Uncertain		Uncertain	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA059131: AB_2683916"	"unprognostic (3.84e-2)"	"unprognostic (5.77e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.54e-1)"	"unprognostic (8.62e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.33e-1)"	"unprognostic (4.48e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.78e-1)"	0.1	0.6	1.1	0.1	1.9	0.0	2.5	0.6	2.2	1.9	0.6	0.1	0.0	0.6	0.0	0.0	0.1	0.0	0.1	1.5	1.5	0.1	0.0	0.0	0.0	1.3	1.8	1.0	0.1	0.0	3.6	0.2	0.3	1.8	1.7	0.0	0.3	0.0	0.4	0.1	0.0	0.1	0.0	0.5	0.5	0.0	0.9	1.3	0.0	0.1	0.0	0.0	0.0	0.2	3.8	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.4	0.1	0.5	3.2	0.0	0.0	0.0	0.3	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.9	0.6	2.2	1.5	1.5	1.3	1.8	1.0	1.8	0.5	1.3	3.8	0.1	0.0	0.0	0.3	0.1	0.8	0.3	0.3	0.0	0.0	0.9	0.1	10.3	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.1	0.1	1.7	1.0	0.0	0.0	0.7	0.0	1.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.8	0.4	0.0	0.3	0.4	0.3	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.7	0.0	0.6	0.7	0.0	0.1	0.0	0.0	0.6	1.4	1.4	1.3	0.0	1.1	0.5	0.1	0.1	0.1	0.3
RANBP3L	FLJ25422	ENSG00000164188	"RAN binding protein 3 like"	Q86VV4	5	36246913-36302114	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 32.3;kidney: 24.8"	"Cell type enriched"	"Detected in some"	7	"Astrocytes: 355.9"	"Group enriched"	"Detected in some"	5	"breast cancer: 1.4;glioma: 3.7;prostate cancer: 4.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"ASC diff: 12.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA037471, HPA037472, HPA061526"	Approved		Uncertain	Nucleoplasm		NA	NA			Nucleoplasm		"HPA037471: AB_10671756, HPA037472: AB_2675489, HPA061526: AB_2684552"	"unprognostic (1.19e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.41e-3)"	"unprognostic (5.52e-3)"	"unprognostic (2.85e-1)"	"unprognostic (2.35e-3)"	"unprognostic (1.08e-2)"	"unprognostic (9.56e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.81e-1)"	"unprognostic (1.28e-1)"	"unprognostic (3.76e-4)"	"unprognostic (1.68e-2)"	"unprognostic (9.13e-2)"	"unprognostic (8.87e-3)"	"unprognostic (5.71e-2)"	3.8	1.7	26.6	0.3	25.6	0.0	7.6	6.3	32.3	1.2	7.8	0.6	0.2	0.7	1.8	0.5	1.2	1.9	1.5	26.8	13.2	24.8	9.9	2.0	0.2	13.5	15.7	17.4	2.1	0.4	0.2	2.9	5.1	15.1	13.6	0.4	5.3	0.6	3.0	0.4	0.3	0.4	0.6	12.0	0.2	1.8	4.8	18.5	0.1	2.2	3.0	0.6	6.9	0.8	16.8	0.0	0.0	0.1	0.2	12.1	0.4	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.1	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	2.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.1	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.6	25.6	6.3	32.3	26.8	13.2	13.5	15.7	17.4	15.1	12.0	18.5	16.8	0.3	0.0	0.0	355.9	0.0	0.0	0.1	0.0	0.6	0.4	4.1	2.3	0.3	0.0	0.0	9.2	0.0	0.0	1.3	0.0	46.9	0.0	0.1	0.1	0.7	0.4	0.0	0.0	5.1	0.0	0.0	1.5	0.0	0.0	0.0	0.2	0.4	1.3	1.9	0.0	4.5	0.0	0.0	0.0	0.3	0.8	2.1	0.2	1.8	23.4	0.0	16.1	0.0	5.5	2.8	0.0	0.0	2.2	0.0	1.3	0.0	0.2	0.0	0.6	13.1	0.6	8.3	0.0	0.1	0.0	0.0	0.1	0.0	3.0	0.0	0.1
RLN2	"bA12D24.1.1, bA12D24.1.2, H2, RLXH2"	ENSG00000107014	"Relaxin 2"	P04090	9	5299864-5304716	"Predicted intracellular proteins, Predicted secreted proteins"		Hormone		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"fallopian tube: 5.2"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 13.0;Muller glia cells: 9.6;Spermatocytes: 17.3;Syncytiotrophoblasts: 13.5"	"Group enriched"	"Detected in some"	5	"breast cancer: 2.0;prostate cancer: 6.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	26	"gdT-cell: 1.4;MAIT T-cell: 4.2;memory B-cell: 1.9;memory CD4 T-cell: 2.8;memory CD8 T-cell: 2.3;naive B-cell: 1.4;naive CD4 T-cell: 4.0;naive CD8 T-cell: 3.0;NK-cell: 3.5;T-reg: 1.3"	"Group enriched"	"Detected in many"	33	"B-cells: 1.9;NK-cells: 3.5;T-cells: 4.2"	"Cell line enhanced"	"Detected in some"		"Daudi: 5.6;HEL: 21.9;T-47d: 6.1;U-266/84: 10.2"														"Secreted to blood"	NA	NA	24400	10000				"unprognostic (1.63e-3)"	"unprognostic (1.26e-1)"	"unprognostic (2.09e-3)"	"unprognostic (2.84e-1)"	"unprognostic (2.03e-2)"	"unprognostic (9.99e-2)"		"unprognostic (1.48e-1)"	"unprognostic (2.77e-2)"	"unprognostic (2.91e-3)"	"unprognostic (2.50e-3)"	"unprognostic (9.18e-2)"	"unprognostic (1.74e-6)"	"unprognostic (2.36e-1)"	"unprognostic (4.71e-2)"	"unprognostic (1.88e-2)"	"unprognostic (8.41e-4)"	0.4	0.0	0.4	1.4	0.4	0.3	2.3	0.5	0.7	0.4	0.4	0.5	0.0	0.5	0.3	0.3	5.2	0.2	0.5	0.4	0.5	1.5	0.0	0.7	2.8	0.5	0.4	0.3	0.1	0.5	4.2	3.0	0.6	0.6	4.0	0.4	3.0	0.3	0.6	0.0	0.4	0.5	0.2	0.4	0.9	0.5	2.8	0.5	2.8	0.8	0.2	2.3	0.2	0.1	0.4	3.0	0.4	0.6	0.0	0.1	0.0	0.0	0.0	0.1	0.5	1.0	0.3	1.6	5.6	0.4	0.0	0.0	0.9	0.0	2.8	0.7	4.4	2.0	21.9	0.0	0.2	0.2	0.0	0.0	0.0	0.4	0.1	0.2	0.0	0.5	0.0	0.0	0.2	0.1	1.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.0	0.6	2.7	3.0	0.0	0.6	0.1	0.2	6.1	0.1	0.2	0.0	0.5	0.0	0.1	1.3	10.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	4.2	1.9	2.8	2.3	0.0	1.4	4.0	3.0	0.0	3.5	0.0	0.0	1.3	0.8	0.4	0.4	0.5	0.7	0.4	0.5	0.5	0.4	0.3	0.6	0.4	0.5	0.4	0.8	3.2	0.6	0.3	2.6	0.5	2.3	1.5	1.2	1.5	3.8	3.0	1.9	1.5	1.2	1.8	0.0	6.3	1.3	0.1	7.9	2.8	13.0	3.3	0.3	0.8	3.6	1.7	0.4	1.5	2.3	0.4	0.5	0.3	0.0	0.6	0.0	0.0	0.6	3.3	0.9	1.7	2.0	0.0	0.0	5.3	0.6	0.1	0.0	1.0	0.8	9.6	4.1	0.0	0.9	0.8	0.2	0.4	0.5	1.0	0.1	1.4	5.0	1.7	0.0	0.6	0.4	17.3	5.1	1.4	1.3	13.5	3.4	0.0	1.5	0.5
RORB	"NR1F2, ROR-BETA, RZRB"	ENSG00000198963	"RAR related orphan receptor B"	Q92753	9	74497335-74693177	"Disease related genes, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Sensory transduction, Transcription, Transcription regulation, Vision"	"Activator, Developmental protein, DNA-binding, Receptor"	"Disease variant, Epilepsy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 17.7;retina: 56.1"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 393.7;Endometrial stromal cells: 436.8;Excitatory neurons: 190.0;Horizontal cells: 1399.8;Muller glia cells: 390.7;Rod photoreceptor cells: 190.3"	"Group enriched"	"Detected in some"	5	"glioma: 2.1;prostate cancer: 2.3"	"Group enriched"	"Detected in many"	6	"cerebral cortex: 17.7;hippocampal formation: 5.8;pons: 5.2;white matter: 4.9"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"HHSteC: 22.5;HSkMC: 12.4;JURKAT: 23.3;MOLT-4: 6.9;SH-SY5Y: 13.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008393	Uncertain		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA008393: AB_1079830"	"unprognostic (6.89e-3)"	"unprognostic (4.06e-3)"	"unprognostic (1.38e-1)"	"unprognostic (3.97e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.05e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.07e-1)"	"unprognostic (3.52e-1)"	"unprognostic (5.46e-2)"	"unprognostic (8.81e-8)"	"unprognostic (5.97e-3)"	"unprognostic (2.17e-2)"	"unprognostic (2.26e-2)"	"unprognostic (4.00e-2)"	1.1	3.4	1.2	0.1	1.4	0.0	0.3	0.0	17.7	9.8	0.0	0.2	0.1	3.9	0.0	0.4	0.3	1.8	1.6	5.8	0.8	0.5	0.0	0.6	0.0	0.4	1.0	0.7	0.2	0.1	0.4	1.7	2.0	5.2	4.6	0.3	56.1	0.1	5.0	0.0	0.2	0.1	0.3	0.0	0.0	0.3	0.6	0.3	0.4	0.3	0.1	0.3	0.7	0.8	4.9	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	22.5	0.0	0.7	12.4	0.0	0.0	0.0	0.0	0.0	23.3	0.0	3.6	0.0	0.1	6.9	0.0	0.9	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.3	13.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	1.1	0.0	0.0	0.0	0.5	3.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.2	1.4	0.0	17.7	5.8	0.8	0.4	1.0	0.7	5.2	0.0	0.3	4.9	0.1	0.0	4.8	393.7	0.4	1.7	0.8	0.0	6.8	156.4	0.4	0.6	14.1	0.0	0.0	0.0	120.9	0.2	2.7	0.1	0.0	0.0	6.6	11.9	436.8	4.2	0.0	0.0	190.0	0.0	0.4	10.7	0.0	6.9	1.3	0.2	0.7	0.0	0.6	1399.8	6.4	0.0	0.0	0.3	2.1	1.9	0.0	1.8	1.8	10.3	0.1	390.7	1.0	12.5	28.6	0.1	0.0	0.0	0.8	2.8	0.0	8.9	0.7	190.3	0.0	8.7	9.9	3.0	0.7	1.4	0.4	0.1	3.0	0.3	0.1	0.9
SERHL2		ENSG00000183569	"Serine hydrolase like 2"	Q9H4I8	22	42553617-42574382	"Plasma proteins, Predicted intracellular proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"breast: 424.7"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 18.1;Hepatic stellate cells: 21.8;Sertoli cells: 19.7"	"Group enriched"	"Detected in all"	5	"breast cancer: 8.0;prostate cancer: 5.0"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	11	"memory B-cell: 3.5;naive B-cell: 8.4;plasmacytoid DC: 3.9"	"Group enriched"	"Detected in many"	12	"B-cells: 8.4;dendritic cells: 3.9"	"Cell line enriched"	"Detected in many"	10	"SK-BR-3: 276.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.14e-1)"	"unprognostic (1.56e-2)"	"unprognostic (8.61e-2)"	"unprognostic (2.52e-2)"	"unprognostic (3.27e-1)"	"unprognostic (7.24e-2)"	"unprognostic (1.25e-3)"	"unprognostic (1.47e-2)"	"unprognostic (1.55e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.55e-2)"	"unprognostic (2.92e-1)"	"unprognostic (7.04e-2)"	"unprognostic (4.08e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.42e-1)"	1.9	2.6	4.2	1.0	4.9	2.1	424.7	5.2	7.4	3.4	3.0	1.9	0.7	3.1	36.7	2.4	3.4	1.6	3.9	4.4	4.2	2.0	1.7	1.6	4.0	3.8	3.8	4.3	13.8	0.6	5.4	1.1	0.8	4.6	10.3	1.2	1.1	6.4	5.5	1.4	13.5	2.1	2.0	3.5	1.9	3.0	2.9	4.3	0.7	2.9	1.3	1.4	2.6	2.9	4.5	0.7	0.0	1.6	3.0	3.7	8.7	0.5	2.2	2.0	2.0	2.6	0.1	0.5	1.3	1.2	5.4	1.2	1.4	1.5	0.9	1.1	0.5	0.9	1.2	0.1	2.9	1.9	1.8	2.5	8.7	1.5	1.3	0.2	1.7	0.6	0.2	11.7	0.2	2.1	5.8	29.0	1.8	0.3	0.7	0.7	15.6	0.0	0.5	0.9	0.7	0.5	0.8	0.5	276.7	0.3	2.9	1.2	1.9	2.0	1.0	0.3	1.5	0.0	1.2	0.1	13.5	1.8	0.2	1.2	0.0	0.0	0.4	0.1	0.0	0.2	3.5	0.1	0.3	0.1	8.4	0.0	0.1	0.0	0.2	0.1	3.9	0.0	0.3	4.2	4.9	5.2	7.4	4.4	4.2	3.8	3.8	4.3	4.6	3.5	4.3	4.5	2.6	3.2	0.0	3.6	3.2	1.3	6.1	1.5	1.8	1.4	18.1	6.3	0.5	1.5	2.4	12.9	0.0	5.4	3.2	0.5	3.9	1.3	3.5	2.4	2.2	8.5	0.0	2.7	5.0	0.2	3.7	4.0	0.5	5.0	0.0	0.7	21.8	1.2	1.2	1.7	4.4	1.7	0.0	1.6	1.9	3.1	5.3	2.4	5.4	4.7	0.0	4.1	1.0	3.0	9.9	0.5	0.6	6.8	0.1	13.2	0.4	1.0	2.5	1.5	19.7	3.1	3.3	5.3	8.3	2.6	1.6	8.1	1.3	3.3	1.2	4.5
SERPINB11	EPIPIN	ENSG00000206072	"Serpin family B member 11"	Q96P15	18	63647579-63726432	"Plasma proteins, Predicted intracellular proteins"		"Protease inhibitor, Serine protease inhibitor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 27.6;prostate: 32.8"	"Cell type enhanced"	"Detected in some"		"Club cells: 6.8;Prostatic glandular cells: 3.3;Respiratory ciliated cells: 4.4;Squamous epithelial cells: 13.7;Urothelial cells: 21.9"	"Cancer enriched"	"Detected in some"	5	"prostate cancer: 6.2"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"cerebral cortex: 1.2"							NA	NA							"unprognostic (5.04e-3)"				"unprognostic (4.76e-2)"		"unprognostic (4.05e-2)"				"unprognostic (3.44e-1)"					"unprognostic (2.62e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	27.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	32.8	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	9.1	2.9	7.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.3	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	13.7	0.0	0.0	0.2	0.0	0.0	21.9
SLC14A1	"HsT1341, JK, RACH1, RACH2"	ENSG00000141469	"Solute carrier family 14 member 1 (Kidd blood group)"	Q13336	18	45687025-45752520	"Blood group antigen proteins, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	"Blood group antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 136.7;prostate: 79.0;urinary bladder: 91.8"	"Group enriched"	"Detected in many"	7	"Adipocytes: 136.6;Astrocytes: 228.5;Basal prostatic cells: 313.4;Erythroid cells: 102.5;Prostatic glandular cells: 192.6;Urothelial cells: 249.9"	"Group enriched"	"Detected in many"	5	"glioma: 5.3;prostate cancer: 8.6;urothelial cancer: 16.1"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"T-reg: 4.1"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"GAMG: 273.4;RT4: 113.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA059570, HPA077233"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA059570: AB_2684066, HPA077233: "	"unprognostic (2.04e-1)"	"unprognostic (2.56e-3)"	"unprognostic (5.20e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.86e-2)"	"unprognostic (1.84e-2)"	"unprognostic (1.70e-2)"	"unprognostic (7.97e-2)"	"unprognostic (8.17e-2)"	"unprognostic (9.99e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.02e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.52e-1)"	"unprognostic (9.09e-2)"	"unprognostic (6.93e-2)"	2.1	1.7	66.3	1.0	89.5	15.3	2.1	119.5	63.7	2.1	23.7	1.3	1.3	0.5	0.7	0.4	0.3	10.2	15.5	60.1	91.9	11.1	1.1	4.3	2.3	123.0	113.5	26.2	0.3	1.7	0.9	1.0	1.6	110.3	79.0	1.3	0.3	2.3	3.1	4.0	4.0	3.4	0.5	86.7	4.6	1.8	0.2	136.7	7.8	6.4	7.9	2.3	91.8	2.3	103.9	0.0	0.4	0.0	0.1	0.0	0.2	0.7	0.4	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	273.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.2	0.1	0.2	0.0	0.0	0.0	0.0	38.3	0.0	0.2	0.0	0.2	0.3	0.1	0.9	0.3	0.0	0.3	0.2	0.0	0.0	0.2	3.0	113.8	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.0	1.8	0.5	0.9	0.1	4.1	0.2	0.1	2.7	1.3	1.3	0.0	0.0	1.1	0.8	0.0	0.0	0.3	0.9	0.9	0.0	0.3	0.2	1.5	0.0	0.9	0.0	0.1	4.1	0.6	66.3	89.5	119.5	63.7	60.1	91.9	123.0	113.5	26.2	110.3	86.7	136.7	103.9	136.6	0.0	0.6	228.5	3.1	0.3	313.4	0.1	0.6	0.3	5.4	1.5	10.9	5.7	0.0	0.0	0.0	0.0	8.6	0.0	0.0	0.2	0.6	0.0	0.1	28.7	0.0	102.5	0.6	0.2	0.1	3.8	0.0	0.1	0.0	0.2	21.4	0.3	0.1	0.0	0.7	0.2	18.3	0.6	0.3	0.4	0.0	2.0	12.4	5.6	0.1	0.0	5.2	3.5	0.7	0.3	0.0	1.2	2.1	192.6	0.0	0.0	0.0	0.2	0.0	1.7	3.7	0.1	0.2	0.2	0.4	0.0	6.1	0.1	0.0	249.9
SLC23A1	"SLC23A2, SVCT1, YSPL3"	ENSG00000170482	"Solute carrier family 23 member 1"	Q9UHI7	5	139367196-139384553	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"fallopian tube: 54.6;intestine: 65.8;kidney: 40.6;liver: 22.6"	"Cell type enhanced"	"Detected in some"		"Endometrial ciliated cells: 65.2;Hepatocytes: 19.3;Proximal enterocytes: 131.7;Proximal tubular cells: 27.0"	"Group enriched"	"Detected in many"	5	"endometrial cancer: 2.1;liver cancer: 7.7;prostate cancer: 4.0;renal cancer: 3.9"	"Low region specificity"	"Detected in some"			"Immune cell enhanced"	"Detected in single"		"plasmacytoid DC: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"CACO-2: 9.4;HDLM-2: 8.3;Hep G2: 13.6;JURKAT: 15.5;Karpas-707: 10.9;RPMI-8226: 10.9;U-266/70: 16.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA047612	Enhanced					NA	NA					"HPA047612: AB_2680102"	"unprognostic (4.00e-3)"	"unprognostic (2.66e-3)"	"unprognostic (2.63e-2)"	"unprognostic (1.75e-3)"	"unprognostic (1.93e-1)"	"unprognostic (6.36e-6)"	"unprognostic (7.41e-2)"	"unprognostic (6.55e-2)"	"unprognostic (5.88e-2)"	"unprognostic (3.90e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.77e-2)"	"unprognostic (1.22e-1)"	"unprognostic (6.51e-2)"	"unprognostic (4.16e-2)"	"unprognostic (1.55e-2)"	"unprognostic (3.65e-3)"	0.1	0.1	0.2	1.2	0.5	2.8	0.2	1.0	0.3	1.7	0.1	3.3	26.6	0.7	0.0	0.3	54.6	2.4	0.1	0.3	0.4	40.6	22.6	0.9	1.7	0.8	2.1	0.0	0.4	1.2	0.3	0.2	0.1	0.7	6.3	1.5	0.6	3.2	0.6	0.4	1.9	65.8	0.2	0.2	1.3	1.5	0.2	0.8	5.5	0.2	0.0	1.3	0.4	0.3	0.6	0.3	2.1	0.4	0.5	0.0	0.0	1.0	0.0	0.0	0.0	0.0	9.4	1.3	5.8	3.0	0.0	0.1	0.3	0.0	0.0	0.1	8.3	0.1	0.2	0.8	13.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	15.5	0.1	10.9	0.0	0.2	5.7	1.0	0.1	0.8	0.1	6.8	0.3	10.9	0.5	0.4	0.3	0.3	0.3	1.9	0.0	0.7	5.0	0.1	0.3	0.3	0.3	0.1	0.0	16.6	2.2	7.6	0.1	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	1.3	0.1	0.0	0.2	0.5	1.0	0.3	0.3	0.4	0.8	2.1	0.0	0.7	0.2	0.8	0.6	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.3	0.0	0.1	0.3	0.3	0.3	1.5	2.0	0.0	4.2	0.4	0.4	1.9	5.9	0.2	0.0	65.2	0.7	0.1	0.0	0.0	1.1	0.2	0.0	0.0	0.0	1.5	0.0	0.1	0.4	19.3	0.1	0.0	1.2	3.6	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.5	1.4	0.1	3.1	0.0	0.4	0.9	131.7	27.0	13.4	0.7	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.8	0.2	0.0	4.2	0.2
SLC38A11	"AVT2, FLJ39822"	ENSG00000169507	"Solute carrier family 38 member 11"	Q08AI6	2	164896186-164955525	"Predicted membrane proteins, Transporters"	"Amino-acid transport, Ion transport, Sodium transport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"choroid plexus: 24.7;epididymis: 39.0"	"Cell type enhanced"	"Detected in many"		"Cholangiocytes: 28.6;Enteroendocrine cells: 174.1;Excitatory neurons: 53.4;Sertoli cells: 72.3;Smooth muscle cells: 39.8"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 7.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	28	"memory B-cell: 1.6;naive B-cell: 3.9"	"Lineage enriched"	"Detected in single"	39	"B-cells: 3.9"	"Cell line enriched"	"Detected in some"	9	"BJ hTERT+: 249.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA043432	Uncertain					NA	NA					"HPA043432: AB_10793948"	"unprognostic (1.52e-1)"	"unprognostic (2.59e-1)"	"unprognostic (4.14e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.69e-2)"	"unprognostic (6.28e-3)"	"unprognostic (3.53e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.15e-3)"	"unprognostic (1.99e-1)"	"prognostic favorable (2.00e-8)"	"unprognostic (1.69e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.36e-2)"	2.0	4.0	5.4	1.5	6.3	0.1	0.8	4.0	10.3	2.7	24.7	1.5	6.0	1.7	39.0	1.0	0.8	17.8	0.8	6.4	4.2	7.4	2.6	0.4	2.0	4.7	4.6	4.3	0.3	2.2	1.3	3.3	0.3	5.7	10.9	2.7	0.3	0.6	17.0	0.9	0.5	2.8	2.0	3.6	8.1	11.8	0.2	5.1	0.3	2.1	4.1	1.4	1.5	1.1	5.9	0.0	0.6	0.0	0.0	0.0	0.0	0.1	28.9	249.7	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.4	0.0	0.1	0.0	5.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.4	6.3	4.0	10.3	6.4	4.2	4.7	4.6	4.3	5.7	3.6	5.1	5.9	0.9	0.0	0.0	6.2	7.0	0.0	0.3	0.0	0.0	0.1	0.1	0.0	0.9	28.6	0.0	3.7	0.0	0.7	2.7	0.5	0.0	3.2	2.1	0.1	0.5	2.7	174.1	2.7	53.4	0.6	0.6	0.3	5.1	0.1	0.0	0.0	0.4	3.7	0.0	0.0	2.9	6.4	0.0	0.0	0.3	1.2	0.0	0.0	0.0	17.8	0.0	0.1	0.0	0.5	1.2	0.8	2.3	0.0	0.0	3.2	1.0	2.0	0.0	0.1	72.3	0.5	39.8	0.1	0.0	0.2	0.3	1.5	0.9	4.4	0.7	0.2
SLC4A4	"hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5"	ENSG00000080493	"Solute carrier family 4 member 4"	Q9Y6R1	4	71062667-71572087	"Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"		"Disease variant, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 120.6;pancreas: 262.5"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 819.1;Cholangiocytes: 133.0;Distal enterocytes: 282.9;Ductal cells: 129.2;Proximal tubular cells: 211.0"	"Group enriched"	"Detected in many"	5	"glioma: 23.9;pancreatic cancer: 22.5;prostate cancer: 47.4;renal cancer: 19.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 13.0;fHDF/TERT166: 6.1;HBF TERT88: 5.7;hTERT-RPE1: 6.0;RPTEC TERT1: 15.4;U-138 MG: 7.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022493, HPA035628, HPA035629, HPA079220"	Enhanced					NA	NA					"CAB022493: , HPA035628: AB_2674708, HPA035629: AB_2674709, HPA079220: "	"unprognostic (3.92e-2)"	"unprognostic (1.63e-1)"	"prognostic favorable (7.69e-4)"	"unprognostic (5.32e-2)"	"unprognostic (1.01e-1)"	"unprognostic (5.09e-2)"	"unprognostic (4.24e-2)"	"unprognostic (7.49e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.22e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.74e-1)"	"prognostic favorable (1.18e-4)"	"unprognostic (7.00e-2)"	"unprognostic (2.92e-1)"	"unprognostic (2.05e-3)"	"unprognostic (2.04e-1)"	5.2	0.7	31.9	2.2	40.2	0.5	1.0	48.9	33.8	11.6	1.1	41.4	54.8	0.4	0.3	1.2	1.0	29.6	6.3	23.6	61.5	120.6	21.9	7.0	0.2	37.9	28.6	21.9	0.8	262.5	17.3	5.9	2.7	30.2	35.0	41.6	5.1	2.5	1.1	2.3	0.1	14.7	1.7	34.8	0.8	18.8	0.5	29.6	3.5	22.2	3.5	0.0	4.6	0.4	34.0	0.0	3.5	1.0	0.0	0.0	0.0	0.1	13.0	1.9	2.2	1.6	0.0	0.1	0.0	0.1	6.1	0.5	0.0	0.2	0.0	5.7	0.0	1.7	0.9	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	6.0	0.0	0.7	0.0	0.5	1.2	0.0	4.8	0.2	0.1	0.2	0.0	0.0	0.0	0.9	15.4	4.1	0.9	0.1	0.0	0.0	0.2	1.3	0.0	0.0	0.0	7.7	0.7	5.5	0.6	0.0	0.0	0.0	5.1	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.3	0.0	0.1	0.6	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.1	31.9	40.2	48.9	33.8	23.6	61.5	37.9	28.6	21.9	30.2	34.8	29.6	34.0	1.5	3.2	37.1	819.1	2.2	0.0	4.3	3.2	0.6	3.2	0.9	0.3	24.0	133.0	31.1	25.8	0.0	0.3	7.2	282.9	15.6	129.2	11.5	2.8	0.5	1.3	8.5	4.0	51.4	24.2	0.1	4.9	33.1	5.8	1.3	0.6	3.9	35.8	0.2	0.0	93.4	65.6	2.0	0.6	0.2	1.5	0.0	2.3	1.8	34.7	1.0	3.9	1.0	29.1	3.7	16.2	60.8	0.0	1.7	40.8	31.8	211.0	10.4	1.5	6.6	1.0	6.2	0.1	1.0	5.5	0.0	0.3	6.8	2.4	68.1	12.3
SYNPO2	MYOPODIN	ENSG00000172403	"Synaptopodin 2"	Q9UMS6	4	118850688-119061247	"Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 999.7;tongue: 497.9"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 135.4;Endometrial stromal cells: 130.0;Excitatory neurons: 149.6;Peritubular cells: 101.5;Sertoli cells: 131.5;Skeletal myocytes: 93.4;Smooth muscle cells: 206.1"	"Group enriched"	"Detected in all"	5	"prostate cancer: 25.7;stomach cancer: 27.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 57.8;LHCN-M2: 18.5;SH-SY5Y: 83.2"	"Region enriched"	"Detected in all"	4	"thalamus: 27.1"	"Low region specificity"	"Detected in all"			"HPA030665, CAB037231, HPA049707, HPA068563"	Enhanced		Enhanced	"Vesicles,Actin filaments"		NA	NA			"Vesicles, Actin filaments"		"CAB037231: AB_262098, HPA030665: AB_10696210, HPA049707: AB_2680857, HPA068563: AB_2686006"	"unprognostic (1.50e-2)"	"unprognostic (1.73e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.39e-1)"	"unprognostic (5.71e-4)"	"unprognostic (2.18e-1)"	"unprognostic (3.07e-1)"	"unprognostic (3.52e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.66e-1)"	"prognostic unfavorable (5.67e-5)"	"unprognostic (1.82e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.26e-1)"	"prognostic unfavorable (3.91e-4)"	51.6	10.9	6.8	47.8	5.9	0.3	36.2	5.9	8.8	54.7	8.5	253.5	34.6	138.2	33.6	199.0	90.2	50.4	66.8	11.0	36.5	8.8	7.1	16.3	10.6	7.8	4.8	1.4	39.3	3.9	3.6	7.5	21.0	6.0	182.1	58.5	1.2	16.1	270.0	999.7	14.5	76.1	246.6	10.5	10.3	127.3	6.7	6.7	14.4	16.1	497.9	6.6	228.4	54.5	11.7	0.2	4.2	0.2	0.0	10.5	3.5	0.7	13.4	14.1	0.4	0.5	0.0	0.7	1.5	0.1	57.8	0.9	0.2	0.4	0.3	0.7	5.9	0.1	0.8	1.3	0.0	2.4	0.1	0.2	14.5	0.3	4.0	0.2	3.7	0.2	0.2	0.0	0.7	18.5	0.3	0.7	7.2	1.4	0.0	0.0	0.5	1.5	0.4	0.2	0.3	0.4	83.2	0.4	0.3	0.1	3.3	0.0	7.0	0.4	0.6	0.1	0.2	0.1	0.1	0.3	0.1	1.1	0.6	0.2	0.8	0.1	0.5	0.2	0.0	0.4	0.3	0.4	0.2	0.0	0.4	0.4	0.3	0.2	0.3	0.1	0.0	0.5	0.1	6.8	5.9	5.9	8.8	11.0	36.5	7.8	4.8	1.4	6.0	10.5	6.7	11.7	25.5	3.2	1.1	42.7	1.1	13.5	17.9	3.7	46.1	2.5	6.3	30.7	135.4	0.0	0.3	1.8	0.0	1.4	0.5	0.1	0.0	0.1	2.2	6.9	130.0	11.3	0.0	1.7	149.6	1.8	0.5	41.5	0.5	10.6	0.0	16.1	13.9	0.4	1.4	0.0	31.5	0.2	0.0	0.9	11.4	7.0	27.1	3.8	5.4	76.8	12.9	0.0	0.0	6.0	3.0	0.2	0.4	101.5	0.8	24.9	0.1	0.3	2.5	0.5	131.5	93.4	206.1	1.3	0.5	5.3	8.1	0.8	2.6	33.4	0.2	4.0
SYT4	"HsT1192, KIAA1342"	ENSG00000132872	"Synaptotagmin 4"	Q9H2B2	18	43267892-43277535	"Predicted intracellular proteins"	Differentiation			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 80.4;pituitary gland: 31.0;retina: 25.5"	"Cell type enhanced"	"Detected in some"		"Bipolar cells: 66.8;Cone photoreceptor cells: 22.9;Enteroendocrine cells: 28.7;Excitatory neurons: 50.9;Fibroblasts: 23.0;Inhibitory neurons: 34.1"	"Group enriched"	"Detected in some"	5	"glioma: 2.0;pancreatic cancer: 4.1;prostate cancer: 1.2"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	11	"SH-SY5Y: 245.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA010574	Approved		Approved	"Vesicles,Plasma membrane"		NA	NA			"Vesicles, Plasma membrane"		"HPA010574: AB_2668309"			"unprognostic (2.91e-3)"		"unprognostic (2.03e-1)"			"unprognostic (2.37e-2)"		"unprognostic (2.87e-1)"	"unprognostic (7.67e-3)"	"unprognostic (5.30e-3)"	"unprognostic (3.95e-2)"	"unprognostic (1.23e-3)"	"unprognostic (3.61e-1)"	"unprognostic (3.80e-2)"		1.7	16.0	16.8	1.4	21.3	0.1	0.0	80.4	45.7	0.0	0.0	0.9	0.8	0.0	0.0	0.1	0.0	0.0	0.7	18.3	44.1	0.1	0.0	0.9	0.0	11.5	25.1	18.7	0.5	3.7	0.0	31.0	0.1	29.1	0.6	0.8	25.5	0.1	8.4	0.0	0.0	0.8	0.6	5.2	0.0	3.3	1.6	25.4	0.4	0.3	0.0	0.0	0.0	0.5	55.8	0.0	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.4	245.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.8	21.3	80.4	45.7	18.3	44.1	11.5	25.1	18.7	29.1	5.2	25.4	55.8	0.0	0.0	1.1	8.8	0.0	0.1	0.0	0.0	0.0	66.8	0.0	0.0	3.6	0.0	2.5	0.0	22.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	28.7	0.0	50.9	0.0	0.0	23.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.7	34.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	9.4	0.0	2.5	0.0	7.5	7.6	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.7	10.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	4.9	0.0	0.1
TDRD1	CT41.1	ENSG00000095627	"Tudor domain containing 1"	Q9BXT4	10	114179270-114232304	"Plasma proteins, Predicted intracellular proteins"	"Differentiation, Meiosis, RNA-mediated gene silencing, Spermatogenesis"	"Developmental protein"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"testis: 17.7"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 7.1;Late spermatids: 5.3;Spermatocytes: 25.6;Spermatogonia: 25.5"	"Cancer enriched"	"Detected in some"	5	"prostate cancer: 4.1"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in single"		"plasmacytoid DC: 1.4"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	4	"SK-BR-3: 51.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA037729	Enhanced					NA	NA					"HPA037729: AB_10670527"	"unprognostic (6.77e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.10e-2)"	"unprognostic (1.26e-2)"	"unprognostic (3.96e-2)"	"unprognostic (3.15e-2)"		"unprognostic (6.13e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.51e-2)"	"unprognostic (9.60e-2)"	"unprognostic (3.98e-2)"	"unprognostic (4.75e-1)"	"unprognostic (1.68e-1)"	0.2	0.0	0.2	0.1	0.3	0.0	0.3	0.1	0.8	0.1	0.5	0.1	0.2	0.1	0.0	0.2	0.2	0.1	0.6	0.2	0.2	2.0	0.2	0.0	0.2	0.3	0.3	0.1	0.4	0.5	0.0	0.0	0.0	0.4	0.6	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.6	0.1	17.7	0.7	0.3	0.1	0.5	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.0	0.0	0.0	0.0	0.0	51.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.2	0.2	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.2	0.3	0.1	0.8	0.2	0.2	0.3	0.3	0.1	0.4	0.1	0.7	0.4	0.6	0.0	0.5	0.0	0.0	0.3	0.0	0.1	0.0	0.0	1.1	0.9	3.5	2.8	0.0	0.0	0.0	0.3	2.7	0.3	0.0	0.2	7.1	0.4	0.5	0.2	0.0	0.0	0.5	0.6	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.1	2.0	0.0	0.3	5.3	2.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.1	0.7	0.0	0.0	0.0	1.2	2.7	0.0	0.0	0.5	0.5	25.6	25.5	0.0	0.0	0.1	0.1	0.7	0.1	0.0
TNNI1		ENSG00000159173	"Troponin I1, slow skeletal type"	P19237	1	201403768-201429866	"Predicted intracellular proteins"		"Actin-binding, Muscle protein"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	40	"skeletal muscle: 12681.1;tongue: 3186.3"	"Group enriched"	"Detected in some"	17	"Cardiomyocytes: 74.7;Skeletal myocytes: 176.2"	"Group enriched"	"Detected in many"	5	"head and neck cancer: 9.6;prostate cancer: 3.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"RH-30: 491.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028190	Approved		Uncertain	Nucleoplasm,Nucleoli		NA	NA		74000	Nucleoplasm	Nucleoli	"HPA028190: AB_10600831"	"unprognostic (2.82e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.91e-1)"	"unprognostic (5.39e-2)"	"unprognostic (2.31e-2)"	"prognostic unfavorable (9.27e-4)"	"unprognostic (1.93e-2)"	"unprognostic (2.37e-1)"	"unprognostic (4.25e-1)"	"unprognostic (3.81e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.92e-2)"	"unprognostic (1.05e-2)"	"unprognostic (2.59e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.71e-1)"	1.1	0.4	0.0	0.1	0.0	0.1	1.6	0.1	0.1	0.3	0.0	0.8	2.1	1.2	0.4	195.9	0.4	1.2	60.6	0.0	0.1	10.6	1.9	1.1	0.3	0.1	0.0	0.0	0.5	1.5	0.0	0.3	0.1	0.1	86.6	0.0	0.0	57.1	0.0	12681.1	1.7	2.5	0.1	0.0	0.3	1.3	0.5	0.1	1.6	1.4	3186.3	0.4	0.2	1.5	0.1	0.9	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	1.3	0.2	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.9	0.1	0.6	0.0	55.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	0.0	0.0	0.8	0.3	0.0	0.0	491.6	0.9	0.0	0.8	0.3	0.0	0.1	0.1	0.1	4.9	0.4	0.0	0.0	0.0	0.6	0.1	0.0	0.1	0.0	0.2	0.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.9	74.7	0.0	0.0	0.0	0.0	0.4	0.0	0.7	5.9	0.0	3.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.1	7.3	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.5	3.6	0.0	1.9	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	1.7	0.0	0.0	0.0	0.0	176.2	2.2	0.0	0.2	0.0	0.0	0.5	1.0	0.0	0.9	0.1
TRDN	TRISK	ENSG00000186439	Triadin	Q13061	6	123216339-123637093	"Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"			"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 425.5;skeletal muscle: 1962.1;tongue: 1027.2"	"Group enriched"	"Detected in some"	11	"Cardiomyocytes: 1145.1;Muller glia cells: 765.7;Skeletal myocytes: 398.6"	"Group enriched"	"Detected in some"	5	"head and neck cancer: 2.2;prostate cancer: 0.6"	"Region enriched"	"Detected in all"	6	"hypothalamus: 64.2"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"MCF7: 1.9"	"Region enriched"	"Detected in some"	10	"olfactory bulb: 11.0"	"Region enriched"	"Detected in some"	23	"olfactory bulb: 28.9"	"HPA038226, HPA058226"	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA038226: AB_10795574, HPA058226: AB_2683643"	"unprognostic (1.05e-2)"			"unprognostic (1.99e-1)"	"unprognostic (9.20e-2)"	"unprognostic (3.06e-3)"		"unprognostic (2.40e-1)"	"unprognostic (2.38e-1)"	"unprognostic (2.42e-1)"	"unprognostic (8.42e-2)"	"unprognostic (8.71e-2)"	"unprognostic (9.93e-3)"	"unprognostic (2.12e-1)"	"unprognostic (2.55e-2)"		"unprognostic (3.97e-2)"	16.5	2.6	5.1	0.0	3.6	0.0	2.0	5.7	5.8	0.7	3.2	0.4	0.0	1.7	10.5	18.7	12.6	0.2	425.5	2.9	64.2	0.4	0.1	0.4	0.2	7.0	7.5	2.4	1.3	0.1	0.0	15.4	0.2	7.4	17.2	0.4	84.2	13.2	0.9	1962.1	0.4	0.2	1.0	11.3	0.1	0.1	5.1	6.7	0.3	0.3	1027.2	0.1	0.0	0.6	6.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	3.6	5.7	5.8	2.9	64.2	7.0	7.5	2.4	7.4	11.3	6.7	6.6	0.3	0.0	0.0	4.2	0.0	0.0	0.5	0.0	0.0	7.9	0.0	0.3	1145.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	68.0	0.0	0.0	6.0	0.0	0.0	1.1	0.0	0.0	38.4	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.6	0.0	0.0	0.0	0.4	35.5	13.1	0.5	1.8	0.0	0.0	765.7	0.0	3.0	3.2	0.0	0.0	11.3	0.0	0.0	0.0	0.2	0.0	21.8	0.0	398.6	7.1	1.3	0.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0
TRPV6	"CaT1, ECAC2"	ENSG00000165125	"Transient receptor potential cation channel subfamily V member 6"	Q9H1D0	7	142871208-142885745	"Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Ion channel"	"Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 38.6;prostate: 23.7;salivary gland: 69.9"	"Cell type enhanced"	"Detected in many"		"Cholangiocytes: 18.6;Collecting duct cells: 27.6;Cytotrophoblasts: 17.0;Ductal cells: 80.1;Early spermatids: 25.9;Late spermatids: 37.3"	"Cancer enriched"	"Detected in many"	5	"prostate cancer: 16.1"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 9.6;HaCaT: 18.0;RT4: 30.7;SK-BR-3: 23.5;T-47d: 52.8"	"Low region specificity"	"Detected in single"							HPA062864	Approved					NA	NA					"HPA062864: AB_2684885"	"unprognostic (9.85e-2)"	"unprognostic (1.60e-2)"	"unprognostic (6.29e-2)"	"unprognostic (8.72e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.14e-1)"	"unprognostic (7.11e-2)"	"unprognostic (5.43e-2)"	"unprognostic (3.50e-1)"	"unprognostic (4.56e-2)"	"unprognostic (3.89e-2)"	"unprognostic (3.27e-2)"	"unprognostic (8.49e-2)"	"unprognostic (9.39e-3)"	"unprognostic (1.69e-1)"	"unprognostic (7.17e-3)"	"unprognostic (3.53e-2)"	0.0	0.0	0.8	0.0	0.9	0.1	4.3	0.8	1.0	0.5	0.9	0.1	8.2	0.1	0.3	2.8	0.2	8.3	0.0	0.8	0.8	4.9	0.9	0.2	0.0	0.9	0.9	0.8	0.0	38.6	1.5	0.5	12.0	1.0	23.7	0.0	0.0	69.9	1.6	0.0	5.8	2.2	0.0	0.9	0.0	4.5	1.2	0.9	0.0	1.8	0.0	0.2	0.4	1.4	0.9	0.0	0.0	0.0	0.0	0.0	0.0	9.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	18.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.7	1.9	0.1	0.0	23.5	0.6	0.9	52.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.9	0.8	1.0	0.8	0.8	0.9	0.9	0.8	1.0	0.9	0.9	0.9	0.0	3.2	0.0	0.0	0.0	0.5	1.1	0.2	5.2	0.6	2.4	2.0	1.9	18.6	1.4	27.6	0.0	17.0	0.1	0.1	0.0	80.1	25.9	0.7	0.2	0.2	0.0	0.0	0.1	3.3	0.8	0.2	3.6	1.6	0.0	0.0	0.4	0.0	1.6	3.3	0.1	0.3	0.0	0.0	0.0	37.3	0.9	0.2	0.0	0.0	2.0	0.7	0.0	0.0	6.8	8.9	0.1	0.0	0.0	10.6	0.1	0.3	0.7	0.2	0.0	1.0	0.3	0.3	0.4	4.3	1.8	6.0	0.0	0.0	0.2	3.1
VSTM2L	"C20orf102, dJ1118M15.2"	ENSG00000132821	"V-set and transmembrane domain containing 2 like"	Q96N03	20	37903111-37945350	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 89.0;heart muscle: 50.1"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 25.2;Cholangiocytes: 61.5;Club cells: 28.7;Inhibitory neurons: 44.0;Respiratory ciliated cells: 83.0"	"Group enriched"	"Detected in all"	5	"lung cancer: 23.6;pancreatic cancer: 34.4;prostate cancer: 72.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 67.2;HDLM-2: 98.8;hTCEpi: 23.4;SH-SY5Y: 22.5;SK-BR-3: 81.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043832	Uncertain				"Secreted - unknown location"	NA	NA					"HPA043832: AB_10968449"	"unprognostic (1.43e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.33e-2)"	"prognostic unfavorable (1.63e-5)"	"unprognostic (4.96e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.83e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.34e-3)"	"unprognostic (9.86e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.85e-3)"	"unprognostic (1.29e-3)"	"unprognostic (1.68e-1)"	"unprognostic (9.66e-2)"	"prognostic unfavorable (8.14e-4)"	0.7	6.2	32.5	0.8	32.5	0.0	0.5	1.4	79.0	12.6	0.0	2.8	1.2	1.7	9.8	1.0	15.6	17.7	50.1	89.0	34.0	1.4	3.0	11.6	0.4	16.2	26.7	38.1	0.3	2.6	0.0	17.5	0.8	20.5	9.2	0.4	3.0	7.4	16.3	1.1	0.8	1.2	0.9	16.8	29.8	7.9	4.9	28.4	3.0	1.7	0.0	1.0	0.7	0.6	20.3	0.0	0.8	7.7	0.3	0.3	0.4	0.2	0.9	0.0	0.0	0.0	0.3	67.2	0.0	0.4	0.6	0.3	0.2	0.1	3.2	0.0	98.8	1.9	0.1	0.1	0.0	3.6	0.1	2.5	3.2	23.4	0.1	0.7	2.4	0.0	0.1	0.0	0.0	8.4	0.0	0.1	0.1	0.2	2.3	20.1	0.0	0.0	0.3	0.1	0.0	2.6	22.5	2.7	81.0	0.8	0.0	0.4	0.0	4.6	0.0	0.6	0.2	1.5	0.2	0.1	0.0	0.5	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.5	32.5	1.4	79.0	89.0	34.0	16.2	26.7	38.1	20.5	16.8	28.4	20.3	0.1	6.4	1.8	2.0	0.1	0.4	1.2	10.7	1.8	8.5	1.0	0.0	25.2	61.5	28.7	0.0	8.4	0.6	1.3	0.2	0.0	3.7	0.4	0.1	0.5	0.3	18.6	0.0	17.8	0.2	0.2	1.8	4.1	0.0	0.0	1.5	2.9	1.3	0.0	13.5	44.0	1.2	10.2	0.8	1.5	0.9	5.3	0.9	0.0	1.9	0.0	0.9	0.0	3.0	3.2	7.9	2.6	16.1	0.1	5.3	0.1	1.0	83.0	4.6	0.0	0.0	2.9	0.2	0.8	0.1	0.6	0.1	1.2	3.5	0.2	0.7
ZNF761	"FLJ16231, FLJ35333, KIAA2033"	ENSG00000160336	"Zinc finger protein 761"	Q86XN6	19	53431984-53461862	"Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"prostate: 74.6"	"Cell type enhanced"	"Detected in many"		"Syncytiotrophoblasts: 45.3"	"Cancer enriched"	"Detected in all"	5	"prostate cancer: 31.9"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"																	NA	NA						"unprognostic (8.10e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.89e-2)"	"unprognostic (1.39e-1)"	"unprognostic (7.03e-2)"	"unprognostic (1.44e-1)"	"prognostic unfavorable (2.04e-4)"	"unprognostic (4.68e-2)"	"unprognostic (3.74e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.19e-3)"	"unprognostic (1.59e-1)"	"unprognostic (2.33e-3)"	"unprognostic (1.19e-1)"	"unprognostic (4.13e-1)"	"unprognostic (8.71e-2)"	"unprognostic (1.38e-3)"	8.4	9.9	8.8	6.4	10.2	10.7	10.7	14.9	10.6	7.3	9.9	7.2	6.6	6.3	11.1	5.7	9.2	6.5	5.2	9.3	9.2	6.7	6.1	7.2	8.7	10.2	9.5	8.5	12.3	11.9	12.0	7.3	17.1	10.6	74.6	8.8	7.3	8.7	6.3	4.7	11.2	6.9	6.7	8.3	8.2	9.3	6.2	10.1	8.3	8.2	4.8	8.4	8.4	7.8	13.1	17.3	9.6	6.9	14.4	21.0	17.2	25.1	11.0	9.9	7.9	12.0	11.9	6.9	16.2	6.1	10.7	11.4	11.8	18.2	11.9	12.5	2.2	25.9	15.5	12.7	15.4	12.9	1.5	18.4	17.1	13.5	9.5	16.8	11.1	8.9	15.7	16.4	10.7	14.5	10.6	19.0	15.3	12.0	17.1	14.5	15.2	15.2	17.2	8.7	48.9	8.9	6.8	13.2	18.6	8.0	22.4	10.1	14.4	7.6	12.3	9.5	1.7	13.0	13.0	27.6	26.6	0.5	8.8	10.8	7.2	4.4	5.8	5.1	4.8	6.3	6.6	5.9	6.4	4.8	6.4	6.4	6.8	3.8	12.8	4.7	5.2	8.4	4.5	8.8	10.2	14.9	10.6	9.3	9.2	10.2	9.5	8.5	10.6	8.3	10.1	13.1	6.7	3.2	7.3	3.6	6.4	0.0	12.0	0.0	2.8	1.1	7.5	6.1	6.6	12.8	4.3	3.7	0.0	17.3	4.9	4.9	23.5	4.3	0.5	6.2	4.9	5.3	2.4	7.8	2.5	2.9	14.3	7.5	6.1	6.3	9.5	12.0	9.7	10.0	8.6	5.0	5.0	11.5	0.0	7.1	0.0	1.3	12.5	5.0	0.0	3.7	3.5	1.8	5.2	1.5	7.0	5.4	6.1	7.9	9.2	19.6	5.2	11.5	2.2	0.9	19.7	3.7	5.0	1.5	5.6	5.7	0.0	45.3	4.7	5.1	6.7	12.1
AMACR	"P504S, RACE"	ENSG00000242110	"Alpha-methylacyl-CoA racemase"	Q9UHK6	5	33986165-34008104	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		Isomerase	"Disease variant, Intrahepatic cholestasis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 135.5;liver: 182.0"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 19.7;Hepatocytes: 21.6;Late spermatids: 21.6;Proximal tubular cells: 38.5"	"Group enriched"	"Detected in all"	4	"liver cancer: 8.8;prostate cancer: 34.5;renal cancer: 14.7"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-266/70: 175.4;U-266/84: 98.0"	"Low region specificity"	"Detected in all"							"CAB001809, HPA019527, HPA020912"	Enhanced		Supported	"Vesicles,Plasma membrane"		NA	NA		70000	"Vesicles, Plasma membrane"		"CAB001809: AB_2305454, HPA019527: AB_10669651, HPA020912: AB_10670034"	"unprognostic (8.96e-2)"	"unprognostic (5.20e-3)"	"prognostic favorable (7.11e-4)"	"unprognostic (9.55e-2)"	"unprognostic (1.39e-1)"	"unprognostic (9.12e-3)"	"unprognostic (1.68e-1)"	"unprognostic (5.41e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.60e-1)"	"unprognostic (5.59e-5)"	"unprognostic (1.95e-2)"	"unprognostic (5.52e-3)"	"unprognostic (6.32e-2)"	"unprognostic (3.41e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.50e-1)"	8.7	15.1	5.9	5.0	5.3	3.1	6.4	4.7	6.1	6.6	4.5	40.4	18.1	4.7	9.7	15.8	6.2	20.7	10.2	5.1	6.6	135.5	182.0	9.3	3.6	5.9	5.9	5.8	7.8	13.9	13.1	5.7	7.8	6.0	39.6	43.3	12.1	61.2	12.6	19.4	4.7	16.0	7.1	5.1	5.4	35.1	4.4	6.7	4.8	8.3	15.1	5.7	8.9	8.6	7.0	12.7	20.2	11.1	14.3	7.7	11.9	19.1	16.6	12.2	7.6	5.7	66.1	15.1	4.1	8.7	23.6	28.6	5.8	2.8	12.0	7.7	12.7	10.9	9.8	13.7	19.0	5.4	6.0	3.0	18.1	6.0	9.7	3.6	10.7	8.5	8.3	3.8	14.7	22.4	9.6	5.0	7.6	10.0	9.4	32.9	6.0	18.6	6.5	33.2	62.4	6.1	8.7	27.6	19.3	16.9	9.1	14.9	5.9	15.6	24.6	5.4	6.2	13.6	175.4	98.0	7.4	7.0	12.1	18.8	0.3	6.0	9.3	8.3	8.0	7.0	7.1	7.2	6.4	8.9	5.2	6.6	4.8	10.0	8.7	14.2	4.6	7.9	6.0	5.9	5.3	4.7	6.1	5.1	6.6	5.9	5.9	5.8	6.0	5.1	6.7	7.0	0.8	3.2	4.1	0.0	2.2	0.4	0.4	0.9	1.8	4.3	1.4	0.9	1.1	8.6	3.7	1.8	0.0	1.0	2.2	19.7	5.9	0.8	8.9	2.3	1.2	3.0	4.2	2.1	0.0	3.8	1.0	2.9	4.1	1.5	0.0	1.2	1.1	21.6	1.1	5.0	0.0	5.1	4.1	0.9	0.2	21.6	0.6	1.2	0.0	0.0	1.5	9.3	3.1	0.0	0.0	2.6	4.5	2.2	1.6	0.6	4.7	38.5	3.1	0.9	0.0	1.7	3.7	0.7	0.7	3.4	0.6	0.3	1.5	1.2	4.4	0.4
BHLHA15	"BHLHB8, MIST1"	ENSG00000180535	"Basic helix-loop-helix family member a15"	Q7RTS1	7	98211439-98215457	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"pancreas: 507.1;salivary gland: 147.1"	"Cell type enriched"	"Detected in single"	25	"Plasma cells: 12.6"	"Cancer enriched"	"Detected in many"	4	"prostate cancer: 16.2"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"Karpas-707: 53.5;RPMI-8226: 72.0;U-266/70: 67.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB034083, HPA047834"	Enhanced		Approved	"Nucleoplasm,Golgi apparatus"		NA	NA			"Nucleoplasm, Golgi apparatus"		"CAB034083: AB_2065216, HPA047834: AB_2680172"	"unprognostic (2.80e-2)"	"unprognostic (9.45e-3)"	"unprognostic (8.10e-2)"	"unprognostic (6.66e-2)"	"unprognostic (4.33e-3)"	"unprognostic (1.10e-2)"	"unprognostic (4.05e-2)"	"unprognostic (1.37e-1)"	"unprognostic (3.60e-1)"	"unprognostic (4.28e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.70e-4)"	"unprognostic (3.36e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.95e-1)"	"unprognostic (8.25e-3)"	0.1	0.1	0.7	3.7	0.6	0.3	1.5	0.1	2.1	1.9	0.0	4.1	4.0	0.1	0.8	1.0	0.1	0.8	0.2	1.3	0.8	0.4	5.2	0.9	3.9	0.5	0.4	0.7	0.4	507.1	0.1	1.5	0.1	0.6	8.6	1.6	0.0	147.1	4.0	0.2	0.5	3.4	0.0	0.7	5.1	31.6	0.2	1.1	0.7	1.9	0.0	4.7	2.5	0.2	0.4	0.3	0.1	0.0	0.0	0.0	0.3	0.4	0.1	0.0	0.3	0.1	0.8	0.9	0.0	1.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	2.8	0.0	0.6	6.7	5.9	0.0	0.1	0.0	0.4	0.4	0.2	0.0	0.2	0.0	0.0	53.5	0.0	0.9	0.0	0.0	0.8	6.2	0.8	0.4	0.0	72.0	0.3	0.0	4.3	1.2	0.0	11.2	0.0	0.0	0.7	0.1	0.0	0.0	0.7	0.1	0.1	67.6	5.4	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.6	0.1	2.1	1.3	0.8	0.5	0.4	0.7	0.6	0.7	1.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
CEACAM20	UNQ9366	ENSG00000273777	"CEA cell adhesion molecule 20"	Q6UY09	19	44501677-44529788	"Predicted membrane proteins"	Immunity			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"intestine: 38.0"	"Cell type enriched"	"Detected in single"	97	"Proximal enterocytes: 39.0"	"Cancer enriched"	"Detected in some"	4	"prostate cancer: 5.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"U-266/70: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (1.04e-2)"	"unprognostic (5.03e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.92e-1)"			"unprognostic (1.23e-2)"	"unprognostic (3.75e-1)"		"unprognostic (9.89e-2)"	"unprognostic (1.07e-2)"	"unprognostic (7.58e-2)"	"unprognostic (2.14e-5)"	"unprognostic (7.13e-2)"	"unprognostic (2.51e-2)"		"unprognostic (1.44e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.8	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.5	0.1	0.1	0.0	0.0	0.0	0.0	38.0	0.3	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	39.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0
CUX2	"CDP2, CUTL2, KIAA0293"	ENSG00000111249	"Cut like homeobox 2"	O14529	12	111034165-111350554	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Disease variant, Epilepsy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 21.7;choroid plexus: 21.6;liver: 20.5;prostate: 11.5"	"Cell type enhanced"	"Detected in some"		"dendritic cells: 28.1;Excitatory neurons: 175.4;Hepatocytes: 50.9;Horizontal cells: 26.9;Inhibitory neurons: 72.5"	"Group enriched"	"Detected in some"	4	"liver cancer: 5.2;prostate cancer: 11.2"	"Region enhanced"	"Detected in many"		"cerebral cortex: 21.7"	"Immune cell enriched"	"Detected in single"	70	"plasmacytoid DC: 6.9"	"Lineage enriched"	"Detected in single"	70	"dendritic cells: 6.9"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 6.6;HDLM-2: 2.9;hTERT-HME1: 3.5;SCLC-21H: 6.5;SH-SY5Y: 14.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.87e-2)"	"unprognostic (6.98e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.30e-1)"	"unprognostic (2.78e-2)"	"unprognostic (1.22e-2)"	"unprognostic (9.44e-2)"	"unprognostic (2.33e-1)"	"unprognostic (3.30e-2)"	"unprognostic (7.83e-5)"	"unprognostic (2.67e-1)"	"unprognostic (3.54e-3)"	"unprognostic (4.31e-2)"	"unprognostic (9.03e-2)"	"unprognostic (4.64e-2)"	"unprognostic (1.90e-2)"	0.0	0.0	3.7	0.2	1.5	0.2	1.8	0.0	21.7	0.8	21.6	0.3	0.1	0.1	0.3	0.1	0.0	0.0	0.0	4.1	1.6	0.0	20.5	0.0	0.5	0.7	1.6	4.9	0.0	0.1	0.0	2.1	0.0	4.3	11.5	0.0	2.3	0.0	2.9	0.1	0.2	0.2	0.0	0.0	0.2	1.6	0.5	7.9	0.2	4.2	0.1	0.4	0.1	0.0	2.9	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	6.6	0.0	2.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	2.1	0.0	0.0	0.2	0.0	0.1	0.0	0.0	6.5	14.0	0.0	0.0	0.0	0.4	0.3	0.2	0.0	0.0	0.8	0.0	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	3.7	1.5	0.0	21.7	4.1	1.6	0.7	1.6	4.9	4.3	0.0	7.9	2.9	0.0	0.0	0.0	7.2	0.5	0.0	3.5	0.7	0.0	6.4	2.6	3.0	1.0	2.8	0.1	0.0	0.0	0.0	28.1	0.1	0.0	0.0	1.2	3.7	0.1	0.1	0.0	2.7	175.4	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.4	50.9	0.7	26.9	72.5	0.0	0.0	0.6	0.0	0.6	0.0	0.5	0.0	1.9	0.0	0.1	0.0	20.1	1.8	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.1	0.9	0.0	0.3	0.1	0.8	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.6
CWH43	"CWH43-C, FLJ21511, PGAP2IP"	ENSG00000109182	"Cell wall biogenesis 43 C-terminal homolog"	Q9H720	4	48986275-49062081	"Predicted membrane proteins"	"GPI-anchor biosynthesis"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 21.1;prostate: 43.2;skin 1: 25.7"	"Cell type enhanced"	"Detected in some"		"Distal enterocytes: 10.4;Endometrial ciliated cells: 41.3;Gastric mucus-secreting cells: 10.7;Glandular and luminal cells: 21.1;Paneth cells: 15.4;Respiratory ciliated cells: 29.5;Undifferentiated cells: 15.0"	"Cancer enriched"	"Detected in many"	4	"prostate cancer: 20.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA042814, HPA048140"	Uncertain		Uncertain	"Golgi apparatus,Plasma membrane"		NA	NA			"Golgi apparatus, Plasma membrane"		"HPA042814: AB_2678182, HPA048140: AB_2680280"	"unprognostic (9.38e-3)"	"unprognostic (6.23e-2)"	"unprognostic (3.14e-2)"	"prognostic favorable (1.32e-4)"	"unprognostic (2.14e-1)"	"unprognostic (5.00e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.49e-1)"	"unprognostic (1.63e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.49e-4)"	"unprognostic (1.24e-1)"	"prognostic favorable (2.29e-11)"	"unprognostic (5.19e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.82e-2)"	"unprognostic (2.51e-2)"	0.0	0.0	0.0	1.4	0.0	0.0	2.0	0.0	0.0	3.2	0.0	17.1	0.4	0.6	0.4	21.1	14.7	0.0	0.0	0.0	0.1	9.1	0.7	0.7	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	43.2	15.7	0.0	3.0	7.8	0.0	25.7	0.0	0.8	0.1	0.0	9.7	0.0	0.0	0.1	10.3	0.0	1.5	2.1	9.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.2	1.9	0.1	0.8	0.0	0.0	0.6	0.1	0.6	0.0	2.3	7.3	0.0	0.0	0.0	10.4	1.9	0.0	0.2	41.3	2.4	0.1	0.0	0.0	0.1	0.0	0.0	0.2	10.7	21.1	0.0	0.0	0.0	0.4	0.0	0.0	0.2	4.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	15.4	0.0	0.0	7.6	0.0	2.9	29.5	0.0	0.0	0.0	0.5	0.0	0.5	3.2	9.1	0.0	0.2	0.0	15.0	0.3
DEFB132	"DEFB32, RP5-1103G7.6"	ENSG00000186458	"Defensin beta 132"	Q7Z7B7	20	257724-261096	"Predicted secreted proteins"		"Antibiotic, Antimicrobial, Defensin"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"epididymis: 273.5"	"Cell type enriched"	"Detected in some"	7	"Collecting duct cells: 11.0"	"Group enriched"	"Detected in some"	4	"liver cancer: 0.8;prostate cancer: 1.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"											HPA046399	Approved				"Secreted in male reproductive system"	NA	NA					"HPA046399: AB_10960992"	"unprognostic (9.27e-3)"						"unprognostic (1.61e-2)"					"unprognostic (2.54e-2)"						26.2	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	273.5	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	20.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	1.5	0.0	11.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
ERG	"erg-3, p55"	ENSG00000157554	"ETS transcription factor ERG"	P11308	21	38380027-38661780	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Adipocytes: 94.4;Endothelial cells: 105.5;Hepatic stellate cells: 69.9;Microglial cells: 88.1"	"Cancer enriched"	"Detected in all"	4	"prostate cancer: 18.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HUVEC TERT2: 138.3;MOLT-4: 47.7;REH: 151.5;TIME: 113.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018377, HPA046598"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB018377: AB_675518, HPA046598: AB_2679715"	"unprognostic (2.14e-1)"	"prognostic unfavorable (6.18e-6)"	"unprognostic (6.44e-3)"	"unprognostic (8.64e-3)"	"unprognostic (5.65e-2)"	"unprognostic (1.91e-1)"	"unprognostic (9.03e-4)"	"unprognostic (4.30e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavorable (3.94e-4)"	"unprognostic (4.31e-3)"	"unprognostic (3.88e-2)"	"unprognostic (2.64e-2)"	"unprognostic (5.63e-3)"	24.8	4.2	5.6	7.2	5.1	7.7	20.2	5.0	5.7	10.1	4.6	5.3	3.4	11.7	1.9	5.3	9.2	12.1	11.1	4.5	5.0	8.9	6.2	19.8	7.6	5.9	5.4	3.4	4.5	4.9	2.4	2.5	24.5	5.8	7.1	3.5	0.5	3.7	4.3	8.0	4.5	6.5	12.1	4.5	26.8	4.7	1.6	6.6	4.2	10.1	10.0	3.7	9.3	7.0	5.4	0.0	0.0	1.5	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.6	0.0	0.0	0.2	22.3	0.0	0.1	0.9	0.0	0.0	138.3	0.1	0.0	0.0	0.0	1.0	47.7	0.0	0.5	0.0	0.0	151.5	0.0	0.0	0.0	0.1	0.1	0.0	1.1	0.2	0.0	0.0	0.0	0.0	113.4	0.7	2.2	0.5	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	5.6	5.1	5.0	5.7	4.5	5.0	5.9	5.4	3.4	5.8	4.5	6.6	5.4	94.4	0.0	3.9	0.3	0.7	3.4	1.7	0.6	3.4	0.0	0.6	4.3	3.8	4.3	1.3	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.7	0.7	0.4	105.5	0.0	13.5	13.3	0.0	0.0	5.7	0.0	2.1	24.0	4.4	69.9	1.3	0.3	0.0	1.7	0.4	0.0	5.9	3.4	2.1	0.9	0.9	3.6	88.1	0.2	0.0	0.0	7.1	1.4	0.0	0.0	0.0	1.5	1.4	0.0	0.0	0.0	0.1	0.0	2.4	3.7	0.3	1.4	0.5	3.4	0.0	0.6	0.5	0.3	0.6
GHR	GHBP	ENSG00000112964	"Growth hormone receptor"	P10912	5	42423439-42721878	"Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Endocytosis	Receptor	"Disease variant, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 85.5;liver: 215.0"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 53.3;Hepatocytes: 141.3;Inhibitory neurons: 115.7;Oligodendrocyte precursor cells: 181.0"	"Group enriched"	"Detected in many"	4	"breast cancer: 2.8;liver cancer: 7.6;prostate cancer: 8.1;renal cancer: 2.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HSkMC: 21.2;T-47d: 56.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045339, HPA057705"	Enhanced		Supported	"Plasma membrane,Cytosol,Cytoplasmic bodies"	"Secreted to blood"	NA	NA	2200000	24000000	"Plasma membrane, Cytosol, Cytoplasmic bodies"		"HPA045339: AB_2679294, HPA057705: AB_2683507"	"unprognostic (2.18e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.96e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.57e-1)"	"prognostic favorable (2.73e-6)"	"unprognostic (1.06e-1)"	"unprognostic (3.92e-2)"	"unprognostic (3.73e-2)"	"unprognostic (6.15e-3)"	"unprognostic (2.67e-2)"	"unprognostic (1.67e-3)"	"unprognostic (4.29e-4)"	"unprognostic (7.82e-2)"	"unprognostic (7.33e-4)"	"unprognostic (8.35e-6)"	85.5	5.6	1.6	1.7	2.3	0.2	30.3	1.9	1.7	5.1	2.4	5.3	1.1	4.5	4.6	3.9	5.4	5.2	9.0	1.8	4.2	11.9	215.0	4.0	1.3	1.1	1.9	1.5	7.6	2.2	5.5	1.2	4.9	1.4	11.2	5.7	0.4	3.8	4.7	46.1	5.6	4.3	4.0	1.1	4.1	6.1	1.7	2.6	2.3	4.7	11.7	0.9	5.0	5.9	1.5	0.0	0.0	0.6	5.0	3.3	0.7	0.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	0.0	0.0	0.3	4.3	0.0	0.0	2.6	0.0	0.1	0.0	0.6	0.0	0.0	21.2	7.0	0.0	1.0	0.1	0.1	0.0	0.0	0.0	1.8	0.2	0.0	0.0	0.3	0.0	0.7	0.0	0.3	0.0	0.0	0.6	0.0	0.0	0.3	0.1	3.5	0.6	56.0	0.1	3.0	4.8	2.1	2.6	0.5	0.5	0.0	0.0	0.5	0.0	2.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.6	2.3	1.9	1.7	1.8	4.2	1.1	1.9	1.5	1.4	1.1	2.6	1.5	17.2	0.0	0.5	14.7	0.4	4.7	4.5	17.8	10.2	0.6	9.7	16.0	18.6	1.5	1.9	1.8	0.0	17.4	0.5	2.8	1.9	0.0	5.1	0.5	9.4	4.8	3.0	5.3	53.3	0.2	2.2	23.8	0.5	0.3	0.0	1.1	6.1	141.3	1.9	0.0	115.7	1.9	0.0	3.0	1.8	2.8	18.6	0.7	1.8	36.5	0.0	0.7	0.0	181.0	3.6	0.2	1.7	12.0	0.0	5.2	0.0	9.6	0.6	0.4	13.1	18.7	15.1	0.7	0.3	2.9	3.7	40.2	0.5	49.4	2.2	0.9
KLK15	"ACO, HSRNASPH, prostinogen"	ENSG00000174562	"Kallikrein related peptidase 15"	Q9H2R5	19	50825289-50837213	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 3.3;salivary gland: 5.7"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 5.5;Intestinal goblet cells: 34.6;Late spermatids: 8.8;Spermatocytes: 15.0;Spermatogonia: 9.5"	"Group enriched"	"Detected in some"	4	"prostate cancer: 3.5;renal cancer: 1.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	5	"RPMI-8226: 2.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA019802	Uncertain				"Secreted to blood"	NA	NA					"HPA019802: AB_1852601"		"unprognostic (6.06e-2)"	"unprognostic (2.85e-1)"	"unprognostic (8.13e-2)"		"unprognostic (2.90e-1)"				"unprognostic (2.29e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.17e-1)"		"unprognostic (1.55e-1)"	"unprognostic (2.52e-1)"	"unprognostic (2.72e-2)"		0.0	1.3	0.0	0.2	0.0	0.0	0.0	0.1	0.2	0.0	0.0	3.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.5	1.2	0.0	5.7	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	5.5	0.0	0.0	0.1	1.8	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	34.6	0.0	0.0	0.0	8.8	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	9.5	0.0	0.0	0.0	0.0	0.0	0.8	0.0
LDB3	"CMD1C, KIAA0613, PDLIM6, ZASP"	ENSG00000122367	"LIM domain binding 3"	O75112	10	86668507-86736072	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cardiomyopathy, Disease variant, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	26	"heart muscle: 1079.8;skeletal muscle: 2973.6;tongue: 1825.5"	"Cell type enriched"	"Detected in many"	7	"Cardiomyocytes: 1825.0"	"Group enriched"	"Detected in some"	4	"head and neck cancer: 1.7;melanoma: 2.5;prostate cancer: 3.6;stomach cancer: 1.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HSkMC: 3.0;hTERT-RPE1: 3.3;SCLC-21H: 4.9;SK-MEL-30: 2.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048955	Enhanced		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA		750000	"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA048955: AB_2680568"	"unprognostic (1.60e-1)"	"unprognostic (9.01e-2)"	"unprognostic (4.87e-2)"	"unprognostic (6.92e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.61e-2)"	"unprognostic (2.54e-3)"	"unprognostic (3.55e-2)"	"unprognostic (4.72e-4)"	"unprognostic (3.07e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.62e-2)"	"unprognostic (3.16e-1)"	9.2	1.4	12.9	2.8	35.5	0.4	6.6	26.8	32.4	9.6	1.7	26.0	2.4	15.2	5.0	55.0	17.4	3.1	1079.8	12.5	23.2	2.0	0.8	5.2	0.5	52.7	36.0	6.5	6.4	1.3	0.5	2.4	2.8	52.5	38.5	5.4	0.7	21.0	25.4	2973.6	4.0	8.9	23.9	32.2	0.6	9.1	4.8	30.8	0.7	5.2	1825.5	0.3	7.0	10.3	76.2	0.1	0.1	0.2	1.7	0.2	0.0	0.2	0.2	0.1	0.0	0.1	0.1	0.2	0.1	0.3	0.0	0.3	0.2	0.0	0.0	0.0	0.5	0.4	0.4	0.7	0.0	0.0	0.0	0.9	3.0	0.2	0.0	0.0	3.3	0.0	0.3	0.1	1.0	0.0	0.8	0.2	0.1	0.2	0.2	0.2	0.0	1.1	0.0	0.0	0.6	4.9	0.9	0.2	0.1	2.4	0.7	0.2	0.1	0.0	0.1	0.2	0.2	0.0	0.1	0.3	0.2	0.4	0.1	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.9	35.5	26.8	32.4	12.5	23.2	52.7	36.0	6.5	52.5	32.2	30.8	76.2	1.5	0.0	0.0	1.0	0.0	1.0	0.5	0.2	0.0	1.5	0.2	0.3	1825.0	0.0	0.2	1.8	0.0	0.1	0.0	0.0	0.0	0.0	23.4	0.1	0.4	15.5	0.0	0.0	4.5	1.1	0.0	31.5	0.0	0.2	0.0	0.9	0.0	0.0	0.1	0.0	2.6	0.0	4.1	0.0	1.2	19.6	11.1	0.5	1.8	1.9	0.0	0.7	0.0	1.5	245.1	0.1	0.0	6.8	0.0	0.3	0.0	0.1	0.1	4.1	39.5	48.0	54.9	1.0	1.0	0.0	0.0	0.0	0.2	0.2	0.0	0.2
MESP1	"bHLHc5, MGC10676"	ENSG00000166823	"Mesoderm posterior bHLH transcription factor 1"	Q9BRJ9	15	89748661-89751310	"Predicted intracellular proteins, Transcription factors"	"Notch signaling pathway, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 4.5;prostate: 7.4;skeletal muscle: 4.6"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 52.2;Breast myoepithelial cells: 58.9;Distal enterocytes: 40.1;Exocrine glandular cells: 43.0;Spermatocytes: 41.5"	"Cancer enriched"	"Detected in many"	4	"prostate cancer: 26.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 3.5;HDLM-2: 3.1;HEK 293: 3.0;PC-3: 5.7;SCLC-21H: 2.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA069981			Supported	Nucleoplasm,Nucleoli		NA	NA			Nucleoplasm	Nucleoli	"HPA069981: AB_2686225"	"unprognostic (4.17e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.27e-1)"	"unprognostic (4.83e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.68e-2)"	"unprognostic (4.95e-3)"	"unprognostic (2.26e-2)"	"unprognostic (2.47e-1)"	"unprognostic (8.38e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.24e-3)"	"unprognostic (2.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.10e-1)"	"unprognostic (7.03e-2)"	4.5	1.4	1.9	0.0	2.6	0.1	3.1	1.6	3.1	0.5	0.3	1.2	0.1	0.1	0.0	0.3	0.2	0.0	1.3	2.4	1.9	0.7	0.8	0.2	0.0	1.6	1.5	3.1	0.2	1.2	0.2	1.0	0.0	1.4	7.4	0.0	0.2	2.1	0.1	4.6	0.2	0.5	0.0	0.6	0.2	0.5	1.3	1.9	0.0	0.5	0.3	0.0	0.3	0.4	1.8	3.5	1.3	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.2	0.0	1.3	0.0	0.4	0.0	0.2	0.0	0.0	3.1	3.0	0.1	0.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.9	0.0	0.1	0.0	0.1	0.5	0.8	0.0	0.0	5.7	0.1	0.0	0.8	0.0	0.0	2.6	0.1	0.7	1.1	0.8	0.0	0.0	0.4	0.0	0.0	0.2	2.0	0.6	1.3	0.5	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	2.6	1.6	3.1	2.4	1.9	1.6	1.5	3.1	1.4	0.6	1.9	1.8	1.7	0.0	1.1	2.6	2.9	0.3	2.8	5.1	0.6	11.6	52.2	58.9	6.3	17.2	33.9	1.8	10.4	3.0	3.2	40.1	11.7	18.6	5.3	0.3	0.3	2.1	6.1	3.0	2.8	43.0	0.2	3.5	0.5	0.9	4.5	22.1	4.2	12.8	2.0	8.4	3.0	7.4	12.2	1.6	2.1	2.1	1.2	2.5	7.2	1.0	2.1	19.2	2.1	1.5	1.7	4.8	17.9	0.0	4.6	35.7	7.2	16.2	8.7	20.6	0.0	4.0	3.7	41.5	21.7	2.0	0.3	0.3	2.2	18.0	15.5	6.2
MT1G	"MT1, MT1K"	ENSG00000125144	"Metallothionein 1G"	P13640	16	56666730-56668065	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 3506.9;liver: 7016.2;thyroid gland: 2912.8"	"Cell type enriched"	"Detected in many"	4	"Proximal tubular cells: 77919.3"	"Group enriched"	"Detected in all"	4	"liver cancer: 320.1;ovarian cancer: 106.9;prostate cancer: 103.9;testis cancer: 269.9;thyroid cancer: 369.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	4	"U-937: 1103.8"														"Intracellular and membrane"	NA	NA						"unprognostic (1.62e-1)"	"unprognostic (4.21e-1)"	"unprognostic (2.77e-2)"	"unprognostic (3.15e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.97e-2)"	"unprognostic (2.49e-2)"	"unprognostic (4.21e-1)"	"prognostic unfavorable (1.67e-7)"	"unprognostic (1.42e-1)"	"unprognostic (3.50e-2)"	"unprognostic (7.92e-2)"	"unprognostic (2.26e-2)"	124.7	21.7	342.2	106.7	413.9	2.9	28.3	393.5	919.5	12.4	301.5	828.7	518.4	8.4	2.4	257.4	76.2	12.1	6.8	338.0	346.5	3506.9	7016.2	50.3	5.6	403.6	361.9	358.6	3.2	1822.1	0.3	21.8	2.1	372.5	428.9	521.1	43.0	44.5	5.9	8.5	56.7	1105.7	77.0	331.0	3.9	1272.7	4.0	363.1	0.9	2912.8	1.0	2.6	14.3	26.1	402.5	0.4	0.0	0.0	0.0	0.0	0.0	4.4	8.6	1.7	1.1	0.4	0.0	0.0	0.1	16.2	0.0	0.1	1.8	0.2	1.2	0.9	0.8	0.0	4.3	0.0	3.5	4.5	1.0	0.6	1.7	0.0	11.4	0.0	0.1	0.0	0.0	0.3	1.2	0.7	0.0	3.7	251.3	0.5	0.0	0.0	0.0	0.8	70.8	40.8	0.0	21.8	3.0	0.5	1.3	1.1	10.8	0.0	107.8	0.0	0.0	0.8	1.7	0.3	0.6	1.9	0.6	2.0	1103.8	0.0	0.2	0.3	0.1	0.3	0.3	0.3	0.0	0.4	0.6	0.3	0.0	0.4	0.7	0.0	0.0	0.1	0.1	0.7	0.5	342.2	413.9	393.5	919.5	338.0	346.5	403.6	361.9	358.6	372.5	331.0	363.1	402.5	10.6	28.9	8.7	38.5	338.7	57.9	26.0	4.5	46.1	0.0	87.0	116.2	11.7	330.3	9.1	2302.6	0.0	3.9	9.8	3657.8	6849.7	74.4	0.3	2960.7	777.1	49.2	246.7	878.6	0.1	283.4	403.2	50.7	443.9	8167.8	17.2	16.8	310.2	16307.3	26.3	0.0	0.1	3688.0	0.0	379.5	4.9	0.9	23.3	765.6	30.2	2.8	10.6	0.0	2.1	2.0	0.1	339.8	10431.2	2.2	26.3	823.7	8631.3	77919.3	3.9	0.0	0.0	25.1	42.9	0.3	0.8	42.2	77.9	132.7	247.5	4.7	3786.7	21.1
MYH3	"HEMHC, MYHC-EMB, MYHSE1, SMHCE"	ENSG00000109063	"Myosin heavy chain 3"	P11055	17	10628526-10657309	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 29.3;seminal vesicle: 18.5;skeletal muscle: 20.8"	"Cell type enriched"	"Detected in many"	7	"Early spermatids: 411.9"	"Group enriched"	"Detected in many"	4	"head and neck cancer: 3.3;prostate cancer: 4.6;testis cancer: 2.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	26	"HSkMC: 59.6"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"			HPA021808	Enhanced					NA	NA		29000000			"HPA021808: AB_1854242"	"unprognostic (1.70e-2)"	"unprognostic (1.10e-3)"	"unprognostic (4.19e-4)"	"unprognostic (3.35e-1)"	"unprognostic (7.66e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.10e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.67e-2)"	"unprognostic (3.54e-1)"	"unprognostic (7.84e-4)"	"unprognostic (1.29e-1)"	"unprognostic (3.24e-4)"	"unprognostic (1.91e-2)"	"unprognostic (6.17e-3)"	"unprognostic (3.40e-2)"	"unprognostic (3.49e-1)"	1.4	0.9	2.0	1.1	2.0	0.8	1.5	1.7	1.8	3.0	1.7	4.8	1.1	3.4	1.2	9.2	2.6	0.5	1.0	1.8	1.7	1.8	3.4	1.2	1.3	2.0	2.1	1.6	2.3	2.5	0.3	1.5	0.4	2.1	29.3	1.0	1.8	1.5	18.5	20.8	2.4	2.5	1.7	1.6	2.7	1.7	4.6	2.0	3.1	3.5	6.1	0.6	4.5	3.8	1.9	0.2	1.1	0.8	1.1	1.0	0.3	1.0	0.8	0.4	0.5	0.5	1.0	0.1	0.7	0.3	0.4	0.2	1.1	0.5	0.2	1.0	0.7	0.9	1.0	0.3	1.6	0.3	0.6	1.4	59.6	0.4	0.6	0.8	0.1	0.1	1.3	0.4	0.1	0.2	0.7	1.0	2.3	0.9	0.3	0.6	0.8	0.8	0.3	0.3	0.3	0.0	0.4	0.4	0.0	0.3	0.7	0.3	0.3	0.3	0.1	1.0	0.3	0.1	1.3	1.1	0.3	0.3	0.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.0	1.7	1.8	1.8	1.7	2.0	2.1	1.6	2.1	1.6	2.0	1.9	0.5	0.0	9.8	4.6	0.7	2.9	0.9	0.1	0.6	4.9	0.7	1.8	3.6	1.5	0.7	0.0	6.2	0.4	0.8	0.9	0.0	0.6	411.9	0.5	0.8	1.4	0.0	2.7	3.9	0.6	0.8	1.1	1.1	0.5	7.6	0.8	0.4	0.6	0.1	0.0	3.4	0.5	0.0	0.8	0.3	56.0	2.8	1.2	1.8	1.9	0.2	1.8	0.0	7.5	5.4	0.7	0.2	2.6	0.0	1.5	1.8	0.3	0.3	4.6	0.0	5.5	0.8	10.7	4.2	0.3	1.6	0.5	1.4	0.2	0.8	0.3
MYL3	"CMH8, MLC1SB, MLC1V, VLC1"	ENSG00000160808	"Myosin light chain 3"	P08590	3	46835111-46882172	"Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Motor protein, Muscle protein, Myosin"	"Cardiomyopathy, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	26	"heart muscle: 4888.7;skeletal muscle: 5183.9;tongue: 2092.6"	"Cell type enriched"	"Detected in some"	53	"Cardiomyocytes: 3626.2"	"Group enriched"	"Detected in many"	4	"head and neck cancer: 3.0;prostate cancer: 3.4;renal cancer: 8.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 8.6;HSkMC: 8.7;RPTEC TERT1: 34.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA016564, CAB018662, HPA046859, HPA063034"	Enhanced		Approved	Nucleoli,Mitochondria		NA	NA		7300000	"Nucleoli, Mitochondria"		"CAB018662: AB_627952, HPA016564: AB_1854244, HPA046859: AB_2679842, HPA063034: AB_2684927"	"unprognostic (3.11e-1)"	"unprognostic (2.64e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.77e-1)"	"unprognostic (4.44e-2)"	"unprognostic (9.67e-3)"	"unprognostic (3.37e-2)"	"unprognostic (4.72e-3)"	"unprognostic (3.63e-2)"	"unprognostic (1.08e-1)"	"unprognostic (7.88e-2)"	"prognostic favorable (1.22e-8)"	"unprognostic (1.16e-3)"	"unprognostic (9.45e-3)"	"unprognostic (7.18e-5)"	"unprognostic (2.53e-3)"	5.8	4.2	9.8	1.0	9.6	1.5	9.0	10.2	14.9	6.7	7.2	2.3	1.6	3.4	3.4	158.4	4.2	3.6	4888.7	9.8	11.1	49.4	4.1	5.8	3.3	13.9	11.0	8.7	5.2	2.7	1.3	1.7	4.7	11.2	25.3	0.8	1.9	19.8	1.5	5183.9	3.5	2.3	2.0	11.9	8.0	2.1	2.3	11.9	0.7	2.4	2092.6	0.6	2.4	4.8	12.1	0.5	0.7	0.4	0.3	4.4	1.5	3.6	0.7	0.4	0.4	0.6	8.6	0.8	1.6	1.4	0.1	0.2	0.5	0.4	0.1	0.7	0.3	0.1	0.8	2.6	0.3	0.7	0.9	0.8	8.7	0.2	0.3	0.1	0.2	0.1	0.5	0.4	1.2	0.2	1.2	0.3	0.5	1.0	0.4	0.4	0.9	0.3	0.1	34.2	1.3	0.6	0.4	0.3	0.7	0.1	0.7	0.3	0.5	0.2	1.0	0.8	0.6	0.3	0.5	0.4	0.7	0.3	0.8	0.8	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.2	0.0	0.4	0.1	0.1	0.3	0.0	0.1	0.4	0.0	0.0	9.8	9.6	10.2	14.9	9.8	11.1	13.9	11.0	8.7	11.2	11.9	11.9	12.1	0.7	0.0	0.0	1.0	0.0	0.8	0.2	0.0	0.0	0.2	2.3	0.1	3626.2	0.0	0.0	1.8	0.0	0.4	0.0	0.0	54.8	0.0	2.4	0.1	2.2	32.8	0.0	0.0	0.1	0.0	16.4	23.7	0.0	0.0	0.0	0.0	1.1	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.6	12.8	1.2	0.7	0.0	0.0	0.0	2.8	0.0	0.5	0.0	0.0	0.0	0.7	0.0	0.0	0.0	68.1	0.0	0.4	6.6	27.9	20.4	0.2	0.5	0.0	0.4	0.8	0.4	0.1	0.0	0.0
NAAA	ASAHL	ENSG00000138744	"N-acylethanolamine acid amidase"	Q02083	4	75913660-75941013	"Enzymes, Metabolic proteins, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 142.2;Kupffer cells: 115.8;Langerhans cells: 109.9;Proximal enterocytes: 167.7"	"Cancer enriched"	"Detected in all"	4	"prostate cancer: 31.8"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in all"		"intermediate monocyte: 672.4;non-classical monocyte: 583.3"	"Lineage enriched"	"Detected in all"	5	"monocytes: 672.4"	"Cell line enhanced"	"Detected in many"		"U-2197: 78.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB026135	Approved				"Intracellular and membrane"	NA	NA					"CAB026135: "	"unprognostic (5.30e-3)"	"unprognostic (1.23e-2)"	"unprognostic (1.41e-2)"	"prognostic favorable (1.93e-4)"	"unprognostic (1.10e-1)"	"unprognostic (2.17e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.87e-2)"	"prognostic favorable (4.90e-4)"	"unprognostic (1.63e-1)"	"unprognostic (2.15e-2)"	"unprognostic (2.54e-1)"	"unprognostic (3.20e-2)"	"unprognostic (3.42e-3)"	"unprognostic (6.21e-2)"	19.2	14.7	9.8	30.3	10.8	18.6	37.8	11.6	10.9	23.2	13.9	62.3	31.2	13.0	9.2	28.7	16.5	15.9	20.1	10.1	13.4	41.0	68.9	23.2	48.8	11.1	11.2	9.6	8.3	7.7	11.8	7.8	19.5	12.5	71.5	70.5	33.0	31.7	11.5	8.7	23.0	61.2	15.5	10.8	64.3	18.7	3.5	12.6	16.5	16.1	13.1	28.1	20.2	18.6	14.3	11.9	26.6	1.1	0.7	62.4	62.8	1.1	17.5	11.6	11.8	4.0	9.3	41.1	1.0	8.9	43.5	0.4	23.1	34.8	13.4	7.1	17.0	1.3	8.4	19.4	22.6	14.3	31.4	29.6	16.0	10.0	10.3	3.5	18.4	19.1	18.7	9.6	35.9	10.6	43.5	20.2	20.5	13.5	53.4	10.5	13.5	0.4	55.6	12.4	6.7	15.9	2.3	18.1	56.2	5.4	1.8	63.3	54.1	28.8	0.7	1.5	78.6	0.8	8.8	3.8	5.9	14.8	44.5	7.4	48.6	270.1	110.3	62.0	672.4	67.5	58.8	78.4	61.8	143.2	40.4	65.2	54.5	90.3	35.5	583.3	53.2	114.6	233.7	9.8	10.8	11.6	10.9	10.1	13.4	11.1	11.2	9.6	12.5	10.8	12.6	14.3	10.6	0.0	7.3	7.2	31.2	11.3	18.8	5.7	4.0	11.5	31.3	14.2	4.4	25.8	10.9	5.5	18.8	24.6	19.5	142.2	13.7	5.7	0.5	12.1	18.1	14.6	48.0	10.8	17.7	8.4	19.2	28.2	3.1	11.9	15.2	3.5	18.5	37.2	39.7	11.8	27.4	45.4	8.2	115.8	109.9	0.0	10.5	80.3	17.8	7.5	77.8	7.7	16.5	5.0	4.8	4.1	46.7	7.5	16.8	55.4	167.7	12.4	27.7	86.9	0.0	31.8	16.7	1.1	0.9	15.9	18.9	13.3	34.8	9.1	24.4	14.0
NEFH	"NF-H, NFH"	ENSG00000100285	"Neurofilament heavy"	P12036	22	29480218-29491390	"Disease related genes, Human disease related genes, Predicted intracellular proteins"			"Amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Disease variant, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"brain: 527.8;prostate: 248.1"	"Cell type enhanced"	"Detected in many"		"Inhibitory neurons: 20.9;monocytes: 34.6;Prostatic glandular cells: 44.0;Spermatogonia: 29.5;Theca cells: 49.7"	"Cancer enriched"	"Detected in many"	4	"prostate cancer: 130.0"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"non-classical monocyte: 4.7"	"Lineage enriched"	"Detected in single"	5	"monocytes: 4.7"	"Cell line enriched"	"Detected in many"	5	"SiHa: 182.2"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"spinal cord: 1241.2"	"CAB007786, HPA061615"	Enhanced					NA	NA					"CAB007786: AB_598179, HPA061615: AB_2684568"	"prognostic favorable (2.33e-6)"	"unprognostic (6.17e-3)"	"unprognostic (9.74e-2)"	"unprognostic (3.20e-2)"	"unprognostic (1.13e-1)"	"unprognostic (6.19e-3)"	"unprognostic (2.63e-4)"	"unprognostic (2.95e-2)"	"unprognostic (1.68e-1)"	"unprognostic (6.42e-2)"	"unprognostic (5.85e-2)"	"unprognostic (6.64e-3)"	"unprognostic (1.57e-3)"	"unprognostic (1.54e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.31e-2)"	"unprognostic (1.47e-1)"	0.6	21.2	69.2	1.6	20.1	0.6	1.5	141.1	527.8	0.5	0.0	1.2	0.4	0.5	0.7	0.3	0.5	0.4	0.3	25.7	67.9	1.0	0.3	0.4	0.9	352.2	78.4	2.2	20.1	0.3	0.9	15.5	0.6	388.6	248.1	0.5	40.0	0.9	0.6	0.3	0.2	0.9	1.0	59.1	1.2	0.6	7.8	169.3	0.7	0.3	0.3	1.1	0.4	1.2	443.8	0.0	0.0	2.4	0.6	0.1	0.3	1.8	3.2	0.0	0.0	0.0	0.0	0.0	0.1	0.8	1.9	9.5	0.1	0.0	0.0	0.0	9.0	34.2	0.1	24.2	0.0	1.4	0.2	10.5	3.5	0.0	0.5	0.0	0.0	1.3	0.0	28.0	0.0	11.7	0.0	12.0	1.2	17.4	0.0	0.0	0.1	0.1	1.9	0.0	0.0	1.5	19.5	182.2	0.1	0.0	5.9	0.0	9.9	25.2	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	1.0	0.0	0.4	2.7	0.8	0.1	0.5	0.4	0.6	0.0	0.1	0.5	0.0	0.2	4.7	0.1	0.2	0.6	69.2	20.1	141.1	527.8	25.7	67.9	352.2	78.4	2.2	388.6	59.1	169.3	443.8	0.7	0.0	0.0	3.9	1.0	0.1	1.0	0.1	2.2	3.2	1.4	5.3	0.9	1.5	0.0	1.8	2.1	1.4	1.6	0.5	0.0	0.2	0.4	0.3	7.7	1.0	0.0	5.9	13.6	0.4	1.1	2.4	0.0	0.8	1.3	8.8	0.0	0.0	5.6	8.4	20.9	0.0	0.0	4.2	2.3	1.0	5.9	5.2	1.8	5.6	34.6	3.6	0.0	2.0	2.6	0.3	0.0	3.0	1.7	44.0	0.2	1.0	0.0	9.9	6.6	1.3	2.0	4.4	29.5	3.0	0.1	0.4	1.7	49.7	0.2	0.7
NUDT11	"DIPP3b, FLJ10628, hDIPP3beta"	ENSG00000196368	"Nudix hydrolase 11"	Q96G61	X	51490011-51496592	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.3;testis: 36.5"	"Cell type enhanced"	"Detected in many"		"Basal keratinocytes: 15.3;Late spermatids: 17.1;Peritubular cells: 20.7;Spermatocytes: 14.6;Spermatogonia: 20.3"	"Group enriched"	"Detected in many"	4	"glioma: 12.1;prostate cancer: 10.6;testis cancer: 17.4"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"gdT-cell: 1.2"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HAP1: 69.3;NTERA-2: 42.9"					"Low region specificity"	"Detected in many"			"HPA047027, HPA057684"	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA047027: AB_2679907, HPA057684: AB_2683501"	"unprognostic (2.01e-1)"	"unprognostic (2.57e-1)"	"unprognostic (8.21e-2)"	"unprognostic (1.93e-3)"	"unprognostic (6.61e-2)"	"unprognostic (1.13e-3)"	"unprognostic (5.52e-3)"	"unprognostic (1.25e-1)"	"unprognostic (2.25e-2)"	"unprognostic (2.18e-1)"	"unprognostic (8.41e-2)"	"unprognostic (1.33e-1)"	"unprognostic (7.80e-12)"	"unprognostic (4.34e-4)"	"unprognostic (1.17e-2)"	"unprognostic (2.78e-1)"	"unprognostic (3.94e-4)"	1.0	4.6	11.8	0.9	16.3	1.4	2.2	6.5	13.7	4.0	4.4	2.3	1.1	5.2	3.5	1.3	2.0	1.6	0.3	14.5	25.3	0.5	0.1	0.5	0.6	8.7	9.4	14.8	9.0	4.9	0.2	4.3	0.0	8.8	9.2	0.8	2.2	0.7	10.5	0.1	1.2	1.0	4.4	6.5	0.3	1.1	36.5	20.1	2.7	0.6	0.5	0.6	1.9	2.4	10.7	0.0	1.0	20.6	0.0	17.5	22.0	0.1	9.8	2.7	0.5	0.5	0.0	0.0	0.0	0.5	11.9	11.4	1.5	69.3	23.9	0.3	0.0	4.7	0.0	0.0	0.0	8.2	0.0	4.6	13.5	9.3	6.2	22.4	3.9	16.4	21.6	0.1	0.0	19.6	0.5	27.6	0.1	42.9	0.0	17.5	0.0	14.4	0.0	4.3	0.0	0.0	13.4	4.2	0.0	4.0	10.2	0.0	0.1	9.6	4.8	22.4	1.4	0.0	9.0	4.5	15.2	3.1	0.0	1.9	0.0	0.0	0.0	1.2	0.0	0.5	0.1	0.3	0.6	0.1	0.1	0.0	0.9	0.0	0.7	0.1	0.0	0.0	0.3	11.8	16.3	6.5	13.7	14.5	25.3	8.7	9.4	14.8	8.8	6.5	20.1	10.7	0.4	0.0	0.0	0.3	0.3	15.3	6.4	12.8	12.0	1.6	0.5	3.9	0.6	0.0	1.6	0.0	0.0	0.3	3.5	0.0	0.0	0.2	11.3	0.5	9.0	0.9	0.0	1.3	6.3	1.5	1.0	7.7	0.0	0.3	0.0	3.4	0.4	0.0	0.1	0.0	3.8	0.0	0.0	0.3	3.8	17.1	8.7	0.6	5.4	2.8	0.0	1.4	3.1	4.0	0.6	1.4	0.0	20.7	0.3	10.4	0.0	0.2	0.2	0.2	0.0	3.0	5.3	14.6	20.3	1.6	9.1	0.3	0.8	7.5	0.0	1.3
PDE5A		ENSG00000138735	"Phosphodiesterase 5A"	O76074	4	119494397-119628804	"Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins"		"Allosteric enzyme, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 66.1;Inhibitory neurons: 58.3;Oligodendrocyte precursor cells: 56.8;Peritubular cells: 104.9;Smooth muscle cells: 80.9"	"Group enriched"	"Detected in all"	4	"prostate cancer: 7.0;thyroid cancer: 27.3"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 47.5;HHSteC: 65.9;hTERT-RPE1: 24.6"	"Region enhanced"	"Detected in all"		"cerebellum: 18.2"	"Low region specificity"	"Detected in all"			"HPA004729, HPA012873"	Approved		Approved	Cytosol		NA	NA		850000	Cytosol		"HPA004729: AB_1079588, HPA012873: AB_1855124"	"unprognostic (6.95e-2)"	"prognostic favorable (5.20e-4)"	"unprognostic (1.28e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.66e-2)"	"unprognostic (7.36e-2)"	"unprognostic (2.58e-2)"	"unprognostic (2.29e-2)"	"unprognostic (6.97e-2)"	"unprognostic (2.05e-2)"	"unprognostic (2.54e-1)"	"unprognostic (2.16e-2)"	"unprognostic (1.52e-2)"	"unprognostic (8.98e-2)"	"unprognostic (8.71e-3)"	"prognostic unfavorable (1.17e-4)"	14.2	11.4	1.1	11.0	3.4	2.1	9.7	5.0	4.3	33.0	13.1	27.6	15.6	14.6	41.9	41.7	23.1	10.5	12.9	1.6	2.3	5.9	1.6	22.3	6.4	4.9	8.2	1.3	5.4	12.5	8.4	3.6	13.3	5.5	60.3	26.2	9.6	9.9	50.2	7.0	4.3	19.0	11.5	0.1	5.8	9.7	9.5	3.3	3.7	17.0	5.7	3.5	14.8	15.9	2.2	16.7	0.8	11.0	1.2	3.7	5.5	1.9	10.7	47.5	0.5	1.0	1.0	1.3	1.6	0.5	13.4	3.0	5.8	3.5	1.7	1.3	0.4	7.4	18.5	2.6	0.9	65.9	3.9	1.7	6.1	3.3	1.1	0.1	24.6	1.4	3.7	2.0	2.9	1.6	0.9	5.0	0.6	2.3	1.8	2.8	0.7	5.9	4.3	4.1	4.9	4.3	8.8	13.0	15.3	1.3	8.1	2.7	2.1	2.5	6.2	5.2	3.4	1.5	4.1	2.0	1.5	5.9	1.0	0.9	0.0	0.0	0.0	0.1	0.0	0.5	0.4	0.3	0.1	0.0	0.3	0.1	0.2	0.4	0.2	0.1	0.1	0.1	1.2	1.1	3.4	5.0	4.3	1.6	2.3	4.9	8.2	1.3	5.5	0.1	3.3	2.2	7.8	6.4	3.9	19.9	1.3	3.4	2.8	1.1	5.7	8.1	11.0	8.4	5.5	14.3	3.7	1.8	14.6	0.4	0.9	15.5	0.0	15.8	30.6	5.0	12.6	7.8	2.4	0.0	66.1	2.9	0.3	28.1	1.1	3.9	1.3	1.6	0.7	0.9	0.3	5.0	58.3	9.5	2.0	0.0	3.5	11.5	20.8	11.3	5.4	40.3	1.3	28.5	2.1	56.8	41.1	3.9	10.3	104.9	1.4	3.6	7.9	0.5	0.8	5.8	19.7	5.5	80.9	5.4	6.3	3.5	2.4	0.3	1.7	7.0	11.1	2.6
PLA2G4D	cPLA2delta	ENSG00000159337	"Phospholipase A2 group IVD"	Q86XP0	15	42067009-42094562	"Enzymes, Metabolic proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"prostate: 19.3;skin 1: 16.1;vagina: 22.7"	"Cell type enhanced"	"Detected in some"		"Cone photoreceptor cells: 2.1;Glandular and luminal cells: 1.1;Ionocytes: 2.0;Prostatic glandular cells: 3.0;Rod photoreceptor cells: 1.0;Suprabasal keratinocytes: 3.4"	"Group enriched"	"Detected in some"	4	"cervical cancer: 1.1;head and neck cancer: 2.0;melanoma: 1.8;prostate cancer: 1.3;urothelial cancer: 0.6"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	13	"RPMI-8226: 15.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA074206			Approved	"Plasma membrane,Cytosol"		NA	NA			Cytosol	"Plasma membrane"	"HPA074206: "	"unprognostic (1.16e-1)"	"unprognostic (1.10e-2)"	"unprognostic (2.91e-2)"	"unprognostic (9.16e-3)"	"unprognostic (9.33e-3)"	"unprognostic (4.35e-2)"		"unprognostic (5.39e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.28e-2)"	"unprognostic (2.75e-1)"	"unprognostic (2.64e-7)"	"unprognostic (2.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.47e-2)"	"unprognostic (4.32e-2)"	0.0	0.2	0.1	0.0	0.1	0.0	0.3	0.0	0.3	2.5	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.7	0.0	0.0	19.3	0.0	0.2	0.8	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.4	22.7	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.0	0.0	15.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.5	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	2.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.0	0.1	0.1	0.0	1.0	0.0	0.0	0.1	0.0	0.4	0.0	3.4	0.0	0.0	0.0	0.1	0.4
PPFIA2		ENSG00000139220	"PTPRF interacting protein alpha 2"	O75334	12	81257975-81759553	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"brain: 55.5;retina: 50.5"	"Cell type enhanced"	"Detected in some"		"Excitatory neurons: 806.6;Inhibitory neurons: 641.1;Oligodendrocyte precursor cells: 609.7;Oligodendrocytes: 409.8;Rod photoreceptor cells: 195.9"	"Group enriched"	"Detected in some"	4	"glioma: 0.8;prostate cancer: 1.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 29.8;hTERT-RPE1: 5.0;SCLC-21H: 10.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.31e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.82e-2)"	"unprognostic (6.78e-5)"	"unprognostic (4.69e-3)"	"unprognostic (2.13e-1)"	"unprognostic (6.67e-2)"	"unprognostic (7.10e-2)"	"unprognostic (8.92e-2)"	"unprognostic (3.97e-2)"	"unprognostic (3.76e-1)"	"unprognostic (9.84e-2)"	"unprognostic (3.27e-3)"	"unprognostic (2.45e-2)"	"unprognostic (4.88e-2)"	"unprognostic (4.49e-3)"	"unprognostic (1.06e-3)"	1.5	5.8	24.6	0.3	26.8	0.0	1.1	0.4	50.3	3.9	0.0	1.1	0.3	2.3	0.6	0.6	2.6	1.7	0.5	55.5	12.8	0.8	0.2	0.8	0.1	6.5	9.4	27.4	1.1	0.5	0.1	4.6	0.0	6.6	1.4	1.4	50.5	0.5	3.2	0.3	0.7	0.7	2.1	1.5	0.2	0.9	6.2	6.6	0.1	0.9	0.1	0.1	1.3	2.2	21.1	0.0	0.0	2.7	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	29.8	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.7	0.0	0.1	0.0	1.4	0.0	10.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.7	0.0	2.0	0.0	0.0	0.0	0.9	0.0	0.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.6	26.8	0.4	50.3	55.5	12.8	6.5	9.4	27.4	6.6	1.5	6.6	21.1	0.6	0.0	1.1	136.8	0.0	0.4	0.0	0.0	0.0	107.8	0.0	0.9	0.6	0.0	0.0	0.0	89.6	0.0	0.0	0.1	1.9	0.0	140.3	0.7	16.0	0.7	16.3	0.0	806.6	0.0	0.0	2.3	0.0	0.4	0.0	0.1	0.0	0.0	0.1	48.8	641.1	0.2	0.0	0.0	0.5	61.5	0.0	0.0	0.0	11.2	0.0	12.6	0.0	609.7	409.8	0.0	0.0	16.6	0.0	0.3	0.0	0.1	0.0	195.9	0.0	2.4	8.6	6.5	2.4	0.0	0.6	0.1	0.0	0.2	0.0	0.1
PRKG2	"cGKII, PKG2, PRKGR2"	ENSG00000138669	"Protein kinase cGMP-dependent 2"	Q13237	4	81087370-81215117	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 13.2;prostate: 9.7"	"Cell type enhanced"	"Detected in some"		"Alveolar cells type 1: 35.3;Excitatory neurons: 32.6;Inhibitory neurons: 66.1;Oligodendrocyte precursor cells: 106.6;Proximal enterocytes: 19.7;Smooth muscle cells: 29.8"	"Group enriched"	"Detected in some"	4	"melanoma: 4.1;prostate cancer: 2.3"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 5.0;ASC TERT1: 3.8;HEL: 21.2;hTCEpi: 4.0;SCLC-21H: 6.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA007386, CAB018739"	Approved					NA	NA					"CAB018739: AB_2284387, HPA007386: AB_1079678"	"unprognostic (6.14e-2)"	"unprognostic (2.77e-1)"	"unprognostic (2.14e-1)"	"unprognostic (5.01e-4)"	"unprognostic (4.33e-2)"	"unprognostic (6.85e-2)"	"unprognostic (1.13e-1)"	"unprognostic (5.57e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.70e-2)"	"unprognostic (1.48e-1)"	"unprognostic (8.27e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.58e-1)"	"unprognostic (4.00e-3)"	"unprognostic (1.06e-1)"	0.6	0.2	2.2	0.2	1.6	0.5	1.6	0.6	1.9	1.0	0.2	2.4	9.7	0.4	0.3	2.8	0.4	0.2	4.3	1.6	1.5	0.5	0.0	3.4	0.2	3.1	2.6	1.6	0.0	1.4	0.0	2.2	0.0	4.1	9.7	2.9	0.3	0.3	3.4	0.0	1.1	13.2	0.5	1.3	0.0	1.0	0.9	4.5	1.0	0.9	0.0	0.4	0.5	0.6	3.8	0.1	0.3	0.1	0.0	5.0	3.8	0.0	0.3	0.0	0.0	0.0	0.4	2.4	0.0	0.2	0.9	0.0	0.1	0.3	1.5	0.0	0.4	0.0	21.2	0.6	0.1	0.0	0.0	0.0	0.5	4.0	0.0	0.0	1.0	0.0	0.6	0.0	0.6	0.0	0.0	0.0	0.1	0.9	0.6	0.4	0.0	0.0	0.1	0.0	0.9	6.3	0.0	0.0	0.2	0.0	0.3	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	2.2	1.6	0.6	1.9	1.6	1.5	3.1	2.6	1.6	4.1	1.3	4.5	3.8	0.3	35.3	2.6	1.0	0.3	0.0	0.9	0.1	1.2	0.0	0.3	0.1	4.9	0.0	2.0	0.0	0.0	0.0	0.1	5.5	0.0	0.2	10.3	0.3	0.6	0.1	0.0	8.0	32.6	0.0	0.1	2.5	0.0	0.1	1.3	0.1	0.0	0.0	0.1	0.0	66.1	1.7	0.0	0.0	0.0	2.2	0.0	0.1	0.0	12.2	0.1	0.0	0.0	106.6	1.1	0.9	9.2	0.0	0.5	0.8	19.7	0.2	0.8	0.0	0.0	0.1	29.8	0.0	1.3	0.8	0.1	0.0	0.4	0.0	0.7	0.3
SLC39A6	LIV-1	ENSG00000141424	"Solute carrier family 39 member 6"	Q13433	18	36108531-36129385	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport, Zinc transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"Breast glandular cells: 307.0;Prostatic glandular cells: 197.9"	"Group enriched"	"Detected in all"	4	"breast cancer: 361.9;prostate cancer: 127.3"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042377	Approved		Uncertain	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Plasma membrane"	"HPA042377: AB_2677968"	"unprognostic (7.60e-2)"	"unprognostic (2.27e-2)"	"unprognostic (5.50e-3)"	"unprognostic (2.58e-3)"	"unprognostic (1.02e-1)"	"unprognostic (4.87e-3)"	"prognostic unfavorable (5.33e-4)"	"unprognostic (1.79e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.19e-1)"	"unprognostic (4.50e-2)"	"unprognostic (7.63e-3)"	"unprognostic (2.16e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.30e-1)"	27.5	26.1	23.0	21.8	27.1	11.7	148.7	27.7	26.3	34.8	43.1	12.7	9.7	57.5	56.7	17.1	64.1	24.4	14.1	20.8	27.1	28.5	16.6	19.1	17.5	28.5	26.8	19.6	43.5	38.0	87.2	24.1	31.9	30.1	130.2	13.5	50.6	31.2	115.4	12.8	51.8	8.9	30.4	28.7	15.6	16.6	19.5	28.4	18.7	37.6	16.7	28.6	53.1	16.2	34.2	43.7	54.0	127.1	75.1	131.4	96.6	33.0	116.2	137.3	76.5	88.7	30.3	47.5	47.1	57.3	113.1	53.1	104.1	112.4	109.2	115.5	105.4	40.7	20.6	69.5	44.4	83.2	69.8	49.6	88.7	236.1	116.2	100.5	69.9	11.7	38.6	10.7	92.1	108.9	67.0	69.0	15.6	30.6	24.0	30.4	70.6	72.8	61.4	84.4	145.2	132.8	116.8	143.5	41.5	200.6	52.1	56.7	32.4	18.9	184.9	30.5	35.5	59.2	85.9	90.0	35.7	64.0	48.3	99.8	29.2	13.3	31.2	16.3	19.7	19.7	16.7	13.8	14.7	16.4	17.3	12.0	17.7	10.2	18.1	19.4	33.6	17.0	14.2	23.0	27.1	27.7	26.3	20.8	27.1	28.5	26.8	19.6	30.1	28.7	28.4	34.2	13.3	38.5	18.7	8.8	22.5	45.9	58.2	79.6	59.2	41.5	307.0	132.2	19.6	10.0	66.4	42.3	33.3	6.6	36.7	4.0	1.9	53.1	21.3	37.1	76.1	12.9	25.6	4.6	13.0	37.8	56.7	45.6	9.2	73.8	23.5	18.9	8.9	11.0	20.4	23.5	23.9	7.4	38.7	20.1	30.0	18.1	37.3	26.0	67.6	1.9	25.7	38.2	10.3	34.2	36.5	39.5	1.9	47.8	24.4	197.9	2.7	13.6	44.3	41.3	39.5	40.4	38.6	43.9	27.8	32.6	74.4	23.8	23.2	23.0	5.7	69.3
SORD		ENSG00000140263	"Sorbitol dehydrogenase"	Q00796	15	45023147-45077185	"Disease related genes, Enzymes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		Oxidoreductase	"Disease variant, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"cervix: 165.2;liver: 249.0"	"Cell type enhanced"	"Detected in many"		"Exocrine glandular cells: 138.7;Hepatocytes: 649.4;Prostatic glandular cells: 218.8;Proximal tubular cells: 270.2"	"Group enriched"	"Detected in all"	4	"liver cancer: 30.3;prostate cancer: 72.5;thyroid cancer: 30.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	10	"basophil: 86.3;eosinophil: 55.9"	"Lineage enriched"	"Detected in all"	12	"granulocytes: 86.3"	"Cell line enhanced"	"Detected in many"		"SK-BR-3: 57.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA040260, HPA040621"	Enhanced		Approved	Cytosol		NA	NA		2800000	Cytosol		"HPA040260: AB_10794872, HPA040621: AB_10795384"	"unprognostic (8.18e-2)"	"unprognostic (7.58e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.51e-1)"	"unprognostic (5.69e-3)"	"unprognostic (3.90e-2)"	"prognostic favorable (6.14e-5)"	"unprognostic (3.33e-3)"	"unprognostic (1.67e-1)"	"unprognostic (4.95e-2)"	"unprognostic (7.04e-3)"	"unprognostic (1.40e-1)"	"unprognostic (4.26e-2)"	"unprognostic (1.23e-2)"	"unprognostic (8.53e-2)"	"unprognostic (2.31e-2)"	"unprognostic (1.56e-1)"	1.9	15.9	4.9	3.1	3.7	2.9	54.3	8.3	8.5	165.2	1.7	5.4	7.6	4.3	6.9	10.3	6.8	8.3	5.7	5.0	3.4	50.8	249.0	3.2	2.6	4.5	3.7	2.9	2.4	5.7	4.5	3.2	2.5	4.3	88.6	7.8	4.9	5.4	27.3	2.2	16.7	7.3	3.5	3.9	2.4	9.3	12.3	3.8	3.8	90.2	2.8	3.5	9.2	7.0	6.1	12.3	12.2	4.7	20.8	4.4	5.3	5.9	1.8	3.5	12.2	7.0	12.2	5.8	2.7	8.0	5.4	4.1	17.6	19.9	19.1	9.2	29.9	12.3	13.5	12.1	50.3	0.2	18.0	25.5	6.7	18.0	6.6	9.5	5.4	12.5	15.1	11.7	10.6	14.9	8.1	18.4	38.3	39.0	29.4	13.8	0.9	16.6	6.4	16.8	12.1	25.1	12.2	2.1	57.3	5.9	5.2	16.4	22.5	4.7	3.5	38.0	1.6	5.8	8.7	4.5	4.4	14.2	18.6	10.6	86.3	1.7	55.9	1.6	1.5	1.7	5.4	1.3	1.6	1.7	6.9	1.6	1.4	3.8	1.1	2.1	2.4	2.5	2.0	4.9	3.7	8.3	8.5	5.0	3.4	4.5	3.7	2.9	4.3	3.9	3.8	6.1	3.9	0.0	3.1	5.5	11.9	7.8	26.5	14.8	17.6	10.8	24.7	17.5	3.2	25.8	28.1	33.1	0.0	1.3	2.3	15.0	29.4	68.2	31.7	40.2	17.4	4.9	84.8	37.5	4.8	138.7	5.1	7.5	31.1	43.7	8.8	11.5	15.7	649.4	16.0	3.3	5.4	32.5	22.4	24.2	6.4	24.1	3.7	12.2	16.0	1.0	13.3	9.0	2.1	7.1	8.9	89.0	18.1	6.0	7.9	218.8	8.0	270.2	42.5	4.7	0.0	8.9	8.9	7.4	2.8	35.1	20.3	1.0	6.5	15.3	39.4	131.2
SRARP	"C1orf64, ERRF, MGC24047"	ENSG00000183888	"Steroid receptor associated and regulated protein"	Q8NEQ6	1	16004236-16008807	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 11.4;breast: 5.2;choroid plexus: 5.5"	"Group enriched"	"Detected in some"	4	"Breast glandular cells: 25.0;Distal tubular cells: 90.1"	"Group enriched"	"Detected in some"	4	"breast cancer: 7.7;endometrial cancer: 2.2;prostate cancer: 6.5"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"neutrophil: 1.8"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.8"	"Group enriched"	"Detected in some"	13	"Hep G2: 7.9;SK-BR-3: 13.6;T-47d: 4.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA026676	Uncertain		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA026676: AB_1853866"	"unprognostic (8.55e-2)"	"unprognostic (1.01e-1)"		"prognostic favorable (1.68e-6)"	"unprognostic (3.32e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.41e-2)"		"unprognostic (3.49e-1)"		"unprognostic (8.25e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.53e-1)"	"unprognostic (1.65e-3)"	"unprognostic (6.32e-2)"	0.1	0.2	10.3	0.2	8.2	0.7	5.2	7.9	11.4	2.3	5.5	0.1	0.2	1.2	0.1	0.2	0.1	0.2	0.5	7.8	8.2	1.5	0.1	0.1	0.3	8.8	8.5	6.5	0.2	0.2	0.0	0.0	0.1	8.9	0.7	0.0	0.8	3.1	0.0	0.2	0.6	0.1	0.0	7.5	0.2	0.3	0.2	9.5	0.0	1.2	0.0	0.0	0.1	0.0	9.5	0.3	0.1	0.3	0.4	0.0	0.1	0.1	0.4	0.0	0.0	0.0	0.0	0.3	0.4	0.2	0.0	0.3	0.2	0.0	0.0	0.0	0.2	0.1	0.4	0.6	7.9	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	0.0	0.4	0.6	0.5	0.0	0.4	0.3	0.3	0.1	0.1	0.2	0.2	0.3	0.2	0.0	0.1	0.4	0.6	0.3	13.6	0.2	0.4	4.3	0.4	0.2	0.4	0.3	0.3	0.1	0.2	0.5	0.2	0.2	0.2	0.6	0.8	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.2	0.2	0.2	1.8	0.3	0.1	0.1	0.0	0.0	10.3	8.2	7.9	11.4	7.8	8.2	8.8	8.5	6.5	8.9	7.5	9.5	9.5	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	25.0	11.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	90.1	0.0	0.0	1.3	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
TMEM178A	"MGC33926, TMEM178"	ENSG00000152154	"Transmembrane protein 178A"	Q8NBL3	2	39664982-39717963	"Predicted intracellular proteins, Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 143.7;choroid plexus: 48.1"	"Cell type enhanced"	"Detected in many"		"Breast myoepithelial cells: 32.4;Excitatory neurons: 109.1;Inhibitory neurons: 109.2;Oligodendrocyte precursor cells: 33.7"	"Group enriched"	"Detected in many"	4	"endometrial cancer: 10.2;glioma: 13.2;prostate cancer: 19.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"AF22: 138.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA052128	Uncertain		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA052128: AB_2681738"	"unprognostic (3.35e-2)"	"unprognostic (3.18e-1)"	"unprognostic (5.94e-2)"	"unprognostic (2.86e-1)"	"unprognostic (1.04e-1)"	"unprognostic (5.85e-2)"	"unprognostic (3.24e-3)"	"unprognostic (1.82e-3)"	"unprognostic (2.22e-1)"	"unprognostic (9.74e-2)"	"unprognostic (5.11e-4)"	"unprognostic (1.13e-1)"	"unprognostic (6.01e-3)"	"unprognostic (2.80e-3)"	"unprognostic (3.46e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.01e-3)"	5.1	7.7	67.5	0.6	79.4	0.2	6.3	143.7	91.3	4.0	48.1	7.1	2.0	3.6	1.5	1.8	6.4	2.8	4.2	81.0	62.2	42.6	10.0	6.7	0.5	74.6	68.0	75.3	5.9	4.6	2.3	13.0	3.2	88.1	11.7	1.7	15.8	22.1	1.6	2.8	3.2	3.3	2.4	79.0	2.6	8.7	2.2	64.0	0.5	12.4	1.9	0.5	3.9	3.1	119.0	0.0	0.0	138.7	0.1	0.1	3.3	0.2	0.6	0.1	0.0	0.3	0.0	0.3	0.0	3.7	0.0	0.0	0.3	4.5	0.0	0.5	0.3	0.1	0.0	0.0	0.4	1.1	0.1	0.0	2.6	0.3	0.0	0.4	4.3	0.0	0.0	0.0	0.3	0.4	0.0	0.1	0.2	17.7	0.2	0.1	1.7	0.0	0.0	1.0	0.2	25.7	0.6	0.0	0.6	0.3	23.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.5	79.4	143.7	91.3	81.0	62.2	74.6	68.0	75.3	88.1	79.0	64.0	119.0	3.2	0.0	2.0	14.7	0.0	0.4	0.5	0.6	1.8	9.1	1.1	32.4	3.9	0.0	1.3	12.9	6.2	0.3	0.1	0.8	0.0	0.2	0.4	3.0	1.2	4.3	16.1	0.0	109.1	0.2	0.0	2.6	0.0	6.5	0.0	1.4	0.7	0.5	0.2	1.7	109.2	0.4	2.0	0.0	0.4	0.1	0.0	0.2	1.8	7.5	0.0	1.1	0.0	33.7	19.3	0.4	0.3	0.0	0.0	3.7	0.5	0.7	4.3	6.1	0.0	0.9	0.6	0.2	0.5	0.1	0.6	0.5	0.1	0.5	0.4	0.3
TMEM26	"Em:AC068892.1, MGC35010"	ENSG00000196932	"Transmembrane protein 26"	Q6ZUK4	10	61406642-61453381	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 8.9"	"Cell type enhanced"	"Detected in some"		"Breast glandular cells: 8.2;Endometrial stromal cells: 5.4;Excitatory neurons: 5.3;Hepatic stellate cells: 4.6;Inhibitory neurons: 4.8;Kupffer cells: 12.2;Late spermatids: 5.6;Theca cells: 15.0"	"Group enriched"	"Detected in some"	4	"breast cancer: 2.5;endometrial cancer: 1.0;prostate cancer: 1.8;renal cancer: 0.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 4.7;fHDF/TERT166: 1.1;HSkMC: 2.0;HUVEC TERT2: 1.5;MOLT-4: 2.3"	"Region enhanced"	"Detected in some"		"hypothalamus: 2.3"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.21e-3)"	"unprognostic (2.84e-1)"	"unprognostic (7.34e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.38e-3)"	"unprognostic (1.30e-1)"	"unprognostic (7.56e-2)"	"unprognostic (3.69e-2)"	"unprognostic (3.13e-1)"	"unprognostic (9.41e-2)"	"unprognostic (5.38e-2)"	"unprognostic (5.24e-2)"	"unprognostic (2.29e-5)"	"unprognostic (2.55e-2)"	"unprognostic (1.51e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.95e-1)"	0.4	0.5	1.3	0.9	1.6	0.1	5.3	0.3	1.0	2.3	0.2	0.7	1.4	4.0	0.1	0.6	0.4	1.0	0.1	1.1	0.7	2.2	2.5	1.4	0.7	1.8	1.0	0.9	0.5	0.0	1.4	0.2	1.5	0.6	2.6	0.9	0.0	0.0	2.4	0.8	0.0	0.8	2.0	0.3	8.9	0.2	3.7	1.2	2.1	0.4	0.2	0.2	0.7	0.5	0.8	0.0	0.0	0.1	0.0	0.1	0.8	0.1	0.0	4.7	0.4	0.6	0.0	0.0	0.0	0.0	1.1	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	2.0	0.0	0.5	0.0	0.5	1.5	0.5	0.0	0.0	0.1	0.0	2.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.6	0.3	1.0	1.1	0.7	1.8	1.0	0.9	0.6	0.3	1.2	0.8	1.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	8.2	2.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.8	0.7	5.4	1.7	0.0	0.0	5.3	0.0	0.0	1.4	0.0	1.6	0.0	0.1	4.6	0.2	0.3	0.0	4.8	0.0	0.0	12.2	0.0	5.6	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.0	0.2	0.0	1.7	0.0	0.0	0.0	0.1	1.2	0.5	0.2	0.0	0.1	0.0	0.1	15.0	0.0	0.0
TMSB15A	"TMSL8, TMSNB"	ENSG00000158164	"Thymosin beta 15A"	P0CG34	X	102513682-102516739	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 13.1;prostate: 15.9"	"Cell type enhanced"	"Detected in some"		"Breast myoepithelial cells: 12.8;Granulosa cells: 25.9;Prostatic glandular cells: 13.8;Smooth muscle cells: 13.5;Spermatogonia: 19.8"	"Group enriched"	"Detected in many"	4	"glioma: 20.1;prostate cancer: 56.4;testis cancer: 14.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 571.5;HAP1: 110.2;MOLT-4: 113.4;NTERA-2: 148.0;RH-30: 259.9;SH-SY5Y: 148.1"					"Low region specificity"	"Detected in all"									NA	NA		130000				"unprognostic (5.33e-3)"	"unprognostic (3.09e-2)"	"unprognostic (1.70e-2)"	"unprognostic (5.82e-3)"	"unprognostic (1.34e-1)"	"unprognostic (4.03e-2)"	"unprognostic (5.65e-2)"	"unprognostic (1.34e-1)"	"unprognostic (6.88e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.53e-1)"	"unprognostic (3.18e-3)"	"unprognostic (2.96e-4)"	"unprognostic (2.14e-1)"	"unprognostic (7.83e-2)"	"unprognostic (2.07e-1)"	1.0	1.0	1.0	1.1	1.2	1.0	5.1	1.7	2.1	4.7	1.2	1.0	0.4	5.1	0.7	0.3	1.9	1.2	1.3	1.1	1.2	2.4	0.2	7.1	4.1	1.2	1.1	1.1	4.8	0.9	0.8	0.8	0.5	1.3	15.9	1.1	1.4	4.0	1.3	0.3	0.5	0.6	2.4	1.0	0.4	0.5	4.8	1.1	13.1	6.0	0.3	2.8	0.7	2.3	1.4	0.1	0.0	571.5	107.7	2.4	0.3	0.2	12.4	0.7	1.7	4.8	0.0	0.7	0.0	1.3	2.1	28.5	0.0	110.2	0.7	1.2	0.0	5.6	10.3	1.7	0.3	0.3	0.2	10.1	1.4	0.0	1.1	0.0	14.3	6.7	5.5	1.0	0.0	41.2	0.1	113.4	0.2	148.0	0.0	1.4	0.2	259.9	0.0	11.7	0.2	98.1	148.1	14.0	0.9	0.3	22.0	1.4	3.2	2.4	0.3	62.6	1.4	10.5	11.8	2.1	0.0	6.7	0.0	25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.1	1.0	1.2	1.7	2.1	1.1	1.2	1.2	1.1	1.1	1.3	1.0	1.1	1.4	1.4	0.0	0.0	0.0	0.0	0.8	0.9	0.1	1.8	0.3	7.3	12.8	0.1	0.0	0.0	0.0	0.0	0.5	0.5	0.5	0.0	0.5	0.3	0.5	5.6	1.2	0.0	0.8	0.0	0.0	0.5	4.6	0.0	1.2	0.0	25.9	2.5	0.0	0.5	0.0	0.0	0.6	0.0	0.6	0.5	0.1	0.3	0.1	1.8	0.0	0.0	0.7	1.0	0.5	0.0	0.0	0.1	2.6	0.3	13.8	0.1	0.4	0.0	0.1	6.6	1.2	13.5	3.4	19.8	1.8	0.0	0.3	0.7	0.9	0.9	1.0
TRPM4	FLJ20041	ENSG00000130529	"Transient receptor potential cation channel subfamily M member 4"	Q8TD43	19	49157741-49211836	"Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Adaptive immunity, Immunity, Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"Disease variant, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 179.2;Hepatocytes: 81.7;Intestinal goblet cells: 114.8;Paneth cells: 77.1;Undifferentiated cells: 88.9"	"Cancer enriched"	"Detected in all"	4	"prostate cancer: 85.3"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"dendritic cells: 3.3;granulocytes: 2.8;monocytes: 4.3"	"Cell line enhanced"	"Detected in many"		"OE19: 32.7;RT4: 60.8;SK-BR-3: 38.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA041169	Enhanced		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA041169: AB_2677343"	"unprognostic (8.20e-3)"	"unprognostic (1.41e-1)"	"unprognostic (7.86e-2)"	"prognostic favorable (2.88e-7)"	"unprognostic (1.62e-2)"	"unprognostic (9.78e-2)"	"unprognostic (1.77e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.33e-2)"	"unprognostic (3.38e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.79e-1)"	"prognostic favorable (2.53e-7)"	"unprognostic (8.46e-3)"	"unprognostic (2.16e-1)"	"unprognostic (5.70e-2)"	"unprognostic (1.00e-2)"	10.3	6.1	7.5	6.1	5.9	4.6	13.6	8.3	7.0	11.2	5.2	30.1	25.5	10.0	2.6	13.2	9.3	7.5	22.5	6.7	4.8	22.8	15.5	16.2	1.8	6.3	5.6	5.5	3.3	10.2	3.8	5.6	5.3	7.0	36.0	13.0	1.3	27.5	6.2	14.2	25.8	23.1	3.5	3.9	5.6	20.7	5.4	8.3	1.0	17.4	5.3	2.0	13.8	14.5	10.1	11.9	9.0	2.1	9.5	7.7	6.6	6.6	10.0	6.0	2.7	3.7	6.1	18.7	0.4	2.7	6.8	3.6	15.7	1.3	3.0	1.0	0.2	3.4	1.9	4.0	3.7	6.6	0.3	11.7	9.3	13.6	5.3	2.6	3.3	4.6	1.0	4.9	2.1	6.9	17.4	0.8	0.9	1.0	32.7	13.3	4.1	2.0	0.6	4.6	60.8	0.8	2.2	4.1	38.6	2.2	0.7	22.6	3.7	11.8	14.4	7.8	7.9	0.2	3.9	4.3	0.4	7.9	7.4	5.3	2.2	4.3	0.7	0.3	2.5	0.2	0.5	0.2	0.2	3.3	0.5	0.3	0.3	2.8	0.5	1.0	3.1	0.2	1.4	7.5	5.9	8.3	7.0	6.7	4.8	6.3	5.6	5.5	7.0	3.9	8.3	10.1	12.8	32.1	2.6	9.8	3.5	12.5	15.3	9.9	9.1	2.0	19.0	14.6	16.7	17.2	12.3	14.7	0.0	6.6	0.2	179.2	19.6	7.9	2.9	17.5	8.2	11.7	21.7	0.0	5.4	18.5	6.8	6.0	71.4	36.2	5.7	2.9	11.4	81.7	19.9	0.0	8.5	114.8	14.2	9.8	19.0	3.1	6.8	8.5	39.2	9.4	12.8	6.7	0.0	3.5	0.9	32.9	77.1	7.2	7.6	35.5	55.3	3.8	8.9	2.6	32.9	2.2	8.5	6.1	15.7	8.4	11.5	3.4	1.9	4.1	88.9	33.1
ZNF350	"ZBRK1, ZFQR"	ENSG00000256683	"Zinc finger protein 350"	Q9GZX5	19	51964340-51986856	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Cancer enriched"	"Detected in all"	4	"prostate cancer: 16.2"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in many"			HPA001521	Uncertain		Supported	"Nucleoplasm,Nuclear bodies"		NA	NA			Nucleoplasm	"Nuclear bodies"	"HPA001521: AB_1080705"	"unprognostic (7.26e-3)"	"unprognostic (4.02e-2)"	"unprognostic (2.51e-2)"	"unprognostic (5.84e-2)"	"unprognostic (1.03e-2)"	"unprognostic (4.17e-2)"	"unprognostic (7.08e-2)"	"unprognostic (6.64e-2)"	"unprognostic (2.08e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.76e-1)"	"unprognostic (3.25e-3)"	"unprognostic (6.64e-3)"	"unprognostic (1.19e-2)"	"unprognostic (3.16e-1)"	"unprognostic (8.30e-2)"	"prognostic favorable (2.54e-4)"	5.9	4.5	5.9	5.5	7.2	26.5	13.9	8.8	6.8	5.5	4.3	6.6	5.5	6.4	8.3	4.7	5.8	5.2	5.0	6.4	6.3	7.1	5.4	6.3	9.7	6.0	5.7	5.8	8.4	4.5	9.3	4.9	9.3	6.2	27.7	9.2	9.8	6.5	6.4	4.5	7.5	6.1	5.8	5.8	9.1	7.3	6.4	6.3	9.1	9.9	5.9	9.2	6.3	5.2	7.3	0.8	4.4	5.6	6.8	7.5	6.7	1.1	4.6	6.5	4.8	9.5	0.0	3.5	2.1	3.6	5.5	8.8	5.8	4.9	6.5	6.6	0.0	10.5	8.6	7.5	3.9	6.3	2.2	10.1	9.5	9.9	6.4	6.6	9.4	5.5	3.5	2.3	0.1	5.8	2.8	8.5	10.2	3.7	0.5	6.8	4.0	8.0	6.9	7.6	11.9	4.7	6.3	0.0	6.0	5.0	7.9	9.8	7.7	5.9	5.2	3.7	3.1	4.7	1.6	2.8	2.7	1.0	0.1	5.6	65.3	11.2	26.9	16.2	12.7	16.4	16.8	15.3	15.6	13.6	17.2	17.7	14.2	30.8	21.5	16.2	8.8	13.4	8.1	5.9	7.2	8.8	6.8	6.4	6.3	6.0	5.7	5.8	6.2	5.8	6.3	7.3	9.1	0.0	7.3	4.6	13.1	5.9	11.0	11.1	5.7	9.9	6.0	5.3	6.6	2.8	10.7	9.2	12.5	12.2	12.9	5.1	7.9	6.7	13.0	4.5	4.7	8.0	7.3	2.5	4.2	5.3	9.9	7.1	3.6	6.7	12.0	9.7	6.4	3.1	7.8	6.7	4.1	5.9	16.2	9.5	12.0	3.4	11.1	10.8	12.4	6.5	11.6	7.9	23.7	4.0	9.1	6.0	5.7	6.0	7.5	14.5	7.6	3.9	7.8	13.1	0.0	7.2	8.4	10.2	5.7	3.5	7.0	23.1	15.1	6.8	3.8	13.4
ZNF615	FLJ33710	ENSG00000197619	"Zinc finger protein 615"	Q8N8J6	19	51991332-52008230	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Cancer enriched"	"Detected in all"	4	"prostate cancer: 11.4"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA052422	Uncertain		Approved	Nucleoli,Mitochondria		NA	NA			Mitochondria	Nucleoli	"HPA052422: AB_2681825"	"unprognostic (2.20e-1)"	"unprognostic (4.66e-2)"	"unprognostic (4.56e-1)"	"unprognostic (2.64e-1)"	"unprognostic (4.08e-3)"	"unprognostic (7.28e-2)"	"unprognostic (5.23e-2)"	"unprognostic (3.68e-1)"	"unprognostic (4.44e-3)"	"unprognostic (2.44e-2)"	"unprognostic (4.41e-2)"	"unprognostic (4.80e-2)"	"unprognostic (1.77e-1)"	"unprognostic (8.16e-3)"	"unprognostic (3.03e-1)"	"unprognostic (1.82e-1)"	"prognostic favorable (2.98e-4)"	5.3	3.7	3.7	3.0	6.0	5.7	6.7	9.4	5.4	4.9	4.0	4.2	3.5	7.9	4.8	4.2	6.5	5.1	6.0	4.6	3.7	6.1	3.9	5.2	4.4	3.9	4.2	4.4	10.2	3.8	10.2	4.6	5.7	4.5	17.7	3.7	9.9	5.5	6.4	3.8	4.7	3.2	6.6	1.6	5.3	4.2	3.7	4.2	4.8	7.7	6.8	4.3	4.2	3.5	8.5	1.5	6.2	5.8	12.4	11.2	8.1	4.7	4.5	6.9	6.4	5.7	1.2	1.7	2.2	2.4	5.0	3.9	1.5	4.7	3.1	5.2	0.3	10.0	7.5	5.6	4.3	8.6	0.0	4.1	6.8	3.7	10.2	10.2	10.6	3.0	2.7	0.0	0.0	4.3	0.5	0.0	3.8	6.1	0.2	9.6	4.7	10.2	4.0	3.9	10.3	5.4	4.7	5.4	4.7	3.2	6.3	7.1	3.4	5.9	5.4	6.2	3.3	3.3	4.3	12.3	2.8	3.0	0.0	8.7	5.8	2.2	4.2	2.5	3.2	5.3	2.8	4.5	3.6	3.3	2.9	4.3	3.1	2.5	8.2	2.0	2.0	4.2	2.9	3.7	6.0	9.4	5.4	4.6	3.7	3.9	4.2	4.4	4.5	1.6	4.2	8.5	5.1	6.4	7.2	7.5	4.5	2.8	2.1	1.0	1.8	6.4	4.4	3.4	6.9	5.7	1.4	3.7	6.2	4.1	5.9	2.4	3.9	2.2	2.6	2.3	4.4	3.5	9.0	2.1	10.2	1.2	2.9	5.3	2.0	2.4	0.0	6.2	4.2	2.1	3.0	3.3	7.8	2.7	2.0	3.5	3.6	1.0	2.5	4.1	7.2	5.6	3.8	3.2	7.2	8.0	12.0	1.2	3.9	4.1	3.4	4.3	2.2	3.1	3.1	7.0	6.6	5.2	6.7	3.8	2.2	2.6	4.0	5.1	3.9	2.8	2.8	2.0
ACTG2	"ACTA3, ACTL3, ACTSG"	ENSG00000163017	"Actin gamma 2, smooth muscle"	P63267	2	73892314-73919865	"Disease related genes, Human disease related genes, Predicted intracellular proteins"		"Muscle protein"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 6240.2;seminal vesicle: 6298.2;smooth muscle: 8688.4"	"Group enriched"	"Detected in many"	4	"Breast myoepithelial cells: 394.2;Smooth muscle cells: 287.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 255.0;stomach cancer: 237.2"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	11	"T-reg: 8.6"	"Lineage enriched"	"Detected in single"	17	"T-cells: 8.6"	"Cell line enhanced"	"Detected in many"		"BEWO: 63.8;BJ hTERT+: 53.5;BJ hTERT+ SV40 Large T+: 214.8;HHSteC: 55.1;SuSa: 52.5;U-251 MG: 229.9"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	4	"midbrain: 11.8;spinal cord: 4.7"	"HPA041264, HPA041271"	Supported					NA	NA					"HPA041264: AB_2677383, HPA041271: AB_2677386"	"unprognostic (5.79e-3)"	"unprognostic (2.25e-1)"	"unprognostic (2.36e-2)"	"unprognostic (2.91e-1)"	"unprognostic (4.56e-3)"	"unprognostic (2.50e-1)"	"unprognostic (8.05e-2)"	"unprognostic (6.53e-2)"	"unprognostic (4.48e-2)"	"unprognostic (2.93e-1)"	"unprognostic (7.23e-2)"	"unprognostic (4.75e-2)"	"prognostic unfavorable (3.95e-7)"	"unprognostic (9.30e-3)"	"unprognostic (6.84e-2)"	"unprognostic (2.29e-2)"	"unprognostic (7.57e-3)"	191.4	37.5	2.5	731.4	3.1	0.0	139.7	2.4	8.9	448.4	12.1	6240.2	395.6	3653.5	125.6	1973.1	864.9	333.3	24.2	2.5	2.6	6.8	10.9	138.8	6.8	4.1	2.9	2.5	89.3	8.2	0.9	6.2	97.2	2.7	2269.1	1189.8	0.0	75.8	6298.2	16.5	78.7	1365.4	8688.4	2.5	16.7	2117.5	4.9	2.6	2.8	34.0	7.0	1.2	2939.0	673.0	2.8	0.7	0.3	20.5	0.3	0.0	0.0	63.8	13.5	53.5	214.8	38.6	6.7	0.0	0.3	0.9	0.0	0.4	0.1	36.9	0.0	28.3	0.1	0.0	0.0	2.9	0.5	55.1	0.2	0.6	0.5	0.3	29.0	0.0	1.5	0.0	0.2	0.0	0.0	0.5	0.0	2.9	7.9	0.2	0.0	0.1	0.2	0.4	3.1	0.5	13.6	0.6	2.3	0.3	2.8	1.2	52.5	0.0	0.3	0.0	1.1	2.3	2.5	229.9	0.1	0.3	0.8	0.7	1.0	0.9	0.2	0.5	0.3	0.2	0.3	0.1	0.1	0.8	0.3	0.4	0.1	0.4	0.5	0.1	0.2	0.4	0.1	8.6	2.4	2.5	3.1	2.4	8.9	2.5	2.6	4.1	2.9	2.5	2.7	2.5	2.6	2.8	3.5	0.0	0.5	0.0	0.4	4.5	2.7	0.5	0.6	0.0	9.8	394.2	14.6	0.0	0.1	0.0	0.0	7.4	0.7	0.0	0.0	0.0	5.8	2.8	1.5	3.1	0.0	0.0	0.1	0.0	36.8	74.1	0.0	4.8	0.0	1.0	22.9	0.3	5.4	0.0	0.1	0.0	0.0	0.0	10.4	26.6	0.3	1.0	7.2	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.1	0.0	10.8	0.0	0.4	0.8	0.0	6.6	1.8	287.8	0.2	3.2	0.4	7.7	6.4	1.7	8.4	0.0	3.7
ADAMTSL1	"ADAMTSR1, C9orf94, FLJ35283"	ENSG00000178031	"ADAMTS like 1"	Q8N6G6	9	17906563-18910950	"Predicted intracellular proteins, Predicted secreted proteins"		Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 13.4"	"Cell type enriched"	"Detected in some"	6	"Excitatory neurons: 245.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 2.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 118.3;HSkMC: 61.2;hTEC/SVTERT24-B: 64.3;hTERT-RPE1: 55.8;LHCN-M2: 64.3;TIME: 207.9;U-138 MG: 96.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA057437, HPA074973"	Uncertain		Approved	Vesicles	"Secreted in other tissues"	NA	NA		28000000	Vesicles		"HPA057437: AB_2683440, HPA074973: "	"unprognostic (4.64e-2)"	"unprognostic (2.41e-1)"	"unprognostic (3.95e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.45e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.52e-2)"	"unprognostic (7.77e-2)"	"unprognostic (2.01e-4)"	"unprognostic (3.66e-2)"	"unprognostic (1.21e-1)"	"unprognostic (6.41e-2)"	"unprognostic (7.29e-3)"	"unprognostic (2.58e-2)"	"unprognostic (1.87e-1)"	"unprognostic (6.59e-2)"	"unprognostic (1.50e-2)"	3.9	5.6	0.9	1.9	0.8	0.0	2.4	1.6	0.8	3.9	0.0	3.1	1.8	13.4	1.2	5.5	4.1	5.0	1.0	3.5	8.1	2.1	0.9	1.2	0.8	2.1	3.4	0.9	1.6	1.4	0.2	1.8	0.6	0.5	8.2	2.9	0.4	1.3	1.6	0.4	0.9	1.8	11.3	0.8	0.7	5.2	1.0	6.3	0.5	0.9	0.8	0.9	2.6	2.0	1.1	6.4	0.5	1.2	0.0	17.5	118.3	0.0	3.6	16.3	14.8	33.3	0.0	0.1	0.1	0.1	44.1	5.5	0.0	6.6	1.1	41.7	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	61.2	0.0	64.3	0.2	55.8	27.1	0.0	0.1	0.3	64.3	0.0	0.2	0.1	5.6	0.0	0.3	0.0	10.1	0.2	0.9	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	207.9	96.9	2.5	2.6	15.8	0.0	0.0	0.0	31.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.8	1.6	0.8	3.5	8.1	2.1	3.4	0.9	0.5	0.8	6.3	1.1	1.6	0.0	0.0	5.2	0.0	0.1	0.1	0.3	0.0	0.0	0.1	0.4	1.4	0.0	0.6	0.0	0.0	0.0	0.0	3.1	0.0	0.1	7.2	0.3	1.1	8.9	0.0	0.0	245.4	0.0	0.0	15.1	0.5	0.5	0.0	0.1	1.1	0.0	0.1	0.0	39.5	0.4	0.0	0.0	0.8	2.9	5.0	0.1	0.0	1.9	0.0	0.0	0.0	9.0	5.7	0.0	0.4	1.2	0.0	0.6	0.2	0.4	0.0	0.0	0.0	0.1	1.2	2.9	1.6	0.1	0.1	0.1	0.0	0.1	1.7	0.1
ADRA1A	"ADRA1C, ADRA1L1"	ENSG00000120907	"Adrenoceptor alpha 1A"	P35348	8	26748150-26867278	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 22.0;brain: 43.4;liver: 60.6"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 105.4;Early spermatids: 51.3;Inhibitory neurons: 123.2;Late spermatids: 28.3;Oligodendrocyte precursor cells: 114.1"	"Cancer enhanced"	"Detected in some"		"liver cancer: 0.9;prostate cancer: 0.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA029678, HPA029679, HPA076693"	Approved	Supported	Supported	Nucleoplasm,Vesicles,Cytosol		NA	NA			Cytosol	"Nucleoplasm, Vesicles"	"HPA029678: AB_10602108, HPA029679: AB_2673143, HPA076693: "	"unprognostic (1.27e-1)"		"unprognostic (1.68e-2)"		"unprognostic (1.99e-1)"	"unprognostic (3.57e-1)"	"unprognostic (5.04e-4)"	"unprognostic (1.97e-1)"	"unprognostic (9.55e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.58e-2)"	"unprognostic (7.47e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.06e-3)"	"unprognostic (7.41e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.30e-1)"	22.0	0.5	13.7	1.1	11.5	0.0	3.7	4.2	23.3	0.5	0.0	1.1	0.9	1.5	0.6	0.8	0.2	0.3	6.1	43.4	16.3	0.7	60.6	3.9	1.8	8.3	4.9	3.4	0.9	0.0	0.0	0.1	0.0	11.5	12.5	0.5	0.3	6.2	13.7	0.2	0.5	1.1	2.9	1.6	9.3	0.9	0.1	3.6	0.1	0.1	1.4	0.4	0.4	0.3	7.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.7	11.5	4.2	23.3	43.4	16.3	8.3	4.9	3.4	11.5	1.6	3.6	7.5	0.0	0.0	0.0	105.4	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	51.3	0.0	0.0	0.1	0.0	0.0	15.5	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.7	16.2	0.0	0.0	123.2	0.0	0.0	0.0	0.5	28.3	0.6	0.0	0.0	9.4	0.0	0.0	0.0	114.1	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	1.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0
ADRB2	"ADRB2R, ADRBR, B2AR, BAR"	ENSG00000169252	"Adrenoceptor beta 2"	P07550	5	148826611-148828623	"FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Adipocytes: 196.1;Basal keratinocytes: 387.5;Basal respiratory cells: 146.6;Squamous epithelial cells: 276.0;Suprabasal keratinocytes: 245.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 9.0"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 72.4;hTERT-HME1: 74.1;PC-3: 31.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003431, HPA075322"	Uncertain		Uncertain	Cytosol		NA	NA			Cytosol		"HPA003431: AB_1845333, HPA075322: "	"unprognostic (2.28e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.17e-1)"	"unprognostic (9.35e-3)"	"unprognostic (5.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (9.85e-2)"	"unprognostic (3.17e-2)"	"unprognostic (2.23e-1)"	"prognostic favorable (3.15e-9)"	"unprognostic (1.55e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.49e-1)"	"unprognostic (7.65e-2)"	19.7	1.7	3.9	3.3	4.2	12.6	18.8	4.6	4.3	13.6	1.9	2.3	1.9	2.4	1.7	15.2	4.1	3.8	6.7	4.8	3.6	1.1	14.3	19.7	4.1	5.5	4.6	2.4	0.9	1.2	2.2	0.3	10.0	7.5	9.1	2.9	0.6	4.2	1.5	11.8	20.1	2.2	3.8	4.9	7.9	7.5	0.5	6.2	2.7	1.0	8.7	6.0	6.9	7.3	7.1	23.3	0.1	0.1	0.0	0.8	0.2	0.0	4.3	13.2	6.0	6.7	0.0	9.7	0.1	6.1	1.3	21.5	20.0	0.0	27.9	6.9	0.0	0.6	0.0	5.1	0.0	0.6	0.1	11.0	0.1	72.4	2.0	74.1	5.0	2.8	0.0	0.1	8.3	16.0	0.0	0.0	12.9	0.4	0.2	31.2	6.7	4.1	13.0	3.2	5.8	0.1	0.1	5.4	0.4	2.0	2.5	0.0	7.0	12.3	0.0	5.0	7.2	3.5	1.9	0.0	0.2	0.0	15.1	2.6	16.5	21.8	67.8	151.4	37.1	112.3	21.5	34.3	93.0	24.7	15.6	5.8	53.3	35.4	37.2	53.3	28.4	2.3	53.4	3.9	4.2	4.6	4.3	4.8	3.6	5.5	4.6	2.4	7.5	4.9	6.2	7.1	196.1	112.2	31.6	1.6	16.5	387.5	36.6	146.6	127.5	0.5	23.3	15.2	18.6	0.0	67.4	0.0	0.0	0.4	59.2	3.7	0.0	2.4	0.5	3.2	0.5	40.3	3.0	1.3	0.0	0.2	0.3	6.2	35.7	3.0	118.6	0.1	6.8	14.1	17.7	0.0	0.0	3.1	16.2	20.8	54.9	0.7	0.0	21.1	30.2	15.9	4.0	4.1	90.6	0.0	0.1	8.6	0.1	0.0	23.2	23.5	0.1	0.1	27.8	5.0	0.0	19.8	9.6	0.7	0.1	276.0	245.4	0.5	40.1	0.1	3.5	61.5
AMD1	SAMDC	ENSG00000123505	"Adenosylmethionine decarboxylase 1"	P17707	6	110874770-110898879	"Enzymes, Metabolic proteins, Predicted intracellular proteins"	"Polyamine biosynthesis, Spermidine biosynthesis"	"Decarboxylase, Lyase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"prostate: 204.7"	"Low cell type specificity"	"Detected in all"			"Cancer enhanced"	"Detected in all"		"prostate cancer: 70.4"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029281, HPA029282"	Approved		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA029281: AB_10600101, HPA029282: AB_10599965"	"prognostic unfavorable (3.87e-4)"	"unprognostic (4.68e-2)"	"unprognostic (1.85e-3)"	"unprognostic (1.01e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (1.91e-6)"	"unprognostic (1.18e-1)"	"unprognostic (2.03e-2)"	"unprognostic (6.50e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.20e-1)"	"prognostic favorable (4.28e-4)"	"unprognostic (8.62e-3)"	"unprognostic (1.55e-1)"	"unprognostic (4.41e-2)"	"unprognostic (7.71e-2)"	32.1	28.6	42.8	35.0	51.4	90.7	34.3	46.1	53.8	33.1	38.2	37.3	29.5	35.8	26.0	56.5	25.9	33.6	33.7	44.9	66.1	49.1	33.8	33.7	40.2	48.1	46.3	42.2	30.2	40.1	40.7	26.2	60.4	48.4	204.7	36.9	36.2	37.7	34.8	26.9	27.1	26.8	35.7	49.3	27.6	31.5	32.2	44.9	40.9	46.6	50.7	50.8	37.7	26.0	72.5	85.8	57.4	68.6	130.6	101.1	63.9	89.8	119.9	131.8	91.4	106.7	92.2	52.3	149.7	56.7	76.7	97.0	57.4	163.9	108.6	125.1	88.5	94.6	155.4	47.5	96.5	60.2	135.7	88.9	43.4	98.0	63.4	126.4	31.8	81.0	75.4	118.2	126.8	156.3	51.8	181.9	103.3	84.7	84.1	51.9	98.5	68.9	89.3	103.9	112.9	87.4	62.2	73.2	91.7	110.7	55.5	59.5	114.9	53.8	60.5	45.7	325.0	131.5	34.4	59.7	152.8	69.6	106.7	79.4	42.9	23.9	37.7	17.4	28.9	20.2	14.5	17.4	20.3	31.5	14.8	20.4	20.8	102.6	15.5	37.3	13.9	22.5	17.0	42.8	51.4	46.1	53.8	44.9	66.1	48.1	46.3	42.2	48.4	49.3	44.9	72.5	169.5	38.5	92.5	23.2	164.8	315.3	241.5	49.5	262.4	101.4	178.5	151.1	95.7	125.8	82.7	55.2	60.5	44.5	208.7	144.1	146.8	67.2	31.8	145.0	106.2	104.4	124.4	184.1	39.2	70.0	152.0	132.1	96.4	214.8	93.9	36.9	53.6	59.3	77.0	77.4	37.9	108.2	28.5	109.1	244.2	53.6	43.8	176.7	131.6	23.4	92.0	303.7	60.8	36.7	111.6	87.6	95.9	50.0	118.9	379.4	66.2	89.9	29.3	105.6	19.7	170.5	124.9	93.0	76.7	246.4	288.1	54.6	184.6	45.7	128.8	147.7
ANKRD34B	DP58	ENSG00000189127	"Ankyrin repeat domain 34B"	A5PLL1	5	80556755-80570280	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	16	"brain: 27.2"	"Cell type enhanced"	"Detected in some"		"Cardiomyocytes: 2.0;Collecting duct cells: 3.7;Enteroendocrine cells: 1.8;Inhibitory neurons: 6.0;Kupffer cells: 1.2"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 2.3"	"Region enhanced"	"Detected in many"		"thalamus: 27.2"	"Immune cell enriched"	"Detected in single"	5	"neutrophil: 3.8"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 3.8"	"Cell line enriched"	"Detected in some"	29	"RPTEC TERT1: 97.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA043327	Uncertain		Approved	Nucleoplasm,Mitochondria,Cytosol		NA	NA			"Nucleoplasm, Mitochondria"	Cytosol	"HPA043327: AB_10794180"	"unprognostic (1.05e-1)"	"unprognostic (4.16e-6)"		"unprognostic (2.07e-4)"	"unprognostic (1.05e-1)"	"unprognostic (3.03e-1)"		"unprognostic (8.25e-4)"	"unprognostic (6.44e-2)"	"unprognostic (1.80e-1)"	"unprognostic (9.41e-2)"	"unprognostic (6.52e-3)"	"unprognostic (1.93e-1)"	"unprognostic (4.28e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.33e-1)"	"unprognostic (2.94e-2)"	0.0	0.0	3.1	0.4	14.1	1.7	0.0	3.6	2.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	5.6	0.7	0.0	0.1	0.9	5.1	1.4	0.9	0.0	0.0	0.1	0.1	0.1	4.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.8	0.0	0.2	27.2	0.0	0.0	0.0	1.3	0.0	0.0	1.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	1.2	0.0	0.1	0.0	1.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.2	97.9	0.1	0.3	0.4	0.0	0.3	0.0	0.1	3.3	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.1	3.1	14.1	3.6	2.9	1.1	5.6	5.1	1.4	0.9	4.1	1.4	27.2	1.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.1	2.0	0.0	0.1	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.0	0.1	1.8	0.0	0.6	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.8	0.0	6.0	0.0	0.0	1.2	0.0	0.7	0.0	0.6	0.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0
APELA	"ELA, Ende, tdl"	ENSG00000248329	"Apelin receptor early endogenous ligand"	P0DMC3	4	164877178-164898965	"Predicted secreted proteins"	"Angiogenesis, Differentiation, Gastrulation"	"Developmental protein, Hormone"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"kidney: 2.2;prostate: 4.2"	"Group enriched"	"Detected in some"	5	"Cytotrophoblasts: 28.2;Proximal tubular cells: 28.5;Syncytiotrophoblasts: 40.9"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"NTERA-2: 41.7;SuSa: 25.1"														"Secreted in other tissues"	NA	NA						"unprognostic (2.97e-2)"	"unprognostic (6.97e-2)"	"unprognostic (9.83e-4)"	"unprognostic (8.92e-3)"		"unprognostic (1.43e-3)"		"unprognostic (4.50e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.38e-3)"	"unprognostic (1.68e-1)"	"unprognostic (2.18e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.34e-1)"	"unprognostic (8.35e-2)"	"unprognostic (1.95e-4)"	0.0	0.0	0.0	0.2	0.0	0.2	1.5	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.0	2.2	0.1	0.1	0.2	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.1	4.2	0.0	0.2	0.1	0.0	0.1	1.1	0.1	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.4	0.0	0.0	0.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.5	0.0	0.1	0.0	0.0	0.1	0.0	8.1	0.0	0.0	0.0	0.1	0.5	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.0	41.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	25.1	0.0	0.0	0.0	0.1	0.2	0.1	0.0	3.2	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	5.7	4.3	0.3	0.0	0.0	1.8	0.0	28.2	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	3.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	28.5	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	40.9	0.1	0.1	0.0	0.3
AR	"AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1"	ENSG00000169083	"Androgen receptor"	P10275	X	67544021-67730619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease variant, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 38.6"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 93.7;Granulosa cells: 104.8;Hepatocytes: 269.2;Leydig cells: 77.9;Peritubular cells: 86.5;Skeletal myocytes: 75.0"	"Cancer enhanced"	"Detected in many"		"breast cancer: 15.6;prostate cancer: 16.9"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 13.3;BJ hTERT+: 10.3;HAP1: 14.9;LHCN-M2: 16.1;RH-30: 23.6;T-47d: 10.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000001, HPA004733, CAB065764"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: "	"unprognostic (1.34e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.49e-2)"	"unprognostic (5.95e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.35e-2)"	"prognostic favorable (8.77e-4)"	"unprognostic (4.99e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.29e-1)"	"prognostic favorable (1.03e-8)"	"unprognostic (8.23e-3)"	"unprognostic (8.90e-2)"	"unprognostic (4.23e-2)"	"unprognostic (7.97e-2)"	6.8	1.0	1.6	0.5	1.1	0.0	8.8	1.7	1.1	23.8	0.4	1.5	0.2	18.8	16.3	1.2	20.9	2.0	5.9	0.7	5.3	3.6	38.6	1.5	0.3	3.4	2.5	0.1	14.8	0.8	0.1	1.9	0.1	2.6	16.6	0.6	0.2	1.4	18.4	14.1	5.3	0.9	9.5	2.2	1.3	1.5	3.9	3.6	2.7	2.1	6.2	0.5	3.5	13.0	2.8	0.0	4.8	13.3	0.0	0.0	0.0	0.0	7.3	10.3	0.3	0.1	0.1	0.0	0.0	0.0	1.0	0.0	0.0	14.9	0.0	0.0	0.0	2.4	0.0	1.5	0.0	0.8	0.0	0.0	5.5	0.0	1.8	0.0	0.0	3.9	0.1	4.6	2.2	16.1	1.5	0.0	0.0	5.4	0.0	0.0	0.0	23.6	0.1	0.4	0.0	0.0	0.0	0.0	0.3	0.0	3.6	10.9	7.6	0.3	0.3	2.2	0.0	3.5	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.1	1.7	1.1	0.7	5.3	3.4	2.5	0.1	2.6	2.2	3.6	2.8	3.1	0.0	5.0	28.4	0.4	9.7	17.8	0.2	15.9	0.7	93.7	33.7	37.4	14.3	10.7	3.7	0.0	3.5	14.0	0.0	1.9	11.3	1.1	2.9	49.1	10.5	0.0	5.3	7.7	0.0	0.2	39.4	0.0	5.8	1.3	104.8	36.0	269.2	0.8	0.0	17.8	0.3	0.0	2.2	4.2	4.4	77.9	3.3	10.6	1.0	1.7	0.2	0.0	26.7	0.2	0.6	0.0	86.5	0.0	36.5	0.6	27.7	3.6	0.3	65.7	75.0	20.8	0.8	3.3	12.7	16.1	1.0	1.7	37.8	0.2	22.0
ARFGEF3	"BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33"	ENSG00000112379	"ARFGEF family member 3"	Q5TH69	6	138161939-138344663	"Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 28.2;salivary gland: 18.2"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 114.6;Excitatory neurons: 200.9;Inhibitory neurons: 207.8;Oligodendrocyte precursor cells: 173.9;Oligodendrocytes: 378.1"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 24.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"MCF7: 14.8;RH-30: 13.4;RT4: 19.4;SK-BR-3: 22.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA036350	Uncertain					NA	NA					"HPA036350: AB_10672084"	"prognostic unfavorable (8.20e-4)"	"unprognostic (4.31e-2)"	"unprognostic (9.91e-3)"	"unprognostic (5.91e-2)"	"unprognostic (2.20e-2)"	"unprognostic (4.53e-2)"	"unprognostic (4.30e-3)"	"unprognostic (1.21e-2)"	"unprognostic (7.41e-2)"	"unprognostic (7.82e-2)"	"unprognostic (3.46e-2)"	"unprognostic (4.93e-2)"	"unprognostic (1.31e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.38e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.69e-2)"	0.9	3.8	13.0	0.7	15.3	0.4	8.0	19.6	14.8	5.0	0.0	4.3	2.2	0.7	0.9	0.4	2.2	1.7	1.0	15.5	12.8	2.1	0.1	6.4	0.2	11.8	9.7	16.3	0.1	8.7	16.0	7.0	1.5	12.6	12.1	4.8	2.8	18.2	1.0	0.2	1.1	1.9	0.7	7.3	0.4	10.1	0.6	12.2	0.1	1.9	0.7	0.2	3.4	0.5	28.2	8.0	3.1	0.0	0.6	0.0	0.0	4.7	0.3	0.2	0.2	0.0	0.1	0.4	0.0	3.1	0.3	2.7	2.6	3.8	2.0	0.0	0.0	4.9	0.0	1.5	0.9	0.0	3.0	0.0	0.0	0.9	0.0	0.9	3.5	4.1	2.7	0.0	4.9	0.0	14.8	0.0	0.0	2.7	8.5	3.4	0.6	13.4	2.6	2.6	19.4	6.9	0.0	7.8	22.2	0.9	0.3	4.4	0.0	0.4	0.2	2.2	0.0	7.9	1.7	6.7	0.0	3.2	1.8	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.0	15.3	19.6	14.8	15.5	12.8	11.8	9.7	16.3	12.6	7.3	12.2	28.2	9.4	16.0	114.6	34.3	0.5	0.0	18.8	0.0	6.2	19.0	39.9	12.6	6.4	14.3	44.6	3.7	0.0	16.5	0.8	2.5	3.9	11.4	83.0	8.6	1.4	11.9	66.7	2.7	200.9	24.7	2.4	4.1	41.3	17.7	2.5	0.1	8.2	0.3	1.4	11.8	207.8	44.2	0.0	0.0	0.0	22.0	0.0	0.5	0.0	36.5	2.0	0.9	0.0	173.9	378.1	14.2	8.4	0.0	0.9	67.6	2.5	0.3	37.2	3.3	0.0	3.5	0.9	4.1	1.1	3.0	0.0	6.2	0.8	0.1	13.2	42.7
ARG2		ENSG00000081181	"Arginase 2"	P78540	14	67619920-67651708	"Cancer-related genes, Enzymes, Metabolic proteins, Predicted intracellular proteins"	"Adaptive immunity, Arginine metabolism, Immunity, Innate immunity, Urea cycle"	Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 221.9;prostate: 109.5;thyroid gland: 105.8"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 190.1;Collecting duct cells: 165.5;Glandular and luminal cells: 145.2;Proximal tubular cells: 220.9;Syncytiotrophoblasts: 601.3;Urothelial cells: 165.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 49.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HAP1: 58.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA000663, CAB009435"	Enhanced		Supported	Mitochondria		NA	NA			Mitochondria		"CAB009435: AB_2059089, HPA000663: AB_1078192"	"unprognostic (8.74e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.35e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.30e-1)"	"unprognostic (9.13e-2)"	"unprognostic (1.10e-2)"	"unprognostic (3.43e-3)"	"unprognostic (4.62e-3)"	"unprognostic (5.37e-2)"	"unprognostic (4.66e-3)"	"unprognostic (1.72e-1)"	"unprognostic (9.39e-2)"	"unprognostic (4.26e-1)"	"unprognostic (2.31e-1)"	"unprognostic (4.34e-1)"	"unprognostic (1.26e-1)"	2.3	7.4	6.8	2.9	7.4	0.5	4.8	8.1	11.4	17.2	8.5	2.5	3.7	7.0	3.7	16.4	1.8	9.3	2.1	7.4	18.5	64.6	3.8	3.8	0.5	7.6	7.7	6.8	18.9	5.1	221.9	45.9	8.9	9.2	109.5	1.4	22.5	17.2	5.8	36.0	1.9	15.4	3.8	6.8	0.9	3.3	3.4	9.1	3.0	105.8	53.0	1.7	17.9	9.9	8.9	8.9	1.5	14.4	9.4	2.1	0.1	20.1	6.7	17.4	20.6	34.5	36.3	4.5	14.6	1.9	4.3	9.4	2.1	58.2	26.8	24.9	0.7	14.6	6.7	2.6	41.9	6.2	1.8	37.8	1.1	33.6	10.2	49.7	1.6	35.4	37.7	19.4	0.1	1.4	4.4	2.5	1.4	27.2	4.0	0.5	0.8	2.0	16.8	16.8	14.3	31.5	12.2	4.2	4.2	6.4	32.9	15.1	1.2	7.3	6.4	15.9	0.7	5.0	1.3	2.4	4.9	12.8	7.5	10.9	0.1	0.4	0.7	0.3	0.1	0.1	0.2	0.1	0.3	0.5	0.7	0.2	0.2	0.6	0.1	0.4	0.0	0.9	1.0	6.8	7.4	8.1	11.4	7.4	18.5	7.6	7.7	6.8	9.2	6.8	9.1	8.9	3.9	0.0	5.8	5.5	8.4	8.8	190.1	17.0	7.4	5.2	41.6	28.7	6.3	4.3	20.3	165.5	10.4	86.5	14.6	9.0	37.2	8.4	16.5	75.1	18.7	5.9	36.8	8.8	20.3	3.3	6.2	5.6	37.8	145.2	7.0	23.9	2.9	1.3	14.7	10.1	41.8	24.5	12.2	0.6	3.6	3.2	0.3	9.3	10.6	7.5	0.9	40.5	1.0	9.0	9.2	5.0	5.0	0.4	5.7	95.4	72.8	220.9	3.0	17.6	6.6	6.2	8.9	8.4	3.4	9.7	5.4	601.3	15.1	2.2	8.7	165.2
ARHGAP6	rhoGAPX-1	ENSG00000047648	"Rho GTPase activating protein 6"	O43182	X	11117651-11665920	"Plasma proteins, Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Inhibitory neurons: 44.3;Microglial cells: 127.4;Oligodendrocyte precursor cells: 60.3;Prostatic glandular cells: 54.4;Sertoli cells: 46.0;Skeletal myocytes: 62.3;Smooth muscle cells: 44.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 12.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 26.2;ASC TERT1: 34.2;HEL: 36.4;HMC-1: 24.7;HSkMC: 33.8;K-562: 26.5;RT4: 20.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA001798, HPA036779, HPA064390"	Enhanced		Supported	Cytosol	"Intracellular and membrane"	NA	NA		350000	Cytosol		"HPA001798: , HPA036779: AB_10672229, HPA064390: AB_2685253"	"unprognostic (2.36e-1)"	"unprognostic (1.68e-2)"	"unprognostic (3.49e-2)"	"unprognostic (7.31e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.69e-2)"	"unprognostic (4.70e-2)"	"unprognostic (2.79e-1)"	"unprognostic (1.70e-1)"	"unprognostic (7.46e-4)"	"unprognostic (1.53e-1)"	"unprognostic (1.59e-1)"	"prognostic favorable (1.55e-8)"	"unprognostic (1.60e-2)"	"unprognostic (5.96e-2)"	"unprognostic (1.28e-2)"	"unprognostic (7.99e-4)"	9.3	1.1	9.2	1.7	5.3	0.7	5.7	2.2	3.8	7.1	3.3	10.7	2.1	10.6	8.2	3.8	8.5	4.2	3.8	4.6	5.4	6.6	0.9	9.7	1.2	3.2	3.6	4.0	16.6	2.0	1.2	3.2	7.1	3.5	27.9	3.9	1.0	2.6	31.2	9.7	2.2	4.8	13.1	3.0	6.0	4.1	1.9	4.8	1.0	25.6	8.2	0.8	10.5	5.7	3.9	0.0	0.0	2.4	0.0	26.2	34.2	0.6	0.4	0.6	1.4	0.9	0.4	0.0	0.0	0.0	5.0	0.0	0.1	0.9	0.0	1.2	0.6	0.5	36.4	0.4	0.0	9.7	0.1	24.7	33.8	0.0	2.5	0.1	3.1	0.7	0.1	26.5	12.3	1.5	0.0	0.0	0.2	0.7	0.2	0.4	0.1	11.6	15.7	8.3	20.3	0.0	1.6	0.0	0.0	0.0	1.0	0.0	0.4	0.3	1.6	0.7	7.1	0.2	0.7	0.0	0.0	0.5	0.2	4.0	0.2	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.5	9.2	5.3	2.2	3.8	4.6	5.4	3.2	3.6	4.0	3.5	3.0	4.8	3.9	9.6	0.0	1.7	10.4	5.3	2.0	16.9	0.3	2.8	4.3	2.3	3.3	4.7	0.0	2.6	33.1	0.0	0.6	0.4	0.0	25.4	0.0	0.1	0.1	5.1	9.2	1.2	2.1	5.5	1.1	0.7	29.1	3.6	0.2	40.0	3.0	8.2	0.0	4.9	0.0	44.3	0.4	0.0	2.2	18.9	0.9	16.1	29.1	5.4	127.4	3.4	7.2	0.0	60.3	3.5	0.7	0.0	10.1	4.9	54.4	0.0	7.4	5.6	0.7	46.0	62.3	44.4	0.2	0.4	4.5	1.7	0.0	1.2	2.1	0.0	22.3
ARHGEF26	"DKFZP434D146, SGEF"	ENSG00000114790	"Rho guanine nucleotide exchange factor 26"	Q96DR7	3	154121003-154257827	"Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 339.7;Astrocytes: 248.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 19.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"U-251 MG: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017722, HPA049195"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA017722: AB_1856800, HPA049195: AB_2680671"	"unprognostic (1.41e-1)"	"unprognostic (1.43e-3)"	"unprognostic (3.55e-1)"	"unprognostic (7.99e-3)"	"unprognostic (2.82e-1)"	"unprognostic (9.42e-3)"	"prognostic favorable (9.74e-4)"	"unprognostic (7.06e-2)"	"unprognostic (1.16e-1)"	"unprognostic (6.01e-5)"	"unprognostic (1.44e-3)"	"unprognostic (4.36e-2)"	"unprognostic (2.22e-1)"	"unprognostic (5.53e-3)"	"unprognostic (3.11e-1)"	"unprognostic (1.07e-1)"	"unprognostic (5.24e-3)"	8.1	2.1	5.4	1.8	5.1	0.3	6.1	4.7	5.2	4.9	6.6	13.7	7.4	4.4	1.2	7.5	6.2	5.5	2.1	4.8	5.0	1.7	15.6	16.5	0.3	6.0	5.8	3.4	4.0	6.0	10.0	1.7	3.5	5.4	3.4	2.6	7.2	3.1	4.9	0.4	6.1	6.7	7.2	5.2	0.8	8.8	5.1	5.8	0.8	3.1	1.4	0.9	5.1	6.4	4.9	8.5	3.7	10.6	6.8	5.1	1.4	0.3	0.3	0.0	3.1	4.3	6.5	0.8	5.0	0.5	0.6	4.9	8.9	6.7	4.4	3.9	0.0	8.8	0.1	2.6	1.5	4.7	1.6	0.2	1.3	0.4	4.0	0.5	1.8	0.6	5.4	0.0	0.0	2.0	8.1	2.0	0.1	6.7	2.4	3.0	0.0	12.9	0.0	0.7	4.1	3.2	1.1	1.7	14.4	1.5	4.6	10.1	0.5	0.0	1.1	5.3	0.1	26.6	4.5	0.7	0.0	2.5	0.0	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	5.1	4.7	5.2	4.8	5.0	6.0	5.8	3.4	5.4	5.2	5.8	4.9	5.0	339.7	26.8	248.8	1.7	19.5	9.0	2.7	17.6	11.6	54.2	6.6	1.8	20.0	10.8	3.7	4.2	1.8	4.3	1.5	0.0	2.2	11.9	4.7	4.5	4.3	0.0	2.7	4.2	2.5	1.1	12.0	14.3	2.1	5.1	3.6	8.6	60.8	0.6	5.0	10.1	7.9	6.1	2.5	3.4	3.4	10.5	1.3	3.6	7.5	2.7	58.1	12.3	41.7	5.1	2.0	6.9	18.8	0.7	7.5	21.4	0.1	14.9	47.8	0.0	14.1	3.7	4.7	37.0	11.7	23.7	6.2	4.7	2.5	8.1	5.7
ARHGEF38	FLJ20184	ENSG00000236699	"Rho guanine nucleotide exchange factor 38"	Q9NXL2	4	105552620-105708093	"Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 7.9;pancreas: 6.5"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 48.5;Breast glandular cells: 17.9;Respiratory ciliated cells: 31.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"OE19: 2.8;RPTEC TERT1: 14.3;SK-BR-3: 8.0;T-47d: 8.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA036510, HPA045484"	Uncertain		Approved	Nucleoplasm,Centrosome		NA	NA			Nucleoplasm	Centrosome	"HPA036510: AB_10672357, HPA045484: AB_2679345"	"unprognostic (1.49e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.62e-1)"	"unprognostic (6.19e-3)"	"unprognostic (2.09e-2)"	"unprognostic (2.24e-3)"	"unprognostic (1.85e-1)"	"unprognostic (5.47e-3)"	"unprognostic (2.79e-1)"	"unprognostic (6.14e-5)"	"unprognostic (1.17e-1)"	"unprognostic (3.53e-3)"	"unprognostic (3.16e-8)"	"unprognostic (2.33e-3)"	"unprognostic (6.16e-2)"	"unprognostic (3.19e-3)"	"unprognostic (6.45e-3)"	0.0	0.0	0.0	0.3	0.0	0.0	7.9	0.0	0.0	2.5	0.0	2.7	1.9	0.3	5.6	0.1	0.6	3.2	0.0	0.0	0.0	2.5	0.1	3.7	0.0	0.0	0.0	0.0	0.0	6.5	0.0	2.0	0.0	0.0	5.8	4.2	0.0	4.9	0.4	0.3	0.5	2.6	0.0	0.0	0.0	3.1	0.0	0.0	0.0	1.4	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	2.8	0.3	0.0	0.0	0.1	14.3	0.0	0.0	0.0	0.0	8.0	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	6.4	48.5	0.0	0.2	0.0	1.1	1.1	0.0	0.0	17.9	6.1	1.8	4.3	12.6	12.9	0.0	0.2	0.2	9.8	9.8	6.8	1.9	12.6	0.5	0.3	8.4	0.0	0.3	5.8	0.1	0.3	9.2	7.8	0.0	0.0	0.0	0.1	0.1	0.0	0.3	14.8	10.2	0.0	0.2	0.4	0.0	0.1	3.6	0.0	0.0	0.0	0.0	0.0	0.1	2.4	6.4	0.0	0.1	9.4	4.8	0.5	31.9	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.4	0.0	11.4	0.8
ASB5		ENSG00000164122	"Ankyrin repeat and SOCS box containing 5"	Q8WWX0	4	176213673-176277571	"Predicted intracellular proteins, Predicted membrane proteins"	"Ubl conjugation pathway"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"skeletal muscle: 219.2;tongue: 67.6"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 52.7;Late spermatids: 293.6;Skeletal myocytes: 79.6"	"Cancer enhanced"	"Detected in some"		"head and neck cancer: 1.5;prostate cancer: 1.6"	"Low region specificity"	"Detected in some"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	16	"LHCN-M2: 1184.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA028870			Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA028870: AB_10611679"					"unprognostic (1.76e-1)"	"prognostic unfavorable (5.67e-4)"		"unprognostic (1.90e-1)"			"unprognostic (7.38e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.06e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.65e-1)"		"unprognostic (6.80e-3)"	0.0	0.0	0.4	0.9	0.6	0.0	0.0	1.3	0.8	0.8	0.2	6.5	0.3	0.6	0.1	10.6	0.1	1.2	3.9	0.5	0.4	0.7	0.0	0.2	0.0	0.9	1.3	0.4	0.0	0.1	0.1	0.4	0.0	0.8	13.0	3.4	0.0	24.1	0.3	219.2	0.1	1.2	2.5	0.7	0.0	4.7	7.3	0.4	0.1	0.0	67.6	0.0	19.3	0.9	1.2	0.0	0.0	0.0	0.0	0.0	0.9	0.0	29.1	0.0	25.9	54.7	0.0	0.1	0.0	0.0	0.0	2.5	0.0	0.0	0.0	61.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1184.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	74.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.6	1.3	0.8	0.5	0.4	0.9	1.3	0.4	0.8	0.7	0.4	1.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52.7	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	293.6	1.2	0.3	0.0	0.0	0.0	0.0	0.0	11.6	0.8	0.0	0.0	1.2	0.0	0.1	0.0	0.3	0.0	0.0	0.0	79.6	0.6	0.9	1.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1
ASTN2	KIAA0634	ENSG00000148219	"Astrotactin 2"	O75129	9	116423112-117415070	"Predicted intracellular proteins, Predicted membrane proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 40.0"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 354.6;Excitatory neurons: 370.0;Inhibitory neurons: 1011.0;Late spermatids: 228.2;Oligodendrocyte precursor cells: 900.3;Oligodendrocytes: 225.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 15.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"SH-SY5Y: 37.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA027035	Uncertain		Approved	Nucleoplasm,Cytosol		No	No			Cytosol	Nucleoplasm	"HPA027035: AB_1845122"	"unprognostic (3.25e-2)"	"unprognostic (2.70e-2)"	"unprognostic (7.41e-3)"	"unprognostic (5.42e-3)"	"unprognostic (1.89e-1)"	"unprognostic (2.67e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.94e-1)"	"unprognostic (2.80e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.93e-1)"	"prognostic favorable (6.66e-16)"	"unprognostic (3.28e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.57e-1)"	3.3	9.9	29.3	2.7	26.9	3.7	4.3	38.1	36.7	5.1	8.2	4.4	3.4	3.2	3.9	2.2	8.1	2.5	13.4	27.8	33.1	5.3	4.1	2.3	2.4	31.2	29.6	20.3	2.8	6.7	3.1	11.7	1.9	29.2	25.5	3.2	13.5	5.8	11.4	7.4	2.4	4.1	2.9	22.8	2.4	5.7	17.8	32.7	6.1	1.8	5.7	1.9	3.2	3.6	40.0	3.7	12.0	4.3	7.1	7.6	7.0	15.4	5.7	2.3	2.5	2.8	8.1	4.4	8.8	6.1	3.8	9.3	1.3	11.5	0.6	3.1	4.8	2.9	3.1	5.8	17.0	3.0	1.8	6.2	9.5	1.1	7.8	0.7	5.4	1.8	10.5	3.9	5.9	7.9	3.8	4.1	1.4	13.2	10.6	6.4	4.9	27.5	2.5	8.0	12.3	6.3	37.9	6.8	2.0	4.8	14.5	15.5	1.3	3.5	5.9	9.1	5.6	4.9	9.0	5.0	8.3	10.5	2.0	25.8	2.5	0.4	0.5	2.8	0.3	3.6	1.5	3.1	2.4	0.2	1.6	3.0	2.5	1.9	5.9	0.6	0.9	8.8	1.0	29.3	26.9	38.1	36.7	27.8	33.1	31.2	29.6	20.3	29.2	22.8	32.7	40.0	0.6	6.4	8.9	354.6	1.1	1.3	3.2	0.4	1.2	4.9	4.2	4.8	22.7	2.8	5.0	1.8	10.4	0.4	1.0	0.4	3.9	0.8	122.5	4.7	5.5	1.3	12.6	0.4	370.0	1.1	0.4	4.9	4.1	0.7	6.3	37.0	0.7	2.9	3.2	10.1	1011.0	1.0	0.0	0.0	1.6	228.2	2.8	1.0	0.0	36.5	0.2	3.0	0.0	900.3	225.9	0.5	2.1	5.7	3.6	11.7	5.7	6.9	11.7	5.1	0.0	1.9	2.0	7.7	13.2	0.3	0.6	0.3	3.8	1.9	1.8	2.2
BANK1	"BANK, FLJ20706"	ENSG00000153064	"B cell scaffold protein with ankyrin repeats 1"	Q8NDB2	4	101411286-102074812	"Disease related genes, Human disease related genes, Predicted intracellular proteins"	"B-cell activation"		"Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"intestine: 24.4;lymphoid tissue: 97.2"	"Cell type enriched"	"Detected in many"	10	"B-cells: 455.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 6.9"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	14	"memory B-cell: 310.4;naive B-cell: 253.0"	"Lineage enriched"	"Detected in many"	16	"B-cells: 310.4"	"Cell line enhanced"	"Detected in some"		"Daudi: 13.6;HEL: 10.6;HL-60: 9.6;U-266/70: 31.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA037002	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA		19000	"Plasma membrane, Cytosol"	Nucleoplasm	"HPA037002: AB_10672383"	"unprognostic (1.59e-2)"	"unprognostic (2.08e-2)"	"unprognostic (6.43e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.73e-2)"	"unprognostic (4.89e-2)"	"unprognostic (1.62e-2)"	"unprognostic (1.01e-1)"	"unprognostic (9.97e-2)"	"unprognostic (4.25e-2)"	"unprognostic (7.89e-2)"	"unprognostic (2.80e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.75e-2)"	"unprognostic (6.09e-3)"	"unprognostic (1.75e-1)"	8.6	3.6	0.6	35.4	0.5	6.3	2.2	1.5	0.9	2.4	0.3	2.8	2.4	0.8	3.3	0.9	2.3	3.0	0.6	0.5	1.3	3.2	0.3	8.1	82.9	0.7	0.9	0.4	0.1	0.5	0.4	1.5	0.8	0.9	5.8	3.3	0.3	2.4	4.8	0.1	0.7	24.4	1.0	0.7	56.6	7.5	3.0	0.8	9.8	13.0	0.2	97.2	7.6	0.7	0.7	0.0	3.0	0.0	0.0	3.4	1.4	0.1	0.1	0.1	0.4	0.6	0.1	4.6	13.6	1.2	0.0	0.0	0.2	0.1	1.5	0.4	0.0	0.0	10.6	2.6	0.0	0.1	9.6	0.0	0.6	0.4	0.0	0.0	1.2	0.1	0.0	0.1	4.0	0.6	0.5	0.0	0.6	0.0	0.4	5.7	0.2	0.6	0.0	0.4	6.1	2.6	0.0	0.3	0.2	0.0	0.1	0.5	2.5	1.3	0.0	0.6	0.0	0.0	31.0	0.0	2.2	0.1	5.3	0.0	10.8	1.7	19.7	0.4	0.5	0.1	310.4	0.1	0.2	10.5	253.0	0.1	0.1	0.9	1.5	0.2	5.2	0.2	11.3	0.6	0.5	1.5	0.9	0.5	1.3	0.7	0.9	0.4	0.9	0.7	0.8	0.7	3.5	44.8	27.1	6.8	455.9	0.1	2.2	0.5	0.0	0.2	1.7	0.4	0.5	0.0	10.0	3.7	0.0	2.1	5.8	0.0	0.0	0.2	2.8	13.1	1.0	1.3	0.0	6.1	7.3	0.2	0.6	1.4	6.1	15.2	1.3	0.1	0.0	0.1	1.5	0.0	1.6	0.4	2.0	2.9	25.1	2.0	0.0	13.0	5.4	4.7	2.8	1.8	1.0	1.0	1.3	4.1	1.3	0.4	13.7	4.4	0.2	4.2	2.2	0.1	0.0	0.1	0.8	1.9	5.6	0.8	1.1	0.3	12.9	2.1	1.1	4.3
BMPR1B	"ALK6, CDw293"	ENSG00000138696	"Bone morphogenetic protein receptor type 1B"	O00238	4	94757955-95158448	"CD markers, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Chondrogenesis	"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Disease variant, Dwarfism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 22.0;cervix: 24.9;prostate: 22.6"	"Cell type enriched"	"Detected in many"	7	"Astrocytes: 480.6"	"Cancer enhanced"	"Detected in many"		"breast cancer: 32.4;prostate cancer: 24.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"A549: 22.0;MCF7: 11.1;SH-SY5Y: 18.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.25e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.40e-3)"	"prognostic favorable (2.84e-4)"	"unprognostic (1.57e-1)"	"unprognostic (4.22e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.86e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.97e-2)"	"unprognostic (3.93e-1)"	"unprognostic (1.62e-3)"	"unprognostic (7.89e-4)"	"unprognostic (6.22e-2)"	"unprognostic (3.81e-3)"	"unprognostic (2.63e-2)"	0.6	4.6	16.6	0.3	14.0	0.1	1.0	15.1	15.1	24.9	2.8	0.8	0.1	4.4	2.4	0.2	12.6	2.7	0.7	13.4	22.0	7.8	0.8	1.7	0.0	20.2	17.5	10.2	6.2	1.1	0.1	1.9	0.7	16.8	22.6	0.2	8.2	1.0	14.3	3.0	0.8	0.1	0.6	14.8	0.9	2.4	3.7	15.1	6.5	0.5	1.1	0.0	0.2	0.5	12.9	0.0	22.0	5.6	0.0	2.3	4.8	0.2	0.1	0.0	0.1	0.5	0.0	0.1	0.0	0.2	1.0	0.0	1.3	3.6	8.4	0.1	0.0	4.9	0.0	1.4	0.0	0.6	0.5	0.1	2.7	9.0	2.8	6.2	0.4	0.1	0.0	0.0	0.0	7.1	11.1	0.6	0.1	2.1	0.1	3.2	0.2	3.4	0.1	4.3	0.1	0.2	18.8	0.3	3.2	3.2	0.8	1.7	0.0	0.0	4.0	3.8	0.2	4.3	0.0	0.0	0.0	1.5	0.0	0.5	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.0	16.6	14.0	15.1	15.1	13.4	22.0	20.2	17.5	10.2	16.8	14.8	15.1	12.9	0.0	6.4	0.0	480.6	0.0	2.7	1.3	13.1	1.2	0.4	3.8	1.0	3.4	2.8	33.4	60.7	0.0	0.0	0.0	0.0	1.9	3.0	1.4	28.5	1.4	1.1	18.4	0.0	51.0	0.4	0.3	1.5	0.0	20.8	0.0	38.6	2.9	0.0	0.1	0.0	2.5	0.0	8.2	0.0	1.2	1.4	3.1	0.4	28.4	22.5	0.0	38.5	0.0	10.1	2.8	0.7	0.0	3.8	0.0	28.5	0.0	0.2	15.7	1.6	0.0	1.7	2.9	1.2	10.6	0.4	2.3	0.0	0.5	4.4	0.0	1.6
C1orf116	"FLJ36507, MGC2742, MGC4309, SARG"	ENSG00000182795	"Chromosome 1 open reading frame 116"	Q9BW04	1	207018522-207032756	"Predicted intracellular proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 103.2;lung: 73.6;stomach 1: 59.2"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 176.3;Alveolar cells type 2: 99.4;Club cells: 68.5;Urothelial cells: 128.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 65.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 57.7;CAPAN-2: 99.5;HaCaT: 123.1;HBEC3-KT: 118.6;hTCEpi: 61.4;RPTEC TERT1: 56.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA011888, HPA011889"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		180000	"Plasma membrane, Cytosol"		"HPA011888: AB_1853872, HPA011889: AB_1853873"	"unprognostic (1.52e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.95e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.35e-1)"	"unprognostic (5.78e-2)"	"unprognostic (3.27e-1)"	"unprognostic (5.19e-2)"	"unprognostic (8.07e-2)"	"unprognostic (4.18e-2)"	"unprognostic (2.87e-3)"	"unprognostic (7.09e-3)"	"prognostic favorable (1.01e-5)"	"unprognostic (5.17e-1)"	"unprognostic (2.48e-1)"	"unprognostic (7.57e-3)"	"unprognostic (1.19e-1)"	0.1	0.4	0.0	1.7	0.0	0.8	10.5	0.0	0.1	7.6	0.0	8.9	24.8	0.2	0.7	103.2	2.6	9.9	0.3	0.0	0.0	5.8	0.5	73.6	0.0	0.0	0.0	0.0	0.1	13.0	0.0	0.3	0.2	0.0	51.4	8.4	0.0	29.7	1.9	0.5	38.0	20.4	0.3	0.0	0.2	59.2	0.9	0.0	0.3	4.3	0.5	16.2	20.8	31.4	0.0	57.7	7.7	0.0	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.0	5.1	99.5	0.0	6.5	0.0	0.0	123.1	0.0	118.6	0.0	0.1	0.0	10.6	1.0	1.6	0.0	0.0	0.6	0.0	61.4	0.0	34.2	0.0	0.0	0.2	6.9	0.1	0.0	0.1	0.1	0.2	0.1	37.3	3.3	0.0	0.0	0.2	56.4	15.1	0.1	0.3	1.1	11.1	0.5	0.4	0.2	0.2	0.0	0.0	0.3	0.1	0.3	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	176.3	99.4	0.0	0.3	20.8	53.0	26.8	10.8	0.0	5.4	7.2	49.9	30.0	68.5	11.0	0.0	0.1	0.1	40.7	15.6	24.3	5.7	6.7	1.4	1.7	10.7	0.0	0.1	24.4	0.0	1.6	50.4	14.9	6.3	0.0	0.0	0.0	0.2	0.0	0.1	19.8	12.2	0.0	1.2	5.5	0.3	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	60.7	35.3	0.0	0.3	56.5	31.8	0.3	41.0	0.0	0.0	0.0	2.8	0.1	0.0	24.3	23.3	0.0	0.3	0.1	8.9	128.1
C1QTNF9B	CTRP9B	ENSG00000205863	"C1q and TNF related 9B"	B2RNN3	13	23891099-23897502	"Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;skin 1: 18.0;testis: 8.9"	"Cell type enhanced"	"Detected in some"		"Adipocytes: 4.3;Early spermatids: 2.3;Endothelial cells: 1.4;Late spermatids: 2.1"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.8"	"Region enriched"	"Detected in many"	4	"hippocampal formation: 8.1"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"JURKAT: 4.8;OE19: 3.6"									HPA056632	Uncertain				"Secreted - unknown location"	NA	NA					"HPA056632: AB_2683197"	"unprognostic (3.43e-1)"	"unprognostic (3.42e-1)"	"unprognostic (2.18e-2)"	"unprognostic (9.51e-2)"	"unprognostic (2.18e-1)"	"unprognostic (4.10e-2)"	"unprognostic (2.43e-1)"	"unprognostic (3.32e-3)"	"unprognostic (1.52e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.01e-3)"	"unprognostic (7.04e-2)"	"unprognostic (5.56e-3)"	"unprognostic (3.89e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.34e-1)"	1.2	0.7	1.2	0.6	1.2	0.2	0.4	0.5	1.3	0.3	0.5	0.4	0.5	0.7	0.0	1.7	0.3	0.8	3.5	8.1	1.8	0.2	0.1	0.4	0.2	0.5	0.9	0.6	0.4	0.6	0.1	1.1	0.6	0.5	4.3	0.1	0.7	1.6	0.2	4.1	18.0	0.2	0.7	0.5	1.3	0.8	8.9	1.4	0.0	0.5	2.0	0.0	0.6	0.1	1.0	0.7	1.7	0.6	0.7	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.7	1.0	0.1	0.0	0.0	1.3	1.7	0.0	0.0	0.0	1.0	1.4	0.3	0.9	0.9	0.1	0.1	0.4	0.0	0.0	0.0	0.0	0.8	0.0	4.8	0.4	0.9	0.0	1.1	0.2	0.0	1.1	3.6	1.6	0.6	0.8	1.3	0.0	0.0	2.0	0.0	1.0	0.0	1.7	0.4	0.5	0.2	0.1	1.6	0.4	0.0	1.0	1.4	0.2	0.7	1.9	0.6	0.3	0.0	0.2	0.4	0.3	0.3	0.1	0.2	0.0	0.0	0.1	0.5	0.1	0.1	0.0	0.4	0.4	0.7	0.0	0.1	1.2	1.2	0.5	1.3	8.1	1.8	0.5	0.9	0.6	0.5	0.5	1.4	1.0	4.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.3	0.0	0.2	1.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.9	0.0	0.3	0.0	0.0	0.4	0.0	0.0
C9orf152	bA470J20.2	ENSG00000188959	"Chromosome 9 open reading frame 152"	Q5JTZ5	9	110190048-110208159	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 42.0;salivary gland: 25.6;stomach 1: 33.2"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 35.4;Intestinal goblet cells: 139.7;Ionocytes: 40.7;Paneth cells: 40.0;Undifferentiated cells: 79.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 27.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	8	"OE19: 149.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA050769	Approved		Approved	Nucleoplasm,Nucleoli		NA	NA			Nucleoplasm	Nucleoli	"HPA050769: AB_2681230"	"unprognostic (1.90e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.16e-1)"	"prognostic favorable (7.22e-5)"	"unprognostic (2.28e-1)"	"unprognostic (1.79e-3)"	"unprognostic (6.86e-2)"	"unprognostic (1.34e-1)"	"unprognostic (4.84e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.14e-1)"	"unprognostic (5.09e-2)"	"unprognostic (5.46e-3)"	"unprognostic (2.64e-1)"	"unprognostic (4.57e-1)"	"unprognostic (2.49e-1)"	"unprognostic (1.06e-2)"	0.1	0.0	0.5	2.2	0.4	0.0	12.5	0.2	0.4	10.5	0.1	33.1	19.2	2.3	0.0	3.0	3.8	5.5	0.0	0.4	0.2	0.2	0.8	5.9	0.0	0.5	0.4	0.2	0.0	5.1	0.0	0.1	0.0	0.6	17.2	42.0	0.0	25.6	1.4	0.0	5.0	15.2	1.2	0.3	0.1	33.2	0.0	0.3	0.1	0.1	0.0	0.2	1.2	0.4	0.7	0.0	1.3	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.2	2.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.0	0.0	0.0	0.1	0.0	0.5	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	1.9	0.0	0.1	0.0	149.2	0.2	0.0	0.0	0.2	0.0	0.6	0.1	0.1	0.0	9.3	0.0	0.0	18.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.2	0.4	0.4	0.2	0.5	0.4	0.2	0.6	0.3	0.3	0.7	0.4	9.6	16.3	0.3	0.2	0.3	3.4	5.9	6.2	0.0	20.5	10.8	0.1	20.0	14.5	0.0	0.0	0.0	0.1	35.4	0.0	6.0	0.0	4.0	2.0	0.5	25.9	0.0	0.1	11.1	0.0	0.2	25.0	13.9	0.0	0.0	0.0	3.3	0.1	0.0	0.1	139.7	40.7	0.0	1.0	0.0	0.0	0.6	10.6	0.0	0.0	0.0	0.0	0.0	0.1	3.9	40.0	0.0	0.0	12.4	4.4	0.0	5.2	0.0	0.0	0.4	0.9	0.0	0.0	10.9	0.4	0.0	0.4	0.0	79.8	5.5
CAB39L	"bA103J18.3, FLJ12577, MO2L"	ENSG00000102547	"Calcium binding protein 39 like"	Q9H9S4	13	49308650-49444064	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Early spermatids: 200.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 28.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CACO-2: 41.8;RT4: 43.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003686, HPA045954, HPA076632"	Approved		Approved	Vesicles		NA	NA			Vesicles		"CAB003686: AB_426084, HPA045954: AB_2679512, HPA076632: "	"unprognostic (3.90e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.13e-1)"	"unprognostic (5.01e-1)"	"unprognostic (3.29e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.82e-1)"	"unprognostic (2.94e-2)"	"unprognostic (2.78e-2)"	"prognostic unfavorable (2.28e-4)"	"unprognostic (3.08e-2)"	"prognostic favorable (7.91e-4)"	"prognostic favorable (1.94e-13)"	"unprognostic (6.59e-2)"	"unprognostic (8.31e-2)"	"unprognostic (4.96e-2)"	"unprognostic (8.05e-3)"	23.3	37.7	25.1	4.4	25.2	2.2	37.7	23.2	21.2	13.1	59.2	42.5	6.1	15.4	16.5	31.4	18.4	16.6	17.9	23.7	37.2	14.1	5.3	19.7	4.3	28.5	32.8	17.5	21.7	12.1	29.4	8.5	12.5	23.8	41.8	11.7	14.9	17.1	22.7	7.6	15.0	12.6	11.6	26.8	4.1	27.4	33.7	28.3	9.5	9.8	13.1	5.2	26.7	17.4	28.9	1.6	1.7	9.8	2.8	9.3	8.7	14.8	9.3	17.9	5.9	4.1	41.8	6.0	14.2	1.2	6.5	6.5	3.4	5.4	6.2	10.2	4.7	4.5	3.7	2.0	2.6	5.2	3.3	1.6	6.4	4.8	4.4	6.8	7.3	8.0	2.2	0.7	3.2	8.1	2.8	3.2	2.4	7.6	5.4	2.7	2.8	1.3	2.3	8.3	43.4	1.2	3.7	5.1	11.8	12.1	11.8	18.4	4.9	7.6	2.5	2.7	5.3	7.6	2.5	2.3	16.3	2.8	2.5	5.7	6.7	2.6	5.4	2.6	2.4	2.0	2.7	3.2	3.4	2.6	1.6	2.3	2.3	5.6	1.9	2.1	0.4	3.6	2.3	25.1	25.2	23.2	21.2	23.7	37.2	28.5	32.8	17.5	23.8	26.8	28.3	28.9	6.9	16.0	11.9	52.2	2.4	3.1	12.6	6.6	7.4	6.4	27.1	14.4	14.5	4.3	13.4	11.0	6.2	26.4	3.1	3.9	11.7	10.1	200.0	8.3	9.2	5.4	2.4	1.7	45.0	10.6	14.0	42.5	5.6	3.7	4.5	4.2	3.9	1.9	6.4	1.7	32.4	2.4	16.2	3.5	4.7	32.1	15.5	5.0	12.4	24.4	5.6	14.9	7.2	50.3	43.3	10.3	2.0	11.7	4.6	16.7	0.8	5.0	17.7	5.2	6.6	9.4	16.8	46.0	5.0	16.0	4.4	29.0	3.6	3.9	2.3	21.7
CACNA1D	"CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2"	ENSG00000157388	"Calcium voltage-gated channel subunit alpha1 D"	Q01668	3	53328963-53813733	"Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Cancer-related genes, Deafness, Disease variant, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 10.2"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 251.2;Inhibitory neurons: 354.1;Microglial cells: 126.5;Oligodendrocyte precursor cells: 197.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.9"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	10	"basophil: 3.7"	"Lineage enriched"	"Detected in single"	21	"granulocytes: 3.7"	"Cell line enhanced"	"Detected in some"		"HMC-1: 22.7;RPMI-8226: 55.5;SK-BR-3: 10.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020215	Uncertain		Approved	"Nuclear membrane"		NA	NA			"Nuclear membrane"		"HPA020215: AB_1845860"	"unprognostic (5.85e-2)"	"unprognostic (4.90e-3)"	"unprognostic (5.09e-2)"	"unprognostic (2.24e-2)"	"unprognostic (7.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.32e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.42e-2)"	"unprognostic (3.90e-3)"	"unprognostic (1.53e-1)"	"prognostic favorable (8.34e-8)"	"unprognostic (1.14e-1)"	"unprognostic (3.05e-2)"	"unprognostic (8.09e-3)"	"unprognostic (6.70e-3)"	0.1	6.6	8.0	0.2	5.4	0.7	1.9	2.7	10.2	6.1	0.0	1.5	1.7	3.8	7.3	0.5	7.8	2.1	0.4	4.3	1.6	2.2	1.0	3.7	0.1	0.8	1.3	5.5	0.5	2.8	1.2	3.5	0.6	3.9	3.0	1.6	4.4	0.5	1.8	0.2	0.7	2.4	0.7	2.1	1.8	0.8	1.6	6.2	0.2	2.9	0.2	0.1	0.6	0.1	7.0	0.0	0.5	0.1	0.0	0.0	0.0	1.4	0.0	0.1	0.0	0.0	2.7	2.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	22.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	2.1	0.1	0.0	0.4	0.9	0.0	0.0	0.2	55.5	0.5	3.6	4.7	2.1	0.3	10.1	1.1	0.0	2.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	3.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	8.0	5.4	2.7	10.2	4.3	1.6	0.8	1.3	5.5	3.9	2.1	6.2	7.0	0.6	3.2	36.2	7.8	0.6	0.9	0.8	4.6	2.2	33.3	7.2	1.8	2.3	10.0	9.1	1.8	35.5	0.9	0.5	3.0	0.0	7.2	4.9	4.3	40.1	2.4	59.4	2.7	251.2	2.3	0.2	3.4	5.1	3.3	12.6	1.7	0.0	3.4	0.2	8.4	354.1	3.8	2.0	0.8	4.0	8.3	4.4	2.1	5.4	126.5	0.5	4.0	0.0	197.5	29.9	3.8	5.6	27.1	0.1	1.7	9.5	2.7	9.5	12.9	0.0	0.2	8.6	1.0	3.7	0.5	1.0	0.3	1.7	9.6	7.6	0.9
CCDC154	"C16orf29, LOC645811"	ENSG00000197599	"Coiled-coil domain containing 154"		16	1434383-1444556	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"			"Tissue enhanced"	"Detected in many"		"testis: 11.7"	"Cell type enriched"	"Detected in some"	4	"Early spermatids: 51.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 4.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 9.5;NB-4: 4.7;SCLC-21H: 33.2;U-266/70: 5.8"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"cerebellum: 1.9"	"HPA041158, HPA043535, HPA048237"	Uncertain		Approved	"Golgi apparatus,Plasma membrane"		NA	NA			"Plasma membrane"	"Golgi apparatus"	"HPA041158: , HPA043535: AB_2678536, HPA048237: AB_2680323"	"unprognostic (2.40e-1)"	"unprognostic (1.42e-2)"	"unprognostic (5.97e-4)"	"unprognostic (3.28e-2)"	"unprognostic (1.97e-1)"	"unprognostic (5.76e-3)"	"unprognostic (7.96e-2)"	"unprognostic (3.01e-3)"	"unprognostic (1.67e-1)"	"unprognostic (5.34e-2)"	"unprognostic (4.19e-5)"	"unprognostic (2.35e-2)"	"unprognostic (8.02e-6)"	"unprognostic (9.33e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.33e-1)"	"unprognostic (9.35e-5)"	0.6	0.8	1.8	0.9	1.6	1.0	0.8	1.6	2.2	1.7	0.5	0.9	1.4	1.0	0.3	0.4	1.9	0.5	0.6	1.4	1.1	1.3	0.7	0.8	1.5	1.7	1.3	1.0	1.5	1.2	0.1	3.8	0.4	2.1	1.6	0.1	0.8	0.7	0.4	0.8	1.6	1.2	0.2	1.0	2.2	2.0	11.7	1.6	0.4	2.8	0.1	0.4	0.8	0.9	2.4	9.5	0.4	0.3	0.6	0.4	0.2	0.4	0.1	0.0	0.0	0.0	0.3	0.8	0.1	0.3	0.0	0.4	0.1	0.0	0.0	0.0	0.5	0.1	0.0	0.3	0.4	0.3	0.1	0.5	0.1	0.3	0.1	0.0	0.1	0.0	0.1	1.2	0.5	0.0	0.7	0.0	4.7	0.2	0.0	0.1	2.8	0.1	0.2	0.0	0.2	33.2	0.5	0.1	0.2	1.4	0.1	1.0	2.4	0.0	0.4	0.1	0.4	0.0	5.8	1.6	0.1	0.0	4.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	1.6	1.6	2.2	1.4	1.1	1.7	1.3	1.0	2.1	1.0	1.6	2.4	0.2	0.0	0.0	9.8	1.4	0.0	0.5	0.2	0.0	3.2	0.5	0.6	0.6	1.5	0.1	3.7	8.4	0.0	0.4	0.1	0.0	0.1	51.6	0.3	0.3	0.1	0.0	0.0	3.9	0.4	0.0	0.3	1.1	0.3	1.3	1.5	0.4	0.2	0.8	6.7	4.8	0.5	0.0	0.3	0.8	11.1	1.5	0.6	1.8	7.5	0.8	2.4	0.0	2.0	3.8	0.0	0.0	0.4	0.0	0.1	0.2	0.2	0.8	4.2	0.0	0.3	0.6	10.1	1.2	0.0	0.4	0.0	0.7	0.4	0.0	0.2
CD177	"HNA2A, NB1, PRV1"	ENSG00000204936	"CD177 molecule"		19	43353686-43363172	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"			"Tissue enhanced"	"Detected in many"		"bone marrow: 288.7;intestine: 166.2"	"Group enriched"	"Detected in some"	5	"Distal enterocytes: 632.4;Paneth cells: 314.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 27.6"	"Group enriched"	"Detected in some"	6	"cerebellum: 3.5;cerebral cortex: 6.7;midbrain: 2.3;pons: 2.4"	"Immune cell enriched"	"Detected in some"	7	"neutrophil: 8.7"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 8.7"	"Cell line enriched"	"Detected in some"	26	"RPMI-8226: 98.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA041820, HPA046601, HPA077640"	Enhanced				"Intracellular and membrane"	NA	NA					"HPA041820: AB_2677691, HPA046601: AB_2679716, HPA077640: "	"unprognostic (4.32e-2)"	"prognostic favorable (3.66e-4)"	"unprognostic (1.04e-2)"	"unprognostic (2.04e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.89e-2)"	"unprognostic (7.10e-2)"	"unprognostic (2.94e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.45e-1)"	"unprognostic (8.38e-2)"	"unprognostic (1.90e-2)"	"unprognostic (2.45e-1)"	"unprognostic (2.70e-1)"	"unprognostic (1.16e-1)"	"unprognostic (5.01e-2)"	"unprognostic (1.24e-1)"	4.3	0.4	0.2	7.2	0.4	288.7	1.3	3.5	6.7	3.1	4.3	156.7	0.3	0.4	0.2	2.2	2.3	0.2	2.1	0.3	0.2	1.8	2.7	20.8	0.2	0.5	2.3	0.2	0.3	1.1	0.0	3.0	1.6	2.4	65.4	166.2	0.1	1.8	0.2	0.7	0.4	0.7	3.0	0.3	64.9	1.5	0.2	0.4	1.4	0.7	0.8	10.5	2.2	5.5	0.6	2.1	0.0	0.0	0.0	0.0	0.0	0.3	1.0	1.3	0.6	0.6	0.0	0.0	0.1	2.4	0.6	1.7	0.2	0.1	0.0	1.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	1.2	0.0	0.0	0.0	0.3	0.1	0.2	0.1	0.4	1.2	0.0	0.2	0.0	0.0	98.0	1.4	0.3	0.7	0.0	0.5	0.1	0.0	0.2	0.0	0.0	0.0	1.0	0.3	2.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.0	1.2	0.0	0.7	0.0	0.2	0.4	3.5	6.7	0.3	0.2	0.5	2.3	0.2	2.4	0.3	0.4	0.6	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.5	0.0	3.1	0.0	0.0	0.0	0.0	632.4	0.0	0.5	0.4	0.2	0.1	0.0	8.4	3.6	0.0	0.2	0.0	0.2	0.0	0.9	0.0	0.1	0.0	0.0	0.0	0.0	0.2	87.2	0.0	0.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	314.8	0.0	0.1	29.2	0.0	0.1	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.6	0.0	28.0	0.2
CDH7		ENSG00000081138	"Cadherin 7"	Q9ULB5	18	65750252-65890337	"Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 16.9"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 45.7;Inhibitory neurons: 111.4;Muller glia cells: 39.3"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 15.2;HEK 293: 2.9;Karpas-707: 5.6;RH-30: 7.3;U-87 MG: 3.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA061419	Supported					NA	NA					"HPA061419: AB_2684511"	"unprognostic (2.81e-3)"		"unprognostic (6.95e-2)"		"unprognostic (2.26e-1)"			"unprognostic (2.24e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.41e-1)"	"unprognostic (3.95e-3)"	"unprognostic (2.88e-1)"	"unprognostic (4.28e-4)"	"unprognostic (2.70e-2)"	"unprognostic (1.49e-1)"		"unprognostic (1.72e-1)"	0.0	0.1	0.9	0.0	3.2	0.0	0.0	11.6	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	3.2	0.0	0.0	0.0	0.0	13.8	5.0	0.9	0.3	0.0	0.0	0.4	0.0	16.9	0.8	0.0	3.7	0.0	0.3	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.4	5.5	0.4	0.0	0.1	0.0	0.0	0.0	14.8	0.0	0.2	15.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.6	0.0	0.3	0.1	7.3	0.0	0.0	0.0	0.1	0.4	0.0	0.0	1.7	0.3	1.2	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	3.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.9	3.2	11.6	3.9	0.6	3.2	13.8	5.0	0.9	16.9	0.4	5.5	14.8	0.0	0.0	0.0	2.3	0.0	0.0	0.4	0.0	0.0	14.9	0.1	0.3	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	4.2	0.0	0.1	0.6	3.5	0.0	45.7	0.0	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	111.4	0.0	0.0	0.0	0.0	3.2	0.6	0.1	0.0	1.0	0.0	39.3	0.0	11.1	1.4	0.0	0.0	0.0	0.1	0.8	0.0	0.1	0.0	4.1	6.6	0.1	0.2	1.4	4.4	0.0	0.0	0.0	0.1	1.1	0.0	0.2
CDK19	"bA346C16.3, CDC2L6, CDK11, KIAA1028"	ENSG00000155111	"Cyclin dependent kinase 19"	Q9BWU1	6	110609978-110815958	"Enzymes, Human disease related genes, Metabolic proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Disease variant, Epilepsy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 43.6"	"Cell type enhanced"	"Detected in all"		"Late spermatids: 137.1;Oligodendrocyte precursor cells: 154.8;Oligodendrocytes: 476.3"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 23.3"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"neutrophil: 4.6"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007053, HPA007062"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"HPA007053: AB_1233803, HPA007062: "	"unprognostic (1.66e-2)"	"unprognostic (1.84e-1)"	"unprognostic (3.63e-1)"	"unprognostic (3.00e-3)"	"unprognostic (1.62e-1)"	"unprognostic (2.66e-3)"	"prognostic unfavorable (3.56e-4)"	"unprognostic (1.47e-2)"	"unprognostic (2.96e-2)"	"unprognostic (2.00e-3)"	"unprognostic (3.94e-1)"	"unprognostic (4.04e-1)"	"prognostic unfavorable (4.72e-5)"	"unprognostic (1.75e-1)"	"unprognostic (9.78e-2)"	"unprognostic (6.51e-2)"	"unprognostic (9.50e-3)"	6.2	3.4	23.9	7.3	33.6	11.8	6.5	20.4	27.0	6.7	11.4	7.0	5.4	10.3	3.8	8.2	5.4	8.4	4.5	23.3	23.3	6.5	5.0	6.8	9.5	29.1	28.0	19.1	9.9	3.9	6.5	2.3	11.6	27.0	27.0	6.5	8.9	4.5	6.0	3.3	8.6	6.8	7.4	22.6	8.1	7.2	18.7	26.1	13.8	6.2	5.4	9.3	5.4	6.7	43.6	5.7	6.1	21.8	26.4	11.1	15.6	10.8	18.8	19.4	6.7	8.8	7.6	6.4	14.7	6.5	13.2	13.9	3.2	8.0	3.9	15.4	18.2	4.5	26.0	8.8	8.9	6.8	10.5	18.2	10.7	8.6	9.7	14.1	17.0	6.8	12.3	7.6	20.2	14.5	9.7	14.3	15.0	2.0	8.1	4.1	14.8	11.3	5.8	7.8	11.0	10.6	19.8	14.4	11.3	17.0	7.2	3.9	37.1	7.7	14.2	7.6	29.6	11.4	2.1	3.2	12.8	15.6	13.7	14.9	2.1	1.2	0.9	0.4	0.7	0.4	0.6	0.3	0.3	1.0	0.6	0.2	0.3	4.6	0.7	0.4	0.5	0.4	0.3	23.9	33.6	20.4	27.0	23.3	23.3	29.1	28.0	19.1	27.0	22.6	26.1	43.6	15.9	3.2	17.8	50.6	19.2	9.8	14.4	6.7	12.0	19.2	14.6	9.4	8.2	18.6	8.7	16.5	16.7	7.0	17.8	27.0	1.9	10.5	102.3	13.7	16.5	13.6	12.6	21.6	85.3	4.7	18.4	12.0	13.7	25.6	7.0	23.0	20.0	12.2	16.4	23.5	51.5	13.5	8.2	33.9	19.9	137.1	10.8	22.1	26.6	62.8	19.6	33.9	22.6	154.8	476.3	7.0	20.0	16.1	5.9	30.0	16.1	7.7	6.9	13.9	6.6	11.2	12.3	56.6	15.8	20.3	16.2	7.9	13.3	10.1	13.8	11.1
CDYL2	FLJ38866	ENSG00000166446	"Chromodomain Y like 2"	Q8N8U2	16	80597907-80804598	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 12.9"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 69.6;Glandular and luminal cells: 34.3;Late spermatids: 26.4;Microglial cells: 30.9;Oligodendrocyte precursor cells: 27.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 9.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"intermediate monocyte: 1.0;non-classical monocyte: 4.0"	"Lineage enriched"	"Detected in single"	8	"monocytes: 4.0"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 15.9;HUVEC TERT2: 22.7;MCF7: 20.2;TIME: 33.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041016	Approved					NA	NA					"HPA041016: AB_10794183"	"unprognostic (8.63e-2)"	"unprognostic (7.37e-2)"	"unprognostic (2.93e-3)"	"prognostic favorable (6.13e-4)"	"unprognostic (1.48e-1)"	"unprognostic (4.38e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.40e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.33e-2)"	"unprognostic (9.11e-2)"	"unprognostic (2.12e-1)"	"unprognostic (3.69e-3)"	3.0	1.3	4.3	3.4	5.6	5.7	3.1	12.9	9.8	4.3	0.1	1.2	3.2	2.3	1.9	1.9	0.8	1.6	0.9	5.3	5.0	3.6	1.8	2.2	3.7	2.7	7.7	5.2	0.3	1.2	2.7	0.8	11.1	6.0	9.9	1.4	1.2	2.6	6.1	0.4	0.8	2.9	2.9	0.9	2.2	1.8	11.2	8.0	1.7	1.4	0.7	3.4	3.5	1.2	5.2	0.0	0.0	0.3	0.0	5.3	5.3	4.6	5.6	3.7	1.5	0.4	0.2	2.8	0.5	1.8	3.4	0.0	0.1	0.2	5.6	0.8	15.9	3.1	2.0	8.3	0.2	0.2	0.2	0.2	1.7	2.1	2.9	2.6	8.1	22.7	1.8	0.0	0.2	0.8	20.2	0.0	0.1	1.7	0.2	6.1	0.0	0.0	0.0	8.8	7.1	1.4	0.0	0.7	4.6	0.0	1.3	4.5	3.3	33.9	0.1	9.9	0.0	1.4	0.0	0.0	0.0	3.4	4.3	0.1	0.3	0.1	0.5	0.1	1.0	0.0	0.0	0.1	0.3	0.2	0.0	0.1	0.1	0.0	0.0	4.0	0.0	0.2	0.1	4.3	5.6	12.9	9.8	5.3	5.0	2.7	7.7	5.2	6.0	0.9	8.0	5.2	5.2	3.2	1.7	15.0	1.7	2.8	2.7	0.3	0.6	0.6	7.7	2.7	1.6	2.8	1.0	3.7	0.0	11.8	2.7	0.7	3.9	2.4	13.1	7.4	7.2	7.0	1.2	4.4	69.6	4.2	5.9	3.1	0.5	34.3	0.0	3.1	6.1	4.5	2.3	0.0	21.8	2.6	0.0	9.1	1.7	26.4	2.8	4.3	0.0	30.9	16.2	0.7	0.0	27.6	2.0	2.1	0.5	4.5	1.1	8.3	4.8	5.9	0.2	0.4	0.0	0.1	3.8	4.7	10.2	0.7	1.1	16.3	4.9	4.3	2.0	2.9
CFAP69	"C7orf63, FAP69, FLJ21062"	ENSG00000105792	"Cilia and flagella associated protein 69"	A5D8W1	7	90245174-90311063	"Disease related genes, Human disease related genes, Predicted intracellular proteins"	"Differentiation, Olfaction, Sensory transduction, Spermatogenesis"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Astrocytes: 28.4;Endometrial ciliated cells: 55.3;Excitatory neurons: 57.6;Inhibitory neurons: 46.4;Respiratory ciliated cells: 51.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 4.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 6.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA062883	Uncertain					NA	NA					"HPA062883: AB_2684893"	"unprognostic (7.69e-4)"	"unprognostic (9.93e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.11e-2)"	"unprognostic (3.13e-3)"	"unprognostic (3.12e-2)"	"unprognostic (4.11e-1)"	"unprognostic (2.83e-1)"	"unprognostic (4.51e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.80e-2)"	"unprognostic (9.83e-2)"	"unprognostic (1.30e-1)"	"unprognostic (6.46e-3)"	"unprognostic (2.44e-3)"	7.8	3.0	5.9	1.7	4.1	0.0	8.1	3.4	5.1	6.0	17.2	5.1	1.9	4.7	12.6	3.0	14.4	3.1	4.0	3.8	5.3	8.1	6.7	7.5	0.4	6.8	5.4	3.2	6.9	4.8	5.1	11.9	0.7	4.6	25.0	2.2	12.0	5.9	3.0	1.9	4.3	3.4	3.4	7.1	3.7	4.5	7.7	3.7	0.1	10.3	0.6	0.7	4.7	3.8	4.2	2.8	1.7	0.2	3.2	3.5	3.6	0.6	0.1	2.5	1.0	1.5	6.0	2.4	0.3	0.1	2.9	3.9	1.0	1.1	1.4	1.7	0.0	1.1	0.0	0.8	1.7	2.0	0.3	0.0	4.1	1.6	4.2	1.5	5.6	1.1	0.3	1.4	0.0	1.8	1.6	0.0	2.6	1.6	0.1	0.8	0.0	0.4	0.0	5.6	0.7	0.6	1.4	2.6	0.3	0.7	0.6	1.0	0.1	0.2	3.2	0.7	3.2	1.1	0.6	0.2	0.0	1.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.9	4.1	3.4	5.1	3.8	5.3	6.8	5.4	3.2	4.6	7.1	3.7	4.2	1.5	3.2	6.3	28.4	0.2	0.0	1.5	0.0	3.4	4.8	5.5	4.3	3.0	8.6	6.8	5.5	18.8	0.2	0.0	0.9	1.9	1.9	24.1	55.3	5.6	1.0	0.0	0.8	57.6	1.6	0.1	9.1	2.6	3.4	0.0	4.2	1.1	1.6	0.1	8.4	46.4	0.8	0.0	0.3	0.0	6.2	1.2	0.4	0.0	12.2	0.0	4.2	0.0	13.0	8.2	0.6	1.0	2.2	0.0	7.0	1.9	3.7	51.7	18.2	0.0	9.5	3.8	22.7	1.8	1.5	0.0	0.1	0.1	4.9	1.1	1.4
CHRDL1	"CHL, MGC1, NRLN1"	ENSG00000101938	"Chordin like 1"	Q9BU40	X	110673856-110795819	"Disease related genes, Human disease related genes, Predicted secreted proteins"	"Differentiation, Neurogenesis, Osteogenesis"	"Developmental protein"	"Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 190.0;seminal vesicle: 226.5"	"Group enriched"	"Detected in many"	4	"Astrocytes: 50.3;Fibroblasts: 83.8;Leydig cells: 41.0;Muller glia cells: 81.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 16.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	9	"ASC diff: 537.8;ASC TERT1: 724.7;hTERT-RPE1: 341.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000226, HPA000250"	Approved				"Secreted in other tissues"	NA	NA		610000			"HPA000226: AB_1078522, HPA000250: AB_1078521"	"unprognostic (5.13e-2)"	"unprognostic (6.31e-2)"	"unprognostic (8.50e-3)"	"unprognostic (2.48e-3)"	"unprognostic (1.99e-2)"	"unprognostic (1.72e-2)"	"unprognostic (7.26e-3)"	"unprognostic (1.42e-2)"	"unprognostic (4.89e-2)"	"unprognostic (5.54e-2)"	"unprognostic (3.43e-2)"	"unprognostic (3.56e-1)"	"prognostic unfavorable (2.36e-4)"	"unprognostic (4.75e-3)"	"unprognostic (7.91e-2)"	"unprognostic (5.01e-2)"	"prognostic unfavorable (2.23e-4)"	190.0	7.4	7.8	26.4	11.1	0.9	70.4	8.5	14.2	30.6	7.0	57.2	10.9	149.5	20.3	58.5	54.0	48.3	12.9	9.6	6.6	15.2	1.8	77.0	24.6	4.8	4.6	9.3	7.2	12.6	85.5	6.4	22.1	6.7	142.9	35.8	56.1	23.5	226.5	6.1	14.9	22.3	102.1	4.5	16.2	18.0	6.6	4.7	11.0	38.1	35.2	11.8	28.6	20.1	7.3	0.0	0.1	3.3	0.0	537.8	724.7	0.3	7.6	3.3	18.8	16.1	0.0	0.0	0.0	0.0	0.7	0.0	0.0	23.0	0.0	17.6	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	58.7	0.1	1.6	0.0	341.2	0.0	2.0	0.0	0.0	0.1	0.0	1.0	0.3	21.3	0.0	0.0	0.0	0.0	0.1	3.0	0.0	1.7	5.2	0.0	0.0	0.4	1.4	0.0	0.0	0.0	5.8	4.2	60.4	7.8	0.1	0.1	0.0	5.9	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	7.8	11.1	8.5	14.2	9.6	6.6	4.8	4.6	9.3	6.7	4.5	4.7	7.3	8.4	0.0	2.7	50.3	0.1	4.8	0.0	0.0	0.6	1.5	0.3	0.4	2.3	0.0	1.8	1.8	0.0	0.1	0.1	0.0	0.0	0.3	0.3	0.0	1.0	13.8	0.0	0.0	4.2	0.0	0.1	83.8	2.0	0.2	1.3	0.3	2.2	0.1	0.2	0.0	9.3	0.0	0.0	0.0	8.1	1.4	41.0	1.1	8.8	1.0	0.0	81.6	0.0	13.6	0.2	0.0	0.0	9.1	1.4	0.3	0.0	4.1	1.5	2.9	0.0	2.7	11.2	0.2	8.2	0.3	4.4	0.1	1.0	0.0	0.0	0.1
CLDN8		ENSG00000156284	"Claudin 8"	P56748	21	30214006-30216097	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 69.6;intestine: 51.3;kidney: 69.9;salivary gland: 40.5"	"Group enriched"	"Detected in some"	5	"Collecting duct cells: 224.3;Distal enterocytes: 110.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 31.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	18	"HaCaT: 33.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA060605	Approved					NA	NA					"HPA060605: AB_2684331"	"unprognostic (3.74e-2)"	"unprognostic (3.12e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.02e-1)"		"unprognostic (3.04e-2)"		"unprognostic (1.17e-1)"		"unprognostic (1.87e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.52e-1)"	"prognostic favorable (3.32e-4)"			"unprognostic (2.55e-1)"	"unprognostic (1.48e-2)"	0.1	0.0	0.0	0.0	0.0	0.0	69.6	0.0	0.0	0.9	0.0	27.5	0.0	0.1	9.4	3.9	1.1	0.0	0.0	0.0	0.0	69.9	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.5	0.0	7.6	51.3	0.0	40.5	14.0	0.0	7.3	0.5	0.1	0.0	0.0	0.1	0.0	0.0	0.0	22.1	0.0	0.3	0.4	10.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	1.0	10.8	2.7	0.0	0.0	29.9	11.6	0.0	0.0	10.5	224.3	0.0	0.0	0.1	110.2	11.7	0.1	0.0	0.8	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.3	22.4	0.0	0.3	0.0	0.0	0.1	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.2	0.0	0.0	15.9	0.6	0.4	20.3	0.0	0.0	0.0	0.3	0.0	0.0	4.6	8.4	0.0	0.4	0.0	18.0	23.1
CLGN		ENSG00000153132	Calmegin	O14967	4	140388453-140427661	"Predicted intracellular proteins, Predicted membrane proteins"		Chaperone		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 60.0;testis: 114.6"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 313.3;Early spermatids: 162.4;Endometrial ciliated cells: 93.4;Muller glia cells: 176.4;Spermatocytes: 465.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 19.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 53.0;MOLT-4: 47.8;U-251 MG: 73.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB020709, HPA048761, HPA058627"	Enhanced		Supported	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB020709: , HPA048761: AB_2680514, HPA058627: AB_2683782"	"unprognostic (6.74e-2)"	"unprognostic (8.28e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.30e-2)"	"unprognostic (2.56e-1)"	"unprognostic (3.73e-3)"	"unprognostic (6.14e-2)"	"unprognostic (4.80e-2)"	"unprognostic (3.11e-1)"	"unprognostic (5.38e-3)"	"unprognostic (2.29e-2)"	"unprognostic (2.45e-3)"	"unprognostic (3.00e-3)"	"unprognostic (1.29e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.01e-1)"	0.4	6.7	1.4	1.0	0.9	2.4	2.7	3.9	1.7	0.9	1.8	2.0	0.5	1.6	0.6	1.2	13.8	0.4	60.0	1.0	2.0	0.4	3.2	0.5	0.7	2.6	2.0	0.9	0.3	2.2	0.6	11.3	0.2	2.8	22.7	1.3	17.4	1.0	0.7	0.4	0.2	1.3	1.5	1.4	0.2	2.1	114.6	1.7	2.4	2.7	1.6	1.2	0.6	0.1	3.5	0.2	10.2	10.3	6.9	4.0	21.1	2.4	0.1	9.4	10.0	18.6	0.3	0.9	0.0	27.8	0.9	8.4	0.2	7.5	0.1	16.2	0.4	9.0	3.0	9.8	7.4	41.4	38.9	0.6	2.2	39.2	1.0	0.9	53.0	0.2	9.6	2.0	0.0	0.0	0.5	47.8	0.5	12.0	0.2	28.1	31.5	0.0	0.4	0.0	0.3	16.8	29.8	6.5	4.1	1.8	3.8	1.9	5.6	0.0	27.4	4.7	9.7	73.6	14.4	31.7	19.9	43.4	1.6	2.9	0.9	0.2	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.9	3.9	1.7	1.0	2.0	2.6	2.0	0.9	2.8	1.4	1.7	3.5	0.8	0.0	2.2	0.3	0.1	0.0	0.9	8.5	1.2	9.2	3.3	1.8	313.3	0.0	6.4	0.0	4.2	0.5	0.0	0.5	0.0	1.2	162.4	93.4	1.3	11.9	5.3	8.6	7.2	4.2	0.1	10.2	0.0	11.3	0.0	10.1	0.7	3.7	0.1	25.2	6.7	0.4	30.5	0.0	0.0	60.2	5.0	0.7	1.8	0.0	0.1	176.4	0.0	6.6	0.6	0.9	3.9	4.5	0.1	33.8	0.2	0.1	24.6	16.3	0.0	0.6	2.0	465.5	23.9	2.8	0.1	0.3	0.7	0.2	0.8	1.3
CNN1	"Sm-Calp, SMCC"	ENSG00000130176	"Calponin 1"	P51911	19	11538767-11550323	"Cancer-related genes, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 1888.1;intestine: 1864.8;seminal vesicle: 1600.6;smooth muscle: 2227.2"	"Group enriched"	"Detected in many"	5	"Breast myoepithelial cells: 191.0;Early spermatids: 335.0;Late spermatids: 554.6;Peritubular cells: 221.2;Smooth muscle cells: 180.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 142.1;stomach cancer: 103.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 91.5;BJ hTERT+: 34.9;BJ hTERT+ SV40 Large T+: 48.0;BJ hTERT+ SV40 Large T+ RasG12V: 64.6;HBF TERT88: 71.2;K-562: 35.8;SuSa: 72.5;U-2 OS: 34.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000007, HPA014263"	Enhanced		Approved	"Actin filaments"		No	No			"Actin filaments"		"CAB000007: AB_2082148, HPA014263: AB_1847039"	"unprognostic (4.98e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.04e-3)"	"unprognostic (1.95e-1)"	"unprognostic (2.47e-1)"	"unprognostic (4.20e-1)"	"unprognostic (5.10e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.35e-1)"	"unprognostic (7.06e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.01e-1)"	"prognostic unfavorable (5.43e-6)"	"unprognostic (1.70e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.78e-3)"	"unprognostic (6.11e-3)"	112.7	59.0	5.7	162.0	6.7	0.0	90.5	5.1	14.3	354.9	12.5	1864.8	137.5	1888.1	178.5	683.9	661.4	236.4	234.2	6.0	7.1	21.9	10.6	99.6	7.3	7.0	6.3	5.5	115.1	24.4	3.0	9.0	28.7	6.6	681.8	329.4	0.7	62.1	1600.6	21.9	48.8	435.0	2227.2	5.4	22.3	679.4	92.1	6.3	2.6	38.8	11.8	0.9	1398.2	308.3	5.9	0.1	1.3	5.9	1.0	0.6	0.2	3.2	91.5	34.9	48.0	64.6	27.9	0.0	0.4	2.7	26.1	4.4	0.3	0.0	0.0	71.2	0.0	0.2	0.1	0.1	2.3	2.5	0.0	0.4	3.0	0.1	28.7	0.1	1.6	0.0	0.0	35.8	0.0	0.0	0.0	0.3	3.8	2.9	0.0	0.7	0.2	0.6	3.8	0.0	0.0	0.1	1.3	0.1	0.2	0.2	72.5	0.1	0.1	0.4	0.4	34.6	1.2	1.2	0.1	0.4	0.1	3.2	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	5.7	6.7	5.1	14.3	6.0	7.1	7.0	6.3	5.5	6.6	5.4	6.3	5.9	2.4	0.0	0.0	0.0	0.2	4.8	4.1	1.6	0.6	0.0	4.2	191.0	51.4	0.0	0.3	1.8	0.0	0.8	0.7	0.0	0.0	14.5	335.0	3.1	20.7	2.4	0.0	0.0	0.5	0.4	1.0	21.5	0.5	0.7	0.0	0.5	6.8	0.0	2.3	0.0	0.3	0.0	0.0	0.0	9.4	554.6	8.4	0.9	3.6	2.8	0.6	0.5	0.0	0.0	0.1	0.9	0.0	221.2	0.0	4.0	0.0	0.4	0.4	0.0	39.5	1.1	180.9	8.3	19.5	0.4	7.1	0.7	1.1	0.7	0.0	1.1
CNTN3	"BIG-1, PANG"	ENSG00000113805	"Contactin 3"	Q9P232	3	74262568-74521140	"Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 11.1"	"Group enriched"	"Detected in many"	7	"Excitatory neurons: 274.0;Inhibitory neurons: 195.1;Oligodendrocyte precursor cells: 228.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 2.9"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"BJ: 7.1;fHDF/TERT166: 19.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003341	Approved				"Intracellular and membrane"	NA	NA		130000000			"HPA003341: AB_1078556"	"unprognostic (1.66e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.35e-3)"	"unprognostic (9.86e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.94e-5)"	"unprognostic (4.25e-2)"	"unprognostic (2.13e-3)"	"unprognostic (8.42e-2)"	"unprognostic (3.85e-2)"	"unprognostic (1.50e-1)"	"unprognostic (7.25e-2)"	"unprognostic (9.30e-7)"	"unprognostic (4.23e-2)"	"unprognostic (1.63e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.36e-2)"	1.8	3.0	6.7	0.4	8.4	0.0	1.4	0.5	11.1	2.4	0.8	3.2	0.4	0.9	1.7	0.4	7.6	2.1	1.6	7.1	3.5	3.7	3.1	0.8	0.1	2.7	1.9	10.4	1.3	2.0	0.2	4.0	0.1	3.0	5.8	2.8	1.3	0.8	4.3	0.2	0.6	0.5	0.4	0.0	1.9	1.4	0.7	2.1	0.9	1.6	0.2	0.5	4.3	0.5	6.9	0.0	0.0	0.6	0.0	0.0	0.1	0.0	7.1	0.0	1.1	0.3	0.0	0.0	0.0	0.0	19.6	0.0	0.0	0.4	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	2.4	0.0	1.4	0.0	0.1	1.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	8.4	0.5	11.1	7.1	3.5	2.7	1.9	10.4	3.0	0.0	2.1	6.9	0.2	3.2	1.7	21.9	0.0	0.6	0.8	0.3	0.0	6.2	2.2	1.3	3.5	10.0	4.2	9.2	0.0	0.0	0.0	3.3	1.9	1.9	2.9	32.7	1.8	0.7	1.2	0.0	274.0	0.5	0.0	4.5	0.0	10.8	0.0	0.4	5.7	6.6	0.1	21.9	195.1	6.4	0.0	0.0	2.1	1.8	0.0	0.1	0.0	3.7	0.0	0.2	0.0	228.7	9.8	0.9	3.9	0.0	0.0	4.0	0.6	7.4	4.8	0.9	0.0	2.3	0.9	0.1	1.1	0.0	0.3	0.0	0.5	0.1	7.1	1.9
CNTNAP2	"Caspr2, KIAA0868, NRXN4"	ENSG00000174469	"Contactin associated protein 2"	Q9UHC6	7	146116002-148420998	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Autism, Autism spectrum disorder, Epilepsy, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"brain: 35.9;retina: 14.5"	"Group enriched"	"Detected in many"	4	"Excitatory neurons: 3383.0;Inhibitory neurons: 6845.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.0"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in single"		"naive B-cell: 2.5"	"Lineage enriched"	"Detected in single"	25	"B-cells: 2.5"	"Cell line enhanced"	"Detected in some"		"AF22: 8.0;CACO-2: 6.7;NTERA-2: 12.0;SCLC-21H: 21.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002739	Enhanced					NA	NA					"HPA002739: AB_1078545"	"unprognostic (2.49e-2)"	"unprognostic (1.49e-2)"	"unprognostic (4.05e-1)"	"unprognostic (3.08e-3)"	"unprognostic (1.77e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.19e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.68e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.33e-1)"	"unprognostic (1.00e-3)"	0.1	0.8	4.6	0.2	11.5	0.0	0.6	1.1	18.4	0.0	0.0	0.7	0.0	0.0	0.0	0.4	0.6	0.0	0.1	5.2	10.8	0.1	1.9	0.0	0.4	5.6	3.4	16.7	1.1	0.2	0.3	3.9	0.5	4.1	4.1	0.4	14.5	0.1	0.1	0.0	0.0	0.9	0.0	0.0	0.4	0.2	0.5	6.7	3.8	0.3	0.0	0.2	0.1	0.1	35.9	0.0	0.0	8.0	3.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	6.7	0.1	0.0	0.0	0.2	0.0	2.0	1.7	0.6	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.1	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	12.0	1.4	0.0	0.0	0.0	2.2	0.0	0.0	21.5	1.4	0.0	0.0	0.0	0.3	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.6	11.5	1.1	18.4	5.2	10.8	5.6	3.4	16.7	4.1	0.0	6.7	35.9	0.1	0.0	0.0	65.6	9.3	0.1	0.3	15.5	1.8	33.9	0.3	0.0	1.2	7.2	4.1	0.0	2.1	40.8	0.0	1.8	0.0	1.4	7.2	0.6	0.0	0.6	2.4	0.0	3383.0	0.7	6.8	1.1	0.5	0.7	0.0	0.2	0.0	8.9	3.3	1031.4	6845.7	3.9	0.0	0.6	2.0	2.7	1.2	0.4	0.0	180.8	0.2	8.2	1.0	429.3	914.7	4.1	2.1	0.0	0.3	7.4	4.7	0.5	0.9	16.7	0.0	0.0	0.9	2.4	12.0	9.1	0.0	6.3	0.0	1.2	6.8	0.2
COL9A2	"EDM2, MED"	ENSG00000049089	"Collagen type IX alpha 2 chain"	Q14055	1	40300489-40317813	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Deafness, Disease variant, Dwarfism, Stickler syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 89.0;pituitary gland: 108.9"	"Cell type enhanced"	"Detected in many"		"Muller glia cells: 295.4;Oligodendrocyte precursor cells: 62.4;Oligodendrocytes: 128.1"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 68.2"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"eosinophil: 3.2;myeloid DC: 1.2"	"Group enriched"	"Detected in many"	6	"dendritic cells: 1.2;granulocytes: 3.2"	"Group enriched"	"Detected in many"	4	"HDLM-2: 98.6;Hep G2: 27.6;HMC-1: 90.3;THP-1: 105.0"	"Low region specificity"	"Detected in all"							"HPA056316, HPA075286"	Supported		Approved	Nucleoplasm,Vesicles	"Secreted to extracellular matrix"	NA	NA		510000	Vesicles	Nucleoplasm	"HPA056316: AB_2683099, HPA075286: AB_2732288"	"unprognostic (1.42e-2)"	"unprognostic (3.54e-2)"	"unprognostic (8.94e-2)"	"prognostic unfavorable (5.13e-4)"	"unprognostic (4.46e-2)"	"unprognostic (1.83e-3)"	"unprognostic (2.06e-2)"	"unprognostic (9.00e-3)"	"unprognostic (1.73e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.56e-3)"	"unprognostic (2.26e-1)"	"unprognostic (1.16e-3)"	"unprognostic (4.28e-2)"	"unprognostic (2.56e-1)"	"unprognostic (5.89e-2)"	"unprognostic (1.71e-2)"	1.7	3.4	46.9	3.7	69.0	11.0	6.0	60.9	49.4	12.2	26.6	4.7	5.8	5.1	1.7	1.6	11.5	8.5	1.4	40.1	53.2	17.0	0.9	4.3	6.0	78.2	76.7	32.8	1.3	2.3	21.2	108.9	1.1	83.3	13.8	3.2	23.3	16.5	24.4	0.3	4.2	10.5	1.4	58.2	9.9	16.6	2.6	62.5	1.8	12.3	0.4	3.2	12.2	2.0	89.0	12.0	0.3	1.8	0.8	2.6	1.3	7.8	0.0	0.0	0.6	1.3	0.4	6.8	3.4	10.0	0.3	0.0	2.0	0.1	0.0	0.3	98.6	1.4	2.0	0.8	27.6	1.5	0.9	90.3	4.8	0.0	0.1	0.0	0.7	0.0	1.5	0.1	19.8	0.0	2.7	1.2	2.1	2.2	0.0	1.2	2.3	0.0	6.9	0.0	14.3	1.4	2.3	0.1	11.8	1.3	6.6	15.0	105.0	0.1	0.0	11.6	0.2	0.4	1.4	0.2	3.4	1.0	12.3	0.6	0.0	0.1	3.2	0.0	0.2	0.0	0.2	0.1	0.0	1.2	0.2	0.0	0.0	0.5	0.2	0.3	0.1	0.1	0.0	46.9	69.0	60.9	49.4	40.1	53.2	78.2	76.7	32.8	83.3	58.2	62.5	89.0	0.5	0.0	3.3	26.1	10.8	1.0	3.0	8.5	0.0	2.0	7.1	9.7	1.0	7.2	10.0	25.8	0.0	3.2	2.5	7.2	0.0	11.7	0.2	13.6	0.9	0.6	12.7	0.4	0.3	0.8	0.6	2.1	26.0	20.0	26.1	1.6	1.1	0.0	3.4	0.0	0.3	6.6	2.0	0.3	22.4	0.9	2.1	6.4	1.8	3.7	22.1	295.4	1.0	62.4	128.1	4.9	9.6	0.0	4.0	6.1	5.0	0.3	12.9	10.9	0.0	1.3	1.8	3.4	6.2	0.2	0.6	1.4	2.7	1.8	13.4	13.4
COLEC12	"CL-P1, SCARA4, SRCL"	ENSG00000158270	"Collectin subfamily member 12"	Q5KU26	18	316737-500722	"Predicted membrane proteins"		Receptor		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix: 24.6"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 104.4;Cytotrophoblasts: 149.0;Fibroblasts: 79.6;Hofbauer cells: 155.9;Microglial cells: 245.4;Muller glia cells: 74.5;Syncytiotrophoblasts: 111.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 14.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 24.3;BJ: 12.1;HSkMC: 20.0;U-2197: 31.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA047917, HPA071056"	Enhanced		Approved	"Golgi apparatus,Vesicles,Cell Junctions"		NA	NA		580000	"Golgi apparatus, Vesicles"	"Cell Junctions"	"HPA047917: AB_2680208, HPA071056: AB_2686338"	"unprognostic (8.67e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.51e-2)"	"unprognostic (3.60e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.14e-4)"	"unprognostic (2.21e-1)"	"unprognostic (1.21e-1)"	"unprognostic (4.86e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.61e-1)"	"unprognostic (2.24e-3)"	"unprognostic (1.52e-2)"	"prognostic unfavorable (8.10e-4)"	"unprognostic (3.01e-3)"	10.0	1.7	5.7	2.4	4.7	0.2	5.6	5.1	5.8	24.6	9.6	4.9	1.5	9.0	1.0	2.0	6.6	4.4	6.2	4.7	8.7	1.2	0.3	11.5	2.0	7.6	6.4	4.1	2.0	1.1	0.9	0.9	20.2	5.2	4.0	2.5	5.4	4.1	1.4	3.1	3.4	3.6	5.1	4.3	0.3	3.4	1.4	7.0	1.3	5.3	2.0	2.5	8.2	4.0	5.7	0.0	0.0	2.1	0.0	2.3	24.3	0.8	12.1	4.2	1.7	3.1	0.0	0.0	0.0	0.1	2.0	0.1	0.0	0.3	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.1	0.0	0.0	20.0	0.0	1.0	0.0	0.7	4.7	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.4	0.0	0.0	0.7	0.0	6.5	0.0	0.0	0.1	0.3	0.0	0.1	0.0	1.9	0.1	0.0	0.0	2.8	0.4	31.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.1	0.1	0.1	0.0	0.0	5.7	4.7	5.1	5.8	4.7	8.7	7.6	6.4	4.1	5.2	4.3	7.0	5.7	6.8	3.2	104.4	34.3	2.1	4.1	3.2	0.0	1.2	6.4	2.6	1.7	4.0	2.8	10.7	3.7	10.4	149.0	1.4	0.3	0.0	0.2	11.1	0.5	3.9	15.8	15.7	2.7	0.5	0.0	5.3	79.6	0.0	0.8	13.9	1.2	5.7	0.4	155.9	6.7	1.4	1.0	0.0	4.9	8.9	31.4	61.5	32.1	1.8	245.4	16.2	74.5	3.1	2.0	10.4	0.3	0.6	7.2	1.2	6.5	1.4	0.2	1.7	12.4	0.0	13.2	21.6	1.3	2.5	1.8	3.8	111.2	4.8	11.6	0.8	1.3
CREB3L1	OASIS	ENSG00000157613	"CAMP responsive element binding protein 3 like 1"	Q96BA8	11	46277662-46321409	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 135.1;salivary gland: 83.7"	"Cell type enhanced"	"Detected in many"		"Exocrine glandular cells: 89.2;Gastric mucus-secreting cells: 105.0;Glandular and luminal cells: 120.5;Intestinal goblet cells: 280.5"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 87.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 134.3;BJ hTERT+: 130.7;BJ hTERT+ SV40 Large T+: 120.6;fHDF/TERT166: 321.8;OE19: 129.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA024069, CAB026151"	Enhanced					NA	NA					"CAB026151: , HPA024069: AB_1854750"	"unprognostic (2.46e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.34e-1)"	"prognostic favorable (3.92e-4)"	"unprognostic (1.66e-3)"	"unprognostic (2.93e-1)"	"unprognostic (5.41e-2)"	"unprognostic (2.75e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-1)"	"prognostic unfavorable (2.97e-4)"	"unprognostic (2.62e-1)"	"unprognostic (1.93e-1)"	"prognostic unfavorable (8.59e-4)"	"unprognostic (1.12e-2)"	8.7	15.2	3.4	8.1	3.4	0.1	10.8	0.8	4.2	43.6	1.8	41.6	28.0	20.5	2.4	3.2	5.2	25.2	11.8	7.5	2.7	2.8	1.1	14.9	0.7	2.1	4.5	3.0	9.4	135.1	2.3	10.8	26.9	3.1	42.7	43.8	0.1	83.7	27.0	4.4	5.3	30.8	13.4	0.8	3.3	68.6	4.0	5.7	1.1	4.5	4.2	4.8	21.6	15.5	3.8	0.9	0.8	1.3	26.1	81.9	77.9	0.6	134.3	130.7	120.6	83.3	13.7	0.3	0.0	0.7	321.8	8.3	0.0	1.6	0.4	66.6	0.1	1.5	2.0	0.8	0.0	113.5	0.0	1.9	75.2	0.0	68.6	2.5	109.0	1.0	0.5	11.2	0.0	102.5	0.0	0.1	0.4	17.0	129.0	13.7	0.1	18.0	0.2	0.2	0.0	0.0	0.2	0.9	3.4	0.2	23.3	0.1	4.9	0.0	62.7	18.3	48.6	83.4	0.1	0.1	0.0	75.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	3.4	0.8	4.2	7.5	2.7	2.1	4.5	3.0	3.1	0.8	5.7	3.8	10.3	0.0	46.4	0.3	0.6	1.5	44.4	2.6	0.0	0.0	52.0	5.1	15.9	25.8	10.0	29.5	0.0	1.2	0.1	56.8	3.9	42.0	2.1	37.2	24.1	9.0	9.1	0.0	2.1	89.2	2.3	49.4	105.0	120.5	4.5	1.9	3.3	0.0	1.9	0.0	1.0	280.5	6.1	0.0	3.5	6.6	83.6	1.0	10.6	2.8	2.0	0.0	0.0	19.6	0.1	49.2	59.8	44.4	0.2	40.4	9.5	0.7	3.6	0.0	0.0	0.7	29.3	1.0	1.5	0.6	2.3	3.4	1.8	10.7	57.7	51.3
CRYM	DFNA40	ENSG00000103316	"Crystallin mu"	Q14894	16	21238874-21303083	"Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins"		Oxidoreductase	"Deafness, Disease variant, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 87.7;heart muscle: 177.0"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 126.0;Ionocytes: 114.0;Muller glia cells: 640.7;Proximal tubular cells: 190.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 14.6"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	21	"plasmacytoid DC: 82.0"	"Lineage enriched"	"Detected in many"	21	"dendritic cells: 82.0"	"Cell line enriched"	"Detected in some"	4	"RPTEC TERT1: 100.3"	"Group enriched"	"Detected in all"	11	"amygdala: 124.0;basal ganglia: 275.1;cerebral cortex: 124.7;hippocampal formation: 324.3;white matter: 128.4"	"Low region specificity"	"Detected in all"			"HPA019086, HPA030619"	Enhanced		Supported	Cytosol		NA	NA		150000	Cytosol		"HPA019086: AB_1847260, HPA030619: AB_2673551"	"unprognostic (1.32e-1)"	"unprognostic (2.93e-3)"	"unprognostic (8.96e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.13e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.88e-1)"	"unprognostic (5.75e-3)"	"unprognostic (2.81e-1)"	"unprognostic (7.37e-2)"	"unprognostic (2.05e-2)"	"unprognostic (5.95e-2)"	"unprognostic (2.11e-3)"	"unprognostic (7.79e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.87e-3)"	"unprognostic (1.31e-1)"	1.2	0.8	37.1	0.9	87.7	1.0	2.7	52.4	60.1	3.8	24.4	7.0	1.7	1.0	0.2	7.7	1.2	7.0	177.0	58.8	74.3	65.0	14.3	8.6	1.1	25.7	27.9	66.9	0.3	1.9	9.0	56.1	0.4	32.3	35.7	8.5	55.1	20.7	0.2	13.5	4.1	2.6	0.3	24.1	0.3	1.4	5.1	29.2	0.3	0.4	0.9	3.8	22.0	3.7	43.8	0.2	4.0	0.0	0.0	0.2	0.4	0.7	0.0	2.1	0.1	0.2	0.2	0.2	0.3	1.0	0.0	1.8	0.6	5.4	0.0	0.0	0.0	0.8	23.2	0.1	2.3	0.0	0.1	2.2	0.8	0.0	0.8	1.0	0.0	0.0	0.5	0.0	0.4	0.7	0.3	0.0	0.9	9.7	1.6	0.1	0.1	0.0	0.5	100.3	0.1	3.7	5.2	0.2	0.1	2.6	4.8	0.1	0.0	0.0	0.5	0.7	6.8	0.0	0.2	0.0	0.5	16.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.2	0.0	0.0	0.1	3.9	0.0	0.0	0.3	0.0	0.0	82.0	0.0	1.2	37.1	87.7	52.4	60.1	58.8	74.3	25.7	27.9	66.9	32.3	24.1	29.2	43.8	0.3	0.0	20.1	5.2	4.1	2.3	25.4	16.3	0.0	6.3	0.4	11.7	126.0	2.8	56.1	14.7	4.2	0.0	11.4	7.1	17.6	0.1	19.7	3.2	1.5	3.0	13.1	4.8	43.8	0.0	0.0	7.1	6.1	7.7	1.3	1.3	0.4	8.3	0.1	1.7	5.9	20.6	114.0	1.6	0.7	12.4	0.0	1.5	33.8	10.3	0.7	640.7	0.0	7.1	6.6	0.4	2.8	0.0	0.3	19.0	7.5	190.1	19.9	26.2	0.0	0.2	4.3	6.7	7.3	0.2	1.3	0.1	1.1	0.1	8.2	68.0
CSGALNACT1	"ChGn, CSGalNAcT-1, FLJ11264"	ENSG00000147408	"Chondroitin sulfate N-acetylgalactosaminyltransferase 1"	Q8TDX6	8	19404161-19758029	"Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		Transferase	"Disease variant, Dwarfism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"thyroid gland: 87.5"	"Cell type enhanced"	"Detected in many"		"Astrocytes: 494.3;Excitatory neurons: 144.4;Granulosa cells: 214.1;Microglial cells: 224.9;Oligodendrocyte precursor cells: 355.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 22.9"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"T-reg: 62.6"	"Group enriched"	"Detected in all"	5	"B-cells: 44.5;granulocytes: 24.9;T-cells: 62.6"	"Cell line enhanced"	"Detected in many"		"A549: 57.8;BJ hTERT+: 32.3;GAMG: 22.9;RPTEC TERT1: 39.6;U-2197: 36.8;U-87 MG: 26.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA068462			Approved	"Golgi apparatus,Cytosol"	"Intracellular and membrane"	NA	NA			Cytosol	"Golgi apparatus"	"HPA068462: "	"unprognostic (8.90e-2)"	"unprognostic (1.57e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.58e-1)"	"unprognostic (6.03e-2)"	"unprognostic (3.17e-3)"	"unprognostic (9.78e-2)"	"unprognostic (7.76e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.60e-2)"	"unprognostic (8.22e-2)"	"unprognostic (6.82e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.89e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.46e-3)"	"unprognostic (1.02e-2)"	19.6	12.7	20.9	8.9	15.9	11.2	7.4	5.7	18.5	18.1	2.0	4.2	3.5	7.1	5.4	31.5	11.9	16.3	36.1	17.2	12.4	6.1	2.9	11.8	7.6	10.5	10.7	13.7	57.5	8.0	11.5	3.0	39.2	11.6	32.1	2.5	2.6	6.8	9.8	5.9	4.4	4.7	12.4	6.3	8.8	7.0	2.8	9.5	11.8	87.5	11.1	8.9	23.6	8.1	11.9	2.1	57.8	0.5	0.0	9.3	2.1	7.9	1.4	32.3	0.3	0.3	3.1	1.0	0.0	0.3	0.0	22.9	0.7	0.0	0.0	0.4	7.5	0.4	0.2	16.2	1.9	4.1	0.0	0.1	0.9	1.6	0.7	0.3	0.4	11.6	0.2	0.0	0.1	0.1	2.6	2.9	0.2	0.3	8.3	1.7	0.3	0.1	0.0	39.6	1.6	0.2	0.3	17.2	6.9	2.4	1.5	0.1	0.4	1.0	1.1	1.3	36.8	0.9	0.3	0.0	0.0	26.0	3.4	11.4	0.1	2.9	24.9	5.6	0.1	0.6	44.5	25.7	8.5	2.8	15.9	44.6	11.6	15.6	8.4	0.4	4.2	62.6	11.7	20.9	15.9	5.7	18.5	17.2	12.4	10.5	10.7	13.7	11.6	6.3	9.5	11.9	33.3	3.2	1.1	494.3	27.3	4.5	7.4	0.2	0.6	0.3	4.1	0.8	45.8	0.0	0.9	12.9	10.4	1.9	6.2	0.0	1.9	5.7	6.9	7.5	1.2	38.5	3.0	3.2	144.4	1.7	14.6	20.9	2.0	2.0	0.0	214.1	26.7	0.2	15.8	18.5	76.5	0.0	16.2	27.4	6.5	7.4	5.3	14.1	12.4	224.9	3.5	1.0	6.2	355.9	4.6	3.1	0.0	12.0	21.3	21.8	0.0	0.1	1.5	1.0	6.6	2.1	12.0	0.7	0.1	0.5	3.1	8.3	9.6	77.0	0.1	2.8
CST2		ENSG00000170369	"Cystatin SA"	P09228	20	23823769-23826729	"Predicted secreted proteins"		"Protease inhibitor, Thiol protease inhibitor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	638	"salivary gland: 6041.2"	"Group enriched"	"Detected in some"	4	"Granulosa cells: 5.2;Melanocytes: 16.0"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 24.8"	"Region enriched"	"Detected in single"	13	"hypothalamus: 1.4"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	12	"RT4: 67.7"									"CAB024963, HPA043706, HPA044763"	Enhanced				"Secreted to digestive system"	NA	NA					"CAB024963: , HPA043706: AB_2678627, HPA044763: AB_2679080"	"unprognostic (1.57e-2)"	"unprognostic (3.23e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.10e-1)"	"unprognostic (1.64e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.28e-2)"	"unprognostic (2.75e-3)"	"unprognostic (2.73e-1)"	"unprognostic (4.82e-3)"	"unprognostic (6.43e-3)"	"unprognostic (2.51e-1)"	"unprognostic (4.58e-11)"	"unprognostic (1.29e-3)"	"unprognostic (3.22e-1)"	"unprognostic (4.30e-1)"	"unprognostic (1.71e-1)"	0.5	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.5	0.0	0.1	0.1	0.2	0.1	0.0	0.2	4.8	2.4	0.0	1.4	0.1	0.1	0.8	0.0	0.0	0.0	0.0	1.6	9.4	0.1	2.0	1.0	0.0	2.5	0.0	0.0	6041.2	1.3	0.0	0.4	0.2	3.8	0.0	0.1	0.6	0.0	0.0	0.8	0.1	0.0	0.0	0.1	0.3	0.0	0.0	0.5	0.0	0.0	0.4	0.0	0.1	0.0	0.1	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.4	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.2	0.0	0.0	0.0	1.8	67.7	0.0	0.0	0.0	0.0	5.4	0.9	0.0	0.0	4.7	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.4	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.0	0.0	16.0	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0
CYP39A1		ENSG00000146233	"Cytochrome P450 family 39 subfamily A member 1"	Q9NYL5	6	46549580-46652830	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Monooxygenase, Oxidoreductase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"liver: 100.1"	"Cell type enhanced"	"Detected in many"		"Hepatocytes: 62.9;Late spermatids: 20.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 11.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Daudi: 6.5;hTCEpi: 13.6;OE19: 6.1;SiHa: 8.4;U-698: 10.4"	"Region enhanced"	"Detected in all"		"olfactory bulb: 22.9"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.33e-1)"	"unprognostic (1.62e-2)"	"unprognostic (8.46e-3)"	"unprognostic (5.89e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.08e-1)"	"unprognostic (1.03e-1)"	"unprognostic (5.78e-2)"	"unprognostic (1.61e-1)"	"unprognostic (4.99e-2)"	"unprognostic (7.33e-2)"	"unprognostic (6.11e-2)"	"prognostic favorable (1.86e-4)"	"unprognostic (1.54e-1)"	"unprognostic (5.48e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.20e-1)"	1.9	2.5	2.3	1.0	2.5	0.0	5.5	3.6	2.4	3.7	4.6	2.7	0.8	3.6	21.2	3.3	4.2	6.3	4.0	2.4	4.1	5.8	100.1	3.3	0.5	2.3	2.4	1.6	11.6	5.7	15.5	3.0	0.4	2.4	14.9	3.6	4.2	23.7	2.6	0.6	16.0	1.7	2.4	2.7	0.7	2.9	4.2	2.5	0.4	6.2	1.2	1.4	2.7	3.0	2.9	0.2	0.4	0.3	1.8	0.3	0.0	0.0	0.0	1.1	0.3	0.1	0.0	0.5	6.5	4.4	0.0	0.9	1.7	0.8	1.4	0.0	0.0	2.8	0.0	1.7	1.8	4.0	0.0	0.0	0.5	13.6	0.0	1.6	1.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	6.1	1.5	0.5	1.1	0.1	2.9	4.0	0.7	0.0	8.4	0.0	0.2	0.4	1.5	0.0	0.0	0.2	0.9	0.0	0.1	0.0	0.0	10.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	2.5	3.6	2.4	2.4	4.1	2.3	2.4	1.6	2.4	2.7	2.5	2.9	3.3	16.0	1.5	3.9	0.2	4.0	8.8	2.7	2.8	1.4	4.6	6.5	5.8	10.0	4.3	3.7	2.1	0.0	0.0	1.1	5.9	2.9	12.7	4.4	1.0	3.5	0.0	5.3	3.2	0.4	0.9	4.5	1.5	3.1	0.0	2.7	1.1	62.9	0.2	0.0	2.0	4.0	10.2	2.5	0.9	20.1	6.2	0.3	3.6	8.4	0.0	8.6	0.0	1.0	7.2	0.5	2.7	9.4	0.0	7.9	0.3	5.3	7.2	1.5	0.0	1.9	2.3	0.7	0.8	2.6	15.3	0.0	0.2	6.3	2.5	8.1
DES	"CMD1I, CSM1, CSM2"	ENSG00000175084	Desmin	P17661	2	219418377-219426734	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Muscle protein"	"Cancer-related genes, Cardiomyopathy, Desmin-related myopathy, Disease variant, Limb-girdle muscular dystrophy, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 9831.5;skeletal muscle: 16668.0"	"Cell type enriched"	"Detected in many"	5	"Cardiomyocytes: 2531.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 562.1;stomach cancer: 400.2"	"Region enhanced"	"Detected in all"		"cerebral cortex: 13.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HSkMC: 70.2;LHCN-M2: 145.3;NB-4: 39.5;RH-30: 333.1"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"midbrain: 29.5"	"CAB000034, HPA018803"	Enhanced		Supported	"Intermediate filaments"		NA	NA		1600000	"Intermediate filaments"		"CAB000034: , HPA018803: AB_1847616"	"unprognostic (1.75e-1)"	"unprognostic (1.95e-3)"	"unprognostic (3.43e-2)"	"unprognostic (8.76e-2)"	"unprognostic (7.75e-3)"	"unprognostic (6.61e-3)"	"unprognostic (1.55e-1)"	"unprognostic (2.72e-2)"	"unprognostic (4.67e-1)"	"unprognostic (3.84e-2)"	"unprognostic (2.57e-1)"	"unprognostic (7.43e-2)"	"prognostic unfavorable (5.08e-4)"	"unprognostic (3.49e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.22e-1)"	"unprognostic (9.25e-3)"	170.8	57.6	1.7	440.0	3.3	1.1	51.7	1.8	13.7	490.7	19.3	5828.2	293.9	3040.5	86.7	1494.9	1094.5	456.2	9831.5	2.0	2.0	17.0	15.6	175.5	7.3	4.2	2.6	1.8	173.3	14.7	0.5	8.5	53.2	2.0	2237.7	247.9	0.0	257.4	2274.3	16668.0	123.2	1355.1	2581.7	2.0	25.4	1982.2	16.2	2.0	3.2	66.7	5804.8	1.2	4801.7	675.1	2.5	0.0	0.0	0.1	0.0	0.0	2.2	5.3	0.2	0.0	0.1	0.1	0.5	0.0	0.0	9.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.2	17.0	0.1	1.3	70.2	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	145.3	0.0	0.0	39.5	0.5	0.0	0.0	0.0	333.1	2.1	0.0	0.0	0.2	1.2	0.0	0.0	0.0	9.2	0.0	5.0	0.0	0.0	0.1	1.7	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	1.7	3.3	1.8	13.7	2.0	2.0	4.2	2.6	1.8	2.0	2.0	2.0	2.5	0.4	0.0	0.0	0.0	0.0	4.1	2.7	0.0	0.0	0.0	0.1	0.0	2531.9	1.5	0.0	0.0	0.0	1.9	0.0	0.4	0.0	0.0	90.6	0.5	6.7	22.7	0.0	0.0	0.1	0.0	5.2	104.6	0.0	0.1	0.0	0.0	1.8	0.0	5.6	0.0	0.0	0.9	0.0	0.0	10.7	71.6	28.9	2.8	12.4	0.0	0.6	0.0	0.0	0.5	0.0	0.5	0.0	50.4	0.0	8.7	0.0	0.1	0.0	0.0	46.0	497.8	210.5	5.0	5.1	0.1	9.8	8.5	2.4	0.0	0.2	2.9
DLX1		ENSG00000144355	"Distal-less homeobox 1"	P56177	2	172084740-172089677	"Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"brain: 9.0"	"Cell type enriched"	"Detected in some"	23	"Inhibitory neurons: 30.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 11.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 134.5;U-138 MG: 36.9;WM-115: 42.1"	"Group enriched"	"Detected in many"	5	"basal ganglia: 28.6;olfactory bulb: 82.6"	"Region enriched"	"Detected in many"	4	"olfactory bulb: 48.8"	"HPA007175, HPA045884"	Approved		Supported	Nucleoplasm,Vesicles,Cytosol		NA	NA			Nucleoplasm	"Vesicles, Cytosol"	"HPA007175: , HPA045884: AB_10960361"	"unprognostic (2.14e-2)"	"unprognostic (5.09e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.89e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.18e-1)"	"unprognostic (7.92e-3)"	"unprognostic (8.86e-2)"	"unprognostic (2.80e-2)"	"unprognostic (2.03e-1)"	"unprognostic (5.74e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.40e-9)"	"unprognostic (2.22e-1)"	"unprognostic (9.19e-2)"	"unprognostic (1.25e-1)"	"unprognostic (5.91e-3)"	0.0	1.3	5.3	0.2	5.1	0.0	0.1	0.0	4.4	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	3.2	9.0	0.0	0.0	0.0	0.0	0.3	0.2	3.0	0.0	0.0	0.0	0.1	0.0	1.1	0.7	0.2	0.0	0.1	0.0	0.1	0.4	0.2	0.1	0.0	0.0	0.1	0.0	4.4	0.0	1.0	0.2	0.3	0.1	0.2	2.7	2.4	0.6	0.6	134.5	2.0	4.5	0.3	3.2	6.5	7.7	4.1	1.0	0.2	0.0	7.8	7.2	7.5	9.4	7.4	1.2	5.2	0.3	33.3	21.1	14.4	5.7	0.1	7.9	15.9	0.0	2.2	1.9	3.2	5.4	0.0	6.7	12.4	0.0	6.3	8.1	0.1	1.9	0.1	0.0	22.9	0.4	15.8	0.0	0.9	4.5	11.3	0.0	6.1	0.8	17.5	0.4	5.2	9.5	7.1	36.9	0.2	16.4	16.4	0.2	0.0	0.1	15.2	21.4	42.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	5.3	5.1	0.0	4.4	3.2	9.0	0.3	0.2	3.0	1.1	0.0	4.4	2.7	0.1	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.3	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	30.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DMXL1		ENSG00000172869	"Dmx like 1"	Q9Y485	5	119037772-119249138	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"Excitatory neurons: 122.3;Inhibitory neurons: 147.3;Oligodendrocytes: 224.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 14.0"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036431, HPA036432"	Approved		Approved	Nucleoli,Cytosol		NA	NA			Nucleoli	Cytosol	"HPA036431: AB_10669791, HPA036432: AB_2675120"	"unprognostic (2.47e-1)"	"unprognostic (4.84e-2)"	"unprognostic (7.87e-3)"	"unprognostic (3.51e-1)"	"unprognostic (1.08e-1)"	"unprognostic (5.80e-3)"	"unprognostic (2.80e-1)"	"unprognostic (6.77e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.88e-2)"	"unprognostic (5.93e-2)"	"unprognostic (2.26e-1)"	"prognostic favorable (5.16e-5)"	"unprognostic (4.04e-2)"	"unprognostic (3.99e-1)"	"unprognostic (2.12e-2)"	"unprognostic (5.18e-2)"	7.0	4.8	2.3	7.3	5.8	26.1	9.3	7.2	5.9	7.5	10.2	6.9	6.2	8.8	5.7	8.3	6.7	7.6	6.2	2.6	4.3	14.0	7.2	6.6	10.2	6.6	5.2	2.3	10.5	12.1	11.9	2.6	7.2	7.3	27.4	7.1	9.1	8.0	5.9	4.1	8.3	6.1	8.2	5.7	8.2	8.0	5.9	4.7	10.4	13.5	7.3	9.8	6.2	4.6	14.8	10.4	8.0	8.8	9.0	9.3	12.2	9.4	8.4	8.4	8.3	9.6	9.6	6.2	20.2	8.5	10.8	12.9	6.1	9.9	10.0	10.7	15.6	9.9	14.2	14.0	3.4	7.8	9.4	11.8	9.8	5.5	9.6	7.9	8.5	11.0	12.4	12.1	13.3	6.7	6.5	12.6	5.3	4.8	3.6	4.7	9.8	16.3	7.9	6.4	11.9	8.2	8.3	14.5	5.2	12.6	9.4	8.6	10.7	10.7	9.8	8.2	9.9	9.0	12.4	9.4	17.6	12.2	9.1	8.0	4.1	4.9	3.6	2.4	4.4	3.0	8.8	1.9	2.0	3.4	9.1	3.0	1.8	3.8	1.3	8.9	8.3	2.6	2.7	2.3	5.8	7.2	5.9	2.6	4.3	6.6	5.2	2.3	7.3	5.7	4.7	14.8	23.7	28.9	20.1	93.4	56.5	13.6	16.5	17.7	22.8	36.8	22.8	15.4	25.7	7.2	17.6	16.5	25.0	12.6	27.5	16.2	17.6	12.0	10.2	19.8	21.1	16.7	6.0	19.1	122.3	20.1	10.3	20.4	27.5	25.0	14.0	15.6	11.0	15.6	16.6	21.9	147.3	12.2	10.2	21.9	19.9	12.1	15.2	31.0	33.8	68.4	29.1	16.9	25.7	111.6	224.0	14.1	11.6	15.4	27.2	36.0	15.8	32.5	13.9	22.6	13.1	28.6	24.7	28.0	23.2	35.0	18.8	16.3	24.3	17.8	11.3	15.0
DNAH5	"CILD3, Dnahc5, HL1, KTGNR, PCD"	ENSG00000039139	"Dynein axonemal heavy chain 5"	Q8TE73	5	13690328-14011818	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"		"Motor protein"	"Ciliopathy, Disease variant, Kartagener syndrome, Primary ciliary dyskinesia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 4.4;choroid plexus: 11.9;fallopian tube: 3.9"	"Cell type enhanced"	"Detected in many"		"Club cells: 61.7;Endometrial ciliated cells: 190.3;Respiratory ciliated cells: 258.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 3.0"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 1.6;LHCN-M2: 1.1;PC-3: 2.7;RPTEC TERT1: 1.3;TIME: 1.0"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA037469, HPA037470"	Enhanced					NA	NA					"HPA037469: AB_10672791, HPA037470: AB_10672348"	"unprognostic (3.85e-1)"	"unprognostic (8.17e-2)"	"unprognostic (5.94e-2)"	"unprognostic (1.12e-1)"	"unprognostic (4.58e-3)"	"unprognostic (6.23e-2)"	"unprognostic (3.33e-3)"	"unprognostic (2.86e-2)"	"unprognostic (9.94e-2)"	"unprognostic (4.39e-2)"	"unprognostic (1.59e-1)"	"unprognostic (9.99e-2)"	"unprognostic (9.97e-3)"	"unprognostic (8.87e-2)"	"unprognostic (8.72e-2)"	"unprognostic (2.82e-2)"	"unprognostic (1.65e-1)"	0.0	0.1	3.2	0.0	1.1	0.0	1.6	1.5	0.8	0.3	11.9	0.1	0.0	0.1	0.1	0.0	3.9	0.1	0.0	0.8	3.1	0.8	1.0	1.7	0.0	3.8	4.4	0.4	0.0	0.9	0.0	2.0	0.0	3.8	1.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	2.4	0.0	0.4	0.3	2.8	0.0	1.1	0.0	0.0	0.8	0.0	1.5	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.4	1.6	0.0	0.1	0.0	0.5	0.0	0.5	0.2	0.4	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.2	2.7	0.0	0.0	0.0	1.3	0.4	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	1.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	1.1	1.5	0.8	0.8	3.1	3.8	4.4	0.4	3.8	2.4	2.8	1.5	0.3	3.2	24.4	7.2	0.2	0.0	1.7	5.6	0.0	0.0	11.7	7.0	1.5	14.3	61.7	5.5	0.0	0.0	0.1	0.0	0.0	6.7	7.3	190.3	1.9	1.2	1.8	0.0	12.9	3.6	0.2	1.8	0.0	12.4	2.5	0.0	0.0	10.9	0.0	0.0	7.8	0.0	6.1	0.0	0.0	5.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	4.0	0.4	2.6	0.0	0.0	0.1	14.8	0.0	4.3	258.7	0.0	0.0	1.6	2.6	2.6	3.6	0.0	0.0	0.0	0.4	0.1	0.0	3.8
DPP4	"ADCP2, CD26, DPPIV"	ENSG00000197635	"Dipeptidyl peptidase 4"	P27487	2	161992245-162074394	"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"	"Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 139.1;parathyroid gland: 156.7;placenta: 135.2;prostate: 108.2"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 140.3;Proximal enterocytes: 291.1;Proximal tubular cells: 101.4;Syncytiotrophoblasts: 172.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 55.2"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in many"		"MAIT T-cell: 52.3"	"Lineage enriched"	"Detected in many"	10	"T-cells: 52.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 194.4;ASC TERT1: 212.6;BJ hTERT+: 207.0;RPTEC TERT1: 263.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB045970, HPA068778, HPA071236"	Enhanced				"Secreted to blood"	NA	NA		190000000			"CAB045970: AB_11140529, HPA068778: , HPA071236: "	"unprognostic (4.47e-2)"	"unprognostic (4.47e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.36e-1)"	"unprognostic (7.25e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.78e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.58e-1)"	"unprognostic (4.73e-1)"	"unprognostic (2.36e-1)"	"prognostic unfavorable (1.98e-4)"	"prognostic favorable (1.35e-6)"	"unprognostic (4.68e-2)"	"unprognostic (6.33e-2)"	"prognostic favorable (4.99e-4)"	"unprognostic (1.21e-2)"	12.0	3.1	0.2	5.3	0.3	0.7	8.5	0.2	0.6	11.0	0.2	14.7	108.0	3.6	4.0	3.0	7.4	6.8	2.1	0.2	0.4	95.7	57.6	16.1	5.9	0.3	0.3	0.2	3.5	3.5	156.7	0.1	135.2	0.3	108.2	17.1	0.1	85.2	23.7	1.6	5.1	139.1	3.0	0.3	11.3	7.7	1.3	0.7	12.5	5.0	4.0	4.5	5.8	3.6	0.5	0.2	0.2	1.0	0.0	194.4	212.6	0.6	37.7	207.0	10.9	37.2	38.0	1.0	0.0	13.6	71.0	30.2	1.1	0.4	0.0	6.2	12.3	0.0	0.0	0.0	57.1	77.0	0.0	0.0	22.0	0.1	66.3	0.5	9.1	6.6	0.7	0.0	0.0	3.6	0.0	3.6	0.5	2.0	1.3	72.7	0.0	0.0	0.6	263.3	0.0	0.1	0.4	0.0	0.0	0.0	4.4	0.0	0.3	37.0	21.8	1.1	0.7	0.0	0.0	0.0	0.0	22.5	0.0	0.0	0.0	0.0	0.0	6.6	0.0	52.3	0.2	16.2	10.7	1.2	0.0	15.7	6.6	0.4	5.3	0.0	4.0	2.0	4.7	0.2	0.3	0.2	0.6	0.2	0.4	0.3	0.3	0.2	0.3	0.3	0.7	0.5	10.8	6.4	26.0	0.3	2.1	4.1	0.4	0.1	0.0	1.8	0.2	0.8	3.3	12.8	2.8	14.7	10.4	140.3	10.4	27.4	1.9	3.0	15.0	2.3	7.1	9.4	55.2	0.4	31.6	0.0	59.1	35.3	2.0	68.0	13.9	5.3	9.3	34.5	14.5	0.0	6.3	16.4	0.0	0.9	7.6	7.9	0.0	4.8	5.4	3.7	1.1	0.0	1.0	2.5	0.7	1.4	23.8	0.0	2.1	32.7	291.1	101.4	2.2	0.1	0.0	2.1	1.5	4.0	1.1	0.1	4.1	172.0	25.8	29.2	29.1	0.3
EPHA5	"CEK7, EHK1, Hek7, TYRO4"	ENSG00000145242	"EPH receptor A5"	P54756	4	65319563-65670495	"Enzymes, Metabolic proteins, Predicted membrane proteins"	Neurogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"brain: 22.9"	"Group enriched"	"Detected in some"	10	"Excitatory neurons: 202.5;Inhibitory neurons: 162.8;Oligodendrocyte precursor cells: 96.0"	"Cancer enhanced"	"Detected in some"		"glioma: 0.8;prostate cancer: 0.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"hTERT-RPE1: 10.0;PC-3: 9.4;TIME: 12.6;U-138 MG: 25.5;U-2197: 15.7;U-251 MG: 20.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA		33000				"unprognostic (1.02e-2)"	"unprognostic (4.22e-2)"	"unprognostic (2.38e-1)"	"unprognostic (4.89e-4)"	"unprognostic (7.43e-4)"	"unprognostic (1.60e-1)"		"unprognostic (6.68e-3)"	"unprognostic (2.49e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.03e-2)"	"unprognostic (9.25e-2)"		"unprognostic (5.88e-3)"	"unprognostic (2.55e-2)"	"unprognostic (5.97e-4)"	"unprognostic (3.81e-3)"	0.0	0.8	2.1	0.1	5.9	0.0	0.0	0.0	22.9	2.0	0.0	0.1	0.0	0.4	0.0	0.1	0.0	0.0	0.8	15.9	3.3	0.0	0.0	0.1	0.0	3.1	3.1	5.8	2.3	0.0	0.0	0.7	0.9	4.1	1.5	0.1	1.5	0.3	1.4	0.0	0.2	0.0	0.2	0.9	0.3	0.3	0.7	1.7	0.0	0.9	0.0	0.0	0.1	0.5	8.4	0.0	0.7	0.8	0.0	0.8	0.4	0.0	0.4	1.3	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	4.4	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	10.0	0.3	0.0	0.0	1.5	2.6	0.0	0.0	0.0	0.1	0.0	9.4	0.0	2.9	0.5	0.0	0.0	1.1	0.0	0.0	0.0	4.3	0.0	0.0	0.0	12.6	25.5	3.1	15.7	20.6	0.0	0.0	0.0	2.6	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	5.9	0.0	22.9	15.9	3.3	3.1	3.1	5.8	4.1	0.9	1.7	8.4	0.0	0.0	0.0	8.5	0.0	0.5	0.0	0.0	0.0	2.7	0.0	0.1	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.4	0.0	2.2	0.1	0.0	0.0	202.5	0.0	0.0	0.7	0.0	0.0	0.0	0.8	0.0	0.0	0.1	1.7	162.8	0.0	0.0	0.0	0.0	15.2	0.9	0.0	3.6	5.6	0.0	5.7	0.0	96.0	4.8	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.4	0.0	0.0	0.4	0.7	0.4	0.0	0.1	0.0	0.0	0.7	0.0	0.1
EPHA6	FLJ35246	ENSG00000080224	"EPH receptor A6"	Q9UF33	3	96814581-97752460	"Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 26.2;testis: 8.5"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 421.5;Early spermatids: 401.8;Excitatory neurons: 423.8;Inhibitory neurons: 879.2;Late spermatids: 208.7"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HEK 293: 9.3;U-266/70: 28.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007397, HPA058047"	Uncertain		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA007397: AB_2667821, HPA058047: AB_2683588"	"unprognostic (9.87e-2)"	"unprognostic (1.67e-2)"	"unprognostic (3.42e-4)"	"unprognostic (7.21e-5)"	"unprognostic (8.51e-2)"	"unprognostic (1.32e-1)"		"unprognostic (1.82e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.34e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.71e-4)"	"unprognostic (1.93e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.48e-2)"	"unprognostic (7.14e-3)"	0.2	0.0	7.5	0.0	11.2	0.0	0.2	26.2	11.4	0.8	0.0	2.0	0.1	0.9	0.3	0.8	1.9	0.9	0.3	11.9	5.3	0.4	0.0	0.1	0.0	2.9	1.7	10.9	6.4	0.5	0.1	0.1	0.0	13.2	1.0	0.7	1.1	0.1	0.6	0.0	0.0	0.3	1.4	0.0	0.0	0.6	8.5	3.3	0.2	2.0	0.1	0.1	1.4	0.6	4.4	0.0	0.3	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	9.3	0.0	2.2	0.0	0.0	2.3	0.0	0.0	0.4	0.0	0.9	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.8	1.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	2.4	0.0	0.9	28.1	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	11.2	26.2	11.4	11.9	5.3	2.9	1.7	10.9	13.2	0.0	3.3	4.4	0.0	0.0	0.0	421.5	0.1	0.3	0.3	0.0	5.2	1.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	401.8	0.1	1.4	0.1	0.0	0.0	423.8	0.0	0.0	0.9	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	879.2	0.0	0.0	0.0	0.0	208.7	3.1	0.2	0.0	30.0	0.0	1.0	0.0	31.2	9.0	0.1	0.0	1.5	0.0	0.1	0.0	1.7	0.0	0.3	0.0	0.2	0.1	14.7	2.7	6.0	0.0	0.1	0.0	0.4	0.0	0.1
FAAH	FAAH-1	ENSG00000117480	"Fatty acid amide hydrolase"	O00519	1	46394317-46413848	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Late spermatids: 128.5;Proximal enterocytes: 87.4;Spermatocytes: 89.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 68.2"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"eosinophil: 29.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BEWO: 37.5;OE19: 18.8;RT4: 42.4;SK-BR-3: 21.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007425	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA007425: AB_1078820"	"unprognostic (6.12e-2)"	"unprognostic (2.04e-1)"	"unprognostic (2.51e-2)"	"prognostic favorable (1.51e-4)"	"unprognostic (1.72e-1)"	"unprognostic (4.97e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.64e-3)"	"unprognostic (2.91e-2)"	"unprognostic (2.33e-1)"	"unprognostic (4.39e-3)"	"unprognostic (9.86e-2)"	"prognostic favorable (4.25e-5)"	"prognostic favorable (3.63e-5)"	"unprognostic (2.66e-1)"	"unprognostic (9.97e-2)"	"unprognostic (5.00e-3)"	7.6	14.3	20.9	3.0	28.1	10.5	9.6	24.6	27.0	7.6	26.0	18.5	22.2	3.9	9.2	8.7	12.1	5.2	3.8	24.0	25.5	20.0	33.0	7.8	2.5	31.7	26.3	22.9	3.9	22.6	24.8	19.2	3.4	29.8	44.5	15.3	5.6	17.6	7.2	9.6	12.2	22.2	2.3	27.3	3.3	17.2	47.1	25.7	7.2	38.9	5.7	2.7	7.0	8.2	45.8	5.0	1.2	0.8	1.0	1.2	0.8	37.5	1.0	0.5	0.5	0.8	7.3	11.4	0.3	3.9	0.7	0.4	16.2	0.7	2.3	0.2	2.2	5.4	0.1	0.2	3.5	0.8	1.4	2.8	0.6	10.7	0.4	1.3	0.4	0.0	0.9	0.1	0.8	0.0	10.7	0.8	2.2	3.2	18.8	0.4	0.9	0.4	0.2	9.0	42.4	4.8	3.6	5.6	21.2	0.2	0.9	14.6	14.5	0.0	0.1	0.6	1.1	0.7	2.1	1.0	0.6	0.1	13.4	0.4	0.0	6.9	29.1	0.4	1.9	0.2	0.1	0.4	0.2	8.2	0.1	0.6	0.6	0.4	0.5	1.0	8.8	0.2	1.4	20.9	28.1	24.6	27.0	24.0	25.5	31.7	26.3	22.9	29.8	27.3	25.7	45.8	1.2	22.4	13.2	6.5	2.4	5.2	29.0	6.8	10.2	15.5	15.4	9.0	2.9	27.1	11.0	22.0	43.8	16.3	7.3	51.6	0.0	12.4	50.7	9.5	1.9	1.8	15.5	6.6	15.7	6.4	8.7	3.7	37.8	6.0	0.0	6.3	0.4	37.1	2.8	1.7	11.4	38.2	10.2	2.5	4.2	128.5	7.5	3.3	5.4	1.9	2.5	7.3	0.0	7.5	45.1	4.2	41.3	4.5	0.7	20.1	87.4	22.6	5.2	14.5	0.0	2.9	3.2	89.0	23.0	6.4	6.0	12.4	1.2	1.3	55.2	18.9
FAM13C	FAM13C1	ENSG00000148541	"Family with sequence similarity 13 member C"	Q8NE31	10	59246130-59363181	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 69.7"	"Cell type enriched"	"Detected in many"	6	"Oligodendrocytes: 477.1"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 3.4"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 4.1;HSkMC: 5.1;hTERT-RPE1: 3.4;NTERA-2: 4.5;SCLC-21H: 8.6;SH-SY5Y: 5.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA037888	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA037888: AB_10962981"	"unprognostic (3.68e-1)"	"unprognostic (6.10e-2)"	"unprognostic (2.46e-1)"	"unprognostic (6.69e-5)"	"unprognostic (8.54e-2)"	"unprognostic (4.56e-2)"	"unprognostic (3.30e-2)"	"unprognostic (1.06e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.00e-3)"	"unprognostic (3.27e-1)"	"unprognostic (4.51e-6)"	"unprognostic (1.02e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.94e-3)"	"unprognostic (4.66e-3)"	12.5	16.3	21.3	3.9	44.0	0.0	9.4	32.3	38.2	8.8	4.4	6.6	4.2	8.8	8.1	13.9	14.7	11.6	8.2	21.9	33.6	3.4	2.2	10.0	4.8	42.5	37.7	20.5	21.4	2.3	4.7	4.8	2.6	40.6	17.4	6.3	10.0	5.7	8.0	17.3	7.3	6.0	12.3	37.4	5.2	3.8	5.3	36.5	5.2	6.3	23.1	2.3	4.4	8.0	69.7	0.0	0.1	1.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.0	1.3	0.2	0.1	0.0	1.2	0.0	4.1	1.9	0.1	0.0	0.0	5.1	0.6	0.2	0.0	3.4	0.0	0.0	0.0	0.2	2.1	0.0	0.0	0.0	4.5	0.0	0.4	0.0	0.8	0.0	0.0	1.3	8.6	5.0	0.0	0.2	0.0	0.3	0.7	0.0	0.0	2.5	2.2	0.1	2.1	0.0	0.0	0.1	3.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.3	44.0	32.3	38.2	21.9	33.6	42.5	37.7	20.5	40.6	37.4	36.5	69.7	47.8	0.0	0.0	33.6	0.1	4.8	9.3	0.3	8.0	10.5	0.7	2.7	2.5	0.0	0.7	0.0	6.2	0.0	0.4	0.1	7.9	0.0	49.0	18.6	1.5	35.2	0.0	0.0	66.8	0.0	0.0	19.8	0.5	5.3	0.0	26.9	3.9	0.5	0.0	3.3	73.2	0.2	20.3	0.0	2.5	22.1	23.0	0.7	3.6	7.5	0.0	8.8	0.0	56.8	477.1	0.0	0.0	21.1	0.1	5.4	0.0	0.6	20.7	13.6	39.5	23.4	36.2	1.4	0.7	2.4	6.3	0.0	1.2	17.4	0.2	1.1
FAM3B	"2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44"	ENSG00000183844	"FAM3 metabolism regulating signaling molecule B"	P58499	21	41304212-41357727	"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	Cytokine		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 143.9;pancreas: 214.0;salivary gland: 120.5;stomach 1: 115.9"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 304.6;Exocrine glandular cells: 399.9;Proximal enterocytes: 831.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 40.3"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in some"		"eosinophil: 1.4;neutrophil: 2.8"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 2.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 19.5;CAPAN-2: 11.7;Hep G2: 32.1;OE19: 27.3;RPMI-8226: 80.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA015885, HPA029777, CAB034131"	Enhanced		Approved	Vesicles	"Secreted to blood"	NA	NA	2080000	250000	Vesicles		"CAB034131: AB_2231472, HPA015885: AB_1848396, HPA029777: AB_2673194"	"unprognostic (2.88e-1)"	"unprognostic (3.31e-3)"	"unprognostic (5.13e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.62e-1)"	"unprognostic (6.32e-3)"	"unprognostic (1.41e-1)"	"unprognostic (8.79e-3)"	"unprognostic (9.38e-2)"	"unprognostic (1.70e-1)"	"unprognostic (4.65e-1)"	"unprognostic (3.78e-1)"	"unprognostic (5.60e-3)"	"unprognostic (1.57e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.55e-3)"	1.1	0.1	0.1	2.5	0.1	0.8	17.9	0.1	0.3	3.8	1.1	6.0	143.9	0.3	22.3	56.7	17.4	16.4	0.4	0.1	0.3	18.0	2.6	9.4	1.5	0.1	0.1	0.1	0.2	214.0	0.5	5.5	15.3	0.2	38.2	0.1	0.0	120.5	8.8	0.1	2.0	136.1	0.5	0.1	0.6	115.9	7.0	0.1	3.1	8.0	0.0	17.0	34.7	16.9	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	19.5	11.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	32.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.4	0.9	27.3	0.0	0.2	0.0	80.6	0.0	5.8	0.4	0.4	0.0	0.7	0.4	0.1	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.2	0.0	0.3	1.4	0.0	0.1	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	2.8	0.0	0.3	0.7	0.0	0.0	0.1	0.1	0.1	0.3	0.1	0.3	0.1	0.1	0.1	0.2	0.1	0.1	0.3	1.0	22.4	25.7	0.0	0.8	1.3	17.0	2.9	1.2	0.0	101.3	123.1	0.2	102.9	36.5	66.2	0.0	304.6	1.4	2.7	25.4	172.1	25.2	0.2	0.1	2.5	0.0	0.0	0.1	399.9	11.1	3.4	147.3	0.7	1.3	0.6	0.4	0.3	27.0	0.0	0.1	120.9	42.7	5.0	15.8	11.5	0.6	3.9	5.4	1.9	2.1	0.0	0.0	0.0	0.1	144.6	169.0	0.4	0.2	64.9	831.6	0.7	22.4	0.0	0.0	0.4	1.8	28.0	8.1	29.1	1.3	161.3	0.9	0.0	125.2	130.5
FFAR2	"FFA2R, GPR43"	ENSG00000126262	"Free fatty acid receptor 2"	O15552	19	35443907-35451767	"G-protein coupled receptors, Predicted membrane proteins"	"Immunity, Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 20.5;lymphoid tissue: 22.4"	"Cell type enhanced"	"Detected in some"		"Enteroendocrine cells: 24.1;Intestinal goblet cells: 8.9;Kupffer cells: 11.9;Macrophages: 15.4;Prostatic glandular cells: 7.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 6.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	25	"eosinophil: 85.0;neutrophil: 249.7"	"Lineage enriched"	"Detected in many"	38	"granulocytes: 249.7"	"Cell line enhanced"	"Detected in some"		"HMC-1: 3.9;OE19: 1.8;SK-BR-3: 1.1;THP-1: 1.2;U-937: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA023985	Approved					NA	NA					"HPA023985: AB_1849302"	"unprognostic (7.75e-3)"	"unprognostic (5.65e-2)"	"unprognostic (4.33e-3)"	"unprognostic (1.68e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.55e-2)"	"unprognostic (6.16e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.92e-2)"	"unprognostic (9.04e-2)"	"unprognostic (2.30e-2)"	"unprognostic (4.60e-2)"	"unprognostic (5.17e-4)"	"unprognostic (1.48e-1)"	"unprognostic (4.76e-2)"	"unprognostic (9.42e-2)"	"unprognostic (1.03e-2)"	3.4	0.3	0.2	17.9	0.4	20.5	2.3	0.2	0.4	0.1	0.6	0.8	3.3	0.1	0.0	1.3	1.0	1.4	0.8	0.3	0.3	0.3	1.5	7.6	0.1	0.5	0.3	0.3	0.0	0.6	0.4	0.1	1.6	0.5	1.1	0.7	0.1	0.7	0.0	0.2	1.1	4.6	1.3	0.2	22.4	1.2	0.1	0.4	0.7	0.4	3.7	0.7	6.1	0.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	3.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.8	0.0	0.6	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	1.1	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	3.1	2.1	85.0	0.0	5.6	0.0	0.1	0.0	0.0	0.9	0.2	0.0	0.0	249.7	0.0	6.5	0.1	0.0	0.7	0.2	0.4	0.2	0.4	0.3	0.3	0.5	0.3	0.3	0.5	0.2	0.4	0.9	5.6	0.0	3.2	0.0	0.6	0.1	0.4	0.3	0.0	0.0	0.2	0.3	0.4	0.0	2.7	0.0	0.0	0.0	0.3	0.3	0.0	0.3	0.2	0.0	0.1	0.8	24.1	0.0	0.0	0.0	0.1	1.4	0.0	0.0	5.1	0.0	0.4	0.0	5.0	0.0	0.0	8.9	2.0	11.9	2.6	0.1	0.0	15.4	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	7.7	1.1	0.0	2.2	0.0	0.0	0.4	2.4	0.1	0.2	0.0	0.6	0.1	1.3	0.1	0.6	1.5
FGF13	"FGF2, FHF2, FLJ30672, LINC00889"	ENSG00000129682	"Fibroblast growth factor 13"	Q92913	X	138614727-139222777	"Predicted intracellular proteins"	Neurogenesis			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 49.8;skeletal muscle: 67.9;tongue: 52.8"	"Cell type enriched"	"Detected in many"	6	"Inhibitory neurons: 432.5"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 2.0"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"neutrophil: 3.7"	"Lineage enriched"	"Detected in single"	9	"granulocytes: 3.7"	"Cell line enhanced"	"Detected in many"		"AF22: 43.0;fHDF/TERT166: 38.1;HAP1: 39.8;RPMI-8226: 34.4;U-2197: 69.3;WM-115: 37.5"					"Low region specificity"	"Detected in all"			HPA002809			Supported	Cytosol		NA	NA			Cytosol		"HPA002809: AB_1078855"	"unprognostic (3.23e-1)"	"unprognostic (3.13e-2)"	"unprognostic (5.42e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.87e-1)"	"unprognostic (2.87e-3)"	"unprognostic (9.92e-3)"	"unprognostic (2.97e-3)"	"unprognostic (4.92e-2)"	"unprognostic (5.90e-3)"	"unprognostic (5.22e-3)"	"unprognostic (6.79e-2)"	"unprognostic (4.96e-4)"	"unprognostic (4.36e-3)"	"unprognostic (1.22e-1)"	"unprognostic (2.27e-1)"	"unprognostic (7.48e-2)"	18.7	2.6	20.3	2.9	21.1	4.1	6.6	6.4	33.3	11.4	8.0	5.7	4.0	10.8	3.4	6.7	3.7	6.1	1.9	38.6	23.1	7.5	1.8	2.3	5.4	15.5	22.2	21.2	8.9	1.1	49.8	4.2	13.4	34.9	17.7	4.8	11.4	11.3	4.9	67.9	1.6	4.7	6.7	9.4	6.2	5.3	4.1	20.9	0.9	5.3	52.8	2.2	6.1	4.3	28.0	0.1	0.5	43.0	0.1	0.1	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.2	0.3	0.7	38.1	0.3	2.7	39.8	0.1	0.0	0.3	11.1	0.2	0.3	1.6	1.5	0.3	0.5	0.6	1.0	0.1	0.0	0.2	0.0	2.5	1.8	12.4	4.4	0.3	0.1	0.3	4.4	0.1	14.3	6.6	2.8	34.4	6.3	0.2	0.1	0.2	0.0	0.3	26.8	21.0	0.1	0.2	0.8	1.3	1.8	69.3	19.1	16.2	9.8	0.1	15.3	12.8	37.5	1.6	0.2	0.8	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	3.7	0.1	0.2	0.4	0.1	0.0	20.3	21.1	6.4	33.3	38.6	23.1	15.5	22.2	21.2	34.9	9.4	20.9	28.0	9.7	0.0	0.0	12.7	0.1	0.4	3.0	0.3	2.8	3.6	18.3	4.1	2.6	10.0	3.0	7.3	0.0	0.2	0.0	0.5	17.6	4.2	0.0	7.7	5.0	3.6	2.4	0.0	43.5	5.8	0.3	6.1	3.1	20.5	0.0	1.4	1.4	0.1	29.3	0.0	432.5	0.8	6.1	3.7	1.4	1.4	26.1	0.6	1.8	62.8	0.6	44.8	0.0	14.1	2.4	3.8	6.7	24.5	0.1	16.9	0.0	2.9	1.8	4.2	32.9	18.0	13.7	0.0	3.7	0.1	0.9	0.1	0.3	0.8	0.3	1.0
FOXB2	bA159H20.4	ENSG00000204612	"Forkhead box B2"	Q5VYV0	9	77019655-77020953	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Tissue enriched"	"Detected in single"	48	"brain: 4.7"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.6"	"Region enriched"	"Detected in some"	5	"hypothalamus: 4.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	8	"NTERA-2: 1.3"	"Region enriched"	"Detected in single"	11	"hypothalamus: 1.1"	"Group enriched"	"Detected in many"	4	"basal ganglia: 3.3;hypothalamus: 6.5;medulla oblongata: 2.8;midbrain: 2.8;spinal cord: 5.1"	HPA067947	Approved					NA	NA					"HPA067947: AB_2685930"										"unprognostic (2.02e-1)"		"unprognostic (8.58e-2)"			"unprognostic (2.62e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	4.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.3	4.7	1.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GABRG3		ENSG00000182256	"Gamma-aminobutyric acid type A receptor subunit gamma3"	Q99928	15	26971181-27541984	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"brain: 12.3;retina: 27.3;testis: 9.3"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 444.7;Inhibitory neurons: 615.5;Late spermatids: 351.0;Muller glia cells: 179.9"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"K-562: 4.5;PC-3: 5.5;SK-MEL-30: 3.5;U-2 OS: 2.5;U-266/70: 3.2;U-87 MG: 14.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA054010	Approved					NA	NA					"HPA054010: AB_2682342"	"unprognostic (1.23e-1)"	"unprognostic (1.67e-1)"		"unprognostic (1.02e-2)"	"unprognostic (3.50e-2)"	"unprognostic (2.61e-1)"	"unprognostic (2.33e-3)"	"unprognostic (1.30e-1)"	"unprognostic (2.39e-2)"	"unprognostic (5.15e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.41e-1)"	"unprognostic (1.43e-5)"	"unprognostic (1.52e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.83e-1)"	0.0	0.4	2.6	0.2	3.2	0.0	0.4	0.0	5.9	0.8	0.0	0.0	0.0	0.1	2.0	0.0	0.4	0.0	0.0	1.3	12.3	0.2	0.1	0.0	0.6	1.1	0.2	1.3	0.0	0.0	0.0	3.0	0.0	1.7	6.6	0.0	27.3	0.8	0.2	0.0	0.2	0.0	0.0	0.0	1.0	0.0	9.3	6.8	1.0	1.5	0.0	0.8	0.0	0.2	3.8	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.4	0.3	0.0	5.5	0.0	0.0	1.0	0.0	0.0	0.1	1.0	0.0	0.0	3.5	0.1	0.0	0.0	0.0	0.0	2.5	0.0	0.0	3.2	0.0	0.0	14.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	3.2	0.0	5.9	1.3	12.3	1.1	0.2	1.3	1.7	0.0	6.8	3.8	0.1	0.0	0.0	5.5	0.0	0.0	0.1	0.0	0.0	4.6	2.5	1.4	0.9	0.0	0.0	0.0	2.1	0.0	0.1	0.0	0.0	0.0	86.2	3.2	0.1	0.3	0.0	0.0	444.7	0.0	0.0	0.1	0.0	0.4	0.0	0.5	0.0	0.0	0.1	0.0	615.5	0.0	0.0	0.0	0.0	351.0	0.9	0.2	0.0	7.5	0.0	179.9	0.0	16.1	7.9	0.0	0.0	0.7	0.0	3.1	0.0	0.3	0.0	4.6	0.0	0.1	0.1	1.6	7.4	0.0	0.0	0.0	0.1	0.0	0.0	0.2
GADD45G	"CR6, DDIT2, GADD45gamma, GRP17"	ENSG00000130222	"Growth arrest and DNA damage inducible gamma"	O95257	9	89605012-89606555	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Differentiation"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 369.0"	"Cell type enriched"	"Detected in many"	7	"Syncytiotrophoblasts: 1609.4"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 79.8"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	6	"eosinophil: 4.9"	"Lineage enriched"	"Detected in single"	24	"granulocytes: 4.9"	"Group enriched"	"Detected in many"	4	"HDLM-2: 116.8;SCLC-21H: 58.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023606	Approved					NA	NA					"HPA023606: AB_1849409"	"unprognostic (5.84e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.08e-2)"	"prognostic favorable (7.06e-4)"	"unprognostic (4.45e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.77e-3)"	"unprognostic (3.75e-2)"	"unprognostic (7.65e-3)"	"unprognostic (4.16e-3)"	"prognostic favorable (3.80e-5)"	"unprognostic (1.11e-1)"	"unprognostic (1.63e-2)"	"unprognostic (4.95e-1)"	"unprognostic (3.88e-2)"	"unprognostic (3.41e-1)"	"unprognostic (1.22e-1)"	18.3	144.6	9.9	3.9	14.6	14.8	24.8	18.5	19.6	114.1	7.4	24.8	6.0	53.6	1.9	13.2	26.7	2.9	212.1	9.2	16.9	24.5	369.0	27.1	1.6	11.1	12.9	7.5	74.9	79.1	28.8	128.5	25.5	10.8	75.0	1.5	3.1	19.9	10.5	140.1	32.8	19.8	7.4	10.4	6.7	44.8	30.1	13.7	2.4	20.8	23.7	0.6	30.9	39.1	11.2	3.1	0.0	16.0	0.0	0.0	0.0	21.1	1.1	0.0	0.1	0.0	2.6	0.3	0.0	2.5	0.0	0.8	2.3	5.3	0.1	0.0	116.8	1.0	0.3	0.3	0.0	0.8	0.0	0.4	0.4	2.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	4.9	0.2	1.1	14.7	2.7	0.2	1.2	4.7	1.2	0.2	0.7	58.6	13.4	1.1	6.3	0.1	3.0	2.5	0.1	2.1	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	9.9	14.6	18.5	19.6	9.2	16.9	11.1	12.9	7.5	10.8	10.4	13.7	11.2	124.2	6.4	53.7	4.6	15.4	28.6	50.9	9.9	40.5	43.9	118.2	215.3	196.8	62.9	22.5	11.0	6.2	80.7	46.6	21.6	92.0	18.3	2.1	40.7	98.3	48.8	54.8	6.6	1.1	43.4	12.1	138.9	97.3	29.3	19.6	24.7	11.0	215.2	57.0	3.3	2.2	55.9	50.8	12.4	121.1	9.0	84.5	77.6	35.6	2.8	11.7	35.7	0.0	0.0	1.1	20.4	11.1	45.5	13.2	88.9	24.9	40.6	23.5	22.0	131.5	90.9	144.4	3.6	2.0	95.5	19.6	1609.4	57.5	165.8	20.0	12.4
GALNT17	"GalNAc-T17, GalNAc-T19, GalNAc-T5L, GALNTL3, ppGalNAc-T17, WBSCR17"	ENSG00000185274	"Polypeptide N-acetylgalactosaminyltransferase 17"	Q6IS24	7	71132144-71713600	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		"Glycosyltransferase, Transferase"	"Williams-Beuren syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 53.0"	"Cell type enhanced"	"Detected in some"		"Collecting duct cells: 1.8;Endometrial stromal cells: 7.4;Fibroblasts: 1.5;Granulosa cells: 1.7;Theca cells: 2.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 8.0"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 14.3;NTERA-2: 10.8;RPMI-8226: 12.6;SK-BR-3: 45.7;SuSa: 14.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013624, HPA047986"	Approved		Uncertain	"Nucleoplasm,Nucleoli,Nuclear bodies,Golgi apparatus"		NA	NA			"Nucleoplasm, Golgi apparatus"	"Nucleoli, Nuclear bodies"	"HPA013624: AB_1858787, HPA047986: "	"unprognostic (2.79e-2)"	"unprognostic (6.83e-2)"	"unprognostic (5.54e-2)"	"unprognostic (3.66e-3)"	"unprognostic (1.50e-1)"	"unprognostic (2.62e-1)"	"unprognostic (6.41e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.00e-1)"	"prognostic favorable (4.60e-4)"	"unprognostic (2.00e-1)"	"unprognostic (4.73e-1)"	"unprognostic (1.96e-2)"	"unprognostic (9.63e-3)"	"prognostic favorable (3.91e-4)"	"unprognostic (1.92e-1)"	"unprognostic (7.94e-3)"	2.7	8.8	24.7	2.0	38.1	0.0	2.0	37.2	53.0	3.3	37.5	12.0	0.3	16.8	3.1	9.4	8.8	2.5	24.3	52.9	15.9	5.5	0.4	9.4	0.0	4.4	8.3	37.3	31.9	10.1	1.2	13.4	0.2	14.8	14.9	1.0	3.3	3.3	8.3	4.8	1.9	3.9	8.3	0.0	3.5	2.4	5.0	16.3	2.6	10.2	3.0	1.5	21.3	3.3	27.6	0.0	0.0	14.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	10.8	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.7	0.0	0.0	45.7	0.0	14.1	0.0	0.0	0.0	0.0	3.8	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	38.1	37.2	53.0	52.9	15.9	4.4	8.3	37.3	14.8	0.0	16.3	27.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	7.4	0.0	0.0	0.0	0.0	0.7	0.0	1.5	0.0	0.1	0.0	1.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0
GLB1L2		ENSG00000149328	"Galactosidase beta 1 like 2"	Q8IW92	11	134331874-134378341	"Predicted secreted proteins"		"Glycosidase, Hydrolase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"retina: 162.0"	"Cell type enriched"	"Detected in many"	4	"Rod photoreceptor cells: 182.0"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 21.0"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in some"		"gdT-cell: 3.2;NK-cell: 3.1"	"Group enriched"	"Detected in many"	24	"NK-cells: 3.1;T-cells: 3.2"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 49.9;HaCaT: 52.6;OE19: 123.6;SCLC-21H: 34.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA054808, HPA059955"	Uncertain		Approved	Nucleoplasm,Vesicles	"Secreted in other tissues"	NA	NA			Nucleoplasm	Vesicles	"HPA054808: AB_2682608, HPA059955: AB_2684178"	"unprognostic (2.63e-2)"	"unprognostic (9.77e-3)"	"unprognostic (2.32e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.07e-2)"	"unprognostic (1.54e-1)"	"unprognostic (5.98e-2)"	"unprognostic (2.08e-2)"	"unprognostic (1.51e-1)"	"unprognostic (8.31e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.48e-1)"	"unprognostic (4.73e-2)"	"unprognostic (1.22e-2)"	"unprognostic (2.64e-1)"	"unprognostic (3.88e-3)"	"unprognostic (1.01e-1)"	1.4	2.1	3.4	2.6	2.2	0.3	7.1	0.2	8.5	5.3	12.2	21.8	5.8	34.2	2.2	3.6	25.9	2.8	0.9	9.3	0.6	20.8	0.6	3.6	0.6	1.4	1.2	2.1	13.9	10.7	25.2	14.2	1.5	1.6	34.8	11.8	162.0	9.2	25.4	1.0	9.5	4.0	4.4	0.1	0.6	9.1	8.4	1.0	0.6	22.9	0.2	0.6	6.8	5.1	1.5	16.0	1.6	8.2	4.7	0.0	0.0	5.5	0.0	0.0	0.0	0.0	13.3	49.9	0.0	16.3	0.0	6.8	52.6	25.2	0.4	0.0	0.0	23.9	0.0	6.7	0.6	2.2	0.0	28.4	0.3	0.7	0.0	0.0	0.0	0.1	7.6	26.3	0.0	0.0	15.3	4.4	3.0	4.7	123.6	18.2	0.0	0.0	1.5	14.1	11.0	34.9	13.1	11.4	14.2	0.0	1.2	18.4	0.2	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	4.1	0.0	3.1	0.0	0.0	0.0	3.2	0.0	1.2	0.0	0.6	1.2	0.0	0.1	0.9	1.4	0.0	3.1	0.0	0.0	0.0	0.5	3.4	2.2	0.2	8.5	9.3	0.6	1.4	1.2	2.1	1.6	0.1	1.0	1.5	0.2	0.0	1.8	0.3	0.4	2.2	5.2	1.0	1.8	6.2	7.2	7.9	1.6	1.5	2.5	0.0	41.7	0.2	3.4	19.5	0.0	2.5	2.1	7.9	22.1	1.2	9.0	0.0	1.6	2.4	1.0	3.6	4.1	2.2	0.0	41.9	0.0	0.2	0.2	5.0	1.2	5.9	0.0	0.0	0.3	6.8	1.2	0.3	5.4	1.0	0.0	10.8	1.0	1.0	0.3	2.2	6.3	0.7	2.2	8.1	3.0	8.4	10.1	182.0	0.0	3.7	2.3	2.6	4.6	1.9	0.9	0.1	2.5	3.4	11.5	2.7
GLB1L3	FLJ90231	ENSG00000166105	"Galactosidase beta 1 like 3"	Q8NCI6	11	134274245-134319564	"Predicted intracellular proteins"		"Glycosidase, Hydrolase"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 4.0;prostate: 8.0;seminal vesicle: 4.4"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 9.8;Excitatory neurons: 39.5;Inhibitory neurons: 20.9;Oligodendrocyte precursor cells: 11.6;Spermatogonia: 7.5"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 5.0"	"Region enhanced"	"Detected in many"		"cerebral cortex: 4.0"	"Group enriched"	"Detected in many"	11	"gdT-cell: 1.2;memory CD4 T-cell: 3.1;memory CD8 T-cell: 1.9;naive CD4 T-cell: 2.4;naive CD8 T-cell: 1.9;T-reg: 1.5"	"Lineage enriched"	"Detected in single"	31	"T-cells: 3.1"	"Cell line enhanced"	"Detected in some"		"HEK 293: 5.5;JURKAT: 11.4;NTERA-2: 3.4;PC-3: 4.5;SCLC-21H: 6.8"	"Not detected"	"Not detected"							HPA039916	Uncertain					NA	NA					"HPA039916: AB_2676746"	"unprognostic (1.64e-3)"	"unprognostic (7.80e-3)"	"unprognostic (5.12e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.55e-2)"	"unprognostic (8.69e-3)"	"prognostic favorable (1.97e-4)"	"unprognostic (6.58e-3)"	"unprognostic (3.81e-1)"	"unprognostic (6.95e-3)"	"unprognostic (9.73e-2)"	"unprognostic (1.52e-5)"	"unprognostic (1.39e-1)"	"unprognostic (6.40e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.07e-1)"	0.0	1.0	0.5	0.4	1.0	0.1	0.3	2.2	4.0	0.4	0.0	0.5	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.4	0.0	0.0	0.9	0.6	0.0	0.8	0.0	0.0	0.0	0.7	0.0	1.0	8.0	0.0	1.6	2.7	4.4	0.0	3.2	0.1	0.0	0.0	0.1	0.0	1.3	0.1	0.1	1.4	0.0	0.1	0.1	0.8	1.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.2	0.0	2.1	5.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	2.2	0.0	3.4	0.0	4.5	0.0	0.0	0.0	0.0	0.0	6.8	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.1	0.0	3.1	1.9	0.0	0.0	2.4	1.9	0.0	0.0	0.0	0.0	1.5	0.6	0.5	1.0	2.2	4.0	0.4	0.5	0.6	0.0	0.8	1.0	0.0	0.1	1.2	0.0	0.0	0.0	1.3	0.1	0.5	0.1	1.3	0.0	0.5	0.4	1.3	0.7	0.0	0.1	0.0	0.0	1.3	0.3	0.0	0.0	0.0	9.8	0.1	0.3	0.3	0.0	0.0	39.5	0.0	3.4	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.4	0.0	20.9	0.0	0.0	0.0	0.0	1.2	0.6	0.1	0.0	1.9	0.0	0.3	0.0	11.6	0.9	0.1	0.0	0.0	0.3	0.4	0.0	0.5	0.0	0.7	0.0	0.0	0.1	4.3	7.5	0.0	0.1	1.2	0.3	0.0	0.0	0.1
GLYATL1B	GLYATL1P3	ENSG00000255151	"Glycine-N-acyltransferase like 1B"	A0A0U1RQE8	11	59086307-59094786	"Enzymes, Predicted intracellular proteins"		"Acyltransferase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"breast: 7.4;lymphoid tissue: 2.8"	"Cell type enriched"	"Detected in single"	57	"Proximal tubular cells: 5.8"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.7"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in single"		"naive B-cell: 1.5"	"Lineage enriched"	"Detected in single"	15	"B-cells: 1.5"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.8;T-47d: 1.2;U-266/70: 1.8"									HPA039501	Uncertain		Uncertain	"Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	Cytosol	"HPA039501: AB_2676545"	"unprognostic (1.39e-1)"	"unprognostic (3.46e-1)"						"unprognostic (1.44e-1)"			"unprognostic (1.25e-1)"	"unprognostic (5.20e-2)"	"unprognostic (2.62e-1)"	"unprognostic (2.11e-1)"	"unprognostic (3.21e-4)"	"unprognostic (3.45e-1)"		0.0	0.0	0.0	0.8	0.0	0.0	7.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.4	0.8	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.9	0.0	1.8	0.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GOLM1	"bA379P1.3, C9orf155, FLJ23608, GOLPH2, GP73"	ENSG00000135052	"Golgi membrane protein 1"	Q8NBJ4	9	86026146-86100173	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"stomach 1: 399.7"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 362.8;Early spermatids: 339.0;Gastric mucus-secreting cells: 245.6;Ionocytes: 325.5;Late spermatids: 391.6;Pancreatic endocrine cells: 282.9;Paneth cells: 265.2;Undifferentiated cells: 245.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 343.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 1.9;classical monocyte: 3.6;gdT-cell: 3.5;intermediate monocyte: 2.6;neutrophil: 4.2;non-classical monocyte: 4.2;plasmacytoid DC: 1.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-266/70: 372.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010638, HPA011929, CAB015341"	Enhanced		Enhanced	"Golgi apparatus"	"Intracellular and membrane"	NA	NA		81000000	"Golgi apparatus"		"CAB015341: AB_2113334, HPA010638: AB_1849886, HPA011929: AB_1849888"	"unprognostic (1.47e-1)"	"unprognostic (2.31e-2)"	"unprognostic (1.10e-1)"	"prognostic favorable (8.14e-5)"	"unprognostic (1.97e-1)"	"unprognostic (4.40e-3)"	"prognostic unfavorable (1.30e-4)"	"unprognostic (4.89e-3)"	"unprognostic (2.81e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.34e-2)"	"unprognostic (5.59e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.25e-1)"	"unprognostic (2.87e-3)"	"unprognostic (1.23e-1)"	18.3	161.1	74.9	34.1	78.2	6.7	39.9	68.5	85.2	70.6	91.0	197.5	237.3	40.5	15.9	13.7	38.4	132.2	11.3	70.6	88.2	75.4	19.1	14.9	9.8	72.3	73.8	68.0	37.2	41.9	37.9	36.6	17.4	68.3	144.4	165.4	25.7	174.8	10.6	9.5	15.0	61.9	28.6	78.5	42.0	399.7	17.6	89.8	45.8	68.8	4.8	5.6	38.6	15.0	79.2	146.0	139.5	102.4	116.7	129.3	74.3	108.0	64.8	46.6	99.9	80.5	69.4	282.9	2.7	62.6	126.2	96.6	109.4	63.7	64.1	71.9	5.0	101.2	45.3	89.1	3.4	76.8	67.3	34.9	113.4	34.2	94.1	34.0	124.9	172.9	21.2	28.7	4.2	57.3	68.4	8.3	49.6	161.9	188.9	99.6	42.9	116.9	21.8	166.0	61.2	115.1	72.0	88.2	189.0	73.8	66.1	106.7	68.1	110.5	25.9	72.6	79.3	78.3	372.3	37.4	0.9	112.2	29.8	57.8	1.9	3.6	0.4	3.5	2.6	0.4	0.6	0.2	0.5	0.4	0.6	0.4	0.7	4.2	0.7	4.2	1.5	0.1	1.8	74.9	78.2	68.5	85.2	70.6	88.2	72.3	73.8	68.0	68.3	78.5	89.8	79.2	13.8	9.6	15.3	30.3	1.7	2.3	10.8	11.3	4.6	20.1	41.4	21.1	4.9	80.1	80.9	35.0	8.4	8.4	10.7	362.8	25.4	168.4	339.0	78.0	49.8	20.5	73.1	11.2	47.0	222.2	35.0	30.4	245.6	56.8	1.3	65.9	8.6	11.1	11.8	67.3	43.2	95.5	325.5	5.0	2.6	391.6	18.3	6.6	23.2	6.5	6.9	16.9	12.3	82.0	19.3	282.9	265.2	13.2	3.2	72.6	71.8	16.0	78.6	6.7	0.0	13.5	19.5	10.3	38.7	2.9	1.0	6.4	5.2	60.7	245.6	29.1
GREB1	KIAA0575	ENSG00000196208	"Growth regulating estrogen receptor binding 1"	Q4ZG55	2	11482341-11642788	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"ovary: 280.7"	"Cell type enriched"	"Detected in many"	9	"Granulosa cells: 545.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 17.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 40.3;Hep G2: 39.6;MCF7: 61.8;SH-SY5Y: 40.5;SK-MEL-30: 30.4;T-47d: 138.0"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA024616, HPA027843, HPA028416"	Uncertain		Approved	Mitochondria,Cytosol		NA	NA			"Mitochondria, Cytosol"		"HPA024616: AB_10599728, HPA027843: AB_10601103, HPA028416: AB_10601344"	"unprognostic (1.52e-2)"	"unprognostic (4.63e-1)"	"unprognostic (1.46e-1)"	"prognostic favorable (1.05e-4)"	"unprognostic (1.23e-2)"	"unprognostic (1.32e-1)"	"unprognostic (6.29e-2)"	"unprognostic (1.24e-1)"	"unprognostic (6.19e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.68e-1)"	"unprognostic (3.63e-2)"	"unprognostic (7.51e-4)"	"unprognostic (2.42e-2)"	"unprognostic (3.34e-1)"	"unprognostic (2.46e-3)"	"unprognostic (4.80e-2)"	1.8	3.4	8.3	0.7	8.8	0.4	13.8	2.3	10.5	49.7	0.7	0.9	0.7	61.8	7.0	0.6	53.9	2.8	4.5	8.0	16.4	1.8	3.1	1.4	0.6	8.9	7.6	5.5	280.7	7.7	0.7	9.0	3.0	5.0	64.0	0.2	1.5	1.1	3.8	4.0	2.6	0.9	12.9	3.4	0.2	3.0	15.1	9.0	0.3	0.6	4.8	0.3	1.7	21.7	7.0	0.1	1.0	40.3	0.5	0.2	0.2	1.8	0.0	0.1	0.1	0.3	0.3	0.2	2.5	0.3	0.0	6.9	0.2	3.1	0.2	0.1	5.1	3.6	0.4	0.3	39.6	0.5	0.3	2.1	0.5	2.2	0.6	0.4	0.4	0.0	3.9	0.5	1.0	0.3	61.8	1.2	2.0	13.0	0.1	0.1	29.1	0.0	1.9	0.1	0.0	11.8	40.5	0.9	1.1	30.4	5.2	138.0	0.7	0.0	4.1	2.0	0.4	0.1	6.0	4.4	24.7	6.8	11.9	1.2	0.6	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.4	0.1	0.1	0.1	0.1	0.0	8.3	8.8	2.3	10.5	8.0	16.4	8.9	7.6	5.5	5.0	3.4	9.0	7.0	0.4	0.0	0.5	20.2	0.7	0.8	1.9	0.0	0.6	4.8	24.7	13.7	8.3	5.7	0.6	0.0	2.1	0.2	0.1	0.1	0.0	0.3	0.8	35.7	36.0	1.3	0.0	0.0	15.0	0.2	3.6	16.9	0.0	23.4	3.8	545.2	0.7	8.9	3.2	3.3	46.9	0.0	0.0	0.0	1.2	2.5	20.2	1.4	5.4	1.0	0.0	0.2	0.0	11.6	20.9	0.4	0.0	55.3	5.0	14.3	0.0	2.5	2.9	0.5	0.0	7.2	14.8	1.1	2.9	0.3	0.3	0.3	1.1	33.1	0.0	2.5
GRIN1	"GluN1, NMDAR1"	ENSG00000176884	"Glutamate ionotropic receptor NMDA type subunit 1"	Q05586	9	137139154-137168756	"Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease variant, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	52	"brain: 196.5"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 132.6;Inhibitory neurons: 134.4"	"Cancer enhanced"	"Detected in some"		"glioma: 1.9;prostate cancer: 1.8"	"Region enriched"	"Detected in many"	4	"cerebral cortex: 196.5"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"OE19: 1.4;REH: 1.9;RPMI-8226: 2.5;SCLC-21H: 5.2;SH-SY5Y: 3.1;T-47d: 1.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA067773	Enhanced					NA	NA					"HPA067773: "	"unprognostic (3.58e-2)"	"unprognostic (4.51e-1)"	"unprognostic (2.68e-2)"	"unprognostic (5.48e-4)"	"unprognostic (5.20e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.34e-2)"	"unprognostic (2.81e-2)"	"unprognostic (6.46e-3)"	"unprognostic (1.51e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.21e-3)"	"unprognostic (4.47e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.56e-3)"	"unprognostic (4.72e-2)"	0.0	0.1	13.1	0.2	46.8	0.0	0.2	0.0	196.5	0.0	0.0	0.7	0.4	0.0	0.0	0.1	0.0	0.0	0.1	37.7	18.4	0.0	0.0	0.1	0.1	12.1	27.3	36.7	0.0	0.1	0.2	0.7	0.0	22.0	0.7	0.0	3.8	1.2	0.0	0.0	0.4	0.4	0.0	0.0	0.0	0.3	0.6	1.8	0.0	0.0	0.0	0.0	0.0	0.1	42.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.8	0.1	0.0	0.2	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.5	0.0	0.0	0.0	1.4	0.0	1.9	0.0	2.5	0.0	0.0	5.2	3.1	0.1	0.3	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.1	46.8	0.0	196.5	37.7	18.4	12.1	27.3	36.7	22.0	0.0	1.8	42.0	0.0	0.0	0.0	8.5	0.0	0.0	0.3	0.1	0.0	28.0	1.2	0.9	2.5	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.3	1.9	0.2	0.1	0.2	1.8	0.0	132.6	0.4	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.1	1.7	134.4	1.8	0.0	0.0	0.0	0.6	0.0	0.2	0.0	9.4	2.0	1.7	0.0	10.1	7.6	0.2	0.1	0.0	0.0	0.7	0.5	0.1	0.3	7.8	0.0	0.0	0.1	0.5	2.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4
GUCY1A1	"GC-SA3, GUC1A3, GUCY1A3"	ENSG00000164116	"Guanylate cyclase 1 soluble subunit alpha 1"	Q02108	4	155666726-155737059	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"cGMP biosynthesis"	Lyase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"Adipocytes: 38.4;Alveolar cells type 2: 56.1;Breast glandular cells: 37.4;Breast myoepithelial cells: 24.9;Distal tubular cells: 19.6;Ductal cells: 21.8;Smooth muscle cells: 49.4"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 24.9"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"NK-cell: 8.2;non-classical monocyte: 10.1;plasmacytoid DC: 11.5"	"Group enriched"	"Detected in many"	35	"dendritic cells: 11.5;monocytes: 10.1;NK-cells: 8.2"	"Cell line enhanced"	"Detected in some"		"HAP1: 6.8;HEK 293: 5.5;Karpas-707: 9.7;MOLT-4: 18.5;RPTEC TERT1: 12.1;RT4: 14.2;SH-SY5Y: 8.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010887, HPA056004, HPA058617"	Uncertain		Supported	Nucleoplasm		NA	NA		7100	Nucleoplasm		"CAB010887: AB_259901, HPA056004: AB_2683007, HPA058617: AB_2732624"	"unprognostic (4.81e-3)"	"unprognostic (2.60e-1)"	"unprognostic (3.03e-1)"	"unprognostic (2.15e-1)"	"unprognostic (1.99e-2)"	"unprognostic (7.77e-3)"	"unprognostic (1.07e-1)"	"prognostic favorable (2.38e-4)"	"unprognostic (1.85e-3)"	"unprognostic (6.46e-2)"	"unprognostic (3.42e-2)"	"unprognostic (7.16e-2)"	"prognostic unfavorable (7.59e-4)"	"unprognostic (1.60e-2)"	"prognostic unfavorable (3.59e-4)"	"unprognostic (2.27e-1)"	"unprognostic (6.55e-3)"	14.6	7.9	9.2	17.1	18.3	1.2	15.6	2.7	12.4	14.6	4.2	20.6	8.8	16.3	6.2	7.6	9.5	12.7	34.0	10.7	6.6	15.8	8.1	21.2	8.5	5.1	10.5	8.8	5.7	13.2	31.6	3.9	26.1	5.2	26.1	10.4	17.1	5.4	14.0	5.2	2.2	9.3	29.1	9.0	14.2	8.6	1.2	9.6	7.6	7.3	18.9	9.3	7.4	6.6	8.2	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	6.8	0.0	0.0	0.0	5.5	1.3	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.1	0.0	3.6	0.0	9.7	0.0	0.0	18.5	0.0	0.0	0.0	0.2	4.1	0.0	3.0	12.1	14.2	2.5	8.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.2	0.2	0.0	2.3	0.1	0.0	0.0	0.0	2.5	0.1	0.0	0.0	0.1	8.2	10.1	11.5	0.0	1.0	9.2	18.3	2.7	12.4	10.7	6.6	5.1	10.5	8.8	5.2	9.0	9.6	8.2	38.4	9.6	56.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	37.4	24.9	0.0	0.0	6.8	11.0	0.0	0.4	1.7	0.0	19.6	21.8	0.0	5.5	9.7	10.9	0.0	0.0	0.0	2.0	0.3	8.3	0.0	15.2	3.8	3.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	12.9	2.2	0.0	0.0	0.0	49.4	0.0	0.0	0.0	0.0	0.3	0.6	0.1	0.0	0.0
H2AC8	"H2A.1, H2A/a, H2AFA, HIST1H2AE"	ENSG00000277075	"H2A clustered histone 8"	P04908	6	26216975-26217483	"Predicted intracellular proteins"		DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 40.5;breast: 41.1"	"Group enriched"	"Detected in some"	9	"Cytotrophoblasts: 6.5;Extravillous trophoblasts: 5.5;Hofbauer cells: 18.0;Syncytiotrophoblasts: 13.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 40.9"	"Region enhanced"	"Detected in many"		"cerebellum: 40.5"	"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-266/70: 37.0"									"CAB012242, HPA041189"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB012242: AB_470265, HPA041189: AB_2677357"	"unprognostic (4.26e-2)"	"unprognostic (1.55e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.45e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.48e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.24e-2)"	"unprognostic (6.99e-2)"	"unprognostic (1.21e-3)"	"unprognostic (1.30e-2)"	"unprognostic (7.64e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.20e-1)"	"unprognostic (9.36e-2)"	2.3	2.4	1.8	1.6	5.1	19.4	41.1	40.5	6.7	11.8	3.4	5.5	3.7	1.6	16.9	8.7	7.8	1.8	3.9	3.7	5.2	5.7	5.7	8.0	2.9	0.2	2.5	3.2	6.8	1.0	0.4	3.4	1.6	4.0	33.1	2.1	1.5	4.8	1.2	0.3	11.4	4.7	0.6	2.3	9.6	5.3	4.3	2.7	9.4	5.9	0.1	0.8	2.3	17.6	10.5	4.1	0.0	3.0	0.0	4.9	0.9	0.8	1.3	2.0	4.3	2.9	2.0	3.3	0.2	10.8	0.4	3.9	3.4	1.5	2.0	1.7	4.5	3.7	2.7	5.9	2.6	0.9	0.3	4.1	8.4	0.9	1.8	0.2	1.2	2.1	0.8	11.4	2.9	0.4	7.5	9.3	7.9	3.5	14.1	3.7	7.3	2.4	14.7	1.8	2.3	11.9	5.0	10.9	3.7	2.4	2.0	14.9	4.1	0.0	0.2	0.8	1.8	1.8	37.0	0.0	0.0	1.5	5.5	2.7	18.2	2.2	8.2	2.8	2.6	4.1	4.7	3.3	4.6	5.9	6.0	1.7	2.3	10.1	4.5	1.6	17.6	4.4	10.4	1.8	5.1	40.5	6.7	3.7	5.2	0.2	2.5	3.2	4.0	2.3	2.7	10.5	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	6.5	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	5.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	18.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.8	0.2	0.0	0.0	0.0
H2AJ	"FLJ10903, H2AFJ, MGC921"	ENSG00000246705	"H2A.J histone"	Q9BTM1	12	14774383-14778002	"Plasma proteins, Predicted intracellular proteins"		DNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 569.4"	"Cell type enhanced"	"Detected in some"		"Adipocytes: 58.1;Cytotrophoblasts: 130.2;dendritic cells: 56.4;Extravillous trophoblasts: 124.3;Fibroblasts: 59.5;Hofbauer cells: 241.2;Syncytiotrophoblasts: 160.3"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 151.0"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A549: 256.2;MCF7: 338.4;RT4: 239.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041189	Supported		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA041189: AB_2677357"	"unprognostic (9.38e-2)"	"unprognostic (8.49e-2)"	"unprognostic (9.15e-2)"	"unprognostic (7.06e-2)"	"unprognostic (2.43e-3)"	"unprognostic (4.70e-2)"	"unprognostic (3.92e-2)"	"unprognostic (7.67e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.14e-1)"	"unprognostic (5.37e-2)"	"unprognostic (4.05e-2)"	"unprognostic (3.32e-3)"	"unprognostic (3.43e-2)"	"unprognostic (8.66e-3)"	"unprognostic (5.22e-3)"	"unprognostic (3.87e-3)"	229.6	187.5	25.0	34.1	28.9	60.9	225.5	28.7	41.2	114.6	34.1	112.1	55.9	106.5	21.1	157.0	107.6	36.4	106.5	22.9	30.6	116.3	83.4	130.7	29.8	32.3	27.4	21.4	64.2	183.8	21.2	34.5	58.2	30.4	278.1	29.6	5.3	168.2	35.3	92.1	189.8	85.9	25.3	30.4	95.6	112.0	569.4	28.7	34.5	85.7	25.0	18.3	123.8	125.9	34.1	107.9	256.2	10.0	0.0	112.2	73.8	163.2	78.9	43.4	31.3	30.4	50.9	172.4	0.1	48.7	38.6	0.2	100.7	6.2	60.1	8.5	5.7	4.6	4.3	92.6	43.8	160.5	0.1	39.0	97.0	64.5	43.3	40.0	12.7	63.0	0.0	0.1	0.1	15.9	338.4	0.7	28.7	16.0	77.8	58.0	42.4	0.0	21.0	51.0	239.0	3.0	1.0	99.8	122.3	0.4	34.6	187.0	32.6	63.1	0.3	29.6	46.2	15.6	25.0	39.4	0.4	8.6	0.3	25.4	84.0	127.6	29.3	51.3	76.4	46.3	16.8	49.6	38.0	117.2	21.7	34.9	38.2	46.6	61.2	69.4	58.2	78.1	72.1	25.0	28.9	28.7	41.2	22.9	30.6	32.3	27.4	21.4	30.4	30.4	28.7	34.1	58.1	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.1	0.0	0.0	0.0	0.0	130.2	56.4	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	124.3	59.5	0.0	0.0	0.0	0.0	0.0	0.0	241.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	32.9	0.0	0.0	0.0	0.0	160.3	6.5	0.0	0.0	0.0
H2BC21	"H2B, H2B.1, H2B/q, H2BE, H2BFQ, HIST2H2BE"	ENSG00000184678	"H2B clustered histone 21"	Q16778	1	149884459-149886652	"Predicted intracellular proteins"		"Antibiotic, Antimicrobial, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"Cardiomyocytes: 86.5;Syncytiotrophoblasts: 160.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 87.3"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in all"		"neutrophil: 58.6"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 58.6"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 56.8;U-266/70: 93.7;U-266/84: 53.8"					"Low region specificity"	"Detected in all"			"HPA042205, HPA043013, HPA048671"	Supported		Approved	Nucleoplasm,Cytosol		NA	Yes			Nucleoplasm	Cytosol	"HPA042205: AB_2677900, HPA043013: AB_2678269, HPA048671: AB_2680488"	"unprognostic (1.49e-1)"	"unprognostic (3.10e-2)"	"prognostic unfavorable (2.90e-4)"	"unprognostic (1.63e-1)"	"unprognostic (1.89e-1)"	"unprognostic (2.52e-1)"	"unprognostic (1.37e-1)"	"unprognostic (8.28e-2)"	"unprognostic (4.65e-2)"	"unprognostic (3.27e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.74e-2)"	"unprognostic (4.41e-2)"	"unprognostic (7.82e-2)"	"unprognostic (2.20e-1)"	"unprognostic (2.86e-3)"	11.4	15.4	36.9	7.2	39.5	21.4	17.8	39.0	37.7	48.5	37.5	21.1	5.2	7.4	23.0	42.1	27.7	5.6	63.2	33.6	53.5	24.9	18.1	37.5	6.2	44.7	37.1	28.5	62.2	13.5	9.6	32.7	14.9	40.1	96.0	6.2	69.7	23.7	6.7	63.4	70.9	15.0	6.2	38.7	27.5	32.3	13.8	42.4	20.2	15.3	29.4	3.4	25.3	80.1	57.4	2.8	2.8	4.5	0.9	23.5	6.3	2.2	9.7	6.5	4.0	1.3	1.1	4.4	0.5	2.6	8.6	5.7	10.9	3.6	1.7	2.2	3.4	2.8	0.8	11.5	2.1	7.4	0.8	12.6	21.4	7.9	1.7	6.6	4.8	1.3	4.0	12.0	56.8	5.0	16.8	3.1	5.1	2.8	22.6	5.8	3.6	1.7	13.7	3.8	2.3	30.3	4.9	33.4	4.5	2.7	10.7	23.4	2.4	1.7	3.0	33.6	2.2	0.9	93.7	53.8	2.6	4.0	3.6	1.9	21.3	4.8	8.2	1.3	6.2	2.3	1.5	1.8	2.1	3.3	3.8	2.2	2.2	58.6	1.3	12.3	8.9	2.2	10.1	36.9	39.5	39.0	37.7	33.6	53.5	44.7	37.1	28.5	40.1	38.7	42.4	57.4	1.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	86.5	0.0	0.0	0.0	0.0	25.5	2.2	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	20.2	4.6	0.0	0.0	0.0	0.0	0.0	0.0	27.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	160.2	0.3	0.0	0.0	0.0
H2BC8	"H2B.1A, H2B/a, H2BFA, HIST1H2BG"	ENSG00000273802	"H2B clustered histone 8"	P62807	6	26215159-26216692	"Plasma proteins, Predicted intracellular proteins"		"Antibiotic, Antimicrobial, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 19.9"	"Group enriched"	"Detected in some"	4	"Cytotrophoblasts: 7.3;Extravillous trophoblasts: 7.4;Hofbauer cells: 22.5;Syncytiotrophoblasts: 24.1"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 23.4"	"Low region specificity"	"Detected in many"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"K-562: 9.6;SiHa: 10.5;T-47d: 21.2;U-266/70: 19.6"									"HPA042205, HPA043013, HPA048671"	Supported		Approved	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA042205: AB_2677900, HPA043013: AB_2678269, HPA048671: AB_2680488"	"unprognostic (1.40e-2)"	"unprognostic (1.34e-2)"	"unprognostic (4.55e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.05e-1)"	"unprognostic (4.19e-2)"	"unprognostic (1.63e-2)"	"unprognostic (8.54e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.36e-2)"	"unprognostic (2.79e-2)"	"prognostic unfavorable (1.70e-8)"	"unprognostic (1.15e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.97e-2)"	1.6	0.9	0.8	1.2	1.5	6.8	13.3	7.5	1.8	14.8	3.9	4.2	1.2	0.9	2.0	9.2	4.4	0.9	2.8	1.3	1.1	3.4	3.1	7.6	1.6	1.0	2.1	0.6	5.8	1.1	0.1	2.9	1.1	2.5	19.9	2.0	1.6	7.0	0.6	0.1	9.6	3.2	0.4	2.9	7.2	3.8	1.8	2.0	4.2	2.6	0.0	1.4	1.6	18.6	4.5	3.0	0.1	1.4	0.0	4.4	0.2	0.4	3.7	0.3	2.3	0.9	0.4	2.6	0.0	3.7	0.3	1.0	3.2	1.3	1.2	1.3	2.6	1.6	0.8	1.5	1.4	0.7	0.3	2.4	1.7	0.6	0.7	0.1	0.1	0.5	0.1	9.6	0.2	0.0	2.2	2.8	2.1	1.5	7.1	1.9	1.8	0.8	5.4	1.3	0.7	8.5	1.3	10.5	3.8	1.2	3.7	21.2	0.9	0.3	0.0	1.2	0.3	0.5	19.6	0.1	0.0	0.3	1.3	0.7	18.1	1.3	3.2	2.0	0.9	6.4	4.4	3.2	4.0	5.1	5.3	1.5	1.3	5.8	1.4	1.8	16.0	3.0	2.2	0.8	1.5	7.5	1.8	1.3	1.1	1.0	2.1	0.6	2.5	2.9	2.0	4.5	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	7.3	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	7.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	22.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	24.1	0.2	0.0	0.0	0.0
HOMER2	"CPD, Cupidin, DFNA68, HOMER-2, HOMER-2A, HOMER-2B, Vesl-2"	ENSG00000103942	"Homer scaffold protein 2"	Q9NSB8	15	82836946-82986153	"Disease related genes, Human disease related genes, Predicted intracellular proteins"	Hearing		"Deafness, Disease variant, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 228.1"	"Cell type enhanced"	"Detected in many"		"Cholangiocytes: 215.9;Endometrial ciliated cells: 184.4;Glandular and luminal cells: 151.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 15.2"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in single"		"myeloid DC: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HAP1: 52.7;Karpas-707: 92.6;SCLC-21H: 50.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA040134, CAB079014"	Uncertain	Supported	Supported	Cytosol		NA	NA			Cytosol		"CAB079014: , HPA040134: AB_10795272"	"unprognostic (7.34e-2)"	"unprognostic (3.58e-2)"	"unprognostic (5.75e-4)"	"unprognostic (3.31e-3)"	"unprognostic (4.85e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.04e-2)"	"unprognostic (7.13e-3)"	"unprognostic (2.69e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.75e-1)"	"unprognostic (8.16e-4)"	"unprognostic (2.30e-1)"	"unprognostic (3.21e-2)"	"unprognostic (1.26e-1)"	"unprognostic (4.45e-3)"	1.5	6.3	6.7	1.1	7.8	4.7	27.2	8.4	13.5	23.3	56.7	2.7	8.6	8.5	34.0	21.4	26.1	12.9	22.1	16.8	6.2	5.7	46.8	5.3	1.4	5.8	6.6	7.3	2.6	228.1	5.2	7.8	0.6	6.6	58.2	1.0	6.4	71.8	4.7	109.8	41.3	1.3	1.4	3.6	4.8	55.8	6.2	6.0	3.0	29.1	56.4	3.6	1.3	11.8	8.0	16.6	6.9	7.2	18.9	0.2	0.1	1.1	1.1	0.0	1.7	0.6	1.2	11.5	0.1	8.8	8.4	8.3	9.1	52.7	24.9	1.2	45.1	33.5	10.6	0.4	8.3	0.7	0.4	32.6	1.8	37.4	0.6	2.1	1.9	0.0	20.6	0.4	92.6	7.0	48.4	3.2	1.1	11.4	1.4	5.1	2.2	11.5	5.5	25.3	20.1	50.8	13.1	18.6	14.1	17.6	5.2	17.1	3.5	0.2	17.2	31.7	1.3	15.3	11.8	5.9	1.8	29.0	0.4	6.4	0.1	0.1	0.4	0.0	0.1	0.0	0.2	0.1	0.0	1.1	0.3	0.1	0.0	0.4	0.0	0.0	0.5	0.2	0.3	6.7	7.8	8.4	13.5	16.8	6.2	5.8	6.6	7.3	6.6	3.6	6.0	8.0	1.9	16.0	10.1	24.8	3.8	4.6	56.1	7.2	10.2	15.0	39.7	20.4	23.0	215.9	14.6	11.0	18.8	1.1	4.4	0.3	7.9	29.6	1.9	184.4	15.4	12.4	3.0	8.2	24.8	76.5	0.4	3.6	14.3	151.9	0.0	11.9	1.4	59.6	13.3	20.2	35.1	0.4	0.0	3.2	73.9	4.0	1.8	9.2	37.4	7.5	7.9	18.5	1.0	6.6	11.8	25.9	0.1	0.7	4.1	81.5	0.7	12.1	4.0	5.1	0.0	7.8	4.8	5.5	16.6	19.4	6.0	0.7	3.1	4.1	0.4	30.5
HOXA13	"HOX1, HOX1J"	ENSG00000106031	"Homeobox A13"	P31271	7	27193503-27200091	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix: 22.5;placenta: 17.2;prostate: 22.5;seminal vesicle: 23.5"	"Cell type enriched"	"Detected in some"	4	"Distal enterocytes: 41.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.9"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HAP1: 26.9;HEK 293: 37.3;PC-3: 18.4;RT4: 42.1;THP-1: 18.2;U-937: 20.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA046098, HPA069061"			Supported	"Nucleoplasm,Mitotic chromosome,Intermediate filaments"		Yes	NA			Nucleoplasm	"Mitotic chromosome, Intermediate filaments"	"HPA046098: AB_2679536, HPA069061: "	"unprognostic (7.20e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.02e-1)"	"unprognostic (8.04e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.40e-2)"	"unprognostic (9.22e-3)"	"unprognostic (7.30e-3)"	"unprognostic (8.39e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.42e-11)"	"unprognostic (2.58e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.36e-2)"	0.3	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.5	0.0	10.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.2	0.0	22.5	12.0	0.0	0.0	23.5	2.1	0.3	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.2	14.3	0.0	2.2	1.6	0.0	2.5	0.2	0.0	0.1	13.2	14.4	5.1	3.3	2.8	0.2	0.0	1.6	6.2	0.7	0.0	26.9	0.0	4.3	0.0	37.3	1.9	6.9	0.2	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.2	0.1	0.0	8.7	0.0	11.8	18.4	2.7	0.6	0.0	0.1	42.1	0.7	0.0	3.3	0.0	0.3	2.0	0.0	18.2	0.0	0.5	4.5	0.3	0.1	0.0	0.0	0.0	0.0	20.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	41.3	0.0	0.0	0.6	0.1	4.0	1.1	8.4	0.0	0.0	0.0	0.1	2.4	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	8.6	0.0	0.0	0.7	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	5.5	0.0	0.1	0.0	0.0	0.0	0.1	2.8	0.5	0.0	0.0	0.1	0.1	0.1	0.0	10.3	3.1
HPSE2	"HPA2, HPR2, UFS"	ENSG00000172987	"Heparanase 2 (inactive)"	Q8WWQ2	10	98457077-99235862	"Disease related genes, Human disease related genes, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.5;cervix: 33.3;vagina: 27.8"	"Cell type enriched"	"Detected in some"	9	"Astrocytes: 900.7"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 4.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	16	"BJ hTERT+: 10.2;HEL: 20.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA044603	Uncertain				"Secreted to extracellular matrix"	NA	NA					"HPA044603: AB_10794051"	"unprognostic (2.44e-1)"	"unprognostic (4.28e-3)"	"unprognostic (4.83e-3)"	"unprognostic (6.00e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.59e-1)"	"unprognostic (3.05e-2)"	"unprognostic (1.82e-2)"	"unprognostic (4.03e-2)"	"unprognostic (7.94e-2)"	"unprognostic (1.38e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.86e-4)"	"unprognostic (5.79e-2)"	"unprognostic (2.51e-1)"	"unprognostic (9.39e-3)"	"unprognostic (6.13e-3)"	1.8	0.0	10.6	2.0	19.2	0.0	5.2	17.1	9.1	33.3	3.4	2.9	2.8	4.5	0.0	14.4	1.8	1.4	0.0	5.8	19.8	1.1	0.0	2.2	0.0	23.6	24.3	4.1	0.2	0.0	0.0	0.3	1.5	23.0	11.2	3.0	0.0	2.4	4.3	0.3	3.0	5.3	1.7	15.1	0.0	4.6	2.7	27.5	0.1	0.1	3.1	0.4	18.5	27.8	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	10.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	20.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	10.6	19.2	17.1	9.1	5.8	19.8	23.6	24.3	4.1	23.0	15.1	27.5	13.8	0.3	0.0	0.0	900.7	0.0	0.0	4.8	0.0	0.0	0.0	0.2	0.8	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.3	0.4	24.8	0.3	0.0	0.0	6.4	0.0	0.0	4.2	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	97.3	0.2	0.0	0.0	0.0	48.6	0.3	0.0	0.0	40.3	0.0	0.0	0.0	16.6	4.6	0.0	0.0	0.4	0.1	1.4	0.0	0.0	0.0	0.0	0.0	0.9	1.9	11.5	2.1	0.0	0.1	0.0	0.2	0.8	0.0	0.7
HS3ST4	3OST4	ENSG00000182601	"Heparan sulfate-glucosamine 3-sulfotransferase 4"	Q9Y661	16	25691959-26137685	"Enzymes, Metabolic proteins, Predicted membrane proteins"		Transferase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"brain: 34.6"	"Group enriched"	"Detected in some"	9	"Excitatory neurons: 431.4;Microglial cells: 536.8"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"NTERA-2: 1.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (1.09e-2)"	"unprognostic (1.87e-1)"	"unprognostic (2.95e-1)"		"unprognostic (2.24e-1)"	"unprognostic (1.43e-3)"		"unprognostic (1.27e-1)"		"unprognostic (3.84e-1)"	"unprognostic (8.81e-3)"	"unprognostic (6.71e-2)"		"unprognostic (2.39e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.51e-2)"	"unprognostic (3.67e-2)"	0.0	0.0	13.8	0.0	17.8	0.0	2.2	7.5	15.2	0.2	3.8	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	34.6	11.3	0.0	0.0	0.0	0.0	18.2	14.2	15.5	0.0	0.0	3.6	0.3	0.0	20.4	0.8	0.0	2.0	0.1	0.0	0.0	0.5	0.0	0.0	8.0	1.6	1.7	0.5	29.1	0.2	0.0	0.0	0.0	0.3	0.5	18.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.8	17.8	7.5	15.2	34.6	11.3	18.2	14.2	15.5	20.4	8.0	29.1	18.5	0.0	0.0	0.0	7.5	0.1	0.0	0.4	0.1	0.0	26.0	2.6	2.7	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	431.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.9	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	536.8	0.0	0.4	0.0	6.6	9.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2
IL5RA	"CD125, CDw125, IL5R"	ENSG00000091181	"Interleukin 5 receptor subunit alpha"	Q01344	3	3066324-3126613	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 5.7;choroid plexus: 7.4;fallopian tube: 10.8"	"Cell type enhanced"	"Detected in some"		"Endometrial ciliated cells: 28.0;granulocytes: 19.0;Plasma cells: 9.9;Respiratory ciliated cells: 13.9"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	192	"basophil: 178.4;eosinophil: 355.1"	"Lineage enriched"	"Detected in many"	255	"granulocytes: 355.1"	"Cell line enriched"	"Detected in some"	28	"HMC-1: 71.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Intracellular and membrane"	NA	NA		910000				"unprognostic (1.38e-3)"	"unprognostic (2.26e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.13e-3)"	"unprognostic (2.66e-1)"	"unprognostic (1.54e-3)"	"unprognostic (7.79e-3)"	"unprognostic (8.42e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.67e-1)"	"unprognostic (9.84e-4)"	"unprognostic (4.32e-3)"	"unprognostic (3.08e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.49e-2)"	"unprognostic (4.93e-2)"	0.2	0.2	3.4	0.6	1.1	0.6	1.0	1.2	0.5	1.0	7.4	0.7	1.7	0.4	0.2	0.5	10.8	0.8	0.5	0.7	1.3	0.2	0.2	2.8	0.4	4.5	3.1	0.3	0.1	0.4	0.0	1.6	0.1	3.0	1.8	1.1	0.0	0.7	0.1	0.4	0.1	1.6	0.3	5.7	1.8	1.1	1.1	1.6	0.5	0.2	0.0	1.5	1.7	0.1	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.0	0.0	2.5	71.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.2	0.0	2.1	0.0	0.0	0.1	0.0	0.0	0.2	0.2	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	178.4	0.1	355.1	0.9	0.1	0.1	0.4	1.0	0.7	0.1	1.3	0.3	0.7	1.0	0.0	0.1	0.1	0.1	0.7	3.4	1.1	1.2	0.5	0.7	1.3	4.5	3.1	0.3	3.0	5.7	1.6	1.0	0.2	0.0	2.5	0.0	4.8	0.1	0.0	0.3	0.0	0.0	0.0	0.0	2.3	1.5	1.4	0.0	0.0	0.1	2.8	0.0	0.0	0.0	2.4	28.0	0.3	0.1	0.0	0.8	0.7	0.0	0.0	0.2	0.0	0.5	19.0	0.0	0.0	0.0	0.1	0.0	0.7	0.2	0.0	0.0	0.3	5.7	0.0	0.1	5.4	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	9.9	0.8	0.0	0.1	13.9	0.0	0.0	0.0	0.3	0.9	0.1	0.0	0.0	0.0	3.2	0.0	0.0	0.1
ITGA8		ENSG00000077943	"Integrin subunit alpha 8"	P53708	10	15513954-15719922	"Disease related genes, Human disease related genes, Plasma proteins, Predicted membrane proteins"	"Cell adhesion, Differentiation, Neurogenesis"	"Developmental protein, Integrin, Receptor"	"Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 37.7"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 82.8;Inhibitory neurons: 56.1;Microglial cells: 34.7;Oligodendrocyte precursor cells: 64.8;Plasma cells: 25.5;Sertoli cells: 52.6;Smooth muscle cells: 57.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 6.3"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 8.4;HMC-1: 19.8;HSkMC: 8.7;U-266/84: 9.7"	"Low region specificity"	"Detected in some"			"Region enhanced"	"Detected in many"		"basal ganglia: 14.1"	HPA003432	Approved		Approved	"Plasma membrane"		NA	NA		200000	"Plasma membrane"		"HPA003432: AB_1851825"	"unprognostic (2.15e-1)"	"unprognostic (1.22e-3)"	"unprognostic (1.05e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.25e-2)"	"unprognostic (8.44e-4)"	"unprognostic (2.23e-1)"	"unprognostic (6.13e-3)"	"unprognostic (6.82e-2)"	"unprognostic (3.80e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.27e-1)"	"unprognostic (4.10e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.26e-1)"	"unprognostic (6.03e-2)"	8.7	10.6	1.5	2.1	2.0	0.1	2.7	1.7	5.0	24.0	8.5	6.1	6.8	9.8	5.6	9.9	8.9	6.7	7.8	6.9	1.0	10.1	0.7	20.9	3.2	1.4	2.6	1.6	5.7	0.8	4.8	3.3	0.2	1.0	37.7	6.2	1.7	1.8	31.1	3.0	2.8	6.9	9.2	1.4	20.1	19.5	0.6	1.3	1.0	5.6	6.9	4.4	15.8	9.1	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.7	1.6	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.1	0.0	0.0	0.0	0.0	0.0	8.4	2.5	0.0	0.0	0.0	0.0	19.8	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	9.7	0.0	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.0	1.7	5.0	6.9	1.0	1.4	2.6	1.6	1.0	1.4	1.3	2.2	1.2	0.0	1.3	0.7	2.4	1.0	1.9	0.0	0.6	6.3	0.1	0.3	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	4.0	11.4	0.0	0.0	82.8	0.0	0.0	10.1	0.0	0.2	0.0	0.0	4.2	0.0	0.1	0.0	56.1	0.0	0.0	0.0	1.8	0.1	0.9	0.5	1.8	34.7	0.0	13.6	0.0	64.8	4.0	0.0	0.0	0.0	25.5	1.5	0.0	0.0	0.0	0.3	52.6	11.3	57.6	0.0	0.2	0.4	1.1	0.0	1.2	0.1	0.1	1.4
KCND3	"KSHIVB, Kv4.3, SCA19, SCA22"	ENSG00000171385	"Potassium voltage-gated channel subfamily D member 3"	Q9UK17	1	111770662-111989668	"Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Brugada syndrome, Disease variant, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 35.0"	"Cell type enhanced"	"Detected in many"		"Bipolar cells: 46.8;Cardiomyocytes: 38.1;Excitatory neurons: 105.7;Hepatocytes: 37.8;Inhibitory neurons: 88.4;Oligodendrocyte precursor cells: 45.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 8.4"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"OE19: 4.8;SCLC-21H: 10.1;U-2 OS: 1.6;WM-115: 2.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029452	Approved					NA	NA					"HPA029452: AB_10602239"	"unprognostic (1.11e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.71e-1)"	"unprognostic (2.60e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.41e-1)"	"unprognostic (9.48e-2)"	"unprognostic (1.15e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.40e-1)"	"unprognostic (7.44e-2)"	"unprognostic (3.64e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.51e-3)"	"unprognostic (6.64e-3)"	4.5	1.5	17.6	4.7	14.3	0.2	3.0	18.5	19.9	2.3	0.0	4.6	0.9	5.3	12.7	4.1	5.1	5.6	8.1	15.9	8.1	1.3	15.5	1.7	0.5	3.0	35.0	13.1	0.5	4.5	3.9	3.5	0.5	9.1	11.4	2.5	12.8	1.6	12.1	2.6	7.1	2.2	9.9	0.3	3.3	3.3	2.0	11.0	0.3	1.1	1.7	0.5	6.0	3.2	12.4	0.0	0.0	0.2	0.0	0.4	0.1	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	1.0	0.4	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.1	0.2	4.8	0.0	0.0	0.0	0.0	0.0	0.2	10.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	17.6	14.3	18.5	19.9	15.9	8.1	3.0	35.0	13.1	9.1	0.3	11.0	12.4	1.1	0.0	9.3	18.3	0.3	7.5	11.9	2.9	0.0	46.8	7.8	1.5	38.1	0.0	1.5	0.0	4.2	0.1	0.4	1.5	0.0	0.8	35.7	0.5	14.5	1.6	0.0	2.7	105.7	23.8	0.2	3.7	0.0	0.7	0.0	0.0	1.8	37.8	0.2	30.3	88.4	0.4	4.1	0.8	1.9	32.3	18.0	0.5	3.6	1.0	0.0	6.2	0.0	45.8	8.7	4.8	1.2	1.9	0.0	21.9	0.1	0.3	0.1	4.8	0.0	0.8	1.7	1.5	1.0	2.0	6.7	0.0	0.5	0.1	2.4	13.4
KCNG3	Kv6.3	ENSG00000171126	"Potassium voltage-gated channel modifier subfamily G member 3"	Q8TAE7	2	42442017-42493982	"Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	6	"brain: 5.3"	"Group enriched"	"Detected in some"	4	"Endometrial ciliated cells: 12.1;Excitatory neurons: 16.4;Glandular and luminal cells: 12.8"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"HAP1: 4.7;HMC-1: 16.2;NTERA-2: 10.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA041625			Approved	"Cytoplasmic bodies"		NA	NA			"Cytoplasmic bodies"		"HPA041625: "	"unprognostic (1.56e-1)"	"unprognostic (4.22e-3)"	"unprognostic (2.48e-1)"	"unprognostic (7.67e-3)"	"unprognostic (7.95e-2)"	"unprognostic (9.14e-3)"		"unprognostic (4.83e-3)"	"unprognostic (6.59e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.75e-1)"	"unprognostic (2.56e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.76e-1)"	"unprognostic (6.47e-2)"	"unprognostic (1.23e-1)"	0.0	0.9	2.0	0.1	2.5	0.0	0.0	0.0	3.3	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	5.3	1.0	0.1	0.0	0.1	0.0	0.6	1.2	3.5	0.2	0.5	0.0	0.4	0.0	0.9	0.1	0.2	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.6	0.0	0.0	0.0	0.1	0.0	1.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	0.2	0.0	4.7	0.0	0.0	0.0	2.5	0.0	0.5	0.9	0.0	0.0	16.2	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.2	0.0	0.0	0.1	0.9	0.0	10.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.5	0.6	1.0	1.6	0.4	1.6	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	2.5	0.0	3.3	5.3	1.0	0.6	1.2	3.5	0.9	0.0	0.2	1.0	0.1	3.2	1.1	0.7	0.0	1.3	0.3	0.0	0.0	1.6	0.1	0.0	0.5	0.0	0.6	0.0	0.0	0.0	0.1	0.4	0.0	0.2	0.6	12.1	1.5	0.2	1.8	0.0	16.4	0.0	0.0	0.5	0.0	12.8	0.0	0.3	0.0	0.0	0.1	0.0	1.4	0.4	0.0	0.0	0.3	0.2	1.8	0.1	0.0	0.0	0.0	2.0	0.0	1.5	0.4	0.2	0.2	2.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.4	1.1	0.0	1.1	0.1	0.1	1.8	0.3	0.3
KCNH6	"erg2, HERG2, Kv11.2"	ENSG00000173826	"Potassium voltage-gated channel subfamily H member 6"	Q9H252	17	63523334-63548977	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 4.8;kidney: 6.8;pituitary gland: 5.4;prostate: 3.9;retina: 4.5"	"Group enriched"	"Detected in some"	8	"Bipolar cells: 44.8;Cardiomyocytes: 25.6;Cone photoreceptor cells: 31.3;Enteroendocrine cells: 34.6;Proximal enterocytes: 40.3;Proximal tubular cells: 14.1"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 5.3"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"SCLC-21H: 3.3;SH-SY5Y: 1.1"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"medulla oblongata: 1.1;olfactory bulb: 2.4;spinal cord: 2.5"	HPA061704	Approved					NA	NA					"HPA061704: "	"unprognostic (8.00e-2)"	"unprognostic (1.80e-1)"	"unprognostic (5.46e-2)"	"unprognostic (5.68e-2)"	"unprognostic (5.98e-5)"	"unprognostic (3.39e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.03e-1)"	"unprognostic (1.28e-2)"	"unprognostic (3.25e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.95e-1)"	"unprognostic (1.19e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.66e-1)"	"unprognostic (8.05e-2)"	"unprognostic (9.15e-2)"	0.0	0.1	1.4	0.0	1.0	0.2	0.0	0.9	1.1	0.0	0.3	0.2	2.2	0.0	0.0	0.0	0.1	0.0	0.0	0.6	1.3	6.8	0.0	0.3	0.0	1.6	2.1	0.7	0.0	1.3	0.0	5.4	0.1	1.6	3.9	0.2	4.5	0.0	0.0	0.1	0.1	4.8	0.0	1.0	0.1	0.8	1.2	1.5	0.7	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.3	1.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.4	1.0	0.9	1.1	0.6	1.3	1.6	2.1	0.7	1.6	1.0	1.5	1.6	0.0	0.0	0.0	0.3	0.0	0.3	0.2	0.0	0.0	44.8	0.0	0.3	25.6	0.0	0.0	0.0	31.3	0.0	0.0	0.1	0.0	0.0	3.0	0.6	0.1	1.3	34.6	0.0	1.1	0.0	0.0	0.8	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.9	3.8	0.0	0.0	0.0	3.4	0.0	0.1	1.8	0.0	0.0	1.1	0.0	0.5	0.1	0.1	1.2	0.0	0.0	1.4	40.3	14.1	0.0	3.1	0.0	0.2	1.0	0.0	0.7	0.0	0.1	0.1	0.1	0.0	0.8	0.1
KCNMB1	hslo-beta	ENSG00000145936	"Potassium calcium-activated channel subfamily M regulatory beta subunit 1"	Q16558	5	170374671-170389634	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 59.7;intestine: 53.6;seminal vesicle: 51.1;smooth muscle: 53.6"	"Cell type enriched"	"Detected in many"	6	"Peritubular cells: 354.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 6.0"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"dendritic cells: 5.7;monocytes: 5.9"	"Cell line enhanced"	"Detected in some"		"REH: 8.8;SK-BR-3: 2.1;U-937: 3.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (2.06e-2)"	"unprognostic (2.70e-4)"	"unprognostic (1.69e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.37e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.46e-1)"	"unprognostic (2.28e-1)"	"unprognostic (4.68e-2)"	"unprognostic (5.37e-1)"	"unprognostic (1.00e-1)"	"prognostic unfavorable (4.13e-6)"	"unprognostic (1.08e-1)"	"unprognostic (2.49e-1)"	"unprognostic (4.31e-2)"	"unprognostic (1.04e-2)"	5.8	1.8	2.6	10.6	2.5	1.7	7.0	2.4	3.5	14.8	1.7	53.6	4.3	59.7	6.2	16.8	20.8	7.3	4.2	1.9	1.8	1.2	0.7	4.0	1.7	5.3	3.2	1.5	4.1	0.7	0.3	0.5	1.1	6.2	24.7	9.0	1.1	6.9	51.1	1.1	2.6	14.4	53.6	3.6	2.3	21.6	2.8	4.0	1.0	1.4	1.1	1.4	32.8	11.2	5.6	0.1	0.1	1.5	0.3	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.3	0.3	0.1	1.0	0.1	0.4	0.1	0.0	0.0	0.0	0.3	0.1	1.2	0.6	0.2	0.0	0.4	0.2	0.2	0.0	0.1	0.2	0.1	0.1	0.4	0.3	0.7	0.1	0.7	0.0	0.8	0.3	0.0	0.1	8.8	0.0	0.2	0.0	0.2	0.4	0.2	0.1	2.1	0.0	0.7	0.1	1.0	0.5	0.2	0.3	0.3	0.0	0.4	0.2	0.1	0.1	3.8	0.1	1.3	3.3	0.3	0.1	5.9	0.1	0.2	0.2	0.1	5.7	0.3	0.1	0.1	0.9	0.4	5.1	2.0	0.2	1.0	2.6	2.5	2.4	3.5	1.9	1.8	5.3	3.2	1.5	6.2	3.6	4.0	5.6	1.3	0.0	6.3	0.3	1.2	2.0	1.2	0.4	0.0	1.6	2.5	55.1	3.7	4.3	4.5	1.8	6.2	0.5	1.7	0.1	0.0	0.1	0.6	0.6	14.4	3.6	0.0	1.3	0.1	0.4	0.6	9.8	0.0	0.6	19.7	0.4	1.8	0.4	7.4	1.7	0.3	0.2	0.0	18.9	10.9	4.5	38.5	15.6	3.6	4.7	27.8	0.6	2.1	0.0	0.1	0.0	0.0	354.3	0.3	1.3	0.0	0.1	4.5	2.3	46.0	2.2	43.6	0.7	1.2	0.1	1.7	0.5	1.7	1.4	0.0	0.7
KIAA1210		ENSG00000250423	KIAA1210	Q9ULL0	X	119078635-119150579	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"epididymis: 39.7;seminal vesicle: 20.0;testis: 31.1"	"Cell type enhanced"	"Detected in some"		"Early spermatids: 4.0;Endometrial stromal cells: 25.2;Granulosa cells: 11.1;Late spermatids: 11.5;Peritubular cells: 6.0"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"MCF7: 1.0"	"Not detected"	"Not detected"							"HPA000551, HPA048322"	Enhanced		Approved	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"HPA000551: AB_1079165, HPA048322: AB_2680358"	"unprognostic (2.48e-1)"	"unprognostic (5.63e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.43e-1)"	"unprognostic (3.90e-1)"	"unprognostic (2.25e-2)"	"unprognostic (1.16e-2)"	"unprognostic (6.29e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.92e-2)"	"unprognostic (5.69e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.24e-1)"	"unprognostic (6.26e-4)"	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.2	0.0	0.0	1.6	39.7	0.0	5.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	4.7	0.0	0.0	0.0	20.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.2	0.4	1.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	4.0	1.9	25.2	0.2	0.0	0.0	0.1	0.0	0.2	0.3	0.0	1.6	0.0	11.1	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.3	11.5	3.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.5	2.4	1.1	0.0	0.0	0.3	0.1	0.3	0.0	0.0
KIF5C		ENSG00000168280	"Kinesin family member 5C"	O60282	2	148875227-149026759	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"	Transport	"Motor protein"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 65.1"	"Cell type enhanced"	"Detected in many"		"Bipolar cells: 252.2;Early spermatids: 568.4;Excitatory neurons: 267.2;Inhibitory neurons: 249.1;Late spermatids: 702.5;Oligodendrocytes: 270.7"	"Cancer enhanced"	"Detected in many"		"glioma: 11.7;prostate cancer: 19.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	4	"SCLC-21H: 117.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035210, HPA062272"	Enhanced		Approved	Vesicles		NA	NA			Vesicles		"HPA035210: AB_10671931, HPA062272: AB_2732678"	"unprognostic (1.95e-1)"	"unprognostic (2.39e-1)"	"unprognostic (2.54e-1)"	"unprognostic (4.70e-4)"	"unprognostic (1.89e-1)"	"unprognostic (3.79e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.90e-2)"	"unprognostic (2.86e-1)"	"unprognostic (1.41e-2)"	"unprognostic (6.61e-3)"	"unprognostic (1.56e-1)"	"unprognostic (6.55e-6)"	"unprognostic (8.34e-3)"	"unprognostic (3.69e-1)"	"unprognostic (3.63e-2)"	"unprognostic (4.46e-2)"	0.5	5.2	44.5	0.6	23.3	0.0	0.5	16.9	65.1	1.1	0.0	0.9	0.3	0.5	3.7	0.1	0.9	0.1	0.4	33.8	19.0	0.1	0.0	0.2	0.3	23.5	17.6	16.1	1.6	2.4	0.3	5.6	0.0	28.1	10.5	0.7	7.8	0.2	2.8	0.3	0.2	0.8	0.4	17.9	0.2	0.6	12.2	25.2	0.1	1.4	0.9	0.2	0.6	1.4	36.5	0.0	0.0	17.8	3.6	0.0	0.0	0.0	0.0	0.0	0.8	0.6	0.2	0.0	0.7	0.0	0.2	5.4	0.0	14.1	0.0	1.3	13.7	3.0	0.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.2	0.7	0.0	0.7	0.0	0.1	0.0	0.8	0.0	0.0	22.4	0.0	9.2	0.0	0.1	0.1	0.0	3.6	117.1	27.1	0.2	0.5	0.2	2.8	0.0	0.0	0.0	0.0	3.3	0.0	3.7	3.0	0.4	0.0	8.8	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.5	23.3	16.9	65.1	33.8	19.0	23.5	17.6	16.1	28.1	17.9	25.2	36.5	1.8	0.0	0.0	33.6	2.4	1.3	6.1	0.1	2.2	252.2	8.0	3.7	14.9	4.3	0.0	18.4	108.4	0.0	0.8	1.1	0.0	0.3	568.4	0.9	1.6	6.1	129.7	0.0	267.2	0.0	0.1	4.9	2.0	0.2	0.0	1.1	0.7	0.0	0.2	99.3	249.1	2.7	4.1	0.3	1.9	702.5	8.1	0.8	5.4	10.3	0.8	8.5	2.1	125.2	270.7	0.9	3.4	12.8	1.7	35.8	0.1	0.1	0.0	15.1	6.6	1.6	9.1	15.8	10.7	0.2	0.4	0.0	11.9	0.3	4.9	2.3
KLK11	"PRSS20, TLSP"	ENSG00000167757	"Kallikrein related peptidase 11"	Q9UBX7	19	51022216-51028039	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 326.8;salivary gland: 170.9;skin 1: 232.6;vagina: 188.0"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 152.1;Club cells: 217.9;Late spermatids: 339.0;Prostatic glandular cells: 234.8;Squamous epithelial cells: 176.4;Suprabasal keratinocytes: 217.1;Urothelial cells: 186.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 53.3"	"Region enhanced"	"Detected in single"		"hippocampal formation: 1.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"EFO-21: 13.0;HaCaT: 41.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB026340	Approved				"Secreted in other tissues"	NA	NA		1800000			"CAB026340: "	"unprognostic (4.23e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.27e-1)"	"prognostic favorable (3.78e-4)"		"unprognostic (2.08e-2)"	"unprognostic (4.67e-1)"	"unprognostic (5.32e-2)"	"unprognostic (3.72e-1)"	"unprognostic (3.02e-1)"	"prognostic unfavorable (4.17e-4)"	"unprognostic (2.92e-2)"	"unprognostic (4.16e-6)"	"unprognostic (3.90e-2)"	"unprognostic (2.73e-1)"	"unprognostic (4.40e-2)"	"unprognostic (2.53e-1)"	13.2	0.2	0.0	0.4	0.0	0.0	17.3	0.9	0.1	55.0	35.5	2.0	0.7	7.3	2.6	326.8	34.5	59.9	1.4	1.7	0.0	0.1	0.8	19.1	0.0	0.1	0.5	0.0	1.6	89.8	0.0	8.9	0.0	0.2	65.5	0.6	0.7	170.9	4.2	2.0	232.6	1.4	0.3	0.0	0.1	114.2	14.5	0.5	2.5	0.4	0.3	27.4	1.4	188.0	0.2	1.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	6.4	0.1	13.0	0.0	0.0	41.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.1	4.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.1	1.7	0.0	0.1	0.5	0.0	0.2	0.0	0.5	0.2	0.2	86.6	10.4	0.0	0.4	106.9	152.1	131.6	13.1	0.2	33.4	35.3	0.8	88.6	217.9	0.0	0.0	0.0	0.0	0.1	0.0	9.2	111.6	4.7	1.1	3.8	20.3	0.0	0.0	130.2	0.0	9.1	91.3	15.6	1.3	0.0	0.0	0.0	0.3	0.0	0.0	10.7	118.0	0.0	11.4	339.0	2.8	1.8	8.8	0.0	0.1	0.1	0.0	0.0	0.0	79.4	0.0	0.4	0.5	234.8	0.1	0.0	26.9	1.3	0.0	0.2	7.9	2.1	2.5	176.4	217.1	0.0	1.7	0.0	0.4	186.1
KRTAP13-2	KAP13-2	ENSG00000182816	"Keratin associated protein 13-2"	Q52LG2	21	30371390-30372271	"Plasma proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"intestine: 1.9;skin 1: 7.6"	"Group enriched"	"Detected in some"	4	"Distal enterocytes: 31.1;Paneth cells: 27.0;Prostatic glandular cells: 11.0"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.0"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																	NA	NA		1000000												"unprognostic (2.44e-2)"			"unprognostic (5.68e-2)"						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	0.0	0.0	0.0	0.0	7.6	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.1	0.0	0.0	0.9	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.0	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	5.4
LMOD1	"1D, 64kD, D1"	ENSG00000163431	"Leiomodin 1"	P29536	1	201896456-201946588	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Cone photoreceptor cells: 135.5;Leydig cells: 125.6;Peritubular cells: 275.3;Rod photoreceptor cells: 70.2;Sertoli cells: 197.2;Smooth muscle cells: 224.3"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 43.9"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 15.8;BJ: 21.3;BJ hTERT+: 34.4;fHDF/TERT166: 17.4;HSkMC: 14.5;hTERT-RPE1: 54.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA028325, HPA028435, HPA030097"	Enhanced		Approved	Cytosol		No	No			Cytosol		"HPA028325: AB_10600300, HPA028435: AB_10602180, HPA030097: AB_10601223"	"unprognostic (3.84e-2)"	"unprognostic (5.01e-2)"	"unprognostic (1.44e-2)"	"unprognostic (1.27e-1)"	"unprognostic (5.64e-1)"	"unprognostic (6.35e-2)"	"prognostic favorable (2.52e-5)"	"unprognostic (1.27e-1)"	"unprognostic (6.10e-2)"	"unprognostic (1.73e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (1.05e-4)"	"unprognostic (4.30e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.44e-3)"	"unprognostic (1.15e-2)"	115.7	52.9	7.6	28.8	7.8	0.0	76.1	5.4	9.2	153.1	10.1	364.2	25.3	312.1	50.1	137.1	196.4	86.3	26.2	5.8	7.9	11.6	5.1	44.7	7.4	12.9	6.9	4.9	72.8	8.5	18.4	5.8	35.6	6.6	166.6	47.3	48.4	21.4	244.8	138.8	33.5	116.5	208.4	4.8	18.6	220.5	18.0	6.9	2.6	40.1	46.1	1.6	371.8	112.9	6.4	0.0	0.1	0.4	1.2	15.8	2.0	1.3	21.3	34.4	1.3	1.5	0.1	0.2	0.0	0.7	17.4	0.2	0.3	0.5	0.0	0.4	0.0	1.4	0.0	0.1	0.0	1.5	0.1	0.1	14.5	0.0	1.0	0.0	54.4	0.1	0.0	0.2	0.2	0.7	0.0	0.0	0.5	0.1	0.0	0.1	0.0	0.0	0.5	0.1	0.4	0.1	0.3	0.0	0.5	0.4	9.5	0.7	0.0	0.0	0.1	0.8	0.3	0.0	0.7	0.6	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6	7.8	5.4	9.2	5.8	7.9	12.9	6.9	4.9	6.6	4.8	6.9	6.4	16.1	0.0	1.1	8.5	0.3	1.3	1.0	0.3	0.0	4.8	1.6	40.8	25.1	0.0	0.0	0.0	135.5	1.7	0.0	0.1	0.0	0.0	2.1	2.6	64.5	5.8	0.0	0.0	0.5	0.6	0.3	20.4	0.5	1.2	0.0	0.7	9.3	0.4	1.0	3.3	1.0	0.0	0.0	0.0	2.3	8.2	125.6	0.9	3.6	3.7	0.0	7.3	0.0	4.0	1.0	0.0	0.0	275.3	0.0	0.9	0.0	0.1	0.9	70.2	197.2	5.2	224.3	1.2	0.5	0.8	2.3	1.2	1.3	2.1	0.0	0.4
MCCC2	MCCB	ENSG00000131844	"Methylcrotonoyl-CoA carboxylase 2"	Q9HCC0	5	71587288-71658706	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"		Ligase	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 121.5"	"Cell type enhanced"	"Detected in all"		"Glandular and luminal cells: 107.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 81.0"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038300, HPA038301, HPA061546"	Enhanced		Enhanced	Mitochondria		NA	NA			Mitochondria		"HPA038300: AB_2675941, HPA038301: AB_10670661, HPA061546: AB_2684557"	"unprognostic (2.39e-1)"	"unprognostic (6.89e-3)"	"prognostic favorable (3.62e-4)"	"unprognostic (1.79e-2)"	"unprognostic (1.89e-2)"	"unprognostic (8.07e-2)"	"prognostic favorable (1.70e-4)"	"unprognostic (1.01e-1)"	"unprognostic (3.37e-1)"	"unprognostic (5.39e-2)"	"unprognostic (2.90e-1)"	"unprognostic (2.38e-1)"	"prognostic favorable (6.43e-8)"	"unprognostic (1.27e-1)"	"unprognostic (1.29e-1)"	"unprognostic (5.15e-2)"	"unprognostic (3.47e-2)"	21.5	48.0	13.5	13.7	14.2	6.1	60.6	12.8	15.6	21.5	22.5	30.8	27.5	14.5	39.2	25.6	17.4	15.4	51.4	12.2	18.6	74.0	121.5	13.5	18.0	14.5	13.3	11.7	14.4	24.8	33.0	14.2	14.3	14.6	48.7	36.3	12.3	28.4	20.8	34.7	19.7	20.9	11.8	16.5	15.8	26.0	8.7	15.1	14.3	45.0	35.7	21.7	27.3	15.1	18.8	38.5	52.4	21.4	82.5	22.4	23.0	36.9	16.4	29.4	35.7	25.7	91.1	46.9	90.4	62.8	25.9	28.0	30.8	37.8	58.8	44.3	47.6	45.6	48.2	24.7	100.5	39.2	24.4	42.8	29.5	30.1	32.6	25.8	15.8	31.7	24.9	63.2	31.6	24.9	103.0	0.3	42.9	29.0	33.2	27.2	46.3	64.5	130.9	92.5	66.9	32.9	36.7	80.1	111.8	38.8	10.1	92.7	59.6	22.7	14.4	22.1	26.1	49.9	22.4	46.2	54.6	23.7	66.3	36.6	2.0	8.4	1.9	6.5	13.5	8.5	9.7	8.4	7.4	19.4	9.9	8.3	9.1	1.3	14.7	8.1	8.1	12.1	8.3	13.5	14.2	12.8	15.6	12.2	18.6	14.5	13.3	11.7	14.6	16.5	15.1	18.8	9.1	16.0	23.6	27.4	26.8	13.3	17.5	20.2	22.2	12.6	54.9	28.3	61.5	20.0	22.3	16.5	6.2	48.5	17.6	26.3	21.5	20.6	4.3	94.0	24.0	15.1	29.5	13.9	22.2	18.2	23.0	13.1	30.1	107.0	12.7	22.7	9.7	93.1	18.0	3.3	21.6	22.8	8.2	12.1	11.2	9.8	13.7	14.0	12.4	11.2	17.9	15.4	20.6	30.2	28.0	15.3	17.0	20.3	27.2	29.6	23.6	59.1	17.7	10.8	6.6	15.2	9.0	4.2	12.0	35.9	13.8	63.6	17.9	30.9	33.9	20.9
MME	"CALLA, CD10, NEP"	ENSG00000196549	"Membrane metalloendopeptidase"	P08473	3	155024124-155183704	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease variant, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 336.5;kidney: 305.3"	"Cell type enhanced"	"Detected in many"		"Endometrial stromal cells: 273.3;Proximal enterocytes: 372.4;Proximal tubular cells: 125.7;Syncytiotrophoblasts: 126.0"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 17.6"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in some"	122	"neutrophil: 139.4"	"Lineage enriched"	"Detected in many"	122	"granulocytes: 139.4"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 684.4;BJ hTERT+: 1116.9;HSkMC: 651.1"	"Region enhanced"	"Detected in many"		"basal ganglia: 28.1"	"Group enriched"	"Detected in many"	4	"basal ganglia: 32.3;olfactory bulb: 8.5;spinal cord: 15.9"	"CAB000013, HPA052583, HPA056072"	Enhanced					NA	NA		320000			"CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027"	"unprognostic (1.36e-1)"	"unprognostic (1.02e-3)"	"unprognostic (8.52e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.78e-2)"	"unprognostic (6.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.67e-2)"	"unprognostic (8.67e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.30e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.71e-3)"	"unprognostic (1.50e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.37e-2)"	104.8	1.0	0.6	4.6	13.6	11.6	38.9	1.4	2.5	22.9	0.6	2.0	336.5	13.5	22.7	2.3	1.9	13.5	4.4	0.1	1.6	305.3	56.5	27.9	10.3	7.5	3.7	0.5	0.9	1.2	0.5	0.6	73.6	11.0	80.3	3.5	0.1	6.2	45.0	20.5	1.9	292.1	1.5	0.4	8.0	1.6	1.4	3.0	16.8	1.2	23.7	12.4	6.0	7.6	9.0	0.1	0.0	0.9	0.3	280.1	684.4	1.6	160.3	1116.9	82.2	209.8	0.0	0.3	172.9	0.1	130.1	107.4	0.5	5.2	6.1	201.3	0.0	0.8	0.0	0.1	0.2	229.6	0.0	0.0	651.1	1.0	40.4	308.1	89.4	59.5	0.4	0.2	0.3	135.1	0.7	0.4	1.0	6.1	0.5	1.1	303.3	139.9	1.6	5.2	1.9	0.5	1.5	0.1	0.5	31.9	68.3	0.2	0.2	165.8	356.4	0.8	115.7	27.9	0.1	0.0	217.3	42.5	0.1	7.3	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	139.4	0.0	0.0	1.1	0.0	0.0	0.6	13.6	1.4	2.5	0.1	1.6	7.5	3.7	0.5	11.0	0.4	3.0	9.0	5.9	9.6	13.0	0.3	2.3	0.8	74.1	2.5	0.0	0.0	1.5	64.1	1.6	21.5	11.2	22.0	0.0	82.1	6.9	0.0	9.8	0.2	0.5	6.2	273.3	6.6	0.0	0.0	2.2	0.0	57.8	40.6	0.0	5.7	2.5	0.0	2.9	53.2	8.9	0.0	8.1	9.9	2.0	3.1	1.2	0.5	4.1	10.7	0.0	0.0	0.2	0.0	0.0	0.5	0.3	0.6	13.8	1.2	0.1	40.0	372.4	125.7	1.6	0.0	0.0	17.4	11.1	0.2	0.5	0.1	0.3	126.0	2.5	0.1	12.6	33.6
MTARC1	"FLJ22390, MARC1, MOSC1"	ENSG00000186205	"Mitochondrial amidoxime reducing component 1"	Q5VT66	1	220786913-220819659	"Predicted intracellular proteins"		Oxidoreductase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adipose tissue: 194.0;breast: 87.0;liver: 85.2"	"Group enriched"	"Detected in some"	6	"Cytotrophoblasts: 109.8;Extravillous trophoblasts: 47.9;Syncytiotrophoblasts: 75.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 14.3"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	12	"basophil: 30.2;classical monocyte: 33.6;eosinophil: 12.3;neutrophil: 42.8"	"Group enriched"	"Detected in many"	31	"granulocytes: 42.8;monocytes: 33.6"	"Cell line enhanced"	"Detected in many"		"BEWO: 126.5;HeLa: 56.2;Hep G2: 67.6;NTERA-2: 57.8;OE19: 49.4"									HPA028702	Approved		Supported	Mitochondria		NA	NA			Mitochondria		"HPA028702: AB_10601135"	"unprognostic (3.15e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.16e-2)"	"unprognostic (5.04e-2)"	"unprognostic (2.90e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.71e-3)"	"unprognostic (1.39e-1)"	"unprognostic (7.51e-2)"	"unprognostic (7.71e-3)"	"unprognostic (3.71e-1)"	"unprognostic (4.30e-1)"	"prognostic unfavorable (4.51e-4)"	"unprognostic (3.85e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.50e-1)"	194.0	7.5	8.8	6.9	9.9	18.0	87.0	9.3	13.3	7.9	7.1	19.0	7.6	2.8	14.1	7.6	6.3	4.2	7.0	9.4	29.3	8.3	85.2	9.4	2.8	9.5	10.3	8.9	5.5	9.7	5.4	7.0	16.2	8.7	36.5	17.5	5.7	27.4	13.6	11.1	3.6	9.8	4.0	8.2	10.3	9.4	1.4	11.6	1.6	54.0	9.3	2.1	8.9	5.0	9.0	15.0	7.8	5.9	0.2	1.3	0.3	126.5	1.4	1.2	0.8	1.5	45.4	1.0	0.1	5.3	1.6	0.1	0.1	28.3	2.9	2.1	0.2	25.7	0.1	56.2	67.6	2.7	0.3	0.5	4.5	1.3	0.2	0.0	0.2	1.1	0.1	4.3	0.3	1.1	14.7	0.1	31.9	57.8	49.4	23.8	0.1	0.0	0.3	7.1	17.4	16.4	36.1	8.1	11.4	0.2	16.4	38.5	34.7	0.4	0.1	12.6	0.1	0.1	0.2	0.1	0.1	0.2	0.0	1.1	30.2	33.6	12.3	0.1	2.5	0.0	0.4	0.0	0.0	1.2	0.2	0.1	0.0	42.8	0.0	1.3	0.3	0.0	9.2	8.8	9.9	9.3	13.3	9.4	29.3	9.5	10.3	8.9	8.7	8.2	11.6	9.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	109.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	47.9	0.7	0.0	0.0	0.0	0.0	0.0	0.0	11.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	75.1	0.0	0.0	0.0	0.0
MYBPC1	ssMyBP-C	ENSG00000196091	"Myosin binding protein C1"	Q00872	12	101568353-101686028	"Disease related genes, Human disease related genes, Predicted intracellular proteins"	"Cell adhesion"	"Actin-binding, Muscle protein"	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	87	"skeletal muscle: 11397.7;tongue: 5253.9"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 34.6;Breast glandular cells: 102.4;Breast myoepithelial cells: 81.4;Cardiomyocytes: 64.7;Skeletal myocytes: 184.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 33.0"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	11	"HAP1: 6.8"	"Group enriched"	"Detected in many"	9	"cerebellum: 39.6;olfactory bulb: 10.6"	"Region enhanced"	"Detected in many"		"thalamus: 6.9"	"HPA021004, HPA027614"	Enhanced					NA	NA		240000			"HPA021004: AB_1854232, HPA027614: AB_10602711"	"prognostic favorable (4.76e-5)"	"unprognostic (7.72e-2)"	"unprognostic (1.09e-1)"		"unprognostic (1.81e-2)"	"unprognostic (3.33e-2)"	"unprognostic (4.63e-2)"	"unprognostic (8.67e-2)"	"unprognostic (2.93e-1)"	"unprognostic (9.98e-3)"	"unprognostic (2.56e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.19e-2)"	"unprognostic (4.10e-2)"	"unprognostic (7.96e-2)"	"unprognostic (6.13e-2)"	"unprognostic (5.55e-3)"	1.2	0.3	55.5	0.1	63.8	0.0	64.4	63.0	72.2	1.9	37.2	3.0	0.1	0.2	1.1	95.5	0.8	0.3	1.7	50.8	56.2	0.3	0.7	0.7	0.0	55.9	61.3	48.4	0.5	1.1	0.0	0.3	0.0	54.0	84.3	0.8	0.0	48.8	0.3	11397.7	4.6	7.5	0.0	49.5	0.4	1.3	3.4	65.7	2.7	1.2	5253.9	4.0	0.3	0.7	50.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.5	63.8	63.0	72.2	50.8	56.2	55.9	61.3	48.4	54.0	49.5	65.7	50.7	1.3	0.0	0.0	34.6	0.3	0.0	2.2	0.0	0.0	0.0	102.4	81.4	64.7	0.0	0.0	0.0	0.0	0.0	0.6	2.7	0.0	0.0	16.5	0.1	0.1	1.2	0.0	0.0	5.3	0.0	0.0	3.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.2	0.0	0.8	0.3	23.7	0.6	1.2	1.8	1.0	0.0	0.0	0.0	0.5	0.5	0.1	1.6	0.4	0.0	16.3	0.3	0.1	0.0	0.0	0.0	184.6	2.7	1.4	1.4	0.0	0.0	0.0	0.7	0.0	0.3	2.9
NAALADL2		ENSG00000177694	"N-acetylated alpha-linked acidic dipeptidase like 2"	Q58DX5	3	174438573-175810548	"Enzymes, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Astrocytes: 311.5;Inhibitory neurons: 135.1;Microglial cells: 155.5;Oligodendrocyte precursor cells: 468.0;Oligodendrocytes: 532.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.2"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 14.5;BJ hTERT+: 5.4;fHDF/TERT166: 6.4;WM-115: 5.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA012413, HPA017425, CAB025586"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB025586: , HPA012413: AB_1854274, HPA017425: AB_1854275"	"unprognostic (7.28e-3)"	"unprognostic (1.10e-1)"	"unprognostic (6.28e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.56e-1)"	"unprognostic (2.56e-1)"	"unprognostic (2.29e-4)"	"unprognostic (3.44e-3)"	"unprognostic (5.70e-2)"	"unprognostic (7.42e-2)"	"unprognostic (7.85e-3)"	"unprognostic (9.49e-2)"	"unprognostic (3.66e-6)"	"unprognostic (7.11e-2)"	"unprognostic (1.48e-1)"	"unprognostic (9.05e-2)"	"unprognostic (2.22e-2)"	2.5	1.1	1.0	1.0	2.3	0.2	5.9	1.1	1.1	6.4	1.2	3.1	1.7	3.7	5.5	1.5	3.9	4.3	2.6	1.2	1.8	3.4	2.9	2.0	0.5	2.0	1.2	0.8	3.9	2.2	10.3	0.5	1.2	2.0	5.0	2.4	1.6	5.8	3.8	1.0	0.8	1.6	3.5	1.3	1.9	2.7	1.0	1.5	1.2	2.3	1.7	0.5	3.8	1.3	3.4	0.0	0.0	0.3	0.0	4.4	14.5	0.1	3.1	5.4	0.7	0.9	0.2	1.7	0.0	0.6	6.4	0.2	0.1	0.0	0.0	2.3	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	4.1	0.8	0.1	0.0	3.8	0.5	0.0	0.0	0.1	3.1	0.6	0.2	0.0	0.0	2.2	0.0	0.0	0.2	0.1	2.2	0.3	0.1	0.1	0.3	0.3	1.2	0.3	4.0	0.2	0.7	2.9	0.1	0.1	0.6	0.0	0.0	0.0	1.9	0.1	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.0	2.3	1.1	1.1	1.2	1.8	2.0	1.2	0.8	2.0	1.3	1.5	3.4	5.1	0.0	11.5	311.5	0.1	2.3	8.9	2.7	1.2	7.7	35.1	13.7	3.0	12.8	9.1	12.9	12.5	19.6	0.3	11.1	7.9	10.1	74.9	23.7	8.7	2.8	9.0	2.7	113.4	2.5	1.4	15.0	23.9	30.2	4.5	3.4	2.9	4.5	1.8	0.0	135.1	2.6	10.2	0.3	3.0	39.6	15.2	1.1	3.6	155.5	0.0	6.7	0.0	468.0	532.9	3.6	4.4	12.0	0.0	13.6	13.2	2.4	21.9	6.2	0.0	23.4	4.9	3.2	2.8	5.3	1.8	12.3	0.8	5.7	16.4	16.0
NAP1L2	"BPX, MGC26243"	ENSG00000186462	"Nucleosome assembly protein 1 like 2"	Q9ULW6	X	73212299-73214851	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 58.8"	"Cell type enhanced"	"Detected in many"		"Bipolar cells: 24.4;Excitatory neurons: 34.3;Horizontal cells: 18.5;Inhibitory neurons: 33.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 7.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"EFO-21: 16.6;Karpas-707: 14.1;NTERA-2: 18.1;U-2197: 14.6;U-266/84: 31.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054050, HPA057065"			Enhanced	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA054050: AB_2682357, HPA057065: AB_2797258"	"unprognostic (1.12e-1)"	"unprognostic (6.64e-5)"	"unprognostic (4.22e-2)"	"unprognostic (9.64e-4)"	"unprognostic (1.78e-1)"	"unprognostic (2.74e-3)"	"unprognostic (1.01e-1)"	"unprognostic (8.51e-3)"	"unprognostic (1.76e-2)"	"unprognostic (2.66e-1)"	"prognostic favorable (5.41e-4)"	"unprognostic (1.53e-2)"	"unprognostic (1.54e-2)"	"unprognostic (6.95e-4)"	"unprognostic (1.07e-1)"	"unprognostic (1.19e-1)"	"unprognostic (2.45e-2)"	2.1	6.1	26.3	2.2	34.1	0.5	3.1	38.7	58.8	4.3	14.2	2.9	0.9	5.2	8.3	2.6	4.1	2.3	8.0	35.7	34.6	8.4	1.0	2.3	3.2	27.9	27.3	32.5	9.0	2.5	12.2	14.7	0.0	33.2	11.1	2.9	19.2	3.2	5.9	1.3	5.2	2.2	4.8	20.2	4.3	2.2	2.1	30.5	1.7	8.6	2.9	1.6	3.0	2.7	49.5	0.0	4.8	0.1	9.4	0.6	0.0	0.0	0.1	0.1	0.0	0.0	1.0	0.3	0.0	16.6	0.0	8.9	1.0	3.4	0.4	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.8	0.4	1.3	0.2	2.4	0.1	0.3	6.6	0.4	14.1	0.0	1.7	5.9	0.0	18.1	0.0	8.4	0.0	0.0	0.4	2.0	0.0	0.0	0.0	0.0	1.1	0.0	3.5	1.8	0.0	0.1	0.0	10.3	14.6	1.2	6.6	31.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.5	0.3	1.2	0.8	0.0	0.0	0.6	1.3	0.0	0.5	0.0	0.0	1.0	0.5	26.3	34.1	38.7	58.8	35.7	34.6	27.9	27.3	32.5	33.2	20.2	30.5	49.5	1.0	0.0	3.0	8.5	0.9	6.4	6.2	1.0	8.0	24.4	0.7	2.9	11.1	2.8	0.8	12.9	0.0	0.0	2.9	1.8	13.7	1.1	0.0	0.0	0.2	3.1	7.2	0.0	34.3	0.2	0.0	4.1	1.1	0.1	4.5	0.2	3.6	0.7	0.1	18.5	33.7	0.4	0.0	0.3	0.0	0.4	0.3	0.1	0.0	9.4	0.0	13.7	0.0	9.5	9.1	0.8	0.5	0.4	1.9	3.3	0.0	3.3	0.0	9.9	0.0	5.5	4.0	0.2	0.1	2.6	3.0	0.0	3.5	0.2	0.5	1.0
NEDD4L	"KIAA0439, NEDD4-2, RSP5"	ENSG00000049759	"NEDD4 like E3 ubiquitin protein ligase"	Q96PU5	18	58044226-58401540	"Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"	"Differentiation, Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 253.2;Excitatory neurons: 280.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 29.1"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	4	"T-reg: 5.1"	"Lineage enriched"	"Detected in many"	4	"T-cells: 5.1"	"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 146.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA024618	Approved				"Intracellular and membrane"	NA	NA					"HPA024618: AB_1854362"	"unprognostic (2.56e-1)"	"unprognostic (2.41e-2)"	"unprognostic (1.58e-2)"	"unprognostic (3.14e-1)"	"unprognostic (3.90e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.11e-3)"	"unprognostic (2.26e-2)"	"unprognostic (9.24e-3)"	"unprognostic (4.39e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.27e-1)"	"prognostic favorable (6.55e-15)"	"unprognostic (2.42e-1)"	"unprognostic (8.26e-2)"	"unprognostic (8.49e-3)"	"unprognostic (4.75e-2)"	10.6	17.0	18.2	6.8	31.3	27.2	26.1	27.4	30.3	7.7	4.1	39.2	18.9	5.4	10.1	12.1	9.2	9.6	21.4	33.4	22.4	53.0	36.8	48.3	4.1	15.5	21.0	25.1	6.5	61.0	13.8	28.6	12.1	17.5	64.8	43.2	20.7	27.7	20.6	34.3	11.1	34.1	6.2	11.4	8.0	51.9	7.9	18.2	4.5	17.5	13.2	8.0	19.5	5.9	19.4	70.7	24.5	14.6	20.9	5.1	2.1	49.8	19.2	88.2	48.6	74.6	28.6	37.1	15.1	57.7	7.4	51.3	50.3	19.5	86.1	100.8	34.9	15.5	10.6	14.3	111.3	2.4	0.5	6.0	13.0	54.6	66.4	78.8	39.1	4.0	13.2	18.7	6.3	20.0	16.2	1.0	1.0	12.2	26.7	33.3	14.3	20.1	17.6	47.0	88.7	17.5	5.0	16.1	5.1	146.1	28.3	29.4	5.6	28.8	131.5	38.5	7.5	83.4	8.3	15.3	9.5	27.6	10.8	10.8	0.7	0.3	1.2	0.2	0.3	0.5	0.8	0.6	0.1	0.1	0.3	0.3	0.2	0.2	0.3	0.1	0.1	5.1	0.3	18.2	31.3	27.4	30.3	33.4	22.4	15.5	21.0	25.1	17.5	11.4	18.2	19.4	6.0	253.2	144.8	110.4	5.1	112.8	161.2	34.0	86.6	18.1	99.5	65.9	47.8	64.3	112.8	62.5	173.0	13.0	3.6	144.5	49.0	35.7	22.6	64.0	7.3	14.7	45.2	57.9	280.9	49.2	4.7	9.5	114.7	75.0	3.8	4.7	17.5	41.3	7.3	62.2	173.3	201.5	101.7	8.4	8.2	6.6	3.4	13.3	14.2	88.1	7.3	45.2	2.1	11.1	105.0	49.9	145.3	17.7	12.7	126.9	127.3	91.6	72.7	10.0	0.0	34.3	6.0	1.1	12.5	62.3	53.0	80.0	6.6	8.2	72.9	155.5
NPDC1	"CAB-, CAB1, DKFZp586J0523"	ENSG00000107281	"Neural proliferation, differentiation and control 1"	Q9NQX5	9	137039463-137046179	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Adipocytes: 397.0;Endothelial cells: 307.2;Enteroendocrine cells: 281.6;Hepatic stellate cells: 406.2;Intestinal goblet cells: 589.1"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 146.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 12.3;MAIT T-cell: 14.7;memory CD4 T-cell: 19.0;memory CD8 T-cell: 18.9;T-reg: 15.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 19.0"	"Cell line enhanced"	"Detected in many"		"MCF7: 138.4;RPMI-8226: 132.8;T-47d: 140.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008189	Approved		Approved	Nucleoplasm,Cytosol		NA	NA		240000	Nucleoplasm	Cytosol	"HPA008189: AB_1854584"	"unprognostic (6.94e-2)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (2.01e-5)"	"prognostic favorable (6.19e-5)"	"unprognostic (2.06e-1)"	"unprognostic (4.83e-3)"	"unprognostic (1.24e-1)"	"unprognostic (4.35e-2)"	"unprognostic (8.65e-2)"	"unprognostic (1.53e-1)"	"prognostic favorable (3.18e-4)"	"unprognostic (2.40e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.35e-1)"	"unprognostic (4.20e-2)"	"unprognostic (8.84e-2)"	121.0	46.1	117.4	12.3	105.6	3.5	134.1	86.5	182.8	120.3	42.6	93.4	23.6	122.6	4.3	54.2	149.9	25.2	128.8	120.4	112.2	76.1	23.9	116.5	13.1	117.6	120.6	111.3	68.8	81.8	23.2	268.1	21.3	102.5	262.7	13.6	9.3	138.5	35.4	34.3	50.9	72.7	17.0	92.3	146.4	127.3	35.6	121.0	2.9	68.9	12.6	4.0	98.8	91.2	93.8	33.6	41.9	10.1	67.1	23.7	23.8	2.8	68.7	23.0	16.9	6.7	17.1	18.5	30.3	50.7	28.6	4.6	122.4	8.6	20.5	1.6	25.0	40.4	13.6	123.7	12.9	33.3	11.9	0.3	16.5	31.9	8.7	17.9	43.1	43.6	13.2	0.7	0.8	3.5	138.4	1.0	1.1	21.1	111.0	68.1	19.9	0.0	132.8	28.6	22.7	77.2	50.0	18.4	65.3	46.5	3.6	140.1	17.9	73.9	12.4	21.6	84.1	21.0	0.1	0.4	1.4	17.7	1.2	10.5	0.0	0.6	0.9	12.3	0.1	14.7	0.1	19.0	18.9	1.1	0.0	0.5	3.1	0.0	0.2	0.1	3.4	15.9	3.3	117.4	105.6	86.5	182.8	120.4	112.2	117.6	120.6	111.3	102.5	92.3	121.0	93.8	397.0	0.0	7.7	64.3	3.4	23.6	77.6	15.0	31.3	97.5	174.0	139.7	18.3	71.4	19.8	29.5	16.7	1.1	5.5	122.2	0.0	52.5	1.8	39.0	27.7	307.2	281.6	19.3	71.7	66.0	1.3	61.2	153.9	101.3	0.0	9.2	406.2	1.9	22.2	62.2	64.7	589.1	18.3	21.0	20.0	6.9	161.2	6.6	30.2	37.5	3.0	38.5	1.0	38.2	39.0	33.0	106.0	145.6	1.4	234.9	37.5	0.7	7.5	62.0	39.5	23.9	38.9	2.8	19.0	15.9	23.7	1.8	12.3	9.1	98.1	103.1
NPY4R	"PP1, PPYR1, Y4"	ENSG00000204174	"Neuropeptide Y receptor Y4"	P50391	10	46461099-46465958	"G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"intestine: 6.0;skin 1: 3.1"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.8"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"A549: 28.6"									HPA027863	Approved					NA	NA					"HPA027863: AB_10602819"		"unprognostic (2.26e-6)"	"unprognostic (2.94e-1)"			"unprognostic (8.17e-2)"		"unprognostic (1.20e-1)"		"unprognostic (1.30e-1)"	"unprognostic (1.77e-3)"	"unprognostic (1.98e-1)"	"unprognostic (2.64e-3)"	"unprognostic (6.58e-2)"			"unprognostic (9.79e-2)"	0.2	0.0	0.3	0.7	0.1	0.0	0.2	0.6	0.2	0.0	0.0	4.9	1.5	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.2	0.0	0.0	0.7	0.0	0.4	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.5	1.4	6.0	0.0	0.0	0.0	0.0	3.1	1.2	1.1	0.3	0.0	1.9	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.5	28.6	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.3	0.1	0.0	0.8	0.0	0.0	5.9	0.0	0.4	0.1	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.2	1.5	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.6	0.2	0.2	0.2	0.4	0.5	0.1	0.5	0.3	1.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
OAZ3		ENSG00000143450	"Ornithine decarboxylase antizyme 3"	Q9UMX2	1	151762899-151771334	"Predicted intracellular proteins"	"Polyamine biosynthesis"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	16	"testis: 246.6"	"Cell type enriched"	"Detected in many"	5	"Late spermatids: 12007.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 3.8"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA030136, HPA045808"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA030136: AB_2673331, HPA045808: "	"unprognostic (2.12e-1)"	"unprognostic (3.86e-1)"	"unprognostic (1.53e-1)"	"unprognostic (5.44e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.48e-3)"	"unprognostic (1.08e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.01e-4)"	"unprognostic (1.57e-2)"	"unprognostic (2.89e-1)"	"unprognostic (8.05e-6)"	"unprognostic (3.94e-2)"	"unprognostic (1.32e-1)"	"unprognostic (2.50e-2)"	"unprognostic (8.36e-2)"	1.5	1.6	2.4	1.6	2.4	0.6	2.4	4.3	2.7	0.6	1.5	1.3	0.7	0.5	2.7	1.7	0.9	0.8	1.0	2.6	2.4	1.6	2.8	1.5	1.5	2.9	2.5	2.3	0.3	2.1	4.3	2.7	0.6	2.9	15.4	1.7	2.7	8.2	1.3	3.0	1.2	1.2	0.5	1.9	1.3	1.4	246.6	2.4	0.6	3.3	0.9	0.6	1.1	1.0	2.4	0.9	1.8	1.0	2.5	0.8	2.4	2.3	1.9	0.4	1.7	0.7	1.0	2.3	0.8	1.5	0.6	1.2	0.9	1.0	1.7	0.5	5.8	5.3	0.8	3.2	1.5	1.0	0.4	0.9	3.8	1.0	1.9	2.3	1.1	2.6	2.3	1.2	2.8	1.9	7.7	0.7	1.3	2.5	3.6	1.9	0.4	0.8	1.3	0.3	2.3	1.2	2.8	0.8	3.7	3.6	2.3	8.2	2.1	2.3	1.0	0.5	1.9	1.0	4.0	7.5	2.0	1.3	1.2	2.7	0.6	0.8	0.1	0.3	0.4	0.3	0.3	0.3	0.6	1.0	0.2	0.3	0.6	0.4	0.7	1.5	0.3	0.7	0.4	2.4	2.4	4.3	2.7	2.6	2.4	2.9	2.5	2.3	2.9	1.9	2.4	2.4	2.3	0.0	1.7	0.3	0.3	0.8	2.6	1.8	1.8	0.5	16.0	6.2	1.4	0.0	2.2	0.0	2.1	1.7	0.9	4.2	1.9	2.4	2386.5	3.4	0.6	5.3	3.6	0.4	0.4	3.1	3.0	1.0	1.5	1.5	1.3	0.5	1.8	3.1	4.8	0.0	0.3	7.4	2.0	4.2	1.6	12007.9	46.0	5.1	1.8	0.0	1.8	1.7	0.0	0.0	0.3	3.3	4.9	42.5	1.6	20.4	5.7	7.4	3.2	1.6	0.0	0.4	0.8	67.6	31.8	1.2	0.6	1.5	0.6	1.4	2.7	3.2
OPRK1	"KOR, OPRK"	ENSG00000082556	"Opioid receptor kappa 1"	P41145	8	53225724-53251637	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"brain: 10.9"	"Group enriched"	"Detected in some"	5	"Endometrial ciliated cells: 4.5;Excitatory neurons: 6.7;Extravillous trophoblasts: 8.0;Glandular and luminal cells: 9.8;Inhibitory neurons: 10.1;Leydig cells: 4.7"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.8"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"U-937: 21.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA067549	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA067549: AB_2732770"	"unprognostic (1.01e-1)"	"unprognostic (1.17e-2)"		"unprognostic (8.70e-3)"	"unprognostic (3.73e-2)"	"unprognostic (6.74e-2)"		"unprognostic (2.22e-3)"		"unprognostic (8.09e-2)"	"unprognostic (9.71e-2)"	"unprognostic (4.28e-3)"		"unprognostic (3.29e-1)"	"unprognostic (3.35e-2)"	"unprognostic (9.54e-4)"	"unprognostic (1.61e-1)"	0.1	0.1	7.6	0.0	10.9	0.0	0.0	1.4	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	3.4	3.5	0.0	0.0	0.1	0.0	4.4	2.0	7.9	0.0	0.0	0.0	0.0	0.2	5.4	1.6	0.0	0.6	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	5.7	0.1	0.1	0.0	0.0	0.0	0.0	5.6	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.3	21.6	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6	10.9	1.4	4.0	3.4	3.5	4.4	2.0	7.9	5.4	0.0	5.7	5.6	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.6	1.3	0.0	0.0	0.0	0.2	4.5	0.6	0.1	0.0	0.0	6.7	0.0	8.0	0.1	0.0	9.8	0.0	0.0	0.0	0.0	0.2	0.0	10.1	0.0	0.0	0.0	0.0	0.3	4.7	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.4	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.0	1.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0
PCDHGA5	"CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5"	ENSG00000253485	"Protocadherin gamma subfamily A, 5"	Q9Y5G8	5	141364232-141512979	"Plasma proteins, Predicted membrane proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 5.1"	"Cell type enhanced"	"Detected in some"		"Bipolar cells: 11.5;Endometrial stromal cells: 9.2;Horizontal cells: 10.1;Sertoli cells: 6.6;Skeletal myocytes: 5.7"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.5"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"ASC diff: 15.8;ASC TERT1: 6.2"	"Low region specificity"	"Detected in all"							"HPA008755, HPA010580"	Uncertain		Uncertain	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"		NA	NA			"Vesicles, Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA008755: AB_1079577, HPA010580: AB_2732401"	"unprognostic (3.61e-2)"	"unprognostic (1.04e-2)"	"unprognostic (5.28e-2)"	"unprognostic (4.83e-1)"	"unprognostic (6.60e-3)"	"unprognostic (5.71e-2)"	"unprognostic (8.46e-2)"	"unprognostic (6.53e-3)"	"unprognostic (4.07e-1)"	"unprognostic (9.40e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.90e-2)"	"unprognostic (3.93e-2)"	"unprognostic (1.55e-2)"	"unprognostic (8.38e-4)"	1.0	0.6	1.4	0.3	1.6	0.1	1.2	5.1	1.1	2.3	0.1	0.9	0.1	2.0	0.6	0.8	1.4	1.1	1.9	1.2	2.7	0.3	0.2	1.1	0.2	2.2	1.8	0.7	2.0	0.6	0.6	0.9	0.6	2.0	1.4	0.3	1.2	0.8	0.9	0.6	0.7	0.4	1.1	1.4	0.2	0.5	0.3	1.2	0.3	0.5	0.7	0.1	1.0	1.3	2.2	0.0	0.4	0.2	0.1	15.8	6.2	0.0	0.7	0.1	0.1	0.3	0.0	0.0	0.8	0.3	0.3	0.8	0.0	0.0	0.3	0.2	0.0	0.2	0.0	0.2	0.1	0.1	0.1	0.0	1.5	0.2	0.0	0.0	0.4	0.5	0.0	0.1	0.5	0.6	0.3	0.5	0.6	0.1	0.0	0.3	0.8	0.6	0.1	0.0	0.0	0.2	0.2	0.0	0.2	0.3	0.2	1.4	0.0	0.9	0.5	0.1	0.9	0.6	0.1	0.9	0.1	0.3	0.1	0.7	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.2	0.0	0.1	0.0	0.0	1.4	1.6	5.1	1.1	1.2	2.7	2.2	1.8	0.7	2.0	1.4	1.2	2.2	1.8	0.0	1.1	0.0	0.2	0.1	0.8	0.1	0.6	11.5	0.3	0.4	2.6	0.0	0.7	0.0	0.0	0.1	0.3	0.0	0.0	0.1	0.1	0.4	9.2	1.9	0.0	0.0	0.0	0.2	0.0	4.0	0.0	0.2	1.3	0.6	1.4	0.3	0.1	10.1	0.0	0.0	0.0	0.3	0.0	0.0	3.7	0.4	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.2	0.0	1.9	0.0	0.5	0.0	0.1	0.1	1.3	6.6	5.7	1.7	0.0	0.3	0.3	0.0	0.0	0.6	0.9	0.0	0.4
PCP4	PEP-19	ENSG00000183036	"Purkinje cell protein 4"	P48539	21	39867438-39929397	"Predicted intracellular proteins"		Calmodulin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 609.6;seminal vesicle: 1292.4"	"Group enriched"	"Detected in many"	4	"Bipolar cells: 600.9;Distal tubular cells: 645.6;Horizontal cells: 1398.2;Proximal tubular cells: 941.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 41.7;thyroid cancer: 48.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"RPMI-8226: 215.9;T-47d: 64.7"					"Low region specificity"	"Detected in all"			HPA005792	Enhanced	Supported	Approved	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			"Nucleoplasm, Nucleoli fibrillar center"		"HPA005792: AB_1855086"	"unprognostic (6.82e-2)"	"prognostic favorable (9.76e-4)"	"unprognostic (5.26e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.03e-2)"		"unprognostic (2.94e-1)"	"unprognostic (2.87e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.95e-3)"	"unprognostic (2.63e-1)"	"prognostic favorable (1.85e-7)"	"unprognostic (9.00e-2)"	"unprognostic (2.99e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.07e-2)"	5.3	53.4	196.0	2.0	501.1	0.0	8.5	161.8	168.6	173.9	429.8	81.3	5.2	128.0	368.8	230.4	10.3	4.2	4.5	126.1	185.8	52.7	0.5	0.6	0.2	163.0	321.1	66.0	3.6	6.2	19.8	8.9	2.0	145.7	326.3	32.6	388.7	21.5	1292.4	0.6	13.6	6.0	55.1	59.0	2.7	7.1	0.9	609.6	8.0	229.9	0.0	1.0	471.9	129.7	89.2	0.0	0.0	3.1	0.5	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	6.1	0.0	2.3	1.9	0.0	0.0	0.0	0.0	215.9	0.5	0.0	0.3	0.3	0.0	34.8	0.0	0.2	64.7	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	196.0	501.1	161.8	168.6	126.1	185.8	163.0	321.1	66.0	145.7	59.0	609.6	89.2	0.0	0.0	1.5	15.3	2.9	3.1	0.4	0.0	0.0	600.9	0.4	0.4	8.8	2.8	0.0	77.3	62.6	0.3	0.0	0.1	645.6	0.4	1.3	0.0	0.2	5.0	1.2	0.0	71.3	0.2	0.3	1.5	0.0	0.0	0.0	0.4	0.0	0.1	0.2	1398.2	21.5	0.2	0.0	0.0	7.5	0.4	9.6	7.0	21.4	8.4	0.0	68.4	0.0	7.5	11.9	0.8	0.2	0.4	0.0	4.4	0.0	941.2	0.0	200.0	0.0	0.0	77.4	3.4	9.5	0.0	6.0	2.9	2.2	0.5	0.5	1.0
PDE11A		ENSG00000128655	"Phosphodiesterase 11A"	Q9HCR9	2	177623244-178072777	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Predicted intracellular proteins"		"Allosteric enzyme, Hydrolase"	"Cushing syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 6.4;parathyroid gland: 9.8"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 37.0;Hepatocytes: 11.1;Late spermatids: 46.4;Oligodendrocytes: 14.9"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 1.6;fHDF/TERT166: 2.4;HAP1: 1.4;Hep G2: 2.8"									HPA034560	Approved				"Intracellular and membrane"	NA	NA					"HPA034560: AB_10602140"	"unprognostic (1.02e-1)"	"unprognostic (4.73e-2)"	"unprognostic (1.02e-1)"	"unprognostic (9.61e-3)"	"unprognostic (2.34e-2)"	"unprognostic (1.43e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.28e-2)"	"unprognostic (2.23e-1)"	"unprognostic (3.91e-1)"	"unprognostic (9.95e-2)"	"unprognostic (2.80e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.75e-1)"	"unprognostic (4.11e-4)"	"unprognostic (1.64e-3)"	2.3	0.3	1.2	0.1	2.0	0.2	1.7	1.9	1.3	0.6	0.7	0.5	0.9	1.2	0.4	0.0	0.3	0.4	0.2	0.9	1.9	0.5	6.4	0.0	0.0	2.7	2.3	0.8	0.4	1.1	9.8	0.9	0.0	2.9	5.3	0.4	1.4	1.4	0.8	4.4	0.1	0.5	1.1	3.0	0.1	0.4	2.8	1.8	0.1	1.3	1.3	0.0	0.0	0.1	3.6	0.0	0.4	0.2	0.1	0.0	0.0	0.0	1.1	0.2	0.0	0.3	0.2	1.6	0.0	0.6	2.4	0.3	0.1	1.4	0.0	0.0	0.0	0.9	1.1	0.1	2.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.9	0.0	0.2	0.2	0.4	0.1	0.6	0.0	0.3	0.2	0.0	0.2	0.0	0.5	0.0	0.3	0.7	0.0	0.1	0.1	0.2	0.1	0.0	0.0	0.1	0.3	0.0	0.1	0.2	0.0	0.0	0.4	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.0	1.2	2.0	1.9	1.3	0.9	1.9	2.7	2.3	0.8	2.9	3.0	1.8	3.6	0.1	0.0	0.0	2.3	0.2	0.6	1.4	0.1	0.0	1.7	4.2	0.8	0.0	1.5	0.1	0.0	0.0	0.1	0.3	0.8	0.0	0.8	37.0	0.3	0.2	0.6	6.7	2.7	1.6	6.7	0.0	0.6	0.0	0.2	0.0	0.0	1.4	11.1	0.1	0.0	8.2	0.9	6.1	1.2	2.1	46.4	1.5	0.3	0.0	0.0	0.0	4.7	0.0	6.0	14.9	2.3	0.0	0.7	0.0	5.4	0.6	1.3	0.1	1.0	0.0	2.0	0.6	6.8	6.9	0.0	1.3	0.3	0.3	0.3	1.3	1.0
PGM5	PGMRP	ENSG00000154330	"Phosphoglucomutase 5"	Q15124	9	68328308-68531061	"Metabolic proteins, Predicted intracellular proteins"	"Carbohydrate metabolism, Cell adhesion, Glucose metabolism"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 216.0;urinary bladder: 218.5"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 107.2;Endothelial cells: 36.6;Hepatic stellate cells: 39.3;Microglial cells: 124.6;Sertoli cells: 52.6;Smooth muscle cells: 35.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 16.2"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	48	"neutrophil: 4.8"	"Lineage enriched"	"Detected in single"	48	"granulocytes: 4.8"	"Group enriched"	"Detected in some"	5	"hTERT-RPE1: 28.7;PC-3: 56.5;RH-30: 38.8;SK-BR-3: 47.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034397, HPA046329, HPA067102"	Enhanced		Uncertain	Cytosol		NA	NA		450000	Cytosol		"CAB034397: AB_1118633, HPA046329: AB_2679625, HPA067102: AB_2732758"	"unprognostic (3.43e-1)"	"unprognostic (2.17e-2)"	"unprognostic (3.98e-3)"	"unprognostic (5.75e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.09e-1)"	"unprognostic (3.15e-4)"	"unprognostic (1.22e-3)"	"unprognostic (2.79e-1)"	"unprognostic (5.28e-3)"	"unprognostic (4.78e-2)"	"unprognostic (2.28e-2)"	"prognostic favorable (1.83e-5)"	"unprognostic (3.04e-2)"	"unprognostic (2.91e-1)"	"unprognostic (2.48e-1)"	"unprognostic (4.73e-2)"	26.5	61.6	3.5	12.7	3.4	0.0	21.2	5.4	3.9	46.2	4.3	191.7	15.5	155.3	41.2	99.5	97.3	19.8	127.2	2.7	3.9	10.5	5.1	14.7	5.8	4.0	4.5	2.0	20.0	2.7	5.1	4.3	5.9	4.2	160.5	34.5	8.0	6.8	216.0	37.9	9.8	72.7	133.6	4.1	10.9	65.8	3.0	5.2	2.9	13.2	30.8	3.0	218.5	41.0	4.0	0.2	0.2	0.0	0.0	0.7	0.0	0.3	8.2	6.3	3.8	1.7	0.0	0.0	0.2	0.0	0.0	0.1	0.1	9.2	0.0	9.4	0.0	0.1	0.3	0.0	0.0	0.0	0.1	0.1	0.8	0.0	0.0	0.0	28.7	0.0	0.0	0.0	0.1	0.0	4.1	0.1	0.7	0.0	0.0	56.5	0.0	38.8	1.8	1.5	0.0	0.0	0.2	0.1	47.8	2.8	1.2	0.0	0.0	0.1	0.0	5.7	0.3	0.3	0.0	0.1	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	3.5	3.4	5.4	3.9	2.7	3.9	4.0	4.5	2.0	4.2	4.1	5.2	4.0	21.6	0.0	1.7	0.7	0.2	2.3	5.6	0.0	0.6	25.3	0.2	1.5	107.2	2.8	1.8	12.9	4.2	0.0	0.1	0.1	1.9	0.1	1.8	3.7	2.8	36.6	0.0	4.0	1.4	0.0	0.2	12.4	0.0	1.1	0.0	18.7	39.3	0.1	0.1	0.0	1.7	2.7	0.0	4.0	2.8	0.5	8.1	2.1	3.6	124.6	1.0	8.3	0.0	1.0	2.3	0.1	0.1	4.9	0.0	2.1	0.8	1.2	0.8	1.9	52.6	1.7	35.9	0.1	0.2	0.4	2.4	0.0	0.6	30.0	1.6	1.5
PHF21B	"BHC80L, FLJ34161, PHF4"	ENSG00000056487	"PHD finger protein 21B"	Q96EK2	22	44881162-45010005	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix: 9.0;pituitary gland: 19.0"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 96.6;Cone photoreceptor cells: 22.9;Horizontal cells: 28.6;Late spermatids: 41.9;Oligodendrocyte precursor cells: 29.1;Rod photoreceptor cells: 23.3"	"Cancer enhanced"	"Detected in some"		"glioma: 1.9;prostate cancer: 1.5"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 11.2;AN3-CA: 10.0;JURKAT: 8.8;SCLC-21H: 8.7;SH-SY5Y: 37.5;U-2 OS: 8.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA053834, HPA074665"	Enhanced		Approved	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"		NA	NA			"Nucleoplasm, Nucleoli fibrillar center"	Cytosol	"HPA053834: AB_2682276, HPA074665: "	"unprognostic (1.04e-1)"	"unprognostic (7.76e-2)"		"unprognostic (2.00e-1)"	"unprognostic (7.44e-2)"	"unprognostic (1.37e-1)"		"unprognostic (5.45e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.83e-3)"	"unprognostic (1.86e-3)"	"unprognostic (2.02e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.27e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.22e-1)"	0.1	1.2	6.4	0.1	6.3	0.0	0.4	4.8	6.1	9.0	1.0	0.2	0.1	3.2	0.4	0.4	2.6	0.1	0.6	5.0	4.2	1.9	0.0	0.1	0.0	8.1	6.5	2.7	4.0	0.5	0.9	19.0	0.0	5.0	5.2	0.0	6.2	0.3	0.5	0.2	0.1	0.2	0.7	3.7	0.1	0.6	5.5	6.6	0.2	2.0	0.3	0.0	0.2	3.2	5.8	0.0	0.0	11.2	10.0	0.0	0.0	0.7	0.0	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.0	2.0	0.1	2.1	0.0	0.1	0.2	0.7	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.3	0.6	0.0	0.0	8.8	0.0	0.0	0.1	0.9	1.3	0.0	6.7	0.0	0.4	0.0	2.6	0.2	0.0	0.1	8.7	37.5	0.0	0.0	0.1	0.7	0.0	0.0	0.0	1.5	8.5	0.0	0.2	0.4	0.0	5.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	6.3	4.8	6.1	5.0	4.2	8.1	6.5	2.7	5.0	3.7	6.6	5.8	0.0	0.0	0.0	96.6	0.0	0.1	0.6	0.0	0.0	14.1	0.0	0.3	2.0	0.0	0.0	0.0	22.9	0.0	0.0	0.0	1.9	0.0	16.2	0.1	3.2	0.4	0.0	0.0	1.0	0.0	0.0	0.8	0.0	0.3	0.0	0.6	0.0	0.0	0.1	28.6	9.1	0.0	0.0	0.0	0.0	41.9	0.6	0.1	0.0	5.6	0.0	5.0	0.0	29.1	9.3	0.1	0.0	1.9	0.0	1.7	0.0	0.0	0.7	23.3	0.0	1.1	0.5	1.2	2.9	0.0	0.0	0.0	0.3	1.9	0.0	0.1
PLA2G2A	"PLA2B, PLA2L"	ENSG00000188257	"Phospholipase A2 group IIA"	P14555	1	19975431-19980416	"Enzymes, FDA approved drug targets, Metabolic proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Inflammatory response, Lipid metabolism, Phospholipid metabolism"	"Antimicrobial, Bacteriolytic enzyme, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adipose tissue: 1314.5;intestine: 1990.3;placenta: 763.1;urinary bladder: 821.3"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 536.5;Exocrine glandular cells: 1031.5;Fibroblasts: 656.0;Intestinal goblet cells: 393.6;Paneth cells: 574.1;Prostatic glandular cells: 921.1;Undifferentiated cells: 861.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 875.7"	"Region enhanced"	"Detected in some"		"hypothalamus: 4.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"Hep G2: 645.0;OE19: 2384.4"					"Not detected"	"Not detected"			HPA015236	Enhanced				"Secreted to blood"	NA	NA	1000000	680000			"HPA015236: AB_10601047"	"unprognostic (2.33e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.85e-3)"	"unprognostic (8.71e-2)"	"unprognostic (9.27e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.80e-1)"	"prognostic favorable (1.49e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.58e-2)"	"unprognostic (3.77e-15)"	"unprognostic (2.72e-2)"	"unprognostic (9.14e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.51e-1)"	1314.5	7.1	0.1	282.7	0.1	0.0	27.7	0.1	0.7	3.7	2.3	1487.3	794.0	4.3	3.3	29.6	14.9	58.2	90.5	0.0	4.7	6.6	240.6	16.9	5.4	0.6	0.5	1.4	44.5	7.9	0.9	2.5	763.1	0.2	205.7	1685.8	0.1	24.8	6.1	6.0	16.1	1990.3	166.0	0.1	0.4	11.7	37.1	1.0	1.7	11.2	115.3	15.2	821.3	12.2	0.2	0.0	0.0	1.6	0.0	248.3	0.0	8.5	0.0	0.1	0.1	0.0	11.2	0.0	0.0	1.1	0.0	0.8	18.7	0.0	0.0	0.0	0.1	0.3	0.0	0.3	645.0	0.0	0.1	1.1	2.6	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	6.2	0.4	2384.4	0.0	0.0	0.0	7.6	0.0	198.2	1.0	4.7	0.0	20.1	0.0	31.1	0.1	0.0	0.0	0.0	0.0	44.7	0.2	0.4	0.3	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.7	0.0	4.7	0.6	0.5	1.4	0.2	0.1	1.0	0.2	20.6	6.4	6.7	0.0	9.1	13.9	10.8	0.2	0.6	0.9	1.0	0.8	14.9	12.8	9.3	0.0	0.0	3.6	0.4	536.5	1.9	0.7	4.0	0.7	43.1	6.9	62.3	13.5	0.0	1031.5	4.6	656.0	6.1	0.6	4.5	0.0	30.0	310.9	9.5	0.0	0.0	393.6	2.0	18.8	31.1	11.6	171.2	3.5	14.2	0.0	0.0	0.0	0.0	0.0	0.0	4.7	574.1	1.2	2.6	921.1	328.2	0.2	1.9	0.0	0.0	2.4	37.8	0.9	1.5	4.9	16.8	6.8	6.2	0.1	861.9	32.2
PLA2G7	"LDL-PLA2, PAFAH"	ENSG00000146070	"Phospholipase A2 group VII"	Q13093	6	46704201-46735693	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism, Phospholipid degradation, Phospholipid metabolism"	Hydrolase	"Asthma, Disease variant"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 27.4;placenta: 23.5"	"Group enriched"	"Detected in many"	5	"Hofbauer cells: 372.2;Macrophages: 140.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 37.2"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"classical monocyte: 43.4"	"Group enriched"	"Detected in many"	49	"dendritic cells: 14.1;monocytes: 43.4"	"Cell line enhanced"	"Detected in some"		"NTERA-2: 1.7;PC-3: 3.4;RT4: 1.6;U-2 OS: 1.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to blood"	NA	NA	7380000	290000000				"unprognostic (3.63e-3)"	"unprognostic (2.82e-3)"	"unprognostic (8.69e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.47e-1)"	"unprognostic (6.26e-2)"	"unprognostic (9.45e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.06e-2)"	"unprognostic (5.33e-2)"	"unprognostic (2.35e-2)"	"unprognostic (2.47e-1)"	"unprognostic (9.20e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.08e-2)"	4.3	3.1	2.6	23.1	4.4	2.8	2.7	3.1	5.7	2.5	0.8	7.6	4.2	4.8	1.1	0.6	1.9	6.0	0.6	3.0	4.0	0.3	7.0	7.3	27.1	4.3	2.7	2.4	1.1	0.8	21.2	2.1	23.5	4.6	13.2	10.4	0.6	1.4	2.6	0.4	3.6	3.4	2.8	5.8	27.4	3.0	0.9	7.4	5.0	20.4	0.0	10.1	11.2	0.3	4.8	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.9	0.7	0.0	0.0	0.0	0.1	0.8	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.7	0.0	3.4	0.0	0.0	0.0	0.0	1.6	0.0	0.2	0.0	0.0	0.0	0.4	0.4	0.4	0.0	0.0	1.6	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.6	0.3	43.4	0.3	0.1	9.2	0.3	0.3	0.0	0.0	14.1	0.0	0.0	0.1	0.5	0.0	0.5	0.3	0.0	11.9	2.6	4.4	3.1	5.7	3.0	4.0	4.3	2.7	2.4	4.6	5.8	7.4	4.8	0.5	0.0	1.3	0.3	3.6	0.8	4.4	0.0	0.0	0.2	0.3	4.3	0.3	0.0	0.0	0.0	0.0	1.6	0.0	0.2	0.0	0.6	0.1	1.6	50.3	0.6	3.5	0.0	7.1	0.0	5.1	1.8	0.0	1.5	0.0	0.0	0.0	0.0	372.2	1.7	4.8	0.3	0.0	24.6	4.9	0.1	0.0	140.9	10.6	11.2	29.3	0.3	0.0	6.0	0.3	0.3	0.0	0.0	0.1	6.9	0.0	0.1	0.0	0.1	0.0	0.9	0.6	0.1	0.0	0.1	0.1	3.1	0.8	8.9	0.2	3.8
PLPP1	"LPP1, PAP-2a, PPAP2A"	ENSG00000067113	"Phospholipid phosphatase 1"	O14494	5	55424854-55534969	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Adipocytes: 359.1;Endometrial stromal cells: 206.7;Hepatic stellate cells: 267.0;Leydig cells: 219.3;Prostatic glandular cells: 182.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 200.4"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 445.7;fHDF/TERT166: 142.8;HMC-1: 235.8;HSkMC: 171.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033331, HPA047815"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB033331: AB_2168044, HPA047815: AB_2680164"	"unprognostic (1.22e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.55e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.36e-1)"	"prognostic favorable (6.06e-4)"	"unprognostic (2.81e-1)"	"unprognostic (2.20e-1)"	"unprognostic (4.05e-3)"	"unprognostic (2.43e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.37e-3)"	"prognostic unfavorable (5.77e-4)"	"unprognostic (3.94e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.11e-2)"	166.2	78.8	53.0	42.6	60.0	0.9	141.9	64.8	59.5	88.1	61.3	106.4	47.8	120.5	40.1	42.8	74.0	168.9	105.0	50.7	68.3	103.3	68.3	56.7	32.5	63.6	57.8	48.7	29.6	35.9	49.4	28.0	37.9	64.4	256.3	66.4	9.8	33.1	61.9	70.5	55.2	79.7	109.8	67.7	31.4	71.5	21.2	58.7	15.9	113.8	82.3	24.4	129.9	64.4	76.3	9.8	24.4	7.0	14.2	445.7	51.8	9.6	21.8	61.4	11.9	27.9	16.7	17.7	10.2	20.0	142.8	31.9	6.5	25.2	12.6	13.5	6.8	20.1	1.1	9.6	21.3	70.5	2.5	235.8	171.3	25.7	17.6	10.9	23.3	19.9	9.1	0.2	27.0	24.1	6.0	6.8	5.5	15.5	1.1	20.0	2.0	11.7	0.9	46.3	79.8	8.4	5.8	21.5	4.2	13.4	28.8	15.6	1.6	24.0	4.0	6.9	17.8	15.5	16.6	7.4	11.8	15.7	1.3	19.5	0.0	0.4	4.0	1.6	0.5	1.7	6.7	5.3	3.4	2.0	3.3	9.5	7.7	0.3	3.0	0.9	15.0	2.6	1.8	53.0	60.0	64.8	59.5	50.7	68.3	63.6	57.8	48.7	64.4	67.7	58.7	76.3	359.1	6.4	9.4	0.0	9.8	0.0	51.0	0.0	10.2	4.0	8.4	45.7	0.0	21.5	5.6	29.5	2.1	3.3	5.4	61.0	5.9	25.2	44.4	10.7	206.7	112.3	1.2	5.7	0.0	28.5	11.1	115.5	11.2	18.5	27.8	4.0	267.0	48.3	12.8	1.7	0.0	20.2	0.0	12.0	0.0	21.0	219.3	8.1	0.0	0.0	4.5	16.6	1.0	0.0	0.0	30.0	24.6	88.4	13.0	182.0	49.4	29.3	2.2	5.6	59.2	89.7	49.7	54.4	17.7	10.0	0.0	4.9	11.3	3.1	12.1	42.8
PMEPA1	"STAG1, TMEPAI"	ENSG00000124225	"Prostate transmembrane protein, androgen induced 1"	Q969W9	20	57648392-57711536	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Ubl conjugation pathway"	"Signal transduction inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"prostate: 111.7"	"Cell type enhanced"	"Detected in many"		"Ductal cells: 339.6;Muller glia cells: 325.9;Pancreatic endocrine cells: 827.5"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 157.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"naive B-cell: 6.3;plasmacytoid DC: 23.9"	"Group enriched"	"Detected in many"	8	"B-cells: 6.3;dendritic cells: 23.9"	"Cell line enhanced"	"Detected in many"		"SiHa: 206.1;U-2 OS: 129.9;U-251 MG: 481.8;WM-115: 237.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA072291			Supported	Vesicles	"Intracellular and membrane"	NA	NA			Vesicles		"HPA072291: AB_2686509"	"unprognostic (2.72e-3)"	"prognostic unfavorable (2.45e-4)"	"unprognostic (5.77e-2)"	"unprognostic (1.73e-1)"	"unprognostic (6.61e-2)"	"unprognostic (2.11e-3)"	"unprognostic (3.13e-2)"	"prognostic unfavorable (4.73e-5)"	"unprognostic (5.53e-1)"	"unprognostic (1.32e-3)"	"unprognostic (7.83e-3)"	"unprognostic (2.02e-1)"	"prognostic unfavorable (2.87e-7)"	"unprognostic (1.16e-1)"	"unprognostic (2.35e-1)"	"unprognostic (9.87e-3)"	"prognostic unfavorable (7.60e-4)"	50.9	14.6	26.8	14.3	65.3	1.3	25.3	39.7	29.3	95.6	7.5	24.7	6.5	48.8	7.2	7.7	20.1	26.3	28.3	24.1	26.5	15.1	3.8	22.0	7.5	32.7	32.3	13.9	15.1	31.6	5.0	13.6	4.0	40.5	111.7	8.4	23.9	30.7	20.8	33.6	17.5	12.7	29.1	24.9	6.7	12.3	5.4	30.9	2.4	13.7	13.8	9.0	13.2	29.9	32.7	32.2	75.4	2.3	3.9	2.4	0.0	0.8	4.9	0.2	1.7	0.8	1.5	97.4	0.2	17.7	7.4	51.8	121.1	1.6	100.8	1.3	1.0	4.1	0.0	23.2	0.1	1.5	0.3	0.8	1.2	55.8	4.4	12.1	16.5	13.0	67.8	0.8	1.2	6.2	66.1	3.8	0.7	9.4	15.0	9.6	0.3	36.0	11.3	24.2	0.0	17.7	13.7	206.1	120.3	15.1	5.6	18.8	4.1	33.1	17.9	129.9	1.9	481.8	5.9	0.8	0.5	8.1	1.1	237.1	0.0	0.4	0.0	0.0	0.0	0.0	2.6	0.8	0.2	0.1	6.3	1.8	1.2	0.1	0.0	0.1	23.9	0.5	0.6	26.8	65.3	39.7	29.3	24.1	26.5	32.7	32.3	13.9	40.5	24.9	30.9	32.7	59.4	57.7	32.3	4.9	32.7	167.0	143.1	120.6	30.7	59.0	38.0	23.0	23.2	125.8	31.7	11.0	2.1	0.2	27.8	57.3	3.9	339.6	1.2	33.4	88.8	55.6	10.1	0.0	19.1	62.5	4.1	40.5	5.1	80.2	59.8	17.5	24.7	0.5	6.1	1.7	32.7	16.9	14.2	3.5	68.0	2.7	3.1	13.4	32.0	31.9	5.8	325.9	0.0	17.6	9.0	827.5	54.2	21.8	25.3	203.1	6.2	2.7	10.1	11.5	72.3	43.8	155.2	0.2	8.8	10.0	178.4	0.1	17.8	9.1	19.3	87.5
PNPLA7	"C9orf111, FLJ31318, FLJ43070, FLJ44279, NTE-R1, NTEL1, RP11-48C7.2"	ENSG00000130653	"Patatin like phospholipase domain containing 7"	Q6ZV29	9	137459952-137550402	"Enzymes, Metabolic proteins, Predicted membrane proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Astrocytes: 56.2;Excitatory neurons: 23.6;Inhibitory neurons: 21.5;Oligodendrocytes: 21.0"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 9.4"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"naive B-cell: 1.0;T-reg: 1.2"	"Group enriched"	"Detected in many"	4	"B-cells: 1.0;T-cells: 1.2"	"Cell line enriched"	"Detected in some"	22	"HMC-1: 83.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA009130	Uncertain		Uncertain	"Centriolar satellite,Cytosol"		NA	NA			Cytosol	"Centriolar satellite"	"HPA009130: AB_2268411"	"unprognostic (1.49e-1)"	"unprognostic (1.40e-2)"	"unprognostic (3.61e-3)"	"unprognostic (2.38e-2)"	"unprognostic (3.68e-2)"	"unprognostic (6.69e-3)"	"unprognostic (2.72e-3)"	"unprognostic (5.14e-4)"	"unprognostic (3.24e-1)"	"unprognostic (1.40e-2)"	"prognostic favorable (2.24e-5)"	"unprognostic (1.09e-1)"	"unprognostic (2.23e-3)"	"unprognostic (2.42e-1)"	"unprognostic (6.80e-2)"	"unprognostic (8.81e-2)"	"unprognostic (3.45e-3)"	9.5	7.1	4.7	2.2	4.8	2.1	11.4	1.6	8.7	16.4	1.1	9.9	2.3	12.4	1.0	2.7	13.1	3.7	6.5	6.1	2.7	6.2	14.1	4.8	4.4	4.5	2.1	4.3	21.6	18.1	2.0	9.0	0.6	4.3	22.6	1.4	1.4	16.1	2.7	17.4	13.8	8.4	1.6	1.9	7.0	16.5	2.6	2.8	1.4	17.5	3.4	1.4	10.6	7.7	4.5	0.1	1.0	0.2	0.3	0.8	0.5	0.4	0.8	0.8	0.2	0.2	0.1	0.5	0.6	0.8	0.4	0.4	0.3	0.1	0.0	0.0	1.6	0.9	0.8	1.0	0.3	0.5	0.4	83.7	1.2	0.1	0.3	0.0	1.4	0.1	0.1	0.1	2.3	0.1	1.6	0.2	1.6	0.0	1.2	0.9	2.0	1.3	2.8	0.1	0.3	1.6	0.4	0.1	0.6	0.3	0.2	3.7	1.2	0.6	0.0	0.1	0.4	0.1	0.8	0.2	0.2	1.2	0.8	0.1	0.0	0.1	0.0	0.2	0.1	0.0	0.2	0.1	0.1	0.2	1.0	0.3	0.2	0.0	0.0	0.0	0.1	1.2	0.2	4.7	4.8	1.6	8.7	6.1	2.7	4.5	2.1	4.3	4.3	1.9	2.8	4.5	3.0	9.6	5.9	56.2	4.8	1.5	1.1	0.9	2.2	2.5	6.5	8.3	3.9	4.3	2.6	1.8	6.2	0.2	2.1	6.6	0.0	0.7	0.5	1.7	4.8	1.2	17.3	0.8	23.6	0.0	0.3	3.6	12.2	3.8	7.0	1.2	2.5	10.2	2.6	5.0	21.5	9.2	0.0	4.5	1.0	0.6	4.4	1.2	0.0	9.4	1.3	2.5	1.0	11.6	21.0	0.6	7.1	1.9	1.6	2.5	3.8	1.0	1.6	9.6	0.0	2.3	2.1	3.1	4.0	0.9	3.3	0.0	2.3	0.6	2.0	0.7
POTEG	"A26C2, CT104.4, POTE-14, POTE14, POTE14alpha"	ENSG00000187537	"POTE ankyrin domain family member G"	Q6S5H5	14	19402486-19434341	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in single"		"prostate: 1.1"	"Cell type enhanced"	"Detected in single"		"Spermatocytes: 1.1"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.5"	"Not detected"	"Not detected"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Not detected"	"Not detected"																	NA	NA						"unprognostic (4.01e-1)"				"unprognostic (1.51e-1)"	"unprognostic (6.00e-2)"		"unprognostic (1.17e-1)"	"unprognostic (2.02e-1)"	"unprognostic (2.69e-2)"		"unprognostic (1.05e-1)"	"unprognostic (2.05e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.29e-1)"		"unprognostic (2.50e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	7.6	15.0	4.7	11.1	3.5	2.9	4.1	4.5	10.6	2.7	3.1	5.0	7.6	3.7	11.3	2.9	7.0	18.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.1
PPM1E	"CaMKP-N, KIAA1072, POPX1, PP2CH"	ENSG00000175175	"Protein phosphatase, Mg2+/Mn2+ dependent 1E"	Q8WY54	17	58755854-58985179	"Enzymes, Metabolic proteins, Predicted intracellular proteins"		"Hydrolase, Protein phosphatase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 34.7;retina: 22.5"	"Group enriched"	"Detected in some"	4	"Excitatory neurons: 220.9;Horizontal cells: 77.4;Inhibitory neurons: 288.4;Oligodendrocyte precursor cells: 109.1"	"Cancer enhanced"	"Detected in some"		"glioma: 2.7;prostate cancer: 3.0"	"Group enriched"	"Detected in many"	5	"cerebral cortex: 32.8;hippocampal formation: 34.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 12.2;HAP1: 19.9;MOLT-4: 9.9;SCLC-21H: 9.1;SH-SY5Y: 18.7;THP-1: 8.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018462, HPA019263"	Approved		Approved	Nucleoplasm,Nucleoli		Yes	No			Nucleoli	Nucleoplasm	"HPA018462: AB_1855623, HPA019263: AB_1855624"	"unprognostic (2.50e-2)"	"unprognostic (5.75e-2)"	"unprognostic (8.12e-2)"	"unprognostic (2.99e-2)"	"unprognostic (5.30e-1)"	"unprognostic (8.19e-2)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (3.22e-2)"	"unprognostic (5.24e-2)"	"unprognostic (8.80e-5)"	"unprognostic (4.97e-2)"	"unprognostic (1.23e-7)"	"unprognostic (1.05e-4)"	"unprognostic (1.64e-2)"	"unprognostic (1.27e-1)"	"unprognostic (9.12e-2)"	0.1	5.5	5.6	0.1	5.2	0.0	0.1	1.3	32.8	0.2	0.0	0.1	0.1	0.3	0.9	0.0	1.5	0.1	1.0	34.7	6.3	0.7	1.0	0.2	0.2	2.0	4.3	4.6	0.2	0.6	0.3	1.3	0.0	2.8	1.4	0.0	22.5	0.2	0.0	0.0	0.0	0.2	0.4	0.3	0.2	0.5	6.7	6.7	0.2	0.1	0.1	0.2	0.1	0.1	6.3	0.0	0.1	12.2	0.6	0.0	0.0	0.9	0.0	0.0	0.9	1.4	0.0	0.0	8.0	0.1	0.1	2.7	0.0	19.9	0.0	0.5	0.2	5.9	0.0	0.2	0.0	1.3	0.6	2.6	0.3	1.6	0.1	0.0	0.6	0.0	4.9	2.1	0.0	0.0	3.6	9.9	0.0	3.5	0.0	1.0	0.0	1.5	0.0	0.0	0.0	9.1	18.7	0.3	0.0	1.3	0.1	0.0	8.7	0.0	0.0	2.2	0.0	2.9	0.1	0.1	5.4	0.3	0.0	2.9	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	5.2	1.3	32.8	34.7	6.3	2.0	4.3	4.6	2.8	0.3	6.7	6.3	0.1	0.0	0.0	32.7	0.0	0.0	0.0	0.0	0.0	22.0	0.1	0.4	3.3	0.0	1.8	0.0	31.3	0.0	0.0	0.1	0.0	0.0	30.8	3.9	0.1	0.3	3.0	0.0	220.9	0.0	0.0	0.4	0.0	0.1	0.0	0.1	0.0	1.4	0.1	77.4	288.4	0.0	0.0	0.3	0.0	17.6	0.0	0.1	0.0	5.6	0.0	4.2	0.0	109.1	38.4	0.0	0.2	0.4	0.0	1.3	0.0	0.1	0.0	13.8	0.0	0.0	0.5	12.1	2.8	0.0	0.0	0.0	0.0	0.8	0.0	0.0
PRDM8	KMT8D	ENSG00000152784	"PR/SET domain 8"	Q9NQV8	4	80183879-80204329	"Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Neurogenesis, Transcription, Transcription regulation"	"DNA-binding, Methyltransferase, Transferase"	"Disease variant, Epilepsy, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 26.3;retina: 24.3;seminal vesicle: 27.4"	"Cell type enriched"	"Detected in many"	9	"Bipolar cells: 271.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 4.6"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 27.3;LHCN-M2: 41.7;NB-4: 48.2;SCLC-21H: 99.3"	"Region enhanced"	"Detected in many"		"hippocampal formation: 28.7"	"Low region specificity"	"Detected in all"			HPA057253			Supported	"Nucleoplasm,Nuclear bodies"		No	NA			"Nuclear bodies"	Nucleoplasm	"HPA057253: AB_2683382"	"unprognostic (2.33e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.65e-1)"	"unprognostic (7.95e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.34e-1)"	"unprognostic (2.80e-2)"	"unprognostic (1.89e-11)"	"unprognostic (4.64e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.56e-1)"	3.9	2.3	5.7	5.1	8.7	4.0	4.0	0.0	17.4	11.1	0.0	8.4	1.1	9.4	1.9	1.7	5.3	1.7	1.7	14.9	0.0	0.9	0.3	1.6	5.2	2.8	0.7	5.3	5.2	0.9	0.0	5.4	4.4	6.3	26.3	1.6	24.3	1.5	27.4	2.2	2.5	5.8	3.8	0.8	1.8	5.0	1.1	0.7	0.7	1.2	1.0	2.4	10.3	9.9	6.0	2.3	0.2	0.7	0.0	2.1	7.2	0.1	5.8	20.5	2.8	3.2	0.0	2.2	0.0	0.0	7.2	1.8	0.7	0.1	2.4	12.1	8.8	1.8	0.8	0.0	0.0	4.1	9.1	2.5	4.4	0.2	11.1	3.2	27.3	0.4	2.4	0.0	3.7	41.7	0.0	4.2	48.2	0.0	0.2	17.0	1.6	0.0	0.2	1.2	0.3	99.3	13.8	0.3	0.0	0.1	0.1	0.0	4.5	8.8	7.1	1.0	5.2	0.4	1.7	0.0	0.0	17.8	4.2	1.0	0.0	0.0	0.0	0.4	0.0	0.6	0.1	0.5	0.5	0.1	0.7	0.3	0.1	0.5	0.2	0.0	0.1	0.2	0.1	5.7	8.7	0.0	17.4	14.9	0.0	2.8	0.7	5.3	6.3	0.8	0.7	6.0	0.9	0.0	0.5	2.3	8.2	0.6	3.4	0.4	0.0	271.5	0.1	0.4	1.8	0.0	5.2	1.8	2.1	0.0	2.5	0.0	0.0	0.0	1.5	0.3	6.5	2.2	0.0	2.5	29.9	0.2	0.2	8.8	0.0	0.5	0.0	0.1	0.0	0.0	0.5	3.3	2.0	0.2	2.0	1.2	6.2	6.7	3.1	5.9	1.8	3.7	0.9	6.1	2.1	7.1	17.0	0.7	0.0	3.4	2.7	3.7	0.0	0.2	5.0	11.6	0.0	4.2	2.9	0.3	0.4	0.0	0.1	0.1	5.0	0.1	0.0	0.6
PRKD1	"PKC-mu, PKCM, PKD, PRKCM"	ENSG00000184304	"Protein kinase D1"	Q15139	14	29576479-30191898	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Angiogenesis, Apoptosis, Differentiation, Immunity, Inflammatory response, Innate immunity, Neurogenesis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Disease variant, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Astrocytes: 362.1;Excitatory neurons: 147.4;Inhibitory neurons: 171.1;Microglial cells: 89.0;Oligodendrocyte precursor cells: 390.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 10.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 21.6;fHDF/TERT166: 19.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018367, HPA029834"	Uncertain		Supported	"Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	Cytosol	"CAB018367: AB_2253119, HPA029834: AB_10602821"	"unprognostic (5.35e-2)"	"unprognostic (3.20e-1)"	"unprognostic (2.27e-2)"	"unprognostic (6.70e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.92e-1)"	"unprognostic (1.08e-3)"	"unprognostic (8.88e-2)"	"unprognostic (2.37e-2)"	"unprognostic (5.29e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.56e-1)"	"prognostic favorable (2.44e-5)"	"unprognostic (9.45e-4)"	"unprognostic (1.99e-1)"	"prognostic unfavorable (2.91e-4)"	"unprognostic (3.89e-1)"	7.6	9.7	8.3	2.2	8.1	0.0	7.7	7.2	6.0	5.8	3.8	7.2	1.0	7.9	3.6	2.1	6.5	4.4	4.8	7.5	9.6	11.7	1.6	7.5	0.3	9.3	7.9	4.7	11.3	5.5	10.7	5.7	1.9	8.1	14.8	1.3	4.7	2.9	9.3	1.7	2.7	3.6	6.4	8.3	2.3	4.6	11.7	7.0	2.5	6.0	2.6	0.6	13.2	4.7	10.3	0.0	4.4	4.8	3.1	21.6	16.5	0.1	14.1	10.4	16.7	7.3	0.0	0.3	0.0	1.9	19.4	4.0	0.1	7.9	2.1	6.8	0.0	6.2	0.0	0.0	0.5	8.8	0.0	0.1	18.4	0.3	1.4	1.5	6.1	2.6	0.0	1.4	0.4	17.4	1.8	0.0	0.0	2.6	0.0	9.6	0.0	6.3	5.2	9.7	6.6	4.3	13.0	2.6	0.0	4.5	4.6	0.0	0.1	5.6	13.6	6.7	1.0	3.7	0.0	0.0	0.0	3.5	0.0	14.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	8.1	7.2	6.0	7.5	9.6	9.3	7.9	4.7	8.1	8.3	7.0	10.3	4.6	0.0	7.4	362.1	0.2	0.5	4.8	0.4	0.6	1.4	1.4	1.5	1.2	10.0	0.0	12.9	6.2	0.0	0.0	0.1	29.4	2.4	39.5	2.8	9.2	6.1	3.0	2.7	147.4	4.2	0.1	6.4	0.5	8.4	0.0	18.7	10.8	2.5	0.2	1.7	171.1	0.2	0.0	1.6	0.9	16.9	7.5	0.7	7.2	89.0	0.0	16.7	0.0	390.6	76.6	2.0	0.1	12.8	0.4	12.4	0.2	4.5	0.1	2.9	0.0	13.3	4.5	3.2	7.8	0.0	0.9	0.3	0.6	29.6	0.1	1.3
PTPRN2	"IA-2beta, ICAAR, KIAA0387, phogrin"	ENSG00000155093	"Protein tyrosine phosphatase receptor type N2"	Q92932	7	157539056-158587823	"Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid metabolism, Phospholipid metabolism"	"Hydrolase, Protein phosphatase, Receptor"	"Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 53.7;pancreas: 98.9"	"Group enriched"	"Detected in many"	4	"Enteroendocrine cells: 131.1;Excitatory neurons: 439.6;Inhibitory neurons: 433.4;Oligodendrocyte precursor cells: 138.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 40.8"	"Low region specificity"	"Detected in many"			"Immune cell enhanced"	"Detected in many"		"neutrophil: 23.6"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 23.6"	"Cell line enhanced"	"Detected in many"		"AF22: 45.5;HDLM-2: 42.0;MOLT-4: 22.1;NB-4: 43.0;SCLC-21H: 23.8;SH-SY5Y: 25.4;U-87 MG: 27.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006900, HPA007255, HPA026656"	Enhanced		Approved	Vesicles		NA	NA		1600000	Vesicles		"HPA006900: AB_1079715, HPA007255: , HPA026656: AB_1855912"	"unprognostic (2.42e-1)"	"unprognostic (4.17e-2)"	"unprognostic (7.82e-2)"	"unprognostic (2.69e-2)"	"prognostic unfavorable (9.37e-5)"	"unprognostic (7.12e-3)"	"unprognostic (1.04e-1)"	"unprognostic (4.55e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.39e-1)"	"prognostic favorable (8.68e-4)"	"unprognostic (2.60e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.43e-3)"	"unprognostic (6.16e-2)"	3.3	16.7	27.4	2.7	36.5	1.3	3.0	0.0	53.7	2.1	0.0	7.8	8.4	3.0	4.3	2.0	10.9	7.6	2.9	38.1	18.3	3.9	1.6	4.8	3.4	11.2	8.3	42.2	8.8	98.9	1.1	41.3	2.1	13.3	17.4	6.2	9.3	13.0	3.6	1.2	0.8	6.7	2.1	0.0	13.6	40.6	6.2	11.4	1.6	8.8	1.9	2.5	4.3	2.2	23.3	0.1	0.4	45.5	3.6	0.1	0.2	0.1	0.4	0.3	0.0	0.1	0.0	4.0	0.0	1.2	0.5	9.4	0.3	1.0	0.0	0.0	42.0	0.8	0.0	0.0	7.3	1.1	0.0	0.1	2.0	0.8	0.1	0.5	0.3	0.0	3.4	0.1	0.3	0.0	0.7	22.1	43.0	5.7	13.7	3.2	0.0	2.7	0.2	0.2	0.0	23.8	25.4	0.0	0.1	0.0	0.0	0.0	20.9	6.2	9.2	4.3	0.1	1.5	0.3	0.1	0.0	27.7	17.4	6.8	14.1	1.5	2.8	1.3	0.2	0.5	3.5	2.1	1.4	2.1	4.2	2.4	1.4	23.6	2.4	0.0	0.6	5.3	1.3	27.4	36.5	0.0	53.7	38.1	18.3	11.2	8.3	42.2	13.3	0.0	11.4	23.3	40.7	3.2	12.9	16.3	18.4	2.3	12.7	1.3	4.0	30.2	1.9	2.2	3.1	10.0	9.1	40.5	10.4	0.4	8.7	5.9	35.2	22.9	51.9	8.7	2.5	26.3	131.1	6.6	439.6	13.1	0.4	13.0	41.8	0.8	19.0	14.1	44.3	0.8	44.5	11.8	433.4	43.3	6.1	7.0	11.3	19.3	12.5	7.9	12.4	27.2	5.7	67.3	15.5	138.2	11.0	7.3	7.0	19.5	5.4	15.0	6.5	3.8	52.6	8.0	26.3	1.4	7.0	62.8	16.3	4.8	1.4	0.7	14.8	32.7	9.7	24.8
RAB6D	"RAB6CL, WTH3DI"	ENSG00000233087	"RAB6D, member RAS oncogene family"	Q53S08	2	131361111-131364142	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Tissue enriched"	"Detected in some"	5	"parathyroid gland: 7.5"	"Cell type enriched"	"Detected in single"	15	"Respiratory ciliated cells: 1.5"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"MOLT-4: 2.2"									HPA059131	Uncertain		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA059131: AB_2683916"	"unprognostic (4.19e-2)"	"unprognostic (8.54e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.03e-2)"	"unprognostic (4.08e-1)"	"unprognostic (4.79e-2)"		"unprognostic (4.41e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.87e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.21e-1)"	"unprognostic (2.55e-2)"	"unprognostic (2.61e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.12e-1)"	0.0	0.2	0.4	0.1	0.6	0.0	0.0	0.0	0.9	0.0	0.0	1.0	0.2	0.1	0.3	0.0	0.1	0.2	0.0	0.7	0.7	0.1	0.0	0.0	0.0	0.4	0.3	0.4	0.1	0.0	7.5	0.0	0.0	0.6	1.4	0.8	0.1	0.0	0.0	0.0	0.0	0.7	0.2	0.2	0.0	0.0	1.0	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.2	0.0	0.3	0.9	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.6	0.0	0.9	0.7	0.7	0.4	0.3	0.4	0.6	0.2	0.5	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RAMP1		ENSG00000132329	"Receptor activity modifying protein 1"	O60894	2	237858893-237912106	"FDA approved drug targets, Predicted membrane proteins, Transporters"	Transport	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 711.9"	"Cell type enhanced"	"Detected in many"		"Cardiomyocytes: 190.0;Endometrial stromal cells: 546.4;Exocrine glandular cells: 278.2;monocytes: 433.5"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 152.7"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in some"	18	"NK-cell: 70.1"	"Lineage enriched"	"Detected in many"	18	"NK-cells: 70.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 47.4;HDLM-2: 146.0;PC-3: 173.8;SH-SY5Y: 201.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA057814			Approved	"Nucleoplasm,Nuclear membrane"		NA	NA			"Nucleoplasm, Nuclear membrane"		"HPA057814: AB_2683536"	"unprognostic (1.13e-2)"	"unprognostic (5.96e-2)"	"unprognostic (3.03e-3)"	"unprognostic (3.69e-1)"	"unprognostic (4.29e-1)"	"unprognostic (1.75e-1)"	"prognostic favorable (7.61e-4)"	"unprognostic (2.54e-1)"	"unprognostic (3.49e-1)"	"unprognostic (5.45e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.46e-3)"	"prognostic unfavorable (1.68e-4)"	"unprognostic (1.74e-1)"	"unprognostic (3.98e-2)"	"unprognostic (2.08e-3)"	13.5	29.5	136.3	21.2	129.5	0.9	7.5	136.8	255.5	315.6	116.0	243.0	58.1	711.9	25.2	9.5	258.8	28.8	241.2	134.1	149.8	23.5	83.4	32.8	6.7	162.4	127.5	118.3	45.5	226.9	1.4	15.4	8.7	131.3	143.4	6.4	0.9	10.0	55.1	214.0	11.2	74.2	126.5	135.9	12.4	104.3	5.1	147.7	2.9	6.8	69.4	3.0	172.9	75.7	142.0	29.8	0.0	0.5	0.0	12.4	17.9	1.1	2.1	3.6	1.7	1.5	0.0	47.4	0.3	0.4	0.9	0.1	0.2	7.6	0.1	0.2	146.0	4.0	0.1	0.0	1.2	40.6	0.0	0.2	15.6	22.3	0.1	0.3	0.2	0.0	0.0	0.0	0.3	3.7	2.7	0.1	1.3	0.4	0.1	173.8	0.0	1.5	0.8	0.0	0.0	1.5	201.7	3.5	0.0	0.1	1.8	1.3	0.1	0.0	0.8	0.6	0.4	0.5	0.3	0.3	0.0	0.6	0.1	2.7	0.0	0.0	0.0	3.8	0.0	0.0	0.3	0.6	0.1	1.0	0.0	0.5	0.2	0.4	70.1	0.0	0.2	0.0	3.4	136.3	129.5	136.8	255.5	134.1	149.8	162.4	127.5	118.3	131.3	135.9	147.7	142.0	1.0	0.0	1.5	64.9	3.1	11.6	13.2	26.9	10.2	2.0	4.4	4.4	190.0	78.6	43.8	11.0	0.0	3.0	44.0	2.1	0.0	62.7	0.2	26.5	546.4	6.2	115.4	4.4	14.2	278.2	5.5	41.7	31.1	11.3	1.3	0.6	30.7	104.0	22.7	1.7	19.2	73.7	10.2	3.1	50.3	0.6	8.4	20.3	64.0	13.1	433.5	6.9	61.8	71.9	11.5	63.5	87.7	11.3	1.9	66.1	96.8	0.2	97.0	2.7	6.6	16.6	78.6	0.3	5.8	2.6	5.8	2.3	7.3	0.5	105.8	28.5
RBFOX3	"FOX-3, HRNBP3, NeuN"	ENSG00000167281	"RNA binding fox-1 homolog 3"	A6NFN3	17	79089345-79516148	"Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 204.4;intestine: 68.0;urinary bladder: 81.1"	"Group enriched"	"Detected in many"	7	"Excitatory neurons: 320.4;Inhibitory neurons: 163.9;Skeletal myocytes: 124.4"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.1"	"Region enhanced"	"Detected in many"		"cerebellum: 204.4"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"A549: 16.1;NTERA-2: 14.2;SCLC-21H: 22.4;U-2 OS: 11.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030790, HPA075862, CAB078782"	Enhanced	Supported	Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB078782: , HPA030790: AB_10602305, HPA075862: "	"unprognostic (2.84e-1)"	"unprognostic (1.88e-1)"	"unprognostic (4.10e-2)"	"unprognostic (9.23e-3)"	"unprognostic (8.85e-2)"	"unprognostic (2.34e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.72e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.19e-1)"	"unprognostic (1.04e-1)"	"unprognostic (3.22e-15)"	"unprognostic (8.92e-3)"	"unprognostic (1.92e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.88e-1)"	0.5	0.9	15.6	0.4	32.4	0.6	0.3	204.4	124.6	2.4	0.0	68.0	1.5	40.3	3.1	9.7	3.6	0.0	0.3	28.1	6.9	0.3	0.2	0.6	0.1	16.8	5.6	9.4	1.3	0.5	0.9	7.6	0.0	71.5	22.5	2.4	3.4	0.2	24.6	0.5	0.4	9.2	9.6	0.0	0.5	4.2	7.6	2.5	0.0	0.3	0.0	0.0	81.1	8.3	48.5	0.0	16.1	0.2	0.2	0.0	0.0	0.4	0.5	0.0	0.1	0.0	0.3	0.1	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.7	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	14.2	0.0	0.2	0.3	0.7	0.1	0.0	0.0	22.4	0.4	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	11.1	0.6	0.0	0.9	0.0	0.4	0.5	0.4	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	15.6	32.4	204.4	124.6	28.1	6.9	16.8	5.6	9.4	71.5	0.0	2.5	48.5	0.5	0.0	0.0	5.9	0.2	2.0	8.1	0.0	0.0	11.5	0.2	0.0	2.3	0.0	0.0	0.0	0.0	0.1	2.3	0.0	0.0	0.0	5.7	0.3	0.4	7.5	0.0	0.0	320.4	0.0	0.1	11.8	0.0	0.7	0.0	0.1	0.0	0.2	0.1	5.0	163.9	0.0	0.0	0.6	5.5	10.1	0.3	7.6	5.4	10.3	0.0	1.2	2.1	11.1	4.8	0.0	0.0	10.5	0.0	15.2	0.0	0.1	0.0	3.1	0.0	124.4	7.5	2.4	26.4	0.0	1.4	0.1	2.3	0.1	0.0	2.8
REPS2	POB1	ENSG00000169891	"RALBP1 associated Eps domain containing 2"	Q8NFH8	X	16946658-17153272	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 24.1"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 117.9;Inhibitory neurons: 142.7;Oligodendrocyte precursor cells: 84.9;Oligodendrocytes: 204.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 13.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"basophil: 5.8;eosinophil: 4.5;neutrophil: 14.3"	"Lineage enriched"	"Detected in single"	28	"granulocytes: 14.3"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 30.2;Karpas-707: 11.7;RH-30: 8.4;RPMI-8226: 9.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000565, HPA026073"	Uncertain				"Intracellular and membrane"	NA	NA					"HPA000565: AB_1079800, HPA026073: AB_1856176"	"unprognostic (6.58e-2)"	"unprognostic (2.14e-1)"	"unprognostic (3.35e-2)"	"unprognostic (7.83e-2)"	"unprognostic (4.23e-2)"	"unprognostic (3.70e-3)"	"prognostic favorable (5.36e-4)"	"unprognostic (4.85e-2)"	"unprognostic (2.87e-2)"	"unprognostic (5.53e-2)"	"prognostic unfavorable (3.24e-4)"	"unprognostic (1.83e-1)"	"prognostic favorable (4.08e-4)"	"unprognostic (5.89e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.43e-2)"	"prognostic favorable (4.56e-4)"	2.4	11.2	5.0	1.3	10.5	3.0	3.4	2.4	24.1	16.0	1.7	4.3	2.1	4.2	12.7	1.4	2.1	2.1	1.6	10.4	9.1	11.1	7.6	4.7	0.5	3.1	5.3	9.5	4.1	10.4	9.4	6.1	2.7	5.7	8.3	4.7	9.4	5.1	7.9	0.9	0.9	2.0	4.2	1.8	1.2	6.4	2.1	9.8	0.7	2.0	1.3	0.6	1.9	1.0	12.6	1.4	0.6	0.0	0.1	0.8	0.5	0.1	0.0	0.0	0.1	0.2	0.1	5.2	0.0	0.6	0.0	3.9	0.2	1.1	2.8	0.5	30.2	0.6	0.0	0.7	0.0	0.7	0.0	0.1	5.3	0.9	0.0	4.7	4.9	1.6	0.0	0.0	11.7	0.3	1.4	0.0	0.4	0.2	4.3	0.9	0.0	8.4	9.4	0.3	2.8	4.2	0.3	2.2	2.1	1.7	1.7	3.9	0.2	0.2	0.0	0.2	0.1	0.4	0.5	0.0	0.4	0.0	0.4	0.2	5.8	0.3	4.5	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	14.3	0.0	0.2	0.3	0.0	0.1	5.0	10.5	2.4	24.1	10.4	9.1	3.1	5.3	9.5	5.7	1.8	9.8	12.6	11.7	32.1	13.5	6.5	0.9	0.6	9.6	4.4	1.2	49.5	7.9	5.5	6.6	4.3	8.8	14.7	0.0	0.2	1.5	10.4	1.9	3.0	0.2	7.1	4.0	2.3	9.5	4.4	117.9	14.6	9.1	4.1	9.7	9.6	0.0	7.9	4.2	15.1	4.2	38.7	142.7	7.8	0.0	5.7	6.4	0.9	9.3	6.6	1.8	21.5	4.9	0.9	0.0	84.9	204.0	7.9	5.1	12.8	1.3	10.6	2.3	11.6	2.7	2.6	0.0	0.8	2.0	0.7	2.6	0.9	1.3	0.7	0.5	16.3	10.2	6.5
RIMS1	"CORD7, KIAA0340, RAB3IP2, RIM, RIM1"	ENSG00000079841	"Regulating synaptic membrane exocytosis 1"	Q86UR5	6	71886703-72403143	"Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Exocytosis, Neurotransmitter transport, Sensory transduction, Transport, Vision"		"Cone-rod dystrophy, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	49	"brain: 367.0"	"Group enriched"	"Detected in many"	4	"Excitatory neurons: 653.2;Inhibitory neurons: 572.7;Oligodendrocyte precursor cells: 323.2"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.7"	"Region enriched"	"Detected in many"	5	"cerebellum: 367.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Daudi: 5.2;EFO-21: 8.8;LHCN-M2: 10.0;RPTEC TERT1: 15.0;SH-SY5Y: 10.7;TIME: 5.4;U-138 MG: 5.1"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 352.9"	HPA076565	Enhanced					NA	NA					"HPA076565: "	"unprognostic (1.34e-3)"	"unprognostic (3.47e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.63e-3)"	"unprognostic (6.62e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.73e-2)"	"unprognostic (8.57e-2)"		"unprognostic (2.85e-1)"	"unprognostic (7.76e-4)"	"unprognostic (2.42e-2)"	"unprognostic (2.29e-1)"	"unprognostic (7.91e-2)"	"unprognostic (2.76e-1)"	"unprognostic (5.74e-2)"	"unprognostic (1.07e-2)"	0.2	1.2	7.2	0.8	13.5	0.0	0.5	367.0	24.4	0.3	0.0	0.2	0.7	0.2	0.0	2.1	0.0	3.9	0.1	15.9	8.5	0.0	0.0	0.2	0.0	3.2	26.2	6.0	0.0	0.5	1.6	2.4	0.0	76.6	3.0	0.1	7.5	1.1	0.3	0.2	0.1	0.4	0.7	0.0	0.0	1.4	4.2	6.7	0.0	0.0	0.9	0.0	0.1	0.0	15.2	0.0	0.0	1.0	0.0	0.0	0.5	0.0	0.2	1.4	0.0	0.2	0.0	0.0	5.2	8.8	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.4	1.6	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.0	0.5	15.0	0.0	0.4	10.7	0.0	0.0	0.0	0.3	0.7	0.0	5.4	5.1	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	13.5	367.0	24.4	15.9	8.5	3.2	26.2	6.0	76.6	0.0	6.7	15.2	0.2	0.0	0.5	120.2	0.0	0.0	0.2	2.1	0.0	69.1	3.0	3.2	1.4	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	15.2	0.0	0.9	2.5	0.0	0.0	653.2	0.8	0.0	1.8	0.0	0.0	1.3	0.3	3.6	0.0	0.0	62.2	572.7	0.0	2.0	0.0	0.0	10.2	0.3	0.3	3.6	16.9	0.0	109.7	0.0	323.2	76.5	0.5	0.0	1.5	0.0	1.0	0.0	0.4	3.6	9.9	0.0	1.3	2.7	21.3	13.6	0.0	0.1	0.0	0.1	0.3	0.0	0.5
RPS4Y1	"MGC119100, MGC5070, RPS4Y, S4"	ENSG00000129824	"Ribosomal protein S4 Y-linked 1"	P22090	Y	2841602-2932000	"Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Basal respiratory cells: 1273.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 187.7"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 1076.6;HSkMC: 1195.7;U-698: 1701.8"									HPA000857	Approved					NA	NA					"HPA000857: AB_1079849"			"unprognostic (7.04e-2)"		"unprognostic (2.21e-2)"	"unprognostic (1.32e-3)"	"unprognostic (3.93e-2)"	"unprognostic (6.31e-2)"	"unprognostic (7.35e-2)"		"unprognostic (1.26e-2)"	"unprognostic (1.75e-1)"	"unprognostic (8.11e-2)"	"unprognostic (5.87e-3)"	"unprognostic (1.81e-1)"	"unprognostic (1.49e-2)"	"unprognostic (4.55e-2)"	249.1	241.9	161.5	81.4	164.4	229.1	236.8	151.8	343.5	0.2	152.1	199.5	80.6	0.4	304.6	179.0	0.3	131.0	179.3	165.6	155.9	251.7	175.6	177.8	59.6	167.1	151.3	150.3	0.9	330.1	117.8	116.6	117.3	179.4	299.7	260.9	84.1	180.0	227.5	298.0	228.8	190.0	0.2	153.9	204.3	223.7	103.4	184.5	0.0	174.2	386.1	256.0	216.9	0.6	240.4	2.8	270.9	0.0	0.1	0.2	0.8	383.9	452.8	783.0	697.8	586.5	0.5	0.0	1076.6	1.4	645.0	0.0	0.6	0.0	0.3	849.8	317.4	0.1	683.8	0.1	829.0	953.5	1.4	0.7	1195.7	784.4	0.0	0.0	0.0	0.6	97.3	1.7	0.0	717.3	0.4	615.0	1.9	0.6	0.0	0.9	0.6	342.6	163.5	658.9	507.6	391.3	1.2	1.0	1.0	1.3	252.6	0.7	481.4	579.5	263.3	4.5	0.9	451.8	410.9	1.1	1701.8	0.0	1.1	0.1	42.4	97.3	21.2	112.8	84.1	168.6	156.3	187.2	116.0	159.3	142.4	227.6	213.3	21.8	125.1	56.8	65.4	170.1	252.1	161.5	164.4	151.8	343.5	165.6	155.9	167.1	151.3	150.3	179.4	153.9	184.5	240.4	0.0	201.9	459.1	9.8	493.4	849.9	981.5	1273.9	537.3	115.3	0.0	0.0	109.8	343.1	479.2	215.2	41.7	568.8	126.2	24.6	471.6	302.8	13.7	0.0	0.0	354.9	99.5	292.5	10.9	8.3	368.5	281.0	208.5	0.0	354.6	0.0	476.2	51.1	281.6	53.8	9.4	159.2	256.3	426.3	758.3	52.3	809.3	248.7	588.7	11.2	407.2	321.0	472.7	5.0	6.4	213.6	56.1	431.8	202.7	816.8	115.7	893.6	314.5	153.4	276.1	292.4	214.8	103.3	227.3	594.7	989.7	464.4	523.1	0.0	183.8	904.0
RWDD2A	"dJ747H23.2, MGC13523, RWDD2"	ENSG00000013392	"RWD domain containing 2A"	Q9UIY3	6	83193357-83198935	"Metabolic proteins, Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Early spermatids: 52.3;Spermatocytes: 65.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 11.6"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030105, HPA030106, HPA030107"	Uncertain		Approved	Vesicles		NA	NA			Vesicles		"HPA030105: AB_10599826, HPA030106: AB_10600896, HPA030107: AB_10601009"	"unprognostic (2.51e-3)"	"unprognostic (1.25e-1)"	"unprognostic (2.48e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.19e-3)"	"unprognostic (3.99e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.60e-1)"	"prognostic favorable (3.82e-5)"	"prognostic favorable (1.38e-4)"	"unprognostic (1.26e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.91e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.59e-2)"	2.8	6.9	7.0	2.1	7.2	0.5	3.2	6.4	8.1	3.1	6.1	2.7	2.5	3.3	9.4	1.7	3.8	4.6	4.5	6.8	7.5	4.5	6.0	2.9	2.5	5.9	5.9	7.0	4.0	9.7	4.0	5.7	2.5	6.1	11.6	2.5	4.7	6.1	4.7	2.3	2.0	2.8	3.3	5.7	2.9	3.9	9.0	7.7	1.8	6.2	4.0	2.7	2.6	1.8	6.7	2.1	1.9	4.4	8.3	5.2	3.7	3.0	4.8	10.1	3.5	4.2	2.8	1.1	1.6	3.8	5.8	8.0	2.1	3.7	2.8	5.4	2.0	3.8	1.9	3.0	6.2	8.0	0.5	1.5	4.9	4.6	4.4	9.2	11.5	6.6	4.5	3.1	2.8	4.3	3.1	0.7	1.5	1.5	1.9	1.9	2.4	9.1	1.0	7.4	2.4	1.5	5.3	2.9	4.5	4.4	6.3	2.8	2.9	7.1	2.4	1.5	3.5	2.1	6.2	2.7	0.9	2.8	0.8	2.9	0.3	0.9	0.0	1.2	0.8	1.8	1.9	1.7	1.7	1.0	1.0	2.2	2.1	0.3	0.4	2.2	3.5	2.2	1.0	7.0	7.2	6.4	8.1	6.8	7.5	5.9	5.9	7.0	6.1	5.7	7.7	6.7	2.4	0.0	6.7	9.8	4.2	3.7	3.6	5.3	3.4	5.6	3.7	3.2	5.4	2.8	3.3	1.8	0.0	7.7	3.9	2.4	5.9	8.9	52.3	4.8	4.5	3.5	5.4	0.4	10.8	9.1	3.3	6.5	3.6	4.0	0.0	7.0	5.0	6.8	5.0	1.7	11.2	6.1	8.2	1.6	2.5	14.8	9.0	2.2	8.8	3.7	3.8	11.0	0.0	13.6	4.5	5.8	2.5	6.0	11.2	8.7	4.1	13.3	4.9	5.0	6.6	7.0	5.2	65.2	10.5	1.2	2.4	5.7	2.9	6.3	3.4	2.8
SERTM2	LINC00890	ENSG00000260802	"Serine rich and transmembrane domain containing 2"	A0A1B0GWG4	X	111511662-111522399	"Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Group enriched"	"Detected in many"	5	"endometrium 1: 27.6;epididymis: 42.3;seminal vesicle: 76.5"	"Cell type enhanced"	"Detected in some"		"Alveolar cells type 1: 3.2;Alveolar cells type 2: 4.6;granulocytes: 1.3"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 2.9;renal cancer: 1.7"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"HMC-1: 16.9"	"Region enhanced"	"Detected in some"		"basal ganglia: 2.8"	"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (9.56e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.42e-1)"	"unprognostic (2.65e-1)"		"unprognostic (3.79e-2)"	"unprognostic (5.74e-2)"		"unprognostic (1.93e-2)"	"unprognostic (4.03e-2)"	"unprognostic (3.51e-1)"	"unprognostic (8.77e-3)"	"unprognostic (3.86e-3)"	"unprognostic (1.94e-1)"	"unprognostic (2.26e-1)"	"unprognostic (9.57e-3)"	0.0	0.1	0.1	0.8	0.0	0.0	0.3	0.0	0.1	9.0	0.0	1.3	0.1	27.6	42.3	0.0	4.2	0.2	0.0	0.0	0.5	0.2	5.4	0.2	0.1	0.3	0.2	0.0	0.8	0.0	0.0	1.0	0.3	0.3	9.9	0.1	0.3	0.0	76.5	0.0	0.0	0.4	4.8	0.1	0.4	2.1	0.0	0.5	0.0	0.0	0.0	0.3	0.7	3.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.7	0.0	16.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.9	0.0	0.0	0.0	0.0	0.0	0.9	0.0	2.8	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.3	0.2	0.0	0.3	0.1	0.5	0.2	0.1	3.2	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0
SGCA	"A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1"	ENSG00000108823	"Sarcoglycan alpha"	Q16586	17	50164214-50175928	"Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Disease variant, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"heart muscle: 145.1;skeletal muscle: 527.4;tongue: 239.1"	"Cell type enhanced"	"Detected in some"		"Cardiomyocytes: 128.4;Early spermatids: 162.6;Late spermatids: 705.4;Skeletal myocytes: 195.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 4.5"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"intermediate monocyte: 1.4;memory B-cell: 3.3;myeloid DC: 2.2;naive B-cell: 3.3;non-classical monocyte: 1.8"	"Group enriched"	"Detected in many"	15	"B-cells: 3.3;dendritic cells: 2.2;monocytes: 1.8"	"Cell line enriched"	"Detected in some"	16	"LHCN-M2: 78.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA007537	Uncertain				"Intracellular and membrane"	NA	NA					"HPA007537: AB_1079944"	"unprognostic (1.34e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.89e-3)"	"unprognostic (1.25e-1)"	"unprognostic (9.87e-2)"	"unprognostic (2.43e-2)"	"unprognostic (9.25e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.91e-1)"	"unprognostic (7.01e-2)"	"unprognostic (2.57e-1)"	"unprognostic (2.07e-3)"	"unprognostic (4.96e-2)"	"unprognostic (2.16e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.15e-2)"	10.0	1.5	2.1	7.4	2.3	0.0	4.3	3.4	2.6	9.7	1.8	38.5	5.3	37.2	1.6	23.0	18.3	12.0	145.1	1.2	1.7	2.7	4.8	29.9	0.5	1.5	1.3	1.2	5.2	1.3	0.8	0.9	6.8	2.1	26.2	3.2	0.1	8.7	27.4	527.4	10.5	15.0	23.2	1.1	3.4	24.3	1.8	1.5	2.3	3.4	239.1	0.4	46.9	11.7	4.5	0.0	0.0	0.0	0.0	0.0	0.5	0.9	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	78.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	4.9	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.8	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.4	0.1	0.0	1.4	0.0	3.3	0.0	0.0	2.2	3.3	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.4	2.1	2.3	3.4	2.6	1.2	1.7	1.5	1.3	1.2	2.1	1.1	1.5	4.5	1.1	0.0	0.0	0.0	1.3	8.7	0.5	0.4	0.0	0.6	0.1	0.5	128.4	0.0	0.3	0.0	0.0	0.5	1.4	0.0	0.0	0.6	162.6	0.0	0.2	4.6	0.0	0.0	0.0	5.8	0.1	30.4	0.5	0.0	0.0	0.0	2.2	0.1	0.5	0.0	0.0	0.0	0.0	0.0	16.5	705.4	3.1	0.8	8.8	1.9	1.9	0.0	0.0	0.0	0.1	4.1	0.0	3.8	0.1	0.6	0.0	2.1	0.0	0.0	13.1	195.2	48.2	2.3	1.9	0.1	9.9	0.3	0.9	0.0	0.0	0.2
SIM2	"bHLHe15, MGC119447, SIM"	ENSG00000159263	"SIM bHLH transcription factor 2"	Q14190	21	36699115-36749917	"Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"esophagus: 31.4;kidney: 16.7;skeletal muscle: 10.7"	"Group enriched"	"Detected in some"	4	"Basal squamous epithelial cells: 100.7;Squamous epithelial cells: 68.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 11.8"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 24.9;PC-3: 43.0;RPTEC TERT1: 54.3;RT4: 33.5"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"hypothalamus: 1.2"	HPA029295	Approved		Supported	"Nucleoplasm,Nuclear bodies"		No	No			"Nucleoplasm, Nuclear bodies"		"HPA029295: AB_10610425"	"unprognostic (1.17e-3)"	"unprognostic (6.46e-2)"	"unprognostic (5.03e-2)"	"prognostic unfavorable (2.10e-4)"	"unprognostic (8.62e-2)"	"unprognostic (1.43e-2)"	"unprognostic (8.30e-2)"	"unprognostic (5.46e-3)"	"unprognostic (1.65e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.16e-3)"	"unprognostic (9.18e-2)"	"unprognostic (9.18e-7)"	"unprognostic (2.98e-2)"	"unprognostic (3.79e-2)"	"unprognostic (1.07e-2)"	"prognostic favorable (2.88e-4)"	0.2	0.3	1.8	0.0	1.1	0.0	0.4	0.6	1.4	2.4	0.3	0.4	0.0	0.5	0.8	31.4	0.6	0.0	0.2	1.5	2.4	16.7	0.4	0.2	0.0	0.9	1.3	0.4	0.2	0.3	1.8	1.6	0.0	0.7	6.6	0.0	0.0	0.6	0.0	10.7	0.3	0.3	0.0	0.5	0.3	9.6	0.5	1.9	0.0	0.4	0.0	3.5	0.7	0.7	0.8	6.4	9.6	0.0	0.3	0.0	0.0	9.4	0.0	0.0	0.9	0.0	5.0	14.7	0.0	8.6	0.2	17.0	3.2	4.8	0.0	0.5	7.8	15.0	0.0	14.3	0.3	0.0	0.0	0.0	1.6	1.4	0.0	2.6	24.9	0.0	0.0	0.0	0.0	16.0	3.7	0.0	0.0	0.0	6.4	43.0	0.0	0.0	0.0	54.3	33.5	0.4	0.0	15.7	0.0	0.9	1.6	4.1	0.0	0.6	0.0	2.5	1.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	1.1	0.6	1.4	1.5	2.4	0.9	1.3	0.4	0.7	0.5	1.9	0.8	0.2	0.0	0.0	0.0	0.0	0.3	19.1	0.0	100.7	0.2	0.1	0.1	2.0	0.0	0.0	9.2	0.0	0.0	0.0	0.2	9.8	0.1	2.2	0.3	0.3	0.4	0.0	0.0	0.3	0.0	0.0	0.8	12.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.4	5.8	0.3	0.3	0.0	0.0	0.0	0.0	0.0	7.1	1.1	0.0	0.0	0.0	1.3	9.5	0.1	0.2	0.0	0.5	0.0	1.5	0.9	0.5	0.2	68.3	0.4	0.0	0.4	0.0	0.2	4.0
SLC15A2	PEPT2	ENSG00000163406	"Solute carrier family 15 member 2"	Q16348	3	121894401-121944188	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Immunity, Innate immunity, Peptide transport, Protein transport, Symport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix: 51.3;epididymis: 39.6;prostate: 40.0"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 1: 99.3;Astrocytes: 139.7;Club cells: 64.8;Microglial cells: 49.6;Muller glia cells: 51.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 12.1"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"NB-4: 5.7;U-937: 4.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.72e-2)"	"prognostic favorable (2.37e-4)"	"unprognostic (3.50e-2)"	"prognostic favorable (6.96e-4)"	"unprognostic (1.80e-2)"	"unprognostic (1.78e-1)"	"unprognostic (8.03e-3)"	"prognostic favorable (6.74e-4)"	"unprognostic (3.21e-1)"	"unprognostic (1.28e-1)"	"unprognostic (9.92e-2)"	"unprognostic (1.43e-1)"	"unprognostic (5.53e-3)"	"unprognostic (1.63e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.67e-2)"	"unprognostic (4.60e-2)"	1.0	1.4	14.3	3.0	15.2	5.9	4.8	11.9	16.2	51.3	4.6	2.6	2.2	2.0	39.6	3.4	11.4	6.3	1.8	13.5	11.3	11.1	0.9	20.2	6.0	10.7	11.5	12.7	0.8	5.5	1.7	3.4	2.3	15.1	40.0	2.9	21.1	24.8	22.2	0.8	0.9	2.1	1.2	9.1	6.1	1.6	4.2	13.1	1.6	6.7	0.4	6.0	4.9	2.3	10.4	1.3	0.6	0.7	0.2	0.8	0.4	0.9	0.1	0.1	0.3	0.4	1.2	2.1	2.4	0.1	0.1	0.4	1.4	0.5	1.2	0.4	2.0	0.5	3.3	1.0	0.6	0.1	3.6	3.2	0.7	3.6	0.4	0.2	0.4	0.2	0.7	0.5	1.0	0.4	1.0	0.7	5.7	3.7	1.4	0.3	0.8	0.3	0.7	0.8	0.8	0.3	0.3	0.3	0.2	0.1	1.1	0.2	3.1	0.1	0.3	0.2	0.2	0.3	1.2	0.4	3.3	0.4	4.8	0.3	0.9	0.4	0.1	0.0	0.1	0.1	1.3	0.1	0.0	0.1	1.3	0.1	0.1	0.2	0.0	1.0	0.6	0.0	0.1	14.3	15.2	11.9	16.2	13.5	11.3	10.7	11.5	12.7	15.1	9.1	13.1	10.4	0.4	99.3	22.8	139.7	5.9	0.5	2.8	22.5	1.2	1.0	5.0	2.0	2.6	4.3	64.8	11.0	0.0	2.5	3.2	1.4	3.9	0.6	0.4	8.9	2.0	1.0	0.0	1.7	15.4	8.3	0.6	1.3	0.5	21.3	3.8	1.0	1.4	0.0	2.7	0.0	22.6	1.4	14.2	13.5	3.8	0.6	6.5	5.3	0.0	49.6	3.1	51.4	1.0	16.6	5.0	2.0	1.0	5.3	7.7	14.4	0.2	1.6	28.8	2.9	0.0	0.9	2.4	0.4	0.5	10.4	0.6	1.4	1.2	0.3	1.6	12.7
SLC22A3	"EMT, OCT3"	ENSG00000146477	"Solute carrier family 22 member 3"	O75751	6	160348378-160452577	"Metabolic proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 67.9"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 78.9;Hepatocytes: 68.8;Leydig cells: 33.8;Pancreatic endocrine cells: 57.3;Skeletal myocytes: 29.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 19.6"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 27.6;HeLa: 38.1;Hep G2: 23.7;OE19: 12.0;RPTEC TERT1: 13.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA029750	Approved		Approved	Vesicles,Cytosol		NA	NA			Vesicles	Cytosol	"HPA029750: AB_10603888"	"unprognostic (8.61e-2)"	"prognostic unfavorable (7.19e-5)"	"unprognostic (4.14e-1)"	"unprognostic (1.49e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.28e-1)"	"unprognostic (3.36e-2)"	"unprognostic (9.74e-2)"	"unprognostic (9.36e-4)"	"unprognostic (1.33e-2)"	"unprognostic (2.58e-2)"	"unprognostic (7.28e-2)"	"unprognostic (7.96e-2)"	"unprognostic (5.21e-2)"	"unprognostic (8.13e-4)"	"prognostic unfavorable (7.26e-4)"	11.8	15.3	2.8	3.9	2.8	0.0	6.6	3.5	2.4	13.9	2.2	7.3	1.7	18.6	27.8	7.8	18.9	11.1	1.5	2.1	3.5	6.3	35.2	16.6	16.3	6.2	3.7	1.7	21.3	0.7	0.2	1.3	44.7	4.6	43.8	2.4	0.2	52.2	53.1	67.9	10.4	5.7	26.6	3.2	0.6	6.1	2.7	4.1	0.5	2.0	8.5	5.0	6.2	15.9	3.3	0.0	27.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.3	1.5	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.4	0.0	0.0	0.0	38.1	23.7	1.2	0.0	0.0	0.8	6.9	3.4	0.0	9.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.0	12.0	7.7	0.0	0.0	0.0	13.8	0.0	0.0	0.0	3.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	2.8	3.5	2.4	2.1	3.5	6.2	3.7	1.7	4.6	3.2	4.1	3.3	0.6	16.0	78.9	6.2	0.1	4.7	0.3	2.1	2.8	0.2	0.2	0.3	2.9	5.7	6.4	0.0	0.0	0.3	0.1	0.2	5.9	8.2	0.6	0.2	10.2	1.0	0.0	0.0	0.5	3.0	0.3	10.0	12.8	0.3	2.5	0.8	0.0	68.8	0.7	0.0	25.1	1.6	2.0	1.0	2.4	1.6	33.8	0.3	3.6	7.5	0.0	0.0	0.0	19.6	0.2	57.3	0.1	24.5	0.1	6.1	2.1	2.9	0.8	0.1	0.0	29.8	12.3	0.3	0.2	3.7	6.7	0.4	1.2	0.0	2.8	0.8
SLC44A4	"C6orf29, CTL4, DFNA72, FLJ14491, NG22, TPPT"	ENSG00000204385	"Solute carrier family 44 member 4"	Q53GD3	6	31863192-31879046	"Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters"			"Deafness, Disease variant, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 101.7;prostate: 83.7;stomach 1: 84.0"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 546.0;Exocrine glandular cells: 213.4;Intestinal goblet cells: 327.8;Paneth cells: 299.3;Proximal enterocytes: 267.7;Respiratory ciliated cells: 406.7;Undifferentiated cells: 259.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 222.3"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	8	"OE19: 14.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA046977, HPA054176"	Enhanced					NA	NA					"HPA046977: AB_2679887, HPA054176: AB_2682404"	"unprognostic (5.84e-2)"	"unprognostic (4.90e-2)"	"unprognostic (3.86e-3)"	"unprognostic (4.85e-3)"	"unprognostic (2.75e-2)"	"prognostic favorable (3.54e-4)"	"unprognostic (2.65e-3)"	"unprognostic (2.44e-3)"	"unprognostic (3.08e-1)"	"unprognostic (2.45e-1)"	"unprognostic (2.89e-2)"	"unprognostic (1.89e-1)"	"prognostic favorable (1.06e-6)"	"unprognostic (1.37e-2)"	"unprognostic (2.48e-1)"	"unprognostic (4.54e-2)"	"prognostic favorable (6.06e-4)"	0.5	8.3	0.0	2.6	0.0	1.0	5.3	0.0	0.0	22.6	0.0	78.0	101.7	5.9	2.6	2.0	47.4	19.0	0.0	0.0	0.0	31.7	0.4	15.0	0.2	0.2	0.0	0.0	1.6	8.9	0.0	16.3	3.5	0.1	83.7	30.6	0.0	42.9	4.0	0.0	1.0	87.5	2.9	0.0	1.6	84.0	0.7	0.0	0.2	1.9	0.0	0.8	11.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	14.6	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.3	0.7	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	3.7	22.4	36.0	0.0	3.8	0.5	23.0	71.4	0.6	0.3	14.6	6.1	0.4	38.6	180.2	66.2	0.0	0.3	0.5	546.0	3.9	111.2	2.3	127.4	8.9	6.2	46.7	0.0	0.1	213.4	0.5	2.4	208.5	67.5	2.5	1.1	0.4	0.0	0.5	0.0	0.1	327.8	91.6	0.0	0.0	3.2	1.5	2.5	0.0	0.0	1.6	0.7	0.0	0.0	0.0	184.0	299.3	0.4	0.3	142.0	267.7	61.5	406.7	0.6	0.0	0.8	11.9	0.2	0.2	0.5	0.4	0.7	2.3	5.5	259.6	139.4
SLCO5A1	"OATP-J, OATP5A1, OATPRP4, SLC21A15"	ENSG00000137571	"Solute carrier organic anion transporter family member 5A1"	Q9H2Y9	8	69667046-69834978	"Predicted membrane proteins, Transporters"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 6.6;skeletal muscle: 7.7;tongue: 11.2"	"Group enriched"	"Detected in many"	4	"Bipolar cells: 10.1;Cardiomyocytes: 14.4;Enteroendocrine cells: 15.6;Excitatory neurons: 8.6;Inhibitory neurons: 30.1;monocytes: 21.2;Oligodendrocyte precursor cells: 26.2;Plasma cells: 14.3;Prostatic glandular cells: 11.8"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.5"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 5.5;NTERA-2: 3.7;RPMI-8226: 3.6;SCLC-21H: 3.9;U-266/70: 2.1"	"Group enriched"	"Detected in some"	7	"basal ganglia: 2.3;olfactory bulb: 6.7"	"Region enriched"	"Detected in some"	7	"olfactory bulb: 12.8"	HPA025062	Uncertain		Supported	"Vesicles,Plasma membrane"		NA	NA			"Plasma membrane"	Vesicles	"HPA025062: AB_1857220"	"unprognostic (1.30e-3)"	"unprognostic (7.35e-3)"	"unprognostic (4.13e-2)"	"unprognostic (1.14e-2)"	"unprognostic (1.48e-1)"	"unprognostic (5.70e-2)"	"unprognostic (1.46e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.37e-4)"	"unprognostic (1.75e-1)"	"unprognostic (4.48e-4)"	"unprognostic (1.74e-2)"	"unprognostic (2.92e-6)"	"unprognostic (2.20e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.13e-1)"	"unprognostic (4.50e-2)"	0.1	0.0	0.3	0.9	0.4	0.9	0.1	0.0	0.4	0.2	0.0	0.2	0.2	0.2	0.0	0.5	0.3	0.2	3.1	0.3	0.6	0.0	0.0	0.1	1.0	0.2	0.0	0.1	0.0	0.4	0.0	1.5	0.0	0.2	2.3	0.4	0.7	0.3	0.0	7.7	0.0	0.3	0.1	0.0	0.5	0.2	0.3	0.2	6.6	0.0	11.2	0.9	0.6	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	1.5	1.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.7	3.7	0.0	0.6	0.6	0.6	3.6	0.0	0.0	3.9	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.7	2.1	0.3	0.0	0.2	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.4	0.3	0.6	0.2	0.0	0.1	0.2	0.0	0.2	0.2	0.1	3.2	0.0	3.6	3.6	0.3	1.8	0.0	0.6	10.1	0.2	0.3	14.4	0.0	0.6	0.0	2.1	0.0	0.0	0.6	0.0	1.8	0.6	0.4	1.7	2.0	15.6	0.0	8.6	1.3	0.0	4.0	0.0	1.7	0.0	0.0	0.0	0.2	0.1	1.7	30.1	2.0	0.0	0.0	3.6	0.6	0.0	0.7	0.0	3.7	21.2	0.5	0.0	26.2	2.2	2.1	0.1	0.0	14.3	11.8	0.0	0.1	0.0	0.3	0.0	3.4	2.0	1.1	2.6	0.4	0.4	0.0	0.1	0.4	1.5	1.5
SMCO3	"C12orf69, LOC440087"	ENSG00000179256	"Single-pass membrane protein with coiled-coil domains 3"	A2RU48	12	14804650-14814182	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix: 3.5;kidney: 3.0"	"Cell type enhanced"	"Detected in some"		"Cholangiocytes: 2.8;Collecting duct cells: 1.8;Distal tubular cells: 5.9;Erythroid cells: 2.7;Hepatic stellate cells: 4.6;Proximal tubular cells: 7.3"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 3.4"	"Not detected"	"Not detected"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"AN3-CA: 1.9"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in single"	7	"spinal cord: 3.6"	"HPA040574, HPA047804"	Uncertain		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA040574: AB_2677026, HPA047804: AB_2680160"	"unprognostic (1.16e-1)"	"unprognostic (2.09e-4)"	"unprognostic (2.40e-4)"	"unprognostic (5.10e-2)"	"unprognostic (3.88e-2)"	"unprognostic (6.45e-2)"	"unprognostic (4.43e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.32e-1)"	"unprognostic (7.31e-2)"	"unprognostic (3.66e-2)"	"unprognostic (1.48e-8)"	"unprognostic (2.85e-1)"	"unprognostic (7.53e-3)"	"unprognostic (2.05e-1)"	"unprognostic (1.38e-1)"	0.5	0.4	0.1	0.1	0.1	0.3	0.2	0.0	0.1	3.5	0.4	0.2	0.0	0.3	0.1	0.1	0.3	1.9	0.6	0.1	0.1	3.0	1.5	1.1	0.5	0.1	0.2	0.0	0.2	0.2	0.5	0.2	1.1	0.1	0.8	0.1	1.3	0.1	1.6	0.1	0.1	0.1	0.1	0.1	1.8	0.1	0.2	0.1	0.0	0.8	0.0	0.1	0.1	0.6	0.3	0.0	0.0	0.1	1.9	0.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.6	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.5	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.4	0.1	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.1	0.5	2.8	0.0	1.8	0.0	0.1	0.0	0.0	5.9	0.2	0.0	0.0	0.2	0.3	0.0	2.7	0.1	0.2	0.3	0.2	0.0	0.0	0.0	0.0	4.6	0.2	0.1	0.0	0.1	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	7.3	0.0	0.9	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0
SMIM31	LINC01207	ENSG00000248771	"Small integral membrane protein 31"	A0A1B0GVY4	4	164754064-164803795	"Predicted secreted proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"Evidence at transcript level"	"Tissue enhanced"	"Detected in some"		"gallbladder: 7.9;intestine: 24.8;prostate: 11.1"	"Group enriched"	"Detected in some"	5	"Exocrine glandular cells: 93.3;Pancreatic endocrine cells: 139.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 8.8"	"Not detected"	"Not detected"			"Immune cell enhanced"	"Detected in single"		"basophil: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in single"		"RPTEC TERT1: 1.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"								"Secreted - unknown location"	NA	NA						"unprognostic (2.84e-1)"	"unprognostic (1.18e-1)"	"unprognostic (2.47e-2)"	"unprognostic (1.87e-4)"			"unprognostic (2.95e-2)"	"unprognostic (1.78e-1)"			"unprognostic (4.17e-2)"	"unprognostic (4.82e-1)"		"unprognostic (9.47e-2)"			"unprognostic (5.63e-3)"	0.1	0.1	0.4	1.5	0.3	1.0	1.0	0.5	0.6	5.1	0.3	15.6	22.2	0.3	1.0	0.1	0.1	7.9	0.1	0.3	0.2	0.1	0.1	0.4	0.3	0.4	0.2	0.4	0.1	0.5	0.1	0.0	0.1	0.5	11.1	15.7	0.2	1.2	0.1	0.2	0.2	24.8	0.7	0.1	0.1	0.6	0.1	0.3	0.0	0.1	0.0	0.1	1.7	0.0	0.9	0.1	0.8	0.0	0.2	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	0.1	0.1	0.3	0.1	0.4	0.0	0.1	0.0	0.3	1.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.0	0.2	0.1	0.4	0.1	0.1	0.1	0.2	0.3	1.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.1	0.1	0.6	0.3	0.1	0.3	0.0	0.0	0.4	0.3	0.5	0.6	0.3	0.2	0.4	0.2	0.4	0.5	0.1	0.3	0.9	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	1.1	0.0	0.0	9.3	3.7	0.0	0.1	0.0	0.0	0.0	3.8	0.0	2.5	2.2	0.3	0.0	0.0	0.0	93.3	0.0	0.2	0.0	22.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	139.7	0.0	0.0	0.0	0.0	0.0	0.8	10.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.3	0.2	0.0	0.0
SNAP91	"AP180, CALM, KIAA0656"	ENSG00000065609	"Synaptosome associated protein 91"	O60641	6	83552880-83709691	"Predicted intracellular proteins"	"Protein transport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"brain: 84.5;pituitary gland: 26.0;retina: 92.6"	"Cell type enhanced"	"Detected in some"		"Astrocytes: 91.1;Excitatory neurons: 336.6;Inhibitory neurons: 296.9;Oligodendrocyte precursor cells: 209.1;Oligodendrocytes: 89.0"	"Cancer enhanced"	"Detected in some"		"glioma: 2.5;prostate cancer: 2.0"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	25	"plasmacytoid DC: 2.8"	"Lineage enriched"	"Detected in single"	25	"dendritic cells: 2.8"	"Group enriched"	"Detected in some"	10	"GAMG: 7.4;SCLC-21H: 23.7;SH-SY5Y: 14.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009745, HPA029632, HPA029633"	Enhanced		Uncertain	Centrosome,Cytosol		NA	NA		28000	"Centrosome, Cytosol"		"CAB009745: AB_2302221, HPA029632: AB_10794614, HPA029633: AB_10794615"	"unprognostic (1.07e-2)"	"unprognostic (1.74e-1)"	"unprognostic (7.55e-3)"	"unprognostic (3.68e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.42e-1)"		"unprognostic (2.56e-2)"		"unprognostic (1.17e-1)"	"unprognostic (4.54e-4)"	"unprognostic (6.99e-2)"	"unprognostic (1.75e-2)"	"unprognostic (4.82e-2)"	"unprognostic (2.15e-2)"	"unprognostic (1.51e-2)"	"unprognostic (3.14e-2)"	0.1	7.9	30.0	1.0	56.8	0.0	0.6	66.2	84.5	1.0	0.0	1.0	0.3	0.8	0.1	0.1	0.7	1.0	0.5	47.7	45.3	0.1	0.0	0.3	3.0	41.6	20.7	47.5	2.1	1.5	1.1	26.0	0.5	48.0	3.1	0.6	92.6	0.5	0.6	0.2	0.1	0.8	0.7	5.8	1.4	0.9	12.3	36.1	0.4	0.9	1.5	1.9	0.4	0.4	80.8	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	7.4	0.3	1.0	0.0	0.0	0.4	1.4	0.6	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.4	0.0	0.0	0.1	0.2	0.3	23.7	14.7	0.0	0.1	0.0	0.2	0.0	0.6	0.0	0.0	0.5	0.0	0.0	1.3	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	30.0	56.8	66.2	84.5	47.7	45.3	41.6	20.7	47.5	48.0	5.8	36.1	80.8	0.0	0.0	0.0	91.1	0.0	0.0	0.0	0.0	0.0	49.8	0.1	0.0	1.3	0.0	0.0	0.0	62.6	1.5	0.1	0.1	0.0	0.0	23.9	0.2	1.4	0.3	0.0	0.0	336.6	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	32.0	296.9	0.0	0.0	0.0	0.0	12.8	0.9	0.0	0.0	31.9	0.0	10.9	0.0	209.1	89.0	0.4	0.0	1.2	0.0	0.5	0.0	0.0	0.0	59.8	0.0	0.0	0.1	29.6	4.8	0.0	0.0	4.4	0.0	0.1	0.0	0.0
SOCS2	"CIS2, Cish2, SOCS-2, SSI-2, SSI2, STATI2"	ENSG00000120833	"Suppressor of cytokine signaling 2"	O14508	12	93569814-93583487	"Predicted intracellular proteins"	"Growth regulation, Ubl conjugation pathway"	"Signal transduction inhibitor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Adipocytes: 203.6;Hepatic stellate cells: 134.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 16.6"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in many"	5	"basophil: 177.8"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 177.8"	"Cell line enhanced"	"Detected in many"		"CACO-2: 192.0;K-562: 145.6;REH: 336.6;THP-1: 142.3"	"Low region specificity"	"Detected in all"							CAB010356	Approved		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB010356: AB_2239660"	"unprognostic (4.16e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.87e-1)"	"unprognostic (9.67e-2)"	"unprognostic (1.64e-2)"	"prognostic favorable (1.09e-6)"	"unprognostic (1.07e-1)"	"unprognostic (1.49e-1)"	"unprognostic (5.35e-3)"	"prognostic favorable (8.17e-7)"	"unprognostic (1.71e-1)"	"unprognostic (1.67e-3)"	"unprognostic (2.35e-2)"	"unprognostic (1.51e-1)"	"unprognostic (7.40e-2)"	"unprognostic (9.09e-2)"	53.6	35.2	8.0	10.5	11.3	11.6	68.6	7.8	8.9	91.0	21.6	32.7	11.8	92.5	42.4	16.7	42.8	20.9	25.9	10.0	35.8	29.6	59.5	62.4	9.2	8.8	10.6	7.8	19.4	13.9	65.0	55.7	36.8	10.6	82.1	17.2	4.9	9.6	45.9	9.6	9.0	17.5	90.2	6.3	8.6	31.0	8.7	10.4	21.6	33.1	6.2	9.2	32.3	50.8	8.5	3.5	4.9	16.8	15.2	9.1	16.6	19.8	20.8	77.0	15.2	6.6	192.0	7.8	1.0	0.7	19.3	4.1	39.8	88.6	5.9	17.3	69.0	2.5	13.9	1.2	2.7	13.8	4.2	28.5	28.3	4.9	16.7	22.7	1.6	2.1	8.7	145.6	3.1	2.4	1.8	0.8	6.8	47.4	3.2	7.4	336.6	0.3	3.6	4.1	7.4	28.8	34.2	7.3	11.5	57.5	16.0	0.2	142.3	2.3	47.2	0.7	0.3	11.7	2.0	1.1	1.4	0.9	12.0	28.8	177.8	0.2	7.7	25.4	0.5	34.2	0.4	31.2	23.3	0.2	4.3	30.6	18.4	1.1	26.8	0.4	2.0	19.8	14.4	8.0	11.3	7.8	8.9	10.0	35.8	8.8	10.6	7.8	10.6	6.3	10.4	8.5	203.6	9.6	78.7	1.0	1.4	18.0	46.0	3.2	1.2	8.2	30.5	16.9	6.5	0.0	24.3	22.0	4.2	36.3	15.5	20.8	62.6	13.7	9.8	10.5	94.9	100.5	8.3	33.2	10.9	37.4	6.7	34.6	7.1	20.2	24.1	9.9	134.6	11.6	14.2	69.0	12.3	13.3	4.1	8.9	20.7	20.3	91.6	6.0	17.8	8.4	108.4	1.5	18.6	1.0	1.3	8.8	21.2	101.2	6.4	95.2	20.0	27.5	5.4	1.2	78.9	15.8	32.9	9.9	10.5	1.8	10.5	35.0	15.7	12.7	15.7	30.1
SOX14	SOX28	ENSG00000168875	"SRY-box transcription factor 14"	O95416	3	137764315-137766334	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 8.8"	"Cell type enriched"	"Detected in some"	5	"Cytotrophoblasts: 18.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 2.8"	"Region enhanced"	"Detected in many"		"thalamus: 8.8"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"hypothalamus: 1.7;midbrain: 4.9"	"Group enriched"	"Detected in some"	6	"midbrain: 7.1;pons: 4.5;thalamus: 11.8"							NA	NA								"unprognostic (1.43e-1)"	"unprognostic (1.63e-1)"								"unprognostic (1.88e-2)"		"unprognostic (2.49e-3)"	"unprognostic (5.08e-1)"			0.0	0.0	1.6	0.0	0.3	0.0	0.0	1.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.5	4.1	0.0	0.0	0.0	0.0	0.0	1.7	1.5	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.3	1.5	0.4	0.0	1.5	0.5	4.1	0.0	1.5	0.1	8.8	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	18.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0
SPDEF	"bA375E1.3, PDEF"	ENSG00000124664	"SAM pointed domain containing ETS transcription factor"	O95238	6	34537802-34556333	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 141.9;salivary gland: 115.8"	"Cell type enhanced"	"Detected in many"		"Breast glandular cells: 94.2;Breast myoepithelial cells: 61.1;Intestinal goblet cells: 315.1;Prostatic glandular cells: 72.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 388.1"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"MCF7: 288.4;OE19: 118.0;SK-BR-3: 192.2;T-47d: 154.0"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	7	"midbrain: 2.9"	HPA055707			Approved	Nucleoplasm,Nucleoli,Cytosol		NA	NA			"Nucleoplasm, Nucleoli"	Cytosol	"HPA055707: AB_2682894"	"unprognostic (2.98e-1)"	"unprognostic (9.68e-2)"	"unprognostic (2.84e-1)"	"prognostic favorable (9.26e-9)"	"unprognostic (1.57e-1)"	"unprognostic (7.10e-3)"	"unprognostic (2.56e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.63e-1)"	"unprognostic (7.39e-3)"	"unprognostic (3.48e-3)"	"unprognostic (2.92e-1)"	"unprognostic (6.16e-11)"	"unprognostic (8.04e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.12e-2)"	0.3	0.1	0.6	1.4	0.6	0.1	36.9	0.8	1.1	28.2	0.0	16.7	11.7	9.1	0.5	2.2	6.4	2.5	0.3	0.6	0.3	0.1	0.1	1.2	0.0	0.3	0.5	0.6	0.1	0.6	0.0	0.2	0.0	0.4	141.9	10.3	0.0	115.8	0.1	0.3	8.5	14.4	0.6	0.1	0.1	35.7	0.3	0.6	0.0	0.1	0.0	0.0	1.0	0.3	0.7	0.0	30.9	0.1	0.2	0.0	0.0	0.5	0.0	0.0	0.1	0.2	0.3	0.3	0.0	0.1	0.0	0.0	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	288.4	0.3	0.4	0.0	118.0	38.6	0.1	0.0	0.3	0.3	0.3	2.1	0.2	0.0	192.2	0.0	0.0	154.0	0.0	0.0	0.0	0.5	0.4	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.8	1.1	0.6	0.3	0.3	0.5	0.6	0.4	0.1	0.6	0.7	0.8	0.0	2.2	0.7	0.3	0.1	13.3	20.7	0.0	0.0	94.2	61.1	0.3	5.7	31.7	0.0	0.0	0.0	1.4	27.1	0.0	2.6	1.1	6.2	0.7	0.6	5.4	0.0	0.8	1.2	0.0	0.4	28.1	18.7	0.0	0.2	0.4	0.0	0.0	0.0	0.6	315.1	12.2	0.0	0.2	5.5	0.0	0.9	3.6	0.0	0.0	0.0	0.0	0.0	0.2	20.2	12.3	0.0	0.1	72.7	5.7	0.0	2.9	0.0	0.0	0.0	1.2	0.1	0.2	0.0	0.0	0.3	0.8	0.0	30.0	11.5
SPOCK3	testican-3	ENSG00000196104	"SPARC (osteonectin), cwcv and kazal like domains proteoglycan 3"	Q9BQ16	4	166733384-167234796	"Predicted intracellular proteins, Predicted secreted proteins"		"Metalloenzyme inhibitor, Metalloprotease inhibitor, Protease inhibitor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 156.3;parathyroid gland: 176.1;prostate: 74.6"	"Cell type enhanced"	"Detected in many"		"Inhibitory neurons: 1010.6;Oligodendrocyte precursor cells: 399.1;Oligodendrocytes: 1851.1"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 7.4"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"classical monocyte: 1.2;myeloid DC: 1.8"	"Group enriched"	"Detected in many"	12	"dendritic cells: 1.8;monocytes: 1.2"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 2.2;hTERT-RPE1: 6.5;PC-3: 2.7;RH-30: 7.1;SCLC-21H: 2.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (3.54e-2)"	"unprognostic (8.69e-2)"		"unprognostic (2.90e-3)"	"unprognostic (1.20e-1)"	"unprognostic (4.09e-4)"	"unprognostic (3.75e-1)"	"unprognostic (1.97e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.94e-4)"	"unprognostic (8.92e-2)"	"unprognostic (4.18e-3)"	"unprognostic (2.62e-2)"	"unprognostic (2.48e-1)"	"unprognostic (3.60e-3)"	"unprognostic (1.64e-1)"	0.3	24.9	60.4	0.6	97.4	0.1	0.3	79.9	87.5	0.9	30.9	0.9	0.8	2.9	19.0	0.2	1.1	0.3	0.3	59.1	80.0	0.2	0.4	0.4	0.5	87.7	76.2	51.0	17.5	0.7	176.1	0.3	0.0	90.0	74.6	0.5	14.5	0.3	35.2	0.2	0.0	1.3	2.8	78.2	0.4	0.7	0.5	80.8	0.3	0.2	24.2	0.3	1.7	0.2	156.3	0.0	1.6	0.2	0.0	0.0	0.0	0.2	0.0	2.2	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.4	0.1	0.2	0.0	1.0	0.1	0.0	0.0	0.2	0.0	0.0	0.2	0.0	6.5	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.3	0.0	2.7	0.0	7.1	0.4	0.0	1.1	2.8	1.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.8	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	1.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.5	60.4	97.4	79.9	87.5	59.1	80.0	87.7	76.2	51.0	90.0	78.2	80.8	156.3	0.0	0.0	0.0	12.7	0.1	0.0	1.5	8.1	0.0	43.7	0.0	0.0	1.6	0.0	10.1	0.0	0.0	0.0	1.4	0.0	0.0	0.0	15.0	0.0	0.2	1.6	0.0	1.3	106.7	0.0	0.1	15.7	2.0	0.0	1.3	3.2	0.0	0.0	0.1	15.2	1010.6	0.0	6.1	0.0	0.0	2.9	0.9	0.5	0.0	98.4	0.2	1.3	0.0	399.1	1851.1	0.1	0.0	0.4	0.0	3.3	0.0	0.1	6.7	6.3	0.0	0.0	2.5	0.5	0.7	0.0	0.0	0.1	0.0	55.4	0.0	0.8
SSTR1		ENSG00000139874	"Somatostatin receptor 1"	P30872	14	38207904-38213067	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 11.1;intestine: 13.9;stomach 1: 21.9"	"Cell type enhanced"	"Detected in some"		"Enteroendocrine cells: 18.1;Gastric mucus-secreting cells: 16.8;Hepatic stellate cells: 27.1;Oligodendrocyte precursor cells: 24.1;Paneth cells: 10.7;Proximal enterocytes: 11.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.3"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 118.9;BJ hTERT+: 32.5;BJ hTERT+ SV40 Large T+: 21.4;fHDF/TERT166: 70.7;HeLa: 26.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA003207, HPA031506"	Approved		Uncertain	Vesicles		NA	NA			Vesicles		"HPA003207: , HPA031506: AB_2673913"	"unprognostic (1.40e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.36e-1)"	"unprognostic (2.50e-3)"	"unprognostic (4.34e-2)"	"unprognostic (9.90e-2)"	"unprognostic (3.66e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.16e-3)"	"unprognostic (3.20e-2)"	"unprognostic (1.72e-2)"	"unprognostic (9.19e-2)"	"prognostic favorable (4.28e-4)"	"unprognostic (2.17e-1)"	"unprognostic (1.67e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.28e-2)"	0.8	0.3	3.8	0.3	10.2	0.0	0.9	0.8	7.4	0.8	0.0	3.6	13.9	1.0	0.4	0.3	0.9	0.4	0.9	9.9	11.1	2.0	6.9	5.3	0.0	4.6	6.4	8.6	0.8	3.6	0.0	0.9	2.7	7.8	1.0	2.3	0.3	0.3	0.4	0.7	0.3	8.2	0.5	0.6	0.6	21.9	0.1	4.5	0.0	0.3	0.9	0.0	1.8	0.7	6.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	118.9	32.5	21.4	1.8	1.2	0.0	0.0	0.0	70.7	0.0	0.2	0.0	0.0	15.4	0.0	0.0	0.0	26.7	0.1	6.3	0.0	0.0	0.2	0.0	0.0	0.3	0.4	1.5	0.0	0.0	0.0	13.9	0.0	0.0	0.0	0.1	9.6	0.2	0.0	0.0	0.1	4.7	0.0	3.4	0.0	1.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	10.2	0.8	7.4	9.9	11.1	4.6	6.4	8.6	7.8	0.6	4.5	6.0	1.7	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	1.5	0.2	0.0	0.8	2.8	0.0	1.8	0.0	0.0	0.0	7.8	0.0	0.0	0.0	0.0	0.0	2.4	18.1	0.0	3.9	0.8	0.0	1.0	16.8	0.0	0.0	0.0	27.1	7.2	0.0	0.0	5.5	6.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.8	0.0	0.0	0.0	24.1	0.3	0.2	10.7	0.0	0.1	0.1	11.8	1.9	0.0	0.1	0.0	1.0	0.6	0.0	0.1	0.1	0.1	0.1	0.0	0.2	6.2	0.0
STEAP4	"FLJ23153, SchLAH, STAMP2, TIARP, TNFAIP9"	ENSG00000127954	"STEAP4 metalloreductase"	Q687X5	7	88270892-88306894	"Enzymes, Predicted membrane proteins, Transporters"	"Electron transport, Ion transport, Iron transport, Transport"	Oxidoreductase		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adipose tissue: 114.7"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 402.5;Club cells: 152.8;Sertoli cells: 460.2;Smooth muscle cells: 255.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 45.9"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in some"	12	"neutrophil: 163.6"	"Lineage enriched"	"Detected in many"	12	"granulocytes: 163.6"	"Group enriched"	"Detected in some"	6	"HSkMC: 122.1;SiHa: 119.7;U-2197: 166.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA065201			Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA065201: "	"unprognostic (3.76e-2)"	"unprognostic (2.16e-2)"	"unprognostic (8.82e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.62e-1)"	"unprognostic (9.96e-2)"	"prognostic favorable (2.97e-4)"	"unprognostic (7.40e-2)"	"unprognostic (3.12e-1)"	"unprognostic (4.66e-2)"	"unprognostic (4.21e-1)"	"unprognostic (2.98e-1)"	"unprognostic (7.51e-3)"	"prognostic unfavorable (5.77e-4)"	"unprognostic (1.72e-1)"	"unprognostic (2.00e-1)"	"unprognostic (4.53e-2)"	114.7	46.6	0.9	32.0	0.8	7.2	69.2	2.6	2.0	19.2	14.7	11.7	3.8	18.0	7.9	15.6	36.4	22.9	23.3	1.3	0.8	7.2	24.5	68.1	7.2	0.9	0.7	1.2	4.4	10.7	16.2	13.1	15.5	1.6	60.5	9.3	1.9	27.1	10.7	13.5	17.7	10.7	29.6	0.3	5.4	10.6	13.6	0.7	7.9	53.6	16.7	5.1	34.6	22.9	1.4	4.9	0.0	0.1	0.1	0.1	1.9	0.3	0.0	0.3	0.0	0.1	0.1	23.6	0.1	0.1	0.0	0.4	18.7	0.1	0.0	0.1	0.0	0.1	0.1	7.9	0.1	0.1	0.1	0.2	122.1	0.1	0.4	0.9	0.0	0.0	0.1	0.3	0.4	0.0	3.0	0.1	0.5	0.1	1.0	0.0	0.2	0.1	0.3	0.0	0.3	0.2	0.2	119.7	9.9	0.0	0.1	0.8	0.0	0.1	0.4	0.3	166.4	0.1	0.1	0.1	0.1	0.2	0.9	0.2	0.4	13.5	1.4	0.0	0.8	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	163.6	0.2	0.1	0.3	0.0	3.2	0.9	0.8	2.6	2.0	1.3	0.8	0.9	0.7	1.2	1.6	0.3	0.7	1.4	77.2	54.5	402.5	0.0	0.8	9.4	5.8	8.6	1.8	1.8	21.6	8.3	9.1	0.0	152.8	0.0	2.1	0.4	1.1	0.4	0.0	14.6	23.8	14.6	20.5	14.7	0.0	0.0	0.5	9.6	10.6	39.8	1.1	51.2	16.4	0.0	15.4	0.7	2.8	0.0	0.8	0.2	16.2	7.2	7.4	10.9	114.9	12.2	5.4	6.5	19.0	2.7	0.0	1.0	0.1	18.6	0.0	9.1	0.2	49.3	0.1	0.1	72.8	0.3	460.2	9.6	255.3	0.9	0.3	1.5	18.8	10.9	3.1	57.7	0.2	16.6
STRIT1	DWORF	ENSG00000240045	"Small transmembrane regulator of ion transport 1"	P0DN84	3	155290227-155293683	"Predicted membrane proteins, Transporters"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	85	"skeletal muscle: 1725.4;tongue: 704.6"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in some"		"head and neck cancer: 1.1;prostate cancer: 1.3"	"Low region specificity"	"Detected in all"			"Immune cell enriched"	"Detected in single"	7	"basophil: 1.0"	"Lineage enriched"	"Detected in single"	10	"granulocytes: 1.0"	"Not detected"	"Not detected"																	NA	NA									"unprognostic (6.77e-4)"		"unprognostic (1.60e-2)"					"unprognostic (6.62e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.82e-3)"	"unprognostic (1.33e-2)"				0.4	0.1	3.3	0.2	12.2	0.2	0.5	3.8	3.5	0.0	2.7	0.2	6.3	0.2	0.5	14.2	0.1	0.5	5.6	3.1	2.3	5.9	0.3	0.2	0.3	3.2	4.4	3.2	0.1	0.3	0.1	0.1	0.1	3.5	12.2	0.2	0.3	8.8	0.1	1725.4	1.3	3.6	0.0	2.5	0.2	0.2	0.2	4.7	0.0	0.4	704.6	0.1	0.0	0.1	4.7	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.4	0.1	0.5	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.2	0.3	0.0	0.0	0.4	0.2	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.0	0.2	0.2	0.2	0.2	0.4	0.2	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.3	12.2	3.8	3.5	3.1	2.3	3.2	4.4	3.2	3.5	2.5	4.7	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STX19	MGC21382	ENSG00000178750	"Syntaxin 19"	Q8N4C7	3	94014365-94028597	"Predicted intracellular proteins, Transporters"	Transport			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"epididymis: 16.5;intestine: 13.5"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 39.4;Glandular and luminal cells: 19.7;Intestinal goblet cells: 31.7;Paneth cells: 38.0;Proximal enterocytes: 19.2"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.7"	"Low region specificity"	"Detected in single"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 6.0;HaCaT: 1.3;hTCEpi: 4.0"	"Not detected"	"Not detected"							HPA030604	Uncertain		Approved	"Intermediate filaments,Cytosol"		NA	NA			"Intermediate filaments"	Cytosol	"HPA030604: AB_10601268"	"unprognostic (7.35e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.17e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.21e-1)"	"unprognostic (9.42e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.29e-2)"	"unprognostic (4.32e-2)"	"unprognostic (7.00e-3)"	"unprognostic (1.19e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.12e-1)"	"unprognostic (4.87e-3)"	0.1	0.0	0.5	1.7	0.4	0.0	5.4	0.4	0.6	2.8	3.0	13.1	7.7	0.8	16.5	6.1	1.4	1.8	0.1	0.3	1.0	0.2	0.1	4.0	0.0	0.5	0.5	0.2	0.1	6.8	4.6	0.1	0.1	0.2	3.9	13.5	1.2	8.9	0.1	0.1	9.2	8.2	0.3	0.3	0.4	7.4	0.2	0.1	0.2	0.1	0.0	1.3	0.2	2.9	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.1	1.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	4.0	0.0	0.4	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.6	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.4	0.6	0.3	1.0	0.5	0.5	0.2	0.2	0.3	0.1	0.4	0.4	16.0	15.9	1.0	0.2	1.7	2.2	6.4	2.8	3.0	5.6	3.7	0.1	0.0	9.9	0.0	12.5	0.2	0.1	39.4	1.9	4.4	1.9	15.9	2.1	0.2	0.0	0.0	3.9	8.2	0.0	0.1	10.2	19.7	0.0	0.1	0.0	0.0	0.2	0.0	2.4	31.7	10.2	0.0	0.0	0.6	0.0	0.1	0.0	1.0	0.0	0.5	0.0	1.0	1.6	7.1	38.0	0.7	0.0	1.5	19.2	0.1	16.1	14.8	0.0	1.0	0.5	0.2	0.1	2.7	1.8	0.3	0.3	0.0	15.7	1.6
SYNM	"DMN, KIAA0353, SYN"	ENSG00000182253	Synemin	O15061	15	99098217-99135593	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 414.2;skeletal muscle: 630.6;urinary bladder: 409.7"	"Cell type enhanced"	"Detected in many"		"Breast myoepithelial cells: 103.5;Cardiomyocytes: 502.5;Muller glia cells: 127.8;Smooth muscle cells: 98.5"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 28.8"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"A549: 36.8;HeLa: 58.0;WM-115: 124.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017192, HPA040066, HPA044200, HPA077856"	Enhanced		Supported	"Intermediate filaments"		NA	NA			"Intermediate filaments"		"CAB017192: , HPA040066: AB_2676830, HPA044200: AB_2678854, HPA077856: AB_2686861"	"unprognostic (1.04e-2)"	"unprognostic (1.37e-1)"	"unprognostic (3.00e-2)"	"unprognostic (6.10e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.52e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.34e-2)"	"unprognostic (6.75e-2)"	"unprognostic (3.54e-3)"	"unprognostic (2.80e-2)"	"unprognostic (7.27e-2)"	"unprognostic (5.92e-3)"	"unprognostic (3.26e-3)"	37.6	20.5	61.9	26.8	67.4	0.4	57.3	78.6	58.7	11.3	57.2	414.2	27.3	51.2	12.8	171.2	36.8	19.4	138.6	49.8	102.4	4.4	4.9	23.3	4.3	88.2	70.6	46.8	14.2	6.4	8.3	23.3	14.1	83.3	151.9	52.5	40.7	25.8	294.1	630.6	15.7	106.6	162.5	82.4	2.9	159.7	5.2	78.5	3.8	11.3	279.6	4.1	409.7	41.3	91.5	6.6	36.8	8.1	21.9	15.9	0.9	0.5	3.7	5.3	2.1	1.3	5.4	4.9	0.0	5.3	5.3	17.7	4.2	5.5	0.1	1.6	0.5	9.0	0.1	58.0	5.4	9.0	0.0	1.0	0.9	0.3	3.7	0.8	6.0	4.3	0.0	0.2	7.4	5.5	3.7	0.7	0.8	7.2	0.7	11.4	0.0	7.5	5.5	2.1	3.6	3.6	4.2	21.9	3.4	13.5	12.7	0.2	3.6	4.8	4.1	0.4	2.9	8.9	0.1	1.0	0.0	0.4	0.0	124.5	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	61.9	67.4	78.6	58.7	49.8	102.4	88.2	70.6	46.8	83.3	82.4	78.5	91.5	14.8	0.0	1.7	15.3	0.9	2.3	0.7	0.9	2.8	12.6	32.7	103.5	502.5	0.0	1.2	0.0	16.7	1.5	6.6	2.1	0.0	0.5	9.5	1.3	1.0	24.2	3.0	0.0	15.6	1.3	0.7	20.3	5.1	4.2	0.0	1.1	3.6	1.3	0.3	42.1	9.8	0.9	0.0	0.0	5.1	4.5	1.2	2.0	5.4	12.2	0.6	127.8	1.0	2.5	14.0	0.2	2.3	4.1	5.4	2.0	0.6	0.3	3.1	10.2	32.9	19.6	98.5	7.9	11.5	2.1	3.7	0.4	5.9	0.2	0.7	0.9
SYT7	"IPCA-7, MGC150517, PCANAP7, SYT-VII"	ENSG00000011347	"Synaptotagmin 7"	O43581	11	61513714-61581148	"Predicted intracellular proteins, Predicted membrane proteins"	Exocytosis	Calmodulin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 80.3;liver: 87.4;salivary gland: 57.5"	"Cell type enhanced"	"Detected in many"		"Cytotrophoblasts: 45.2;Enteroendocrine cells: 49.8;Excitatory neurons: 82.1;Hepatocytes: 70.7;Prostatic glandular cells: 36.8;Syncytiotrophoblasts: 66.4"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 54.4"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 35.0;hTERT-HME1: 89.5;RT4: 37.8;SCLC-21H: 28.4;SK-BR-3: 40.7;T-47d: 39.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012869	Enhanced					NA	NA					"HPA012869: AB_1857698"	"unprognostic (7.09e-2)"	"unprognostic (8.26e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.10e-2)"	"unprognostic (5.42e-2)"	"prognostic unfavorable (1.20e-4)"	"unprognostic (4.37e-2)"	"unprognostic (5.08e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.79e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.54e-2)"	"prognostic unfavorable (1.16e-4)"	"unprognostic (2.08e-1)"	"unprognostic (1.69e-1)"	"unprognostic (2.23e-3)"	"unprognostic (2.47e-1)"	3.0	4.4	10.6	1.3	33.1	0.1	9.3	0.0	80.3	3.1	0.0	5.1	2.3	2.6	1.8	3.6	3.5	1.2	16.7	26.5	13.9	5.6	87.4	2.0	0.3	8.5	3.8	44.3	1.4	16.9	5.7	52.0	18.6	9.9	51.3	5.4	8.1	57.5	0.9	3.6	3.9	5.3	1.8	0.0	2.1	3.7	4.1	12.1	0.4	8.1	1.9	0.3	1.9	3.4	39.6	13.4	1.9	0.5	0.2	1.0	14.1	10.4	0.2	35.0	0.6	0.5	3.5	6.9	0.0	0.6	0.2	1.3	6.9	0.9	0.2	0.2	0.2	1.7	0.0	1.7	2.1	0.9	0.1	0.1	0.4	7.8	4.2	89.5	0.2	0.2	0.8	0.1	0.2	0.5	21.6	0.1	0.3	2.4	24.8	14.1	0.0	0.7	1.7	0.0	37.8	28.4	5.2	1.9	40.7	0.3	5.6	39.8	0.0	0.0	8.6	3.1	10.1	0.2	0.0	0.0	0.1	0.9	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	33.1	0.0	80.3	26.5	13.9	8.5	3.8	44.3	9.9	0.0	12.1	39.6	10.6	0.0	0.5	4.2	0.2	0.3	0.4	5.1	0.0	22.6	23.2	16.3	22.3	1.5	5.0	5.5	0.0	45.2	0.6	1.9	5.9	1.2	8.4	0.3	4.3	4.9	49.8	2.7	82.1	1.6	3.4	3.0	0.0	0.5	0.0	5.9	4.6	70.7	4.0	21.9	17.8	30.2	6.1	1.0	0.0	7.6	3.4	0.1	1.8	7.5	0.0	0.6	0.0	6.0	2.5	1.0	4.6	2.2	0.0	36.8	3.5	0.1	1.3	3.5	0.0	2.8	1.4	0.8	3.9	0.9	0.1	66.4	0.2	0.6	2.4	1.7
TAGLN	"DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10"	ENSG00000149591	Transgelin	Q01995	11	117199370-117207464	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"endometrium 1: 9709.3;intestine: 8197.3"	"Group enriched"	"Detected in many"	4	"Breast myoepithelial cells: 2508.6;Peritubular cells: 2306.4;Sertoli cells: 2866.2;Smooth muscle cells: 4563.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 279.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	10	"intermediate monocyte: 41.6;non-classical monocyte: 63.1"	"Lineage enriched"	"Detected in many"	12	"monocytes: 63.1"	"Cell line enhanced"	"Detected in all"		"BJ: 1913.4;BJ hTERT+ SV40 Large T+: 1641.8;CACO-2: 1531.4;EFO-21: 2145.6;fHDF/TERT166: 2094.4;hTERT-RPE1: 1499.7;LHCN-M2: 1377.1;U-138 MG: 1598.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001447, HPA019467"	Enhanced		Approved	Microtubules,Mitochondria,Cytosol		No	No		6300000	"Microtubules, Mitochondria"	Cytosol	"CAB001447: AB_564012, HPA019467: AB_1857245"	"unprognostic (1.36e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.57e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.58e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.39e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.76e-1)"	"prognostic unfavorable (2.12e-7)"	"unprognostic (9.58e-3)"	"unprognostic (3.03e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.52e-3)"	1957.4	516.9	119.4	972.5	130.7	12.3	1695.0	123.4	200.7	3360.7	255.4	8197.3	455.2	9709.3	700.0	1972.9	4651.1	901.8	1034.7	116.3	122.9	774.0	305.3	1269.7	247.5	147.7	128.4	114.0	1657.2	220.4	65.8	256.6	350.9	130.8	4663.2	1165.3	23.1	465.6	6444.1	359.3	513.8	1965.1	7170.7	125.9	536.3	3175.0	204.1	129.0	52.6	729.2	153.8	60.4	5568.4	2351.1	127.0	17.5	5.5	293.3	8.2	140.0	123.8	226.7	1913.4	788.1	1641.8	609.0	1531.4	28.4	3.2	2145.6	2094.4	1.7	46.1	4.4	16.8	543.3	6.8	4.4	5.0	66.9	130.2	708.7	1.7	5.2	304.6	57.5	267.1	36.1	1499.7	3.3	4.5	3.3	6.7	1377.1	4.5	1.7	15.8	84.6	18.8	2.1	2.7	23.1	12.0	4.4	25.8	1.9	9.6	29.9	11.0	1.5	807.6	9.2	5.1	182.0	1598.8	276.9	14.4	86.6	8.9	8.8	21.7	9.1	7.7	6.2	1.8	2.7	0.1	0.3	41.6	0.5	3.6	0.1	0.0	3.2	5.1	0.2	0.1	0.3	0.0	63.1	1.6	0.5	2.1	119.4	130.7	123.4	200.7	116.3	122.9	147.7	128.4	114.0	130.8	125.9	129.0	127.0	264.8	38.5	6.1	4.6	10.3	63.9	453.4	248.6	10.8	9.9	74.0	2508.6	1.3	4.3	22.5	40.5	18.8	57.0	8.6	3.1	0.0	577.8	3.3	14.6	455.5	260.3	3.0	2.7	4.5	74.5	35.3	464.4	41.3	12.8	1.3	32.4	639.7	8.9	41.5	1.7	6.5	18.3	24.4	23.1	91.8	23.9	48.4	33.8	96.0	37.5	8.1	4.9	2.1	3.0	11.9	38.4	4.5	2306.4	3.2	414.0	12.1	2.2	23.0	9.9	2866.2	177.6	4563.9	6.0	13.7	8.6	60.9	32.2	15.1	8.3	3.1	62.0
TBX3	"TBX3-ISO, UMS, XHL"	ENSG00000135111	"T-box transcription factor 3"	O15119	12	114670255-114684175	"Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 179.9"	"Cell type enriched"	"Detected in many"	4	"Syncytiotrophoblasts: 613.9"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 49.7"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 103.0;BJ hTERT+: 97.3;RT4: 129.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA005799, HPA075876"			Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA005799: AB_1857817, HPA075876: "	"unprognostic (3.27e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.84e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.40e-2)"	"unprognostic (5.97e-3)"	"unprognostic (1.56e-1)"	"unprognostic (2.99e-2)"	"unprognostic (9.43e-2)"	"unprognostic (1.15e-1)"	"unprognostic (3.35e-1)"	"unprognostic (3.06e-1)"	"unprognostic (3.64e-3)"	"unprognostic (1.09e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.01e-1)"	"prognostic favorable (3.28e-4)"	13.0	179.9	6.0	2.5	4.3	0.0	34.4	3.8	5.8	35.8	3.3	7.3	37.9	33.1	45.0	2.9	24.2	4.6	10.3	3.8	18.8	9.5	31.5	33.1	1.4	4.5	4.4	2.7	44.6	2.9	1.0	13.0	41.6	5.1	81.1	3.8	1.9	19.1	53.7	10.5	14.7	30.5	10.1	3.6	7.1	6.1	1.3	6.0	1.3	50.5	16.7	1.8	54.4	34.5	4.5	2.4	18.2	0.0	0.0	26.1	35.6	40.1	103.0	97.3	39.0	38.3	16.3	4.4	0.0	1.6	18.0	2.4	4.7	8.4	3.6	47.7	0.0	12.3	0.0	4.8	48.1	8.4	0.0	0.0	16.0	2.4	13.1	26.8	0.0	0.5	0.0	3.8	0.0	3.4	1.6	0.0	0.5	0.2	53.0	5.4	0.0	0.0	2.6	0.0	129.3	6.6	19.4	14.6	6.6	3.6	44.6	5.1	0.2	0.0	11.9	7.7	6.8	33.9	0.0	0.0	0.0	24.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	4.3	3.8	5.8	3.8	18.8	4.5	4.4	2.7	5.1	3.6	6.0	4.5	48.9	0.0	1.9	0.3	1.8	9.8	85.2	5.8	7.4	14.3	110.3	80.5	12.5	0.0	1.1	35.0	4.2	60.7	0.7	12.0	0.0	0.6	1.5	3.3	144.7	38.6	4.9	0.0	0.0	0.0	7.0	41.3	5.1	3.8	0.0	3.9	1.1	40.2	6.1	1.7	0.0	23.9	4.1	0.9	4.6	2.8	5.3	2.9	3.6	14.0	0.0	1.9	0.0	0.0	0.0	0.3	22.4	6.0	0.0	72.4	37.9	0.1	0.4	2.0	39.5	27.2	58.2	0.1	3.8	3.2	9.8	613.9	2.0	112.0	12.1	69.1
TDRD6	"bA446F17.4, CT41.2, NY-CO-45, SPATA36"	ENSG00000180113	"Tudor domain containing 6"	O60522	6	46687875-46704319	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Spermatogenesis"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"testis: 30.6"	"Group enriched"	"Detected in many"	4	"Early spermatids: 224.8;Spermatocytes: 82.7"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 2.1"	"Low region specificity"	"Detected in all"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HeLa: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA075923, HPA077353"	Enhanced		Approved	"Vesicles,Microtubules,Cytokinetic bridge,Mitotic spindle"		Yes	NA			"Microtubules, Cytokinetic bridge, Mitotic spindle"	Vesicles	"HPA075923: , HPA077353: "	"unprognostic (2.01e-1)"	"unprognostic (7.41e-3)"	"unprognostic (7.25e-3)"	"unprognostic (3.88e-2)"	"unprognostic (3.54e-1)"	"unprognostic (4.10e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.32e-2)"	"unprognostic (7.97e-2)"	"unprognostic (2.50e-1)"	"unprognostic (2.20e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.79e-1)"	"unprognostic (2.86e-1)"	"unprognostic (2.00e-1)"	"unprognostic (2.16e-2)"	"unprognostic (4.38e-3)"	0.7	1.7	3.5	3.0	5.6	0.2	0.8	8.4	5.4	1.0	2.4	0.9	0.7	0.9	3.4	0.6	0.8	2.2	1.4	4.5	4.0	1.8	2.6	0.7	4.0	4.3	4.5	4.3	1.1	1.1	0.4	3.0	1.6	5.0	2.0	0.3	9.0	1.3	0.6	2.3	3.5	0.7	0.4	3.6	2.5	0.8	30.6	4.1	0.0	5.7	0.1	0.1	1.1	0.9	5.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.0	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	5.6	8.4	5.4	4.5	4.0	4.3	4.5	4.3	5.0	3.6	4.1	5.0	0.8	9.6	0.5	3.9	0.0	0.5	0.4	0.1	1.2	11.3	0.4	0.8	3.4	0.0	3.8	7.3	6.2	0.0	0.0	0.0	1.9	0.3	224.8	1.0	2.2	1.2	4.2	0.0	13.6	0.2	0.0	1.0	0.0	0.7	0.0	0.4	0.7	3.0	0.1	5.0	14.7	0.3	0.0	0.3	0.0	33.8	4.1	0.5	3.6	6.5	0.0	1.1	0.0	14.6	17.8	0.1	0.0	4.5	0.0	0.6	0.4	0.4	0.2	7.5	13.1	3.0	0.5	82.7	34.7	0.0	1.6	0.0	0.0	1.4	0.5	0.2
TMEM121B	CECR6	ENSG00000183307	"Transmembrane protein 121B"	Q9BXQ6	22	17116297-17121367	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 9.0;prostate: 6.6"	"Cell type enhanced"	"Detected in some"		"granulocytes: 1.3;Hofbauer cells: 2.8"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 6.0"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in some"		"classical monocyte: 1.1;neutrophil: 1.6"	"Group enriched"	"Detected in many"	7	"granulocytes: 1.6;monocytes: 1.1"	"Cell line enhanced"	"Detected in some"		"AF22: 6.0;SCLC-21H: 14.2;THP-1: 11.9;U-937: 9.8"	"Low region specificity"	"Detected in all"							HPA068790	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane"		NA	NA			Vesicles	"Nucleoplasm, Plasma membrane"	"HPA068790: AB_2686036"	"unprognostic (2.30e-1)"	"unprognostic (1.05e-1)"	"unprognostic (7.11e-3)"	"unprognostic (4.49e-3)"	"unprognostic (3.36e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.12e-3)"	"unprognostic (5.32e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.01e-2)"	"unprognostic (6.88e-4)"	"unprognostic (6.08e-2)"	"unprognostic (3.10e-4)"	"unprognostic (1.02e-2)"	"unprognostic (4.37e-2)"	"unprognostic (3.49e-3)"	"unprognostic (1.71e-1)"	0.3	0.6	5.4	0.9	6.9	1.0	0.7	3.7	7.8	0.2	1.8	0.2	0.2	0.3	0.9	0.3	0.3	0.2	1.0	9.0	4.4	0.2	0.1	0.3	0.1	4.1	3.6	6.8	0.2	1.1	0.1	1.6	0.7	5.2	6.6	0.2	1.3	0.4	0.2	1.3	0.5	0.2	0.3	4.0	0.7	0.2	1.9	4.4	0.1	0.1	0.4	0.1	0.3	0.2	6.8	0.0	0.0	6.0	0.8	0.0	0.0	0.0	0.1	0.1	0.2	0.4	0.2	0.0	0.2	0.1	0.0	0.2	0.0	0.7	0.0	0.2	0.1	0.9	0.0	0.0	0.0	0.0	0.7	0.4	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.1	0.1	0.3	0.0	0.8	3.2	2.1	0.0	0.1	0.2	3.0	0.0	0.3	0.1	14.2	2.1	0.0	0.0	0.3	0.8	0.0	11.9	0.6	0.6	0.2	0.2	0.0	0.2	0.4	0.9	0.0	9.8	0.3	0.0	1.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.2	5.4	6.9	3.7	7.8	9.0	4.4	4.1	3.6	6.8	5.2	4.0	4.4	6.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.4	1.3	0.9	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0
TMEM210		ENSG00000185863	"Transmembrane protein 210"	A6NLX4	9	137170858-137172056	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"testis: 15.0"	"Group enriched"	"Detected in some"	68	"Early spermatids: 900.5;Late spermatids: 1815.1"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.2"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	33	"plasmacytoid DC: 3.2"	"Lineage enriched"	"Detected in single"	33	"dendritic cells: 3.2"	"Cell line enriched"	"Detected in some"	8	"RPMI-8226: 13.5"	"Not detected"	"Not detected"							HPA066907	Enhanced					NA	NA					"HPA066907: AB_2685747"	"unprognostic (5.17e-2)"		"unprognostic (5.04e-2)"	"unprognostic (2.87e-5)"						"unprognostic (4.18e-2)"		"unprognostic (3.63e-2)"		"unprognostic (3.14e-2)"	"unprognostic (8.00e-2)"			0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.1	0.0	1.5	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	13.5	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	1.6	1.3	0.0	0.0	0.1	0.0	0.0	0.0	8.1	0.0	0.0	0.0	900.5	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.7	1815.1	12.2	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	6.4	0.0	1.1	0.0	0.0	0.0	0.0	19.7	0.0	0.1	9.1	4.9	0.0	0.1	0.0	0.1	0.0	0.0	0.2
TRIM36	"HAPRIN, RBCC728, RNF98"	ENSG00000152503	"Tripartite motif containing 36"	Q9NQ86	5	115124762-115180546	"Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Disease variant"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"retina: 44.6;testis: 175.8"	"Group enriched"	"Detected in many"	26	"Early spermatids: 2120.7;Late spermatids: 4980.3"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 9.0"	"Low region specificity"	"Detected in all"			"Immune cell enhanced"	"Detected in many"		"myeloid DC: 5.8;non-classical monocyte: 6.5"	"Group enriched"	"Detected in many"	48	"dendritic cells: 5.8;granulocytes: 3.2;monocytes: 6.5"	"Cell line enhanced"	"Detected in many"		"RH-30: 24.5;SCLC-21H: 28.3;SH-SY5Y: 19.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA061321			Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA061321: AB_2684479"	"unprognostic (6.36e-2)"	"unprognostic (2.99e-1)"	"unprognostic (4.54e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.31e-2)"	"unprognostic (5.33e-6)"	"unprognostic (2.19e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.82e-13)"	"unprognostic (4.95e-2)"	"unprognostic (1.38e-1)"	"unprognostic (2.19e-1)"	"unprognostic (6.80e-3)"	0.5	1.3	14.7	1.6	19.2	0.5	4.5	5.7	14.1	2.4	9.6	7.5	14.2	0.9	0.6	0.3	2.2	0.5	0.2	19.2	14.4	0.3	0.4	1.8	0.3	16.5	15.5	14.3	4.7	1.6	0.2	13.5	1.1	17.5	10.1	7.6	44.6	0.5	0.6	0.2	0.6	13.9	0.8	12.0	0.5	4.6	175.8	12.3	0.7	0.2	0.4	0.4	0.4	1.3	21.6	3.6	0.9	1.6	8.4	0.2	0.1	2.0	0.7	2.8	1.5	1.7	1.2	1.7	0.0	1.4	0.1	11.9	1.1	7.9	1.5	1.1	0.6	2.7	6.0	3.3	1.7	0.3	6.0	4.8	0.1	1.4	0.7	2.0	1.9	0.1	11.2	0.2	7.9	2.3	4.6	1.6	5.4	6.7	0.6	3.8	1.3	24.5	1.9	0.9	0.1	28.3	19.6	5.3	0.5	3.2	0.8	5.8	7.4	0.7	2.3	1.8	1.7	2.7	1.2	0.8	0.0	2.5	3.4	1.1	0.0	1.2	3.2	0.0	1.3	0.0	0.0	0.0	0.0	5.8	0.1	0.0	0.0	0.3	0.0	6.5	1.2	0.0	0.6	14.7	19.2	5.7	14.1	19.2	14.4	16.5	15.5	14.3	17.5	12.0	12.3	21.6	0.4	0.0	3.4	1.0	0.1	2.3	0.6	0.2	0.6	5.0	14.8	9.3	2.3	0.0	0.5	1.8	56.3	0.0	1.8	27.6	0.0	0.4	2120.7	3.3	0.3	2.0	3.5	0.0	39.7	1.8	0.5	1.4	6.6	1.1	1.3	0.1	0.4	0.0	2.8	5.0	14.0	15.8	2.0	1.9	18.1	4980.3	14.9	6.0	8.8	29.0	3.4	6.9	0.0	2.5	53.4	1.5	20.4	12.8	0.1	12.1	28.2	0.2	5.0	76.8	6.6	2.0	2.3	136.2	26.9	1.2	1.3	0.3	0.7	0.1	8.8	0.2
TSPAN1	"NET-1, TSPAN-1"	ENSG00000117472	"Tetraspanin 1"	O60635	1	46175073-46185962	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 599.6"	"Cell type enhanced"	"Detected in many"		"Club cells: 723.5;Distal enterocytes: 1983.8;Late spermatids: 838.1;Paneth cells: 1127.7;Respiratory ciliated cells: 1817.6"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 455.6"	"Low region specificity"	"Detected in many"			"Immune cell enriched"	"Detected in single"	57	"plasmacytoid DC: 5.6"	"Lineage enriched"	"Detected in single"	57	"dendritic cells: 5.6"	"Cell line enhanced"	"Detected in many"		"A-431: 129.6;CAPAN-2: 216.7;HaCaT: 151.4;hTCEpi: 173.6;OE19: 257.9;RPTEC TERT1: 628.4;RT4: 308.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			HPA011909	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"HPA011909: AB_2668565"	"unprognostic (1.21e-1)"	"unprognostic (3.11e-1)"	"unprognostic (3.67e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.35e-1)"	"unprognostic (4.41e-2)"	"unprognostic (4.68e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.88e-3)"	"unprognostic (8.73e-2)"	"prognostic favorable (9.28e-6)"	"unprognostic (5.90e-2)"	"unprognostic (2.61e-1)"	"unprognostic (4.90e-2)"	"unprognostic (4.30e-2)"	1.5	4.3	0.6	53.7	0.8	0.0	6.3	1.8	1.1	78.9	1.3	528.2	25.6	17.9	35.0	5.6	123.5	29.2	0.8	0.6	0.7	242.5	3.9	32.4	0.5	1.3	0.8	0.6	0.4	3.1	72.5	17.5	1.1	1.1	196.4	599.6	0.0	101.8	66.5	0.8	2.4	97.5	21.0	1.2	0.7	215.0	27.5	0.8	2.0	123.1	0.1	5.0	105.9	9.9	1.9	129.6	2.0	0.0	0.0	0.2	0.0	1.8	0.1	2.7	0.1	0.0	0.0	216.7	0.0	40.2	0.3	0.2	151.4	0.0	111.2	0.1	0.0	0.0	0.0	1.1	7.6	0.0	0.0	0.2	0.0	173.6	0.7	60.9	3.6	0.3	1.3	0.0	0.0	1.6	4.9	0.0	0.5	0.1	257.9	8.1	0.1	0.1	1.6	628.4	308.2	1.9	0.0	0.3	13.0	0.5	0.5	9.0	0.1	1.4	0.0	0.7	0.4	0.7	1.5	0.1	0.1	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.6	0.8	1.8	1.1	0.6	0.7	1.3	0.8	0.6	1.1	1.2	0.8	1.9	2.5	25.6	29.5	0.3	7.4	1.0	194.4	499.9	4.0	0.0	14.5	11.0	0.7	11.5	723.5	579.4	0.0	0.3	0.2	1983.8	46.9	61.3	141.3	268.3	14.1	4.5	201.8	0.0	1.2	525.1	0.1	6.0	223.3	144.3	11.4	0.0	1.4	3.6	0.3	0.0	1.3	648.1	242.1	0.3	0.3	838.1	5.0	5.3	5.4	1.0	1.6	0.0	0.0	0.5	1.6	484.4	1127.7	1.9	0.7	211.7	505.4	477.8	1817.6	0.0	0.0	0.4	54.1	4.7	2.6	2.9	1.3	0.0	7.4	0.0	275.9	517.0
TXNDC16	KIAA1344	ENSG00000087301	"Thioredoxin domain containing 16"	Q9P2K2	14	52430596-52552522	"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"Endometrial ciliated cells: 69.8;Glandular and luminal cells: 124.9;Inhibitory neurons: 88.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 18.2"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002543	Approved		Approved	Mitochondria	"Secreted to blood"	NA	NA			Mitochondria		"HPA002543: AB_1079199"	"unprognostic (1.37e-1)"	"unprognostic (7.79e-3)"	"unprognostic (5.95e-3)"	"unprognostic (2.36e-1)"	"unprognostic (5.95e-3)"	"unprognostic (9.73e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.43e-2)"	"unprognostic (7.01e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.07e-2)"	"unprognostic (1.21e-1)"	"prognostic favorable (6.79e-4)"	"unprognostic (1.39e-1)"	"unprognostic (1.56e-1)"	"unprognostic (3.55e-3)"	"unprognostic (2.04e-1)"	6.2	4.0	4.5	3.5	5.1	5.1	7.0	10.7	6.0	9.3	1.4	5.9	4.1	7.0	14.8	3.7	4.1	5.3	3.8	5.0	5.0	5.0	7.4	4.5	4.5	4.3	5.5	4.5	10.3	6.5	7.1	3.9	5.9	5.7	27.0	6.0	9.2	4.0	13.1	2.0	4.7	4.8	4.3	4.8	10.3	6.3	7.1	4.5	5.9	4.0	4.0	3.9	3.4	3.9	6.9	8.3	0.8	8.9	5.0	6.5	4.7	7.0	2.7	3.6	4.5	8.7	3.0	6.6	13.5	8.9	2.2	2.8	7.7	10.3	3.7	6.9	5.7	13.5	6.2	6.2	2.8	4.7	7.4	2.9	8.8	3.4	5.8	4.2	4.0	5.1	5.8	8.0	20.4	3.9	4.0	9.3	5.1	9.9	5.5	4.9	18.4	16.9	12.4	5.7	8.4	29.0	10.0	13.2	13.5	3.9	7.5	8.6	5.4	2.7	6.0	3.0	6.9	4.6	5.6	8.0	13.5	1.7	7.7	3.5	1.3	3.0	1.2	1.3	2.4	1.3	0.5	1.3	0.9	2.6	0.3	0.6	0.6	1.7	0.6	2.9	1.0	2.4	1.0	4.5	5.1	10.7	6.0	5.0	5.0	4.3	5.5	4.5	5.7	4.8	4.5	6.9	9.1	9.6	6.4	23.2	6.1	6.6	6.0	2.5	9.6	42.3	26.6	19.0	10.1	8.6	5.0	7.3	8.4	2.3	15.1	8.8	1.9	5.2	4.0	69.8	9.6	7.4	18.5	21.8	61.0	3.9	1.6	7.2	13.3	124.9	2.5	13.9	15.4	14.1	3.3	10.1	88.8	17.9	0.0	18.8	8.6	4.2	27.7	13.0	1.8	24.4	5.9	7.3	7.2	45.8	51.5	1.3	8.5	52.3	11.3	19.0	5.9	2.8	4.4	44.8	0.0	11.1	11.2	12.0	9.5	8.1	8.4	1.1	7.7	5.7	10.9	4.5
UNC5D	"KIAA1777, Unc5h4"	ENSG00000156687	"Unc-5 netrin receptor D"	Q6UXZ4	8	35235475-35796550	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis	"Developmental protein, Receptor"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 13.7;intestine: 6.0"	"Group enriched"	"Detected in some"	5	"Excitatory neurons: 638.7;Inhibitory neurons: 768.3"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.4;renal cancer: 1.0"	"Region enhanced"	"Detected in many"		"hypothalamus: 13.7"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 2.5;HeLa: 2.9;NTERA-2: 8.6;SH-SY5Y: 2.9;SuSa: 2.8;U-251 MG: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042940	Uncertain					NA	NA					"HPA042940: AB_10959525"	"unprognostic (7.88e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.41e-2)"	"unprognostic (2.29e-1)"	"unprognostic (7.60e-2)"	"unprognostic (1.87e-1)"		"unprognostic (8.47e-2)"	"unprognostic (3.82e-2)"	"unprognostic (2.04e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.99e-1)"	"unprognostic (4.48e-8)"	"unprognostic (1.34e-1)"	"unprognostic (9.15e-2)"	"unprognostic (4.28e-1)"		0.0	1.7	1.8	0.0	3.0	0.0	0.0	0.0	3.7	2.3	0.0	0.3	6.0	1.7	0.0	0.0	0.1	0.0	0.0	2.4	13.7	2.1	0.0	0.0	0.0	1.4	3.1	3.1	0.0	0.1	0.1	3.3	0.0	0.3	4.9	0.6	5.0	0.0	0.2	0.0	0.0	1.9	0.9	0.0	0.0	0.1	0.7	4.9	0.4	0.8	0.0	0.0	0.0	0.0	0.3	0.0	1.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.5	0.2	2.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	3.0	0.0	3.7	2.4	13.7	1.4	3.1	3.1	0.3	0.0	4.9	0.3	0.0	0.0	0.0	129.6	0.0	0.0	0.0	0.0	0.0	13.8	0.0	0.0	0.7	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	30.7	0.0	0.1	0.1	0.0	0.0	638.7	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	40.4	768.3	0.7	0.0	0.0	0.0	4.4	0.0	0.0	0.0	42.2	0.0	1.8	0.0	43.2	10.2	0.0	0.0	0.0	0.0	1.8	2.0	0.6	0.0	2.6	0.0	0.0	0.7	0.7	1.2	0.1	0.1	0.0	0.0	0.0	2.6	0.0
UNC80	"C2orf21, FLJ33496, KIAA1843, UNC-80"	ENSG00000144406	"Unc-80 homolog, NALCN channel complex subunit"	Q8N2C7	2	209771832-209999300	"Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters"			"Disease variant, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 21.6;pituitary gland: 13.7;retina: 19.1"	"Cell type enhanced"	"Detected in some"		"Bipolar cells: 117.7;Excitatory neurons: 432.0;Inhibitory neurons: 354.7;Oligodendrocyte precursor cells: 290.5"	"Cancer enhanced"	"Detected in some"		"glioma: 0.8;prostate cancer: 0.7"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"AF22: 2.5;SCLC-21H: 4.0;SH-SY5Y: 2.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042472, HPA050959"	Enhanced		Approved	"Nuclear bodies,Vesicles"		NA	NA			"Nuclear bodies"	Vesicles	"HPA042472: AB_10965318, HPA050959: "	"unprognostic (7.91e-3)"	"unprognostic (2.25e-4)"	"unprognostic (1.44e-2)"	"unprognostic (3.20e-4)"	"unprognostic (1.92e-1)"	"unprognostic (3.40e-2)"	"unprognostic (3.31e-3)"	"unprognostic (5.36e-2)"	"unprognostic (5.16e-1)"	"unprognostic (7.85e-2)"	"unprognostic (5.24e-3)"	"unprognostic (8.94e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.51e-2)"	"unprognostic (6.50e-2)"	"unprognostic (1.95e-1)"	"unprognostic (7.40e-3)"	0.0	3.9	3.8	0.0	10.3	0.0	0.0	15.9	21.6	0.0	0.0	0.1	0.0	0.1	0.4	0.0	0.4	1.2	0.0	6.5	7.4	0.1	0.0	0.1	0.0	7.2	3.6	7.6	0.5	1.0	0.2	13.7	0.0	6.8	0.9	0.1	19.1	0.1	0.2	0.0	0.1	0.1	0.2	0.9	0.2	0.4	3.5	4.3	0.1	0.3	0.0	0.0	0.2	0.0	12.2	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.5	0.0	0.0	0.0	4.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	10.3	15.9	21.6	6.5	7.4	7.2	3.6	7.6	6.8	0.9	4.3	12.2	0.2	0.0	1.1	49.0	0.0	0.8	0.3	1.9	0.0	117.7	0.2	0.1	2.1	0.0	0.7	0.0	66.7	0.0	0.0	0.0	0.0	0.0	31.9	1.1	1.7	0.5	0.0	0.0	432.0	0.0	0.0	1.1	0.0	0.1	1.3	0.6	0.0	0.0	0.1	52.2	354.7	0.0	0.0	0.0	0.0	10.5	0.9	0.3	0.0	10.3	0.0	26.6	0.0	290.5	12.8	0.1	0.0	1.9	0.0	1.2	0.0	0.2	0.8	75.6	0.0	0.2	0.1	7.5	3.8	0.0	0.1	0.0	0.0	15.1	0.0	0.3
USP9Y	"AZFA, DFFRY"	ENSG00000114374	"Ubiquitin specific peptidase 9 Y-linked"	O00507	Y	12537650-12860839	"Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Hydrolase, Protease, Thiol protease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"Cone photoreceptor cells: 64.6;Excitatory neurons: 89.5;Inhibitory neurons: 69.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.7"	"Region enhanced"	"Detected in many"		"white matter: 18.0"	"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"RPTEC TERT1: 21.5;RT4: 17.4"	"Not detected"	"Not detected"							HPA057687			Uncertain	Vesicles		NA	NA			Vesicles		"HPA057687: "			"unprognostic (2.63e-1)"		"unprognostic (8.97e-2)"	"unprognostic (1.10e-5)"	"unprognostic (8.46e-3)"	"unprognostic (4.93e-2)"	"unprognostic (2.53e-2)"	"unprognostic (2.77e-1)"	"unprognostic (3.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.05e-2)"	"unprognostic (1.41e-4)"	"unprognostic (2.28e-1)"	"unprognostic (1.19e-2)"	"unprognostic (1.42e-1)"	3.6	5.2	2.7	1.7	1.8	2.6	3.4	0.5	11.6	0.0	0.0	4.0	1.8	0.0	7.2	5.2	0.0	4.6	5.4	4.9	0.0	5.6	3.1	5.3	2.2	2.9	0.0	0.0	0.0	6.1	3.5	8.9	2.3	5.1	9.8	4.9	13.0	4.9	7.1	5.2	3.0	4.5	0.0	0.0	5.1	3.9	4.2	6.6	0.0	5.8	9.8	5.7	4.6	0.0	18.0	0.0	4.7	0.0	0.0	0.0	0.0	5.3	14.2	14.6	7.2	8.5	0.0	0.0	7.7	0.0	12.2	0.0	0.0	0.0	0.0	8.6	8.1	0.0	7.3	0.0	9.5	5.8	0.0	0.0	9.7	8.9	0.0	0.0	0.0	0.0	3.0	0.0	0.0	12.2	0.0	9.8	0.0	4.6	0.0	0.0	0.0	3.5	2.1	21.5	17.4	7.2	0.0	0.0	0.0	4.4	12.5	0.0	0.2	10.6	9.5	0.0	0.0	7.0	0.0	9.7	15.1	0.5	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.9	0.4	0.7	0.5	0.1	0.7	0.8	0.5	0.0	0.1	0.0	0.6	0.6	0.0	2.7	1.8	0.5	11.6	4.9	0.0	2.9	0.0	0.0	5.1	0.0	6.6	18.0	0.0	25.6	23.5	29.4	11.0	11.7	8.5	9.5	18.2	23.6	0.0	0.0	26.5	7.2	12.6	20.2	64.6	6.3	5.3	0.3	1.9	6.9	0.5	0.0	0.0	5.8	0.0	5.9	89.5	0.0	1.7	8.1	6.6	0.0	2.5	0.0	6.1	2.3	3.1	26.9	69.5	1.1	8.2	5.6	9.3	1.1	12.5	3.6	3.6	31.9	3.6	8.8	14.4	28.6	17.4	2.3	0.0	15.4	4.1	13.2	0.7	6.3	19.9	23.1	0.0	5.2	4.4	2.8	2.6	20.6	11.6	3.4	14.7	0.0	1.5	11.9
VGLL3	VGL-3	ENSG00000206538	"Vestigial like family member 3"	A8MV65	3	86876388-86991149	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 40.5"	"Cell type enhanced"	"Detected in many"		"Early spermatids: 138.1;Extravillous trophoblasts: 178.1;Late spermatids: 71.8;Leydig cells: 132.3;Peritubular cells: 149.3;Skeletal myocytes: 65.9;Syncytiotrophoblasts: 80.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 7.9;urothelial cancer: 6.1"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	5	"U-2197: 518.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA054983	Approved		Approved	Nucleoli,Cytosol		NA	NA			"Nucleoli, Cytosol"		"HPA054983: AB_2682663"	"unprognostic (9.08e-2)"	"unprognostic (4.47e-3)"	"unprognostic (5.97e-2)"	"unprognostic (1.54e-1)"	"unprognostic (2.98e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.77e-2)"	"unprognostic (3.86e-2)"	"unprognostic (1.38e-2)"	"unprognostic (4.94e-2)"	"unprognostic (3.70e-2)"	"unprognostic (3.44e-2)"	"unprognostic (2.73e-8)"	"unprognostic (3.85e-3)"	"unprognostic (1.27e-1)"	"unprognostic (5.42e-3)"	"unprognostic (1.05e-1)"	21.2	1.5	5.8	3.3	1.6	0.4	7.5	0.5	1.6	5.5	7.1	5.3	1.1	8.1	1.4	3.0	5.5	9.6	3.5	2.0	5.3	1.5	0.6	16.1	2.3	0.9	2.1	0.3	14.4	4.0	1.2	0.3	40.5	1.0	11.1	2.3	1.1	1.6	4.2	1.7	3.6	2.2	9.1	0.7	2.0	2.6	3.5	3.1	0.5	3.1	1.5	0.8	9.4	4.1	0.7	8.1	13.1	69.5	0.2	90.5	112.2	1.1	48.6	34.0	40.8	50.8	15.2	3.1	0.0	0.1	76.9	4.6	6.9	4.8	4.6	55.9	28.4	0.1	3.6	4.8	0.3	41.3	0.5	0.2	86.6	7.6	60.1	26.9	21.8	6.1	0.1	0.0	0.1	51.5	0.1	0.5	0.4	1.4	0.1	0.3	0.1	91.7	0.4	0.0	8.3	0.2	0.1	20.8	0.7	0.1	2.4	0.2	0.3	2.8	90.3	13.4	518.3	1.6	0.2	0.2	0.0	16.8	0.0	3.8	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	5.8	1.6	0.5	1.6	2.0	5.3	0.9	2.1	0.3	1.0	0.7	3.1	0.7	2.5	3.2	2.2	0.0	0.0	8.0	11.1	2.1	4.0	0.0	0.9	4.6	1.2	1.5	3.3	11.0	0.0	35.6	0.1	0.0	0.0	13.4	138.1	1.3	31.0	1.7	0.0	0.0	0.4	2.6	178.1	33.4	1.1	1.2	0.0	0.1	2.5	0.0	7.5	0.0	2.0	0.0	2.0	0.0	10.3	71.8	132.3	0.7	3.6	6.5	0.0	17.1	0.0	0.0	1.4	13.2	0.0	149.3	0.0	17.7	0.0	0.1	3.2	0.3	13.1	65.9	21.8	1.1	1.4	1.8	5.3	80.7	0.5	23.1	0.0	4.5
VIPR1	"HVR1, RDC1, VPAC1, VPAC1R"	ENSG00000114812	"Vasoactive intestinal peptide receptor 1"	P32241	3	42489299-42537573	"G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 133.2"	"Cell type enhanced"	"Detected in many"		"Distal enterocytes: 71.8;Intestinal goblet cells: 48.6;Paneth cells: 96.2;Proximal enterocytes: 58.6"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.7"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in many"			"Group enriched"	"Detected in many"	22	"dendritic cells: 2.1;monocytes: 1.8;T-cells: 2.7"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 60.8;OE19: 36.2;RT4: 44.0;SK-BR-3: 24.7;WM-115: 79.0"	"Group enriched"	"Detected in many"	4	"amygdala: 6.3;basal ganglia: 4.5;cerebral cortex: 9.6;hippocampal formation: 7.7;white matter: 2.5"	"Low region specificity"	"Detected in all"			HPA026777	Approved					NA	NA					"HPA026777: AB_10604003"	"unprognostic (9.02e-2)"	"unprognostic (9.34e-3)"	"unprognostic (3.70e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.47e-2)"	"unprognostic (8.89e-4)"	"unprognostic (4.00e-3)"	"unprognostic (1.03e-1)"	"unprognostic (2.95e-2)"	"unprognostic (1.28e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.82e-3)"	"unprognostic (7.70e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.03e-2)"	"unprognostic (1.05e-2)"	14.3	2.7	8.4	3.4	12.4	2.3	17.0	13.3	15.4	2.9	5.4	28.3	34.8	1.2	6.7	5.3	1.3	6.1	5.5	12.7	6.9	2.6	32.7	133.2	4.6	5.9	5.9	12.0	0.6	2.5	4.2	1.9	2.9	9.2	25.3	28.0	4.3	22.9	9.0	1.2	28.6	30.2	1.3	4.4	5.7	6.2	1.4	5.0	1.9	15.2	4.9	2.4	8.8	5.0	11.9	0.1	2.4	0.1	0.0	0.0	0.0	2.1	0.0	0.0	0.1	0.4	2.2	60.8	0.2	3.1	0.0	0.0	2.4	0.0	1.6	0.1	0.0	5.2	3.8	1.8	0.0	0.3	0.0	0.5	0.0	3.8	0.2	1.2	0.0	0.7	0.6	0.0	0.0	0.0	5.2	0.0	0.3	3.8	36.2	0.2	0.5	0.0	2.8	0.0	44.0	1.3	0.0	0.0	24.7	0.0	7.1	15.2	0.5	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	79.0	0.0	1.8	0.0	0.2	1.5	1.0	0.0	2.4	1.0	2.1	0.0	2.7	0.8	0.0	0.0	1.3	0.0	0.4	0.9	8.4	12.4	13.3	15.4	12.7	6.9	5.9	5.9	12.0	9.2	4.4	5.0	11.9	16.0	3.2	6.0	3.3	1.3	7.6	4.5	2.2	22.2	0.2	19.2	21.5	2.6	5.7	2.1	1.8	8.4	0.1	0.4	71.8	0.0	0.3	3.0	0.2	0.1	2.8	4.8	0.0	26.9	0.9	1.0	1.0	16.3	0.6	0.0	0.3	19.6	0.4	0.7	0.0	1.5	48.6	0.0	8.7	4.0	0.6	0.0	5.9	0.0	3.7	8.9	1.4	0.0	3.0	1.7	1.2	96.2	0.0	1.5	6.3	58.6	0.1	1.0	5.4	32.9	0.2	20.8	0.1	0.1	4.1	7.7	0.3	2.9	0.1	24.0	3.9
ZBTB16	"PLZF, ZNF145"	ENSG00000109906	"Zinc finger and BTB domain containing 16"	Q05516	11	114059711-114256765	"Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor"	"Cancer-related genes, Disease variant, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"tongue: 106.8"	"Cell type enhanced"	"Detected in many"		"Excitatory neurons: 134.8;Inhibitory neurons: 125.9;NK-cells: 119.4;Skeletal myocytes: 163.9"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.2"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 23.3;MAIT T-cell: 39.4;naive B-cell: 11.0;NK-cell: 10.9"	"Group enriched"	"Detected in many"	5	"B-cells: 11.0;NK-cells: 10.9;T-cells: 39.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 71.5;ASC TERT1: 38.6;HEL: 40.7;HHSteC: 26.6;HSkMC: 26.7;hTCEpi: 30.6;hTERT-HME1: 25.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001499, CAB004540"	Uncertain					NA	NA					"CAB004540: AB_2218941, HPA001499: AB_1079640"	"unprognostic (2.21e-1)"	"unprognostic (2.17e-1)"	"unprognostic (7.30e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.53e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.25e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.09e-1)"	"unprognostic (8.79e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"prognostic favorable (2.21e-4)"	"unprognostic (2.57e-3)"	"unprognostic (2.67e-1)"	"unprognostic (1.00e-1)"	"unprognostic (5.90e-2)"	56.3	21.0	4.7	3.4	12.6	7.7	32.6	10.9	21.2	23.0	14.9	18.4	0.9	29.9	4.1	28.3	31.1	13.2	28.4	10.6	13.9	10.7	14.7	27.3	8.9	20.5	9.9	2.6	51.9	62.2	34.6	6.4	9.7	21.2	15.3	3.4	2.2	13.5	7.1	89.4	28.1	16.5	16.0	5.6	13.3	18.5	4.0	7.8	6.6	29.5	106.8	2.0	29.7	19.9	16.0	0.0	0.0	13.0	0.0	71.5	38.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.5	40.7	0.0	0.0	26.6	0.9	0.7	26.7	30.6	0.0	25.6	0.0	4.6	5.5	0.1	0.0	0.8	0.0	2.2	9.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.0	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	4.2	1.2	23.3	1.2	39.4	0.4	1.2	3.5	0.1	11.0	1.3	0.6	0.3	10.9	1.2	0.0	0.4	5.7	4.7	12.6	10.9	21.2	10.6	13.9	20.5	9.9	2.6	21.2	5.6	7.8	16.0	95.3	22.4	7.7	59.1	16.3	11.1	81.7	7.7	8.6	32.6	12.6	16.8	35.1	42.9	7.1	9.2	0.0	0.1	51.2	0.7	1.9	1.9	21.1	1.7	41.3	49.5	7.2	18.1	134.8	0.9	0.2	59.8	1.1	3.8	14.5	38.2	65.7	50.9	0.8	0.0	125.9	3.7	8.2	27.0	5.3	27.7	89.8	32.1	7.2	65.6	7.6	20.2	119.4	45.8	43.4	0.3	0.1	92.2	17.7	38.6	28.8	6.6	6.8	1.9	105.2	163.9	75.3	0.4	9.9	1.8	6.8	0.3	27.8	0.2	3.5	9.4
ZG16B	"HRPE773, JCLN2, PRO1567"	ENSG00000162078	"Zymogen granule protein 16B"	Q96DA0	16	2830169-2839585	"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	717	"salivary gland: 64448.9"	"Cell type enhanced"	"Detected in many"		"Basal prostatic cells: 194.0;Basal respiratory cells: 181.6;Breast glandular cells: 154.9;Club cells: 343.9;Intestinal goblet cells: 232.2;Prostatic glandular cells: 398.1;Urothelial cells: 357.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 47.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"classical monocyte: 6.3;intermediate monocyte: 11.4;non-classical monocyte: 7.4"	"Lineage enriched"	"Detected in many"	7	"monocytes: 11.4"	"Cell line enhanced"	"Detected in some"		"MCF7: 27.1;OE19: 57.5;SK-BR-3: 24.1;T-47d: 22.2"	"Not detected"	"Not detected"							"HPA041125, HPA053549"	Enhanced		Approved	Nucleoplasm,Vesicles	"Secreted to digestive system"	NA	NA		690000	Vesicles	Nucleoplasm	"HPA041125: AB_10794264, HPA053549: AB_2682184"	"unprognostic (5.29e-2)"	"unprognostic (2.71e-1)"	"unprognostic (4.37e-2)"	"prognostic favorable (3.48e-6)"	"unprognostic (1.39e-3)"	"unprognostic (1.94e-2)"	"unprognostic (2.34e-3)"	"unprognostic (4.13e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.45e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.47e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.04e-1)"	"unprognostic (8.33e-2)"	2.0	13.3	0.0	3.9	0.0	4.6	33.5	0.0	0.1	33.2	0.0	13.7	11.6	0.6	1.5	25.5	4.4	34.7	9.1	0.0	0.0	2.6	8.3	3.4	0.3	0.0	0.3	0.0	10.4	47.0	30.6	6.1	4.8	0.0	89.9	18.0	0.0	64448.9	7.1	6.1	40.5	9.6	0.4	0.0	4.2	33.5	4.4	0.1	0.2	2.9	0.1	5.9	11.3	16.4	0.1	0.0	1.1	0.0	0.0	0.3	1.9	0.2	0.0	0.0	0.0	0.0	0.3	2.5	0.0	0.3	0.0	0.2	2.1	0.0	4.4	0.0	0.0	0.0	9.0	2.8	2.4	1.6	0.0	0.0	0.1	0.2	0.0	1.2	0.1	0.0	0.0	0.2	3.6	0.2	27.1	0.0	0.4	0.1	57.5	5.0	0.0	0.0	8.6	0.2	6.3	0.0	0.0	0.1	24.1	0.0	0.1	22.2	0.0	3.1	0.1	0.5	1.9	0.1	0.0	0.5	0.3	0.3	6.5	0.3	1.7	6.3	0.0	0.0	11.4	0.0	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.4	1.2	7.4	0.0	0.5	1.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.1	1.3	0.0	0.0	0.0	0.5	9.1	194.0	181.6	0.0	0.0	154.9	82.5	0.0	70.1	343.9	1.8	0.0	0.1	2.0	107.1	0.0	5.9	7.7	3.5	1.6	2.8	58.2	0.4	0.0	28.1	3.2	1.8	21.9	13.0	5.7	1.7	0.7	0.1	14.6	0.0	0.0	232.2	140.4	4.6	0.5	5.7	0.0	4.4	83.6	0.0	5.6	0.0	0.0	0.0	0.0	46.4	65.3	0.0	0.0	398.1	12.5	0.0	74.7	0.0	0.0	0.0	19.2	1.4	0.6	9.5	24.0	0.3	2.5	21.3	76.7	357.4
ZNF385B	"FLJ25270, ZNF533"	ENSG00000144331	"Zinc finger protein 385B"	Q569K4	2	179441982-179861612	"Predicted intracellular proteins"	Apoptosis			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 89.5"	"Cell type enhanced"	"Detected in many"		"Alveolar cells type 2: 124.2;Bipolar cells: 220.1;Excitatory neurons: 566.5;Inhibitory neurons: 393.1;Rod photoreceptor cells: 133.7"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 6.2"	"Low region specificity"	"Detected in many"			"Not detected in immune cells"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Daudi: 17.6;HAP1: 31.9;U-698: 91.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA046086			Approved	"Nucleoli fibrillar center"		NA	NA			"Nucleoli fibrillar center"		"HPA046086: AB_2679532"	"prognostic favorable (4.86e-8)"	"unprognostic (8.05e-3)"	"unprognostic (1.14e-1)"	"unprognostic (3.91e-2)"	"unprognostic (3.49e-1)"	"unprognostic (1.51e-2)"	"unprognostic (3.49e-3)"	"unprognostic (1.14e-1)"	"unprognostic (8.99e-3)"	"unprognostic (3.56e-2)"	"unprognostic (4.59e-2)"	"unprognostic (2.69e-1)"	"prognostic favorable (1.04e-9)"	"unprognostic (7.76e-2)"	"unprognostic (2.94e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.20e-3)"	1.6	5.3	2.7	0.3	18.9	0.4	7.0	26.4	17.2	1.6	0.0	2.3	0.3	1.5	3.8	1.1	1.1	0.7	20.5	6.9	4.1	8.6	19.3	18.5	1.6	9.5	6.2	4.0	15.4	0.3	0.0	1.0	2.2	12.4	12.7	0.7	89.5	1.2	0.5	17.2	1.3	0.8	0.4	0.0	0.5	14.3	10.4	7.9	0.5	1.2	11.0	0.6	1.5	2.2	12.5	0.0	0.0	7.3	0.3	0.1	0.3	0.1	0.0	0.0	0.4	0.8	0.0	0.0	17.6	0.1	0.0	5.9	0.0	31.9	0.0	0.4	0.0	4.3	0.2	0.7	1.2	0.0	0.0	0.0	3.6	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.1	0.3	0.1	0.1	1.3	0.0	2.0	0.0	1.3	1.3	1.8	0.0	0.7	0.2	0.0	0.0	0.0	0.7	0.5	0.0	0.0	0.3	2.3	0.3	1.5	0.0	0.0	91.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	18.9	26.4	17.2	6.9	4.1	9.5	6.2	4.0	12.4	0.0	7.9	12.5	1.0	28.9	124.2	12.1	0.0	3.4	0.7	0.0	0.0	220.1	5.1	2.2	32.4	5.7	1.3	0.0	54.2	0.0	0.0	0.3	82.2	0.0	58.4	1.0	0.1	0.5	1.8	0.0	566.5	0.0	0.0	6.4	3.1	1.7	1.3	19.6	1.4	14.3	0.3	1.7	393.1	0.0	0.0	0.0	0.3	29.2	0.6	0.5	1.8	89.0	0.0	6.4	0.0	20.1	10.7	0.1	0.0	0.4	0.1	4.9	0.0	24.5	1.5	133.7	0.0	5.2	1.6	6.2	1.8	0.1	0.9	0.1	0.3	3.3	0.1	0.9
ZNF613	FLJ13590	ENSG00000176024	"Zinc finger protein 613"	Q6PF04	19	51927147-51948759	"Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"prostate: 19.6"	"Low cell type specificity"	"Detected in many"			"Cancer enhanced"	"Detected in all"		"prostate cancer: 10.1"	"Low region specificity"	"Detected in all"			"Low immune cell specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA026833	Uncertain		Approved	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA026833: AB_1859377"	"unprognostic (1.10e-1)"	"unprognostic (2.57e-1)"	"unprognostic (9.27e-2)"	"unprognostic (2.84e-1)"	"unprognostic (9.31e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.25e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.73e-1)"	"unprognostic (5.30e-2)"	"unprognostic (5.30e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.79e-1)"	"unprognostic (4.78e-3)"	"prognostic favorable (1.92e-6)"	3.1	3.3	3.2	2.7	3.5	1.4	7.1	4.4	4.2	3.0	3.0	5.2	2.3	3.5	3.9	3.4	3.2	2.8	3.3	3.3	4.1	4.9	2.9	3.8	4.2	3.9	3.9	2.9	3.8	2.5	6.1	3.2	6.6	3.9	19.6	5.1	7.2	2.9	4.0	2.8	3.6	2.9	4.2	3.4	4.3	2.9	2.9	3.9	5.6	4.3	3.5	4.3	3.6	2.8	4.0	2.9	3.8	6.2	6.3	5.5	5.7	1.5	5.0	7.8	6.4	8.1	1.3	3.5	2.7	2.6	6.1	5.8	3.2	6.3	6.1	6.9	0.1	8.2	5.4	2.8	3.7	5.5	0.3	7.2	4.6	7.1	6.2	5.0	7.7	7.1	6.2	2.5	0.0	6.6	0.5	8.9	4.1	4.5	1.3	5.9	4.7	7.0	2.8	6.5	9.9	4.2	4.0	8.0	5.8	4.6	9.8	6.3	6.4	4.6	2.7	5.3	2.2	5.3	5.5	0.0	4.9	0.1	0.0	8.5	5.7	5.2	10.5	7.1	5.3	6.5	6.0	7.4	8.3	7.0	9.0	7.6	9.9	5.4	7.7	9.4	3.5	7.7	5.4	3.2	3.5	4.4	4.2	3.3	4.1	3.9	3.9	2.9	3.9	3.4	3.9	4.0	2.0	3.2	2.6	2.0	0.9	0.5	0.6	0.8	0.6	2.4	1.6	1.0	4.6	1.5	2.7	3.7	0.0	6.1	1.5	1.9	3.9	2.5	2.3	1.2	1.2	3.0	1.2	0.0	2.4	2.2	1.7	1.2	1.5	1.6	1.3	4.9	3.3	1.5	3.2	0.0	2.0	3.7	6.1	1.6	1.5	1.2	1.2	1.2	0.0	4.7	3.0	2.3	3.1	4.5	4.6	1.8	2.1	1.5	0.5	1.6	1.0	1.4	0.5	4.0	0.0	1.6	1.5	1.9	2.1	1.5	0.6	7.1	1.4	2.3	2.1	0.7
ZP1		ENSG00000149506	"Zona pellucida glycoprotein 1"	P60852	11	60867562-60875693	"Disease related genes, Human disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Fertilization			"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"Early spermatids: 32.3;Late spermatids: 87.6"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 0.6"	"Not detected"	"Not detected"			"Immune cell enriched"	"Detected in single"	32	"plasmacytoid DC: 3.1"	"Lineage enriched"	"Detected in single"	32	"dendritic cells: 3.1"	"Group enriched"	"Detected in some"	40	"RPMI-8226: 12.4;SK-BR-3: 3.3"	"Not detected"	"Not detected"												"Secreted in female reproductive system"	NA	NA						"unprognostic (6.40e-3)"	"unprognostic (2.18e-4)"	"unprognostic (1.63e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.14e-1)"	"unprognostic (7.02e-2)"	"unprognostic (8.27e-2)"	"unprognostic (9.95e-2)"	"unprognostic (1.94e-2)"	"unprognostic (8.15e-3)"	"unprognostic (2.52e-1)"	"unprognostic (9.25e-4)"	"unprognostic (5.31e-13)"	"unprognostic (4.13e-2)"	"unprognostic (2.38e-1)"	"unprognostic (6.27e-2)"	"unprognostic (5.61e-2)"	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.4	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	0.0	1.3	0.3	0.0	0.1	0.0	0.0	0.0	1.3	0.1	0.1	0.7	0.0	0.6	0.0	0.0	0.2	0.1	0.0	0.0	0.0	32.3	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.3	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	87.6	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	6.6	0.1	5.0	1.9	0.0	0.0	0.1	0.3	0.8	0.0	0.0	0.1
